number,rank,title,recruitment,recruitment_bin,postedresults,resultsarrived_bin,conditions,intervention.merge,phase2,enrollment,gender,fund_source_grp,interventionmodel,randomized,purpose,yearreceived,yearstart,primarylength,intervention.model,phase,masking,testing,masking2,enrollment.log,enrollment.log.cut
3234,4539,td-6450 mad study in hcv infected subjects,Completed,4,0,0,Hepatitis C|HCV,drug or biologic,Early,47,All,Industry&Combos,0,0,0,2014,2014,153,0,Phase 1,1,NA,1,3.8501476017100584,"(3,4]"
1596,1746,"study of immune checkpoint inhibition with radiation therapy in unresectable, non-metastatic pancreatic cancer",Withdrawn,7,0,0,Pancreatic Cancer,drug or biologic,Early,NA,All,Industry&Combos,1,1,0,2016,2016,939,1,Phase 1,0,NA,0,NA,NA
3412,5149,a study of dkn-01 in combination with paclitaxel or pembrolizumab,"Active, not recruiting",1,0,0,Esophageal Neoplasms|Adenocarcinoma of the Gastroesophageal Junction|Gastroesophageal Cancer|Squamous Cell Carcinoma|Gastric Adenocarcinoma,drug or biologic,Early,151,All,Industry&Combos,1,1,0,2013,2014,2526,1,Phase 1,0,NA,0,5.017279836814924,"(5,6]"
152,152,irinotecan-eluting beads in treating patients with refractory metastatic colon or rectal cancer that has spread to the liver,Terminated,5,0,0,Liver Metastases|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,procedure,Others,2,All,NIH&Combos,0,NA,0,2014,2016,431,0,Others,1,NA,1,0.6931471805599453,"(0,1]"
226,229,sirolimus for eosinophil-associated gastrointestinal disorders,Terminated,5,0,0,Eosinophilic Gastroenteritis|Eosinophilic Esophagitis,drug or biologic,Early,4,All,NIH&Combos,0,1,0,2013,2013,796,0,Phase 1,1,NA,1,1.3862943611198906,"(1,2]"
3020,4055,a study to investigate how the study drug shp626 is eliminated from the body after one dose,Completed,4,0,0,Non-Alcoholic Steatohepatitis,drug or biologic,Early,8,Male,Industry&Combos,0,NA,4,2015,2015,0,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
3721,6221,impact of probiotics on oral microbiota in older adults with dysphagia,Suspended,6,0,0,Dysphagia,drug or biologic,Early,20,All,AllOther,0,NA,0,2018,2018,1145,0,Early Phase 1,1,NA,1,2.995732273553991,"(2,3]"
507,528,induction of gut permeability by an oral vaccine,Recruiting,2,0,0,Intestinal Permeability|Inflammation|Vaccine|Typhoid Fever,drug or biologic,Early,15,Female,AllOther,0,NA,4,2019,2019,758,0,Early Phase 1,1,NA,1,2.70805020110221,"(2,3]"
1647,1811,pk and pd study of idn-6556 in subjects with hepatic impairment and matched healthy volunteers,Completed,4,1,1,Hepatic Impairment|Liver Diseases|Digestive System Diseases,drug or biologic,Early,37,All,Industry&Combos,1,1,0,2014,2014,91,1,Phase 1,0,NA,0,3.6109179126442243,"(3,4]"
2007,2364,postoperative chemoradiation or chemotherapy after preoperative chemotherapy for gastric cancers,Terminated,5,1,1,Gastrointestinal Cancer,drug or biologic,Early,6,All,AllOther,1,1,0,2018,2018,634,1,Early Phase 1,0,NA,0,1.791759469228055,"(1,2]"
4107,8192,a study to evaluate the effects of food and esomeprazole on the pharmacokinetics of crizotinib in a coated microsphere formulation.,Completed,4,0,0,Healthy,drug or biologic,Early,18,All,Industry&Combos,3,0,4,2017,2017,91,3,Phase 1,0,pharmacokinetics only,0,2.8903717578961645,"(2,3]"
213,216,improving pancreas radiotherapy plans using respiration-driven anatomic deformation: a pilot study,Completed,4,0,0,Pancreatic Cancer,other,Others,15,All,AllOther,0,NA,4,2013,2013,608,0,Others,1,NA,1,2.70805020110221,"(2,3]"
281,286,dc vaccine in pancreatic cancer,Recruiting,2,0,0,Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,12,All,AllOther,0,NA,0,2018,2018,1046,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
523,544,early serum infliximab levels in severe ulcerative colitis.,Completed,4,0,0,Ulcerative Colitis (UC)|Inflammatory Bowel Disease,drug or biologic,Early,11,All,AllOther,0,NA,4,2013,2013,426,0,Phase 1,1,NA,1,2.3978952727983707,"(2,3]"
1483,1603,"a phase i study of the safety, reactogenicity, and immunogenicity of sm-tsp-2/alhydrogel Â® with or without gla-af for intestinal schistosomiasis in healthy adults",Completed,4,0,0,Schistosomiasis,drug or biologic,Early,72,All,NIH&Combos,1,0,1,2015,2015,723,1,Phase 1,2,safety,2,4.276666119016055,"(4,5]"
1539,1675,impact of fecal biotherapy (fbt) on microbial diversity in patients with moderate to severe inflammatory bowel disease,Completed,4,0,0,Crohn's Disease,drug or biologic,Early,22,All,AllOther,0,NA,4,2013,2013,1280,0,Phase 1,1,NA,1,3.091042453358316,"(3,4]"
859,901,"bruog 302:byl719, capecitabine and radiation for rectal cancer: a brown university oncology research group study",Terminated,5,1,1,Rectal Cancer,drug or biologic,Early,7,All,AllOther,NA,1,0,2015,2016,896,NA,Phase 1,0,NA,0,1.9459101490553132,"(1,2]"
271,275,phase 0 biodistribution of novel imaging for resectable pancreatic cancer,Terminated,5,0,0,Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,3,All,AllOther,0,NA,2,2013,2013,791,0,Early Phase 1,1,NA,1,1.0986122886681098,"(1,2]"
1420,1527,fmt for mdro colonization after infection in renal transplant recipients,Recruiting,2,0,0,Infection Due to Resistant Organism,drug or biologic,Early,20,All,Industry&Combos,1,0,0,2016,2016,1643,1,Phase 1,0,NA,0,2.995732273553991,"(2,3]"
935,983,a study of evacetrapib (ly2484595) in participants with hepatic (liver) impairment,Completed,4,1,1,Hepatic Insufficiency,drug or biologic,Early,32,All,Industry&Combos,1,1,4,2013,2013,183,1,Phase 1,0,NA,0,3.4657359027997265,"(3,4]"
2047,2422,gb004 in adult subjects with active ulcerative colitis,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,34,All,Industry&Combos,1,0,0,2019,2019,237,1,Phase 1,2,NA,2,3.5263605246161616,"(3,4]"
598,624,fecal microbiota transplant in the treatment of ulcerative colitis,Unknown status,8,0,0,"Ulcerative Colitis, Active Moderate",drug or biologic,Early,20,All,AllOther,1,0,0,2015,2015,731,1,Early Phase 1,2,NA,2,2.995732273553991,"(2,3]"
158,158,trial of pallov-cc in colon cancer,Recruiting,2,0,0,Colon Cancer,drug or biologic,Early,24,All,Industry&Combos,NA,1,0,2019,2019,823,NA,Phase 1,0,NA,0,3.1780538303479458,"(3,4]"
1248,1333,a study to assess the effect of high fat meal and increased gastric ph on the bioavailability of an extended release formulation of bms-663068 in healthy subjects,Completed,4,0,0,"Infection, Human Immunodeficiency Virus",drug or biologic,Early,72,All,Industry&Combos,3,0,4,2016,2016,26,3,Phase 1,NA,NA,NA,4.276666119016055,"(4,5]"
703,737,proton beam therapy to treat esophageal cancer,Terminated,5,0,0,Esophageal Squamous Cell Carcinoma|Adenocarcinoma Of Esophagus,other,Others,3,All,AllOther,0,1,0,2013,2014,455,0,Others,1,NA,1,1.0986122886681098,"(1,2]"
3266,4598,"a phase 1, open-label study of intravenous sildenafil in patients with cirrhosis",Terminated,5,0,0,Cirrhosis,drug or biologic,Early,2,All,AllOther,0,NA,0,2013,2014,518,0,Phase 1,1,NA,1,0.6931471805599453,"(0,1]"
1917,2233,defined green tea catechin extract in preventing liver cancer in patients with cirrhosis,Recruiting,2,0,0,Cirrhosis,drug or biologic,Early,48,All,NIH&Combos,0,NA,1,2017,2018,1056,0,Phase 1,1,NA,1,3.871201010907891,"(3,4]"
448,460,veliparib in combination with gemcitabine and intensity modulated radiation therapy in patients with pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,34,All,Industry&Combos,0,NA,0,2013,2013,1381,0,Phase 1,1,NA,1,3.5263605246161616,"(3,4]"
2018,2384,"amp-224, a pd-1 inhibitor, with stereotactic body radiation therapy in metastatic colorectal cancer",Completed,4,1,1,Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma,drug or biologic,Early,17,All,NIH&Combos,0,1,0,2014,2014,600,0,Phase 1,1,NA,1,2.833213344056216,"(2,3]"
56,56,the gut-brain study,Recruiting,2,0,0,Autism Spectrum Disorder (ASD)|Gastro-Intestinal Disorder,drug or biologic,Early,10,All,AllOther,1,0,0,2018,2019,929,1,Phase 1,4,NA,2,2.302585092994046,"(2,3]"
1776,1998,regorafenib and nivolumab in mismatch repair (mmr) refractory colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Cancer|Metastatic Colorectal Cancer|Colon Cancer,drug or biologic,Early,52,All,Industry&Combos,NA,1,0,2018,2018,1044,NA,Phase 1,0,NA,0,3.9512437185814275,"(3,4]"
2271,2828,safety and efficacy study of pri-724 plus gemcitabine in subjects with advanced or metastatic pancreatic adenocarcinoma,Completed,4,0,0,Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer|Pancreatic Adenocarcinoma,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2013,2013,913,0,Phase 1,1,safety/efficacy,1,2.995732273553991,"(2,3]"
820,858,trametinib and hydroxychloroquine in treating patients with pancreatic cancer,Recruiting,2,0,0,Metastatic Pancreatic Carcinoma|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma,drug or biologic,Early,33,All,Industry&Combos,0,NA,0,2019,2019,1826,0,Phase 1,1,NA,1,3.4965075614664802,"(3,4]"
189,191,localized therapeutics for the treatment of gastrointestinal disorders ii,Completed,4,0,0,"Colitis, Ulcerative",drug or biologic,Early,3,All,AllOther,0,NA,0,2016,2016,670,0,Phase 1,1,NA,1,1.0986122886681098,"(1,2]"
911,957,"trial of hypofractionated radiotherapy in combination with medi4736 and tremelimumab for patients with metastatic melanoma and lung, breast and pancreatic cancers","Active, not recruiting",1,0,0,Metastatic|Melanoma|Non Small Cell Lung Cancer (NSCLC)|Breast Cancer|Pancreatic Cancer,drug or biologic,Early,30,All,AllOther,1,1,0,2015,2016,2013,1,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
2629,3531,vemurafenib and panitumumab combination therapy in patients with braf v600e mutated metastatic colorectal cancer,Completed,4,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2013,2013,789,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
1651,1816,"radiation therapy in treating patients with hepatocellular carcinoma, cholangiocarcinoma, or liver metastasis who have impaired liver function",Recruiting,2,0,0,Cholangiocarcinoma|Cirrhosis|Hepatocellular Carcinoma|Metastatic Malignant Neoplasm in the Liver,procedure,Others,88,All,NIH&Combos,0,NA,0,2015,2016,2205,0,Others,1,NA,1,4.477336814478207,"(4,5]"
2301,2890,clinical trial of metastasis inhibitor np-g2-044 in patients with advanced or metastatic treatment-refractory solid tumor malignancies,Completed,4,0,0,Breast Cancer|Pancreas Cancer|Prostate Cancer|Lung Cancer|Colon Cancer|Esophagus Cancer|Liver Cancer|Ovary Cancer|Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies,drug or biologic,Early,23,All,Industry&Combos,0,NA,0,2017,2017,868,0,Phase 1,1,NA,1,3.1354942159291497,"(3,4]"
3604,5678,stem cell fistula plug in perianal crohn's disease,Completed,4,0,0,Perianal Crohn's Disease,drug or biologic,Early,20,All,AllOther,0,NA,0,2013,2013,2344,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
2298,2879,study of high-dose oral vitamin d for the prevention of liver cancer,Withdrawn,7,0,0,Cirrhosis|Hepatocellular Carcinoma,drug or biologic,Early,NA,All,AllOther,2,1,4,2013,2013,893,1,Phase 1,0,NA,0,NA,NA
98,98,a dose escalation trial of sbrt after induction chemotherapy for locally advanced pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,15,All,AllOther,0,NA,0,2016,2016,932,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
1595,1745,24hr imaging of hcc after eovist,Withdrawn,7,0,0,Hepatocellular Carcinoma,drug or biologic,Early,NA,All,AllOther,0,NA,2,2013,2013,577,0,Early Phase 1,1,NA,1,NA,NA
1620,1775,probiotic detection and persistence study,Completed,4,0,0,Healthy,drug or biologic,Early,31,All,AllOther,0,NA,4,2019,2019,82,0,Early Phase 1,1,NA,1,3.4339872044851463,"(3,4]"
701,735,a study to evaluate the effect of iv doses of rivipansel in subjects with moderate hepatic impairment and in healthy subjects with normal hepatic function,Completed,4,1,1,Moderate Hepatic Impairment|Normal Hepatic Function,drug or biologic,Early,16,All,Industry&Combos,1,1,4,2016,2016,153,1,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
2153,2591,digestive endoscopy suite radiation controlling protective strategies,Completed,4,0,0,Radiation Exposure,device,Others,2,All,AllOther,3,0,1,2014,2013,92,3,Others,2,NA,2,0.6931471805599453,"(0,1]"
3781,6555,naproxen in preventing dna mismatch repair deficient colorectal cancer in patients with lynch syndrome,Completed,4,0,0,Lynch Syndrome,drug or biologic,Early,81,All,NIH&Combos,1,0,1,2014,2014,2097,1,Phase 1,2,NA,2,4.394449154672439,"(4,5]"
3553,5450,regorafenib plus pembrolizumab in first line systemic treatment of hcc,"Active, not recruiting",1,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,57,All,Industry&Combos,NA,1,0,2017,2018,913,NA,Phase 1,0,NA,0,4.04305126783455,"(4,5]"
1113,1180,"a study to evaluate the pharmacokinetics, safety and tolerability of pf-06651600 in subjects with hepatic impairment and healthy volunteers",Completed,4,1,1,Hepatic Impairment|Healthy Participants,drug or biologic,Early,18,All,Industry&Combos,1,1,4,2019,2019,230,1,Phase 1,0,safety,0,2.8903717578961645,"(2,3]"
4108,8202,a study to evaluate the effect of multiple doses of esomeprazole on the pharmacokinetics of isavuconazole,Completed,4,0,0,Pharmacokinetics of Isavuconazole|Healthy Subjects,drug or biologic,Early,24,All,Industry&Combos,1,0,4,2014,2014,31,1,Phase 1,0,pharmacokinetics only,0,3.1780538303479458,"(3,4]"
3847,6947,"a study to assess cyp3a4 modulator, oral contraceptive, and ph modifier drug interactions for abi-h2158 in healthy adults",Completed,4,0,0,Chronic Hepatitis B,drug or biologic,Early,80,All,Industry&Combos,1,1,0,2019,2019,86,1,Phase 1,0,NA,0,4.382026634673881,"(4,5]"
2029,2398,momelotinib combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma,Terminated,5,0,0,Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,16,All,Industry&Combos,1,1,0,2014,2014,854,1,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
4101,8126,"to assess the effect of renal impairment on the blood levels of daclatasvir (dcv), asunaprevir (asv) and bms-791325 after multiple doses of a fixed dose combination tablet",Completed,4,0,0,Hepatitis C,drug or biologic,Early,41,All,Industry&Combos,0,NA,NA,2014,2014,61,0,Phase 1,1,NA,1,3.713572066704308,"(3,4]"
3145,4276,(navigator) study of blu-285 in patients with gastrointestinal stromal tumors (gist) and other relapsed and refractory solid tumors,Completed,4,1,1,Gastrointestinal Stromal Tumors (GIST)|Other Relapsed or Refractory Solid Tumors,drug or biologic,Early,250,All,Industry&Combos,NA,1,0,2015,2015,1679,NA,Phase 1,0,NA,0,5.521460917862246,"(5,6]"
1092,1154,autologous redirected rna meso car t cells for pancreatic cancer,Completed,4,0,0,Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (PDA),drug or biologic,Early,16,All,AllOther,0,NA,0,2013,2013,883,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
1203,1281,elafibranor pharmacokinetic parameters in hepatic impaired patients,Completed,4,0,0,Hepatic Impairment|Liver Disease|Pharmacokinetics,drug or biologic,Early,30,All,Industry&Combos,1,1,4,2018,2018,177,1,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
4065,7784,effect of proton pump inhibitors on endothelial function,Unknown status,8,0,0,Endothelial Dysfunction,drug or biologic,Early,20,All,AllOther,3,0,NA,2013,2013,426,3,Phase 1,0,NA,0,2.995732273553991,"(2,3]"
2129,2552,"a study of bms-986171 in healthy people to assess safety, to measure blood levels of drug, and to find out what the drug does to the body",Completed,4,0,0,Liver Fibrosis/NASH,drug or biologic,Early,275,All,Industry&Combos,1,0,4,2015,2015,370,1,Phase 1,3,safety,2,5.616771097666572,"(5,6]"
3840,6907,a pharmacokinetic study of ustekinumab in pediatric subjects with moderately to severely active crohn's disease,"Active, not recruiting",1,0,0,Crohn Disease,drug or biologic,Early,45,All,Industry&Combos,1,0,0,2016,2017,608,1,Phase 1,2,NA,2,3.8066624897703196,"(3,4]"
2133,2559,spif clinical study protocol in autoimmune hepatitis,Completed,4,1,1,Autoimmune Hepatitis,drug or biologic,Early,36,Female,Industry&Combos,1,0,0,2014,2014,528,1,Phase 1,4,NA,2,3.58351893845611,"(3,4]"
2232,2750,hepatic arterial infusion with floxuridine and dexamethasone in combination with gemcitabine as adjuvant treatment after resection of intrahepatic cholangiocarcinoma,Completed,4,0,0,Intrahepatic Cholangiocarcinoma|Peripheral Cholangiocarcinoma|Cholangiolar Carcinoma|Cholangiocellular Carcinoma) (ICC),drug or biologic,Early,8,All,AllOther,0,NA,0,2013,2013,2562,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
3743,6317,"safety and immunogenicity of two live, attenuated oral shigella sonnei vaccines: wrss2 and wrss3",Completed,4,0,0,Shigella Infection,drug or biologic,Early,89,All,NIH&Combos,1,0,1,2011,2013,855,1,Phase 1,2,safety,2,4.48863636973214,"(4,5]"
2520,3356,stereotactic body radiotherapy (sbrt) followed by immunotherapy in liver cancer,Terminated,5,0,0,Hepatocellular Carcinoma,drug or biologic,Early,14,All,AllOther,1,0,0,2017,2017,565,1,Phase 1,0,NA,0,2.6390573296152584,"(2,3]"
2533,3397,"ph1b study of oraxol in comb. w. ramucirumab in patients w. gastric, gastro-esophageal, or esophageal cancers","Active, not recruiting",1,0,0,Gastric Cancer|Esophageal Cancer|Gastro-esophageal Cancer,drug or biologic,Early,36,All,Industry&Combos,NA,NA,0,2016,2016,839,NA,Phase 1,0,NA,0,3.58351893845611,"(3,4]"
3101,4204,a study to test the safety and feasibility of nivolumab with drug eluting bead transarterial chemoembolization in patients with liver cancer,Recruiting,2,0,0,Liver Cancer,drug or biologic,Early,14,All,Industry&Combos,1,1,0,2017,2017,1799,1,Early Phase 1,0,safety,0,2.6390573296152584,"(2,3]"
2974,3988,safety of secretrol Â® in the short-term management of patients undergoing endoscopic mucosal resection (emr),Unknown status,8,0,0,EMR Ulcer,drug or biologic,Early,5,All,Industry&Combos,0,NA,0,2014,2013,852,0,Phase 1,1,safety,1,1.6094379124341003,"(1,2]"
3935,7329,a study of the immune response to heplisav in healthy older adults,Completed,4,0,0,Hepatitis B,drug or biologic,Early,25,All,Industry&Combos,0,NA,4,2013,2013,457,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
72,72,gerd and anti-reflux therapy between able-bodied and sci individuals,Unknown status,8,0,0,Gastro Esophageal Reflux Disorder,drug or biologic,Early,110,All,AllOther,1,0,0,2015,2016,730,1,Phase 1,0,NA,0,4.700480365792417,"(4,5]"
1337,1429,temporary celiac ganglion block as a test before celiac ganglion resection for dysautonomia-related bowel dysmotility,Completed,4,0,0,Dysautonomia,drug or biologic,Early,15,All,AllOther,0,NA,2,2019,2019,523,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
3108,4217,trametinib in treating patients with advanced cancer with or without hepatic dysfunction,Recruiting,2,0,0,Advanced Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Liver|Metastatic Malignant Solid Neoplasm|Unresectable Solid Neoplasm,drug or biologic,Early,68,All,NIH&Combos,0,NA,0,2014,2014,2726,0,Phase 1,1,NA,1,4.219507705176107,"(4,5]"
2189,2662,cpi-613 and fluorouracil in treating patients with metastatic colorectal cancer that cannot be removed by surgery,"Active, not recruiting",1,0,0,Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,drug or biologic,Early,19,All,NIH&Combos,0,NA,0,2014,2015,1505,0,Phase 1,1,NA,1,2.9444389791664403,"(2,3]"
740,774,phase i study mk-3475 with chemotherapy in patients with advanced gi cancers,Terminated,5,0,0,Advanced GI Cancer,drug or biologic,Early,39,All,Industry&Combos,0,NA,0,2014,2015,733,0,Phase 1,1,NA,1,3.6635616461296463,"(3,4]"
3450,5241,"utomilumab, cetuximab, and irinotecan hydrochloride in treating patients with metastatic colorectal cancer","Active, not recruiting",1,0,0,Metastatic Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,drug or biologic,Early,42,All,NIH&Combos,0,NA,0,2017,2017,1465,0,Phase 1,1,NA,1,3.7376696182833684,"(3,4]"
1527,1659,assessment of gut absorption of experimental medication bms-986165 in healthy males,Completed,4,0,0,Psoriasis,drug or biologic,Early,9,Male,Industry&Combos,3,0,0,2019,2019,96,3,Phase 1,0,NA,0,2.1972245773362196,"(2,3]"
2515,3346,health service intervention for the improvement of access and adherence to colorectal cancer screening,Completed,4,0,0,Colorectal Carcinoma,other,Others,185,All,NIH&Combos,0,NA,4,2020,2019,256,0,Others,1,NA,1,5.220355825078324,"(5,6]"
1205,1283,a pharmacokinetic study of baricitinib in participants with liver disease,Completed,4,1,1,Liver Diseases|Hepatic Insufficiency,drug or biologic,Early,16,All,Industry&Combos,1,1,4,2013,2013,30,1,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
1143,1214,low dose il-2 for ulcerative colitis,"Active, not recruiting",1,1,1,Ulcerative Colitis,drug or biologic,Early,26,All,AllOther,0,NA,0,2014,2015,2069,0,Phase 1,1,NA,1,3.258096538021482,"(3,4]"
745,779,"a study to evaluate the safety, tolerability and microbiome dynamics of ser-287 in subjects with mild-to-moderate ulcerative colitis",Completed,4,1,1,Ulcerative Colitis,drug or biologic,Early,58,All,Industry&Combos,1,0,0,2015,2016,693,1,Phase 1,2,safety,2,4.060443010546419,"(4,5]"
2004,2358,fecal microbiota transplant (fmt) for pouchitis,Completed,4,0,0,Pouchitis,drug or biologic,Early,19,All,AllOther,0,NA,0,2015,2015,1047,0,Early Phase 1,1,NA,1,2.9444389791664403,"(2,3]"
2513,3344,palbociclib with cisplatin or carboplatin in advanced solid tumors,Recruiting,2,0,0,Solid Neoplasm|Stage III Pancreatic Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IVA Pancreatic Cancer|Stage IVB Pancreatic Cancer|Sarcoma|Colorectal Cancer|Head and Neck Cancer|Cancer of Unknown Primary|Bladder Cancer|Ovarian Cancer,drug or biologic,Early,90,All,Industry&Combos,1,1,0,2016,2016,1864,1,Phase 1,0,NA,0,4.499809670330265,"(4,5]"
1278,1365,pdt plus vitamin d3 for anal dysplasia,Recruiting,2,0,0,Anal Dysplasia|Carcinoma in Situ,drug or biologic,Early,12,All,AllOther,0,0,0,2016,2019,1127,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
4064,7783,a study investigating the effect of food and esomeprazole on the single oral dose pharmacokinetics of alectinib (ro5424802) in healthy volunteers.,Completed,4,1,1,Healthy Volunteer,drug or biologic,Early,42,All,Industry&Combos,1,1,0,2013,2013,90,1,Phase 1,0,pharmacokinetics only,0,3.7376696182833684,"(3,4]"
579,603,respiratory-gated stereotactic body radiation therapy for adenocarcinoma of the pancreas or periampullary region,"Active, not recruiting",1,0,0,Pancreatic Neoplasms,other,Others,37,All,AllOther,0,NA,0,2016,2016,1205,0,Others,1,NA,1,3.6109179126442243,"(3,4]"
2514,3345,an open-label study of ruxolitinib given with chemotherapy in patients with advanced solid tumors,Terminated,5,1,1,Solid Tumors|Pancreatic Cancer,drug or biologic,Early,42,All,Industry&Combos,0,1,0,2013,2013,883,0,Phase 1,1,NA,1,3.7376696182833684,"(3,4]"
339,345,a pilot study to characterize bile acid metabolism and dysbiosis in primary sclerosing cholangitis,Completed,4,0,0,Primary Sclerosing Cholangitis|Inflammatory Bowel Disease,drug or biologic,Early,8,All,AllOther,0,1,4,2015,2015,670,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
1661,1829,synergistic effect of vedolizumab and pentoxifylline,Completed,4,0,0,Crohn Disease,drug or biologic,Early,37,All,Industry&Combos,1,0,0,2016,2017,704,1,Early Phase 1,4,NA,2,3.6109179126442243,"(3,4]"
969,1020,dose escalation of neoadjuvant proton beam radiotherapy with concurrent chemotherapy in locally advanced esophageal cancer,Recruiting,2,0,0,Esophageal Cancer,drug or biologic,Early,30,All,AllOther,NA,1,2,2014,2014,3196,NA,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
906,952,pharmacokinetics of pantoprazole and cyp2c19 activity in children and adolescents with gerd: a pilot study,Completed,4,0,0,Obesity|GERD,drug or biologic,Early,62,All,AllOther,0,NA,4,2013,2013,852,0,Phase 1,1,pharmacokinetics only,1,4.127134385045092,"(4,5]"
3248,4567,ocr002-sp103 - oral immediate release study,Completed,4,0,0,Cirrhosis,drug or biologic,Early,30,All,Industry&Combos,3,0,4,2019,2016,472,3,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
1692,1871,evaluation of hepatic function impairment on the pharmacokinetics of lee011,Completed,4,0,0,Normal Hepatic Function|Impaired Hepatic Function,drug or biologic,Early,30,All,Industry&Combos,1,1,0,2015,2015,656,1,Phase 1,0,pharmacokinetics only,0,3.4011973816621555,"(3,4]"
2281,2846,irinotecan and alisertib in treating patients with advanced solid tumors or colorectal cancer,Completed,4,0,0,"Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IIIA Colon Cancer|Unspecified Adult Solid Tumor, Protocol Specific",drug or biologic,Early,17,All,IndustryNIHPartnership,0,NA,0,2013,2013,1173,0,Phase 1,1,NA,1,2.833213344056216,"(2,3]"
1799,2032,yttrium y-90 radioembolization in treating patients with metastatic liver cancer,"Active, not recruiting",1,0,0,Metastatic Liver Carcinoma|Stage IV Liver Cancer|Stage IVA Liver Cancer|Stage IVB Liver Cancer,procedure,Others,12,All,NIH&Combos,0,NA,0,2017,2017,1483,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
2087,2489,a phase i study of tas-102 in patients with advanced gastrointestinal tumors.,Completed,4,0,0,Advanced Gastrointestinal Tumors,drug or biologic,Early,65,All,Industry&Combos,0,NA,0,2013,2013,1461,0,Phase 1,1,NA,1,4.174387269895637,"(4,5]"
661,688,pilot trial of kd018 with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer,Completed,4,0,0,Rectal Cancer,drug or biologic,Early,29,All,AllOther,0,NA,0,2014,2014,1907,0,Phase 1,1,NA,1,3.367295829986474,"(3,4]"
3310,4707,dose escalation study of omp-54f28 in combination with sorafenib in patients with hepatocellular cancer,Completed,4,0,0,Hepatocellular Cancer|Liver Cancer,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2014,2014,1216,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
3896,7192,ser-262 versus placebo in adults with primary clostridium difficile infection to prevent recurrence,Unknown status,8,0,0,Clostridium Difficile Infection,drug or biologic,Early,96,All,Industry&Combos,1,0,1,2016,2016,700,1,Phase 1,4,NA,2,4.564348191467836,"(4,5]"
713,747,low fodmap plus peg 3350 for the treatment of patients with irritable bowel syndrome-constipation,Recruiting,2,0,0,Irritable Bowel Syndrome Characterized by Constipation,other,Others,78,All,AllOther,1,0,0,2018,2018,1456,1,Others,2,NA,2,4.356708826689592,"(4,5]"
2509,3330,"a study to examine the effect of omeprazole, famotidine, and an acidic beverage on the pharmacokinetics of entinostat in healthy adult subjects",Completed,4,0,0,Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers,drug or biologic,Early,66,All,Industry&Combos,1,1,4,2016,2016,176,1,Phase 1,0,pharmacokinetics only,0,4.189654742026425,"(4,5]"
2255,2794,phase i th-302 plus gemcitabine plus nab-paclitaxel in pancreatic cancer,Terminated,5,1,1,Pancreatic Cancer,drug or biologic,Early,19,All,Industry&Combos,0,NA,0,2014,2014,608,0,Phase 1,1,NA,1,2.9444389791664403,"(2,3]"
2387,3065,ph 1 trial of adi peg 20 plus sorafenib to treat patients with liver cancer,Completed,4,0,0,Hepatocellular Carcinoma,drug or biologic,Early,8,All,Industry&Combos,0,NA,0,2014,2014,457,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
151,151,a phase i in-vivo peptide applied in the right colon,Completed,4,0,0,Colon Lesions,drug or biologic,Early,25,All,AllOther,0,NA,2,2012,2013,120,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
1499,1624,fluorescence qrh-882260 peptide imaging in the bile duct,Completed,4,0,0,Cholangiocarcinoma,drug or biologic,Early,1,All,AllOther,0,NA,2,2018,2019,487,0,Phase 1,1,NA,1,0,NA
1291,1378,"a study of nbf-006 in non-small cell lung, pancreatic, or colorectal cancer",Recruiting,2,0,0,Non-Small Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer,drug or biologic,Early,44,All,Industry&Combos,0,NA,0,2019,2019,1232,0,Phase 1,1,NA,1,3.784189633918261,"(3,4]"
4021,7602,identification to elimination in hcv-infected individuals,Completed,4,0,0,Hepatitis C,other,Others,3051,All,Industry&Combos,0,NA,2,2017,2017,1054,0,Others,1,NA,1,8.02322468471667,"(7,13]"
919,965,fecal microbiota transplantation (fmt) in nonalcoholic steatohepatitis(nash). a pilot study,Unknown status,8,0,0,Nonalcoholic Fatty Liver Disease,drug or biologic,Early,5,All,AllOther,0,NA,0,2015,2015,1127,0,Phase 1,1,NA,1,1.6094379124341003,"(1,2]"
909,955,alisertib and gemcitabine hydrochloride in treating patients with solid tumors or pancreatic cancer,Completed,4,0,0,"Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",drug or biologic,Early,26,All,IndustryNIHPartnership,0,NA,0,2013,2013,1279,0,Phase 1,1,NA,1,3.258096538021482,"(3,4]"
989,1043,td-3504 sad in healthy subjects and subjects with ulcerative colitis (uc),Completed,4,0,0,"Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects",drug or biologic,Early,32,All,Industry&Combos,1,0,0,2017,2017,188,1,Phase 1,3,NA,2,3.4657359027997265,"(3,4]"
2363,3015,a phase 1 study of ljpc-501 in patients with hepatorenal syndrome,Terminated,5,0,0,Hepatorenal Syndrome Type I and Type II,drug or biologic,Early,6,All,Industry&Combos,0,NA,0,2013,2014,610,0,Phase 1,1,NA,1,1.791759469228055,"(1,2]"
914,960,arq-761 treatment with gemcitabine/nab-paclitaxel chemotherapy in pancreatic cancer,Suspended,6,0,0,Pancreatic Cancer,drug or biologic,Early,20,All,AllOther,0,NA,4,2015,2016,789,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
2064,2456,pharmacokinetics and safety of abt-493 and/or abt-530 in subjects with normal and impaired hepatic function,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,24,All,Industry&Combos,1,1,4,2014,2014,335,1,Phase 1,0,safety,0,3.1780538303479458,"(3,4]"
2318,2915,near infrared fluorescence cholangiography (nirf-c) during cholecystectomy -- use in acute cholecystitis sub-study,Completed,4,0,0,Acute Cholecystitis|Acute Cholangitis,drug or biologic,Early,6,All,Industry&Combos,0,NA,2,2014,2013,396,0,Phase 1,1,NA,1,1.791759469228055,"(1,2]"
3605,5679,medi9447 alone and in combination with medi4736 in adult subjects with select advanced solid tumors,"Active, not recruiting",1,0,0,Solid Tumors,drug or biologic,Early,192,All,Industry&Combos,1,1,0,2015,2015,2009,1,Phase 1,0,NA,0,5.2574953720277815,"(5,6]"
473,490,chemotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma,Recruiting,2,0,0,Pancreas Cancer,drug or biologic,Early,20,All,AllOther,0,NA,0,2018,2018,1676,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
2421,3137,rifaximin for infection prophylaxis in hematopoietic stem cell transplantation,"Active, not recruiting",1,0,0,Microbial Colonization,drug or biologic,Early,26,All,AllOther,0,1,0,2018,2018,824,0,Early Phase 1,1,NA,1,3.258096538021482,"(3,4]"
1843,2106,vorolanib (x-82) combined with checkpoint inhibitors in patients with solid tumors,Terminated,5,0,0,Solid Tumor|Hepatocellular Carcinoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,16,All,Industry&Combos,1,1,0,2018,2018,338,1,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
1045,1100,effect of mild hepatic impairment on the pharmacokinetics of istradefylline,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,20,All,Industry&Combos,0,NA,4,2014,2014,122,0,Phase 1,1,pharmacokinetics only,1,2.995732273553991,"(2,3]"
2076,2472,reduction of c-difficile infection using stool transplant,Unknown status,8,0,0,C-difficile,drug or biologic,Early,10,All,AllOther,0,NA,0,2014,2014,426,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
4081,7910,drug interaction & methadone & buprenorphine,Completed,4,0,0,Hepatitis C,drug or biologic,Early,32,All,Industry&Combos,1,1,NA,2014,2014,59,1,Phase 1,0,NA,0,3.4657359027997265,"(3,4]"
1078,1137,study of freeze-dried black raspberry in maintenance of ulcerative colitis,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,7,All,AllOther,0,NA,0,2014,2013,795,0,Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
1642,1806,pi pembro in combination with stereotactic body radiotherapy for liver metastatic colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Cancer|Colorectal Adenocarcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer|Metastatic Carcinoma in the Liver,drug or biologic,Early,18,All,Industry&Combos,0,NA,0,2016,2016,1755,0,Phase 1,1,NA,1,2.8903717578961645,"(2,3]"
3622,5716,"a safety, tolerability and pk study of dcc-2618 in patients with advanced malignancies","Active, not recruiting",1,0,0,Gastrointestinal Stromal Tumors|Advanced Systemic Mastocytosis|Advanced Cancers,drug or biologic,Early,320,All,Industry&Combos,1,1,0,2015,2015,2435,1,Phase 1,0,safety,0,5.768320995793772,"(5,6]"
3945,7357,selumetinib and cyclosporine in treating patients with advanced solid tumors or advanced or metastatic colorectal cancer,"Active, not recruiting",1,0,0,Recurrent Colorectal Carcinoma|Solid Neoplasm|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,40,All,NIH&Combos,0,NA,0,2014,2014,910,0,Phase 1,1,NA,1,3.6888794541139363,"(3,4]"
2739,3668,"study of pegph20 with cisplatin (cis) and gemcitabine (gem); pegph20 with atezolizumab (atezo), cis, and gem; and cis and gem alone in participants with previously untreated, unresectable, locally advanced, or metastatic intrahepatic and extrahepatic cholangiocarcinoma and gallbladder adenocarcinoma",Terminated,5,1,1,"Cholangiocarcinoma Non-resectable|Cholangiocarcinoma, Intrahepatic|Cholangiocarcinoma, Extrahepatic|Gallbladder Adenocarcinoma",drug or biologic,Early,85,All,Industry&Combos,NA,0,0,2017,2017,770,NA,Phase 1,0,NA,0,4.442651256490317,"(4,5]"
3768,6513,open-label placebo for functional dyspepsia,Terminated,5,0,0,Dyspepsia,drug or biologic,Early,21,All,AllOther,1,0,0,2018,2018,310,1,Early Phase 1,0,NA,0,3.044522437723423,"(3,4]"
1618,1773,clotfoam as an adjunct to hemostasis in abdominal surgery - liver bleeding is encountered,Unknown status,8,0,0,Bleeding,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2014,2014,184,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
590,616,bone marrow stromal cells for inflammatory bowel diseases,Terminated,5,0,0,Inflammatory Bowel Disease,other,Others,8,All,NIH&Combos,0,1,0,2013,2013,1627,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
1312,1401,a study to evaluate pharmacokinetics (pk) and safety of oral mobocertinib in participants with moderate or severe hepatic impairment (hi) and normal hepatic function,Recruiting,2,0,0,Hepatic Impairment|Healthy Volunteers,drug or biologic,Early,24,All,Industry&Combos,1,1,4,2019,2019,861,1,Phase 1,0,safety,0,3.1780538303479458,"(3,4]"
3735,6259,a dose-finding study of a combination of imatinib and byl719 in the treatment of 3rd line gist patients,Completed,4,0,0,3rd Line GIST,drug or biologic,Early,56,All,Industry&Combos,0,NA,0,2012,2013,2060,0,Phase 1,1,NA,1,4.02535169073515,"(4,5]"
342,349,molecular-guided surgery for pancreatic and gi neuroendocrine cancers,Recruiting,2,0,0,Neuroendocrine Carcinoma of Pancreas|Carcinoid,drug or biologic,Early,12,All,AllOther,0,NA,0,2018,2019,731,0,Early Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
2203,2691,pharmacokinetics of voxilaprevir in adults with normal hepatic function and moderate or severe hepatic impairment,Completed,4,1,1,HCV Infection,drug or biologic,Early,33,All,Industry&Combos,1,1,0,2015,2015,346,1,Phase 1,0,pharmacokinetics only,0,3.4965075614664802,"(3,4]"
718,752,study of multiplexed heptapeptides for detection of neoplasia in the esophagus,Completed,4,0,0,Barrett Esophagus,drug or biologic,Early,27,All,AllOther,0,NA,2,2018,2018,270,0,Phase 1,1,NA,1,3.295836866004329,"(3,4]"
1479,1595,"apn401 in treating patients with melanoma, kidney cancer, pancreatic cancer, or other solid tumors that are metastatic or cannot be removed by surgery",Completed,4,0,0,"Recurrent Melanoma|Recurrent Pancreatic Cancer|Recurrent Renal Cell Cancer|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma|Stage IV Melanoma|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Unspecified Adult Solid Tumor, Protocol Specific",drug or biologic,Early,17,All,NIH&Combos,0,NA,0,2014,2014,517,0,Phase 1,1,NA,1,2.833213344056216,"(2,3]"
815,853,a single dose evaluation of the effects of moderate hepatic impairment on deflazacort pharmacokinetics,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,16,All,Industry&Combos,0,1,4,2014,2014,62,0,Phase 1,1,pharmacokinetics only,1,2.772588722239781,"(2,3]"
3603,5677,study of enzalutamide with and without sorafenib in advanced hepatocellular carcinoma patients,Completed,4,0,0,Hepatocellular Carcinoma,drug or biologic,Early,28,All,Industry&Combos,1,1,0,2015,2015,1917,1,Phase 1,0,NA,0,3.332204510175204,"(3,4]"
679,710,a dose escalation safety study of locally-delivered gemcitabine in pancreatic cancer,Completed,4,1,1,Pancreatic Cancer,drug or biologic,Early,20,All,Industry&Combos,NA,1,4,2014,2015,550,NA,Phase 1,0,safety,0,2.995732273553991,"(2,3]"
2339,2965,study to evaluate the pharmacokinetics of tenofovir alafenamide (taf) in adults with normal hepatic function and adults with severe hepatic impairment,Completed,4,1,1,Hepatitis B Virus,drug or biologic,Early,20,All,Industry&Combos,1,1,0,2014,2014,116,1,Phase 1,0,pharmacokinetics only,0,2.995732273553991,"(2,3]"
329,335,a pilot dosing and timing study to optimize imaging when utilizing endoscopic fluorescence imaging system during laparoscopic biliary and hepatic operations,Completed,4,0,0,Biliary Anatomy,device,Others,38,All,Industry&Combos,1,1,2,2014,2014,304,1,Others,0,NA,0,3.6375861597263857,"(3,4]"
580,604,losartan and hypofractionated rx after chemo for tx of borderline resectable or locally advanced unresectable pancreatic cancer (shaper),Recruiting,2,0,0,Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Ductal Adenocarcinoma|Locally Advanced Unresectable Pancreatic Adenocarcinoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8,drug or biologic,Early,20,All,NIH&Combos,0,NA,0,2019,2019,1827,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
1376,1476,an exploratory rectal safety study of three tenofovir gel formulations,Completed,4,0,0,HIV Prevention,drug or biologic,Early,9,Male,NIH&Combos,3,0,1,2012,2013,245,3,Phase 1,3,safety,2,2.1972245773362196,"(2,3]"
862,904,"the effect of 3 probiotic strains on bile acids, satiety, and inflammation",Completed,4,0,0,Healthy,other,Others,155,All,Industry&Combos,3,0,4,2013,2013,304,3,Others,3,NA,2,5.043425116919247,"(5,6]"
1769,1983,"phase 1 placebo-controlled, randomized trial of an adenoviral-vector based norovirus vaccine",Completed,4,0,0,Norovirus Gastroenteritis,drug or biologic,Early,66,All,Industry&Combos,1,0,1,2016,2016,68,1,Phase 1,4,NA,2,4.189654742026425,"(4,5]"
3704,6153,"a study of toca 511, a retroviral replicating vector, combined with toca fc in patients with solid tumors or lymphoma (toca 6)",Terminated,5,0,0,Colorectal Cancer|Triple Negative Breast Cancer|Pancreatic Cancer|Non-Small Cell Lung Cancer|Head and Neck Cancer|Ovarian Cancer|Lymphoma|Sarcoma|Bladder Cancer|Melanoma|IDH1 Mutated Solid Tumors|IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting),drug or biologic,Early,21,All,Industry&Combos,0,NA,0,2015,2016,1034,0,Phase 1,1,NA,1,3.044522437723423,"(3,4]"
3668,5850,"study of the safety, tolerability and pharmacokinetics of timp-glia in subjects with celiac disease",Completed,4,1,1,Celiac Disease,drug or biologic,Early,23,All,Industry&Combos,NA,1,0,2018,2018,486,NA,Phase 1,0,safety,0,3.1354942159291497,"(3,4]"
1165,1239,pharmacokinetics and safety of alks 5461 in healthy subjects and subjects with hepatic impairment and normal hepatic function,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2015,2015,214,0,Phase 1,1,safety,1,3.6888794541139363,"(3,4]"
634,661,defined fecal microbiota transplantation for clostridium difficile diarrhea,Enrolling by invitation,3,0,0,Active C. Difficile Colitis,drug or biologic,Early,12,All,AllOther,0,NA,0,2013,2013,3652,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
3977,7532,safety study of hepatitis e vaccine (hev239),Completed,4,0,0,Hepatitis E|Immunisation,drug or biologic,Early,25,All,NIH&Combos,1,0,1,2019,2019,505,1,Phase 1,2,safety,2,3.2188758248682006,"(3,4]"
2158,2599,study of crenolanib with ramucirumab and paclitaxel for advanced esophagogastric adenocarcinoma,Completed,4,0,0,Esophagogastric Adenocarcinoma,drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2017,2017,1188,0,Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
2640,3544,research study of a new medicine (nnc9204-1706) in people with overweight or obesity,Completed,4,0,0,Metabolism and Nutrition Disorder|Obesity,drug or biologic,Early,60,All,Industry&Combos,1,0,0,2018,2018,358,1,Phase 1,4,NA,2,4.0943445622221,"(4,5]"
1947,2281,linaclotide acetate in preventing colorectal cancer in healthy volunteers,Completed,4,0,0,"Colorectal Cancer|Healthy, no Evidence of Disease",drug or biologic,Early,24,All,NIH&Combos,1,0,4,2013,2013,970,1,Phase 1,2,NA,2,3.1780538303479458,"(3,4]"
1938,2265,use of erythropoietin to expand regulatory t cells in autoimmune liver disease,Completed,4,0,0,Autoimmune Hepatitis,drug or biologic,Early,6,All,AllOther,0,NA,4,2019,2019,755,0,Early Phase 1,1,NA,1,1.791759469228055,"(1,2]"
148,148,gastric in vivo study,Terminated,5,0,0,Gastric Cancer,drug or biologic,Early,8,All,AllOther,0,NA,2,2014,2015,151,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
787,824,evaluating safety and efficacy of herbal treatment in ulcerative colitis,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,15,All,AllOther,0,1,0,2015,2014,968,0,Phase 1,1,safety/efficacy,1,2.70805020110221,"(2,3]"
3259,4583,phase 1 study of sf1126 in combination with nivolumab in patients with advanced hepatocellular carcinoma,"Active, not recruiting",1,0,0,Advanced Hepatocellular Carcinoma,drug or biologic,Early,14,All,Industry&Combos,0,NA,0,2017,2017,756,0,Phase 1,1,NA,1,2.6390573296152584,"(2,3]"
522,543,(pm-01) imprime pgg Â® with bth1704 and gemcitabine for advanced pancreatic cancer,Terminated,5,0,0,Pancreatic Cancer,drug or biologic,Early,3,All,Industry&Combos,0,NA,0,2014,2014,243,0,Phase 1,1,NA,1,1.0986122886681098,"(1,2]"
4106,8188,study to evaluate the effect of omeprazole on the pharmacokinetics of spd422 (anagrelide hydrochloride) in healthy adult participants,Completed,4,1,1,Healthy Volunteers,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2019,2019,43,0,Phase 1,1,pharmacokinetics only,1,2.995732273553991,"(2,3]"
2049,2424,pharmacokinetics of dabrafenib in subjects with hepatic impairment,Terminated,5,0,0,Hepatic Impairment,drug or biologic,Early,5,All,Industry&Combos,1,1,4,2016,2016,661,1,Phase 1,0,pharmacokinetics only,0,1.6094379124341003,"(1,2]"
1074,1133,a study of ag-120 (ivosidenib) in subjects with mild or moderate hepatic impairment or normal hepatic function,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,33,All,Industry&Combos,1,1,0,2017,2017,186,1,Phase 1,0,NA,0,3.4965075614664802,"(3,4]"
1304,1393,phase i study of neoadjuvant radiotherapy with 5-fluorouracil for rectal cancer,"Active, not recruiting",1,0,0,Mucinous Adenocarcinoma of the Rectum|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Rectum|Rectal Adenocarcinoma|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer,drug or biologic,Early,14,All,NIH&Combos,0,NA,0,2014,2014,1257,0,Phase 1,1,NA,1,2.6390573296152584,"(2,3]"
3172,4346,efficacy of lidocaine gel enema after endoscopic hemorrhoid band ligation for relief of post procedural pain,Completed,4,0,0,Hemorrhoids,drug or biologic,Early,75,All,AllOther,1,0,4,2019,2018,550,1,Phase 1,3,efficacy,2,4.31748811353631,"(4,5]"
3110,4220,a trial to evaluate the safety and tolerability of a novel medical food for management of iron deficiency anemia,Completed,4,0,0,Iron Deficiency Anemia,other,Others,2,All,AllOther,3,1,4,2017,2014,396,3,Others,0,safety,0,0.6931471805599453,"(0,1]"
3208,4465,stem cell fistula plug in cryptoglandular perianal fistulas (msc-afp),Completed,4,0,0,Perianal Fistula|Cryptoglandular Perianal Fistula,drug or biologic,Early,15,All,AllOther,0,NA,0,2015,2016,1339,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
769,805,gastric gluten-degradation activity of pvp001,Terminated,5,0,0,Digestive System Disease,drug or biologic,Early,43,All,Industry&Combos,3,0,4,2018,2018,257,3,Phase 1,1,NA,1,3.7612001156935624,"(3,4]"
1257,1342,study of the effects of itca 650 on gastric emptying and interaction of itca 650 on 4 commonly studied drugs,Completed,4,0,0,Healthy,drug or biologic,Early,33,All,Industry&Combos,0,NA,4,2015,2015,91,0,Phase 1,1,NA,1,3.4965075614664802,"(3,4]"
639,666,gemcitabine hydrochloride in treating patients with locally advanced pancreatic cancer,Completed,4,0,0,Duct Cell Adenocarcinoma of the Pancreas|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,1,All,NIH&Combos,0,NA,0,2013,2013,942,0,Phase 1,1,NA,1,0,NA
3354,4890,melanoma checkpoint and gut microbiome alteration with microbiome intervention,"Active, not recruiting",1,0,0,Metastatic Melanoma,drug or biologic,Early,14,All,Industry&Combos,1,0,0,2019,2019,1069,1,Phase 1,3,NA,2,2.6390573296152584,"(2,3]"
326,332,evaluation of safety and efficacy of electrochemotherapy in the treatment of pancreatic adenocarcinoma,Completed,4,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,6,All,AllOther,0,NA,0,2015,2015,657,0,Phase 1,1,safety/efficacy,1,1.791759469228055,"(1,2]"
1316,1406,dynamic contrast enhanced computed tomography to assess radiation therapy in liver cancer patients,Recruiting,2,0,0,Liver Cancer,other,Others,15,All,NIH&Combos,0,NA,2,2019,2019,700,0,Others,1,NA,1,2.70805020110221,"(2,3]"
3090,4180,"study of leukocyte interleukin, injection for treatment of perianal warts",Terminated,5,0,0,Perianal Warts,drug or biologic,Early,8,All,Industry&Combos,2,1,4,2017,2015,1157,1,Phase 1,0,NA,0,2.0794415416798357,"(2,3]"
3913,7285,"study to evaluate safety, tolerability, pharmacokinetics, and antiviral activity of voxilaprevir in adults with chronic hepatitis c virus infection",Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,101,All,Industry&Combos,1,0,0,2014,2014,192,1,Phase 1,2,safety,2,4.61512051684126,"(4,5]"
1213,1291,single-dose pharmacokinetics of mk-3866 in participants with hepatic impairment (mk-3866-006),Terminated,5,1,1,Hepatic Insufficiency|Antibacterial Agents,drug or biologic,Early,9,All,Industry&Combos,1,1,0,2017,2017,86,1,Phase 1,0,pharmacokinetics only,0,2.1972245773362196,"(2,3]"
1842,2103,phase 1 study of dmlt id vaccination in healthy adults,Completed,4,0,0,Gastroenteritis Escherichia Coli,drug or biologic,Early,100,All,NIH&Combos,NA,0,1,2015,2016,1432,NA,Phase 1,2,NA,2,4.605170185988092,"(4,5]"
238,241,enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,25,All,Industry&Combos,0,NA,0,2014,2014,938,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
3767,6512,a study of safety of pbcln-003 following antibiotic therapy in subjects with c.difficile-associated diarrhea,Terminated,5,0,0,Clostridium Difficile Diarrhea,drug or biologic,Early,26,All,Industry&Combos,NA,0,0,2019,2018,635,NA,Phase 1,2,safety,2,3.258096538021482,"(3,4]"
277,282,plicated laparoscopic adjustable gastric banding study,Unknown status,8,0,0,Weight Loss,device,Others,100,All,AllOther,0,NA,0,2013,2013,365,0,Others,1,NA,1,4.605170185988092,"(4,5]"
3182,4381,study of hepatitis c treatment during pregnancy,Completed,4,0,0,Hepatitis C|Pregnancy,drug or biologic,Early,9,Female,Industry&Combos,0,NA,0,2016,2016,1250,0,Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
2757,3705,"study of 5-fluorouracil (5-fu), nab Â®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic cancer",Completed,4,0,0,Metastatic Pancreas Adenocarcinoma,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2015,2016,1015,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
584,610,a phase i dual dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer,Suspended,6,0,0,Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy|Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy,drug or biologic,Early,42,All,AllOther,0,NA,0,2014,2014,4171,0,Phase 1,1,NA,1,3.7376696182833684,"(3,4]"
1018,1073,a study of pre-operative cyberknife in patients with potentially resectable pancreas cancer,Unknown status,8,0,0,Pancreas Cancer|Pancreatic Cancer|Adenocarcinoma of the Pancreas|Pancreas Adenocarcinoma|Pancreatic Adenocarcinoma,drug or biologic,Early,15,All,AllOther,0,NA,0,2016,2013,1430,0,Early Phase 1,1,NA,1,2.70805020110221,"(2,3]"
1177,1252,hepatic impairment trial of obeticholic acid,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,32,All,Industry&Combos,0,1,4,2013,2013,122,0,Phase 1,1,NA,1,3.4657359027997265,"(3,4]"
2948,3954,a study of ramucirumab (ly3009806) plus medi4736 in participants with advanced gastrointestinal or thoracic malignancies,Completed,4,0,0,Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Non-Small Cell Lung Cancer|Hepatocellular Carcinoma,drug or biologic,Early,85,All,Industry&Combos,1,1,0,2015,2016,767,1,Phase 1,0,NA,0,4.442651256490317,"(4,5]"
3077,4150,stp206 for the prevention of necrotizing enterocolitis (nec),Completed,4,1,1,Necrotizing Enterocolitis,drug or biologic,Early,103,All,Industry&Combos,1,0,1,2013,2014,1490,1,Phase 1,4,NA,2,4.634728988229636,"(4,5]"
1191,1268,duvelisib in hepatically impaired subjects compared to healthy subjects,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,24,All,Industry&Combos,1,1,4,2014,2014,122,1,Phase 1,0,NA,0,3.1780538303479458,"(3,4]"
2548,3425,study of dkn-01 and gemcitabine/cisplatin in patients with carcinoma to primary to the intra- or extra-hepatic biliary system or gallbladder,Completed,4,0,0,Carcinoma of Intrahepatic and Extra-hepatic Biliary System|Carcinoma of Gallbladder|Bile Duct Cancer|Cholangiocarcinoma,drug or biologic,Early,51,All,Industry&Combos,1,1,0,2015,2015,1126,1,Phase 1,0,NA,0,3.9318256327243257,"(3,4]"
2050,2428,peppermint oil pharmacokinetics/dynamics and novel biological signatures in children with functional abdominal pain,Completed,4,0,0,Abdominal Pain,drug or biologic,Early,30,All,AllOther,0,NA,0,2017,2017,529,0,Phase 1,1,pharmacokinetics only,1,3.4011973816621555,"(3,4]"
1151,1223,the influence of hepatic insufficiency on the pharmacokinetics of elbasvir (mk-8742) (mk-8742-009),Completed,4,1,1,Hepatic Insufficiency,drug or biologic,Early,31,All,Industry&Combos,1,1,0,2013,2013,532,1,Phase 1,0,pharmacokinetics only,0,3.4339872044851463,"(3,4]"
4066,7786,prilosec bioequivalence study in healthy volunteers,Completed,4,0,0,"Bioequivalence, AUC, Cmax, Pharmacokinetics",drug or biologic,Early,54,All,Industry&Combos,3,0,4,2013,2013,92,3,Phase 1,0,bio-equivalence,0,3.9889840465642745,"(3,4]"
624,651,dynamic contrast enhanced mri in patients with advanced breast or pancreatic cancer with metastases to the liver or lung,Withdrawn,7,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Liver Metastases|Lung Metastases|Recurrent Breast Cancer|Recurrent Pancreatic Cancer|Stage IV Breast Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,NA,All,NIH&Combos,0,NA,2,2012,2014,731,0,Phase 1,1,NA,1,NA,NA
3766,6511,dose escalating study of intramuscular invaplexar-detox,Completed,4,0,0,Diarrhea,drug or biologic,Early,60,All,AllOther,NA,0,1,2019,2019,416,NA,Phase 1,4,NA,2,4.0943445622221,"(4,5]"
3956,7381,midodrine in hepatopulmonary syndrome,Completed,4,0,0,Hepatopulmonary Syndrome (HPS),drug or biologic,Early,10,All,AllOther,0,NA,0,2018,2018,852,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
3120,4234,study of oraxol and pembrolizumab in subjects with advanced solid tumors,Recruiting,2,0,0,Solid Tumor,drug or biologic,Early,114,All,Industry&Combos,1,1,0,2018,2018,1617,1,Phase 1,0,NA,0,4.736198448394496,"(4,5]"
1756,1966,"phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of mgl-3196 in subjects with varying degrees of hepatic impairment and healthy matched control subjects",Recruiting,2,0,0,"Hepatic Impairment|NASH - Nonalcoholic Steatohepatitis|Cirrhosis, Liver",drug or biologic,Early,90,All,Industry&Combos,1,1,0,2020,2018,799,1,Phase 1,0,safety,0,4.499809670330265,"(4,5]"
1958,2300,role of the foregut in nutrient metabolism in lean and obese humans,Enrolling by invitation,3,0,0,Obesity,drug or biologic,Early,45,All,NIH&Combos,3,0,4,2015,2015,2039,3,Phase 1,1,NA,1,3.8066624897703196,"(3,4]"
2107,2518,sorafenib and bavituximab plus sbrt in unresectable hepatocellular carcinoma,Withdrawn,7,0,0,HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2016,2017,567,0,Phase 1,1,NA,1,NA,NA
866,908,"a study to assess the effects of hepatic impairment on the pharmacokinetics, safety, and tolerability of intranasally administered esketamine",Completed,4,0,0,Hepatic Impairment|Normal Hepatic Function,drug or biologic,Early,24,All,Industry&Combos,1,1,0,2015,2015,455,1,Phase 1,0,safety,0,3.1780538303479458,"(3,4]"
1220,1298,safety study of octreotide injection to prevent gi bleeding in patients with left ventricular assist device (lvad),Completed,4,1,1,Gastrointestinal Bleeding,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2012,2013,607,0,Phase 1,1,safety,1,2.302585092994046,"(2,3]"
3770,6519,dose escalating study of a prototype cs6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic escherichia coli (etec),Completed,4,1,1,Diarrhea,drug or biologic,Early,50,All,AllOther,NA,1,1,2018,2018,434,NA,Phase 1,0,NA,0,3.912023005428146,"(3,4]"
1851,2123,study of sc-fos for pouchitis prevention,Completed,4,0,0,Pouchitis,drug or biologic,Early,13,All,AllOther,1,0,1,2014,2014,1218,1,Phase 1,3,NA,2,2.5649493574615367,"(2,3]"
672,700,study of lonsurf in combination with gemcitabine and nab-paclitaxel in patients with advanced (pdac),Recruiting,2,0,0,Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,18,All,Industry&Combos,NA,NA,0,2019,2019,869,NA,Phase 1,0,NA,0,2.8903717578961645,"(2,3]"
1706,1890,a pharmacokinetic study of omaveloxolone in subjects with hepatic impairment and normal hepatic function,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,48,All,Industry&Combos,1,1,0,2019,2019,192,1,Phase 1,0,NA,0,3.871201010907891,"(3,4]"
405,416,phase i trial of lcl161 and gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer,Unknown status,8,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2013,2014,731,0,Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
4138,8983,"a safety, tolerability, and pharmacokinetics study of onartuzumab as single agent or in combination with sorafenib in participants with advanced hepatocellular carcinoma",Completed,4,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,9,All,Industry&Combos,1,NA,0,2013,2013,546,1,Phase 1,0,safety,0,2.1972245773362196,"(2,3]"
2426,3146,pilot trial of antibiotics versus surgery for treating acute appendicitis,Completed,4,0,0,Acute Uncomplicated Appendicitis,drug or biologic,Early,30,All,NIH&Combos,1,0,0,2015,2015,214,1,Early Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
337,343,high dose rate brachyablation of primary liver lesions,Terminated,5,0,0,Liver Cancer,other,Others,1,All,AllOther,0,NA,0,2016,2017,858,0,Others,1,NA,1,0,NA
194,196,"tolfenamic acid, gemcitabine and radiation for locally advanced or metastatic pancreatic cancer requiring radiation",Withdrawn,7,0,0,Pancreatic Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2014,2014,1249,0,Phase 1,1,NA,1,NA,NA
3342,4825,quilt-2.025 nant neoepitope yeast vaccine (ye-neo-001): adjuvant immunotherapy using a personalized neoepitope yeast-based vaccine to induce t-cell responses in subjects w/ previously treated cancers.,Unknown status,8,0,0,Colorectal Cancer|Breast Cancer|Head and Neck Squamous Cell Carcinoma|Melanoma|Non Small Cell Lung Cancer|Pancreatic Cancer|Liver Cancer,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2018,2018,507,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
2561,3440,dose escalation trial of endoluminal high-dose-rate brachytherapy with concurrent chemotherapy for rectal or anal cancer in patients with recurrent disease or undergoing non-operative management,Recruiting,2,0,0,Rectal or Anal Cancer,drug or biologic,Early,24,All,AllOther,0,NA,0,2014,2014,2922,0,Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
1027,1082,study of sildenafil as a therapy for fatigue in pancreatic cancer,Withdrawn,7,0,0,Pancreatic Cancer|Cholangiocarcinoma,drug or biologic,Early,NA,All,AllOther,1,0,4,2014,2014,1157,1,Phase 1,4,NA,2,NA,NA
3207,4462,effect of acetyl-l-carnitine on chronic pancreatitis,Terminated,5,0,0,Chronic Pancreatitis,other,Others,3,All,AllOther,0,NA,4,2015,2015,427,0,Others,1,NA,1,1.0986122886681098,"(1,2]"
1638,1801,study of single-dose ds-3201b in participants with hepatic impairment,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,28,All,Industry&Combos,1,1,0,2020,2019,460,1,Phase 1,0,NA,0,3.332204510175204,"(3,4]"
336,342,biological effect of warfarin on pancreatic cancer,Withdrawn,7,0,0,Pancreatic Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2018,2019,748,0,Early Phase 1,1,NA,1,NA,NA
2669,3579,a research study of how nnc0174-0833 taken with semaglutide works in people who are overweight or obese,Completed,4,0,0,Obesity|Overweight,drug or biologic,Early,96,All,Industry&Combos,1,0,0,2018,2018,688,1,Phase 1,4,NA,2,4.564348191467836,"(4,5]"
372,381,epidural analgesia use in pancreatic resections,Completed,4,0,0,Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer|Pancreas Neoplasms|Pancreatic Cancer,drug or biologic,Early,23,All,AllOther,1,0,4,2016,2016,1340,1,Phase 1,1,NA,1,3.1354942159291497,"(3,4]"
1783,2008,dose-optimization trial of vxa-g1.1-nn in healthy volunteers,Completed,4,0,0,Norovirus Gastroenteritis,drug or biologic,Early,66,All,Industry&Combos,1,0,1,2017,2017,85,1,Phase 1,0,NA,0,4.189654742026425,"(4,5]"
2288,2867,a study to assess the pharmacokinetics of enasidenib (cc-90007) in subjects with moderate and severe hepatic impairment.,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,31,All,Industry&Combos,0,NA,0,2017,2017,400,0,Phase 1,1,pharmacokinetics only,1,3.4339872044851463,"(3,4]"
1960,2306,pediatric msc-afp sub-study for crohn's fistula,Recruiting,2,0,0,Fistula in Ano|Crohn Disease,drug or biologic,Early,5,All,AllOther,0,NA,0,2018,2018,1316,0,Phase 1,1,NA,1,1.6094379124341003,"(1,2]"
2099,2507,study to evaluate the pharmacokinetics and safety of gsk2336805 in subjects with hepatic impairment and healthy matched control subjects,Completed,4,0,0,Hepatitis C,drug or biologic,Early,31,All,Industry&Combos,1,1,0,2013,2013,296,1,Phase 1,0,safety,0,3.4339872044851463,"(3,4]"
415,426,escalating doses of oxaliplatin and hyperthermic intraperitoneal chemotherapy (hipec) in children and adolescents with extensive colon carcinoma,Completed,4,0,0,Colorectal Cancer,drug or biologic,Early,1,All,AllOther,0,NA,0,2014,2014,1500,0,Phase 1,1,NA,1,0,NA
308,313,fecal microbiota transplantation (fmt) in the management of ulcerative colitis (uc),Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,20,All,AllOther,0,NA,0,2015,2016,91,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
3496,5300,cabozantinib and panitumumab to treat kras wild-type metastatic colorectal cancer,Completed,4,0,0,Colorectal Cancer,drug or biologic,Early,29,All,Industry&Combos,1,1,0,2013,2014,1590,1,Phase 1,0,NA,0,3.367295829986474,"(3,4]"
2555,3434,study of immunopet imaging of pd-l1 in tumors using 89zr-dfo-regn3504 in participants with advanced pd-l1 positive malignancies,Recruiting,2,0,0,Advanced PD-L1 Positive Malignancies|Hepatocellular Carcinoma|Gastroesophageal Junction Adenocarcinoma|Gastric Cancer,drug or biologic,Early,28,All,Industry&Combos,NA,0,4,2018,2019,1136,NA,Phase 1,0,NA,0,3.332204510175204,"(3,4]"
2218,2729,probiotic supplementation in breastfed newborn infants,Withdrawn,7,0,0,Atopic Dermatitis|Food Allergies,drug or biologic,Early,NA,All,AllOther,1,0,1,2014,2015,823,1,Phase 1,4,NA,2,NA,NA
3503,5311,safety of labeled dendritic cell (dc) vaccines and feasibility of tracking by magnetic resonance imaging (mri),Completed,4,0,0,"Colorectal Neoplasms|Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal",drug or biologic,Early,6,All,NIH&Combos,1,0,0,2012,2013,455,1,Phase 1,0,safety,0,1.791759469228055,"(1,2]"
485,503,neoadjuvant chemotherapy followed by radiation therapy and gemcitabine/sorafenib/vorinostat in pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Recurrent Pancreatic Carcinoma,drug or biologic,Early,23,All,NIH&Combos,0,NA,0,2015,2015,2801,0,Phase 1,1,NA,1,3.1354942159291497,"(3,4]"
106,106,borderline pancreas study: folfirinox +sbrt,Completed,4,0,0,Resectable Pancreatic Cancer,drug or biologic,Early,8,All,AllOther,0,NA,0,2013,2014,1671,0,Early Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
790,827,decitabine and gemcitabine for pancreatic cancer and sarcoma,"Active, not recruiting",1,0,0,Pancreatic Ductal Adenocarcinoma|Sarcoma,drug or biologic,Early,36,All,AllOther,0,NA,0,2016,2016,1095,0,Phase 1,1,NA,1,3.58351893845611,"(3,4]"
2065,2457,assessment and management of chronic dyspepsia in eastern uganda,Completed,4,0,0,Helicobacter Pylori Infection|Dyspepsia,drug or biologic,Early,376,All,AllOther,1,1,0,2020,2018,242,1,Early Phase 1,0,NA,0,5.929589143389895,"(5,6]"
1102,1166,"dovitinib lactate, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation in treating patients with advanced solid tumors or pancreatic cancer",Withdrawn,7,0,0,"Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",drug or biologic,Early,NA,All,IndustryNIHPartnership,0,NA,0,2014,2015,245,0,Phase 1,1,NA,1,NA,NA
2941,3943,a study to evaluate the effect of ustekinumab on cytochrome p450 enzyme activities following induction and maintenance dosing in participants with active crohn's disease or ulcerative colitis,Recruiting,2,0,0,Crohn Disease|Ulcerative Colitis,drug or biologic,Early,57,All,Industry&Combos,1,1,4,2017,2018,1565,1,Phase 1,0,NA,0,4.04305126783455,"(4,5]"
4036,7623,"food effect of a fixed dose combination of daclatasvir, asunaprevir and bms-791325",Completed,4,0,0,Hepatitis C,drug or biologic,Early,24,All,Industry&Combos,3,0,NA,2014,2014,30,3,Phase 1,0,NA,0,3.1780538303479458,"(3,4]"
392,403,study of pembrolizumab with reolysin Â® and chemotherapy in patients with advanced pancreatic adenocarcinoma,Completed,4,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,11,All,Industry&Combos,0,NA,0,2015,2015,821,0,Phase 1,1,NA,1,2.3978952727983707,"(2,3]"
6,6,selective transvenous chemoembolization of primary pancreatic tumors,Withdrawn,7,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,NA,All,AllOther,0,NA,0,2019,2019,701,0,Phase 1,1,NA,1,NA,NA
3155,4300,study of cobimetinib in combination with atezolizumab and bevacizumab in participants with gastrointestinal and other tumors,Completed,4,0,0,Colorectal Cancer,drug or biologic,Early,51,All,Industry&Combos,NA,1,0,2016,2016,998,NA,Phase 1,0,NA,0,3.9318256327243257,"(3,4]"
299,304,pilot study of autologous t-cells in patients with metastatic pancreatic cancer,Terminated,5,0,0,Pancreatic Cancer,drug or biologic,Early,4,All,AllOther,0,NA,0,2015,2015,854,0,Phase 1,1,NA,1,1.3862943611198906,"(1,2]"
2219,2730,pembrolizumab plus y90 radioembolization in hcc subjects,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2017,2017,1556,0,Early Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
1185,1262,pharmacokinetics of delafloxacin in subjects with and without hepatic impairment,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2014,2014,153,0,Phase 1,1,pharmacokinetics only,1,3.6888794541139363,"(3,4]"
3783,6576,a study of anti-pd-l1 checkpoint antibody (ly3300054) alone and in combination in participants with advanced refractory solid tumors,"Active, not recruiting",1,0,0,Solid Tumor|Microsatellite Instability-High (MSI-H) Solid Tumors|Cutaneous Melanoma|Pancreatic Cancer|Breast Cancer (HR+HER2-),drug or biologic,Early,215,All,Industry&Combos,1,1,0,2016,2016,1423,1,Phase 1,0,NA,0,5.3706380281276624,"(5,6]"
1839,2096,dolcanatide in preventing colorectal cancer in healthy volunteers,Completed,4,1,1,Colorectal Carcinoma,drug or biologic,Early,27,All,NIH&Combos,1,0,1,2017,2018,159,1,Phase 1,2,NA,2,3.295836866004329,"(3,4]"
2022,2388,tgr-1202 alone and in combination with either nab-paclitaxel + gemcitabine or with folfox in patients with select relapsed or refractory solid tumors,Completed,4,0,0,Pancreatic Cancer|Colorectal Cancer|Rectal Cancer|Gastric Cancer|Esophageal Cancer|Gastrointestinal Stromal Tumor (GIST),drug or biologic,Early,66,All,Industry&Combos,0,1,0,2015,2015,1055,0,Phase 1,1,NA,1,4.189654742026425,"(4,5]"
441,453,gemcitabine and pulse dose erlotinib in second line treatment of advanced pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2014,2013,2621,0,Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
793,830,"mesothelin-targeted immunotoxin lmb-100 in combination with tofacitinib in persons with previously treated pancreatic adenocarcinoma, cholangiocarcinoma and other mesothelin expressing solid tumors",Recruiting,2,0,0,"Neoplasms With Mesothelin Expression|Epithelioid Mesothelioma|Cholangiocarcinoma, Extrahepatic|Adenocarcinoma, Pancreatic",drug or biologic,Early,45,All,NIH&Combos,NA,1,0,2019,2019,825,NA,Phase 1,0,NA,0,3.8066624897703196,"(3,4]"
1930,2253,"mek inhibitor mek162 in combination with leucovorin calcium, fluorouracil, and oxaliplatin in treating patients with advanced metastatic colorectal cancer",Completed,4,0,0,Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,drug or biologic,Early,26,All,IndustryNIHPartnership,1,1,0,2014,2014,1328,1,Phase 1,0,NA,0,3.258096538021482,"(3,4]"
3161,4319,orthostatic intolerance after bariatric surgery,"Active, not recruiting",1,0,0,Orthostatic Intolerance,drug or biologic,Early,16,All,AllOther,1,0,0,2019,2018,1065,1,Phase 1,3,NA,2,2.772588722239781,"(2,3]"
2165,2611,phase i trial hipec with nal-irinotecan,Recruiting,2,0,0,Peritoneal Cancer|Pseudomyxoma Peritonei|Mucinous Adenocarcinoma|Mucinous Tumor|Colorectal Cancer|Gastric Cancer|Primary Peritoneal Carcinoma|Mesothelioma,drug or biologic,Early,15,All,Industry&Combos,0,NA,0,2019,2019,679,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
618,645,bvd-523 plus nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer,Terminated,5,1,1,Pancreatic Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer,drug or biologic,Early,18,All,IndustryNIHPartnership,1,1,0,2015,2016,1024,1,Phase 1,0,NA,0,2.8903717578961645,"(2,3]"
1641,1805,talimogene laherparepvec for the treatment of peritoneal surface malignancies,Recruiting,2,0,0,"Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely Resected",drug or biologic,Early,24,All,AllOther,0,NA,0,2018,2019,846,0,Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
652,679,"a pilot, prospective, non-randomized evaluation of the safety of anakinra plus standard chemotherapy",Unknown status,8,0,0,Pancreas Cancer,drug or biologic,Early,13,All,AllOther,0,NA,0,2013,2013,1644,0,Phase 1,1,safety,1,2.5649493574615367,"(2,3]"
2490,3288,fresh versus frozen stool for fecal transplant in children,Completed,4,0,0,Clostridium Difficile,drug or biologic,Early,28,All,AllOther,1,0,0,2015,2015,1433,1,Phase 1,0,NA,0,3.332204510175204,"(3,4]"
137,137,use of high resolution colonic manometry in studying motility,Unknown status,8,0,0,Gastrointestinal Dysfunction,drug or biologic,Early,16,All,AllOther,0,1,NA,2015,2015,792,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
1565,1706,vx15/2503 and immunotherapy in resectable pancreatic and colorectal cancer,Recruiting,2,0,0,Colon Carcinoma Metastatic in the Liver|Colorectal Adenocarcinoma|Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma|Stage I Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,drug or biologic,Early,32,All,Industry&Combos,1,0,0,2017,2017,1842,1,Phase 1,0,NA,0,3.4657359027997265,"(3,4]"
1015,1070,radiation dose in humans from orally administered tc99m-heparin,Completed,4,0,0,Eosinophilic Esophagitis,drug or biologic,Early,8,All,AllOther,1,1,4,2019,2016,1523,1,Early Phase 1,0,NA,0,2.0794415416798357,"(2,3]"
2998,4021,td-1473 for active ulcerative colitis (uc),Completed,4,0,0,"Ulcerative Colitis, Active Moderate|Ulcerative Colitis, Active Severe",drug or biologic,Early,40,All,Industry&Combos,1,0,0,2016,2016,542,1,Phase 1,4,NA,2,3.6888794541139363,"(3,4]"
3452,5243,glutamine pet imaging colorectal cancer,"Active, not recruiting",1,0,0,RAS Wild Type|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,drug or biologic,Early,30,All,NIH&Combos,0,NA,2,2017,2018,1471,0,Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
1543,1680,er stress in nafld,Withdrawn,7,0,0,Obesity|NAFLD,drug or biologic,Early,NA,Female,AllOther,1,0,4,2013,2013,1461,1,Early Phase 1,1,NA,1,NA,NA
369,377,phase i study of ad5-hgcc (human guanylyl cyclase c)-padre in stage i/ii colon cancer,Completed,4,0,0,Colon Cancer,drug or biologic,Early,10,All,AllOther,0,NA,1,2013,2013,245,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
1162,1236,single-dose pk and safety study of gbt440 in subjects with hepatic impairment,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,29,All,Industry&Combos,1,1,4,2017,2017,348,1,Phase 1,0,safety,0,3.367295829986474,"(3,4]"
1873,2166,optimal human dose for gii.2 norovirus (snow mountain) challenge studies,Completed,4,0,0,Gastroenteritis Norovirus,drug or biologic,Early,44,All,NIH&Combos,NA,0,4,2015,2015,1126,NA,Phase 1,2,NA,2,3.784189633918261,"(3,4]"
3166,4329,"open-label, dose-finding study evaluating safety and pk of fpa144 in patients with advanced solid tumors",Completed,4,1,1,Advanced Solid Tumors|Gastric Cancer|Transitional Cell Carcinoma of the Bladder,drug or biologic,Early,79,All,Industry&Combos,1,1,0,2014,2014,1580,1,Phase 1,0,safety,0,4.3694478524670215,"(4,5]"
3566,5504,study to evaluate the safety and tolerability of andecaliximab as monotherapy and in combination with chemotherapy in participants with advanced solid tumors,Completed,4,1,1,Pancreatic Cancer|Non-small Cell Lung Cancer|Esophagogastric Cancer|Colorectal Cancer|Breast Cancer,drug or biologic,Early,236,All,Industry&Combos,NA,1,0,2013,2013,2216,NA,Phase 1,0,safety,0,5.4638318050256105,"(5,6]"
185,186,novel supplement-based therapy for the treatment of small intestinal bacterial overgrowth,Withdrawn,7,0,0,Small Intestinal Bacterial Overgrowth,other,Others,NA,All,Industry&Combos,0,NA,0,2018,2017,419,0,Others,1,NA,1,NA,NA
526,547,ropidoxuridine in treating patients with advanced gastrointestinal cancer undergoing radiation therapy,"Active, not recruiting",1,0,0,Advanced Bile Duct Carcinoma|Stage II Esophageal Cancer AJCC v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Esophageal Cancer AJCC v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIB Pancreatic Cancer AJCC v6 and v7|Stage III Colon Cancer AJCC v7|Stage III Esophageal Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage III Liver Cancer|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Rectal Cancer AJCC v7|Stage III Small Intestinal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIA Gastric Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIA Small Intestinal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIB Gastric Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIB Small Intestinal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7|Stage IIIC Gastric Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Stage IV Liver Cancer|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Rectal Cancer AJCC v7|Stage IV Small Intestinal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Liver Cancer|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Liver Cancer|Stage IVB Rectal Cancer AJCC v7,drug or biologic,Early,19,All,NIH&Combos,0,NA,0,2015,2016,1011,0,Phase 1,1,NA,1,2.9444389791664403,"(2,3]"
455,470,liposomal irinotecan plus 5-fu / lv combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy,"Active, not recruiting",1,0,0,Pancreatic Cancer|Pancreas Cancer|Cancer of the Pancreas,drug or biologic,Early,20,All,Industry&Combos,1,1,0,2019,2019,782,1,Phase 1,0,NA,0,2.995732273553991,"(2,3]"
1172,1247,pomalidomide in hereditary hemorrhagic telangiectasia and transfusion-dependent vascular ectasia: a phase i study,Completed,4,0,0,Hereditary Hemorrhagic Telangiectasia|Idiopathic Vascular Ectasia,drug or biologic,Early,9,All,AllOther,0,NA,0,2014,2015,1586,0,Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
3683,6055,"a randomized, double-blind, placebo-controlled dose-escalation study to determine the safety and efficacy of intravenous infusion of human placenta-derived cells (pda001) for the treatment of crohn's disease",Completed,4,0,0,Crohns Disease,drug or biologic,Early,14,All,Industry&Combos,1,0,0,2013,2013,610,1,Phase 1,4,safety/efficacy,2,2.6390573296152584,"(2,3]"
1717,1910,a trial to evaluate the pharmacokinetics of abl001 in healthy and hepatic impaired subjects,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,32,All,Industry&Combos,0,NA,0,2016,2016,443,0,Phase 1,1,pharmacokinetics only,1,3.4657359027997265,"(3,4]"
1290,1377,study of 177lu human monoclonal antibody 5b1 (mvt-1075) in combination with a blocking dose of mvt-5873 as radioimmunotherapy,Suspended,6,0,0,Pancreatic Carcinoma|Tumors That Express CA 19-9,drug or biologic,Early,7,All,Industry&Combos,NA,1,0,2017,2017,1644,NA,Phase 1,0,NA,0,1.9459101490553132,"(1,2]"
4174,9165,"dose-ranging study to assess the safety, pk and initial antiviral efficacy of nvr 3-778 in chronic hbv patients",Completed,4,0,0,Chronic Hepatitis B,drug or biologic,Early,58,All,Industry&Combos,0,0,0,2015,2015,473,0,Phase 1,1,safety/efficacy,1,4.060443010546419,"(4,5]"
538,560,study of neo-adjuvant ro7009789 alone or neo-adjuvant ro7009789 plus nab-paclitaxel and gemcitabine followed by adjuvant ro7009789 plus nab-paclitaxel and gemcitabine for patients with newly diagnosed resectable pancreatic carcinoma,Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,10,All,AllOther,1,NA,0,2015,2015,1127,1,Phase 1,NA,NA,NA,2.302585092994046,"(2,3]"
974,1027,a study to evaluate bms-986165 tablet formulation relative to bms-986165 capsule formulation and the effect of a high-fat/ high-calorie meal and increased gastric ph on the bms-986165 tablet formulation,Completed,4,0,0,Systemic Lupus Erythematosus|Arthritic Psoriasis|Psoriasis|Inflammatory Bowel Diseases,drug or biologic,Early,49,All,Industry&Combos,3,0,0,2017,2017,52,3,Phase 1,0,NA,0,3.8918202981106265,"(3,4]"
4110,8207,"a study to evaluate the one-way interaction of calcium carbonate, omeprazole, or rifampin on acp-196",Completed,4,0,0,Healthy Participants,drug or biologic,Early,72,All,Industry&Combos,1,1,0,2021,2014,25,1,Phase 1,0,NA,0,4.276666119016055,"(4,5]"
2388,3066,safety and tolerability study of shp626 in overweight and obese adults,Completed,4,1,1,Non-Alcoholic Steatohepatitis,drug or biologic,Early,84,All,Industry&Combos,1,0,0,2014,2015,151,1,Phase 1,4,safety,2,4.430816798843313,"(4,5]"
750,786,radiofrequency ablation for liver abscesses from chronic granulomatous disease,Withdrawn,7,0,0,Chronic Granulomatous Diseases (CGD) and Liver Lesions,device,Others,NA,All,NIH&Combos,0,NA,0,2013,2013,2512,0,Others,1,NA,1,NA,NA
644,671,study of onivyde and 5-fu in combination with xilonix for pancreatic cancer with cachexia,Completed,4,0,0,Pancreatic Cancer|Cachexia|Weight Loss,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2017,2017,766,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
3435,5226,dc vaccine in colorectal cancer,Recruiting,2,0,0,Colorectal Cancer,drug or biologic,Early,12,All,AllOther,0,NA,0,2018,2019,934,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
4121,8836,study to evaluate the pharmacokinetics of velpatasvir in participants with normal renal function and severe renal impairment,Completed,4,1,1,Hepatitis C Virus,drug or biologic,Early,19,All,Industry&Combos,1,1,0,2013,2013,175,1,Phase 1,0,pharmacokinetics only,0,2.9444389791664403,"(2,3]"
1068,1125,a study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in subjects with pancreatic cancer,Completed,4,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,22,All,AllOther,1,0,0,2014,2014,1332,1,Phase 1,0,NA,0,3.091042453358316,"(3,4]"
1239,1322,a study to evaluate fecal microbiota transplantation engraftment in ibs,Completed,4,0,0,Irritable Bowel Syndrome,drug or biologic,Early,80,All,Industry&Combos,1,0,0,2016,2016,826,1,Phase 1,2,NA,2,4.382026634673881,"(4,5]"
3472,5275,a study of enhancing response to mk-3475 in advanced colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Cancer,drug or biologic,Early,27,All,Industry&Combos,1,0,0,2015,2016,2143,1,Phase 1,4,NA,2,3.295836866004329,"(3,4]"
359,367,the effect of therapeutic fecal transplant on the gut microbiome in children with ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Early,101,All,AllOther,1,0,0,2014,2016,1826,1,Phase 1,4,NA,2,4.61512051684126,"(4,5]"
48,48,examination of the metabolic effects of direct bile salt delivery to the ileum in humans,Terminated,5,0,0,Glucose Intolerance|Gastric Bypass Surgery,drug or biologic,Early,2,All,AllOther,3,0,4,2017,2018,820,3,Phase 1,1,NA,1,0.6931471805599453,"(0,1]"
4041,7637,japanese bridging study conducted in the united states,Withdrawn,7,0,0,Hepatitis C Virus,drug or biologic,Early,NA,All,Industry&Combos,1,0,NA,2009,2014,123,1,Phase 1,3,NA,2,NA,NA
478,496,byl719 in combination with gemcitabine and (nab)-paclitaxel in locally advanced and metastatic pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,15,All,Industry&Combos,0,NA,0,2014,2014,763,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
78,78,study of hyperthermic intraperitoneal chemoperfusion (hipec) in patients with gastric adenocarcinoma and carcinomatosis or positive cytology,"Active, not recruiting",1,0,0,Diseases of Oesophagus Stomach and Duodenum,drug or biologic,Early,29,All,AllOther,0,NA,0,2017,2017,1646,0,Phase 1,1,NA,1,3.367295829986474,"(3,4]"
362,370,the effect of sucralfate slurry in patients with eosinophilic esophagitis,Completed,4,0,0,Eosinophilic Esophagitis,drug or biologic,Early,3,All,AllOther,0,1,0,2015,2015,700,0,Early Phase 1,1,NA,1,1.0986122886681098,"(1,2]"
1161,1235,concurrent chemoradiation + 5-fu + mitomycin-c in anal carcinoma,Unknown status,8,0,0,Carcinoma of the Anal Canal,drug or biologic,Early,25,All,NIH&Combos,0,NA,0,2013,2013,1461,0,Early Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
1795,2028,the effects of bariatric surgeries on glucose metabolism,Recruiting,2,0,0,Post Bariatric Surgery|Gastric Bypass|Sleeve Gastrectomy|Hypoglycemia After Gastric Bypass,drug or biologic,Early,200,All,NIH&Combos,3,0,4,2016,2015,2557,3,Early Phase 1,1,NA,1,5.298317366548036,"(5,6]"
3974,7526,safety and efficacy of a hepatitis b vaccine in immunosuppressed patients,Recruiting,2,0,0,Hepatitis B,drug or biologic,Early,18,All,AllOther,0,NA,4,2019,2019,791,0,Phase 1,1,safety/efficacy,1,2.8903717578961645,"(2,3]"
3131,4255,glypican 3-specific chimeric antigen receptor expressing t cells for hepatocellular carcinoma (glycar),Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Early,14,All,AllOther,0,NA,0,2016,2019,979,0,Phase 1,1,NA,1,2.6390573296152584,"(2,3]"
1181,1258,"a dose-response of the effects of exendin-9,39 on gi symptoms and food intake",Completed,4,0,0,Obesity|Diabetes|Roux-en-Y Gastric Bypass,drug or biologic,Early,3,All,NIH&Combos,3,0,4,2014,2014,670,3,Phase 1,0,NA,0,1.0986122886681098,"(1,2]"
2646,3551,phase 1b study of ccx872-b in patients with pancreatic adenocarcinoma,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,54,All,Industry&Combos,0,NA,0,2015,2015,1795,0,Phase 1,1,NA,1,3.9889840465642745,"(3,4]"
1599,1749,impact of rifaximin therapy on intestinal byproducts in end-stage renal disease,Withdrawn,7,0,0,End Stage Renal Disease,drug or biologic,Early,NA,All,AllOther,0,NA,0,2016,2016,1152,0,Early Phase 1,1,NA,1,NA,NA
690,721,"study of gemcitabine, nab-paclitaxel, and ficlatuzumab (av-299) in patients with advanced pancreatic cancer","Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,26,All,Industry&Combos,0,NA,0,2017,2018,997,0,Phase 1,1,NA,1,3.258096538021482,"(3,4]"
3717,6215,"a randomized, double-blind, study to explore the effect of ged-0301 in subjects with active crohn's disease",Completed,4,0,0,Crohn Disease,drug or biologic,Early,64,All,Industry&Combos,1,0,0,2015,2015,517,1,Phase 1,4,NA,2,4.1588830833596715,"(4,5]"
2226,2741,dose escalation study of omp-54f28 in combination with nab-paclitaxel and gemcitabine in patients with previously untreated stage iv pancreatic cancer,Completed,4,0,0,Pancreatic Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,26,All,Industry&Combos,0,NA,0,2014,2013,1322,0,Phase 1,1,NA,1,3.258096538021482,"(3,4]"
1534,1666,nivolumab with or without ipilimumab in treating patients with recurrent or high grade gynecologic cancer with metastatic peritoneal carcinomatosis,Recruiting,2,0,0,Malignant Peritoneal Neoplasm|Malignant Retroperitoneal Neoplasm|Peritoneal Carcinomatosis|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Cervical Carcinoma|Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IV Cervical Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8,drug or biologic,Early,48,Female,NIH&Combos,1,1,0,2018,2018,833,1,Phase 1,0,NA,0,3.871201010907891,"(3,4]"
1374,1473,ferumoxytol-enhanced mri in imaging lymph nodes in patients with stage iib-iiic esophageal cancer,Recruiting,2,0,0,Stage IIB Esophageal Cancer AJCC v7|Stage III Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7,drug or biologic,Early,7,All,AllOther,0,NA,2,2016,2018,1556,0,Early Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
1874,2167,phase i study to determine the optimal human challenge dose for a norovirus gii.4 challenge stock (cin-1),Withdrawn,7,0,0,Gastroenteritis Norovirus,drug or biologic,Early,NA,All,NIH&Combos,1,0,NA,2015,2015,122,1,Phase 1,2,NA,2,NA,NA
1025,1080,p53/p16-independent epigenetic therapy with oral decitabine/tetrahydrouridine for pancreatic cancer,Completed,4,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,13,All,AllOther,0,NA,0,2016,2016,309,0,Early Phase 1,1,NA,1,2.5649493574615367,"(2,3]"
1385,1485,"apn401 in treating patients with recurrent or metastatic pancreatic cancer, colorectal cancer, or other solid tumors that cannot be removed by surgery","Active, not recruiting",1,0,0,Metastatic Malignant Neoplasm in the Brain|Metastatic Solid Neoplasm|Recurrent Colorectal Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Solid Neoplasm|Stage IV Colorectal Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Pancreatic Cancer|Unresectable Solid Neoplasm,drug or biologic,Early,11,All,NIH&Combos,0,NA,0,2017,2017,824,0,Phase 1,1,NA,1,2.3978952727983707,"(2,3]"
3874,7133,study of pembrolizumab with pemetrexed and oxaliplatin in chemo-refractory metastatic colorectal cancer patients,Recruiting,2,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,33,All,Industry&Combos,1,1,0,2018,2019,901,1,Phase 1,0,NA,0,3.4965075614664802,"(3,4]"
3215,4491,a safety and tolerability study of incagn02390 in select advanced malignancies,"Active, not recruiting",1,0,0,Cervical Cancer|Gastric Cancer|Stomach Cancer|Gastroesophageal Junction Cancer|Esophageal Cancer|Hepatocellular Carcinoma|Melanoma|Uveal Melanoma|Merkel Cell Carcinoma|Mesothelioma|MSI|Non-small Cell Lung Cancer|NSCLC|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck|Small Cell Lung Cancer|Renal Cell Carcinoma|RCC|Triple-negative Breast Cancer|Urothelial Carcinoma|Mismatch Repair Deficiency,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2018,2018,1102,0,Phase 1,1,safety,1,3.6888794541139363,"(3,4]"
2016,2382,"gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a standardized dietary supplement in treating patients with pancreatic cancer that cannot be removed by surgery","Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma|Unresectable Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7,drug or biologic,Early,21,All,NIH&Combos,0,NA,0,2015,2016,1259,0,Phase 1,1,NA,1,3.044522437723423,"(3,4]"
3491,5295,safety study of regorafenib with pf-03446962 to treat colorectal cancer,Completed,4,0,0,Colorectal Cancer,drug or biologic,Early,11,All,Industry&Combos,0,NA,0,2014,2014,549,0,Phase 1,1,safety,1,2.3978952727983707,"(2,3]"
1721,1914,"evaluation of the pharmacokinetics of tropifexor in subjects with mild, moderate, or severe hepatic impairment compared to healthy control subjects",Completed,4,0,0,Non-alcoholic Fatty Liver Disease,drug or biologic,Early,42,All,Industry&Combos,1,1,0,2018,2018,366,1,Phase 1,0,pharmacokinetics only,0,3.7376696182833684,"(3,4]"
2377,3036,vaccine therapy and pembrolizumab in treating patients with solid tumors that have failed prior therapy,"Active, not recruiting",1,0,0,Adult Solid Neoplasm|Bladder Carcinoma|Colon Carcinoma|Estrogen Receptor Negative|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|HER2/Neu Negative|Melanoma|Non-Small Cell Lung Carcinoma|Pancreatic Carcinoma|Progesterone Receptor Negative|Rectal Carcinoma|Renal Cell Carcinoma|Soft Tissue Sarcoma|Triple-Negative Breast Carcinoma|TP53 Gene Mutation|Unresectable Solid Neoplasm,drug or biologic,Early,19,All,NIH&Combos,0,NA,0,2015,2016,534,0,Phase 1,1,NA,1,2.9444389791664403,"(2,3]"
3521,5369,study of asn003 in subjects with advanced solid tumors,Terminated,5,0,0,"Neoplasms|Melanoma|Colorectal Neoplasm|Carcinoma, Non-small Cell Lung",drug or biologic,Early,24,All,Industry&Combos,1,1,0,2016,2016,853,1,Phase 1,0,NA,0,3.1780538303479458,"(3,4]"
2505,3326,safety and effect of gl-onc1 administered iv prior to surgery to patients with solid organ cancers undergoing surgery,Terminated,5,0,0,Solid Organ Cancers,drug or biologic,Early,5,All,Industry&Combos,0,NA,0,2016,2016,1229,0,Phase 1,1,safety,1,1.6094379124341003,"(1,2]"
2517,3350,maintenance dosing of vitamin d in crohn's disease,Terminated,5,0,0,Crohns Disease|Vitamin D Deficiency,other,Others,10,All,AllOther,1,0,0,2018,2018,92,1,Others,2,NA,2,2.302585092994046,"(2,3]"
504,525,pulsed low dose rate radiation with concurrent chemotherapy for non-small cell lung cancer and esophageal cancer,Recruiting,2,0,0,Lung Cancer|Esophageal Cancer,drug or biologic,Early,40,All,AllOther,0,NA,0,2017,2017,1711,0,Phase 1,1,NA,1,3.6888794541139363,"(3,4]"
384,394,safety and tolerability of allogeneic mesenchymal stromal cells in pediatric inflammatory bowel disease,Completed,4,0,0,Inflammatory Bowel Diseases,drug or biologic,Early,1,All,AllOther,0,NA,0,2014,2015,1487,0,Phase 1,1,safety,1,0,NA
808,845,cpi-613 and combination chemotherapy in treating patients with metastatic pancreatic cancer,"Active, not recruiting",1,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,21,All,NIH&Combos,0,NA,0,2013,2013,1429,0,Phase 1,1,NA,1,3.044522437723423,"(3,4]"
781,818,"autonomic neuropathy, gi motility, and inflammation in hiv",Completed,4,1,1,HIV Disease,drug or biologic,Early,76,All,NIH&Combos,0,NA,0,2016,2015,943,0,Early Phase 1,1,NA,1,4.330733340286331,"(4,5]"
3102,4209,a study of pegylated recombinant human hyaluronidase (pegph20) with pembrolizumab in participants with selected hyaluronan high solid tumors,Completed,4,1,1,NSCLC|Gastric Cancer,drug or biologic,Early,56,All,Industry&Combos,1,NA,0,2015,2015,1251,1,Phase 1,0,NA,0,4.02535169073515,"(4,5]"
1425,1533,analysis of the microbiome in rosacea,"Active, not recruiting",1,0,0,Rosacea,drug or biologic,Early,150,All,AllOther,1,1,4,2019,2019,1080,1,Early Phase 1,0,NA,0,5.0106352940962555,"(5,6]"
2931,3932,effect of curcumin on dose limiting toxicity and pharmacokinetics of irinotecan in patients with solid tumors,Completed,4,0,0,Advanced Colorectal Cancer,drug or biologic,Early,23,All,AllOther,0,1,4,2013,2013,1222,0,Phase 1,1,pharmacokinetics only,1,3.1354942159291497,"(3,4]"
3863,7077,a study of omp-305b83 in subjects with metastatic colorectal cancer,Terminated,5,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2017,2016,639,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
3180,4373,surpass: adp-a2m4cd8 in hla-a2+ subjects with mage-a4 positive tumors,Recruiting,2,0,0,Urothelial Carcinoma|Head and Neck|Gastric Cancer|Esophagogastric Junction Disorder|Nonsmall Cell Lung Cancer|Esophageal Cancer,other,Others,45,All,Industry&Combos,0,NA,0,2019,2019,984,0,Others,1,NA,1,3.8066624897703196,"(3,4]"
694,726,a study of cpi-613 with gemcitabine and nab-paclitaxel for patients with advanced or metastatic pancreatic cancer,Unknown status,8,0,0,Pancreatic Cancer|Metastatic Pancreatic Cancer,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2018,2017,378,0,Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
708,742,the safety and tolerability of secretrol in patients with barrett's esophagus,Unknown status,8,0,0,Barrett's Esophagus,drug or biologic,Early,13,All,Industry&Combos,0,NA,0,2013,2013,730,0,Phase 1,1,safety,1,2.5649493574615367,"(2,3]"
1775,1997,a study of apalutamide in participants with severe hepatic impairment compared with participants with normal hepatic function,Recruiting,2,0,0,Hepatic Impairment,drug or biologic,Early,16,Male,Industry&Combos,1,1,0,2019,2019,769,1,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
4127,8955,navitoclax and sorafenib tosylate in treating patients with relapsed or refractory solid tumors,"Active, not recruiting",1,0,0,Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm,drug or biologic,Early,44,All,NIH&Combos,0,NA,0,2014,2014,2738,0,Phase 1,1,NA,1,3.784189633918261,"(3,4]"
3144,4275,a study of sc-007 in subjects with advanced cancer,Terminated,5,0,0,Colorectal Cancer (CRC)|Gastric Cancer,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2017,2017,188,0,Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
3650,5792,antibody ds-8273a administered in combination with nivolumab in subjects with advanced colorectal cancer,Terminated,5,0,0,Colorectal Neoplasm,drug or biologic,Early,4,All,Industry&Combos,0,NA,4,2016,2016,295,0,Phase 1,1,NA,1,1.3862943611198906,"(1,2]"
1847,2114,study to evaluate the safety of combining two radionuclide therapies to treat mid-gut neuroendocrine tumors,"Active, not recruiting",1,0,0,"Neuroendocrine Tumor, Malignant|Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting",drug or biologic,Early,20,All,NIH&Combos,0,1,0,2017,2017,3130,0,Early Phase 1,1,safety,1,2.995732273553991,"(2,3]"
3013,4046,"drug-drug interaction study between edp-305, intraconazole and rifampin in healthy volunteers",Completed,4,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,48,All,Industry&Combos,0,1,4,2017,2017,30,0,Phase 1,1,NA,1,3.871201010907891,"(3,4]"
2937,3938,procaspase activating compound-1 (pac-1) in the treatment of advanced malignancies - component 1,Completed,4,0,0,Solid Tumor|Pancreatic Neuroendocrine Tumor|Neuroendocrine Tumors,drug or biologic,Early,48,All,Industry&Combos,0,NA,0,2015,2015,1933,0,Phase 1,1,NA,1,3.871201010907891,"(3,4]"
2457,3207,the impact of proton pump inhibitors on the fecal microbiome,Completed,4,0,0,Healthy|Clostridium Difficile Infection,drug or biologic,Early,15,All,AllOther,0,NA,NA,2013,2013,275,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
759,795,epacadostat (incb024360) added to preoperative chemoradiation in patients with locally advanced rectal cancer,Recruiting,2,0,0,Rectal Cancer,drug or biologic,Early,39,All,Industry&Combos,NA,1,0,2018,2019,1329,NA,Phase 1,0,NA,0,3.6635616461296463,"(3,4]"
156,156,car-t hepatic artery infusions and sir-spheres for liver metastases,Completed,4,0,0,Liver Metastases,drug or biologic,Early,8,All,Industry&Combos,0,NA,0,2015,2015,600,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
1976,2326,study of humab-5b1 (mvt-5873) in subjects with pancreatic cancer or other cancer antigen 19-9 (ca19-9) positive malignancies,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,162,All,Industry&Combos,0,1,0,2016,2016,2557,0,Phase 1,1,NA,1,5.087596335232384,"(5,6]"
483,501,folfirinox or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for locally advanced pancreatic cancer,Terminated,5,0,0,Locally Advanced Pancreatic Cancer|Borderline Pancreatic Inoperable Cancer|Pancreatic Cancer,drug or biologic,Early,25,All,AllOther,1,1,0,2018,2017,1039,1,Early Phase 1,0,NA,0,3.2188758248682006,"(3,4]"
91,91,gemcitabine & nab-paclitaxel in pancreatic adenocarcinoma with positive peritoneal cytology,Recruiting,2,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,21,All,AllOther,0,NA,0,2018,2018,1461,0,Phase 1,1,NA,1,3.044522437723423,"(3,4]"
2266,2814,mesenchymal stem cell and islet co-transplantation,"Active, not recruiting",1,0,0,Chronic Pancreatitis|Diabetes,drug or biologic,Early,42,All,NIH&Combos,1,0,0,2015,2014,4383,1,Phase 1,3,NA,2,3.7376696182833684,"(3,4]"
1150,1221,nir-guided sentinel lymph-node mapping for esophageal cancer,Completed,4,0,0,Esophageal Cancer,drug or biologic,Early,10,All,AllOther,0,NA,2,2013,2013,294,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
766,802,pembrolizumab with locally delivered radiation therapy for the treatment of metastatic esophageal cancers,"Active, not recruiting",1,0,0,Esophageal Neoplasms|Esophageal Cancer|Cancer of the Esophagus,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2015,2016,1569,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
18,18,therapeutic oxygen for gastrointestinal atony (toga),Completed,4,0,0,Ileus|Ogilvie Syndrome|Small Bowel Obstruction,drug or biologic,Early,17,All,AllOther,0,NA,0,2017,2018,630,0,Phase 1,1,NA,1,2.833213344056216,"(2,3]"
1611,1765,trial of intraperitoneal (ip) oxaliplatin in combination with intravenous folfiri,Recruiting,2,0,0,Colorectal Cancer|Appendix Cancer|Peritoneal Carcinomatosis,drug or biologic,Early,16,All,AllOther,NA,NA,0,2016,2016,1857,NA,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
3246,4555,a safety study of nuc-3373 in combination with standard agents used in colorectal cancer treatment,Recruiting,2,0,0,"Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal",drug or biologic,Early,118,All,AllOther,NA,1,0,2018,2018,1142,NA,Phase 1,0,safety,0,4.770684624465665,"(4,5]"
3061,4116,a study of edp 305 in healthy subjects and subjects with presumptive nafld,Completed,4,0,0,Presumptive NAFLD,drug or biologic,Early,146,All,Industry&Combos,1,0,0,2016,2016,273,1,Phase 1,3,NA,2,4.983606621708336,"(4,5]"
2956,3963,study of sbp-101 combined with nab-paclitaxel and gemcitabine in pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer Metastatic|Pancreatic Cancer Stage IV|Stage IV Pancreatic Cancer,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2018,2018,911,0,Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
1858,2133,"the cirrhosis outpatient optimization, readmission & safety study",Terminated,5,0,0,Cirrhosis,device,Others,120,All,AllOther,1,0,2,2015,2015,914,1,Others,0,safety,0,4.787491742782046,"(4,5]"
1400,1503,"ganetespib in combination with paclitaxel, carboplatin, and radiation therapy in treating patients with stage ii-iii esophageal cancer",Completed,4,0,0,Gastroesophageal Junction Adenocarcinoma|Malignant Neoplasm of the Cervical Esophagus|Malignant Neoplasm of the Thoracic Esophagus|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7,drug or biologic,Early,3,All,NIH&Combos,0,NA,0,2015,2015,1558,0,Phase 1,1,NA,1,1.0986122886681098,"(1,2]"
1919,2236,combining mln8237 with nab-paclitaxel in patients with advanced solid malignancies,Completed,4,0,0,Adenocarcinoma|Pancreatic Neoplasms,drug or biologic,Early,34,All,AllOther,1,1,0,2012,2013,511,1,Phase 1,0,NA,0,3.5263605246161616,"(3,4]"
1765,1978,"phase 0 study in healthy, hepatic and renal impaired subjects to obtain plasma for lenvatinib protein binding",Completed,4,0,0,Hepatic Impairment; Renal Impairment,drug or biologic,Early,54,All,Industry&Combos,1,1,4,2016,2016,218,1,Early Phase 1,0,NA,0,3.9889840465642745,"(3,4]"
503,524,tvb 2640 for resectable colon cancer other resectable cancers; a window trial.,Recruiting,2,0,0,Colon Cancer,drug or biologic,Early,48,All,AllOther,1,0,0,2016,2017,1790,1,Phase 1,2,NA,2,3.871201010907891,"(3,4]"
4109,8204,lesinurad interaction study with ranitidine,Completed,4,0,0,Healthy,drug or biologic,Early,16,Male,Industry&Combos,3,0,4,2013,2013,62,3,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
3661,5831,cgx1321 in subjects with advanced solid tumors and cgx1321 with pembrolizumab in subjects with advanced gi tumors (keynote 596),Recruiting,2,0,0,Solid Tumors|GI Cancer,drug or biologic,Early,72,All,Industry&Combos,0,1,0,2016,2016,2495,0,Phase 1,1,NA,1,4.276666119016055,"(4,5]"
882,926,cpi-613 in treating patients with locally advanced or metastatic pancreatic cancer,Completed,4,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,10,All,NIH&Combos,0,NA,0,2013,2013,822,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
3832,6850,sofosbuvir-containing regimens without interferon for treatment of acute hepatitis c virus (hcv) infection,Completed,4,1,1,HIV-1 Infection|Hepatitis,drug or biologic,Early,44,All,NIH&Combos,0,1,0,2014,2014,1005,0,Phase 1,1,NA,1,3.784189633918261,"(3,4]"
1994,2346,nivolumab and yttrium-90 in treating patients with liver cancer undergoing surgical resection,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma,drug or biologic,Early,2,All,IndustryNIHPartnership,0,NA,0,2019,2019,1393,0,Early Phase 1,1,NA,1,0.6931471805599453,"(0,1]"
3844,6926,a phase 1 study of fisogatinib (blu-554) in patients with hepatocellular carcinoma,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma (HCC),drug or biologic,Early,150,All,Industry&Combos,0,NA,0,2015,2015,2101,0,Phase 1,1,NA,1,5.0106352940962555,"(5,6]"
1894,2198,multiple dose ethnobridging pk study in healthy subjects,Completed,4,0,0,Inflammatory Bowel Diseases|IBD,drug or biologic,Early,60,All,Industry&Combos,NA,0,0,2018,2018,78,NA,Phase 1,4,NA,2,4.0943445622221,"(4,5]"
2528,3388,pharmacokinetic and safety study of nab Â®-paclitaxel (abi-007) plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia,Terminated,5,0,0,Pancreatic Neoplasms|Cholestasis,drug or biologic,Early,1,All,Industry&Combos,1,1,0,2014,2015,259,1,Phase 1,0,safety,0,0,NA
3886,7164,galunisertib (ly2157299) plus stereotactic body radiotherapy (sbrt) in advanced hepatocellular carcinoma (hcc),"Active, not recruiting",1,0,0,ADVANCED HEPATOCELLULAR CARCINOMA (HCC),drug or biologic,Early,15,All,AllOther,0,NA,0,2016,2017,1738,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
1855,2129,peptobismol Â® use to reduce gastrointestinal events in healthy volunteers receiving dmf [tecfidera Â®] twice daily,Completed,4,0,0,Healthy,drug or biologic,Early,175,All,Industry&Combos,1,0,0,2013,2013,122,1,Phase 1,2,NA,2,5.1647859739235145,"(5,6]"
706,740,lde225 + everolimus in advanced gastroesophageal adenocarcinoma,Completed,4,0,0,Esophageal Cancer,drug or biologic,Early,25,All,IndustryNIHPartnership,0,NA,0,2014,2014,2037,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
884,928,pembrolizumab and paricalcitol with or without chemotherapy in patients with pancreatic cancer that can be removed by surgery,"Active, not recruiting",1,0,0,Resectable Pancreatic Carcinoma|Stage I Pancreatic Cancer AJCC v6 and v7|Stage IA Pancreatic Cancer AJCC v6 and v7|Stage IB Pancreatic Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7,drug or biologic,Early,10,All,NIH&Combos,1,1,0,2016,2017,1775,1,Phase 1,0,NA,0,2.302585092994046,"(2,3]"
1920,2238,glucosamine and chondroitin in gut in preventing people from inflammation,Completed,4,0,0,Healthy Subject,other,Others,9,All,AllOther,3,0,1,2019,2018,324,3,Others,0,NA,0,2.1972245773362196,"(2,3]"
3000,4024,effect of hepatic impairment on lde225..,Completed,4,0,0,Normal Hepatic Function|Impaired Hepatic Function,drug or biologic,Early,33,All,Industry&Combos,0,NA,0,2013,2013,730,0,Phase 1,1,NA,1,3.4965075614664802,"(3,4]"
3598,5657,stem cell coated fistula plug in patients with crohn's rvf,Completed,4,0,0,Fistula Vagina|Crohn Disease,drug or biologic,Early,5,Female,AllOther,0,NA,0,2017,2017,1067,0,Phase 1,1,NA,1,1.6094379124341003,"(1,2]"
1235,1315,oral fecal transplant in cirrhosis,Completed,4,0,0,"Hepatic Encephalopathy|Cirrhosis, Liver",drug or biologic,Early,20,All,NA,1,0,1,2017,2017,518,1,Phase 1,2,NA,2,2.995732273553991,"(2,3]"
1087,1148,study to assess the relative potency of multiple oral doses of lum001 and shp626 in overweight and obese adults as assessed by fecal bile acid excretion,Completed,4,0,0,Healthy Volunteers,drug or biologic,Early,84,All,Industry&Combos,1,0,4,2015,2015,183,1,Phase 1,2,NA,2,4.430816798843313,"(4,5]"
1119,1187,a study to evaluate the pharmacokinetics of jnj-56021927 in participants with mild or moderate hepatic impairment compared with participants with normal hepatic function,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,24,Male,Industry&Combos,0,NA,0,2015,2015,546,0,Phase 1,1,pharmacokinetics only,1,3.1780538303479458,"(3,4]"
3490,5293,regorafenib + panitumumab for colorectal cancers,Terminated,5,0,0,KRAS and NRAS Wild-type Colorectal Cancer,drug or biologic,Early,2,All,AllOther,0,NA,0,2014,2014,700,0,Phase 1,1,NA,1,0.6931471805599453,"(0,1]"
2848,3820,study of single agent idelalisib followed by idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma,Terminated,5,1,1,Previously Untreated Pancreatic Ductal Adenocarcinoma|Relapsed/Refractory Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,16,All,Industry&Combos,1,1,0,2015,2015,272,1,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
547,569,"sd-101, nivolumab, and radiation therapy in treating patients with chemotherapy-refractory metastatic pancreatic cancer",Recruiting,2,0,0,Metastatic Pancreatic Adenocarcinoma|Refractory Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8,drug or biologic,Early,6,All,IndustryNIHPartnership,0,NA,0,2019,2019,813,0,Phase 1,1,NA,1,1.791759469228055,"(1,2]"
1111,1177,car-t intraperitoneal infusions for cea-expressing adenocarcinoma peritoneal metastases or malignant ascites (ipc),"Active, not recruiting",1,0,0,Peritoneal Carcinomatosis|Peritoneal Metastases|Colorectal Cancer|Gastric Cancer|Breast Cancer|Pancreas Cancer|Carcinoembryonic Antigen,drug or biologic,Early,18,All,Industry&Combos,0,NA,0,2018,2018,810,0,Phase 1,1,NA,1,2.8903717578961645,"(2,3]"
2574,3461,a research study looking at a new study medicine (nnc0194-0499) for weight control in people with overweight or obesity,Completed,4,0,0,Metabolism and Nutrition Disorder|Obesity,drug or biologic,Early,57,All,Industry&Combos,1,0,0,2018,2018,448,1,Phase 1,4,NA,2,4.04305126783455,"(4,5]"
1354,1448,tas-102 with concurrent radiation for the treatment of untreated resectable stage ii-iii rectal cancer,Recruiting,2,0,0,Rectal Adenocarcinoma|Stage IIA Rectal Cancer AJCC v8|Stage IIB Rectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Rectal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Rectal Cancer AJCC v8,drug or biologic,Early,18,All,Industry&Combos,0,NA,0,2019,2019,911,0,Phase 1,1,NA,1,2.8903717578961645,"(2,3]"
1117,1185,gut microbiome mediated effects of inulin supplementation on mineral and bone metabolism in hemodialysis patients,Completed,4,0,0,"Bone Diseases, Endocrine|Nutritional and Metabolic Diseases",other,Others,20,All,AllOther,3,0,4,2016,2016,579,3,Others,3,NA,2,2.995732273553991,"(2,3]"
981,1035,"a study to investigate the effect of hepatic impairment on the pharmacokinetics, safety and tolerability of asp2215",Completed,4,0,0,Hepatic Impairment|Healthy,drug or biologic,Early,24,All,Industry&Combos,1,1,4,2015,2015,134,1,Phase 1,0,safety,0,3.1780538303479458,"(3,4]"
348,356,phase 1 trial of interleukin 12 gene therapy for metastatic pancreatic cancer,Unknown status,8,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,9,All,AllOther,0,NA,0,2017,2017,729,0,Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
655,682,pharmacokinetics of doxorubicin in ctace of liver cancer,Completed,4,1,1,Liver Cancer,drug or biologic,Early,30,All,AllOther,1,1,0,2016,2015,1491,1,Phase 1,0,pharmacokinetics only,0,3.4011973816621555,"(3,4]"
2054,2434,yttrium-90 dota-toc intra-arterial (ia) peptide receptor radionuclide therapy (prrt) for neuroendocrine tumor,Completed,4,0,0,Neuroendocrine Tumor,drug or biologic,Early,10,All,AllOther,0,1,0,2017,2017,699,0,Early Phase 1,1,NA,1,2.302585092994046,"(2,3]"
1649,1813,vagal nerve stimulation for functional dyspepsia and gastroparesis,Recruiting,2,0,0,Dyspepsia|Gastroparesis,device,Others,50,All,AllOther,NA,NA,4,2018,2018,1065,NA,Others,0,NA,0,3.912023005428146,"(3,4]"
1657,1824,fecal microbiota transplantation in hiv,Completed,4,0,0,HIV,drug or biologic,Early,18,All,NIH&Combos,0,NA,0,2014,2014,882,0,Phase 1,1,NA,1,2.8903717578961645,"(2,3]"
2877,3858,study to test the safety and tolerability of pf-07062119 in patients with selected advanced or metastatic gastrointestinal tumors.,Recruiting,2,0,0,Gastrointestinal Tumors|Colorectal Adenocarcinomas|Gastric Adenocarcinomas|Esophageal Adenocarcinomas,drug or biologic,Early,130,All,Industry&Combos,0,1,0,2019,2019,1409,0,Phase 1,1,safety,1,4.867534450455582,"(4,5]"
1160,1233,ceritinib and combination chemotherapy in treating patients with advanced solid tumors or locally advanced or metastatic pancreatic cancer,Completed,4,0,0,Advanced Malignant Solid Neoplasm|ALK Positive|Metastatic Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,38,All,NIH&Combos,1,1,0,2014,2015,1449,1,Phase 1,0,NA,0,3.6375861597263857,"(3,4]"
533,555,efficacy of fecal immunochemical test using digital rectal exam,Terminated,5,0,0,Fecal Immunochemical Test,device,Others,1,All,AllOther,1,1,2,2017,2016,365,1,Others,0,efficacy,0,0,NA
615,641,stereotactic radiosurgery and metformin in patients with borderline-resectable or locally-advanced pancreatic cancer,Completed,4,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage I-III Pancreatic Cancer,drug or biologic,Early,8,All,NIH&Combos,0,NA,0,2014,2015,1183,0,Early Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
432,444,fecal microbiota transplantation in pediatric patients,Completed,4,1,1,Inflammatory Bowel Diseases (IBD)|Crohn's Disease (CD)|Ulcerative Colitis (UC),drug or biologic,Early,23,All,AllOther,0,NA,0,2014,2014,944,0,Phase 1,1,NA,1,3.1354942159291497,"(3,4]"
705,739,ccr2 pet for pancreatic cancer imaging and prediction of response to standard and ccr2-targeted therapy,Recruiting,2,0,0,Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,75,All,NIH&Combos,1,1,2,2019,2019,2341,1,Phase 1,0,NA,0,4.31748811353631,"(4,5]"
3348,4863,mra with feraheme in hht,Completed,4,0,0,Hereditary Hemorrhagic Telangiectasia,procedure,Others,10,All,AllOther,0,NA,2,2016,2016,730,0,Others,1,NA,1,2.302585092994046,"(2,3]"
4120,8772,dna vaccine therapy in treating patients with chronic hepatitis c virus infection,"Active, not recruiting",1,0,0,Chronic Hepatitis|Hepatitis C Infection,drug or biologic,Early,33,All,IndustryNIHPartnership,0,NA,1,2016,2016,1367,0,Phase 1,1,NA,1,3.4965075614664802,"(3,4]"
2163,2609,mechanisms of preventing antibiotic-associated diarrhea and the role for probiotics,Completed,4,0,0,Antibiotic-associated Diarrhea,drug or biologic,Early,66,All,NIH&Combos,1,0,4,2018,2019,169,1,Early Phase 1,3,NA,2,4.189654742026425,"(4,5]"
315,320,lidocaine infusion in pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,46,All,AllOther,1,0,0,2019,2018,1096,1,Early Phase 1,2,NA,2,3.828641396489095,"(3,4]"
1188,1265,liver glycogen and hypoglycemia in humans,Recruiting,2,0,0,Hypoglycemia; Iatrogenic,drug or biologic,Early,40,All,AllOther,3,0,4,2017,2018,1398,3,Phase 1,1,NA,1,3.6888794541139363,"(3,4]"
4040,7634,study to assess the effect of bms-791325 on the pharmacokinetics of midazolam in healthy subjects,Completed,4,0,0,Hepatitis C,drug or biologic,Early,48,All,Industry&Combos,0,NA,NA,2009,2013,123,0,Phase 1,1,pharmacokinetics only,1,3.871201010907891,"(3,4]"
1757,1967,study of topical abi-1968 in subjects with precancerous anal lesions resulting from human papillomavirus (hpv) infection,Terminated,5,0,0,"HSIL, High-Grade Squamous Intraepithelial Lesions|Human Papilloma Virus Infection|HIV Infection|Anal Cancer|Anus Neoplasm",drug or biologic,Early,6,All,Industry&Combos,NA,1,0,2018,2018,195,NA,Phase 1,0,NA,0,1.791759469228055,"(1,2]"
4123,8878,proof of concept study for safety and efficacy of edp239 in hepatitis c subjects,Completed,4,0,0,Hepatitis C,drug or biologic,Early,28,All,Industry&Combos,1,0,0,2013,2013,518,1,Phase 1,2,safety/efficacy,2,3.332204510175204,"(3,4]"
1949,2284,first-in-human study of bbt-401-1s following single and multiple ascending doses in healthy volunteers,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,80,All,Industry&Combos,1,0,0,2018,2018,190,1,Phase 1,4,NA,2,4.382026634673881,"(4,5]"
1371,1469,role of sildenafil for fontan associated liver disease (sifald) study,Completed,4,0,0,Cirrhosis|Congenital Heart Disease,drug or biologic,Early,32,All,AllOther,1,0,4,2017,2017,725,1,Early Phase 1,4,NA,2,3.4657359027997265,"(3,4]"
698,731,"pilot study with peginterferon, ribavirin, and boceprevir prior to transplantation to clear virus in hepatitis c genotype 1 infected individuals undergoing orthotopic liver transplantation",Completed,4,0,0,Liver Transplantation,drug or biologic,Early,1,All,Industry&Combos,0,NA,0,2013,2013,395,0,Early Phase 1,1,NA,1,0,NA
74,74,aquamin and prevention of colon cancer,Completed,4,0,0,Colonic Cancer,drug or biologic,Early,36,All,AllOther,1,0,1,2016,2016,1795,1,Phase 1,2,NA,2,3.58351893845611,"(3,4]"
924,971,"a study to evaluate the safety, tolerability and efficacy of lb1148 for subjects undergoing elective bowel resection",Completed,4,0,0,Adhesions|Ileus,drug or biologic,Early,11,All,AllOther,0,NA,1,2019,2018,501,0,Phase 1,1,safety/efficacy,1,2.3978952727983707,"(2,3]"
738,772,preoperative rehabilitation during neoadjuvant therapy for pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,behavioral,Others,75,All,AllOther,0,NA,4,2014,2015,1585,0,Others,1,NA,1,4.31748811353631,"(4,5]"
3693,6115,fluorine f 18 clofarabine pet/ct in imaging patients with autoimmune or inflammatory diseases,Completed,4,0,0,Autoimmune Disease|Crohn Disease|Inflammatory Disorder|Rheumatoid Arthritis|Systemic Lupus Erythematosus|Takayasu Arteritis,procedure,Others,8,All,AllOther,0,NA,2,2016,2016,826,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
3464,5260,"study of irinotecan and azd1775, a selective wee 1 inhibitor, in ras or braf mutated, second-line metastatic colorectal cancer",Completed,4,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2016,2016,1288,0,Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
479,497,a phase ib pharmacodynamic study of neoadjuvant paricalcitol in resectable pancreatic cancer a phase ib pharmacodynamic study of neoadjuvant paricalcitol in resectable pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,3,All,AllOther,1,1,0,2017,2017,1067,1,Phase 1,0,NA,0,1.0986122886681098,"(1,2]"
1785,2011,simvastatin metabolism as a test for cd activity (irb 15-007568],Completed,4,0,0,Celiac Disease,drug or biologic,Early,40,All,Industry&Combos,0,NA,2,2017,2016,1036,0,Early Phase 1,1,NA,1,3.6888794541139363,"(3,4]"
3185,4391,"safety tolerability, and pk of ryi-018 after repeat dosing in subjects with non-alcoholic fatty liver disease (nafld)",Completed,4,0,0,"NAFLD",drug or biologic,Early,84,All,Industry&Combos,NA,0,0,2017,2017,361,NA,Phase 1,4,safety,2,4.430816798843313,"(4,5]"
2470,3244,"mln1117 in combination with docetaxel, paclitaxel, and other investigational anticancer agents to treat participants with gastric and gastroesophageal adenocarcinoma",Terminated,5,1,1,Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma,drug or biologic,Early,32,All,Industry&Combos,1,1,0,2015,2015,491,1,Phase 1,0,NA,0,3.4657359027997265,"(3,4]"
225,228,gastric sleeve pilot study in morbidly obese undergoing liver transplantation,Completed,4,0,0,Obesity|Cardiovascular Disease|Type 2 Diabetes|Hypertension|Complication of Transplant,procedure,Others,1,All,AllOther,0,NA,0,2014,2014,89,0,Others,1,NA,1,0,NA
1909,2221,hepatitis c positive donor into hepatitis c negative recipients,Withdrawn,7,0,0,Hepatitis C,drug or biologic,Early,NA,All,AllOther,1,1,4,2018,2019,0,1,Early Phase 1,0,NA,0,NA,NA
1043,1098,"the effect o f hepatic impairment on the pharmacokinetics and pharmacodynamics of betrixiban, an oral fxa antagonist",Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,32,All,Industry&Combos,1,1,1,2018,2017,61,1,Phase 1,0,pharmacokinetics only,0,3.4657359027997265,"(3,4]"
1561,1701,carbon ion radiation therapy for locally advanced pancreatic cancer,Completed,4,0,0,Pancreatic Cancer|Cancer,drug or biologic,Early,14,All,AllOther,0,NA,0,2018,2016,1194,0,Phase 1,1,NA,1,2.6390573296152584,"(2,3]"
971,1022,an evaluation of tilmanocept by iv injection using spect/ct vs pet imaging in subjects with liver metastases.,Terminated,5,1,1,Liver Metastases|Colorectal Carcinoma,drug or biologic,Early,3,All,IndustryNIHPartnership,NA,1,2,2017,2017,425,NA,Phase 1,0,NA,0,1.0986122886681098,"(1,2]"
3074,4142,preoperative radiotherapy and e7046 in rectum cancer,"Active, not recruiting",1,0,0,Neoadjuvant Therapy in Rectal Cancer,drug or biologic,Early,29,All,Industry&Combos,1,1,0,2017,2017,1568,1,Phase 1,0,NA,0,3.367295829986474,"(3,4]"
1993,2345,defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer,"Active, not recruiting",1,0,0,Advanced Solid Tumors|Solid Tumors|Pancreatic Cancer,drug or biologic,Early,43,All,Industry&Combos,1,1,0,2015,2016,653,1,Phase 1,0,NA,0,3.7612001156935624,"(3,4]"
3326,4749,fecal microbial transplantation in patients with crohn's disease,"Active, not recruiting",1,0,0,Crohn Disease,drug or biologic,Early,9,All,AllOther,0,NA,0,2017,2017,1840,0,Early Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
2859,3834,a study to evaluate the safety and tolerability of ab680 in participants with gastrointestinal malignancies,Recruiting,2,0,0,Advanced Pancreatic Cancer,drug or biologic,Early,150,All,Industry&Combos,NA,1,0,2019,2019,1546,NA,Phase 1,0,safety,0,5.0106352940962555,"(5,6]"
988,1042,a study to describe the effect of impaired hepatic function of the pharmacokinetics of palbociclib,Completed,4,1,1,"Healthy, Hepatic Insufficiency",drug or biologic,Early,28,All,Industry&Combos,1,1,4,2015,2015,558,1,Phase 1,0,pharmacokinetics only,0,3.332204510175204,"(3,4]"
2472,3246,"study in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of gs-9674 (cilofexor), and the effect of food on gs-9674 pharmacokinetics and pharmacodynamics",Completed,4,1,1,Nonalcoholic Steatohepatitis (NASH),drug or biologic,Early,120,All,Industry&Combos,1,0,0,2016,2016,176,1,Phase 1,2,safety,2,4.787491742782046,"(4,5]"
4057,7746,68ga-dotatoc positron emission tomography (pet) for somatostatin receptor-positive neuroendocrine tumors (nets),Terminated,5,0,0,Neuroendocrine Tumors|Carcinoid Tumors,drug or biologic,Early,71,All,AllOther,0,NA,2,2015,2014,784,0,Phase 1,1,NA,1,4.2626798770413155,"(4,5]"
3876,7139,tpst-1120 as monotherapy and in combination with nivolumab in subjects with advanced cancers,Recruiting,2,0,0,Hepatocellular Carcinoma|Metastatic Castration Resistant Prostate Cancer|Renal Cell Carcinoma|Non-small Cell Lung Cancer|Colorectal Cancer|Squamous Cell Carcinoma of Head and Neck|Triple-Negative Breast Cancer|Urothelial Carcinoma|Cholangiocarcinoma|GastroEsophageal Cancer|Pancreatic Cancer|Sarcoma,drug or biologic,Early,138,All,Industry&Combos,NA,1,0,2019,2019,1066,NA,Phase 1,0,NA,0,4.927253685157205,"(4,5]"
4083,7923,phase i study of ino-1800 with or without ino-9112 + ep in chronic hepatitis b subjects,Completed,4,0,0,Hepatitis B,drug or biologic,Early,90,All,Industry&Combos,2,0,0,2015,2015,1226,1,Phase 1,0,NA,0,4.499809670330265,"(4,5]"
1106,1170,study to evaluate the pharmacokinetics of lemborexant (e2006) and its metabolites in subjects with mild and moderate hepatic impairment compared to healthy subjects,Completed,4,1,1,Hepatic Impairment,drug or biologic,Early,24,All,Industry&Combos,1,1,0,2018,2018,87,1,Phase 1,0,pharmacokinetics only,0,3.1780538303479458,"(3,4]"
2361,3007,a study of trk-950 in patients with advanced solid tumors,Completed,4,0,0,Locally Advanced or Metastatic Solid Carcinomas|Colon Cancer|Cholangiocarcinoma,drug or biologic,Early,38,All,Industry&Combos,NA,1,0,2016,2017,924,NA,Phase 1,0,NA,0,3.6375861597263857,"(3,4]"
53,53,study of performance of confocal endomicroscope with fluorescein imaging agent in the colon,Recruiting,2,0,0,Colonic Dysplasia|Adenomatous Polyps|Irritable Bowel Disease,drug or biologic,Early,100,All,AllOther,0,NA,NA,2017,2017,1587,0,Phase 1,1,NA,1,4.605170185988092,"(4,5]"
1002,1057,a study to test how different doses of bi 685509 are tolerated in patients with liver problems,Completed,4,0,0,Healthy|Hepatic Insufficiency,drug or biologic,Early,64,All,Industry&Combos,1,0,0,2019,2019,765,1,Phase 1,2,NA,2,4.1588830833596715,"(4,5]"
2176,2635,rq-00000010 for gastroparesis and constipation in parkinson's disease,Completed,4,0,0,Parkinson's Disease|Gastroparesis|Constipation,drug or biologic,Early,51,All,Industry&Combos,1,0,0,2016,2016,1175,1,Phase 1,4,NA,2,3.9318256327243257,"(3,4]"
2436,3165,pk study with pantoprazole in obese children and adolescents,Completed,4,1,1,Gastroesophageal Reflux Disease,drug or biologic,Early,41,All,Industry&Combos,0,NA,4,2014,2014,466,0,Phase 1,1,NA,1,3.713572066704308,"(3,4]"
2111,2522,"safety, tolerability, and pharmacokinetics of oral bt-11 in healthy adult male and female volunteers",Completed,4,0,0,Ulcerative Colitis|Crohn Disease,drug or biologic,Early,70,All,Industry&Combos,1,0,0,2019,2018,80,1,Phase 1,3,safety,2,4.248495242049359,"(4,5]"
2736,3665,"trametinib and trifluridine and tipiracil hydrochloride in treating patients with colon or rectal cancer that is advanced, metastatic, or cannot be removed by surgery","Active, not recruiting",1,0,0,Metastatic Colon Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Rectal Carcinoma|RAS Family Gene Mutation|Stage III Colon Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7,drug or biologic,Early,26,All,NIH&Combos,0,NA,0,2017,2018,1261,0,Phase 1,1,NA,1,3.258096538021482,"(3,4]"
3725,6235,grapiprant and pembrolizumab in patients with advanced or progressive mss colorectal cancer,Recruiting,2,0,0,Microsatellite Stable Colorectal Cancer,drug or biologic,Early,58,All,Industry&Combos,0,1,0,2018,2018,1258,0,Phase 1,1,NA,1,4.060443010546419,"(4,5]"
111,111,"kd019 and trastuzumab in patients with esophagus, gastroesophageal junction and stomach cancer",Withdrawn,7,0,0,Esophageal Cancer|Stomach Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2014,2014,943,0,Phase 1,1,NA,1,NA,NA
1054,1109,improving insulin resistance to treat non-alcoholic fatty liver disease: a pilot study,Withdrawn,7,0,0,Non-alcoholic Fatty Liver Disease (NAFLD),drug or biologic,Early,NA,All,AllOther,1,0,0,2015,2015,761,1,Phase 1,0,NA,0,NA,NA
2299,2886,dinaciclib and akt inhibitor mk2206 in treating patients with pancreatic cancer that cannot be removed by surgery,Completed,4,0,0,Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma,drug or biologic,Early,42,All,NIH&Combos,1,0,0,2013,2013,1274,1,Phase 1,0,NA,0,3.7376696182833684,"(3,4]"
2673,3583,a study of fpa144 combined with modified folfox6 in gastric/gastroesophageal cancer,"Active, not recruiting",1,0,0,Gastrointestinal Cancer|Gastrointestinal Cancer Metastatic|Gastric Cancer,other,Others,10,All,Industry&Combos,0,NA,0,2017,2017,1674,0,Others,1,NA,1,2.302585092994046,"(2,3]"
4058,7752,a study to evaluate the effect of omeprazole on the pharmacokinetics of bms-986205 in healthy participants,Completed,4,0,0,Healthy,drug or biologic,Early,16,All,Industry&Combos,0,NA,4,2019,2019,73,0,Phase 1,1,pharmacokinetics only,1,2.772588722239781,"(2,3]"
215,218,panchromoendoscopy using oral indigo carmine mixed with polyethylene glycol prep,Completed,4,0,0,Colonic Polyps,drug or biologic,Early,21,All,AllOther,1,0,2,2013,2013,426,1,Phase 1,2,NA,2,3.044522437723423,"(3,4]"
1416,1523,cd8+ t cell therapy and pembrolizumab in treating patients with metastatic gastrointestinal tumors,Terminated,5,0,0,Colorectal Adenocarcinoma|Metastatic Cholangiocarcinoma|Metastatic Colorectal Carcinoma|Metastatic Digestive System Carcinoma|Metastatic Esophageal Carcinoma|Metastatic Gastric Carcinoma|Metastatic Pancreatic Adenocarcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,1,All,NIH&Combos,0,NA,0,2016,2019,420,0,Phase 1,1,NA,1,0,NA
1585,1735,nalbuphine er effects of liver disease on pharmacokinetics and itch,"Active, not recruiting",1,0,0,Nalbuphine|Hepatic Impairment,drug or biologic,Early,56,All,Industry&Combos,0,1,0,2019,2018,739,0,Phase 1,1,pharmacokinetics only,1,4.02535169073515,"(4,5]"
1040,1095,effect of aspirin on gut microbiome,Completed,4,0,0,Healthy,drug or biologic,Early,50,All,AllOther,1,0,4,2016,2016,669,1,Phase 1,4,NA,2,3.912023005428146,"(3,4]"
2831,3793,a study of galunisertib (ly2157299) and durvalumab (medi4736) in participants with metastatic pancreatic cancer,Completed,4,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,37,All,Industry&Combos,0,NA,0,2016,2016,778,0,Phase 1,1,NA,1,3.6109179126442243,"(3,4]"
2092,2497,treatment plan for an individual patient with pasireotide for hyperinsulinemic hypoglycemia,Recruiting,2,0,0,Hyperinsulinemic Hypoglycemia|Post Gastrointestinal Tract Surgery Hypoglycaemia,drug or biologic,Early,1,All,Industry&Combos,0,NA,0,2017,2017,1826,0,Phase 1,1,NA,1,0,NA
663,691,effect of fatty liver on tca cycle flux and the pentose phosphate pathway,"Active, not recruiting",1,0,0,Fatty Liver,drug or biologic,Early,16,All,AllOther,1,1,4,2018,2018,1187,1,Early Phase 1,0,NA,0,2.772588722239781,"(2,3]"
4114,8648,drug-drug interaction study with azd9291 and omeprazole in healthy volunteers,Completed,4,1,1,Healthy Volunteer,drug or biologic,Early,136,Male,Industry&Combos,0,NA,0,2014,2014,122,0,Phase 1,1,NA,1,4.912654885736052,"(4,5]"
961,1011,oral administration of mb-102 versus dual sugar testing for gut permeability,Recruiting,2,0,0,Crohn Disease,drug or biologic,Early,20,All,Industry&Combos,3,0,2,2019,2019,522,3,Early Phase 1,0,NA,0,2.995732273553991,"(2,3]"
1879,2173,"an open-label, single- and multi-dose pharmacokinetic (pk) study of oral diltiazem and topical diltiazem hydrochloride",Unknown status,8,0,0,Adult Subjects With Anal Fissures.,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2013,2013,150,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
2924,3925,"indoleamine 2,3-dioxygenase (ido) inhibitor in advanced solid tumors",Completed,4,0,0,Solid Tumor,drug or biologic,Early,22,All,Industry&Combos,0,NA,0,2014,2014,671,0,Phase 1,1,NA,1,3.091042453358316,"(3,4]"
1418,1525,intra-anal oxymetazoline in healthy adult volunteers,Recruiting,2,0,0,Fecal Incontinence,drug or biologic,Early,20,All,NA,NA,NA,0,2018,2018,590,NA,Phase 1,0,NA,0,2.995732273553991,"(2,3]"
1955,2296,chinese herbal formulation phy906 and sorafenib tosylate in treating patients with advanced liver cancer,Completed,4,0,0,Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Advanced Adult Hepatocellular Carcinoma|BCLC Stage B Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma,drug or biologic,Early,18,All,NIH&Combos,0,NA,0,2012,2014,2179,0,Phase 1,1,NA,1,2.8903717578961645,"(2,3]"
2140,2573,trametinib in combination with sorafenib in patients with advanced hepatocellular cancer,Completed,4,0,0,Hepatocellular Cancer|Liver Cancer,drug or biologic,Early,17,All,AllOther,0,NA,0,2014,2015,1399,0,Phase 1,1,NA,1,2.833213344056216,"(2,3]"
3098,4195,meclizine for hepatocellular carcinoma,Suspended,6,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,13,All,AllOther,0,NA,0,2017,2017,1510,0,Phase 1,1,NA,1,2.5649493574615367,"(2,3]"
484,502,quilt-2.001: alt-803 in patients with advanced pancreatic cancer in conjunction with gemcitabine and nab-paclitaxel,Completed,4,0,0,Advanced Pancreatic Cancer,drug or biologic,Early,8,All,Industry&Combos,0,NA,0,2015,2016,600,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
1224,1302,immunotherapy with cea(6d) vrp vaccine (avx701) in patients with stage iii colorectal cancer,Completed,4,0,0,Stage III Colon Cancer,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2013,2013,1308,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
1635,1798,effect of non-alcoholic steatohepatitis (nash) on the pharmacokinetics of 99mtechnetium-mebrofenin,Completed,4,0,0,Non-alcoholic Steatohepatitis,drug or biologic,Early,21,All,NIH&Combos,0,1,4,2014,2015,457,0,Phase 1,1,pharmacokinetics only,1,3.044522437723423,"(3,4]"
3676,6012,treatment of igg4-related disease with revlimid and rituximab,Completed,4,0,0,Immunoglobulin G Subclass 4 Related Disease|IgG4-related Disease|Autoimmune Pancreatitis|IgG4-related Sclerosing Cholangitis|Retroperitoneal Fibrosis,drug or biologic,Early,6,All,Industry&Combos,0,NA,0,2016,2016,1095,0,Phase 1,1,NA,1,1.791759469228055,"(1,2]"
1341,1433,laparoscopic narrow band imaging for detection of occult cancer metastases,Completed,4,1,1,Gastrointestinal and Gynecologic Malignancies,device,Others,23,All,AllOther,3,0,2,2013,2013,608,3,Others,0,NA,0,3.1354942159291497,"(3,4]"
1310,1399,an open-labeled pilot study of biomarker response following short-term exposure to metformin,Terminated,5,0,0,Colorectal Carcinoma,drug or biologic,Early,3,All,AllOther,1,0,NA,2013,2013,457,1,Phase 1,0,NA,0,1.0986122886681098,"(1,2]"
3285,4636,study of pf-05221304 in subjects with varying degrees of hepatic impairment,Completed,4,1,1,Hepatic Impairment,drug or biologic,Early,24,All,Industry&Combos,1,1,4,2017,2017,189,1,Phase 1,0,NA,0,3.1780538303479458,"(3,4]"
2744,3679,evaluation of an oral anti-tnf antibody in patients with active ulcerative colitis,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,33,All,Industry&Combos,1,0,0,2013,2013,303,1,Phase 1,2,NA,2,3.4965075614664802,"(3,4]"
60,60,study of qrh-882260 heptapeptide application in the colon,Terminated,5,0,0,Colon Cancer Prevention,drug or biologic,Early,5,All,AllOther,0,NA,2,2017,2017,102,0,Phase 1,1,NA,1,1.6094379124341003,"(1,2]"
2011,2373,antibody treatment for advanced celiac disease,Completed,4,0,0,Celiac Disease|Celiac Sprue|Gluten Enteropathy|Gluten-Sensitive Enteropathy,drug or biologic,Early,5,All,NIH&Combos,0,NA,0,2013,2013,2382,0,Phase 1,1,NA,1,1.6094379124341003,"(1,2]"
864,906,"pharmacokinetics, safety and tolerability of vortioxetine in normal hepatic function or severe hepatic impairment",Completed,4,1,1,Severe Hepatic Impairment,drug or biologic,Early,12,All,Industry&Combos,1,1,0,2014,2014,123,1,Phase 1,0,safety,0,2.4849066497880004,"(2,3]"
3796,6682,study of personalized immunotherapy in adults with metastatic colorectal cancer,Terminated,5,0,0,Colorectal Neoplasms,drug or biologic,Early,28,All,Industry&Combos,0,NA,0,2017,2017,896,0,Phase 1,1,NA,1,3.332204510175204,"(3,4]"
1419,1526,single-dose pharmacokinetics and safety of oral lofexidine in hepatically-impaired subjects,Completed,4,0,0,Liver Failure,drug or biologic,Early,24,All,IndustryNIHPartnership,1,0,0,2014,2014,122,1,Phase 1,0,safety,0,3.1780538303479458,"(3,4]"
4061,7764,bioequivalence study of dexlansoprazole capsules from two manufacturing plants,Completed,4,1,1,Healthy Volunteers,drug or biologic,Early,116,All,Industry&Combos,3,0,4,2017,2017,69,3,Phase 1,0,bio-equivalence,0,4.7535901911063645,"(4,5]"
1907,2219,vitamin e pharmacokinetics and biomarkers in normal and obese women,Recruiting,2,0,0,Diabetes|Fatty Liver|Obesity|Healthy Volunteers,drug or biologic,Early,326,Female,NIH&Combos,2,1,1,2009,2014,4100,1,Phase 1,0,pharmacokinetics only,0,5.786897381366708,"(5,6]"
2357,3002,nivolumab and yttrium y 90 glass microspheres in treating patients with advanced liver cancer,"Active, not recruiting",1,1,1,Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma,drug or biologic,Early,27,All,IndustryNIHPartnership,0,NA,0,2016,2016,1111,0,Phase 1,1,NA,1,3.295836866004329,"(3,4]"
904,949,tas-102 and irinotecan in 2l+ gastric and gastroesophageal adenocarcinoma,Recruiting,2,0,0,Gastric Adenocarcinoma|GastroEsophageal Cancer,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2019,2019,918,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
2136,2567,a study of edp-305 in subjects with mild and moderate hepatic impairment compared with normal healthy volunteers,Completed,4,0,0,"NASH",drug or biologic,Early,29,All,Industry&Combos,1,1,4,2017,2017,94,1,Phase 1,0,NA,0,3.367295829986474,"(3,4]"
1305,1394,probiotic lgg for prevention of side effects in patients undergoing chemoradiation for gastrointestinal cancer,"Active, not recruiting",1,0,0,Gastrointestinal Neoplasms,drug or biologic,Early,23,All,AllOther,1,0,0,2013,2014,877,1,Phase 1,2,NA,2,3.1354942159291497,"(3,4]"
2376,3035,pharmacokinetics and pharmacodynamics of cilofexor in adults with normal and impaired hepatic function,Completed,4,1,1,Nonalcoholic Steatohepatitis (NASH)|Primary Sclerosing Cholangitis (PSC),drug or biologic,Early,57,All,Industry&Combos,1,1,0,2016,2016,825,1,Phase 1,0,pharmacokinetics only,0,4.04305126783455,"(4,5]"
1019,1074,radiation dose intensification with accelerated hypofractionated intensity modulated radiation therapy and concurrent carboplatin and paclitaxel for inoperable esophageal cancer,Recruiting,2,0,0,Esophagus Cancer|Esophageal Cancer|Cancer of the Esophagus,drug or biologic,Early,20,All,AllOther,0,NA,0,2019,2019,1766,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
333,339,"adh-1, gemcitabine hydrochloride and cisplatin in treating patients with locally advanced or metastatic pancreatic or biliary tract cancer that cannot be removed by surgery",Completed,4,0,0,Ampulla of Vater Adenocarcinoma|Gallbladder Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage III Ampulla of Vater Cancer|Stage III Intrahepatic Cholangiocarcinoma|Stage III Pancreatic Cancer|Stage IIIA Gallbladder Cancer|Stage IIIA Hilar Cholangiocarcinoma|Stage IIIB Gallbladder Cancer|Stage IIIB Hilar Cholangiocarcinoma|Stage IV Ampulla of Vater Cancer|Stage IVA Gallbladder Cancer|Stage IVA Hilar Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma|Stage IVA Pancreatic Cancer|Stage IVB Gallbladder Cancer|Stage IVB Hilar Cholangiocarcinoma|Stage IVB Intrahepatic Cholangiocarcinoma|Stage IVB Pancreatic Cancer,drug or biologic,Early,17,All,IndustryNIHPartnership,0,NA,0,2013,2013,1522,0,Phase 1,1,NA,1,2.833213344056216,"(2,3]"
407,418,a study of live biotherapeutic product mrx0518 with hypofractionated radiation therapy in resectable pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,15,All,Industry&Combos,0,NA,0,2019,2019,559,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
3631,5740,"phase i/iia study to evaluate the safety, pk, pd, and preliminary efficacy of plx8394 in patients with advanced cancers.",Terminated,5,0,0,Melanoma|Thyroid Cancer|Colorectal Cancer|Non-small Cell Lung Cancer|Cholangiocarcinoma|Histiocytosis|Hairy Cell Leukemia,drug or biologic,Early,5,All,Industry&Combos,0,NA,0,2013,2014,212,0,Phase 1,1,safety/efficacy,1,1.6094379124341003,"(1,2]"
1058,1114,impact of severe hepatic impairment on pharmacokinetics of cenicriviroc and its metabolites,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,16,All,Industry&Combos,1,1,0,2017,2017,171,1,Phase 1,0,pharmacokinetics only,0,2.772588722239781,"(2,3]"
599,625,optimal fecal microbiota transplant dosing for mild to moderate ulcerative colitis,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,30,All,AllOther,1,0,0,2016,2017,1159,1,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
1672,1843,fecal microbiota transplantation as a strategy to eradicate resistant organisms,Recruiting,2,0,0,Infection Resistant to Drugs,drug or biologic,Early,20,All,AllOther,0,NA,4,2015,2017,1657,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
595,621,immunogenicity of seasonal influenza by delivery directly to ileum,Completed,4,0,0,Seasonal Influenza,drug or biologic,Early,37,Male,Industry&Combos,0,NA,1,2013,2013,638,0,Phase 1,1,NA,1,3.6109179126442243,"(3,4]"
3249,4569,evaluation of the safety and tolerability of tak-228 with tak-117 and paclitaxel in advanced solid tumors,"Active, not recruiting",1,0,0,Advanced Solid Tumor,drug or biologic,Early,30,All,AllOther,0,1,0,2017,2017,1274,0,Phase 1,1,safety,1,3.4011973816621555,"(3,4]"
516,537,intraoperative radiation therapy for resectable pancreas cancer,Recruiting,2,0,0,Pancreas Cancer,other,Others,12,All,AllOther,0,1,0,2015,2015,2557,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
1214,1292,pharmacokinetics of fevipiprant (qaw039) in patients with hepatic impairment compared to matched healthy subjects,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,42,All,Industry&Combos,1,1,4,2017,2017,691,1,Phase 1,0,pharmacokinetics only,0,3.7376696182833684,"(3,4]"
1931,2254,"a study of pvp001, pvp002, and pvp003 in healthy adults and pvp001 and pvp002 in adults with celiac disease",Completed,4,0,0,Digestive System Disease,drug or biologic,Early,119,All,Industry&Combos,NA,0,4,2018,2018,957,NA,Phase 1,1,NA,1,4.77912349311153,"(4,5]"
938,986,study of the fecal microbiome in patients with parkinson's disease,"Active, not recruiting",1,0,0,Parkinson Disease,drug or biologic,Early,12,All,AllOther,1,0,0,2018,2019,930,1,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
2545,3419,study of personalized tumor vaccines (pcvs) and a pd-l1 blocker in patients with pancreatic cancer that can be treated with surgery,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2019,2019,731,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
1637,1800,investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite,Completed,4,0,0,Hepatic Impairment|Hepatic Insufficiency|Healthy Subjects,drug or biologic,Early,16,All,Industry&Combos,1,1,0,2019,2018,121,1,Phase 1,0,pharmacokinetics only,0,2.772588722239781,"(2,3]"
1848,2117,gvax for colorectal cancer,Recruiting,2,0,0,Colorectal Cancer,drug or biologic,Early,15,All,AllOther,0,NA,1,2013,2013,1826,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
2246,2771,a study of osrhsa in adult healthy male and female volunteers,Completed,4,1,1,Ascites Hepatic,drug or biologic,Early,41,All,Industry&Combos,NA,0,4,2020,2019,134,NA,Phase 1,2,NA,2,3.713572066704308,"(3,4]"
4087,8032,study of safety and tolerability of pdr001 in combination with sorafenib and to identify the maximum tolerated dose and/or phase 2 dose for this combination in advanced hepatocellular patients,Completed,4,0,0,Hepatocellular Carcinoma,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2016,2017,1043,0,Phase 1,1,safety,1,2.995732273553991,"(2,3]"
102,102,vitamin d in patients with stage i-iii colon cancer or resectable colon cancer liver metastases,Recruiting,2,0,0,"Stage, Colon Cancer|Stage I-III Colon Cancer|Stage IV Colon Cancer With Resectable Liver Metastases",drug or biologic,Early,80,All,IndustryNIHPartnership,0,0,4,2014,2014,2817,0,Early Phase 1,1,NA,1,4.382026634673881,"(4,5]"
1771,1985,a study to assess the pharmacokinetics of pxl770 after 4 weeks of treatment in subjects with nafld,Completed,4,0,0,Nonalcoholic Fatty Liver,drug or biologic,Early,17,All,Industry&Combos,1,0,0,2019,2019,241,1,Phase 1,4,pharmacokinetics only,2,2.833213344056216,"(2,3]"
943,991,"afatinib dimaleate and capecitabine in treating patients with advanced refractory solid tumors, pancreatic cancer or biliary cancer",Recruiting,2,0,0,Advanced Malignant Solid Neoplasm|Bile Duct Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IVA Pancreatic Cancer|Stage IVB Pancreatic Cancer,drug or biologic,Early,48,All,NIH&Combos,0,NA,0,2015,2015,2279,0,Phase 1,1,NA,1,3.871201010907891,"(3,4]"
4063,7780,"bioavailability, safety, and pharmacodynamics of dexlansoprazole delayed-release orally disintegrating tablets in healthy participants",Completed,4,1,1,Bioavailability,drug or biologic,Early,52,All,Industry&Combos,3,0,0,2014,2014,28,3,Phase 1,0,safety,0,3.9512437185814275,"(3,4]"
2286,2860,"nab-paclitaxel, capecitabine, and radiation therapy following induction chemotherapy in treating patients with locally advanced pancreatic cancer","Active, not recruiting",1,0,0,Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7,drug or biologic,Early,25,All,NIH&Combos,0,NA,0,2015,2015,1845,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
1591,1741,"to assess the safety of continuous iv administration of plerixafor and assess impact on the immune microenvironment in patients with pancreatic, ovarian and colorectal adenocarcinomas",Terminated,5,0,0,Pancreas Cancer,drug or biologic,Early,2,All,AllOther,0,NA,0,2017,2017,888,0,Phase 1,1,safety,1,0.6931471805599453,"(0,1]"
3008,4035,a drug-drug interaction study to investigate the effect of coadministration of edp-305 on the pk of a combined oral contraceptive in healthy female subjects,Completed,4,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,43,Female,Industry&Combos,0,NA,4,2018,2018,189,0,Phase 1,1,NA,1,3.7612001156935624,"(3,4]"
1449,1558,"atezolizumab, oxaliplatin, and fluorouracil in treating patients with esophageal or gastroesophageal cancer",Recruiting,2,0,0,Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8,drug or biologic,Early,30,All,NIH&Combos,0,NA,0,2018,2019,1046,0,Early Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
854,895,personalized peptide vaccine in treating patients with advanced pancreatic cancer or colorectal cancer,Recruiting,2,0,0,Colorectal Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,60,All,NIH&Combos,0,NA,0,2015,2016,1846,0,Phase 1,1,NA,1,4.0943445622221,"(4,5]"
3286,4640,modulation of heme oxygenase 1 by nizatidine and lisinopril in healthy subjects,Completed,4,0,0,Gastroparesis,drug or biologic,Early,24,All,NIH&Combos,1,0,4,2014,2014,62,1,Phase 1,2,NA,2,3.1780538303479458,"(3,4]"
3309,4706,a study of ursolic acid for primary sclerosing cholangitis,Withdrawn,7,0,0,Primary Sclerosing Cholangitis,drug or biologic,Early,NA,All,AllOther,0,1,0,2017,2017,487,0,Phase 1,1,NA,1,NA,NA
670,698,capecitabine and y-90 radioembolization in treating patients with advanced bile duct cancer in the liver that cannot be removed by surgery,Withdrawn,7,0,0,Bile Duct Adenocarcinoma|Stage III Intrahepatic Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma|Stage IVB Intrahepatic Cholangiocarcinoma,drug or biologic,Early,NA,All,NIH&Combos,0,NA,0,2017,2016,912,0,Phase 1,1,NA,1,NA,NA
1733,1931,quantification of estradiol's impact on nucleotides in cellular populations of the lower gi tract,Completed,4,0,0,HIV/AIDS,drug or biologic,Early,10,Female,NIH&Combos,0,NA,4,2019,2019,162,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
4062,7766,a study to evaluate the bioequivalence of single oral dose of esomeprazole capsule and tablet formulation in healthy participants,Completed,4,1,1,Healthy Participants,drug or biologic,Early,52,All,Industry&Combos,3,0,4,2017,2017,47,3,Phase 1,0,bio-equivalence,0,3.9512437185814275,"(3,4]"
447,459,ultrasound-guided photodynamic therapy with photofrin & gemcitabine for patients with locally advanced pancreatic cancer,Completed,4,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage III Pancreatic Cancer,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2013,2013,1546,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
2840,3806,"a study to assess the safety and pharmacokinetics of subcutaneously administered golimumab, a human anti-tnf Â± antibody, in pediatric patients with moderate to severe active ulcerative colitis","Active, not recruiting",1,0,0,"Colitis, Ulcerative",drug or biologic,Early,35,All,Industry&Combos,0,NA,0,2013,2013,558,0,Phase 1,1,safety,1,3.5553480614894135,"(3,4]"
1330,1420,pharmacokinetics of tivantinib in subjects with advanced solid tumors and hepatic impairment,Completed,4,0,0,Hepatic Impairment|Solid Tumor|Cancer,drug or biologic,Early,29,All,Industry&Combos,0,1,0,2014,2014,609,0,Phase 1,1,pharmacokinetics only,1,3.367295829986474,"(3,4]"
3149,4284,a study of multiple doses of hm15211 in obese subjects with nafld,Completed,4,0,0,"NAFLD",drug or biologic,Early,66,All,Industry&Combos,1,0,0,2018,2018,503,1,Phase 1,2,NA,2,4.189654742026425,"(4,5]"
1509,1637,metformin gastrointestinal intolerance: measurement of mitochondrial complex i,Completed,4,0,0,"Diabetes Mellitus, Type 2|Metformin Adverse Reaction",drug or biologic,Early,15,All,AllOther,3,0,4,2018,2018,743,3,Early Phase 1,4,NA,2,2.70805020110221,"(2,3]"
1831,2085,a study of demcizumab plus paclitaxel in subjects with platinum resistant ovarian,Terminated,5,0,0,Primary Peritoneal Carcinoma,drug or biologic,Early,20,Female,Industry&Combos,0,1,0,2013,2013,1009,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
127,127,car t cell immunotherapy for pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer|Cancer of the Pancreas,drug or biologic,Early,18,All,AllOther,NA,1,0,2017,2017,1447,NA,Phase 1,0,NA,0,2.8903717578961645,"(2,3]"
3688,6084,an open-label safety and tolerability study of incb062079 in subjects with advanced hepatocellular carcinoma and other malignancies,Terminated,5,0,0,Hepatocellular Carcinoma (HCC)|Cholangiocarcinoma|Esophageal Cancer|Nasopharyngeal Cancer|Ovarian Cancer|Solid Tumors,drug or biologic,Early,25,All,Industry&Combos,1,1,0,2017,2017,1112,1,Phase 1,0,safety,0,3.2188758248682006,"(3,4]"
76,76,autologous muscle derived cells for gastro-intestinal repair (amdc-gir) for tongue dysphagia,Recruiting,2,0,0,Oropharyngeal Dysphagia,drug or biologic,Early,20,All,Industry&Combos,0,1,0,2016,2017,1561,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
222,225,study of talimogene laherparepvec (t-vec) in pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,16,All,Industry&Combos,NA,NA,0,2017,2017,1597,NA,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
1574,1718,phase 1 study to evaluate safety of gr-md-02 in subjects with non-alcoholic steatohepatitis (nash) and advanced fibrosis,Completed,4,0,0,Non-Alcoholic Steatohepatitis (NASH),drug or biologic,Early,31,All,Industry&Combos,1,0,0,2013,2013,580,1,Phase 1,4,safety,2,3.4339872044851463,"(3,4]"
2263,2805,"irx-2, cyclophosphamide, and nivolumab in treating patients with recurrent or metastatic and refractory liver cancer",Recruiting,2,0,0,Recurrent Hepatocellular Carcinoma|Refractory Liver Carcinoma|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8,drug or biologic,Early,28,All,NIH&Combos,0,NA,0,2018,2019,1210,0,Phase 1,1,NA,1,3.332204510175204,"(3,4]"
1247,1331,safety of tas-102 in combination with temozolomide for metastatic pancreatic nets,Recruiting,2,0,0,Neuroendocrine Tumors|Neoplasms|Cancer|Tumors,drug or biologic,Early,33,All,Industry&Combos,0,NA,0,2016,2017,2170,0,Phase 1,1,safety,1,3.4965075614664802,"(3,4]"
2191,2665,drug interaction with proton pump inhibitors for nifedipine er tablets,Completed,4,1,1,Healthy Volunteers,drug or biologic,Early,64,All,AllOther,3,0,4,2017,2017,278,3,Phase 1,0,NA,0,4.1588830833596715,"(4,5]"
1653,1819,"a phase 1, open-label study to assess the single-dose pharmacokinetics of eravacycline in subjects with impaired hepatic function and healthy subjects",Completed,4,0,0,Impaired Hepatic Function,drug or biologic,Early,24,All,Industry&Combos,0,1,0,2014,2013,123,0,Phase 1,1,pharmacokinetics only,1,3.1780538303479458,"(3,4]"
3181,4377,"a study of avelumab, binimetinib and talazoparib in patients with locally advanced or metastatic ras-mutant solid tumors",Terminated,5,0,0,Pancreatic Cancer,drug or biologic,Early,36,All,Industry&Combos,NA,0,0,2018,2018,841,NA,Phase 1,0,NA,0,3.58351893845611,"(3,4]"
2552,3429,the safety of high dose minocycline in the patient population undergoing carotid revascularization,Terminated,5,0,0,Stroke,drug or biologic,Early,6,All,AllOther,0,NA,0,2014,2014,731,0,Phase 1,1,safety,1,1.791759469228055,"(1,2]"
1344,1436,a pilot study of ga-68-dota-toc imaging in participants with small bowel carcinoid tumors,Withdrawn,7,0,0,Small Bowel Carcinoid Tumor,drug or biologic,Early,NA,All,AllOther,0,NA,0,2017,2018,364,0,Phase 1,1,NA,1,NA,NA
500,520,alternative neoadjuvant chemotherapy in resectable and borderline resectable pancreatic cancer,Recruiting,2,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,30,All,AllOther,1,1,0,2018,2018,1096,1,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
2066,2458,study of three different stomach acid reducing agents when given with palbociclib (pd-0332991) and food,Completed,4,0,0,Healthy,drug or biologic,Early,27,All,Industry&Combos,1,1,4,2014,2014,61,1,Phase 1,0,NA,0,3.295836866004329,"(3,4]"
3205,4455,re-treatment from a phase i study of msc-afp in patients with perianal fistulas,Completed,4,0,0,Perianal Fistula|Cryptoglandular Perianal Fistula|Crohn's Perianal Fistula,drug or biologic,Early,7,All,AllOther,0,NA,0,2017,2017,873,0,Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
3769,6515,safety and tolerability of cilofexor in participants with primary sclerosing cholangitis (psc) and compensated cirrhosis,Recruiting,2,0,0,Primary Sclerosing Cholangitis|Compensated Cirrhosis,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2019,2019,776,0,Phase 1,1,safety,1,2.995732273553991,"(2,3]"
224,227,a study of niclosamide in patients with resectable colon cancer,Terminated,5,0,0,Colon Cancer,drug or biologic,Early,1,All,AllOther,0,NA,4,2016,2017,35,0,Phase 1,1,NA,1,0,NA
1253,1338,durvalumab and tremelimumab in treating patients with microsatellite stable metastatic colorectal cancer to the liver,Completed,4,0,0,Metastatic Carcinoma in the Liver|MLH1 Gene Mutation|MSH6 Gene Mutation|PMS2 Gene Mutation|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,drug or biologic,Early,9,All,NIH&Combos,0,NA,0,2016,2017,881,0,Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
716,750,fecal microbial transplantation for c. difficile and/or ulcerative colitis or indeterminate colitis,"Active, not recruiting",1,0,0,Clostridium Difficile Infection|Ulcerative Colitis|Indeterminate Colitis,drug or biologic,Early,12,All,AllOther,0,NA,0,2017,2013,3163,0,Early Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
3976,7529,"pembrolizumab in treating younger patients with recurrent, progressive, or refractory high-grade gliomas, diffuse intrinsic pontine gliomas, hypermutated brain tumors, ependymoma or medulloblastoma",Recruiting,2,0,0,Constitutional Mismatch Repair Deficiency Syndrome|Lynch Syndrome|Malignant Glioma|Recurrent Brain Neoplasm|Recurrent Childhood Ependymoma|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma|Refractory Brain Neoplasm|Refractory Diffuse Intrinsic Pontine Glioma|Refractory Ependymoma|Refractory Medulloblastoma,drug or biologic,Early,110,All,NIH&Combos,0,NA,0,2015,2015,3511,0,Phase 1,1,NA,1,4.700480365792417,"(4,5]"
1760,1971,safety and effect of l. reuteri on biomarkers of inflammation in healthy infants with colic,Completed,4,0,0,Gastrointestinal|Colic,drug or biologic,Early,21,All,AllOther,1,0,0,2013,2013,943,1,Phase 1,4,safety,2,3.044522437723423,"(3,4]"
4134,8972,"a study of hypoxia-inducible factor 1a (hif1a) messenger ribonucleic acid (mrna) antagonist (ro7070179), to demonstrate proof-of-mechanism in adult participants with hepatocellular carcinoma (hcc)",Completed,4,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,9,All,Industry&Combos,0,NA,0,2015,2016,630,0,Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
2599,3496,a research study of nnc0165-1875 alone or together with semaglutide in people who are overweight or obese,Completed,4,0,0,Obesity and Overweight,drug or biologic,Early,88,Male,Industry&Combos,1,0,0,2018,2018,302,1,Phase 1,4,NA,2,4.477336814478207,"(4,5]"
3360,4908,open-label multicenter phase 1 study of tbi 302 as second-line therapy in patients with hepatocellular carcinoma,Unknown status,8,0,0,Hepatocellular Carcinoma,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2019,2019,366,0,Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
2036,2407,a lactation study in women who are breastfeeding or pumping and are receiving linaclotide therapeutically,Completed,4,0,0,Breast Feeding|Constipation|Irritable Bowel Syndrome,drug or biologic,Early,7,Female,Industry&Combos,0,NA,4,2014,2014,1765,0,Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
587,613,ulixertinib/palbociclib in patients with advanced pancreatic and other solid tumors,Recruiting,2,0,0,"Tumor, Solid|Pancreatic Cancer",drug or biologic,Early,45,All,Industry&Combos,0,NA,0,2018,2018,1728,0,Phase 1,1,NA,1,3.8066624897703196,"(3,4]"
3202,4448,broccoli sprout extracts in healthy volunteers: a pilot study of nrf2 pathway modulation in oral mucosa,Completed,4,0,0,Healthy Subject,drug or biologic,Early,10,All,NIH&Combos,0,NA,4,2013,2014,31,0,Early Phase 1,1,NA,1,2.302585092994046,"(2,3]"
1827,2081,glypican 3-specific chimeric antigen receptor expressed in t cells for patients with pediatric solid tumors (gap),Recruiting,2,0,0,Liver Cancer,drug or biologic,Early,18,All,AllOther,0,NA,0,2016,2018,1111,0,Phase 1,1,NA,1,2.8903717578961645,"(2,3]"
2284,2854,a study of abemaciclib in participants with varying degrees of liver impairment,Completed,4,1,1,Hepatic Insufficiency,drug or biologic,Early,35,All,Industry&Combos,0,1,4,2015,2015,153,0,Phase 1,1,NA,1,3.5553480614894135,"(3,4]"
9,9,phase 1b study of car2anti-cea car-t cell hepatic infusions for pancreatic carcinoma patients with cea+ liver metastases,"Active, not recruiting",1,0,0,Metastatic Pancreatic Carcinoma,drug or biologic,Early,6,All,Industry&Combos,0,NA,0,2019,2019,731,0,Phase 1,1,NA,1,1.791759469228055,"(1,2]"
843,884,direct peritoneal resuscitation in gastroschisis,Terminated,5,0,0,Gastroschisis,drug or biologic,Early,3,All,AllOther,1,0,4,2017,2018,993,1,Early Phase 1,0,NA,0,1.0986122886681098,"(1,2]"
3241,4549,phase i assay-guided trial of anti-inflammatory phytochemicals in patients with advanced cancer,Completed,4,0,0,Solid Cancers,drug or biologic,Early,22,All,AllOther,0,NA,0,2013,2013,1157,0,Phase 1,1,NA,1,3.091042453358316,"(3,4]"
147,147,treatment of type i diabetes by islet transplantation into the gastric submucosa study protocol,"Active, not recruiting",1,0,0,"Diabetes Mellitus, Type 1",drug or biologic,Early,3,All,AllOther,0,NA,0,2015,2016,2132,0,Phase 1,1,NA,1,1.0986122886681098,"(1,2]"
2101,2509,study of sbp-101 in pancreatic cancer,Completed,4,0,0,Pancreatic Cancer|Ductal Adenocarcinoma of the Pancreas,drug or biologic,Early,29,All,Industry&Combos,0,NA,0,2016,2016,639,0,Phase 1,1,NA,1,3.367295829986474,"(3,4]"
565,589,adjuvant hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer,Completed,4,0,0,Locally Advanced Malignant Neoplasm|Gastric Cancer,drug or biologic,Early,4,All,AllOther,0,NA,0,2016,2016,974,0,Phase 1,1,NA,1,1.3862943611198906,"(1,2]"
1655,1822,modified immune cells (autologous dendritic cells) and a vaccine (prevnar) after high-dose external beam radiation therapy in treating patients with unresectable liver cancer,Recruiting,2,0,0,Stage III Hepatocellular Carcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma,drug or biologic,Early,26,All,NIH&Combos,0,NA,0,2019,2019,1080,0,Early Phase 1,1,NA,1,3.258096538021482,"(3,4]"
1511,1639,a pilot study of folfirinox in combination with neoadjuvant radiation for gastric and ge junction cancers,"Active, not recruiting",1,1,1,GastroEsophageal Cancer,drug or biologic,Early,25,All,NIH&Combos,0,NA,0,2017,2017,392,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
3356,4893,treatment of recurrent clostridium difficile infection with rbx7455,Completed,4,0,0,Clostridium Difficile Infection,drug or biologic,Early,30,All,Industry&Combos,1,1,0,2016,2016,1359,1,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
361,369,ph 1b trial with adi-peg 20 plus nab-paclitaxel and gemcitabine in subjects with pancreatic cancer,Completed,4,0,0,Advanced Pancreatic Cancer,drug or biologic,Early,21,All,Industry&Combos,0,NA,0,2014,2014,900,0,Phase 1,1,NA,1,3.044522437723423,"(3,4]"
1176,1251,to investigate the gastrointestinal behaviour of two triple combination products in healthy male volunteers,Completed,4,1,1,Common Cold,drug or biologic,Early,28,Male,Industry&Combos,1,0,0,2018,2018,28,1,Phase 1,0,NA,0,3.332204510175204,"(3,4]"
396,407,phase 1b study of ksp/qrh dimer for detection of neoplasia in the esophagus,Recruiting,2,0,0,Barrett Esophagus,drug or biologic,Early,50,All,AllOther,0,NA,2,2019,2019,937,0,Phase 1,1,NA,1,3.912023005428146,"(3,4]"
411,422,binimetinib and hydroxychloroquine in treating patients with kras mutant metastatic pancreatic cancer,Recruiting,2,0,0,Metastatic Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8,drug or biologic,Early,39,All,NIH&Combos,0,NA,0,2019,2019,801,0,Phase 1,1,NA,1,3.6635616461296463,"(3,4]"
1323,1413,phase ib study of sunitinib alternating with regorafenib in patients with metastatic and/or unresectable gist,Completed,4,1,1,Gastrointestinal Stromal Tumor,drug or biologic,Early,14,All,Industry&Combos,0,NA,0,2014,2014,884,0,Phase 1,1,NA,1,2.6390573296152584,"(2,3]"
2257,2796,mek162 in healthy subjects with normal hepatic function and subjects with impaired hepatic function,Terminated,5,0,0,Hepatic Impairment,drug or biologic,Early,27,All,Industry&Combos,0,NA,0,2014,2014,884,0,Phase 1,1,NA,1,3.295836866004329,"(3,4]"
1784,2010,"talimogene laherparepvec, chemotherapy, and radiation therapy before surgery in treating patients with locally advanced or metastatic rectal cancer",Recruiting,2,0,0,Rectal Adenocarcinoma|Stage III Rectal Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7,drug or biologic,Early,21,All,NIH&Combos,0,NA,0,2017,2017,1471,0,Phase 1,1,NA,1,3.044522437723423,"(3,4]"
1459,1571,effect of proton pump inhibitors on gut microbiota and systemic inflammation in older adults,Completed,4,0,0,Healthy Volunteers,drug or biologic,Early,25,All,AllOther,0,NA,4,2016,2016,214,0,Early Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
2606,3504,a phase 1 study to evaluate the pharmacokinetics of gs-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment,Completed,4,0,0,Chronic Hepatitis C,drug or biologic,Early,33,All,Industry&Combos,1,1,0,2013,2013,153,1,Phase 1,0,pharmacokinetics only,0,3.4965075614664802,"(3,4]"
3752,6364,"evaluation of the safety, tolerability, and efficacy of mdgn-002 in adults with moderate to severe active crohn's disease",Recruiting,2,0,0,Crohn Disease,drug or biologic,Early,8,All,Industry&Combos,0,NA,0,2017,2017,1510,0,Phase 1,1,safety/efficacy,1,2.0794415416798357,"(2,3]"
1487,1610,"guadecitabine and durvalumab in treating patients with advanced liver, pancreatic, bile duct, or gallbladder cancer",Recruiting,2,0,0,"Extrahepatic Bile Duct Adenocarcinoma, Biliary Type|Gallbladder Adenocarcinoma, Biliary Type|Metastatic Pancreatic Adenocarcinoma|Recurrent Cholangiocarcinoma|Recurrent Gallbladder Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Intrahepatic Cholangiocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Gallbladder Cancer AJCC V7|Stage III Hepatocellular Carcinoma AJCC v7|Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Gallbladder Cancer AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Gallbladder Carcinoma|Unresectable Pancreatic Carcinoma",drug or biologic,Early,90,All,NIH&Combos,0,NA,0,2017,2018,1096,0,Phase 1,1,NA,1,4.499809670330265,"(4,5]"
742,776,a pilot study of bxcl701 in patients with pancreatic cancer,Recruiting,2,0,0,"Cancer of Pancreas|Cancer of the Pancreas|Neoplasms, Pancreatic|Pancreas Cancer|Pancreatic Cancer",drug or biologic,Early,15,All,Industry&Combos,0,NA,0,2019,2019,783,0,Early Phase 1,1,NA,1,2.70805020110221,"(2,3]"
85,85,prospective phase i study of gax for metastatic pancreatic cancer,Withdrawn,7,0,0,Pancreatic Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2015,2016,304,0,Phase 1,1,NA,1,NA,NA
2888,3873,"ricolinostat, gemcitabine hydrochloride, and cisplatin in treating patients with unresectable or metastatic cholangiocarcinoma",Withdrawn,7,0,0,Non-Resectable Cholangiocarcinoma|Recurrent Cholangiocarcinoma|Stage III Extrahepatic Bile Duct Cancer|Stage III Intrahepatic Cholangiocarcinoma|Stage IIIA Hilar Cholangiocarcinoma|Stage IIIB Hilar Cholangiocarcinoma|Stage IVA Extrahepatic Bile Duct Cancer|Stage IVA Hilar Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma|Stage IVB Extrahepatic Bile Duct Cancer|Stage IVB Hilar Cholangiocarcinoma|Stage IVB Intrahepatic Cholangiocarcinoma|Unresectable Extrahepatic Bile Duct Carcinoma,drug or biologic,Early,NA,All,NIH&Combos,0,NA,0,2016,2017,1614,0,Phase 1,1,NA,1,NA,NA
1691,1870,berberine chloride in preventing colorectal cancer in patients with ulcerative colitis in remission,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Early,18,All,NIH&Combos,1,0,1,2015,2016,610,1,Phase 1,2,NA,2,2.8903717578961645,"(2,3]"
1628,1788,study to evaluate the effects of rm-131 in patients with chronic constipation,Completed,4,0,0,Chronic Constipation,drug or biologic,Early,18,All,Industry&Combos,1,0,0,2014,2014,92,1,Phase 1,4,NA,2,2.8903717578961645,"(2,3]"
749,785,study to establish maximum tolerated dose (mtd) of cyberknife in patients with un-resectable pancreas cancer (tl002),Terminated,5,0,0,Pancreas Cancer|Pancreatic Cancer|Adenocarcinoma of the Pancreas|Pancreas Adenocarcinoma|Pancreatic Adenocarcinoma,drug or biologic,Early,30,All,AllOther,0,NA,0,2016,2015,1044,0,Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
4037,7624,study to determine the effect of bms-791325 on the ecg qtcf interval in healthy subjects,Completed,4,0,0,Hepatitis C,drug or biologic,Early,59,All,Industry&Combos,3,0,NA,2014,2014,30,3,Phase 1,4,NA,2,4.07753744390572,"(4,5]"
3201,4445,"a study to understand the safety, tolerability, and activity of drug in body over a period of time of azd2693, in subjects of non-childbearing potential in overweight but otherwise healthy subjects, and healthy chinese and japanese subjects",Recruiting,2,0,0,Metabolic Disorders|Non-alcoholic Steatohepatitis,drug or biologic,Early,68,All,Industry&Combos,1,0,0,2019,2019,704,1,Phase 1,3,safety,2,4.219507705176107,"(4,5]"
3904,7250,probiotics in the reduction of antibiotic associated diarrhea,Terminated,5,0,0,Clostridium Difficile,other,Others,1,All,AllOther,1,0,1,2015,2015,122,1,Others,3,NA,2,0,NA
3079,4152,study of ds-8201a in subjects with advanced solid malignant tumors,"Active, not recruiting",1,1,1,Advanced Solid Tumors,drug or biologic,Early,292,All,Industry&Combos,NA,1,0,2015,2015,1249,NA,Phase 1,0,NA,0,5.676753802268282,"(5,6]"
1396,1497,"pharmacokinetic study comparing topical, rectal, and oral quetiapine",Completed,4,0,0,Dementia|Delirium,drug or biologic,Early,10,All,AllOther,0,NA,4,2014,2014,761,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
3197,4434,"treating acute pancreatitis with dabigatran, a pilot study",Recruiting,2,0,0,Acute Pancreatitis,drug or biologic,Early,30,All,AllOther,1,0,0,2019,2019,980,1,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
2083,2481,improving medication-taking after liver transplant,Completed,4,0,0,Nonadherence|Tacrolimus|Pediatric Liver Transplant Recipients,behavioral,Others,7,All,Industry&Combos,0,NA,0,2013,2014,639,0,Others,1,NA,1,1.9459101490553132,"(1,2]"
3288,4649,a study of xmab Â®18087 in subjects with net and gist,Recruiting,2,0,0,Neuroendocrine Tumor|Gastrointestinal Neoplasm,drug or biologic,Early,87,All,Industry&Combos,NA,NA,0,2018,2018,1134,NA,Phase 1,0,NA,0,4.465908118654584,"(4,5]"
1584,1733,"ganetespib and ziv-aflibercept in refractory gastrointestinal carcinomas, non-squamous non-small cell lung carcinomas, urothelial carcinomas, and sarcomas",Terminated,5,1,1,Neoplasms,drug or biologic,Early,5,All,NIH&Combos,0,NA,0,2014,2014,450,0,Phase 1,1,NA,1,1.6094379124341003,"(1,2]"
3934,7327,td-6450 sad and mad in healthy subjects,Completed,4,0,0,Hepatitis C,drug or biologic,Early,111,All,Industry&Combos,1,0,0,2013,2014,181,1,Phase 1,3,NA,2,4.709530201312334,"(4,5]"
548,570,neoantigen dna vaccine in pancreatic cancer patients following surgical resection and adjuvant chemotherapy,"Active, not recruiting",1,0,0,Pancreatic Cancer|Pancreas Cancer|Cancer of the Pancreas,drug or biologic,Early,13,All,NIH&Combos,0,NA,0,2017,2018,1333,0,Phase 1,1,NA,1,2.5649493574615367,"(2,3]"
1072,1130,contrast-enhanced ultrasound identification of sentinel nodes in esophageal cancer,Recruiting,2,0,0,Esophagus,drug or biologic,Early,40,All,NIH&Combos,0,NA,2,2018,2018,1121,0,Early Phase 1,1,NA,1,3.6888794541139363,"(3,4]"
1507,1635,"safety and pharmacokinetics of sm04755 in subjects with advanced colorectal, gastric, hepatic, or pancreatic cancer",Completed,4,0,0,Colorectal Cancer|Gastric Cancer|Hepatic Cancer|Pancreatic Cancer,drug or biologic,Early,13,All,Industry&Combos,0,NA,0,2014,2014,335,0,Phase 1,1,safety,1,2.5649493574615367,"(2,3]"
1438,1547,"heated carboplatin in treating patients with stage ii-iv ovarian, fallopian tube, or peritoneal cancer",Completed,4,0,0,FIGO Stage IIC-IV Ovarian Carcinoma|Fallopian Tube Carcinoma|Peritoneal Carcinoma,drug or biologic,Early,30,Female,AllOther,0,NA,0,2014,2014,1188,0,Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
3468,5268,"a trial of mfolfiri with mek162 in patients with advanced ras (hras, nras, or kras) positive metastatic colorectal cancers",Recruiting,2,0,0,Advanced KRAS Positive Metastatic Colorectal Cancer,drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2015,2016,2060,0,Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
3848,6969,a study of edp-514 in healthy subjects (part 1) and patients with chronic hepatitis b virus infection (part 2),Recruiting,2,0,0,Chronic HBV Infection,drug or biologic,Early,98,All,Industry&Combos,NA,0,0,2019,2019,736,NA,Phase 1,4,NA,2,4.584967478670572,"(4,5]"
1004,1059,safety and pharmacokinetics study of linzagolix in female subjects with normal and impaired hepatic function,Completed,4,0,0,Hepatic Impairment|Healthy Participants,drug or biologic,Early,24,Female,Industry&Combos,1,1,4,2019,2019,161,1,Phase 1,0,safety,0,3.1780538303479458,"(3,4]"
1604,1756,safety of sublingual dmlt for etec,Completed,4,0,0,Gastroenteritis Escherichia Coli,drug or biologic,Early,80,All,NIH&Combos,1,0,1,2014,2014,968,1,Phase 1,0,safety,0,4.382026634673881,"(4,5]"
1954,2293,role of omalizumab in reducing the incidence of oxaliplatin-induced hypersensitivity reaction,Completed,4,0,0,Colon Cancer,drug or biologic,Early,9,All,AllOther,0,NA,4,2014,2014,1214,0,Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
2128,2551,research study investigating study medicine (nnc9204-1177) for weight management in people with overweight or obesity,Completed,4,0,0,Metabolism and Nutrition Disorder|Obesity,drug or biologic,Early,99,All,Industry&Combos,1,0,0,2017,2017,809,1,Phase 1,4,NA,2,4.59511985013459,"(4,5]"
1773,1992,contrast enhanced ultrasound with lumason in detecting liver cancer in participants with cirrhosis,Completed,4,0,0,Cirrhosis,drug or biologic,Early,9,All,NIH&Combos,0,NA,4,2018,2018,977,0,Early Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
3010,4039,"drug-drug interaction study between edp-305, fluconazole and quinidine in healthy volunteers",Completed,4,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,48,All,Industry&Combos,0,1,4,2018,2018,27,0,Phase 1,1,NA,1,3.871201010907891,"(3,4]"
245,248,initial feasibility study to treat resectable pancreatic cancer with a planar ldr source,Recruiting,2,0,0,Pancreas Cancer|Cancer,device,Others,12,All,Industry&Combos,0,NA,0,2017,2017,1272,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
2180,2644,intraperitoneal mcy-m11 (mesothelin-targeting car) for treatment of advanced ovarian cancer and peritoneal mesothelioma,"Active, not recruiting",1,0,0,Peritoneal Mesothelioma|Fallopian Tube Adenocarcinoma|Adenocarcinoma of the Ovary|Primary Peritoneal Carcinoma,drug or biologic,Early,14,All,Industry&Combos,NA,1,0,2018,2018,899,NA,Phase 1,0,NA,0,2.6390573296152584,"(2,3]"
2063,2452,pioglitazone for idiopathic gastroparesis,Recruiting,2,0,0,Gastroparesis,drug or biologic,Early,10,All,AllOther,0,NA,0,2020,2019,1071,0,Early Phase 1,1,NA,1,2.302585092994046,"(2,3]"
614,640,"a study of armed, activated t-cells in patients with advanced pancreatic cancer",Recruiting,2,0,0,Pancreatic Cancer|Advanced Pancreatic Cancer|Pancreatic Adenocarcinoma|Pancreatic Neoplasms,drug or biologic,Early,25,All,AllOther,0,NA,0,2019,2019,897,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
2102,2510,immunotherapy study of evofosfamide in combination with ipilimumab,Unknown status,8,0,0,Pancreatic Cancer|Melanoma|Squamous Cell Carcinoma of the Head and Neck|Prostate Cancer,drug or biologic,Early,69,All,Industry&Combos,NA,NA,0,2017,2017,601,NA,Phase 1,0,NA,0,4.23410650459726,"(4,5]"
1121,1191,assessment of the single dose pharmacokinetics and tolerability of sativex in patients with impaired hepatic function and healthy patients,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,32,All,Industry&Combos,1,1,0,2013,2013,304,1,Phase 1,0,pharmacokinetics only,0,3.4657359027997265,"(3,4]"
1608,1760,a pharmacokinetic study of padsevonil in study participants with either normal or moderately impaired hepatic function,Terminated,5,0,0,Healthy Study Participants|Impaired Hepatic Function,drug or biologic,Early,12,All,Industry&Combos,1,1,4,2019,2019,207,1,Phase 1,0,NA,0,2.4849066497880004,"(2,3]"
379,388,fecal microbiota transplant for inflammatory bowel disease,Completed,4,0,0,Inflammatory Bowel Disease,drug or biologic,Early,59,All,AllOther,0,NA,0,2015,2015,568,0,Early Phase 1,1,NA,1,4.07753744390572,"(4,5]"
873,916,effectiveness of physiologic testing in ppi non-responders,Enrolling by invitation,3,0,0,Gastro Esophageal Reflux,drug or biologic,Early,240,All,AllOther,0,NA,4,2017,2017,1553,0,Early Phase 1,1,NA,1,5.480638923341991,"(5,6]"
2209,2698,single dose of pf-06835919 escalation study in healthy adult subjects,Completed,4,0,0,Non-alcoholic Fatty Liver Disease,drug or biologic,Early,16,All,Industry&Combos,NA,0,0,2016,2016,92,NA,Phase 1,2,NA,2,2.772588722239781,"(2,3]"
1832,2086,pembrolizumab and xl888 in patients with advanced gastrointestinal cancer,Recruiting,2,0,0,Colorectal Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Recurrent Colorectal Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Pancreatic Cancer|Unresectable Pancreatic Carcinoma,drug or biologic,Early,50,All,Industry&Combos,0,1,0,2017,2017,1425,0,Phase 1,1,NA,1,3.912023005428146,"(3,4]"
3036,4080,study of safety & efficacy of the combination of ljm716 & byl719 in patients with previously treated esophageal squamous cell carcinoma (escc),Completed,4,0,0,Esophageal Squamous Cell Carcinoma,drug or biologic,Early,48,All,Industry&Combos,1,0,0,2013,2013,1043,1,Phase 1,0,safety/efficacy,0,3.871201010907891,"(3,4]"
2465,3230,assessing the role of a fermented soy extract in inflammation and the human microbiome,Completed,4,0,0,Obesity,other,Others,22,All,AllOther,1,1,4,2016,2016,517,1,Others,0,NA,0,3.091042453358316,"(3,4]"
3212,4482,a study of guselkumab in participants with familial adenomatous polyposis,"Active, not recruiting",1,0,0,Adenomatous Polyposis Coli,drug or biologic,Early,77,All,Industry&Combos,1,0,0,2018,2018,984,1,Phase 1,2,NA,2,4.343805421853684,"(4,5]"
1726,1919,"sirolimus, gemcitabine hydrochloride, and cisplatin in treating patients at high risk for cholangiocarcinoma recurrence after liver transplant or surgery",Completed,4,0,0,Hepatic Complication,drug or biologic,Early,1,All,NIH&Combos,0,NA,0,2013,2013,1004,0,Phase 1,1,NA,1,0,NA
1270,1356,a study to evaluate the effect of increased stomach ph on evacetrapib in healthy participants,Completed,4,1,1,Healthy,drug or biologic,Early,34,All,Industry&Combos,0,1,4,2015,2015,90,0,Phase 1,1,NA,1,3.5263605246161616,"(3,4]"
2480,3263,the effect of alendronate on the immune response to hepatitis b vaccine in healthy adults,Completed,4,0,0,Hepatitis B,drug or biologic,Early,28,All,AllOther,1,0,1,2014,2014,671,1,Phase 1,3,NA,2,3.332204510175204,"(3,4]"
380,390,dendritic cell vaccine and chemotherapy for patients with pancreatic cancer,Terminated,5,0,0,Pancreatic Cancer,drug or biologic,Early,7,All,AllOther,1,1,0,2015,2015,632,1,Phase 1,0,NA,0,1.9459101490553132,"(1,2]"
205,208,"effect of relamorelin on satiation, gastric volume, gastric accommodation and distal gastric function in healthy volunteers",Completed,4,0,0,Gastric Motility,drug or biologic,Early,16,All,Industry&Combos,1,0,4,2015,2015,61,1,Phase 1,4,NA,2,2.772588722239781,"(2,3]"
3593,5623,phase 1 study of mgd007 in relapsed/refractory metastatic colorectal carcinoma,Completed,4,0,0,Colorectal Carcinoma,drug or biologic,Early,95,All,Industry&Combos,1,1,0,2014,2014,1370,1,Phase 1,0,NA,0,4.553876891600541,"(4,5]"
1925,2246,a study of tak-164 in participants with advanced gastrointestinal (gi) cancer expressing guanylyl cyclase c (gcc),Terminated,5,1,1,"Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies",drug or biologic,Early,31,All,Industry&Combos,NA,1,4,2018,2018,675,NA,Phase 1,0,NA,0,3.4339872044851463,"(3,4]"
2614,3513,a dose escalation trial of stereotactic body radiotherapy (sbrt) after induction chemotherapy for locally advanced pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,other,Others,11,All,AllOther,0,NA,0,2015,2015,2557,0,Others,1,NA,1,2.3978952727983707,"(2,3]"
545,567,car-t hepatic artery infusions or pancreatic venous infusions for cea-expressing liver metastases or pancreas cancer,"Active, not recruiting",1,0,0,Liver Metastases,drug or biologic,Early,5,All,Industry&Combos,0,NA,0,2016,2017,698,0,Phase 1,1,NA,1,1.6094379124341003,"(1,2]"
2010,2372,sensory evaluation of dexlansoprazole delayed-release orally disintegrating tablets,Completed,4,1,1,Gastroesophageal Reflux Disease|Erosive Esophagitis|Heartburn,drug or biologic,Early,8,All,Industry&Combos,0,NA,0,2014,2014,0,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
2227,2742,a study of vantictumab (omp-18r5) in combination with nab-paclitaxel and gemcitabine in previously untreated stage iv pancreatic cancer,Completed,4,0,0,Pancreatic Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,30,All,Industry&Combos,0,1,0,2013,2013,1491,0,Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
1627,1787,gcsf adjunct therapy for biliary atresia,Completed,4,0,0,Biliary Atresia,drug or biologic,Early,6,All,AllOther,0,NA,4,2018,2018,746,0,Early Phase 1,1,NA,1,1.791759469228055,"(1,2]"
322,327,effects of fish oil on the colon mucosa,Completed,4,0,0,Physiological Effects of Fish Oil,other,Others,48,All,AllOther,0,NA,4,2013,2013,1006,0,Others,1,NA,1,3.871201010907891,"(3,4]"
1547,1685,vm110 in detection of microscopic tumors: a phase i study,Terminated,5,0,0,Ovarian Cancer|Pancreatic Cancer,other,Others,1,All,AllOther,0,NA,2,2017,2017,636,0,Others,1,NA,1,0,NA
1294,1381,a hepatic impairment study for pf-04965842.,Completed,4,1,1,Hepatic Impairment,drug or biologic,Early,24,All,Industry&Combos,1,NA,4,2018,2018,211,1,Phase 1,0,NA,0,3.1780538303479458,"(3,4]"
3045,4090,allogeneic human mesenchymal stem cells (hmsc) in patients with fistulizing crohn's disease via perifistula injections (galene),Withdrawn,7,0,0,Crohn's Disease|Fistulizing Crohn's Disease|Stem Cells,drug or biologic,Early,NA,All,AllOther,0,NA,0,2016,2019,2192,0,Phase 1,1,NA,1,NA,NA
2990,4008,outcomes of renal function in hepatorenal syndrome (hrs) determined by comparison of target mean arterial pressure (map) of 65 - 70 mmhg versus Ã¢â°Â¥ 85 mmhg,Completed,4,0,0,Hepatorenal Syndrome,drug or biologic,Early,18,All,AllOther,1,0,0,2016,2015,1106,1,Early Phase 1,0,NA,0,2.8903717578961645,"(2,3]"
2145,2581,tamoxifen to treat barrett's metaplasia,Terminated,5,0,0,Barrett Metaplasia,drug or biologic,Early,7,All,AllOther,0,NA,1,2014,2014,713,0,Early Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
2144,2580,pembrolizumab in treating patients with metastatic or unresectable gastroesophageal adenocarcinoma,Recruiting,2,0,0,Advanced Gastroesophageal Junction Adenocarcinoma|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage IV Esophageal Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Gastroesophageal Junction Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Unresectable Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,15,All,NIH&Combos,0,NA,0,2018,2018,1461,0,Early Phase 1,1,NA,1,2.70805020110221,"(2,3]"
12,12,irritable bowel syndrome and control volunteers: diet challenge,Recruiting,2,0,0,IBS - Irritable Bowel Syndrome,other,Others,72,All,NIH&Combos,0,1,2,2019,2019,1022,0,Others,1,NA,1,4.276666119016055,"(4,5]"
164,164,curcumin in combination with 5fu for colon cancer,"Active, not recruiting",1,0,0,Metastatic Colon Cancer,drug or biologic,Early,13,All,AllOther,0,NA,0,2016,2016,1473,0,Early Phase 1,1,NA,1,2.5649493574615367,"(2,3]"
1563,1704,nivolumab +/- relatlimab prior to chemoradiation with ii/iii gastro/esophageal cancer,"Active, not recruiting",1,0,0,Gastric Cancer|Esophageal Cancer|GastroEsophageal Cancer,drug or biologic,Early,32,All,Industry&Combos,0,1,0,2017,2017,1666,0,Phase 1,1,NA,1,3.4657359027997265,"(3,4]"
1512,1640,a study to determine the effect of ach-0144471 on subjects with hi compared to healthy matches,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,16,All,Industry&Combos,1,1,0,2018,2018,121,1,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
250,254,ultra low-dose radiation therapy in treating patients with stage i-iv stomach malt lymphoma,Recruiting,2,0,0,Gastric Mucosa-Associated Lymphoid Tissue Lymphoma,drug or biologic,Early,24,All,NIH&Combos,0,NA,0,2018,2019,824,0,Early Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
2061,2447,a phase i study of mln6907 in patients with metastatic colorectal,Completed,4,0,0,Imaging of Solid Gastrointestinal Tumors,drug or biologic,Early,20,All,Industry&Combos,0,NA,2,2014,2015,92,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
3582,5581,safety and efficacy study of cc-122 combined with sorafenib for primary liver cancer,Terminated,5,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2014,2015,705,0,Phase 1,1,safety/efficacy,1,2.4849066497880004,"(2,3]"
1698,1879,"food-effect, drug-drug interaction (ddi), and formulation bridging study",Completed,4,0,0,Inflammatory Bowel Disease,drug or biologic,Early,36,All,Industry&Combos,3,0,4,2018,2018,32,3,Phase 1,0,NA,0,3.58351893845611,"(3,4]"
1781,2005,"ph 1 study of vs-4718, a fak inhibitor, in combination with nab-paclitaxel and gemcitabine in advanced cancer subjects",Terminated,5,0,0,Pancreatic Cancer,drug or biologic,Early,13,All,Industry&Combos,1,0,0,2016,2015,488,1,Phase 1,0,NA,0,2.5649493574615367,"(2,3]"
1801,2034,"a pilot, dose escalating study on vlx103 in moderate alcoholic steatohepatitis",Withdrawn,7,0,0,Hepatic Steatosis,drug or biologic,Early,NA,All,NIH&Combos,NA,1,0,2017,2017,247,NA,Phase 1,0,NA,0,NA,NA
3021,4057,dose-escalation study of palbociclib + nab-paclitaxel in mpdac,Completed,4,1,1,Metastatic Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,76,All,Industry&Combos,NA,NA,0,2015,2015,1052,NA,Phase 1,0,NA,0,4.330733340286331,"(4,5]"
94,94,therapeutic modulation of the intestinal creatine kinase system in inflammatory bowel disease (ibd),Recruiting,2,0,0,"Colitis, Ulcerative",drug or biologic,Early,12,All,AllOther,1,0,0,2015,2016,2070,1,Early Phase 1,3,NA,2,2.4849066497880004,"(2,3]"
1477,1593,"tas-102 and radiation therapy in treating patients with rectal cancer that is locally recurrent, metastatic, or cannot be removed by surgery","Active, not recruiting",1,0,0,Rectal Adenocarcinoma|Recurrent Rectal Carcinoma|Stage IV Rectal Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7,drug or biologic,Early,7,All,NIH&Combos,0,NA,0,2017,2017,826,0,Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
1762,1974,donor-alloantigen-reactive regulatory t cell (dartregs) in liver transplantation,Terminated,5,1,1,Liver Transplantation,drug or biologic,Early,15,All,IndustryNIHPartnership,1,1,0,2014,2014,1644,1,Phase 1,0,NA,0,2.70805020110221,"(2,3]"
941,989,tas-102 and radioembolization with 90y resin microspheres for chemo-refractory colorectal liver metastases,"Active, not recruiting",1,0,0,Colon Cancer|Rectal Cancer|Liver Metastases,drug or biologic,Early,21,All,Industry&Combos,0,NA,0,2015,2017,1592,0,Phase 1,1,NA,1,3.044522437723423,"(3,4]"
494,512,perioperative folfirinox for patients with resectable pancreatic adenocarcinoma: a pilot study,Terminated,5,0,0,Pancreatic Ductal Adenocarcinoma (PDAC),drug or biologic,Early,1,All,AllOther,0,NA,0,2016,2016,639,0,Phase 1,1,NA,1,0,NA
2710,3634,th-302 plus doxorubicin delivered by trans-arterial chemoembolization (tace) in patients with hepatocellular carcinoma,Unknown status,8,0,0,Hepatocellular Carcinoma,drug or biologic,Early,20,All,Industry&Combos,0,1,0,2012,2014,365,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
636,663,evaluating the combined effect of vedolizumab and semi-vegetarian diet on ulcerative colitis.,Withdrawn,7,0,0,Ulcerative Colitis|Dietary Modification,drug or biologic,Early,NA,All,AllOther,0,NA,0,2017,2017,249,0,Early Phase 1,1,NA,1,NA,NA
3024,4062,"study to evaluate the safety, tolerability, pharmacokinetics and efficacy of gs-5745 (andecaliximab) in adults with moderate to severe active ulcerative colitis",Completed,4,1,1,Ulcerative Colitis,drug or biologic,Early,74,All,Industry&Combos,NA,0,0,2013,2013,648,NA,Phase 1,3,safety/efficacy,2,4.30406509320417,"(4,5]"
3109,4219,abi-m201 in adult subjects with mildly-to-moderately active ulcerative colitis,Terminated,5,0,0,Ulcerative Colitis Chronic Mild|Ulcerative Colitis Chronic Moderate,drug or biologic,Early,15,All,Industry&Combos,1,0,0,2019,2019,576,1,Phase 1,4,NA,2,2.70805020110221,"(2,3]"
3797,6684,a study of brontictuzumab with chemotherapy for subjects with previously treated metastatic colorectal cancer,Completed,4,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2017,2017,120,0,Phase 1,1,NA,1,1.9459101490553132,"(1,2]"
1631,1793,a study to evaluate the effect of hepatic insufficiency on the pharmacokinetics (pk) of acp-196,Completed,4,0,0,Hepatic Insufficiency,drug or biologic,Early,18,All,Industry&Combos,1,1,0,2021,2014,104,1,Phase 1,0,pharmacokinetics only,0,2.8903717578961645,"(2,3]"
2080,2476,a study of ly3314814 in participants with liver impairment,Withdrawn,7,0,0,Hepatic Impairment,drug or biologic,Early,NA,All,Industry&Combos,1,1,4,2018,2018,183,1,Phase 1,0,NA,0,NA,NA
3825,6824,pharmacokinetics of voxilaprevir in adults with normal renal function and severe renal impairment,Completed,4,1,1,HCV Infection,drug or biologic,Early,20,All,Industry&Combos,1,1,0,2015,2015,146,1,Phase 1,0,pharmacokinetics only,0,2.995732273553991,"(2,3]"
508,529,nab-paclitaxel plus gemcitabine with concurrent mr-guided imrt in patients with locally advanced pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,30,All,AllOther,0,NA,0,2014,2015,1209,0,Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
1105,1169,role of gastrointestinal microbes on digestion of resistant starch and tryptophan availability to humans,Unknown status,8,0,0,Type II Diabetes,other,Others,20,All,AllOther,1,1,4,2016,2017,334,1,Others,1,NA,1,2.995732273553991,"(2,3]"
2037,2408,an evaluation of the safety of intravenous tc 99m tilmanocept and a comparison of imaging with sulfur colloid in subjects with and without nash,Completed,4,0,0,Nonalcoholic Steatohepatitis|NASH - Nonalcoholic Steatohepatitis,drug or biologic,Early,6,All,Industry&Combos,NA,NA,2,2017,2017,459,NA,Phase 1,0,safety,0,1.791759469228055,"(1,2]"
3179,4372,a multiple ascending dose study to evaluate safety and tolerability of bfkb8488a in participants with type 2 diabetes mellitus and participants with non-alcoholic fatty liver disease,Completed,4,0,0,"Diabetes Mellitus, Type 2|Non-Alcoholic Fatty Liver Disease",drug or biologic,Early,154,All,Industry&Combos,1,0,0,2017,2017,1013,1,Phase 1,2,safety,2,5.0369526024136295,"(5,6]"
2000,2352,pharmacokinetic study of alpelisib in subjects with hepatic impairment.,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,23,All,Industry&Combos,1,1,4,2015,2015,650,1,Phase 1,0,NA,0,3.1354942159291497,"(3,4]"
3228,4524,"a phase 1, multi-center, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of minnelideÃ¢âÂ¢ capsules given alone or in combination with protein-bound paclitaxel in patients with advanced solid tumors",Recruiting,2,0,0,Advanced Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer Metastatic|Colo-rectal Cancer|Solid Tumor|Solid Carcinoma|Solid Carcinoma of Stomach|Cancer of Stomach,drug or biologic,Early,66,All,Industry&Combos,1,1,0,2017,2017,1391,1,Phase 1,0,safety,0,4.189654742026425,"(4,5]"
1081,1141,neomycin and metronidazole hydrochloride with or without polyethylene glycol in reducing infection in patients undergoing elective colorectal surgery,Recruiting,2,0,0,Colorectal Neoplasms|Diverticulitis|Inflammatory Bowel Diseases|Surgical Site Infection,drug or biologic,Early,224,All,AllOther,1,0,4,2017,2016,1491,1,Early Phase 1,0,NA,0,5.4116460518550396,"(5,6]"
69,69,pressure enabled drug delivery by pancreatic retrograde venous infusion for advanced pancreatic carcinoma,Withdrawn,7,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,NA,All,AllOther,0,NA,0,2020,2019,498,0,Phase 1,1,NA,1,NA,NA
1704,1887,probiotics for quality of life in autism spectrum disorders,Completed,4,1,1,Autism Spectrum Disorders|Anxiety,drug or biologic,Early,13,All,AllOther,3,0,0,2016,2016,487,3,Early Phase 1,3,NA,2,2.5649493574615367,"(2,3]"
2315,2912,alisertib and combination chemotherapy in treating patients with gastrointestinal tumors,Completed,4,0,0,Malignant Digestive System Neoplasm,drug or biologic,Early,14,All,NIH&Combos,0,NA,0,2014,2015,1129,0,Phase 1,1,NA,1,2.6390573296152584,"(2,3]"
50,50,study for the detection of duodenal papilla using capsule endoscopy and comparison of images with eus/ercp procedure.,Enrolling by invitation,3,0,0,Patients Indicated for Periampullary or Pancreaticobiliary Examination,device,Others,200,All,Industry&Combos,0,NA,4,2018,2018,644,0,Others,1,NA,1,5.298317366548036,"(5,6]"
3829,6837,value of ondansetron medication vs inhaled isopropyl therapy in the emergency department (vomiited),Recruiting,2,0,0,Nausea|Vomiting,drug or biologic,Early,300,All,AllOther,1,0,4,2017,2017,1598,1,Early Phase 1,0,NA,0,5.703782474656201,"(5,6]"
1634,1797,the use of domperidone for the relief of refractory upper gastrointestinal gi symptoms,Recruiting,2,0,0,Gastroparesis,drug or biologic,Early,40,All,AllOther,0,NA,0,2019,2014,2951,0,Early Phase 1,1,NA,1,3.6888794541139363,"(3,4]"
3271,4606,a study to evaluate immunotherapy combinations in participants with gastrointestinal malignancies,Completed,4,0,0,GastroEsophageal Cancer|Colorectal Cancer,drug or biologic,Early,44,All,Industry&Combos,NA,1,0,2018,2018,801,NA,Phase 1,0,NA,0,3.784189633918261,"(3,4]"
1441,1550,tremelimumab and durvalumab in treating patients with colorectal cancer with liver metastases that can be removed by surgery,"Active, not recruiting",1,0,0,Metastatic Carcinoma in the Liver|Resectable Mass|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,26,All,NIH&Combos,0,NA,0,2016,2016,1828,0,Phase 1,1,NA,1,3.258096538021482,"(3,4]"
174,175,intestinal permeability in preterm infants,Recruiting,2,0,0,Prematurity|Intestinal Permeability,drug or biologic,Early,200,All,AllOther,0,NA,4,2012,2013,3042,0,Phase 1,1,NA,1,5.298317366548036,"(5,6]"
2356,3001,study to evaluate the pharmacokinetics of firsocostat or fenofibrate in adults with normal and impaired hepatic function,Completed,4,1,1,Nonalcoholic Steatohepatitis (NASH),drug or biologic,Early,74,All,Industry&Combos,1,1,0,2016,2016,954,1,Phase 1,0,pharmacokinetics only,0,4.30406509320417,"(4,5]"
2398,3089,atorvastatin  Â± aspirin in lynch syndrome syndrome,Recruiting,2,0,0,Lynch Syndrome,drug or biologic,Early,46,All,AllOther,1,1,1,2020,2018,1452,1,Early Phase 1,0,NA,0,3.828641396489095,"(3,4]"
1837,2093,fecal microbial transplant for alcohol misuse in cirrhosis,Completed,4,0,0,Cirrhosis|Alcohol Abuse,drug or biologic,Early,20,All,Industry&Combos,1,0,0,2018,2018,799,1,Phase 1,2,NA,2,2.995732273553991,"(2,3]"
2495,3307,2-week study in people with nonalcoholic fatty liver disease,Completed,4,1,1,Non-alcoholic Steatohepatitis|Non-alcoholic Fatty Liver Disease,drug or biologic,Early,48,All,Industry&Combos,1,0,4,2018,2018,260,1,Phase 1,2,NA,2,3.871201010907891,"(3,4]"
2842,3808,a study of bbi608 in combination with standard chemotherapies in adult patients with pancreatic cancer,Completed,4,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,139,All,Industry&Combos,1,1,0,2014,2014,2131,1,Phase 1,0,NA,0,4.9344739331306915,"(4,5]"
2605,3503,"a study of ramucirumab plus pembrolizumab in participants with gastric or gej adenocarcinoma, nsclc, transitional cell carcinoma of the urothelium, or biliary tract cancer","Active, not recruiting",1,0,0,"Gastric Adenocarcinoma|Adenocarcinoma of the Gastroesophageal Junction|Non-small Cell Lung Cancer|Carcinoma, Transitional Cell|Biliary Tract Cancer",drug or biologic,Early,155,All,Industry&Combos,1,1,0,2015,2015,1129,1,Phase 1,0,NA,0,5.043425116919247,"(5,6]"
1158,1231,intra-anally administered artesunate in patients with high-grade anal intraepithelial neoplasia (ain 2/3),"Active, not recruiting",1,0,0,HPV-Related Anal Intraepithelial Neoplasia|AIN2/3|Artesunate|Alternative Treatment|Anal Dysplasia|Precancerous Conditions|Human Papilloma Virus,drug or biologic,Early,18,All,Industry&Combos,NA,1,0,2017,2017,1655,NA,Phase 1,0,NA,0,2.8903717578961645,"(2,3]"
1079,1139,a single dose study of oral vadadustat in subjects with normal and impaired hepatic function,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,24,All,Industry&Combos,NA,NA,4,2019,2018,128,NA,Phase 1,0,NA,0,3.1780538303479458,"(3,4]"
128,128,cyp2c19 genotype predictor of gastric acid suppression,Withdrawn,7,0,0,Esophagitis,drug or biologic,Early,NA,All,AllOther,0,NA,0,2013,2013,1341,0,Early Phase 1,1,NA,1,NA,NA
2652,3557,fecal microbial transplant (fmt) for sjogrens syndrome,Completed,4,0,0,Sjogren's Syndrome,drug or biologic,Early,10,All,AllOther,0,NA,0,2019,2019,413,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
2918,3912,chemotherapy and radiation therapy before surgery followed by gemcitabine in treating patients with pancreatic cancer,Completed,4,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer,drug or biologic,Early,23,All,NIH&Combos,0,NA,0,2013,2013,492,0,Early Phase 1,1,NA,1,3.1354942159291497,"(3,4]"
159,159,fecal microbiota transplantation (fmt) for treatment of ulcerative colitis in children,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,6,All,AllOther,0,NA,0,2013,2014,303,0,Phase 1,1,NA,1,1.791759469228055,"(1,2]"
775,812,neoadjuvant sbrt with concomitant capecitabine in resectable pancreatic cancer,Suspended,6,0,0,Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer,drug or biologic,Early,36,All,AllOther,0,NA,0,2013,2014,3006,0,Phase 1,1,NA,1,3.58351893845611,"(3,4]"
134,134,study of kcc peptide application in the colon,Completed,4,0,0,Colon Polyps|Colorectal Cancer|Inflammatory Bowel Disease (IBD),drug or biologic,Early,45,All,Industry&Combos,0,NA,4,2014,2014,761,0,Phase 1,1,NA,1,3.8066624897703196,"(3,4]"
155,155,selinexor in combination with irinotecan in adenocarcinoma of stomach and distal esophagus,Terminated,5,0,0,Esophageal Cancer|Gastric Cancer,drug or biologic,Early,3,All,AllOther,0,NA,0,2014,2014,365,0,Phase 1,1,NA,1,1.0986122886681098,"(1,2]"
1883,2179,high resolution manometry for swallowing,Terminated,5,0,0,Motility Disorder,procedure,Others,71,All,AllOther,0,NA,2,2013,2013,457,0,Others,1,NA,1,4.2626798770413155,"(4,5]"
431,443,effect of flavonoids on gut permeability in cyclists,Completed,4,0,0,"Gut Permeability, Gut Inflammation",drug or biologic,Early,12,All,AllOther,3,0,1,2018,2018,243,3,Phase 1,3,NA,2,2.4849066497880004,"(2,3]"
3165,4324,"double-blinded, placebo-controlled phase 1b study for safety, pk, efficacy, pd of ro7049665 in patients with ulcerative colitis (uc)",Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Early,65,All,Industry&Combos,NA,0,0,2019,2019,1059,NA,Phase 1,2,safety/efficacy,2,4.174387269895637,"(4,5]"
3009,4036,"absorption, metabolism and excretion (ame) study of [14c]edp-305 in healthy male subjects",Completed,4,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,8,Male,Industry&Combos,0,NA,4,2018,2018,8,0,Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
414,425,study of proton therapy in adjuvant pancreatic cancer,Recruiting,2,0,0,Resected Pancreatic Adenocarcinoma,drug or biologic,Early,12,All,AllOther,1,1,0,2019,2019,505,1,Phase 1,0,NA,0,2.4849066497880004,"(2,3]"
557,580,pharmacokinetics of td-4208 in patients with moderate hepatic impairment,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,16,All,Industry&Combos,1,1,4,2015,2015,152,1,Phase 1,0,pharmacokinetics only,0,2.772588722239781,"(2,3]"
2747,3685,disulfiram and chemotherapy in treating patients with refractory solid tumors or metastatic pancreatic cancer,Recruiting,2,0,0,Metastatic Pancreatic Adenocarcinoma|Refractory Malignant Solid Neoplasm|Stage IV Pancreatic Cancer AJCC v6 and v7,drug or biologic,Early,74,All,NIH&Combos,1,0,0,2016,2016,2261,1,Phase 1,2,NA,2,4.30406509320417,"(4,5]"
3883,7158,nivolumab and bevacizumab in patients with advanced and or metastatic hepatocellular carcinoma,Terminated,5,0,0,Hepatocellular Carcinoma,drug or biologic,Early,1,All,Industry&Combos,0,NA,0,2017,2018,106,0,Phase 1,1,NA,1,0,NA
240,243,phase 1 study of multiple-dose pharmacokinetics of cenicriviroc in subjects with mild and moderate hepatic impairment,Completed,4,0,0,Liver Insufficiency,drug or biologic,Early,31,All,Industry&Combos,1,1,NA,2014,2014,122,1,Phase 1,0,pharmacokinetics only,0,3.4339872044851463,"(3,4]"
3761,6494,combination study of urelumab and cetuximab in patients with advanced/metastatic colorectal cancer or advanced/metastatic head and neck cancer,Completed,4,0,0,Colorectal Cancer|Head and Neck Cancer,drug or biologic,Early,66,All,Industry&Combos,1,1,0,2014,2014,975,1,Phase 1,0,NA,0,4.189654742026425,"(4,5]"
1699,1880,mirabegron in achalasia: a clinical and manometric proof of concept pilot study,Terminated,5,0,0,Achalasia,drug or biologic,Early,5,All,Industry&Combos,3,0,0,2018,2018,668,3,Early Phase 1,4,NA,2,1.6094379124341003,"(1,2]"
789,826,"oar-based, dose escalated sbrt with real time adaptive mri guidance for liver metastases",Recruiting,2,0,0,Liver Metastases|Stereotactic Body Radiation Therapy|MRI-guided Treatment,other,Others,48,All,AllOther,0,NA,0,2019,2019,1366,0,Others,1,NA,1,3.871201010907891,"(3,4]"
1284,1371,ferumoxytol-enhanced mri in imaging lymph nodes in patients with locally advanced rectal cancer,Recruiting,2,0,0,Locally Advanced Rectal Carcinoma|Stage III Rectal Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7,drug or biologic,Early,13,All,AllOther,0,NA,2,2017,2018,1556,0,Early Phase 1,1,NA,1,2.5649493574615367,"(2,3]"
920,966,pharmacokinetics of wck 2349 in patients with hepatic impairment,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,48,All,Industry&Combos,0,NA,4,2014,2014,91,0,Phase 1,1,pharmacokinetics only,1,3.871201010907891,"(3,4]"
1673,1844,a phase 1 study of osilodrostat (lci699) in healthy volunteers and subjects with impaired hepatic function,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,33,All,Industry&Combos,0,NA,0,2015,2015,394,0,Phase 1,1,NA,1,3.4965075614664802,"(3,4]"
2598,3495,"a research study of how nnc0174-0833 behaves in japanese and caucasian volunteers who are normal weight, overweight or with obesity",Completed,4,0,0,Obesity|Overweight,drug or biologic,Early,66,Male,Industry&Combos,1,0,0,2018,2019,148,1,Phase 1,4,NA,2,4.189654742026425,"(4,5]"
1675,1846,"td-1473 absorption, distribution, metabolism and excretion (adme) study in healthy male subjects",Completed,4,0,0,"Intestinal Disorders|Bowel Diseases, Inflammatory",drug or biologic,Early,20,Male,Industry&Combos,1,0,4,2018,2018,21,1,Phase 1,0,NA,0,2.995732273553991,"(2,3]"
2177,2638,"detection of integrin avb6 in ipf, psc, and covid19 using pet/ct",Recruiting,2,0,0,Idiopathic Pulmonary Fibrosis|Primary Sclerosing Cholangitis|Covid19 Pneumonia,drug or biologic,Early,30,All,Industry&Combos,0,1,2,2017,2017,1618,0,Early Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
2306,2900,autologous hematopoietic stem cell transplantation for crohn's disease treatment,Withdrawn,7,0,0,Crohn's Disease,drug or biologic,Early,NA,All,AllOther,0,NA,0,2013,2014,759,0,Early Phase 1,1,NA,1,NA,NA
998,1053,capecitabine and lenvatinib with external radiation in rectal adenocarcinoma,"Active, not recruiting",1,0,0,Rectal Cancer|Rectal Adenocarcinoma,drug or biologic,Early,20,All,AllOther,0,NA,0,2016,2016,1092,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
2042,2414,"study to evaluate the pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment and healthy subjects",Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,32,All,Industry&Combos,1,1,0,2017,2017,169,1,Phase 1,0,safety,0,3.4657359027997265,"(3,4]"
764,800,ascorbic acid and combination chemotherapy in treating patients with locally advanced or recurrent pancreatic cancer that cannot be removed by surgery,Completed,4,1,1,Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma,drug or biologic,Early,8,All,AllOther,0,NA,0,2016,2016,520,0,Early Phase 1,1,NA,1,2.0794415416798357,"(2,3]"
1683,1858,study to evaluate the pharmacokinetics of telotristat ethyl in subjects with severe hepatic impairment,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,16,All,Industry&Combos,1,1,0,2018,2017,199,1,Phase 1,0,pharmacokinetics only,0,2.772588722239781,"(2,3]"
2200,2682,a study of experimental medication bms-986036 given to healthy participants,Completed,4,0,0,Hepatic Cirrhosis|Liver Fibrosis|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,drug or biologic,Early,30,All,Industry&Combos,3,1,0,2018,2018,77,3,Phase 1,0,NA,0,3.4011973816621555,"(3,4]"
1951,2287,"randomized,study of apriso 375 mg versus the approved apriso 375 mg capsules in healthy male and female subjects",Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,60,All,Industry&Combos,1,0,0,2017,2017,39,1,Phase 1,2,NA,2,4.0943445622221,"(4,5]"
3742,6297,safety and tolerability of a bioconjugate vaccine against shigella flexneri 2a,Completed,4,0,0,Shigellosis,drug or biologic,Early,30,All,Industry&Combos,1,0,1,2015,2015,89,1,Phase 1,1,safety,1,3.4011973816621555,"(3,4]"
1906,2216,local ablative strategies after endovascular radioembolization,Terminated,5,0,0,Metastatic Colorectal Cancer,device,Others,9,All,AllOther,1,1,0,2015,2016,756,1,Others,0,NA,0,2.1972245773362196,"(2,3]"
4131,8969,a trial of lenvatinib plus pembrolizumab in participants with hepatocellular carcinoma,"Active, not recruiting",1,1,1,Hepatocellular Carcinoma,drug or biologic,Early,104,All,Industry&Combos,0,NA,0,2016,2017,990,0,Phase 1,1,NA,1,4.6443908991413725,"(4,5]"
726,760,study to investigate the influence of hepatic insufficiency on the pharmacokinetics of tozadenant,Terminated,5,0,0,Hepatic Impairment,drug or biologic,Early,20,All,Industry&Combos,NA,1,4,2017,2017,184,NA,Phase 1,0,pharmacokinetics only,0,2.995732273553991,"(2,3]"
2172,2629,a trial of a new type of photodynamic therapy (vtp) in the treatment of patients with cancer of the esophagus who have trouble swallowing,Recruiting,2,0,0,Esophagogastric Cancer|Moderate to Severe Dysphagia,drug or biologic,Early,30,All,AllOther,0,NA,0,2017,2017,1801,0,Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
2386,3064,fecal microbiota transplant for relapsing clostridium difficile infection in adults and children using a frozen encapsulated inoculum,Completed,4,0,0,Clostridium Difficile Infection,drug or biologic,Early,20,All,AllOther,0,NA,0,2013,2013,426,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
2429,3154,radvax: a stratified phase i trial of pembrolizumab with hypofractionated radiotherapy in patients with advanced and metastatic cancers,Completed,4,1,1,Metastatic Cancers,drug or biologic,Early,59,All,AllOther,0,NA,0,2014,2015,1423,0,Phase 1,1,NA,1,4.07753744390572,"(4,5]"
895,939,evaluation of budesonide and how it interacts with antifungal drugs in people with gastrointestinal graft-versus-host disease,Terminated,5,0,0,Stem Cell Transplantation|Graft vs Host Disease,drug or biologic,Early,15,All,NIH&Combos,1,1,0,2013,2014,1540,1,Phase 1,0,NA,0,2.70805020110221,"(2,3]"
1394,1495,a study of mek162 (binimetinib) in combination with pexidartinib in patients with advanced gastrointestinal stromal tumor (gist),Completed,4,0,0,Gastrointestinal Stromal Tumor (GIST),drug or biologic,Early,3,All,Industry&Combos,0,NA,0,2017,2017,1474,0,Phase 1,1,NA,1,1.0986122886681098,"(1,2]"
3211,4475,"a first-in-human, phase 1 study of jab-3312 in adult patients with advanced solid tumors",Recruiting,2,0,0,Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Carcinoma|Esophageal Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Breast Cancer|Other Solid Tumors,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2019,2019,887,0,Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
725,759,paclitaxel for the treatment of gastric or gastroesophageal cancer,Recruiting,2,0,0,Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Peritoneal Carcinomatosis|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8,drug or biologic,Early,24,All,NIH&Combos,0,NA,0,2020,2019,1061,0,Phase 1,1,NA,1,3.1780538303479458,"(3,4]"
3932,7324,a study of sc-006 and in combination with abbv-181 in subjects with advanced colorectal cancer,Terminated,5,0,0,Colorectal Cancer,drug or biologic,Early,29,All,Industry&Combos,NA,1,0,2017,2017,750,NA,Phase 1,0,NA,0,3.367295829986474,"(3,4]"
1279,1366,fecal transplant in recurrent hepatic encephalopathy,Completed,4,0,0,Hepatic Encephalopathy|Cirrhosis,drug or biologic,Early,20,All,Industry&Combos,1,0,NA,2015,2015,305,1,Phase 1,0,NA,0,2.995732273553991,"(2,3]"
1914,2229,"phase 1b/2, open label, repeat dose, dose escalation study of nd-l02-s0201 injection in subjects with moderate to extensive fibrosis (metavir f3-4)",Completed,4,0,0,Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4),drug or biologic,Early,25,All,Industry&Combos,0,0,0,2014,2014,578,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
4059,7757,a study to compare the bioavailability (ba) of dexlansoprazole delayed-release capsules,Completed,4,1,1,Healthy Volunteers,drug or biologic,Early,122,All,Industry&Combos,3,0,4,2019,2019,46,3,Phase 1,0,NA,0,4.804021044733257,"(4,5]"
1678,1851,fecal microbiota transplantation for the treatment of recurrent urinary tract infections,Completed,4,0,0,Recurrent Urinary Tract Infection,drug or biologic,Early,12,Female,AllOther,0,NA,0,2017,2018,510,0,Early Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
2987,4004,a study of rgx-202-01 as a single agent and as combination therapy in patients with advanced gastrointestinal malignancies,Recruiting,2,0,0,Gastrointestinal Cancer|Gastrointestinal Neoplasms|Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Gastric Cancer|Gastric Neoplasm|Pancreatic Cancer|Pancreatic Neoplasm,drug or biologic,Early,60,All,Industry&Combos,1,1,0,2018,2018,1030,1,Phase 1,0,NA,0,4.0943445622221,"(4,5]"
1610,1763,study of minnelideÃ¢âÂ¢ in patients with advanced gi tumors,Completed,4,0,0,Advanced Gastrointestinal Tumors,drug or biologic,Early,45,All,Industry&Combos,0,NA,0,2013,2013,1157,0,Phase 1,1,NA,1,3.8066624897703196,"(3,4]"
888,932,chemopreventive effects of epigallocatechin gallate (egcg) in colorectal cancer (crc) patients,Recruiting,2,0,0,Colon Cancer,drug or biologic,Early,50,All,AllOther,1,0,1,2016,2017,2100,1,Early Phase 1,0,NA,0,3.912023005428146,"(3,4]"
427,439,photoacoustic endoscopy of barrett's esophagus,Completed,4,0,0,Barrett Esophagus,procedure,Others,8,All,AllOther,0,NA,2,2015,2014,731,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
885,929,chemoradiation and radiosurgery boost in treating patients with locally advance pancreatic cancer that may or may not be removed by surgery,Terminated,5,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer,drug or biologic,Early,6,All,NIH&Combos,0,NA,0,2012,2013,944,0,Phase 1,1,NA,1,1.791759469228055,"(1,2]"
1465,1579,determinants of diabetes remission after gastric bypass surgery,Completed,4,0,0,Type 2 Diabetes Mellitus,drug or biologic,Early,25,All,NIH&Combos,0,NA,0,2014,2014,1035,0,Early Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
685,716,cromolyn detection of silent aspiration,Terminated,5,0,0,Gastroesophageal Reflux|Respiratory Aspiration|Idiopathic Pulmonary Fibrosis|Lung Transplantation,drug or biologic,Early,16,All,NIH&Combos,0,NA,2,2013,2015,609,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
551,573,"gemcitabine, ascorbate, radiation therapy for pancreatic cancer, phase i","Active, not recruiting",1,0,0,Pancreatic Neoplasms,drug or biologic,Early,16,All,AllOther,0,1,0,2013,2014,1847,0,Phase 1,1,NA,1,2.772588722239781,"(2,3]"
2486,3275,study of ngm313 in obese participants,Completed,4,0,0,Obese,drug or biologic,Early,25,All,Industry&Combos,1,0,0,2017,2017,281,1,Phase 1,0,NA,0,3.2188758248682006,"(3,4]"
3695,6126,afpÃ¡Â¶Å Â³ Â³ Â²t in advanced hcc,Recruiting,2,0,0,Hepatocellular Cancer|AFP Expressing Tumors,other,Others,45,All,Industry&Combos,0,NA,0,2017,2017,2307,0,Others,1,NA,1,3.8066624897703196,"(3,4]"
782,819,"effects of aprepitant on satiation, gastric volume, gastric accommodation and gastric emptying",Completed,4,0,0,Healthy,drug or biologic,Early,27,All,AllOther,1,0,0,2016,2017,297,1,Phase 1,3,NA,2,3.295836866004329,"(3,4]"
1384,1484,selective intra-arterial injection of prrt in neuroendocrine tumor patients with liver metastases,Enrolling by invitation,3,0,0,Neuroendocrine Tumors,drug or biologic,Early,10,All,NIH&Combos,NA,1,0,2018,2018,2608,NA,Early Phase 1,0,NA,0,2.302585092994046,"(2,3]"
1668,1838,a study to evaluate the effect of hepatic impairment on the pharmacokinetics of glasdegib,Completed,4,0,0,Hepatic Impairment,drug or biologic,Early,24,All,Industry&Combos,1,0,4,2018,2018,157,1,Phase 1,0,pharmacokinetics only,0,3.1780538303479458,"(3,4]"
1778,2000,25-hydroxyvitamin d pharmacokinetic study,Completed,4,0,0,Vitamin D Deficiency|Fat Malabsorption,drug or biologic,Early,16,All,AllOther,3,0,0,2018,2018,182,3,Early Phase 1,2,NA,2,2.772588722239781,"(2,3]"
496,515,study to evaluate hepatic artery injection of autologous human bone marrow-derived mscs in patients with alcoholic lc,Recruiting,2,0,0,Alcoholic Liver Cirrhosis,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2019,2019,620,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
1012,1067,low sulfur fecal transplant for ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Early,20,All,AllOther,1,0,4,2019,2019,519,1,Phase 1,4,NA,2,2.995732273553991,"(2,3]"
872,915,chemoimmunotherapy and radiation in pancreatic cancer,Completed,4,0,0,Locally Advanced Malignant Neoplasm,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2013,2013,1614,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
426,438,in vivo parp-1 expression with 18f-ftt pet/ct in pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,30,All,AllOther,0,NA,4,2018,2018,1461,0,Early Phase 1,1,NA,1,3.4011973816621555,"(3,4]"
4012,7586,a study to assess the relative bioavailability and food effect of abi-h2158 in healthy adults,Completed,4,0,0,Chronic Hepatitis B,drug or biologic,Early,15,All,Industry&Combos,3,0,0,2019,2019,29,3,Phase 1,0,NA,0,2.70805020110221,"(2,3]"
3949,7366,"gevokizumab with standard of care anti-cancer therapies for metastatic colorectal, gastroesophageal, and renal cancers",Recruiting,2,0,0,Colorectal Cancer|Gastroesophageal Cancer|Renal Cell Carcinoma,drug or biologic,Early,172,All,Industry&Combos,1,1,0,2019,2019,1476,1,Phase 1,0,NA,0,5.147494476813453,"(5,6]"
2791,3747,sorafenib concurrent with yttrium-90 transarterial radioembolization in patients with advanced hepatocellular cancer,Withdrawn,7,0,0,Hepatocellular Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2014,2014,639,0,Phase 1,1,NA,1,NA,NA
298,303,laser tissue welding - distal pancreatectomy sealing study,Recruiting,2,0,0,"Pancreatic Tumor, Benign|Pancreatic Neoplasms|Pancreatic Adenocarcinoma|Pancreatic Pseudocyst|Pancreatic Neuroendocrine Tumor|Pancreas; Insulinoma|Pancreatic Cyst|Pancreatic Teratoma|Pancreatic Polypeptide Tumor|Pancreatic Vipoma|Pancreatic Cystadenoma|Pancreas Injury|Pancreatic Gastrinoma|Pancreatic Glucagonoma",device,Others,10,All,IndustryNIHPartnership,0,NA,NA,2017,2018,1460,0,Others,1,NA,1,2.302585092994046,"(2,3]"
2084,2485,a pilot study of optical molecular imaging for percutaneous biopsy of hepatocellular carcinoma using indocyanine green,Completed,4,0,0,Hepatocellular Carcinoma,drug or biologic,Early,20,All,AllOther,0,NA,2,2013,2013,182,0,Early Phase 1,1,NA,1,2.995732273553991,"(2,3]"
774,811,targeted parp or mek/erk inhibition in patients with pancreatic cancer,Recruiting,2,0,0,Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Ductal Adenocarcinoma|Metastatic Pancreatic Ductal Adenocarcinoma|Resectable Pancreatic Ductal Adenocarcinoma|Stage I Pancreatic Cancer AJCC v8|Stage IA Pancreatic Cancer AJCC v8|Stage IB Pancreatic Cancer AJCC v8|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8,drug or biologic,Early,40,All,AllOther,1,1,0,2019,2019,1035,1,Early Phase 1,0,NA,0,3.6888794541139363,"(3,4]"
3018,4053,a study to assess the safety and tolerability of single doses of azd4076 in healthy male subjects,"Active, not recruiting",1,0,0,Non-alcoholic Steatohepatitis (NASH),drug or biologic,Early,40,Male,Industry&Combos,1,0,4,2015,2015,711,1,Phase 1,1,safety,1,3.6888794541139363,"(3,4]"
2109,2520,a phase 1a/1b study of cb4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease,Completed,4,0,0,Nonalcoholic Fatty Liver Disease,drug or biologic,Early,88,All,Industry&Combos,1,0,0,2019,2018,1015,1,Phase 1,3,NA,2,4.477336814478207,"(4,5]"
1990,2341,safety and tolerability of oral proglumide for nash,"Active, not recruiting",1,0,0,Nonalcoholic Steatohepatitis,drug or biologic,Early,18,All,AllOther,NA,NA,4,2019,2019,596,NA,Phase 1,0,safety,0,2.8903717578961645,"(2,3]"
4098,8103,safety study of a capsule-conjugate vaccine to prevent campylobacter-caused diarrhea,Completed,4,1,1,Campylobacter Infection,drug or biologic,Early,48,All,AllOther,1,1,1,2014,2014,156,1,Phase 1,0,safety,0,3.871201010907891,"(3,4]"
2352,2989,fecal transplant for pediatric patients who have recurrent c-diff infection,Recruiting,2,0,0,Clostridium Difficile,drug or biologic,Early,15,All,AllOther,0,NA,0,2014,2013,2953,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
4067,7794,study of intranasal octreotide (dp1038) in healthy adult volunteers,Completed,4,0,0,Healthy Volunteer Study,drug or biologic,Early,32,All,Industry&Combos,3,0,0,2017,2017,59,3,Phase 1,4,NA,2,3.4657359027997265,"(3,4]"
3183,4388,study of safety and efficacy of ribociclib and trametinib in patients with metastatic or advanced solid tumors,Terminated,5,0,0,Solid Tumors for Phase Ib|Pancreatic Cancer for Phase II|Colorectal Cancer for Phase II,drug or biologic,Early,95,All,Industry&Combos,0,NA,0,2016,2016,1182,0,Phase 1,1,safety/efficacy,1,4.553876891600541,"(4,5]"
36,36,"effect of naloxegol on gastric, small bowel, and colonic transit in healthy subjects",Completed,4,0,0,Constipation Drug Induced,drug or biologic,Early,72,All,Industry&Combos,1,0,0,2016,2016,313,1,Phase 1,3,NA,2,4.276666119016055,"(4,5]"
899,944,fusion guided thermal ablation combined with external beam radiation for hepatic neoplasms,Completed,4,0,0,Liver Neoplasms|Hepatic Cancer|Liver Cancer,procedure,Others,5,All,NIH&Combos,0,NA,0,2013,2013,1447,0,Others,1,NA,1,1.6094379124341003,"(1,2]"
2159,2601,lde225 in patients with advanced or metastatic hepatocellular carcinoma and child-pugh a/b7 cirrhosis,Completed,4,0,0,Hepatocellular Carcinoma|Cirrhosis,drug or biologic,Early,9,All,Industry&Combos,0,NA,0,2014,2014,884,0,Phase 1,1,NA,1,2.1972245773362196,"(2,3]"
2541,3413,"a study of abgn-107 in patients with gastric, colorectal, pancreatic or biliary cancer","Active, not recruiting",1,0,0,Gastric Cancer|Colorectal Cancer|Pancreatic Cancer|Biliary Cancer,drug or biologic,Early,136,All,Industry&Combos,0,NA,0,2016,2017,1256,0,Phase 1,1,NA,1,4.912654885736052,"(4,5]"
3689,6086,"phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of h3b-6527 in participants with advanced hepatocellular carcinoma","Active, not recruiting",1,0,0,Advanced Hepatocellular Carcinoma|Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Hepatic Cancer|Hepatic Carcinoma,drug or biologic,Early,128,All,Industry&Combos,0,NA,0,2016,2016,1676,0,Phase 1,1,safety,1,4.852030263919617,"(4,5]"
1180,1257,"study to assess pharmacokinetics, safety, and tolerability of mt-7117 in subjects with normal and impaired hepatic function",Recruiting,2,0,0,Mild and Moderate Hepatic Impairment,drug or biologic,Early,24,All,Industry&Combos,1,0,0,2019,2019,731,1,Phase 1,0,safety,0,3.1780538303479458,"(3,4]"
296,301,integrin alpha-v-beta and [18f]-r01-mg-f2 pet/ct in measuring response in patients with pancreatic cancer and healthy volunteers,Recruiting,2,0,0,Healthy Subject|Pancreatic Carcinoma,drug or biologic,Early,25,All,NIH&Combos,0,1,4,2016,2016,1785,0,Early Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
86,86,can quercetin increase claudin-4 and improve esophageal barrier function in gerd?,Completed,4,0,0,Gastroesophageal Reflux Disease|GERD|Acid Reflux|Reflux,drug or biologic,Early,26,All,NIH&Combos,0,NA,4,2014,2014,639,0,Phase 1,1,NA,1,3.258096538021482,"(3,4]"
4166,9146,a study of abi-h2158 in healthy volunteers and patients with chronic hepatitis b,Completed,4,0,0,Chronic Hepatitis B,drug or biologic,Early,80,All,Industry&Combos,1,0,0,2018,2018,741,1,Phase 1,4,NA,2,4.382026634673881,"(4,5]"
1127,1197,augmenting growth hormone to ameliorate nonalcoholic fatty liver disease in adolescents,Completed,4,1,1,"NAFLD",drug or biologic,Early,24,All,AllOther,1,0,0,2016,2017,1065,1,Early Phase 1,0,NA,0,3.1780538303479458,"(3,4]"
1439,1548,phase 1 imaging study of 89zr-dfo-humab-5b1 with humab-5b1,"Active, not recruiting",1,0,0,Pancreatic Carcinoma|Tumors That Express CA19-9,drug or biologic,Early,15,All,Industry&Combos,0,1,2,2016,2016,1979,0,Phase 1,1,NA,1,2.70805020110221,"(2,3]"
3610,5692,first-in-human study of ca102n monotherapy and of ca102n combined with trifluridine/tipiracil (lonsurf) in subjects with advanced solid tumors,Recruiting,2,0,0,Advanced or Metastatic Solid Tumors|Advanced or Metastatic Colorectal Cancer (mCRC),drug or biologic,Early,33,All,Industry&Combos,NA,1,0,2018,2019,876,NA,Phase 1,0,NA,0,3.4965075614664802,"(3,4]"
1805,2040,evaluation of infectivity and illness of norwalk gi.1 virus lot 001-09nv in the human challenge model,Completed,4,1,1,Norovirus Infection,drug or biologic,Early,16,All,Industry&Combos,NA,1,4,2018,2018,56,NA,Phase 1,0,NA,0,2.772588722239781,"(2,3]"
2188,2658,anti-ox40 antibody (medi6469) in patients with metastatic colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Neoplasms,drug or biologic,Early,4,All,Industry&Combos,1,1,0,2015,2016,1632,1,Phase 1,0,NA,0,1.3862943611198906,"(1,2]"
1953,2290,a multiple dose study to assess the safety and tolerability of bms-986166 in healthy volunteers,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,213,All,Industry&Combos,1,0,4,2017,2017,190,1,Phase 1,2,safety,2,5.3612921657094255,"(5,6]"
3152,4290,evaluation of hepquant shunt to assess liver disease; substudy within gs-us-416-2124,Withdrawn,7,0,0,Severe Alcoholic Hepatitis,drug or biologic,Early,NA,All,Industry&Combos,1,0,2,2017,2016,409,1,Early Phase 1,2,NA,2,NA,NA
319,324,bethanechol prior to pancreatic surgery,Recruiting,2,0,0,Pancreas Cancer,drug or biologic,Early,18,All,AllOther,0,NA,4,2018,2018,845,0,Early Phase 1,1,NA,1,2.8903717578961645,"(2,3]"
1329,1419,kn026 in patients with her2 expressing breast cancer and gastric cancer,Recruiting,2,0,0,Breast Cancer|Gastric/Gastroesophageal Junction Cancer,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2019,2019,562,0,Phase 1,1,NA,1,2.995732273553991,"(2,3]"
893,937,a pilot and feasibility study of fecal microbiota transplantation for ulcerative colitis,Terminated,5,0,0,Ulcerative Colitis,drug or biologic,Early,1,All,AllOther,0,NA,0,2014,2013,1096,0,Phase 1,1,NA,1,0,NA
4035,7622,study assessing the effects of darunavir/ritonavir or lopinavir/ritonavir on the pharmacokinetics of daclatasvir in healthy participants,Completed,4,1,1,Hepatitis C,drug or biologic,Early,49,All,Industry&Combos,1,0,NA,2014,2014,30,1,Phase 1,0,pharmacokinetics only,0,3.8918202981106265,"(3,4]"
1109,1174,safety and pharmacokinetics of zanubrutinib (bgb-3111) in healthy subjects and those with impaired liver function,Completed,4,0,0,Hepatic Insufficiency & Healthy Subjects,drug or biologic,Early,29,All,Industry&Combos,1,1,0,2018,2018,142,1,Phase 1,0,safety,0,3.367295829986474,"(3,4]"
294,299,performance of 13c mannitol for in vivo measurement of small intestinal permeability,Completed,4,0,0,Impaired Small Intestinal Permeability,drug or biologic,Early,25,All,AllOther,0,NA,4,2015,2015,1081,0,Phase 1,1,NA,1,3.2188758248682006,"(3,4]"
1275,1361,daprodustat hepatic impairment study,Completed,4,1,1,Anaemia,drug or biologic,Early,37,All,Industry&Combos,1,1,0,2017,2017,392,1,Phase 1,0,NA,0,3.6109179126442243,"(3,4]"
244,247,sgi-110 in combination with an allogeneic colon cancer cell vaccine (gvax) and cyclophosphamide (cy) in metastatic colorectal cancer (mcrc),Completed,4,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,18,All,AllOther,1,0,0,2013,2014,2245,1,Phase 1,0,NA,0,2.8903717578961645,"(2,3]"
3714,6210,wearable monitoring systems for swallowing function and disorders,Recruiting,2,0,0,Deglutition Disorders,device,Others,200,All,NIH&Combos,3,0,4,2020,2018,1095,3,Others,1,NA,1,5.298317366548036,"(5,6]"
1169,1243,gene expression and fdg pet/mri in evaluating treatment response in patients with locally advanced rectal cancer undergoing chemotherapy and radiation therapy before surgery,Terminated,5,0,0,Rectal Neoplasms,device,Others,2,All,AllOther,0,NA,2,2014,2014,273,0,Others,1,NA,1,0.6931471805599453,"(0,1]"
922,968,"phase ib metformin, digoxin, simvastatin in solid tumors",Recruiting,2,0,0,Advanced Pancreatic Cancer|Advanced Solid Tumor,drug or biologic,Early,15,All,AllOther,NA,NA,0,2019,2019,939,NA,Phase 1,0,NA,0,2.70805020110221,"(2,3]"
593,619,"gemcitabine, nab-paclitaxel, cisplatin and anakinra treatment on patients with pancreatic cancer",Completed,4,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,20,All,AllOther,0,NA,0,2015,2016,1991,0,Early Phase 1,1,NA,1,2.995732273553991,"(2,3]"
3922,7309,safety and efficacy of pembrolizumab (mk-3475) plus binimetinib alone or pembrolizumab plus chemotherapy with or without binimetinib in metastatic colorectal cancer (mcrc) participants (mk-3475-651),Recruiting,2,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,220,All,Industry&Combos,1,1,0,2017,2018,2099,1,Phase 1,0,safety/efficacy,0,5.393627546352362,"(5,6]"
3410,5145,safety of transarterial chemoembolization (tace) in the setting of an elevated bilirubin,Recruiting,2,0,0,Hepatocellular Carcinoma|Bilirubinemia,other,Others,10,All,AllOther,0,NA,0,2017,2018,1429,0,Others,1,safety,1,2.302585092994046,"(2,3]"
1173,1248,itraconazole as a targeted therapy for inhibiting hedgehog pathway signaling in esophageal cancer patients,"Active, not recruiting",1,0,0,Esophageal Cancer,drug or biologic,Early,18,All,AllOther,0,NA,4,2016,2016,2100,0,Early Phase 1,1,NA,1,2.8903717578961645,"(2,3]"
450,463,"pilot study with cy, pembrolizumab, gvax, and imc-cs4 (ly3022855) in patients with borderline resectable adenocarcinoma of the pancreas","Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2017,2018,1070,0,Early Phase 1,1,NA,1,2.4849066497880004,"(2,3]"
1496,1620,tudca as a therapy for ulcerative colitis (uc),Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Early,13,All,AllOther,0,NA,4,2019,2019,926,0,Phase 1,1,NA,1,2.5649493574615367,"(2,3]"
3214,4490,a study in healthy volunteers,Recruiting,2,0,0,Hepatitis B|Infectious Disease|Liver Diseases,drug or biologic,Early,80,All,Industry&Combos,NA,0,0,2018,2019,388,NA,Phase 1,0,NA,0,4.382026634673881,"(4,5]"
1747,1954,intraperitoneal delivery of adaptive natural killer (nk) cells (fate-nk100) with intraperitoneal int,Completed,4,0,0,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer,drug or biologic,Early,10,Female,AllOther,0,NA,0,2017,2017,1238,0,Phase 1,1,NA,1,2.302585092994046,"(2,3]"
1615,1770,safety and efficacy study of anucort hc tm 25mg rectal suppositories to treat symptomatic internal hemorrhoids,Completed,4,0,0,Internal Hemorrhoids,drug or biologic,Early,150,All,Industry&Combos,1,0,0,2013,2013,151,1,Phase 2,4,safety/efficacy,2,5.0106352940962555,"(5,6]"
2968,3981,a phase 2 pilot study to assess asp7147 in patients with diarrhea predominant irritable bowel syndrome (ibs-d),Completed,4,0,0,Diarrhea Predominant Irritable Bowel Syndrome,drug or biologic,Early,64,All,Industry&Combos,1,0,0,2013,2013,120,1,Phase 2,3,NA,2,4.1588830833596715,"(4,5]"
2964,3976,efficacy and safety study of cenicriviroc for the treatment of nonalcoholic steatohepatitis (nash) in adult participants with liver fibrosis,Completed,4,1,1,Nonalcoholic Steatohepatitis,drug or biologic,Early,289,All,Industry&Combos,3,0,0,2014,2014,651,3,Phase 2,3,safety/efficacy,2,5.666426688112432,"(5,6]"
3263,4590,a study of tirzepatide (ly3298176) in participants with nonalcoholic steatohepatitis (nash),Recruiting,2,0,0,Nonalcoholic Steatohepatitis,drug or biologic,Early,196,All,Industry&Combos,1,0,0,2019,2019,946,1,Phase 2,2,NA,2,5.278114659230517,"(5,6]"
232,235,fecal microbiota transplant as treatment of hepatic encephalopathy,"Active, not recruiting",1,0,0,Hepatic Encephalopathy,drug or biologic,Early,30,All,AllOther,1,0,0,2018,2018,1370,1,Phase 2,4,NA,2,3.4011973816621555,"(3,4]"
3141,4272,microbiota restoration therapy for recurrent clostridium difficile infection,Completed,4,1,1,Enterocolitis Clostridium Difficile Recurrent,drug or biologic,Early,150,All,Industry&Combos,3,0,0,2014,2014,396,3,Phase 2,3,NA,2,5.0106352940962555,"(5,6]"
2419,3129,effect of dexlansoprazole 60 mg qd and 60 mg bid on recurrence of intestinal metaplasia in subjects who have achieved complete eradication of barrett's esophagus with radiofrequency ablation,Terminated,5,1,1,Barrett's Esophagus,drug or biologic,Early,6,All,Industry&Combos,1,0,0,2014,2014,640,1,Phase 2,4,NA,2,1.791759469228055,"(1,2]"
1790,2020,panitumumab and chemotherapy in patients with advanced colorectal cancer after prior therapy with bevacizumab,Unknown status,8,0,0,Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2013,2013,2524,0,Phase 2,1,NA,1,2.772588722239781,"(2,3]"
3670,5858,efficacy and safety of filgotinib in the treatment of perianal fistulizing crohn's disease,Completed,4,0,0,Fistulizing Crohn's Disease,drug or biologic,Early,57,All,Industry&Combos,1,0,0,2017,2017,1385,1,Phase 2,2,safety/efficacy,2,4.04305126783455,"(4,5]"
3562,5480,"a study of the safety, efficacy and tolerability of nexvax-2 in patients with celiac disease (ced)",Unknown status,8,0,0,Celiac Disease|Celiac|Intestinal Disease|Malabsorption Syndromes|Gastrointestinal Disease|Digestive System Disease|Gluten Sensitivity|Autoimmune Diseases,drug or biologic,Early,146,All,Industry&Combos,1,0,0,2018,2018,391,1,Phase 2,4,safety/efficacy,2,4.983606621708336,"(4,5]"
3140,4269,saroglitazar magnesium in patients with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis,Completed,4,0,0,Non-Alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,drug or biologic,Early,106,All,Industry&Combos,1,0,0,2017,2017,1303,1,Phase 2,4,NA,2,4.663439094112067,"(4,5]"
2975,3989,study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab for patients with advanced unresectable biliary tract cancer,"Active, not recruiting",1,0,0,Biliary Tract Neoplasms,drug or biologic,Early,75,All,AllOther,1,0,0,2017,2017,816,1,Phase 2,0,NA,0,4.31748811353631,"(4,5]"
258,262,a phase ii trial of lanreotide for the prevention of postoperative pancreatic fistula,"Active, not recruiting",1,0,0,Pancreatic Leak|Pancreatic Fistula|Pancreaticoduodenal; Fistula|Pancreatectomy; Hyperglycemia,drug or biologic,Early,114,All,AllOther,0,NA,1,2017,2018,1077,0,Phase 2,1,NA,1,4.736198448394496,"(4,5]"
2833,3795,long-term safety of pf-00547659 in ulcerative colitis,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Early,330,All,Industry&Combos,1,0,0,2013,2013,1731,1,Phase 2,0,safety,0,5.799092654460526,"(5,6]"
3947,7362,sym004 vs standard of care in subjects with metastatic colorectal cancer,Completed,4,1,1,Metastatic Colorectal Cancer,drug or biologic,Early,254,All,Industry&Combos,1,0,0,2014,2014,963,1,Phase 2,0,NA,0,5.537334267018537,"(5,6]"
3903,7244,clinical trial of pm60184 in advanced colorectal cancer after standard treatment,Completed,4,1,1,Advanced Colorectal Cancer,drug or biologic,Early,32,All,Industry&Combos,0,NA,0,2018,2018,391,0,Phase 2,1,NA,1,3.4657359027997265,"(3,4]"
400,411,laparoscopic hyperthermic intraperitoneal chemoperfusion (hipec) for metastatic gastric cancer,Completed,4,1,1,Gastrointestinal Cancer,drug or biologic,Early,21,All,AllOther,0,NA,0,2014,2014,2196,0,Phase 2,1,NA,1,3.044522437723423,"(3,4]"
4074,7862,safety and efficacy of gs-4774 for the treatment of chronic hepatitis b,Completed,4,1,1,Chronic HBV Infection,drug or biologic,Early,178,All,Industry&Combos,1,0,0,2013,2013,361,1,Phase 2,0,safety/efficacy,0,5.181783550292085,"(5,6]"
2321,2929,novel gallium imaging in hepatocellular carcinoma,Unknown status,8,0,0,Hepatocellular Carcinoma,drug or biologic,Early,18,All,AllOther,0,NA,2,2017,2016,1461,0,Phase 2,1,NA,1,2.8903717578961645,"(2,3]"
3960,7392,sym004 versus futuximab or modotuximab in patients with mcrc,Terminated,5,1,1,Metastatic Colorectal Cancer|Colorectal Cancer Metastatic|Carcinoma,drug or biologic,Early,2,All,Industry&Combos,1,0,0,2018,2018,92,1,Phase 2,0,NA,0,0.6931471805599453,"(0,1]"
3188,4408,"study of safety, tolerability, and efficacy of a combination treatment of ljn452 and cvc in adult patients with nash and liver fibrosis",Completed,4,0,0,Non-alcoholic Steatohepatitis (NASH),drug or biologic,Early,193,All,Industry&Combos,1,0,0,2018,2018,894,1,Phase 2,3,safety/efficacy,2,5.262690188904886,"(5,6]"
809,846,study evaluating neoadjuvant immunotherapy in resectable pancreatic ductal adenocarcinoma,Terminated,5,1,1,Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,1,All,Industry&Combos,1,0,0,2019,2019,2,1,Phase 2,0,NA,0,0,NA
3251,4571,a study to evaluate the effect of camicinal on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis,Completed,4,1,1,Gastroparesis,drug or biologic,Early,114,All,Industry&Combos,1,0,0,2014,2014,362,1,Phase 2,2,NA,2,4.736198448394496,"(4,5]"
3821,6785,evaluate the efficacy and safety of sofosbuvir/velpatasvir fixed-dose combination and ribavirin for 12 weeks in participants with chronic hcv infection and child-pugh-turcotte class c cirrhosis,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,32,All,Industry&Combos,0,NA,0,2016,2017,610,0,Phase 2,1,safety/efficacy,1,3.4657359027997265,"(3,4]"
861,903,a study to assess ari-3037mo on hepatic fat metabolism in patients with dysglycemia and evidence of hepatic steatosis,Unknown status,8,0,0,Nonalcoholic Steatohepatitis,drug or biologic,Early,11,All,Industry&Combos,1,0,0,2015,2015,366,1,Phase 2,3,NA,2,2.3978952727983707,"(2,3]"
3294,4666,an efficacy and safety study of simeprevir and sofosbuvir with and without ribavirin in participants with recurrent genotype 1 hepatitis c post-orthotopic liver transplant,Completed,4,0,0,Hepatitits C,drug or biologic,Early,46,All,Industry&Combos,1,0,0,2014,2014,457,1,Phase 2,0,safety/efficacy,0,3.828641396489095,"(3,4]"
2766,3715,phase 2 study to evaluate lum001 in combination with ursodeoxycholic acid in patients with primary biliary cirrhosis,Completed,4,1,1,PBC|Primary Biliary Cirrhosis,drug or biologic,Early,66,All,Industry&Combos,1,0,0,2013,2013,608,1,Phase 2,2,NA,2,4.189654742026425,"(4,5]"
2535,3402,an extension study of ak002 in patients with eosinophilic gastritis and/or eosinophilic duodenitis,"Active, not recruiting",1,0,0,Eosinophilic Gastritis|Eosinophilic Gastroenteritis|Eosinophilic Duodenitis,drug or biologic,Early,58,All,Industry&Combos,0,NA,0,2018,2018,1175,0,Phase 2,1,NA,1,4.060443010546419,"(4,5]"
983,1037,let-impt and standard chemotherapy in treating patients with newly diagnosed stage i-iii anal canal squamous cell cancer,Recruiting,2,0,0,Anal Canal Squamous Cell Carcinoma|Stage I Anal Cancer AJCC v8|Stage II Anal Cancer AJCC v8|Stage IIA Anal Cancer AJCC v8|Stage IIB Anal Cancer AJCC v8|Stage III Anal Cancer AJCC v8|Stage IIIA Anal Cancer AJCC v8|Stage IIIB Anal Cancer AJCC v8|Stage IIIC Anal Cancer AJCC v8,drug or biologic,Early,48,All,NIH&Combos,0,NA,0,2018,2018,1292,0,Phase 2,1,NA,1,3.871201010907891,"(3,4]"
3682,6046,cm4620 injectable emulsion versus supportive care in patients with acute pancreatitis and sirs,Completed,4,0,0,Acute Pancreatitis|Systemic Inflammatory Response Syndrome,drug or biologic,Early,21,All,Industry&Combos,NA,0,0,2018,2018,339,NA,Phase 2,0,NA,0,3.044522437723423,"(3,4]"
3236,4541,a research study to evaluate safety and efficacy of dur-928 in subjects with primary sclerosing cholangitis (psc),Terminated,5,0,0,Primary Sclerosing Cholangitis,drug or biologic,Early,5,All,Industry&Combos,1,0,0,2018,2018,374,1,Phase 2,0,safety/efficacy,0,1.6094379124341003,"(1,2]"
798,835,"effects of alpha-1 antagonist, stress and relaxation on anorectal functions",Completed,4,1,1,Constipation,drug or biologic,Early,74,Female,NIH&Combos,1,0,0,2013,2013,1650,1,Phase 2,4,NA,2,4.30406509320417,"(4,5]"
530,551,phase ii study to evaluate modified folfirinox and stereotactic body radiation therapy in non-metastatic unresectable pancreatic adenocarcinoma,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,28,All,AllOther,0,NA,0,2019,2019,1047,0,Phase 2,1,NA,1,3.332204510175204,"(3,4]"
1978,2328,intracystic injection of nanopac Â® in subjects with mucinous cystic pancreatic neoplasms,Completed,4,1,1,Pancreatic Mucinous-Cystic Neoplasm,drug or biologic,Early,20,All,Industry&Combos,NA,1,0,2017,2017,1004,NA,Phase 2,0,NA,0,2.995732273553991,"(2,3]"
962,1012,fundamental modification of the gut microbiota in the treatment of refractory crohn's disease,Completed,4,1,1,Crohn's Disease,drug or biologic,Early,8,All,AllOther,1,0,0,2016,2016,852,1,Phase 2,4,NA,2,2.0794415416798357,"(2,3]"
3463,5256,panitumumab with or without trametinib in treating patients with stage iv colorectal cancer,Recruiting,2,0,0,EGFR NP_005219.2:p.S492R|KRAS Gene Mutation|MAP2K1 Gene Mutation|Metastatic Colorectal Adenocarcinoma|Refractory Colorectal Adenocarcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,84,All,NIH&Combos,3,1,0,2017,2017,1462,3,Phase 2,0,NA,0,4.430816798843313,"(4,5]"
857,898,testing effectiveness of losartan in patients with eoe with or without a ctd,Completed,4,1,1,Eosinophilic Esophagitis|Connective Tissue Disorders,drug or biologic,Early,6,All,AllOther,0,NA,0,2013,2013,460,0,Phase 2,1,NA,1,1.791759469228055,"(1,2]"
4137,8982,refametinib(bay86-9766) in ras mutant hepatocellular carcinoma (hcc),Completed,4,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2013,2013,387,0,Phase 2,1,NA,1,2.772588722239781,"(2,3]"
206,209,quilt-3.088: nant pancreatic cancer vaccine,Withdrawn,7,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,NA,All,Industry&Combos,0,0,0,2018,2018,516,0,Phase 2,1,NA,1,NA,NA
739,773,organ preservation in early rectal cancer patients,Recruiting,2,0,0,Rectal Cancer,drug or biologic,Early,19,All,AllOther,0,NA,0,2018,2018,1390,0,Phase 2,1,NA,1,2.9444389791664403,"(2,3]"
3674,5928,a study of arry-382 in combination with pembrolizumab for the treatment of patients with advanced solid tumors,Completed,4,0,0,Advanced Solid Tumors,drug or biologic,Early,82,All,Industry&Combos,0,1,0,2016,2016,1148,0,Phase 2,1,NA,1,4.406719247264253,"(4,5]"
2827,3789,phase 2 study of adxs11-001 in subjects with carcinoma of the anorectal canal,Completed,4,0,0,Anal Cancer|Rectal Cancer,drug or biologic,Early,51,All,Industry&Combos,0,NA,0,2015,2015,639,0,Phase 2,1,NA,1,3.9318256327243257,"(3,4]"
1625,1782,"celecoxib, recombinant interferon alfa-2b, and rintatolimod in treating patients with colorectal cancer metastatic to the liver","Active, not recruiting",1,0,0,Metastatic Carcinoma in the Liver|Recurrent Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,15,All,NIH&Combos,0,NA,0,2018,2018,979,0,Phase 2,1,NA,1,2.70805020110221,"(2,3]"
3619,5709,study of pembrolizumab in combination with chemotherapy for patients with advanced colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Cancer,drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2015,2015,2071,0,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
2542,3415,stereotactic mri-guided on-table adaptive radiation therapy (smart) for locally advanced pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,other,Others,133,All,Industry&Combos,0,NA,0,2018,2019,851,0,Others,1,NA,1,4.890349128221754,"(4,5]"
3866,7097,"study to assess safety, tolerability and efficacy of incremental doses of mgb-bp-3 in patients with cdad",Completed,4,0,0,Clostridium Difficile Infection,drug or biologic,Early,34,All,Industry&Combos,NA,1,0,2019,2019,421,NA,Phase 2,0,safety/efficacy,0,3.5263605246161616,"(3,4]"
1852,2124,doxepin hydrochloride in treating esophageal pain in patients with thoracic cancer receiving radiation therapy to the thorax with or without chemotherapy,Terminated,5,1,1,Esophageal Carcinoma|Hypopharyngeal Carcinoma|Laryngeal Carcinoma|Lymphoma|Mesothelioma|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Pleura|Metastatic Malignant Neoplasm in the Spinal Cord|Non-Small Cell Lung Carcinoma|Sarcoma|Small Cell Lung Carcinoma|Thymic Carcinoma|Thymoma|Thyroid Gland Carcinoma,drug or biologic,Early,5,All,NIH&Combos,1,0,4,2014,2014,410,1,Phase 2,2,NA,2,1.6094379124341003,"(1,2]"
2060,2445,rrx-001 in second line treatment of advanced cholangiocarcinoma prior to readministration of first-line therapy,Terminated,5,0,0,Cholangiocarcinoma,drug or biologic,Early,4,All,Industry&Combos,0,NA,0,2015,2015,299,0,Phase 2,1,NA,1,1.3862943611198906,"(1,2]"
846,887,growth hormone releasing hormone analog to improve nonalcoholic fatty liver disease and associated cardiovascular risk,Recruiting,2,0,0,"Non-Alcoholic Fatty Liver Disease|Obesity|Obesity, Abdominal|Liver Fat|Fatty Liver",drug or biologic,Early,76,All,AllOther,1,0,0,2017,2019,1900,1,Phase 2,4,NA,2,4.330733340286331,"(4,5]"
1070,1128,2 regimens of lactulose for colonoscopy preparation in adults,Completed,4,1,1,Colonoscopy Preparation,drug or biologic,Early,55,All,Industry&Combos,1,0,0,2013,2013,92,1,Phase 2,3,NA,2,4.007333185232471,"(4,5]"
3806,6732,"an efficacy, safety, and pharmacokinetics study of jnj-56136379 in participants with chronic hepatitis b virus infection",Completed,4,0,0,Hepatitis B,drug or biologic,Early,232,All,Industry&Combos,1,0,0,2017,2018,569,1,Phase 2,3,safety/efficacy,2,5.44673737166631,"(5,6]"
2706,3629,dietary manipulation of the microbiome-metabolomic axis for mitigating gvhd in allo hct patients,Recruiting,2,0,0,Hematopoietic Stem Cell Transplantation,drug or biologic,Early,70,All,AllOther,1,0,1,2016,2017,2532,1,Phase 2,1,NA,1,4.248495242049359,"(4,5]"
1334,1426,trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer,Suspended,6,0,0,Advanced Bile Duct Carcinoma|Advanced Gallbladder Carcinoma|Refractory Bile Duct Carcinoma|Refractory Gallbladder Carcinoma|Stage III Distal Bile Duct Cancer AJCC v8|Stage III Gallbladder Cancer AJCC v8|Stage III Intrahepatic Bile Duct Cancer AJCC v8|Stage IIIA Distal Bile Duct Cancer AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8|Stage IIIB Distal Bile Duct Cancer AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8|Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8|Stage IV Distal Bile Duct Cancer AJCC v8|Stage IV Gallbladder Cancer AJCC v8|Stage IV Intrahepatic Bile Duct Cancer AJCC v8|Stage IVA Gallbladder Cancer AJCC v8|Stage IVB Gallbladder Cancer AJCC v8,drug or biologic,Early,28,All,NIH&Combos,0,NA,0,2019,2019,940,0,Phase 2,1,NA,1,3.332204510175204,"(3,4]"
1654,1821,treatment of suspected cholelithiasis with nitroglycerin,Unknown status,8,0,0,COLIC|BILIARY TRACT DISEASES,drug or biologic,Early,62,All,AllOther,1,0,0,2012,2014,1522,1,Phase 2,3,NA,2,4.127134385045092,"(4,5]"
2460,3213,hepatic arterial infusion (hai) with floxuridine (fudr) and dexamethasone (dex) combined with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma (icc),"Active, not recruiting",1,0,0,Intrahepatic Cholangiocarcinoma|Peripheral Cholangiocarcinoma|Cholangiolar Carcinoma|Cholangiocellular Carcinoma,drug or biologic,Early,55,All,AllOther,1,1,0,2013,2013,3287,1,Phase 2,0,NA,0,4.007333185232471,"(4,5]"
453,468,adaptive modification of neoadjuvant therapy based on clinical response in patients with localized pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,125,All,AllOther,1,1,0,2017,2018,1502,1,Phase 2,0,NA,0,4.8283137373023015,"(4,5]"
3966,7442,refametinib in combination with sorafenib in ras mutant hepatocellular carcinoma (hcc),Completed,4,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,14,All,Industry&Combos,0,NA,0,2013,2013,670,0,Phase 2,1,NA,1,2.6390573296152584,"(2,3]"
1792,2025,new treatment response in people with and without cirrhosis from chronic hepatitis c,Completed,4,1,1,"Cirrhosis|Chronic Hepatitis C|Hepatitis C|Hepatitis C, Chronic",drug or biologic,Early,35,All,IndustryNIHPartnership,0,0,0,2013,2013,914,0,Phase 2,1,NA,1,3.5553480614894135,"(3,4]"
2886,3871,phase 2b efficacy/safety of ornithine phenylacetate in hospitalized cirrhotic patients with hepatic encephalopathy (stop-he),Completed,4,0,0,Acute Episode of Overt Hepatic Encephalopathy|Hepatic Encephalopathy,drug or biologic,Early,231,All,Industry&Combos,1,0,0,2013,2013,1126,1,Phase 2,4,safety/efficacy,2,5.442417710521793,"(5,6]"
4049,7672,ledipasvir/sofosbuvir fixed-dose combination with ribavirin or gs-9669 in subjects with chronic genotype 1 hcv infection,Completed,4,1,1,Chronic HCV Infection,drug or biologic,Early,101,All,Industry&Combos,1,0,0,2013,2013,182,1,Phase 2,0,NA,0,4.61512051684126,"(4,5]"
385,395,pilot study of the effect of liraglutide 3.0 mg on weight loss and gastric functions in obesity,Recruiting,2,0,0,Obesity,drug or biologic,Early,112,All,IndustryNIHPartnership,2,0,0,2018,2017,1828,1,Phase 2,2,NA,2,4.718498871295094,"(4,5]"
1129,1199,metformin plus modified folfox 6 in metastatic pancreatic cancer,Completed,4,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,50,All,NIH&Combos,0,NA,0,2012,2013,1993,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
1667,1837,single agent regorafenib in refractory advanced biliary cancers,"Active, not recruiting",1,1,1,Cancer of the Bile Duct,drug or biologic,Early,39,All,Industry&Combos,0,NA,0,2014,2014,1649,0,Phase 2,1,NA,1,3.6635616461296463,"(3,4]"
3538,5406,phase ii study of minocycline for reducing symptom burden in colorectal patients,Completed,4,1,1,Colorectal Cancer,drug or biologic,Early,122,All,AllOther,1,0,0,2013,2013,1931,1,Phase 2,2,NA,2,4.804021044733257,"(4,5]"
2771,3720,"elafibranor, pk and safety in children and adolescents 8 to 17 years of age with non alcoholic steatohepatitis (nash)",Terminated,5,0,0,Non Alcoholic Steatohepatitis,drug or biologic,Early,10,All,Industry&Combos,1,0,0,2019,2019,383,1,Phase 2,0,safety,0,2.302585092994046,"(2,3]"
2904,3893,combination chemotherapy before and after surgery in treating patients with localized pancreatic cancer,Recruiting,2,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage I Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer,drug or biologic,Early,42,All,NIH&Combos,0,NA,0,2014,2014,4331,0,Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
2644,3548,a study of abemaciclib (ly2835219) alone or in combination with other agents in participants with previously treated pancreatic ductal adenocarcinoma,Completed,4,1,1,Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,106,All,Industry&Combos,1,0,0,2016,2017,463,1,Phase 2,0,NA,0,4.663439094112067,"(4,5]"
2211,2702,hepatitis b immune globulin (hbig) to restore immune control in people with chronic hepatitis b,Recruiting,2,0,0,Chronic Hepatitis B,drug or biologic,Early,300,All,NIH&Combos,1,0,0,2018,2019,1202,1,Phase 2,0,NA,0,5.703782474656201,"(5,6]"
2013,2376,surgery in treating patients with early stage anal canal or perianal cancer and hiv infection,Recruiting,2,0,0,Anal Squamous Cell Carcinoma|HIV Infection|Stage 0 Anal Canal Cancer|Stage I Anal Canal Cancer,procedure,Others,56,All,IndustryNIHPartnership,0,NA,0,2015,2015,3775,0,Others,1,NA,1,4.02535169073515,"(4,5]"
1696,1877,ziv-aflibercept in treating and computed tomography perfusion imaging in predicting response in patients with pancreatic neuroendocrine tumors that are metastatic or cannot be removed by surgery,Completed,4,1,1,Multiple Endocrine Neoplasia Type 1|Pancreatic Neuroendocrine Carcinoma,drug or biologic,Early,22,All,NIH&Combos,0,NA,0,2014,2014,1323,0,Phase 2,1,NA,1,3.091042453358316,"(3,4]"
2532,3395,"tas-102, irinotecan, and bevacizumab for the treatment of pre-treated metastatic or unresectable colorectal cancer, the tabasco study",Recruiting,2,0,0,Advanced Colorectal Carcinoma|Metastatic Colon Adenocarcinoma|Metastatic Rectal Adenocarcinoma|Recurrent Colon Adenocarcinoma|Recurrent Colorectal Adenocarcinoma|Recurrent Rectal Adenocarcinoma|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Rectal Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Rectal Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IVC Rectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Colorectal Carcinoma|Unresectable Rectal Adenocarcinoma,drug or biologic,Early,40,All,NIH&Combos,0,NA,0,2019,2019,1212,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
671,699,treatment for non-alcoholic fatty liver with different doses of vitamin e,Completed,4,1,1,Fatty Liver,drug or biologic,Early,22,All,NIH&Combos,1,0,4,2013,2013,2312,1,Phase 2,0,NA,0,3.091042453358316,"(3,4]"
1854,2128,"a phase ii a study of lenvatinib, a multi-targeted tyrosine kinase inhibitor, combined with pembrolizumab (pd-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies",Recruiting,2,0,0,GastroEsophageal Cancer|Gastric Cancer,drug or biologic,Early,24,All,AllOther,0,NA,0,2017,2017,1513,0,Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
2572,3458,ds-8201a in her2-positive gastric cancer that cannot be surgically removed or has spread (destiny-gastric02),"Active, not recruiting",1,0,0,Adenocarcinoma Gastric Stage IV With Metastases|Adenocarcinoma - GEJ,drug or biologic,Early,79,All,Industry&Combos,0,NA,0,2019,2019,764,0,Phase 2,1,NA,1,4.3694478524670215,"(4,5]"
817,855,ursodeoxycholic acid (udca) for hepatic sarcoidosis,Recruiting,2,0,0,"Hepatic Sarcoidosis, Elevated Alkaline Phosphatase",drug or biologic,Early,10,All,Industry&Combos,3,1,0,2018,2018,1776,3,Phase 2,0,NA,0,2.302585092994046,"(2,3]"
2755,3703,an efficacy and safety study of mongersen (ged-0301) in subjects with active ulcerative colitis,Completed,4,1,1,"Colitis, Ulcerative",drug or biologic,Early,41,All,Industry&Combos,0,NA,0,2015,2015,267,0,Phase 2,1,safety/efficacy,1,3.713572066704308,"(3,4]"
2358,3003,"efficacy, safety and tolerability of a bowel cleansing preparation (bli800) in pediatric subjects undergoing colonoscopy",Completed,4,1,1,Colonoscopy,drug or biologic,Early,29,All,Industry&Combos,1,0,0,2014,2014,214,1,Phase 2,0,safety/efficacy,0,3.367295829986474,"(3,4]"
1888,2186,phase ii study of zaltrap and chemotherapy for advanced resectable colorectal cancer,Withdrawn,7,0,0,Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2014,2014,730,1,Phase 2,0,NA,0,NA,NA
1881,2177,surgery plus sulindac or surgery alone for advanced colorectal cancer,Terminated,5,1,1,Colorectal Cancer|Liver Metastasis|Colorectal Adenocarcinoma,drug or biologic,Early,3,All,NIH&Combos,1,0,0,2013,2013,640,1,Phase 2,2,NA,2,1.0986122886681098,"(1,2]"
982,1036,aramchol for hiv-associated nonalcoholic fatty liver disease and lipodystrophy,Completed,4,1,1,Nonalcoholic Fatty Liver Disease|HIV,drug or biologic,Early,50,All,AllOther,1,0,0,2016,2016,762,1,Phase 2,3,NA,2,3.912023005428146,"(3,4]"
1933,2257,doxorubicin-eluting lc bead m1 for patients with hepatocellular carcinoma,Completed,4,1,1,Hepatocellular Carcinoma,device,Others,24,All,AllOther,0,NA,0,2013,2014,556,0,Others,1,NA,1,3.1780538303479458,"(3,4]"
482,500,efficacy and safety of oral rifaximin in patients with active microscopic colitis,Recruiting,2,0,0,Microscopic Colitis,drug or biologic,Early,10,All,AllOther,0,NA,0,2019,2018,1251,0,Phase 2,1,safety/efficacy,1,2.302585092994046,"(2,3]"
1743,1950,2 versus 6 hour oxaliplatin infusions in patients with gastrointestinal cancers,Recruiting,2,0,0,Malignant Digestive System Neoplasm,drug or biologic,Early,60,All,AllOther,1,0,0,2019,2019,1331,1,Phase 2,0,NA,0,4.0943445622221,"(4,5]"
3070,4135,open-label extension study to assess safety and tolerability of lyc-30937-ec in subjects with active ulcerative colitis,Terminated,5,1,1,"Colitis, Ulcerative",drug or biologic,Early,112,All,Industry&Combos,0,NA,0,2016,2016,624,0,Phase 2,1,safety,1,4.718498871295094,"(4,5]"
2494,3305,self-propelled versus standard percutaneous endoscopic gastrojejunostomy(peg-j); rct,Terminated,5,1,1,Feeding Tube,device,Others,19,All,AllOther,1,0,4,2013,2013,451,1,Others,1,NA,1,2.9444389791664403,"(2,3]"
2297,2877,mnk6106 for liver disease (hepatic cirrhosis) that in the past has affected the brain (hepatic encephalopathy),Completed,4,0,0,Hepatic Cirrhosis|Hepatic Encephalopathy (HE),drug or biologic,Early,50,All,Industry&Combos,1,0,0,2018,2018,591,1,Phase 2,0,NA,0,3.912023005428146,"(3,4]"
3492,5296,efficacy and safety study of tisotumab vedotin for patients with solid tumors,Recruiting,2,0,0,"Colorectal Neoplasms|Carcinoma, Non-Small-Cell Lung|Exocrine Pancreatic Cancer|Carcinoma, Squamous Cell of Head and Neck",drug or biologic,Early,392,All,Industry&Combos,1,1,0,2018,2018,1436,1,Phase 2,0,safety/efficacy,0,5.971261839790462,"(5,6]"
183,184,folfox-a for locally advanced pancreatic cancer: a phase ii brown university oncology research group trial,"Active, not recruiting",1,0,0,Locally Advanced Pancreatic Cancer|Pancreatic Cancer,drug or biologic,Early,28,All,AllOther,0,NA,0,2015,2016,1295,0,Phase 2,1,NA,1,3.332204510175204,"(3,4]"
409,420,hepatic artery infusion pump chemotherapy with floxuridine and dexamethasone in combination with systemic chemotherapy for patients with colorectal cancer metastatic to the liver,Recruiting,2,0,0,Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma,drug or biologic,Early,40,All,NIH&Combos,0,NA,0,2017,2019,2017,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
828,867,ezetimibe-ursodiol combination therapy on biomarkers of liver function and sterol balance in subjects with nafld,Terminated,5,1,1,Nonalcoholic Fatty Liver Disease (NAFLD),drug or biologic,Early,2,All,AllOther,0,NA,0,2014,2014,365,0,Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
2324,2937,folfox plus regorafenib in patients with unresectable or metastatic esophagogastric cancer,Completed,4,1,1,Esophageal Cancer|Gastric Cancer,drug or biologic,Early,39,All,Industry&Combos,0,NA,0,2013,2013,2161,0,Phase 2,1,NA,1,3.6635616461296463,"(3,4]"
3958,7383,capecitabine and bevacizumab with or without atezolizumab in treating patients with refractory metastatic colorectal cancer,"Active, not recruiting",1,1,1,Metastatic Colorectal Carcinoma|Recurrent Colorectal Carcinoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,133,All,NIH&Combos,1,0,0,2016,2017,627,1,Phase 2,2,NA,2,4.890349128221754,"(4,5]"
3513,5347,"a pilot study of ""oncozenetm"" microspheres for intra-arterial delivery of doxorubicin","Active, not recruiting",1,0,0,Hepatocellular Cancer,other,Others,20,All,AllOther,0,NA,0,2014,2015,2688,0,Others,1,NA,1,2.995732273553991,"(2,3]"
165,165,gastrointestinal sensorimotor dysfunctions in diabetes mellitus,Completed,4,1,1,Dyspepsia|Diabetes Mellitus With Gastrointestinal Symptoms,drug or biologic,Early,104,All,NIH&Combos,1,0,4,2014,2014,1265,1,Phase 2,3,NA,2,4.6443908991413725,"(4,5]"
2403,3098,11c-acetate for treatment response after radiotherapy for hcc,Terminated,5,1,1,Hepatocellular Carcinoma,drug or biologic,Early,1,All,AllOther,0,NA,4,2015,2015,396,0,Phase 2,1,NA,1,0,NA
2841,3807,a study of safety and effectiveness of jnj-54781532 in patients with moderately to severely active ulcerative colitis,Completed,4,0,0,"Colitis, Ulcerative",drug or biologic,Early,219,All,Industry&Combos,1,0,0,2013,2013,551,1,Phase 2,4,safety,2,5.389071729816501,"(5,6]"
3317,4726,a study to assess the efficacy and safety of vk2809 for 52 weeks in subjects with biopsy proven nash,Recruiting,2,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,337,All,Industry&Combos,1,0,0,2019,2019,747,1,Phase 2,4,safety/efficacy,2,5.820082930352362,"(5,6]"
3389,5039,pci treatment/gemcitabine & chemotherapy vs chemotherapy alone in patients with inoperable extrahepatic bile duct cancer,Recruiting,2,0,0,Cholangiocarcinoma,drug or biologic,Early,186,All,Industry&Combos,1,0,0,2019,2019,1500,1,Phase 2,0,NA,0,5.225746673713202,"(5,6]"
2425,3144,"phii trial panitumumab, nivolumab, ipilimumab in kras/nras/braf wild-type mss refractory mcrc","Active, not recruiting",1,0,0,Colon Cancer,drug or biologic,Early,56,All,Industry&Combos,0,NA,0,2018,2018,927,0,Phase 2,1,NA,1,4.02535169073515,"(4,5]"
2870,3848,efficacy and safety of plecanatide in children 6 to <18 years of age with irritable bowel syndrome with constipation (ibs-c),Recruiting,2,0,0,Irritable Bowel Syndrome With Constipation,drug or biologic,Early,210,All,Industry&Combos,1,0,0,2018,2018,1615,1,Phase 2,4,safety/efficacy,2,5.3471075307174685,"(5,6]"
2674,3586,"study of gemcitabine, abraxane Â® plus placebo versus gemcitabine, abraxane Â® plus 1 or 2 truncated courses of demcizumab in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma",Completed,4,1,1,Pancreatic Cancer,drug or biologic,Early,207,All,Industry&Combos,1,0,0,2014,2015,742,1,Phase 2,3,NA,2,5.332718793265369,"(5,6]"
2850,3822,study of induction pd-1 blockade in subjects with locally advanced mismatch repair deficient rectal adenocarcinoma,Recruiting,2,0,0,"Rectal Adenocarcinoma|Clinical Stage: Stage II (T3-4, N-)|Stage III (Any T, N+)",drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2019,2019,1064,0,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
2596,3492,open label study to evaluate efficacy and long term safety of lum001 in the treatment of cholestatic liver disease in patients with progressive familial intrahepatic cholestasis,Completed,4,0,0,Progressive Familial Intrahepatic Cholestasis (PFIC),drug or biologic,Early,33,All,Industry&Combos,0,NA,0,2014,2014,2260,0,Phase 2,1,safety/efficacy,1,3.4965075614664802,"(3,4]"
4088,8047,a study evaluating abi-h0731+ entecavir vs entecavir alone for the treatment of viremic hbeag-positive participants with chronic hepatitis b virus infection (chbv),Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Early,25,All,Industry&Combos,1,0,0,2018,2018,367,1,Phase 2,3,NA,2,3.2188758248682006,"(3,4]"
2864,3841,a study of idn-6556 in cirrhotic subjects with portal hypertension,Completed,4,1,1,Liver Cirrhosis|Hepatic Cirrhosis|Portal Hypertension,drug or biologic,Early,23,All,Industry&Combos,0,1,0,2014,2014,273,0,Phase 2,1,NA,1,3.1354942159291497,"(3,4]"
930,977,pilot study of lubiprostone as a modulator of gut microbial translocation and systemic immune activation in hiv-infected persons with incomplete cd4+ t-cell recovery on antiretroviral therapy,Unknown status,8,0,0,HIV,drug or biologic,Early,20,All,AllOther,1,0,0,2013,2013,304,1,Phase 2,0,NA,0,2.995732273553991,"(2,3]"
3789,6641,study of ruxolitinib in colorectal cancer patients,Terminated,5,1,1,CRC (Colorectal Cancer),drug or biologic,Early,396,All,Industry&Combos,1,0,0,2014,2014,702,1,Phase 2,2,NA,2,5.981414211254481,"(5,6]"
890,934,perioperative chemo and pembrolizumab in gastric cancer,Recruiting,2,0,0,Gastric Cancer|Adenocarcinoma of the Gastroesophageal Junction,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2016,2017,1680,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3374,4978,nutritional adequacy therapeutic enhancement in the critically ill. the nutriate study,Terminated,5,1,1,Gastroparesis,drug or biologic,Early,91,All,Industry&Combos,1,0,0,2013,2014,826,1,Phase 2,2,NA,2,4.51085950651685,"(4,5]"
860,902,pembrolizumab and gm-csf in biliary cancer,"Active, not recruiting",1,0,0,Biliary Cancer,drug or biologic,Early,42,All,Industry&Combos,0,NA,0,2016,2016,1699,0,Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
3158,4313,study of a combination pill with gs-7977 and gs-5885 for hepatitis c in people with hiv,Completed,4,1,1,Hepatitis C|HIV,drug or biologic,Early,50,All,NIH&Combos,0,NA,0,2013,2013,457,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
328,334,phase ii neoadjuvant chemotheraphy (gemcitabine and nab-paclitaxel vs. mfolfirinox) and sterotatic body radiation therapy for borderline resectable pancreatic cancer,Terminated,5,1,1,Borderline Resectable Pancreatic Cancer,drug or biologic,Early,2,All,AllOther,1,0,0,2014,2014,823,1,Phase 2,0,NA,0,0.6931471805599453,"(0,1]"
3571,5512,a study of bms-986036 in subjects with non-alcoholic steatohepatitis (nash),Completed,4,1,1,Non-Alcoholic Steatohepatitis,drug or biologic,Early,184,All,Industry&Combos,1,0,0,2015,2015,621,1,Phase 2,2,NA,2,5.214935757608986,"(5,6]"
2028,2397,ezetimibe versus placebo in the treatment of non-alcoholic steatohepatitis,Completed,4,1,1,Non Alcoholic Steatohepatitis,drug or biologic,Early,50,All,AllOther,1,0,0,2013,2013,577,1,Phase 2,2,NA,2,3.912023005428146,"(3,4]"
3592,5622,tamoxifen for well differentiated neurodendocrine tumors and hormone receptor positive expression,Recruiting,2,0,0,Neuroendocrine Tumors|Progesterone Receptor Positive Tumor|Estrogen Receptor Positive Tumor,drug or biologic,Early,15,All,AllOther,0,NA,0,2019,2019,931,0,Phase 2,1,NA,1,2.70805020110221,"(2,3]"
3190,4412,vaccine therapy in treating patients with newly diagnosed advanced colon polyps,"Active, not recruiting",1,1,1,Colorectal Adenoma|Colorectal Adenoma With Severe Dysplasia|Colorectal Tubulovillous Adenoma,drug or biologic,Early,110,All,NIH&Combos,1,0,1,2014,2014,949,1,Phase 2,2,NA,2,4.700480365792417,"(4,5]"
2241,2764,"azd9150, a stat3 antisense oligonucleotide, in people with malignant ascites",Terminated,5,1,1,Ovarian Cancer|Ovarian Neoplasms|Ascites|Gastrointestinal Cancer|Gastrointestinal Neoplasms,drug or biologic,Early,1,All,NIH&Combos,0,NA,0,2015,2015,370,0,Phase 2,1,NA,1,0,NA
3882,7156,a study of pembrolizumab and bavituximab in patients with advanced hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Early,28,All,Industry&Combos,0,NA,0,2018,2018,1436,0,Phase 2,1,NA,1,3.332204510175204,"(3,4]"
2728,3654,aprepitant for the relief of nausea in patients with chronic nausea and vomiting of presumed gastric origin trial,Completed,4,1,1,Gastroparesis,drug or biologic,Early,126,All,NIH&Combos,1,0,0,2010,2013,852,1,Phase 2,3,NA,2,4.836281906951478,"(4,5]"
659,686,phase ii study of ibrutinib in advanced carcinoid and pancreatic neuroendocrine tumors,Completed,4,1,1,Carcinoid Tumors|Pancreatic NET,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2015,2015,1264,0,Phase 2,1,NA,1,2.995732273553991,"(2,3]"
3406,5129,budesonide for mycophenolic acid-induced diarrhea in renal transplant recipients,Terminated,5,0,0,Diarrhea,drug or biologic,Early,9,All,AllOther,1,0,0,2016,2017,819,1,Phase 2,2,NA,2,2.1972245773362196,"(2,3]"
449,461,adoptive transfer of tumor infiltrating lymphocytes for biliary tract cancers,Recruiting,2,0,0,Biliary Tract Cancer|Cholangiocarcinoma|Biliary Tract Neoplasms,drug or biologic,Early,59,All,AllOther,0,NA,0,2019,2019,1442,0,Phase 2,1,NA,1,4.07753744390572,"(4,5]"
3686,6074,a poc and dose-ranging study of htd1801 in psc patients,Completed,4,0,0,Primary Sclerosing Cholangitis (PSC),drug or biologic,Early,59,All,Industry&Combos,1,0,0,2017,2018,811,1,Phase 2,4,NA,2,4.07753744390572,"(4,5]"
1997,2349,nab-paclitaxel + cisplatin + gemcitabine in untreated metastatic pancreatic adenocarcinoma,"Active, not recruiting",1,0,0,Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,42,All,Industry&Combos,0,NA,0,2019,2019,1051,0,Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
2020,2386,an efficacy trial of low dose all-trans retinoic acid in patients with primary sclerosing cholangitis,Terminated,5,0,0,"Cholangitis, Sclerosing",drug or biologic,Early,2,All,AllOther,0,NA,0,2017,2018,917,0,Phase 2,1,efficacy,1,0.6931471805599453,"(0,1]"
1513,1643,the graft study: gut recolonization by fecal transplantation,Completed,4,1,1,Clostridium Difficile Infection|C.Difficile Diarrhea|CDI,drug or biologic,Early,1,All,AllOther,1,0,0,2018,2019,343,1,Phase 2,3,NA,2,0,NA
2278,2837,study of pf-03084014 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma not previously treated with anticancer therapies,Terminated,5,1,1,Metastatic Cancer Pancreas,drug or biologic,Early,3,All,Industry&Combos,NA,0,0,2014,2014,64,NA,Phase 2,0,NA,0,1.0986122886681098,"(1,2]"
2664,3573,option: a trial to assess the safety & efficacy of ms1819 in patients with exocrine pancreatic insufficiency due to cystic fibrosis,Completed,4,0,0,Exocrine Pancreatic Insufficiency (EPI)|Cystic Fibrosis (CF),drug or biologic,Early,32,All,Industry&Combos,3,0,0,2018,2019,184,3,Phase 2,0,safety/efficacy,0,3.4657359027997265,"(3,4]"
2712,3636,an investigational study of immunotherapy combinations with chemotherapy in patients with gastric or gastroesophageal junction (gej) cancers,"Active, not recruiting",1,0,0,Gastric Cancer|Cancer of the Stomach|Esophagogastric Junction,drug or biologic,Early,250,All,Industry&Combos,1,0,0,2018,2018,815,1,Phase 2,0,NA,0,5.521460917862246,"(5,6]"
3653,5802,latiglutenase as a treatment for celiac disease,Completed,4,0,0,Celiac Disease,drug or biologic,Early,79,All,IndustryNIHPartnership,1,0,0,2018,2019,327,1,Phase 2,3,NA,2,4.3694478524670215,"(4,5]"
2934,3935,"veliparib, pembrolizumab, and combination chemotherapy in treating patient with locally advanced rectal cancer","Active, not recruiting",1,0,0,Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v7|Stage III Rectal Cancer AJCC v7,drug or biologic,Early,348,All,NIH&Combos,1,0,0,2016,2016,1996,1,Phase 2,0,NA,0,5.8522024797744745,"(5,6]"
1432,1541,anti-lps antibody treatment for pediatric nafld,Completed,4,1,1,Nonalcoholic Fatty Liver Disease (NAFLD),drug or biologic,Early,40,All,Industry&Combos,1,0,0,2017,2017,994,1,Phase 2,2,NA,2,3.6888794541139363,"(3,4]"
1727,1920,surgery and heated chemotherapy for adrenocortical carcinoma,Completed,4,1,1,Adrenocortical Carcinoma|Peritoneal Carcinomatosis,drug or biologic,Early,11,All,NIH&Combos,0,NA,0,2013,2013,1945,0,Phase 2,1,NA,1,2.3978952727983707,"(2,3]"
2224,2738,effects of botox in obstructed defecation syndrome,Terminated,5,1,1,Obstructed Defecation Syndrome (ODS),drug or biologic,Early,1,All,AllOther,1,0,0,2014,2016,1226,1,Phase 2,3,NA,2,0,NA
2648,3553,a study of tak-954 to treat gastrointestinal dysfunction in adults after surgery,Recruiting,2,0,0,Postoperative Gastrointestinal Dysfunction,drug or biologic,Early,180,All,Industry&Combos,1,0,0,2019,2019,1036,1,Phase 2,4,NA,2,5.19295685089021,"(5,6]"
3807,6738,"phase ii study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome",Completed,4,1,1,Dumping Syndrome,drug or biologic,Early,43,All,Industry&Combos,0,1,0,2012,2013,941,0,Phase 2,1,safety/efficacy,1,3.7612001156935624,"(3,4]"
1877,2170,high dose vitamin c intravenous infusion in patients with resectable or metastatic solid tumor malignancies,Recruiting,2,0,0,Colorectal Cancer|Pancreatic Cancer|Lung Cancer,drug or biologic,Early,78,All,AllOther,0,NA,0,2017,2017,1554,0,Phase 2,1,NA,1,4.356708826689592,"(4,5]"
154,154,n-acetylcysteine in biliary atresia after kasai portoenterostomy,Recruiting,2,0,0,Biliary Atresia,drug or biologic,Early,16,All,AllOther,0,NA,0,2018,2018,1534,0,Phase 2,1,NA,1,2.772588722239781,"(2,3]"
289,294,bethanechol for eosinophilic esophagitis,Terminated,5,1,1,Eosinophilic Esophagitis (EoE),drug or biologic,Early,2,All,AllOther,0,NA,0,2014,2014,150,0,Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
2570,3455,liposomal bupivacaine in bariatric surgery,Completed,4,1,1,Bariatric Surgery Analgesia,drug or biologic,Early,219,All,AllOther,1,0,0,2017,2018,151,1,Phase 2,3,NA,2,5.389071729816501,"(5,6]"
2972,3986,"5-fu, aflibercept, and radiation (rt) for preoperative and postoperative patients with stage ii/iii rectal cancer",Completed,4,1,1,Rectal Cancer,drug or biologic,Early,39,All,Industry&Combos,0,NA,0,2012,2013,973,0,Phase 2,1,NA,1,3.6635616461296463,"(3,4]"
2765,3714,safety and efficacy of etrasimod (apd334) in patients with ulcerative colitis,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Early,156,All,Industry&Combos,1,0,0,2015,2015,853,1,Phase 2,3,safety/efficacy,2,5.049856007249537,"(5,6]"
2779,3732,aspirin in preventing disease recurrence in patients with barrett esophagus after successful elimination by radiofrequency ablation,"Active, not recruiting",1,0,0,Barrett Esophagus,drug or biologic,Early,23,All,NIH&Combos,1,0,1,2015,2016,1250,1,Phase 2,2,NA,2,3.1354942159291497,"(3,4]"
2290,2870,a sub-study of bms-986036 in subjects with non-alcoholic steatohepatitis (nash),Completed,4,1,1,Non-Alcoholic Steatohepatitis,drug or biologic,Early,3,All,Industry&Combos,1,0,0,2018,2015,621,1,Phase 2,2,NA,2,1.0986122886681098,"(1,2]"
3810,6753,perseus: preliminary efficacy and safety of cenicriviroc in adult participants with primary sclerosing cholangitis,Completed,4,1,1,Primary Sclerosing Cholangitis,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2016,2016,535,0,Phase 2,1,safety/efficacy,1,3.1780538303479458,"(3,4]"
1069,1127,regorafenib second line treatment of metastatic or advanced upper gi cancers,Terminated,5,1,1,Upper GI Cancer,drug or biologic,Early,5,All,AllOther,0,NA,0,2014,2014,854,0,Phase 2,1,NA,1,1.6094379124341003,"(1,2]"
3484,5287,pacritinib to inhibit jak/stat signaling in refractory colorectal cancer,Terminated,5,1,1,Colorectal Cancer,drug or biologic,Early,11,All,Industry&Combos,0,NA,0,2014,2015,191,0,Phase 2,1,NA,1,2.3978952727983707,"(2,3]"
2745,3681,study of nivolumab and relatlimab in patients with microsatellite stable (mss) advanced colorectal cancer,Recruiting,2,0,0,Microsatellite Stable (MSS) Colorectal Adenocarcinomas|Colorectal Adenocarcinoma,drug or biologic,Early,96,All,Industry&Combos,1,1,0,2018,2019,1815,1,Phase 2,0,NA,0,4.564348191467836,"(4,5]"
4039,7632,heplisav-b hepatitis b vaccine in chronic lymphocytic leukemia (cll) and cll treated with bruton's-tyrosine kinase inhibitor (btk-i),Completed,4,0,0,Hepatitis|Safety and Tolerability,drug or biologic,Early,78,All,NIH&Combos,0,NA,1,2018,2018,740,0,Phase 2,1,NA,1,4.356708826689592,"(4,5]"
2565,3445,a pilot study of bli801 laxative in adults experiencing non-idiopathic constipation,Completed,4,0,0,Constipation,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2016,2016,335,0,Phase 2,1,NA,1,2.772588722239781,"(2,3]"
249,253,"proton radiation for unresectable, borderline resectable, or medically inoperable carcinoma of the pancreas",Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,60,All,AllOther,0,NA,0,2015,2016,8583,0,Phase 2,1,NA,1,4.0943445622221,"(4,5]"
2792,3748,study of dupilumab in adult participants with active eosinophilic esophagitis (eoe),Completed,4,1,1,Eosinophilic Esophagitis,drug or biologic,Early,47,All,Industry&Combos,1,0,0,2015,2015,647,1,Phase 2,3,NA,2,3.8501476017100584,"(3,4]"
686,717,"study of nivolumab, cabiralizumab, and stereotactic body radiotherapy (sbrt) for locally advanced unresectable pancreatic cancer",Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,7,All,AllOther,0,NA,0,2018,2018,685,0,Phase 2,1,NA,1,1.9459101490553132,"(1,2]"
2584,3475,keylargo: pembrolizumab + oxaliplatin + capecitabine in gastric cancer,"Active, not recruiting",1,0,0,Gastric Cancer|Esophagus Cancer,drug or biologic,Early,41,All,Industry&Combos,0,NA,0,2017,2018,1472,0,Phase 2,1,NA,1,3.713572066704308,"(3,4]"
4055,7719,study confirming a human challenge model and investigating the safety of vla1701,Completed,4,1,1,Enterotoxigenic Escherichia Coli Infection|Diarrhea,drug or biologic,Early,34,All,Industry&Combos,1,0,1,2018,2018,22,1,Phase 2,2,safety,2,3.5263605246161616,"(3,4]"
967,1018,tocotrienol against the progression of end stage liver disease,Recruiting,2,0,0,End Stage Liver Disease|NASH - Nonalcoholic Steatohepatitis|NAFLD - Nonalcoholic Fatty Liver Disease,drug or biologic,Early,70,All,AllOther,0,0,4,2015,2019,2222,0,Phase 2,1,NA,1,4.248495242049359,"(4,5]"
1899,2204,epacadostat and pembrolizumab before surgery in treating participants with stage ii-iii esophageal or gastroesophageal cancer,Withdrawn,7,0,0,Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8,drug or biologic,Early,NA,All,NIH&Combos,0,NA,0,2018,2018,640,0,Phase 2,1,NA,1,NA,NA
4152,9042,safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin in treatment-experienced subjects with chronic hcv infection,Completed,4,1,1,Hepatitis C,drug or biologic,Early,323,All,Industry&Combos,1,0,0,2013,2013,334,1,Phase 2,0,safety/efficacy,0,5.777652323222656,"(5,6]"
2179,2643,study of promethazine for treatment of diabetic gastroparesis,Terminated,5,1,1,Diabetic Gastroparesis,drug or biologic,Early,3,All,AllOther,1,0,0,2014,2014,317,1,Phase 2,4,NA,2,1.0986122886681098,"(1,2]"
2296,2876,"ease of use, tolerability, efficacy and safety of the vibrant capsule administered in the home environment",Withdrawn,7,0,0,Constipation,device,Others,NA,All,Industry&Combos,0,NA,0,2016,2016,182,0,Others,1,safety/efficacy,1,NA,NA
2608,3506,comparing the effectiveness of two dietary interventions for fecal incontinence,Completed,4,0,0,Fecal Incontinence,other,Others,40,All,AllOther,1,0,0,2016,2014,1703,1,Others,1,NA,1,3.6888794541139363,"(3,4]"
2671,3581,a study of bemarituzumab (fpa144) combined with modified folfox6 (mfolfox6) in gastric/gastroesophageal junction cancer (fight),"Active, not recruiting",1,0,0,Gastric Cancer,drug or biologic,Early,155,All,Industry&Combos,1,0,0,2018,2018,740,1,Phase 2,2,NA,2,5.043425116919247,"(5,6]"
3191,4416,capecitabine in metastatic breast and gi cancers,Recruiting,2,0,0,Breast Cancer|Gastrointestinal Cancer,drug or biologic,Early,200,All,AllOther,1,0,0,2015,2015,1888,1,Phase 2,0,NA,0,5.298317366548036,"(5,6]"
2680,3597,a study to test combination treatments in patients with advanced gastric cancer,Recruiting,2,0,0,Advanced Gastric Cancer,drug or biologic,Early,600,All,Industry&Combos,1,0,0,2016,2016,1821,1,Phase 2,0,NA,0,6.396929655216146,"(6,7]"
1640,1803,phase 2 study to evaluate safety and efficacy of rm-131 administered to patients with chronic constipation,Completed,4,0,0,Constipation,drug or biologic,Early,48,All,Industry&Combos,1,0,0,2013,2013,549,1,Phase 2,2,safety/efficacy,2,3.871201010907891,"(3,4]"
870,913,a study of perioperative mfolfox6 plus pembrolizumab in patients with potentially resectable adenocarcinoma of the gastroesophageal junction (gej) and stomach,Withdrawn,7,0,0,Adenocarcinoma|Stomach Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2016,2017,730,0,Phase 2,1,NA,1,NA,NA
489,507,aquamin Â® as an adjuvant intervention for ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Early,40,All,AllOther,1,0,4,2019,2019,1362,1,Phase 2,3,NA,2,3.6888794541139363,"(3,4]"
2697,3617,a phase 2 study of ramucirumab (ly3009806) in participants with gastric or gastroesophageal junction (gej) cancer,Completed,4,1,1,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,164,All,Industry&Combos,1,0,0,2015,2015,500,1,Phase 2,0,NA,0,5.099866427824199,"(5,6]"
2268,2821,efficacy and safety study of pbi-05204 in patients with stage iv metastatic pancreatic adenocarcinoma,Unknown status,8,0,0,Pancreatic Cancer,drug or biologic,Early,50,All,Industry&Combos,0,NA,0,2015,2015,610,0,Phase 2,1,safety/efficacy,1,3.912023005428146,"(3,4]"
1524,1656,"fish oil supplementation, nutrigenomics and colorectal cancer prevention",Completed,4,1,1,Colorectal Adenomatous Polyps,drug or biologic,Early,141,All,NIH&Combos,2,0,1,2012,2013,1421,1,Phase 2,4,NA,2,4.948759890378168,"(4,5]"
1875,2168,cabozantinib (xl-184) monotherapy for advanced cholangiocarcinoma,Completed,4,1,1,Bile Duct Cancer|Intrahepatic Cholangiocarcinoma|Cholangiocarcinoma of the Extrahepatic Bile Duct,drug or biologic,Early,19,All,Industry&Combos,0,NA,0,2013,2013,638,0,Phase 2,1,NA,1,2.9444389791664403,"(2,3]"
1448,1557,the effect of an antibiotic on the production of uremic toxins by the gut microbiome,Completed,4,1,1,End Stage Renal Disease,drug or biologic,Early,15,All,AllOther,3,0,0,2018,2017,264,3,Phase 2,2,NA,2,2.70805020110221,"(2,3]"
521,542,proton w/folfirinox-losartan for pancreatic cancer,"Active, not recruiting",1,1,1,Pancreatic Cancer,drug or biologic,Early,50,All,NIH&Combos,0,NA,0,2013,2013,1826,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
442,454,pentoxifylline therapy in biliary atresia,Recruiting,2,0,0,Biliary Atresia,drug or biologic,Early,60,All,AllOther,0,NA,0,2013,2013,3287,0,Phase 2,1,NA,1,4.0943445622221,"(4,5]"
1555,1694,metronomic chemotherapy in advanced gastric cancer,Unknown status,8,0,0,Metastatic Gastric Cancer|Locally Advanced Gastric Cancer,drug or biologic,Early,40,All,AllOther,0,NA,0,2016,2015,1157,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
2636,3540,"a safety and efficacy study of a range of linaclotide doses administered orally to children ages 7-17 years, with irritable bowel syndrome with constipation",Terminated,5,1,1,Irritable Bowel Syndrome With Constipation,drug or biologic,Early,101,All,Industry&Combos,1,0,0,2015,2015,1398,1,Phase 2,4,safety/efficacy,2,4.61512051684126,"(4,5]"
902,947,bruog 295: adjuvant folfox-a for resected pancreatic cancer: a phase ii brown university oncology research group trial,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,38,All,AllOther,0,NA,0,2013,2014,1998,0,Phase 2,1,NA,1,3.6375861597263857,"(3,4]"
2978,3993,phase 2b study of ngm282 extended treatment in patients with primary biliary cirrhosis,Completed,4,0,0,Primary Biliary Cirrhosis,drug or biologic,Early,36,All,Industry&Combos,1,0,0,2014,2014,641,1,Phase 2,4,NA,2,3.58351893845611,"(3,4]"
2829,3791,hyperbaric oxygen therapy for ulcerative colitis flares,Completed,4,0,0,"Colitis, Ulcerative",other,Others,39,All,AllOther,3,0,0,2018,2017,936,3,Others,0,NA,0,3.6635616461296463,"(3,4]"
1551,1690,phase ii trial of vandetanib in children and adults with wild-type gastrointestinal stromal tumors,Completed,4,1,1,GIST,drug or biologic,Early,9,All,NIH&Combos,1,1,0,2013,2013,872,1,Phase 2,0,NA,0,2.1972245773362196,"(2,3]"
390,400,ppis and fat absorption in cf and epi,Recruiting,2,0,0,Pancreatic Insufficiency|Cystic Fibrosis,drug or biologic,Early,24,All,Industry&Combos,3,0,0,2018,2018,998,3,Phase 2,4,NA,2,3.1780538303479458,"(3,4]"
1885,2183,study of orbec Â® as monotherapy in the treatment of patients with upper gi symptoms caused by chronic graft versus host disease (gvhd),Terminated,5,1,1,Chronic Gastrointestinal Graft vs Host Disease,drug or biologic,Early,2,All,Industry&Combos,1,0,0,2013,2013,516,1,Phase 2,4,NA,2,0.6931471805599453,"(0,1]"
1469,1583,safety and efficacy of solithromycin in the treatment of nonalcoholic steatohepatitis without cirrhosis,Completed,4,0,0,Nonalcoholic Steatohepatitis,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2015,2015,423,0,Phase 2,1,safety/efficacy,1,2.302585092994046,"(2,3]"
2289,2869,autologous fecal therapy,Completed,4,1,1,Infectious Disease of Digestive Tract,drug or biologic,Early,10,All,AllOther,1,0,1,2014,2014,1736,1,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
534,556,pembrolizumab and pelareorep in treating patients with advanced pancreatic cancer,"Active, not recruiting",1,1,1,Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8,drug or biologic,Early,17,All,NIH&Combos,0,NA,0,2018,2018,400,0,Phase 2,1,NA,1,2.833213344056216,"(2,3]"
730,764,combination therapy for patients with untreated metastatic pancreatic ductal adenocarcinoma,"Active, not recruiting",1,0,0,Untreated Metastatic Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2016,2016,2100,0,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
1468,1582,"bevacizumab, fluorouracil, leucovorin calcium, and oxaliplatin before surgery in treating patients with stage ii-iii rectal cancer","Active, not recruiting",1,0,0,Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer,drug or biologic,Early,17,All,NIH&Combos,0,NA,0,2013,2013,2940,0,Phase 2,1,NA,1,2.833213344056216,"(2,3]"
582,606,study to evaluate bi-weekly dosing of gemcitabine plus nab-paclitaxel to treat metastatic pancreatic cancer,Terminated,5,1,1,Pancreatic Carcinoma Non-resectable|Stage IV Pancreatic Cancer,drug or biologic,Early,15,All,AllOther,0,NA,0,2013,2013,699,0,Phase 2,1,NA,1,2.70805020110221,"(2,3]"
480,498,"maintenance rucaparib in brca1, brca2 or palb2 mutated pancreatic cancer that has not progressed on platinum-based therapy","Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,50,All,AllOther,0,NA,0,2017,2017,1461,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
965,1016,safety and effectiveness study of cpi-613 and/or gemcitabine to treat metastatic pancreatic cancer,Withdrawn,7,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,NA,All,Industry&Combos,1,1,0,2013,2014,1795,1,Phase 2,0,safety,0,NA,NA
512,533,palliative stereotactic radiation for pancreatic or periampullary adenocarcinoma,"Active, not recruiting",1,0,0,Pancreatic Cancer|Periampullary Adenocarcinoma,other,Others,120,All,AllOther,1,1,4,2013,2013,3317,1,Others,0,NA,0,4.787491742782046,"(4,5]"
26,26,a safety and efficacy trial of circumferential anal canal radiofrequency ablation for high-grade anal intraepithelial neoplasia using the barrxÃ¢âÂ¢ anorectal wand,Unknown status,8,0,0,"HSIL, High Grade Squamous Intraepithelial Lesions|Anal Cancer|HPV-Related Squamous Cell Carcinoma|Human Papilloma Virus|Human Papillomavirus Infection|Ain III",device,Others,70,All,AllOther,0,NA,0,2017,2017,730,0,Others,1,safety/efficacy,1,4.248495242049359,"(4,5]"
1317,1407,sequential melphalan for use with hepatic delivery system treatment followed by sorafenib in patients with unresectable hcc,Withdrawn,7,0,0,Hepatocellular Carcinoma (HCC),drug or biologic,Early,NA,All,Industry&Combos,0,NA,0,2015,2014,1157,0,Phase 2,1,NA,1,NA,NA
2370,3027,temozolomide (tmz) in advanced succinate dehydrogenase (sdh)-mutant/deficient gastrointestinal stromal tumor (gist),Recruiting,2,0,0,Gastrointestinal Stromal Tumors|Sdh|GIST|Cancer,drug or biologic,Early,23,All,AllOther,0,NA,0,2018,2018,1450,0,Phase 2,1,NA,1,3.1354942159291497,"(3,4]"
3146,4277,rollover study of cenicriviroc for the treatment of liver fibrosis in participants with nonalcoholic steatohepatitis,Terminated,5,0,0,Nonalcoholic Steatohepatitis|Liver Cirrhosis|Non-alcoholic Fatty Liver Disease,drug or biologic,Early,187,All,Industry&Combos,0,NA,0,2017,2017,1421,0,Phase 2,1,NA,1,5.231108616854587,"(5,6]"
951,1000,microbiota transfer therapy for adults with autism spectrum disorder (asd) who have gastrointestinal disorders,Recruiting,2,0,0,Autism Spectrum Disorder|Gastrointestinal Disorder,drug or biologic,Early,84,All,AllOther,1,0,0,2018,2018,1734,1,Phase 2,4,NA,2,4.430816798843313,"(4,5]"
2161,2605,probiotics in newly diagnosed t1d,"Active, not recruiting",1,0,0,Type 1 Diabetes|Type1diabetes|Type 1 Diabetes Mellitus,other,Others,60,All,AllOther,1,0,4,2019,2019,1035,1,Others,3,NA,2,4.0943445622221,"(4,5]"
2702,3623,folfiri or modified folfiri and veliparib as second line therapy in treating patients with metastatic pancreatic cancer,"Active, not recruiting",1,1,1,Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer AJCC v6 and v7,drug or biologic,Early,123,All,NIH&Combos,1,0,0,2016,2016,972,1,Phase 2,0,NA,0,4.812184355372417,"(4,5]"
3186,4394,liver test study of using jkb-122 in autoimmune hepatitis (aih) patients who are refractory or intolerant to current therapies,Completed,4,0,0,Autoimmune Hepatitis,drug or biologic,Early,20,All,Industry&Combos,NA,NA,0,2015,2016,996,NA,Phase 2,0,NA,0,2.995732273553991,"(2,3]"
3697,6128,lower or standard dose regorafenib in treating patients with refractory metastatic colorectal cancer,"Active, not recruiting",1,1,1,Colon Adenocarcinoma|Rectal Adenocarcinoma|Stage III Colorectal Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,123,All,NIH&Combos,1,0,0,2015,2015,889,1,Phase 2,0,NA,0,4.812184355372417,"(4,5]"
3990,7549,expanding the pool in orthotopic heart transplantation,Recruiting,2,0,0,Hepatitis C|Heart Transplant|Cardiac Transplant,drug or biologic,Early,20,All,AllOther,1,1,4,2017,2017,2160,1,Phase 2,0,NA,0,2.995732273553991,"(2,3]"
3644,5770,safety and efficacy study of jnj-64304500 in participants with moderately to severely active crohn's disease,"Active, not recruiting",1,0,0,Crohn Disease,drug or biologic,Early,388,All,Industry&Combos,1,0,0,2016,2016,1568,1,Phase 2,2,safety/efficacy,2,5.961005339623274,"(5,6]"
3240,4548,bi 207127 / faldaprevir combination therapy in hepatic impairment (child-pugh b) patients with genotype 1b chronic hepatitis c infection: hcverso3,Completed,4,1,1,"Hepatitis C, Chronic",drug or biologic,Early,35,All,Industry&Combos,1,1,0,2013,2013,548,1,Phase 2,0,NA,0,3.5553480614894135,"(3,4]"
617,643,a phase 2 trial of regorafenib as a single agent in advanced and metastatic biliary tract carcinoma/cholangiocarcinoma patients who have failed first-line chemotherapy,Completed,4,1,1,Metastatic Biliary Tract Carcinoma,drug or biologic,Early,43,All,Industry&Combos,0,NA,0,2014,2014,1467,0,Phase 2,1,NA,1,3.7612001156935624,"(3,4]"
2943,3945,olorinab in ibs-c and ibs-d,Terminated,5,0,0,Irritable Bowel Syndrome,drug or biologic,Early,273,All,Industry&Combos,1,0,0,2019,2019,645,1,Phase 2,4,NA,2,5.60947179518496,"(5,6]"
2723,3648,safety and efficacy of the elad system (elad) to treat acute liver failure (alf),Terminated,5,1,1,Acute Liver Failure|Fulminant Hepatic Failure|Primary Graft Non-Function|Surgically-Induced Liver Failure,drug or biologic,Early,8,All,Industry&Combos,0,NA,0,2013,2014,335,0,Phase 2,1,safety/efficacy,1,2.0794415416798357,"(2,3]"
2304,2895,omega 3 fatty acids in colorectal cancer (crc) prevention in patients with lynch syndrome (colyne),Recruiting,2,0,0,Colorectal Cancer|Lynch Syndrome,drug or biologic,Early,34,All,AllOther,0,NA,0,2019,2019,1456,0,Phase 2,1,NA,1,3.5263605246161616,"(3,4]"
2491,3294,a study of abc294640 (yeliva  Â®) alone and in combination with hydroxychloroquine sulfate in treatment of patients with advanced cholangiocarcinoma,Recruiting,2,0,0,"Cholangiocarcinoma|Cholangiocarcinoma Non-resectable|Cholangiocarcinoma, Perihilar|Cholangiocarcinoma, Extrahepatic|Cholangiocarcinoma, Intrahepatic",drug or biologic,Early,105,All,Industry&Combos,0,NA,0,2017,2018,1730,0,Phase 2,1,NA,1,4.653960350157523,"(4,5]"
3059,4114,volixibat (shp626) in the treatment of adults with nonalcoholic steatohepatitis (nash),Terminated,5,1,1,Non-Alcoholic Steatohepatitis,drug or biologic,Early,197,All,Industry&Combos,1,0,0,2016,2016,641,1,Phase 2,2,NA,2,5.2832037287379885,"(5,6]"
3888,7169,pembrolizumab (keytruda) in advanced hepatocellular carcinoma,Completed,4,1,1,Hepatocellular Carcinoma,drug or biologic,Early,29,All,Industry&Combos,0,NA,0,2016,2016,1283,0,Phase 2,1,NA,1,3.367295829986474,"(3,4]"
1154,1227,everolimus post orthotopic liver transplant,Unknown status,8,0,0,Orthotopic Liver Transplant,drug or biologic,Early,50,All,AllOther,1,0,0,2013,2013,1704,1,Phase 2,0,NA,0,3.912023005428146,"(3,4]"
1617,1772,"pembrolizumab, bevacizumab, and cyclophosphamide in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer","Active, not recruiting",1,1,1,Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma,drug or biologic,Early,40,Female,NIH&Combos,0,NA,0,2016,2016,1029,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
2973,3987,a study to evaluate the efficacy and safety of the investigational drug pf-03446962 (a monoclonal antibody with antiangiogenic features) in combination with best supportive care versus placebo plus best supportive care in patients affected by recurrent liver cancer,Terminated,5,1,1,"Carcinoma, Hepatocellular",drug or biologic,Early,3,All,Industry&Combos,1,0,0,2013,2013,273,1,Phase 2,4,safety/efficacy,2,1.0986122886681098,"(1,2]"
562,585,nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery in treating patients with pancreatic cancer that can be removed by surgery,"Active, not recruiting",1,1,1,Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2015,2016,1391,0,Phase 2,1,NA,1,2.995732273553991,"(2,3]"
3022,4059,long-term safety with vedolizumab intravenous (iv) in pediatric participants with ulcerative colitis (uc) or crohn's disease (cd),"Active, not recruiting",1,0,0,Ulcerative Colitis|Crohn's Disease,drug or biologic,Early,80,All,Industry&Combos,1,0,0,2017,2018,2491,1,Phase 2,2,safety,2,4.382026634673881,"(4,5]"
3512,5341,study of dovitinib and biomarkers in advanced non-small cell lung cancer or advanced colorectal cancer,Completed,4,1,1,Non-Small Cell Lung Cancer|Colorectal Cancer,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2012,2013,1064,0,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
1531,1663,"impact of fructose on metabolism, energy homeostasis and mr biomarkers in nafld",Recruiting,2,0,0,Nonalcoholic Fatty Liver Disease (NAFLD),drug or biologic,Early,100,All,AllOther,1,1,4,2013,2013,2861,1,Phase 2,0,NA,0,4.605170185988092,"(4,5]"
3398,5110,a safety and efficacy study of mycophenolate mofetil and rilonacept in patients with alcoholic hepatitis,Completed,4,1,1,Alcoholic Hepatitis,drug or biologic,Early,4,All,NA,1,0,0,2013,2014,487,1,Phase 2,0,safety/efficacy,0,1.3862943611198906,"(1,2]"
3879,7151,abemaciclib and nivolumab for subjects with hepatocellular carcinoma,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma,drug or biologic,Early,15,All,AllOther,0,NA,0,2018,2019,671,0,Phase 2,1,NA,1,2.70805020110221,"(2,3]"
2719,3644,an open-label study to evaluate the long-term safety and tolerability of lum001 in patients with primary biliary cirrhosis,Withdrawn,7,0,0,Primary Biliary Cirrhosis,drug or biologic,Early,NA,All,Industry&Combos,0,NA,0,2014,2015,945,0,Phase 2,1,safety,1,NA,NA
3600,5671,a study of ridinilazole (smt19969) compared with fidaxomicin for the treatment of clostridium difficile infection (cdi),Completed,4,0,0,Clostridium Difficile Infection,drug or biologic,Early,27,All,Industry&Combos,1,0,0,2016,2014,609,1,Phase 2,0,NA,0,3.295836866004329,"(3,4]"
3171,4342,open label study to evaluate safety and efficacy of lum001 in patients with primary sclerosing cholangitis,Completed,4,1,1,Primary Sclerosing Cholangitis (PSC),drug or biologic,Early,27,All,Industry&Combos,0,NA,0,2014,2014,702,0,Phase 2,1,safety/efficacy,1,3.295836866004329,"(3,4]"
662,689,a phase ii study of pioglitazone for patients with cancer of the pancreas,Completed,4,1,1,Cancer of the Pancreas,drug or biologic,Early,14,All,AllOther,0,1,0,2013,2013,1603,0,Phase 2,1,NA,1,2.6390573296152584,"(2,3]"
1365,1460,efficacy of ferric carboxymaltose in gastrointestinal stromal tumor (gist) patients with iron deficiency anemia (ida) receiving systemic therapy,Terminated,5,1,1,Malignant Neoplasms of Mesothelial and Soft Tissue|Gastrointestinal Stromal Tumor With Neurogenic Differentiation,drug or biologic,Early,3,All,Industry&Combos,1,0,4,2016,2017,443,1,Phase 2,0,efficacy,0,1.0986122886681098,"(1,2]"
2131,2557,sorafenib tosylate and yttrium y 90 glass microspheres in treating patients with liver cancer that cannot be removed by surgery,Completed,4,0,0,Advanced Adult Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Recurrent Adult Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Hepatocellular Carcinoma,drug or biologic,Early,40,All,NIH&Combos,0,NA,0,2013,2013,2645,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
2897,3885,trial of linaclotide in patients with irritable bowel syndrome with constipation (ibs-c),Completed,4,1,1,Irritable Bowel Syndrome With Constipation,drug or biologic,Early,759,All,Industry&Combos,1,0,0,2015,2015,344,1,Phase 2,4,NA,2,6.63200177739563,"(6,7]"
3822,6809,ketamine for endoscopic sedation in outpatient adult endoscopy.,Completed,4,0,0,Administration and Dosage of Ketamine|Endoscopic Sedation,drug or biologic,Early,66,All,AllOther,1,0,0,2018,2018,575,1,Phase 2,1,NA,1,4.189654742026425,"(4,5]"
3011,4042,a study of incmga00012 in squamous carcinoma of the anal canal following platinum-based chemotherapy (pod1um-202),"Active, not recruiting",1,0,0,Squamous Cell Carcinoma of Anal Canal,drug or biologic,Early,94,All,Industry&Combos,0,NA,0,2018,2018,607,0,Phase 2,1,NA,1,4.543294782270004,"(4,5]"
2628,3529,"a study of mm-111 and paclitaxel with trastuzumab in patients her2 positive carcinomas of the distal esophagus, gastroesophageal (ge) junction and stomach",Terminated,5,1,1,HER-2 Gene Amplification|Esophagus Cancer|Gastroesophageal Junction Cancer|Stomach Cancer,drug or biologic,Early,84,All,Industry&Combos,1,0,0,2013,2013,911,1,Phase 2,0,NA,0,4.430816798843313,"(4,5]"
3895,7189,"efficacy, safety, and tolerability study of oral full-spectrum microbiotatm (cp101) in subjects with recurrent c. diff",Completed,4,0,0,Clostridium Difficile Infection Recurrence,drug or biologic,Early,206,All,Industry&Combos,1,0,1,2017,2017,1026,1,Phase 2,4,safety/efficacy,2,5.327876168789581,"(5,6]"
3652,5801,"evaluation of efficacy and safety of medi2070 in patients with active, moderate-to-severe crohn's disease.",Completed,4,1,1,Crohn's Disease,drug or biologic,Early,121,All,Industry&Combos,1,0,0,2012,2013,473,1,Phase 2,4,safety/efficacy,2,4.795790545596741,"(4,5]"
3367,4933,study of ngm282 in patients with nonalcoholic steatohepatitis (nash),Completed,4,0,0,Nonalcoholic Steatohepatitis (NASH),drug or biologic,Early,254,All,Industry&Combos,1,0,0,2015,2015,1589,1,Phase 2,3,NA,2,5.537334267018537,"(5,6]"
1822,2073,evaluating an amino acid based medical food w/ diarrhea in carcinoid syndrome & other nets,Recruiting,2,0,0,Neuroendocrine Tumors|Carcinoid Tumor of GI System|Diarrhea|Carcinoid Syndrome,other,Others,30,All,Industry&Combos,1,1,4,2018,2018,1334,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
2658,3565,a study of rucaparib in patients with pancreatic cancer and a known deleterious brca mutation,Completed,4,0,0,Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,19,All,Industry&Combos,0,NA,0,2014,2014,731,0,Phase 2,1,NA,1,2.9444389791664403,"(2,3]"
586,612,metabolomic and bh3 profiling of esophageal cancers: identification of novel assessment methods of treatment response for precision therapy,Terminated,5,1,1,Esophageal Cancer|Esophageal Adenocarcinoma|Esophageal Squamous Cell Cancer|Esophageal Neoplasms|Squamous Cell Carcinoma,procedure,Others,2,All,NIH&Combos,0,NA,0,2017,2017,269,0,Others,1,NA,1,0.6931471805599453,"(0,1]"
2333,2953,a ph 2 study of fosbretabulin in subjects w pancreatic or gastrointestinal neuroendocrine tumors w elevated biomarkers,Completed,4,1,1,Neuroendocrine Tumors,drug or biologic,Early,18,All,Industry&Combos,0,NA,0,2014,2014,639,0,Phase 2,1,NA,1,2.8903717578961645,"(2,3]"
4115,8655,phase ii trial of nab-paclitaxel and gemcitabine for first-line treatment of patients with cholangiocarcinoma,Completed,4,1,1,Cholangiocarcinoma,drug or biologic,Early,74,All,Industry&Combos,0,NA,0,2014,2014,655,0,Phase 2,1,NA,1,4.30406509320417,"(4,5]"
3274,4613,a phase ii study of abc294640 as monotherapy in patients with advanced hepatocellular carcinoma,Withdrawn,7,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,NA,All,IndustryNIHPartnership,0,NA,0,2016,2019,1461,0,Phase 2,1,NA,1,NA,NA
3532,5387,study of pembrolizumab (mk-3475) in participants with advanced solid tumors (mk-3475-158/keynote-158),Recruiting,2,0,0,Advanced Cancer|Anal Carcinoma|Anal Cancer|Biliary Cancer|Cholangiocarcinoma|Bile Duct Cancer|Neuroendocrine Tumor|Carcinoid Tumor|Endometrial Carcinoma|Endometrial Cancer|Cervical Carcinoma|Cervical Cancer|Vulvar Carcinoma|Vulvar Cancer|Small Cell Lung Carcinoma|Small Cell Lung Cancer (SCLC)|Mesothelioma|Thyroid Carcinoma|Thyroid Cancer|Salivary Gland Carcinoma|Salivary Gland Cancer|Salivary Cancer|Parotid Gland Cancer|Advanced Solid Tumors|Colorectal Carcinoma,drug or biologic,Early,1595,All,Industry&Combos,1,1,0,2015,2015,3835,1,Phase 2,0,NA,0,7.374629015218945,"(7,13]"
3910,7279,study of cdi-31244 in combination with sofosbuvir (sof) and velpatasvir (vel),Completed,4,1,1,Chronic Hepatitis C,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2018,2018,196,0,Phase 2,1,NA,1,2.4849066497880004,"(2,3]"
791,828,effects of folfirinox and stereotactic body radiation therapy for advanced pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer Non-resectable,drug or biologic,Early,28,All,AllOther,0,NA,0,2014,2014,4018,0,Phase 2,1,NA,1,3.332204510175204,"(3,4]"
2665,3574,m7824 monotherapy in locally advanced or metastatic second line (2l) biliary tract cancer (cholangiocarcinoma and gallbladder cancer),"Active, not recruiting",1,0,0,Biliary Tract Cancer|Cholangiocarcinoma|Gallbladder Cancer,drug or biologic,Early,159,All,Industry&Combos,0,NA,0,2019,2019,594,0,Phase 2,1,NA,1,5.0689042022202315,"(5,6]"
3595,5649,"safety, tolerability, and efficacy of monotherapy and combination regimens in adults with nonalcoholic steatohepatitis (nash)",Completed,4,0,0,Nonalcoholic Steatohepatitis,drug or biologic,Early,109,All,Industry&Combos,1,0,0,2019,2019,350,1,Phase 2,0,safety/efficacy,0,4.6913478822291435,"(4,5]"
1942,2272,immunotherapy and sbrt study in borderline resectable pancreatic cancer,Terminated,5,0,0,Pancreatic Cancer|Pancreatic Carcinoma Non-resectable,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2015,2015,456,0,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
1935,2260,ramucirumab plus irinotecan for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma,Recruiting,2,0,0,Gastric Adenocarcinoma|Gastro-esophageal Junction Adenocarcinoma,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2017,2017,2067,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
2174,2631,nitrite infusion in islet cell transplantation,Terminated,5,1,1,Diabetes,drug or biologic,Early,4,All,AllOther,1,0,0,2018,2017,781,1,Phase 2,2,NA,2,1.3862943611198906,"(1,2]"
2959,3968,dose-ranging phase 2b study of abx464 in moderate to severe ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Early,254,All,Industry&Combos,1,0,0,2018,2019,704,1,Phase 2,4,NA,2,5.537334267018537,"(5,6]"
757,793,"pembrolizumab and palliative radiation therapy in treating patients with metastatic esophagus, stomach, or gastroesophageal junction cancer","Active, not recruiting",1,0,0,Gastric Adenocarcinoma|Gastric Squamous Cell Carcinoma|Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Neoplasm in the Stomach|Stage IV Esophageal Adenocarcinoma AJCC v7|Stage IV Esophageal Squamous Cell Carcinoma AJCC v7,drug or biologic,Early,14,All,NIH&Combos,0,NA,0,2016,2016,1933,0,Phase 2,1,NA,1,2.6390573296152584,"(2,3]"
3107,4216,regorafenib in treating patients with locally advanced cancer of the esophagus or gastroesophageal junction who have completed chemoradiation therapy and surgery,Terminated,5,1,1,Adenocarcinoma of the Gastroesophageal Junction|Stage IIB Esophageal Adenocarcinoma|Stage IIIA Esophageal Adenocarcinoma|Stage IIIB Esophageal Adenocarcinoma|Stage IIIC Esophageal Adenocarcinoma,drug or biologic,Early,3,All,NIH&Combos,1,0,0,2014,2014,646,1,Phase 2,2,NA,2,1.0986122886681098,"(1,2]"
1571,1714,"a phase ii, international open label trial of minnelideÃ¢âÂ¢ in patients with refractory pancreatic cancer",Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,19,All,Industry&Combos,0,NA,0,2017,2017,812,0,Phase 2,1,NA,1,2.9444389791664403,"(2,3]"
1697,1878,"viral kinetics, interferon stimulated genes (isgs) and mirrna among subjects infected with different hepatitis c virus genotypes during therapy with sofosbuvir and gs-5816",Completed,4,1,1,Chronic Hepatitis C,drug or biologic,Early,72,All,NIH&Combos,0,NA,0,2015,2015,1193,0,Phase 2,1,NA,1,4.276666119016055,"(4,5]"
3785,6581,trial to evaluate safety and efficacy of treatment of physician choice (tpc) following first-line treatment of lenvatinib in subjects with unresectable hepatocellular carcinoma (uhcc),Terminated,5,1,1,"Carcinoma, Hepatocellular",drug or biologic,Early,8,All,Industry&Combos,0,NA,0,2018,2018,256,0,Phase 2,1,safety/efficacy,1,2.0794415416798357,"(2,3]"
3426,5207,"emricasan, a caspase inhibitor, for treatment of subjects with decompensated nash cirrhosis",Unknown status,8,0,0,Decompensated Cirrhosis,drug or biologic,Early,210,All,Industry&Combos,1,0,0,2017,2017,764,1,Phase 2,3,NA,2,5.3471075307174685,"(5,6]"
1988,2339,evaluation of a new eus guided biopsy needle (sharkcore) comparing to standard eus needle (procore),Withdrawn,7,0,0,Mesenchymal Tumor|Autoimmune Pancreatitis|Lymphoma|Solid Tumors,device,Others,NA,All,AllOther,1,0,2,2016,2016,306,1,Others,1,NA,1,NA,NA
1476,1592,"computed tomography perfusion imaging in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer receiving bevacizumab","Active, not recruiting",1,0,0,Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma,other,Others,186,Female,NIH&Combos,0,NA,2,2018,2018,776,0,Others,1,NA,1,5.225746673713202,"(5,6]"
101,101,"nivolumab (anti-pd1), tadalafil and oral vancomycin in people with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers",Recruiting,2,0,0,Heptocellular Carcinoma|Heptocellular Cancer|Metastatic Pancreatic Cancer|Metastatic Colorectal Cancer|Liver Metastasis,drug or biologic,Early,27,All,NIH&Combos,0,NA,0,2018,2019,1305,0,Phase 2,1,NA,1,3.295836866004329,"(3,4]"
700,733,mtt for children with both pitt hopkins syndrome and gastrointestinal disorders,Recruiting,2,0,0,Pitt Hopkins Syndrome,other,Others,10,All,AllOther,1,0,0,2019,2019,864,1,Others,4,NA,2,2.302585092994046,"(2,3]"
488,506,study of mutation-targeted therapy with sunitinib or everolimus in people with advanced low- or intermediate-grade neuroendocrine tumors of the gastrointestinal tract and pancreas with or without cytoreductive surgery,Terminated,5,1,1,"Neuroendocrine Tumors|Neuroendocrine Carcinoma|Neuroendocrine Neoplasms|Carcinoma, Neuroendocrine|Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas",drug or biologic,Early,16,All,NIH&Combos,3,1,0,2014,2015,1505,3,Phase 2,0,NA,0,2.772588722239781,"(2,3]"
2966,3979,trial evaluating 3-year disease free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy and total mesorectal excision or non-operative management,"Active, not recruiting",1,0,0,Rectal Cancer,drug or biologic,Early,358,All,Industry&Combos,1,0,0,2013,2013,2922,1,Phase 2,0,NA,0,5.8805329864007,"(5,6]"
3275,4615,an investigational study of experimental medication bms-986165 in participants with moderate to severe crohn's disease,Recruiting,2,0,0,Granulomatous Colitis|Crohn's Disease|Crohn's Enteritis|Granulomatous Enteritis,drug or biologic,Early,240,All,Industry&Combos,1,0,0,2018,2018,1393,1,Phase 2,4,NA,2,5.480638923341991,"(5,6]"
2784,3739,seladelpar (mbx-8025) in subjects with primary biliary cholangitis (pbc),Completed,4,0,0,Primary Biliary Cirrhosis,drug or biologic,Early,119,All,Industry&Combos,1,0,0,2016,2016,648,1,Phase 2,0,NA,0,4.77912349311153,"(4,5]"
3306,4700,rifaximin in patients with diabetic gastroparesis,Recruiting,2,0,0,Crohn Disease|Diabetic Gastroparesis,drug or biologic,Early,40,All,AllOther,1,0,0,2020,2019,823,1,Phase 2,2,NA,2,3.6888794541139363,"(3,4]"
833,872,a phase 2 trial of high-dose ascorbate for pancreatic cancer (pacman 2.1),Recruiting,2,0,0,"Pancreatic Neoplasms|Cancer of Pancreas|Cancer of the Pancreas|Neoplasms, Pancreatic|Pancreas Cancer|Pancreas Neoplasms|Adenocarcinoma",drug or biologic,Early,65,All,IndustryNIHPartnership,1,0,0,2016,2018,2590,1,Phase 2,1,NA,1,4.174387269895637,"(4,5]"
2940,3942,bi 655130 long-term treatment in patients with moderate-to severe ulcerative colitis,"Active, not recruiting",1,0,0,"Colitis, Ulcerative",drug or biologic,Early,79,All,Industry&Combos,0,NA,0,2018,2018,3123,0,Phase 2,1,NA,1,4.3694478524670215,"(4,5]"
756,792,movantik for opioid-related esophageal disorders,Terminated,5,0,0,Opioid-Induced Disorders|Esophagus Disorder,drug or biologic,Early,2,All,Industry&Combos,1,0,0,2016,2017,638,1,Phase 2,4,NA,2,0.6931471805599453,"(0,1]"
4162,9140,elbasvir (ebr)/grazoprevir (gzr) in pediatric participants with chronic hepatitis c infection (mk-5172-079),Completed,4,1,1,HCV Infection,drug or biologic,Early,57,All,Industry&Combos,0,NA,0,2017,2018,641,0,Phase 2,1,NA,1,4.04305126783455,"(4,5]"
3494,5298,a phase ii study of ziv-aflibercept in combination with capecitabine/oxaliplatin (xelox) chemotherapy in the front-line treatment of patients with metastatic colorectal cancer,Withdrawn,7,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,NA,All,Industry&Combos,1,1,0,2014,2014,1461,1,Phase 2,0,NA,0,NA,NA
4155,9064,ser-109 versus placebo to prevent recurrent clostridium difficile infection (rcdi),Completed,4,1,1,Clostridium Difficile,drug or biologic,Early,89,All,Industry&Combos,1,0,1,2015,2015,427,1,Phase 2,4,NA,2,4.48863636973214,"(4,5]"
3545,5427,"evaluation of efficacy and safety of brazikumab (medi2070) in participants with active, moderate to severe crohn's disease",Terminated,5,1,1,Crohn's Disease,drug or biologic,Early,29,All,Industry&Combos,1,0,0,2015,2016,570,1,Phase 2,4,safety/efficacy,2,3.367295829986474,"(3,4]"
1871,2161,study of colorectal cancer patients (stage iiic) with either regorafenib or standard of care (no treatment) after adjuvant folfox,Terminated,5,0,0,Colorectal Neoplasms|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum,drug or biologic,Early,24,All,Industry&Combos,1,0,0,2015,2015,910,1,Phase 2,0,NA,0,3.1780538303479458,"(3,4]"
1984,2335,pembrolizumab in metastatic anal cancer,Recruiting,2,0,0,Anal Cancer,drug or biologic,Early,32,All,Industry&Combos,0,NA,0,2016,2016,1967,0,Phase 2,1,NA,1,3.4657359027997265,"(3,4]"
1212,1290,a study of durvalumab in patients with br pda following neoadjuvant therapy and successful surgical resection,Withdrawn,7,0,0,Pancreatic Cancer,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2017,2017,658,1,Phase 2,0,NA,0,NA,NA
1231,1309,secretin for acute pancreatitis,Unknown status,8,0,0,"Pancreatitis, Acute",drug or biologic,Early,40,All,Industry&Combos,1,1,0,2018,2018,365,1,Phase 2,0,NA,0,3.6888794541139363,"(3,4]"
3931,7323,study of durvalumab and tremelimumab after radiation for microsatellite stable metastatic colorectal cancer progressing on chemotherapy,Completed,4,0,0,Colorectal Cancer Metastatic,drug or biologic,Early,33,All,AllOther,0,NA,0,2017,2017,626,0,Phase 2,1,NA,1,3.4965075614664802,"(3,4]"
1532,1664,"tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer","Active, not recruiting",1,1,1,Recurrent Epithelial Ovarian Cancer|Recurrent Fallopian Tube Cancer|Recurrent Primary Peritoneal Cancer,drug or biologic,Early,31,Female,AllOther,0,NA,0,2013,2013,1944,0,Phase 2,1,NA,1,3.4339872044851463,"(3,4]"
3536,5400,saroglitazar magnesium in the treatment of non-alcoholic steatohepatitis,Completed,4,0,0,Non Alcoholic Steatohepatitis,drug or biologic,Early,16,All,Industry&Combos,1,0,0,2019,2019,386,1,Phase 2,3,NA,2,2.772588722239781,"(2,3]"
3759,6480,safety and efficacy of voxilaprevir plus sofosbuvir/velpatasvir fixed dose combination in adults with chronic genotype 1 hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,205,All,Industry&Combos,NA,1,0,2015,2015,349,NA,Phase 2,0,safety/efficacy,0,5.3230099791384085,"(5,6]"
3231,4533,effect of lik066 on reduction of fatty content in livers of obese patients,Completed,4,1,1,Obese Patients With Non-alcoholic Steatohepatitis (NASH),drug or biologic,Early,107,All,Industry&Combos,1,0,0,2017,2017,768,1,Phase 2,3,NA,2,4.672828834461906,"(4,5]"
1372,1470,budesonide for liver transplant immune suppression,Completed,4,0,0,Acute Cellular Graft Rejection|New Onset Diabetes After Transplant,drug or biologic,Early,40,All,AllOther,0,NA,0,2017,2017,917,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
2776,3727,trametinib or combination chemotherapy in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery,Completed,4,1,1,Adult Cholangiocarcinoma|Advanced Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma|BCLC Stage D Adult Hepatocellular Carcinoma|Hilar Cholangiocarcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma|Recurrent Childhood Liver Cancer|Recurrent Extrahepatic Bile Duct Carcinoma|Recurrent Gallbladder Carcinoma|Stage II Gallbladder Cancer|Stage III Childhood Hepatocellular Carcinoma|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IV Childhood Hepatocellular Carcinoma|Stage IV Distal Bile Duct Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Carcinoma,drug or biologic,Early,53,All,NIH&Combos,1,0,0,2014,2014,1065,1,Phase 2,0,NA,0,3.970291913552122,"(3,4]"
3363,4919,efficacy and safety of td-1473 in crohn's disease,Recruiting,2,0,0,Crohn's Disease,drug or biologic,Early,160,All,Industry&Combos,1,0,0,2018,2018,986,1,Phase 2,4,safety/efficacy,2,5.075173815233827,"(5,6]"
3758,6479,safety and efficacy of voxilaprevir plus sofosbuvir/velpatasvir fixed dose combination in adults with chronic non-genotype 1 hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,128,All,Industry&Combos,NA,1,0,2015,2015,217,NA,Phase 2,0,safety/efficacy,0,4.852030263919617,"(4,5]"
3015,4049,treatment of ipf with laparoscopic anti-reflux surgery,Unknown status,8,0,0,Idiopathic Pulmonary Fibrosis|Gastroesophageal Reflux,procedure,Others,58,All,NIH&Combos,1,0,0,2013,2013,1431,1,Others,0,NA,0,4.060443010546419,"(4,5]"
1898,2203,use of trifluridine/tipiracil and oxaliplatin as induction chemotherapy for the treatment of resectable esophageal or gastroesophageal junction (gej) adenocarcinoma,Recruiting,2,0,0,Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8,drug or biologic,Early,45,All,AllOther,0,NA,0,2019,2019,1096,0,Phase 2,1,NA,1,3.8066624897703196,"(3,4]"
3422,5195,jkb-121 for the treatment of nonalcoholic steatohepatitis,Completed,4,1,1,Nonalcoholic Steatohepatitis,drug or biologic,Early,65,All,AllOther,1,0,0,2015,2015,785,1,Phase 2,4,NA,2,4.174387269895637,"(4,5]"
612,638,cetuximab-irdye 800cw and intraoperative imaging in finding pancreatic cancer in patients undergoing surgery,Terminated,5,1,1,Pancreatic Adenocarcinoma,drug or biologic,Early,8,All,NIH&Combos,1,1,2,2016,2016,297,1,Phase 2,0,NA,0,2.0794415416798357,"(2,3]"
2711,3635,pegph20 plus nab-paclitaxel plus gemcitabine compared with nab-paclitaxel plus gemcitabine in participants with stage iv untreated pancreatic cancer,Completed,4,1,1,Metastatic Pancreatic Cancer,drug or biologic,Early,279,All,Industry&Combos,1,0,0,2013,2013,1813,1,Phase 2,0,NA,0,5.631211781821365,"(5,6]"
4132,8970,"a study of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma","Active, not recruiting",1,0,0,Hepatocellular Carcinoma,drug or biologic,Early,433,All,Industry&Combos,1,0,0,2015,2015,1845,1,Phase 2,0,NA,0,6.07073772800249,"(6,7]"
1844,2108,a study of durvalumab (medi4736) in esophageal cancer,"Active, not recruiting",1,0,0,Esophageal Cancer,drug or biologic,Early,39,All,Industry&Combos,0,NA,0,2015,2016,1710,0,Phase 2,1,NA,1,3.6635616461296463,"(3,4]"
4142,9020,microbiota restoration therapy for recurrent clostridium difficile-associated diarrhea,Completed,4,1,1,Recurrent Clostridium Difficile Infection,drug or biologic,Early,34,All,Industry&Combos,0,NA,0,2013,2013,212,0,Phase 2,1,NA,1,3.5263605246161616,"(3,4]"
2544,3418,"folfox-a in the treatment of metastatic or advanced unresectable gastric, gastro-esophageal junction adenocarcinoma",Recruiting,2,0,0,Gastro-Esophageal Junction Adenocarcinoma|Gastric Cancer,drug or biologic,Early,39,All,Industry&Combos,0,NA,0,2017,2017,1410,0,Phase 2,1,NA,1,3.6635616461296463,"(3,4]"
770,807,epacadostat and pembrolizumab in treating patients with metastatic or unresectable gastroesophageal junction or gastric cancer,Completed,4,1,1,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Unresectable Esophageal Carcinoma,drug or biologic,Early,3,All,Industry&Combos,0,NA,0,2017,2017,258,0,Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
1475,1591,liver surgery and chemotherapy in treating patients with colorectal cancer with liver metastases that can be removed by surgery and lung metastases that cannot be removed by surgery,Recruiting,2,0,0,Metastatic Colorectal Carcinoma|Metastatic Malignant Neoplasm in the Liver|Metastatic Malignant Neoplasm in the Lung|Recurrent Colorectal Carcinoma|Resectable Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,80,All,NIH&Combos,1,0,0,2016,2016,2167,1,Phase 2,0,NA,0,4.382026634673881,"(4,5]"
2122,2541,a phase ii study of nivolumab/ bevacizumab/rucaparib,Recruiting,2,0,0,Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer,drug or biologic,Early,76,Female,Industry&Combos,NA,1,0,2016,2016,1847,NA,Phase 2,0,NA,0,4.330733340286331,"(4,5]"
963,1014,combination chemotherapy with or without oregovomab followed by stereotactic body radiation therapy and nelfinavir mesylate in treating patients with locally advanced pancreatic cancer,Completed,4,1,1,Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma|Stage I Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer,drug or biologic,Early,11,All,NIH&Combos,0,NA,0,2013,2013,1673,0,Phase 2,1,NA,1,2.3978952727983707,"(2,3]"
2876,3855,"safety, efficacy, and tolerability study of pf-06480605 in subjects with moderate to severe ulcerative colitis.",Completed,4,1,1,"Colitis, Ulcerative",drug or biologic,Early,50,All,Industry&Combos,NA,NA,0,2016,2016,582,NA,Phase 2,0,safety/efficacy,0,3.912023005428146,"(3,4]"
3775,6534,naloxegol in cancer opioid-induced constipation,Terminated,5,1,1,Constipation,drug or biologic,Early,7,All,Industry&Combos,3,0,0,2016,2016,417,3,Phase 2,0,NA,0,1.9459101490553132,"(1,2]"
2385,3062,trial of obeticholic acid in patients with moderately severe alcoholic hepatitis (ah),Terminated,5,1,1,Alcoholic Hepatitis,drug or biologic,Early,19,All,IndustryNIHPartnership,1,0,0,2014,2014,1000,1,Phase 2,4,NA,2,2.9444389791664403,"(2,3]"
729,763,a randomized phase ii/genomic trial of two chemotherapy regimens in patients with resected pancreatic adenocarcinoma,Completed,4,1,1,Pancreatic Adenocarcinoma,drug or biologic,Early,32,All,AllOther,1,0,0,2013,2013,1461,1,Phase 2,0,NA,0,3.4657359027997265,"(3,4]"
3877,7145,"a phase ii, randomized, controlled trial of nivolumab in combination with bms-986253 or cabiralizumab in advanced hepatocellular carcinoma (hcc) patients",Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Early,74,All,AllOther,1,0,0,2019,2019,1058,1,Phase 2,0,NA,0,4.30406509320417,"(4,5]"
1580,1726,pembrolizumab in refractory advanced esophageal cancer,"Active, not recruiting",1,0,0,Esophageal Cancer|Squamous Cell Esophagus Cancer|Adenocarcinoma Esophagus,drug or biologic,Early,50,All,Industry&Combos,0,NA,0,2016,2017,916,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
2527,3384,combination chemoembolization and stereotactic body radiation therapy in unresectable hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Early,40,All,AllOther,1,1,0,2015,2014,2983,1,Phase 2,0,NA,0,3.6888794541139363,"(3,4]"
2590,3483,a study to evaluate lb1148 for return of gastrointestinal function and adhesions in subjects undergoing bowel resection,Recruiting,2,0,0,Ileus|Post-Operative Adhesions,drug or biologic,Early,120,All,Industry&Combos,1,0,0,2016,2019,792,1,Phase 2,4,NA,2,4.787491742782046,"(4,5]"
1866,2146,the probiotic study: using bacteria to calm your mind,Completed,4,1,1,Anxiety|Abdominal Pain,drug or biologic,Early,9,All,AllOther,0,NA,0,2016,2016,314,0,Phase 2,1,NA,1,2.1972245773362196,"(2,3]"
1605,1757,study of nivolumab in patients with advanced refractory biliary tract cancers,"Active, not recruiting",1,1,1,Biliary Tract Cancer|Biliary Tract Neoplasms,drug or biologic,Early,54,All,Industry&Combos,0,NA,0,2016,2016,903,0,Phase 2,1,NA,1,3.9889840465642745,"(3,4]"
1793,2026,folfirinox in metastatic high grade gastroenteropancreatic neuroendocrine carcinomas,Terminated,5,1,1,Gastro-enteropancreatic Neuroendocrine Tumor|Pancreatic Cancer|Neuroendocrine Carcinomas of Pancreas|Islet Cell Carcinoma,drug or biologic,Early,2,All,AllOther,0,NA,0,2017,2017,336,0,Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
3548,5443,investigating cabozantinib in patients with refractory metastatic colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Cancer,drug or biologic,Early,43,All,Industry&Combos,1,1,0,2018,2018,1399,1,Phase 2,0,NA,0,3.7612001156935624,"(3,4]"
2839,3805,a study of mirikizumab (ly3074828) in participants with moderate to severe ulcerative colitis,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Early,249,All,Industry&Combos,1,0,0,2015,2015,741,1,Phase 2,2,NA,2,5.517452896464707,"(5,6]"
3624,5719,clinical protocol to investigate the long-term safety and efficacy of metreleptin in various forms of partial lipodystrophy,Completed,4,1,1,Familial Partial Lipodystrophy|Nonalcoholic Steatohepatitis|NAFLD,drug or biologic,Early,11,All,AllOther,0,NA,0,2016,2015,1507,0,Phase 2,1,safety/efficacy,1,2.3978952727983707,"(2,3]"
3703,6151,an open-label study to enable continued treatment access for subjects previously enrolled in studies of ruxolitinib,Enrolling by invitation,3,0,0,Pancreatic Cancer|Colorectal Cancer (CRC)|Breast Cancer|Lung Cancer,drug or biologic,Early,150,All,Industry&Combos,1,1,0,2016,2016,2403,1,Phase 2,0,NA,0,5.0106352940962555,"(5,6]"
834,873,repeat quadratus lumborum block to reduce opioid need in patients after pancreatic surgery,Recruiting,2,0,0,Pancreatic Carcinoma,drug or biologic,Early,110,All,NIH&Combos,1,0,0,2018,2019,996,1,Phase 2,3,NA,2,4.700480365792417,"(4,5]"
711,745,safety and efficacy of avelumab in small intestinal adenocarcinoma,"Active, not recruiting",1,0,0,Adenocarcinoma,drug or biologic,Early,25,All,IndustryNIHPartnership,0,NA,0,2016,2017,1869,0,Phase 2,1,safety/efficacy,1,3.2188758248682006,"(3,4]"
2332,2952,long term safety and tolerability of sar339658 in patients with ulcerative colitis (uc),Terminated,5,0,0,Ulcerative Colitis,drug or biologic,Early,6,All,Industry&Combos,0,NA,0,2013,2013,304,0,Phase 2,1,safety,1,1.791759469228055,"(1,2]"
3973,7505,a study of different combination regimens including jnj-73763989 and/or jnj-56136379 for the treatment of chronic hepatitis b virus infection,"Active, not recruiting",1,0,0,"Hepatitis B, Chronic",drug or biologic,Early,471,All,Industry&Combos,1,0,0,2019,2019,606,1,Phase 2,2,NA,2,6.154858094016418,"(6,7]"
3420,5181,a study of cnsa-001 in women with diabetic gastroparesis,Completed,4,0,0,Gastroparesis,drug or biologic,Early,21,Female,Industry&Combos,1,0,0,2018,2019,193,1,Phase 2,2,NA,2,3.044522437723423,"(3,4]"
3038,4082,effect of tu-100 in patients undergoing laparoscopic colectomy,Completed,4,1,1,Postoperative Ileus,drug or biologic,Early,69,All,Industry&Combos,1,0,0,2014,2014,973,1,Phase 2,4,NA,2,4.23410650459726,"(4,5]"
3648,5782,"a multicenter, randomized, double-blind, placebo-controlled study of abt-494 for the induction of symptomatic and endoscopic remission in subjects with moderately to severely active crohn's disease who have inadequately responded to or are intolerant to immunomodulators or anti-tnf therapy",Completed,4,0,0,Crohn's Disease,drug or biologic,Early,219,All,Industry&Combos,1,0,0,2015,2015,619,1,Phase 2,4,NA,2,5.389071729816501,"(5,6]"
3133,4257,"efficacy, safety and tolerability of the combination of tropifexor & licogliflozin and each monotherapy, compared with placebo in adult patients with nash and liver fibrosis.",Recruiting,2,0,0,Non Alcoholic Steatohepatitis (NASH),drug or biologic,Early,380,All,Industry&Combos,1,0,0,2019,2019,1212,1,Phase 2,4,safety/efficacy,2,5.940171252720432,"(5,6]"
1763,1975,surgery and heated intraperitoneal chemotherapy for adrenocortical carcinoma,Recruiting,2,0,0,Adrenocortical Carcinoma|Peritoneal Carcinomatosis,drug or biologic,Early,30,All,AllOther,0,NA,0,2017,2017,1682,0,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
1003,1058,esophageal stent migration with endoscopic suture fixation compared to standard deployment,Withdrawn,7,0,0,Esophageal Strictures|Esophageal Leak|Esophageal Perforation|Esophageal Fistula|Endostitch|Esophageal Stent,device,Others,NA,All,AllOther,1,0,0,2016,2016,337,1,Others,1,NA,1,NA,NA
2900,3889,a study of baricitinib (ly3009104) in participants with primary biliary cholangitis who do not respond or cannot take udca,Terminated,5,1,1,Primary Biliary Cholangitis,drug or biologic,Early,2,All,Industry&Combos,1,0,0,2018,2019,182,1,Phase 2,2,NA,2,0.6931471805599453,"(0,1]"
3671,5882,"study of ppi-668, bi 207127 and faldaprevir, with and without ribavirin, in the treatment of chronic hepatitis c",Completed,4,0,0,Chronic Hepatitis C,drug or biologic,Early,38,All,Industry&Combos,1,0,0,2013,2013,365,1,Phase 2,3,NA,2,3.6375861597263857,"(3,4]"
3635,5744,"dilute povidone-iodine irrigation vs no irrigation for children with acute, perforated appendicitis",Completed,4,1,1,"Acute, Perforated Appendicitis",drug or biologic,Early,100,All,AllOther,1,0,0,2016,2016,699,1,Phase 2,1,NA,1,4.605170185988092,"(4,5]"
3366,4930,"safety, tolerability, and efficacy of selonsertib, firsocostat, and cilofexor in adults with nonalcoholic steatohepatitis (nash)",Completed,4,0,0,Nonalcoholic Steatohepatitis (NASH)|Nonalcoholic Fatty Liver Disease (NAFLD),drug or biologic,Early,220,All,Industry&Combos,1,1,0,2016,2016,1618,1,Phase 2,0,safety/efficacy,0,5.393627546352362,"(5,6]"
2437,3166,niraparib in metastatic pancreatic cancer after previous chemotherapy (nira-panc): a phase 2 trial,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,18,All,Industry&Combos,0,NA,0,2018,2019,1618,0,Phase 2,1,NA,1,2.8903717578961645,"(2,3]"
373,382,trial of pancreatic enzyme supplements (pancrelipase) for treating pain in patients with chronic pancreatitis,Withdrawn,7,0,0,Pancreatitis,drug or biologic,Early,NA,All,AllOther,3,0,0,2016,2016,974,3,Phase 2,2,NA,2,NA,NA
3525,5380,antibiotic treatment and long-term outcomes of patients with pseudomyxoma peritonei of appendiceal origin,"Active, not recruiting",1,0,0,Pseudomyxoma Peritonei|Appendiceal Neoplasms,drug or biologic,Early,80,All,AllOther,0,1,0,2015,2015,2891,0,Phase 2,1,NA,1,4.382026634673881,"(4,5]"
3691,6107,miravirsen in combination with telaprevir and ribavirin in null responder to pegylated-interferon alpha plus ribavirin subjects with chronic hepatitis c virus infection,Unknown status,8,0,0,"Hepatitis C, Chronic",drug or biologic,Early,20,All,Industry&Combos,1,1,0,2013,2013,579,1,Phase 2,0,NA,0,2.995732273553991,"(2,3]"
513,534,phase ii study of chemo-radiotherapy in patients with resectable and borderline resectable pancreatic cancer,Unknown status,8,0,0,Pancreas Neoplasm Malignant Resectable,drug or biologic,Early,20,All,AllOther,0,NA,0,2014,2014,1461,0,Phase 2,1,NA,1,2.995732273553991,"(2,3]"
4054,7700,a study evaluating abi-h0731 as adjunctive therapy in participants with chronic hepatitis b infection,Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Early,73,All,Industry&Combos,1,0,0,2018,2018,389,1,Phase 2,3,NA,2,4.290459441148391,"(4,5]"
2957,3964,a study of ipatasertib (gdc-0068) in combination with fluoropyrimidine plus oxaliplatin in participants with advanced or metastatic gastric or gastroesophageal junction cancer,Completed,4,0,0,Gastric Cancer,drug or biologic,Early,154,All,Industry&Combos,1,0,0,2013,2013,641,1,Phase 2,2,NA,2,5.0369526024136295,"(5,6]"
1794,2027,copanlisib (bay 80-6946) in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma,Completed,4,1,1,Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2015,2016,1207,0,Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
1559,1698,folfirinox followed by ipilimumab with pancreatic tumor vaccine in treatment of metastatic pancreatic cancer,Completed,4,1,1,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,83,All,AllOther,1,0,0,2013,2013,2009,1,Phase 2,0,NA,0,4.418840607796598,"(4,5]"
1682,1857,a study of the effect of syn-010 on subjects with ibs-c,Completed,4,1,1,Irritable Bowel Syndrome With Constipation (IBS-C),drug or biologic,Early,63,All,Industry&Combos,1,0,0,2015,2015,122,1,Phase 2,2,NA,2,4.143134726391533,"(4,5]"
2914,3905,open label transdermal granisetron to relieve chronic nausea and emesis,Withdrawn,7,0,0,Gastroparesis,drug or biologic,Early,NA,All,AllOther,0,NA,0,2020,2019,730,0,Phase 2,1,NA,1,NA,NA
3891,7177,"short duration combination therapy with daclatasvir, asunaprevir, bms-791325 and sofosbuvir in subjects infected with chronic hepatitis-c (fourward study)",Completed,4,1,1,Hepatitis C,drug or biologic,Early,35,All,Industry&Combos,1,0,0,2014,2014,184,1,Phase 2,0,NA,0,3.5553480614894135,"(3,4]"
1136,1206,adoptive transfer of tumor infiltrating lymphocytes for advanced solid cancers,Recruiting,2,0,0,Gastric Cancer|Colorectal Cancer|Pancreatic Cancer|Sarcoma|Mesothelioma|Neuroendocrine Tumors|Squamous Cell Cancer|Merkel Cell Carcinoma|Mismatch Repair Deficiency|Microsatellite Instability,drug or biologic,Early,10,All,AllOther,0,NA,0,2019,2019,3468,0,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
3336,4776,"safety, tolerability, pharmacokinetics and efficacy of lmb763 in patients with nash",Terminated,5,1,1,Non-alcoholic Steatohepatitis NASH,drug or biologic,Early,122,All,Industry&Combos,1,0,0,2016,2016,695,1,Phase 2,3,safety/efficacy,2,4.804021044733257,"(4,5]"
2825,3787,a phase 2 study of sig12d loder in combination with chemotherapy in patients with locally advanced pancreatic cancer,Recruiting,2,0,0,Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer,drug or biologic,Early,80,All,Industry&Combos,0,NA,0,2012,2018,1669,0,Phase 2,1,NA,1,4.382026634673881,"(4,5]"
62,62,hipec as neoadjuvant treatment for resectable pancreatic adenocarcinoma,Withdrawn,7,0,0,Pancreatic Neoplasms|Pancreatic Adenocarcinoma,drug or biologic,Early,NA,All,AllOther,1,1,0,2016,2016,304,1,Phase 2,0,NA,0,NA,NA
1414,1520,daily online adaptation versus localization for mri-guided sbrt for unresectable primary or oligometastatic abdominal malignancies,Terminated,5,1,1,Pancreatic Cancer|Pancreas Cancer|Cancer of the Pancreas|Hepatocellular Carcinoma,device,Others,5,All,AllOther,1,0,0,2016,2017,424,1,Others,0,NA,0,1.6094379124341003,"(1,2]"
3509,5334,sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer,Recruiting,2,0,0,Hepatocellular Cancer,drug or biologic,Early,68,All,AllOther,1,1,0,2017,2017,1870,1,Phase 2,0,NA,0,4.219507705176107,"(4,5]"
3485,5288,a phase 2 study of pembrolizumab (mk-3475) in combination with azacitidine in subjects with chemo-refractory metastatic colorectal cancer,Completed,4,1,1,Metastatic Colorectal Cancer,drug or biologic,Early,31,All,Industry&Combos,0,NA,0,2014,2015,425,0,Phase 2,1,NA,1,3.4339872044851463,"(3,4]"
3104,4213,ibp-9414 for the prevention of necrotizing enterocolitis,Completed,4,0,0,Necrotizing Enterocolitis,drug or biologic,Early,120,All,Industry&Combos,1,0,1,2015,2016,437,1,Phase 2,4,NA,2,4.787491742782046,"(4,5]"
112,112,"pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (proceed)",Recruiting,2,0,0,Locally Advanced Esophageal and Gastric Cancers (EGC),drug or biologic,Early,38,All,AllOther,0,NA,0,2017,2017,1657,0,Phase 2,1,NA,1,3.6375861597263857,"(3,4]"
2772,3722,ph1b/2 study of pf-04136309 in combination with gem/nab-p in first-line metastatic pancreatic patients,Terminated,5,1,1,Metastatic Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,22,All,Industry&Combos,NA,NA,0,2016,2016,499,NA,Phase 2,0,NA,0,3.091042453358316,"(3,4]"
2873,3851,dose-ranging study of rifaximin soluble solid dispersion (ssd) tablets for the prevention of complications of early decompensated liver cirrhosis,Completed,4,0,0,Liver Cirrhosis,drug or biologic,Early,420,All,Industry&Combos,1,0,1,2013,2013,730,1,Phase 2,4,NA,2,6.040254711277414,"(6,7]"
3219,4496,a trial of encapsulated fecal microbiota for vancomycin resistant enterococcus decolonization,Completed,4,1,1,Antibiotic Resistant Strain,drug or biologic,Early,9,All,AllOther,1,0,0,2017,2017,398,1,Phase 2,4,NA,2,2.1972245773362196,"(2,3]"
199,202,"combination chemotherapy in treating patients with advanced stomach, gastroesophageal, or esophageal cancer",Completed,4,1,1,Stomach Neoplasms|Esophageal Neoplasms,drug or biologic,Early,67,All,AllOther,1,1,0,2013,2013,1851,1,Phase 2,0,NA,0,4.204692619390966,"(4,5]"
3315,4724,investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.,Completed,4,1,1,Hepatobiliary Disorders|Non-alcoholic Steatohepatitis,drug or biologic,Early,320,All,Industry&Combos,1,0,0,2016,2016,1170,1,Phase 2,2,safety/efficacy,2,5.768320995793772,"(5,6]"
3339,4790,"a multicenter, double-blind, randomized, placebo-controlled, 12-week, dose-range-finding trial of ykp10811 capsules administered once daily to subjects with chronic idiopathic constipation",Completed,4,0,0,Chronic Idiopathic Constipation,drug or biologic,Early,334,All,Industry&Combos,1,0,0,2013,2013,335,1,Phase 2,4,NA,2,5.811140992976701,"(5,6]"
2498,3312,allostim Â® immunotherapy dosing alone or in combination with cryoablation in metastatic colorectal cancer,Completed,4,0,0,Colorectal Cancer Metastatic,drug or biologic,Early,12,All,Industry&Combos,0,1,0,2015,2016,546,0,Phase 2,1,NA,1,2.4849066497880004,"(2,3]"
2939,3940,"safety, tolerability, and efficacy of asunaprevir and daclatasvir in subjects coinfected with hiv-hcv",Completed,4,1,1,HIV-HCV,drug or biologic,Early,30,All,IndustryNIHPartnership,1,1,0,2014,2014,759,1,Phase 2,0,safety/efficacy,0,3.4011973816621555,"(3,4]"
2913,3904,"phase 2a, dose-ranging study with pf-05221304 in nonalcoholic fatty liver disease (nafld)",Completed,4,1,1,Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,drug or biologic,Early,305,All,Industry&Combos,1,0,0,2017,2017,553,1,Phase 2,2,NA,2,5.720311776607412,"(5,6]"
4167,9148,efficacy and safety of sofosbuvir/velpatasvir fixed dose combination with ribavirin in chronic hcv infected adults who participated in a prior gilead sponsored hcv treatment study,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,69,All,Industry&Combos,0,NA,0,2014,2014,579,0,Phase 2,1,safety/efficacy,1,4.23410650459726,"(4,5]"
2536,3403,testing diet intervention versus non-diet intervention for management of bowel symptoms in rectal cancer survivors,Recruiting,2,0,0,Rectal Carcinoma|Rectosigmoid Carcinoma,other,Others,94,All,NIH&Combos,1,0,4,2019,2019,874,1,Others,1,NA,1,4.543294782270004,"(4,5]"
3446,5237,"pembrolizumab, capecitabine, and bevacizumab in treating patients with microsatellite stable colorectal cancer that is locally advanced, metastatic, or cannot be removed by surgery",Recruiting,2,0,0,Microsatellite Stable|Mismatch Repair Protein Proficient|Stage III Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,56,All,Industry&Combos,0,NA,0,2018,2018,2480,0,Phase 2,1,NA,1,4.02535169073515,"(4,5]"
3476,5279,assess the efficacy of pembrolizumab plus radiotherapy or ablation in metastatic colorectal cancer patients,"Active, not recruiting",1,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,34,All,Industry&Combos,1,1,0,2015,2015,2557,1,Phase 2,0,efficacy,0,3.5263605246161616,"(3,4]"
3753,6369,a phase ii study in patients with moderate to severe active crohn's disease,Recruiting,2,0,0,Crohn's Disease,drug or biologic,Early,144,All,Industry&Combos,1,0,0,2018,2019,749,1,Phase 2,2,NA,2,4.969813299576001,"(4,5]"
2531,3393,phase ii trial of tivozanib in advanced hepatocellular cancer,Terminated,5,1,1,Hepatocellular Cancer,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2013,2013,702,0,Phase 2,1,NA,1,1.9459101490553132,"(1,2]"
3136,4260,evaluation of the efficacy and safety of alv003 in symptomatic in celiac disease patients,Unknown status,8,0,0,Celiac Disease,drug or biologic,Early,500,All,Industry&Combos,1,0,0,2013,2013,608,1,Phase 2,4,safety/efficacy,2,6.214608098422191,"(6,7]"
1388,1489,integrated imaging strategy to phenotype progression of liver tumors during and after chemoembolization,Completed,4,1,1,Liver Cancer|Liver Neoplasm|Hepatocellular Carcinoma|HCC,drug or biologic,Early,3,All,NIH&Combos,0,NA,2,2015,2015,999,0,Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
2971,3985,a study to evaluate the accuracy of a subset of the length-109 probe set panel (a genetic test) in predicting response to golimumab in participants with moderately to severely active ulcerative colitis,Completed,4,0,0,"Colitis, Ulcerative",drug or biologic,Early,103,All,Industry&Combos,0,NA,0,2013,2013,427,0,Phase 2,1,NA,1,4.634728988229636,"(4,5]"
3041,4085,phase 2 study on effects of obeticholic acid (oca) on lipoprotein metabolism in subjects with primary biliary cirrhosis,Completed,4,1,1,Primary Biliary Cirrhosis,drug or biologic,Early,26,All,Industry&Combos,0,NA,4,2013,2013,273,0,Phase 2,1,NA,1,3.258096538021482,"(3,4]"
2651,3556,first-time-in-human (ftih) study of gsk3145095 alone and in combination with other anticancer agents in adults with advanced solid tumors,Terminated,5,1,1,"Neoplasms, Pancreatic",drug or biologic,Early,8,All,Industry&Combos,NA,1,0,2018,2018,270,NA,Phase 2,0,NA,0,2.0794415416798357,"(2,3]"
2718,3643,trichuris suis ova treatment in left-sided ulcerative colitis,Terminated,5,1,1,"Colitis, Ulcerative",drug or biologic,Early,16,All,NA,1,0,0,2013,2013,730,1,Phase 2,2,NA,2,2.772588722239781,"(2,3]"
3744,6326,"study to evaluate the safety, tolerability, and efficacy of cilofexor in adults with primary sclerosing cholangitis without cirrhosis",Completed,4,1,1,Primary Sclerosing Cholangitis,drug or biologic,Early,52,All,Industry&Combos,1,0,0,2016,2016,456,1,Phase 2,2,safety/efficacy,2,3.9512437185814275,"(3,4]"
591,617,pembrolizumab and cxcr4 antagonist bl-8040 in treating patients with metastatic pancreatic cancer,"Active, not recruiting",1,0,0,Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v6 and v7,drug or biologic,Early,23,All,NIH&Combos,0,NA,0,2016,2016,1856,0,Phase 2,1,NA,1,3.1354942159291497,"(3,4]"
2009,2370,neoadjuvant gmci plus chemoradiation for advanced non-metastatic pancreatic adenocarcinoma,Recruiting,2,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,38,All,Industry&Combos,1,0,0,2015,2015,2253,1,Phase 2,0,NA,0,3.6375861597263857,"(3,4]"
3940,7345,phase 2a study of bax69 and 5-fu/leucovorin or panitumumab versus standard of care in subjects with metastatic colorectal cancer,Terminated,5,1,1,Metastatic Colorectal Cancer,drug or biologic,Early,115,All,Industry&Combos,2,0,0,2015,2015,611,1,Phase 2,0,NA,0,4.74493212836325,"(4,5]"
814,852,effects of ondansetron on gastrointestinal sensorimotor dysfunctions in diabetes mellitus and dyspepsia,Recruiting,2,0,0,Indigestion|Diabetes Mellitus,drug or biologic,Early,150,All,NIH&Combos,1,0,0,2019,2019,2160,1,Phase 2,2,NA,2,5.0106352940962555,"(5,6]"
190,192,lymphoseek Â® as lymphoid tissue targeting agents in colon cancer(cnc),Completed,4,1,1,Colon Cancer|Rectal Cancer,drug or biologic,Early,16,All,AllOther,0,NA,2,2013,2013,1188,0,Phase 2,1,NA,1,2.772588722239781,"(2,3]"
2916,3910,study to evaluate the effects of two doses of mbx-8025 in subjects with primary biliary cirrhosis (pbc),Terminated,5,0,0,Primary Biliary Cirrhosis (PBC),drug or biologic,Early,41,All,Industry&Combos,1,0,0,2015,2015,243,1,Phase 2,4,NA,2,3.713572066704308,"(3,4]"
2501,3318,open-label phase iib efficacy trial of cancer macrobeads compared to best supportive care in colorectal cancer patients,Completed,4,1,1,Colorectal Cancers,drug or biologic,Early,70,All,AllOther,1,1,0,2014,2014,1663,1,Phase 2,0,efficacy,0,4.248495242049359,"(4,5]"
2963,3975,safety and efficacy of ledipasvir/sofosbuvir fixed dose combination administered in patients infected with chronic genotype 1 or 4 hcv for use in the peri-operative liver transplantation setting,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,17,All,Industry&Combos,0,NA,0,2015,2015,311,0,Phase 2,1,safety/efficacy,1,2.833213344056216,"(2,3]"
2487,3280,study of oral ceritinib in patients with alk and ros1 activated gastrointestinal malignancies,Terminated,5,0,0,Colorectal Adenocarcinoma|Cholangiocarcinoma|Pancreatic Adenocarcinoma|Hepatocellular Adenocarcinoma|Gastric Adenocarcinoma|Esophageal Adenocarcinoma,drug or biologic,Early,4,All,Industry&Combos,0,NA,0,2015,2015,849,0,Phase 2,1,NA,1,1.3862943611198906,"(1,2]"
3970,7499,tate versus tace in intermediate stage hcc,"Active, not recruiting",1,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,134,All,Industry&Combos,1,0,0,2017,2017,1487,1,Phase 2,1,NA,1,4.897839799950911,"(4,5]"
1474,1590,[18f]fmiso pet/ct after transcatheter arterial embolization in imaging tumors in patients with liver cancer,Completed,4,1,1,Adult Liver Carcinoma|Liver Cirrhosis,drug or biologic,Early,5,All,NIH&Combos,0,NA,2,2016,2016,594,0,Phase 2,1,NA,1,1.6094379124341003,"(1,2]"
3799,6691,efficacy of ginseng for patients on regorafenib,Terminated,5,0,0,Colorectal Cancer|Palliative Medicine|Supportive Care,drug or biologic,Early,10,All,Industry&Combos,1,0,0,2015,2016,812,1,Phase 2,0,efficacy,0,2.302585092994046,"(2,3]"
3737,6277,a study to evaluate seladelpar in subjects with nonalcoholic steatohepatitis (nash),Completed,4,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,181,All,Industry&Combos,1,0,0,2018,2018,373,1,Phase 2,4,NA,2,5.198497031265826,"(5,6]"
3550,5445,"a study to evaluate the efficacy, safety and immunogenicity of a vaccine designed to protect against infection with shigella sonnei in healthy adults",Completed,4,1,1,"Dysentery, Bacillary",drug or biologic,Early,71,All,Industry&Combos,1,0,1,2018,2018,252,1,Phase 2,4,safety/efficacy,2,4.2626798770413155,"(4,5]"
353,361,stool transplants to treat refractory clostridium difficile colitis,Recruiting,2,0,0,Clostridium Difficile Colitis,drug or biologic,Early,10,All,AllOther,0,NA,0,2014,2016,2221,0,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
3869,7110,carfilzomib for the treatment of patients with advanced neuroendocrine cancers,Completed,4,0,0,Neuroendocrine Cancer,drug or biologic,Early,62,All,Industry&Combos,0,NA,0,2014,2015,2131,0,Phase 2,1,NA,1,4.127134385045092,"(4,5]"
3987,7546,ledipasvir/sofosbuvir for hepatitis b virus infection,"Active, not recruiting",1,0,0,Hepatitis B,drug or biologic,Early,25,All,Industry&Combos,0,0,0,2017,2018,921,0,Phase 2,1,NA,1,3.2188758248682006,"(3,4]"
3460,5253,a phase 2 study of lamivudine in patients with p53 mutant metastatic colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Cancer Metastatic,drug or biologic,Early,36,All,AllOther,0,NA,0,2017,2017,877,0,Phase 2,1,NA,1,3.58351893845611,"(3,4]"
3470,5272,"evaluating the safety, tolerability, and efficacy of gs-9674 in participants with nonalcoholic steatohepatitis (nash)",Completed,4,1,1,Nonalcoholic Steatohepatitis (NASH),drug or biologic,Early,140,All,Industry&Combos,1,0,0,2016,2016,440,1,Phase 2,2,safety/efficacy,2,4.941642422609304,"(4,5]"
2618,3518,phase 2 nab Â® -paclitaxel (abraxane Â®) plus gemcitabine in subjects with locally advanced pancreatic cancer (lapc),Completed,4,1,1,Pancreatic Neoplasms,drug or biologic,Early,107,All,Industry&Combos,0,NA,0,2014,2015,945,0,Phase 2,1,NA,1,4.672828834461906,"(4,5]"
3269,4604,study to evaluate the safety and efficacy of switching to tenofovir alafenamide (taf) from tenofovir disoproxil fumarate (tdf) and/or other oral antiviral treatment (oav),Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Early,124,All,Industry&Combos,1,1,0,2017,2017,636,1,Phase 2,0,safety/efficacy,0,4.820281565605037,"(4,5]"
1028,1083,a phase ii study of neoadjuvant folfirinox,"Active, not recruiting",1,1,1,Resectable Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,48,All,AllOther,0,NA,0,2014,2014,1352,0,Phase 2,1,NA,1,3.871201010907891,"(3,4]"
2051,2429,chemoradiation or brachytherapy for rectal cancer,"Active, not recruiting",1,0,0,Rectal Cancer,drug or biologic,Early,138,All,AllOther,1,0,0,2013,2013,2983,1,Phase 2,1,NA,1,4.927253685157205,"(4,5]"
2921,3920,"emricasan, an oral caspase inhibitor, in subjects with non-alcoholic steatohepatitis (nash) cirrhosis and severe portal hypertension",Completed,4,0,0,Cirrhosis|Portal Hypertension|Non-alcoholic Steatohepatitis,drug or biologic,Early,240,All,Industry&Combos,1,0,0,2016,2016,715,1,Phase 2,3,NA,2,5.480638923341991,"(5,6]"
2691,3609,study to evaluate the efficacy and safety of amg 714 in adult patients with type ii refractory celiac disease,Completed,4,1,1,Type II Refractory Celiac Disease (RCD-II)|In-situ Small Bowel T-cell Lymphoma,drug or biologic,Early,28,All,Industry&Combos,1,0,0,2015,2016,363,1,Phase 2,4,safety/efficacy,2,3.332204510175204,"(3,4]"
2039,2410,a trial of maintenance adapt therapy with capecitabine and celecoxib in patients with metastatic colorectal cancer,Terminated,5,1,1,Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,drug or biologic,Early,27,All,NIH&Combos,0,NA,0,2012,2013,1285,0,Phase 2,1,NA,1,3.295836866004329,"(3,4]"
3502,5309,levocetirizine + capecitabine + bevacizumab for patients with refractory colorectal cancer,Completed,4,1,1,Colorectal Neoplasms,drug or biologic,Early,47,All,AllOther,1,0,0,2012,2013,913,1,Phase 2,0,NA,0,3.8501476017100584,"(3,4]"
2890,3875,entinostat neuroendocrine (ne) tumor,Recruiting,2,0,0,Neuroendocrine Tumors,drug or biologic,Early,40,All,AllOther,0,NA,0,2017,2017,586,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3390,5059,theranostics: 68gadotatoc and 90ydotatoc,Unknown status,8,0,0,Neuroendocrine Tumors|Carcinoid Tumors|Neuroblastoma|Medulloblastoma,drug or biologic,Early,25,All,NIH&Combos,0,NA,0,2015,2015,1706,0,Phase 2,1,NA,1,3.2188758248682006,"(3,4]"
1590,1740,tas-102 (lonsurf) in metastatic or locally advanced unresectable pancreatic adenocarcinoma post first line chemotherapy (uf-sto-panc-003),Terminated,5,1,1,Pancreatic Cancer,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2016,2017,990,0,Phase 2,1,NA,1,1.9459101490553132,"(1,2]"
592,618,trial comparing early laparoscopic enterolysis versus nonoperative management for high-grade sbo,Terminated,5,0,0,Small Bowel Obstruction,procedure,Others,3,All,AllOther,1,0,0,2016,2016,254,1,Others,0,NA,0,1.0986122886681098,"(1,2]"
275,280,perioperative mfolfox plus pembrolizumab in gastroesophageal junction (gej) and stomach adenocarcinoma,Recruiting,2,0,0,Gastro Esophageal Junction Cancer|Stomach Cancer|Adenocarcinoma,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2018,2018,1403,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
1458,1570,"efficacy of low dose, subq interleukin-2 (il-2) to expand endogenous regulatory t-cells in liver transplant recipients","Active, not recruiting",1,0,0,Liver Transplantation,drug or biologic,Early,7,All,AllOther,0,NA,0,2016,2016,2221,0,Phase 2,1,efficacy,1,1.9459101490553132,"(1,2]"
96,96,trial to understand efficacy of colesevelam in diarrhea predominant ibs patients with bile acid malabsorption,Completed,4,1,1,Chronic Diarrhea|Irritable Bowel Syndrome With Diarrhea|Bile Acid Malabsorption,drug or biologic,Early,30,All,NIH&Combos,1,0,4,2017,2017,540,1,Phase 2,3,efficacy,2,3.4011973816621555,"(3,4]"
1937,2263,subcutaneous methylnaltrexone versus placebo for postoperative ileus prevention,"Active, not recruiting",1,0,0,Postoperative Ileus,drug or biologic,Early,82,All,AllOther,1,0,1,2019,2019,892,1,Phase 2,3,NA,2,4.406719247264253,"(4,5]"
3278,4625,phase 2 study of mgl-3196 in patients with non-alcoholic steatohepatitis (nash),Unknown status,8,0,0,Non-alcoholic Steatohepatitis,drug or biologic,Early,125,All,Industry&Combos,1,0,0,2016,2016,395,1,Phase 2,4,NA,2,4.8283137373023015,"(4,5]"
1567,1708,ribociclib in treating patients with advanced neuroendocrine tumors of foregut origin,Completed,4,1,1,Advanced Digestive System Neuroendocrine Neoplasm|Duodenal Neuroendocrine Tumor G1|Functional Pancreatic Neuroendocrine Tumor|Gastric Neuroendocrine Tumor|Intermediate Grade Lung Neuroendocrine Neoplasm|Low Grade Lung Neuroendocrine Neoplasm|Nonfunctional Pancreatic Neuroendocrine Tumor|Thymus Neoplasm,drug or biologic,Early,21,All,IndustryNIHPartnership,0,NA,0,2015,2015,1380,0,Phase 2,1,NA,1,3.044522437723423,"(3,4]"
3853,7037,"a randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of nnc0114-0006 in subjects with active crohn's disease",Completed,4,0,0,Inflammation|Crohn's Disease,drug or biologic,Early,53,All,Industry&Combos,1,0,0,2012,2013,668,1,Phase 2,2,safety/efficacy,2,3.970291913552122,"(3,4]"
2793,3749,fdg-pet directed treatment in improving response in patients with locally advanced stomach or gastroesophageal junction cancer,Terminated,5,1,1,Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma|Gastric Cancer,drug or biologic,Early,5,All,NIH&Combos,1,0,0,2015,2015,1096,1,Phase 2,0,NA,0,1.6094379124341003,"(1,2]"
2152,2590,a phase 2 trial of ponatinib in participants with metastatic and/or unresectable gastrointestinal stromal tumor,Completed,4,1,1,GIST,drug or biologic,Early,45,All,Industry&Combos,1,1,0,2013,2013,633,1,Phase 2,0,NA,0,3.8066624897703196,"(3,4]"
4026,7609,study to assess the efficacy of vly-686 in relieving symptoms of gastroparesis,Unknown status,8,0,0,Gastroparesis,drug or biologic,Early,150,All,Industry&Combos,1,0,0,2016,2016,760,1,Phase 2,3,efficacy,2,5.0106352940962555,"(5,6]"
2560,3439,safety and efficacy study of an edible colonoscopy preparation,Completed,4,0,0,Colon Prep for Colonoscopy,drug or biologic,Early,60,All,Industry&Combos,1,0,4,2017,2017,114,1,Phase 2,2,safety/efficacy,2,4.0943445622221,"(4,5]"
3341,4809,a safety and efficacy study of a range of linaclotide doses administered orally to children ages 6-17 years who fulfill modified rome iii criteria for child/adolescent functional constipation (fc),Completed,4,1,1,Functional Constipation in Children Ages 6-17 Years,drug or biologic,Early,173,All,Industry&Combos,1,0,0,2015,2015,899,1,Phase 2,4,safety/efficacy,2,5.153291594497779,"(5,6]"
3115,4227,"study of isis 703802 in participants with hypertriglyceridemia, type 2 diabetes mellitus, and nonalcoholic fatty liver disease",Completed,4,1,1,"NAFLD|Diabetes Mellitus, Type 2|Hypertriglyceridemia|Fatty Liver, Nonalcoholic",drug or biologic,Early,105,All,Industry&Combos,1,0,0,2017,2017,700,1,Phase 2,3,NA,2,4.653960350157523,"(4,5]"
923,970,irinotecan and capecitabine as second-line treatment for advanced/metastatic biliary tract cancers,Withdrawn,7,0,0,Biliary Tract Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2016,2015,851,0,Phase 2,1,NA,1,NA,NA
1297,1384,sglt2 inhibitors as a novel treatment for pediatric non-alcoholic fatty liver disease,Suspended,6,0,0,Non-Alcoholic Fatty Liver Disease|NAFLD|Pediatric NAFLD,drug or biologic,Early,40,All,AllOther,1,0,0,2019,2019,1827,1,Phase 2,2,NA,2,3.6888794541139363,"(3,4]"
1533,1665,phase 2 study to evaluate the preliminary performance of the c13-ura breath test kit in dyspeptic subjects,Completed,4,0,0,Dyspeptic Subjects,drug or biologic,Early,20,All,Industry&Combos,1,1,2,2012,2013,335,1,Phase 2,0,NA,0,2.995732273553991,"(2,3]"
3247,4559,obeticholic acid (oca) in primary sclerosing cholangitis (psc),Completed,4,1,1,Primary Sclerosing Cholangitis (PSC),drug or biologic,Early,77,All,Industry&Combos,1,0,0,2014,2015,757,1,Phase 2,3,NA,2,4.343805421853684,"(4,5]"
3621,5715,niraparib and panitumumab in patients with advanced or metastatic colorectal cancer,Recruiting,2,0,0,Advanced Microsatellite Stable Colorectal Carcinoma|Metastatic Microsatellite Stable Colorectal Carcinoma|Microsatellite Stable|RAS Wild Type|Stage IV Colorectal Cancer AJCC v8|MSI-H Colorectal Cancer,drug or biologic,Early,26,All,Industry&Combos,0,NA,0,2019,2019,1843,0,Phase 2,1,NA,1,3.258096538021482,"(3,4]"
3804,6704,"a research study to assess the safety, pharmacokinetics and pharmacodynamics of dur-928 in patients with alcoholic hepatitis",Completed,4,0,0,Alcoholic Hepatitis,drug or biologic,Early,19,All,Industry&Combos,NA,1,0,2018,2018,509,NA,Phase 2,0,safety,0,2.9444389791664403,"(2,3]"
977,1030,use of novel prebiotic fiber for targeted dietary management of irritable bowel syndrome (nutrabiotix phase ii),Terminated,5,0,0,Constipation-predominant IBS (IBS-C),drug or biologic,Early,120,All,Industry&Combos,1,0,4,2014,2014,762,1,Phase 2,4,NA,2,4.787491742782046,"(4,5]"
227,230,fat malabsorption in chronic pancreatitis,Completed,4,1,1,Chronic Pancreatitis,drug or biologic,Early,48,All,IndustryNIHPartnership,1,1,2,2016,2016,384,1,Phase 2,0,NA,0,3.871201010907891,"(3,4]"
1862,2141,"pistachios blood sugar control, heart and gut health",Recruiting,2,0,0,Type 2 Diabetes|Cardiovascular Diseases,drug or biologic,Early,59,All,AllOther,3,0,1,2019,2019,1057,3,Phase 2,2,NA,2,4.07753744390572,"(4,5]"
1218,1296,nivolumab with or without ipilimumab in treating patients with gastrointestinal stromal tumor that is metastatic or cannot be removed by surgery,Recruiting,2,0,0,Gastrointestinal Stromal Tumor,drug or biologic,Early,40,All,Industry&Combos,1,0,0,2016,2016,1722,1,Phase 2,0,NA,0,3.6888794541139363,"(3,4]"
3711,6203,use of topical subgingival application of simvastatin gel in the treatment of peri-implant mucositis,Completed,4,1,1,Peri-implant Mucositis,drug or biologic,Early,46,All,AllOther,1,0,0,2018,2015,550,1,Phase 2,3,NA,2,3.828641396489095,"(3,4]"
265,269,phase ii study of preoperative folfirinox versus gemcitabine/nab-paclitaxel in patients with resectable pancreatic cancer,Terminated,5,1,1,Resectable Pancreatic Cancer|Pancreatic Ductal Carcinoma,drug or biologic,Early,7,All,AllOther,1,0,0,2014,2014,639,1,Phase 2,0,NA,0,1.9459101490553132,"(1,2]"
3749,6347,ledipasvir/sofosbuvir fixed-dose combination on cerebral metabolism and neurocognition in treatment-naive and treatment-experienced participants with chronic genotype 1 hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,40,All,Industry&Combos,1,0,0,2014,2014,365,1,Phase 2,2,NA,2,3.6888794541139363,"(3,4]"
3340,4808,a phase 2 study to evaluate the safety and efficacy of rm-131 in patients with parkinson's disease & chronic constipation,Terminated,5,0,0,Parkinson's Disease,drug or biologic,Early,18,All,Industry&Combos,1,0,0,2013,2013,607,1,Phase 2,4,safety/efficacy,2,2.8903717578961645,"(2,3]"
558,581,study of combined sgt-53 plus gemcitabine/nab-paclitaxel for metastatic pancreatic cancer,Recruiting,2,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,28,All,Industry&Combos,0,NA,0,2015,2015,2526,0,Phase 2,1,NA,1,3.332204510175204,"(3,4]"
1564,1705,stool transplant in pediatric patients with recurring c. difficile infection,Completed,4,0,0,Clostridium Difficile Colitis,drug or biologic,Early,9,All,AllOther,1,0,0,2013,2013,1004,1,Phase 2,4,NA,2,2.1972245773362196,"(2,3]"
2410,3113,vidofludimus calcium for primary sclerosing cholangitis,Completed,4,1,1,Primary Sclerosing Cholangitis,drug or biologic,Early,18,All,AllOther,0,NA,0,2018,2019,379,0,Phase 2,1,NA,1,2.8903717578961645,"(2,3]"
4007,7580,simeprevir in combination with sofosbuvir in treatment-na Â¯ve or -experienced adults with chronic genotype 4 hepatitis c virus infection,Completed,4,0,0,Chronic Hepatitis C,drug or biologic,Early,30,All,Industry&Combos,1,1,0,2014,2014,457,1,Phase 2,0,NA,0,3.4011973816621555,"(3,4]"
2546,3421,"safety and efficacy of crs-207 with pembrolizumab in gastric, gastroesophageal junction or esophageal cancers",Terminated,5,1,1,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma,drug or biologic,Early,5,All,Industry&Combos,0,NA,0,2017,2017,135,0,Phase 2,1,safety/efficacy,1,1.6094379124341003,"(1,2]"
471,487,maintenance dovitinib for colorectal and pancreas cancer,Terminated,5,1,1,Colorectal Cancer|Pancreas Cancer,drug or biologic,Early,9,All,Industry&Combos,0,NA,0,2013,2013,304,0,Phase 2,1,NA,1,2.1972245773362196,"(2,3]"
3301,4687,ezetimibe as a safe and efficacious treatment for chronic hepatitis c,"Active, not recruiting",1,0,0,Chronic Hepatitis C,drug or biologic,Early,95,All,AllOther,1,0,0,2016,2018,1080,1,Phase 2,2,NA,2,4.553876891600541,"(4,5]"
2752,3695,the effect of ns-0200 versus placebo on hepatic fat content in patients with non alcoholic fatty liver disease,Completed,4,1,1,"NAFLD",drug or biologic,Early,91,All,Industry&Combos,1,0,0,2015,2015,377,1,Phase 2,4,NA,2,4.51085950651685,"(4,5]"
955,1005,preoperative folfirinox for resectable pancreatic adenocarcinoma - a phase ii study,Terminated,5,1,1,Pancreatic Adenocarcinoma|Poorly Differentiated Malignant Neoplasm|Resectable Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Undifferentiated Pancreatic Carcinoma,drug or biologic,Early,1,All,NIH&Combos,0,NA,0,2015,2015,153,0,Phase 2,1,NA,1,0,NA
2082,2478,phase ii trial of azd6738 alone and in combination with olaparib,Recruiting,2,0,0,Clear Cell Renal Cell Carcinoma|Locally Advanced Pancreatic Cancer|Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Metastatic Renal Cell Carcinoma|Metastatic Urothelial Carcinoma|Metastatic Pancreatic Cancer|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer,drug or biologic,Early,68,All,Industry&Combos,1,1,0,2018,2019,1809,1,Phase 2,0,NA,0,4.219507705176107,"(4,5]"
3153,4293,"study of iw-1701, a stimulator of soluble guanylate cyclase (sgc), in patients with type i or ii achalasia",Terminated,5,1,1,Achalasia,drug or biologic,Early,9,All,Industry&Combos,1,0,0,2016,2017,390,1,Phase 2,4,NA,2,2.1972245773362196,"(2,3]"
1982,2333,"trial to improve outcomes in patients with resected pancreatic cancer (azacitidine, abraxane, gemcitabine)","Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,80,All,AllOther,0,0,0,2013,2014,2882,0,Phase 2,1,NA,1,4.382026634673881,"(4,5]"
2944,3946,a study of experimental medication bms-986036 in adults with nonalcoholic steatohepatitis (nash) and stage 3 liver fibrosis,"Active, not recruiting",1,0,0,Liver Fibrosis|Nonalcoholic Fatty Liver Disease (NAFLD)|Nonalcoholic Steatohepatitis,drug or biologic,Early,160,All,Industry&Combos,1,0,0,2018,2018,861,1,Phase 2,4,NA,2,5.075173815233827,"(5,6]"
2813,3772,a study of mln0264 in patients with pancreatic cancer,Terminated,5,1,1,Pancreatic Adenocarcinoma,drug or biologic,Early,43,All,Industry&Combos,0,NA,0,2014,2014,562,0,Phase 2,1,NA,1,3.7612001156935624,"(3,4]"
3734,6255,regorafenib in metastatic colorectal cancer,"Active, not recruiting",1,1,1,Metastatic Colorectal Cancer,drug or biologic,Early,27,All,Industry&Combos,0,NA,0,2015,2015,1583,0,Phase 2,1,NA,1,3.295836866004329,"(3,4]"
3170,4339,losartan for the treatment of pediatric nafld,Completed,4,0,0,"NAFLD - Nonalcoholic Fatty Liver Disease",drug or biologic,Early,83,All,NIH&Combos,1,0,0,2018,2018,607,1,Phase 2,3,NA,2,4.418840607796598,"(4,5]"
1338,1430,vedolizumab induction may prevent celiac enteritis,Terminated,5,0,0,Celiac Disease,drug or biologic,Early,1,All,Industry&Combos,0,NA,0,2016,2018,102,0,Phase 2,1,NA,1,0,NA
4068,7806,"tolerability, pharmacokinetics, and efficacy of apd371 in subjects with crohn's disease experiencing abdominal pain",Completed,4,0,0,Crohn's Disease|Abdominal Pain,drug or biologic,Early,14,All,Industry&Combos,1,0,0,2017,2017,475,1,Phase 2,0,efficacy,0,2.6390573296152584,"(2,3]"
292,297,prospective evaluation of budesonide for prevention of esophageal strictures after endotherapy,Completed,4,1,1,Esophageal Stricture,drug or biologic,Early,90,All,AllOther,0,1,0,2014,2014,1805,0,Phase 2,1,NA,1,4.499809670330265,"(4,5]"
2469,3240,phase ii study of ramucirumab with chemotherapy in patients with metastatic gastroesophageal junction and gastric cancer,Terminated,5,1,1,Gastric Cancer|Gastroesophageal Junction Cancer,drug or biologic,Early,7,All,AllOther,0,NA,0,2016,2016,1075,0,Phase 2,1,NA,1,1.9459101490553132,"(1,2]"
2043,2416,stereotactic body radiation therapy (sbrt) versus trans-arterial chemoembolization (tace) as bridge to liver transplant,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma|HCC,drug or biologic,Early,60,All,Industry&Combos,1,0,0,2014,2014,2679,1,Phase 2,0,NA,0,4.0943445622221,"(4,5]"
383,393,a pilot evaluation of an experimental bli4600 formulation for bowel preparation in adult patients undergoing colonoscopy,Completed,4,0,0,Bowel Preparation for Colonoscopy,drug or biologic,Early,45,All,Industry&Combos,1,1,1,2015,2015,151,1,Phase 2,0,NA,0,3.8066624897703196,"(3,4]"
2773,3723,study to evaluate the efficacy and safety of tilpisertib in adults with moderately to severely active ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Early,19,All,Industry&Combos,1,0,0,2019,2019,426,1,Phase 2,2,safety/efficacy,2,2.9444389791664403,"(2,3]"
1406,1510,efficacy and immunogenicity of norovirus gi.1/gii.4 bivalent virus-like particle vaccine in adults,Completed,4,1,1,Healthy Volunteers,drug or biologic,Early,4748,All,Industry&Combos,1,0,1,2016,2016,732,1,Phase 2,4,efficacy,2,8.465478755729558,"(7,13]"
1163,1237,pembrolizumab with liver-directed or peptide receptor radionuclide therapy for neuroendocrine tumors and liver metastases,Recruiting,2,0,0,Metastatic Malignant Neoplasm in the Liver|Neuroendocrine Neoplasm,drug or biologic,Early,32,All,Industry&Combos,1,1,0,2018,2018,1191,1,Phase 2,0,NA,0,3.4657359027997265,"(3,4]"
3088,4173,nivolumab with or without ipilimumab in treating patients with refractory metastatic anal canal cancer,Recruiting,2,0,0,Anal Canal Squamous Cell Carcinoma|Metastatic Anal Canal Carcinoma|Stage IV Anal Canal Cancer AJCC v6 and v7,drug or biologic,Early,137,All,NIH&Combos,1,NA,0,2014,2015,2482,1,Phase 2,0,NA,0,4.919980925828125,"(4,5]"
3724,6231,herbal mouthrinse for oral mucositis study,Completed,4,1,1,Oral Mucositis,drug or biologic,Early,50,All,NIH&Combos,1,0,4,2013,2013,639,1,Phase 2,4,NA,2,3.912023005428146,"(3,4]"
1956,2297,study to evaluate the effects of ono-2952 on pain perception produced by rectal distention in female subjects with diarrhea-predominant irritable bowel syndrome (ibs-d),Terminated,5,0,0,Irritable Bowel Syndrome (IBS),drug or biologic,Early,39,Female,Industry&Combos,1,0,0,2013,2013,579,1,Phase 2,2,NA,2,3.6635616461296463,"(3,4]"
3085,4165,"a single-dose, open-label, study to evaluate the sustainability of the effects of syn-010 in patients with ibs-c",Completed,4,1,1,Irritable Bowel Syndrome With Constipation (IBS-C),drug or biologic,Early,54,All,Industry&Combos,0,NA,0,2015,2015,61,0,Phase 2,1,NA,1,3.9889840465642745,"(3,4]"
2238,2759,gvax pancreas vaccine (with cy) and crs-207 with or without nivolumab,Completed,4,1,1,Previously Treated Metastatic Adenocarcinoma of the Pancreas,drug or biologic,Early,93,All,Industry&Combos,1,0,0,2014,2015,931,1,Phase 2,0,NA,0,4.532599493153256,"(4,5]"
2346,2974,safety and efficacy of roflumilast and pioglitazone in treating adults with nonalcoholic steatohepatitis,Terminated,5,1,1,Nonalcoholic Steatohapatitis,drug or biologic,Early,20,All,Industry&Combos,1,0,0,2012,2013,457,1,Phase 2,4,safety/efficacy,2,2.995732273553991,"(2,3]"
66,66,effect of tak-954 on gastrointestinal and colonic transit in diabetic or idiopathic gastroparesis participants,Completed,4,1,1,Diabetic Gastroparesis|Idiopathic Gastroparesis,drug or biologic,Early,36,All,Industry&Combos,1,0,0,2017,2018,521,1,Phase 2,4,NA,2,3.58351893845611,"(3,4]"
3740,6292,phase 2b challenge study with the bioconjugate vaccine flexyn2a,Completed,4,1,1,Shigellosis,drug or biologic,Early,67,All,Industry&Combos,1,0,1,2016,2015,275,1,Phase 2,3,NA,2,4.204692619390966,"(4,5]"
2735,3664,a study of md-7246 to treat abdominal pain in patients with diarrhea-predominant irritable bowel syndrome,Completed,4,1,1,Irritable Bowel Syndrome With Diarrhea (IBS-D),drug or biologic,Early,515,All,Industry&Combos,1,0,0,2019,2019,301,1,Phase 2,2,NA,2,6.244166900663736,"(6,7]"
1863,2142,regorafenib in reducing recurrence in patients with non-metastatic rectal cancer who have completed curative-intent treatment,Withdrawn,7,0,0,Rectal Adenocarcinoma|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer,drug or biologic,Early,NA,All,NIH&Combos,0,NA,0,2014,2015,580,0,Phase 2,1,NA,1,NA,NA
4005,7572,"a study of faldaprevir, ribavirin and td-6450 in participants with genotype 4 hepatitis c virus infection",Completed,4,0,0,Hepatitis C Viral Infection|Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 4,drug or biologic,Early,16,All,Industry&Combos,1,0,0,2015,2015,427,1,Phase 2,2,NA,2,2.772588722239781,"(2,3]"
3500,5307,sulfasalazine for the treatment of primary sclerosing cholangitis,Recruiting,2,0,0,Primary Sclerosing Cholangitis,drug or biologic,Early,42,All,AllOther,NA,0,0,2018,2018,731,NA,Phase 2,2,NA,2,3.7376696182833684,"(3,4]"
2932,3933,evaluation of the efficacy and safety of lubiprostone in adults with mixed or unsubtyped irritable bowel syndrome,Terminated,5,1,1,Irritable Bowel Syndrome,drug or biologic,Early,71,All,Industry&Combos,1,0,0,2015,2015,669,1,Phase 2,2,safety/efficacy,2,4.2626798770413155,"(4,5]"
1272,1358,nintedanib alone or in combination with capecitabine in refractory metastatic colorectal cancer [lume-colon 2],Terminated,5,1,1,Colorectal Neoplasms,drug or biologic,Early,1,All,Industry&Combos,1,0,0,2016,2016,66,1,Phase 2,0,NA,0,0,NA
3834,6866,study of efficacy and safety inc280 in patients with advanced hepatocellular carcinoma,Withdrawn,7,0,0,Advanced Hepatocellular Carcinoma,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2013,2016,942,1,Phase 2,4,safety/efficacy,2,NA,NA
1536,1669,niraparib in patients with pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,32,All,Industry&Combos,0,NA,0,2018,2018,1286,0,Phase 2,1,NA,1,3.4657359027997265,"(3,4]"
3078,4151,effects of the probiotic visbiome extra strength on gut microbiome & immune activation markers,Completed,4,1,1,HIV-1 Infection,drug or biologic,Early,93,All,NIH&Combos,1,0,0,2016,2016,430,1,Phase 2,2,NA,2,4.532599493153256,"(4,5]"
2264,2807,enhanced recovery in acute pancreatitis,Completed,4,0,0,Acute Pancreatitis,other,Others,46,All,AllOther,1,0,4,2016,2016,348,1,Others,1,NA,1,3.828641396489095,"(3,4]"
3741,6295,"efficacy, safety and tolerability of ag013 in oral mucositis compared to placebo when administered three times per day",Terminated,5,1,1,Oral Mucositis,drug or biologic,Early,200,All,Industry&Combos,1,0,0,2017,2017,987,1,Phase 2,4,safety/efficacy,2,5.298317366548036,"(5,6]"
915,961,clinical trial to evaluate efficacy of gr-md-02 for treatment of liver fibrosis in patients with nash with advanced fibrosis,Completed,4,1,1,Nonalcoholic Steatohepatitis,drug or biologic,Early,30,All,Industry&Combos,1,0,0,2015,2015,392,1,Phase 2,4,efficacy,2,3.4011973816621555,"(3,4]"
3801,6695,"a phase 2 randomized, open-label study of rrx-001 vs regorafenib in subjects with metastatic colorectal cancer","Active, not recruiting",1,0,0,Colorectal Neoplasms,drug or biologic,Early,57,All,Industry&Combos,1,0,0,2014,2014,2406,1,Phase 2,0,NA,0,4.04305126783455,"(4,5]"
737,771,regorafenib plus gemcitabine in metastatic pancreatic cancer,Terminated,5,1,1,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,2,All,NIH&Combos,0,NA,0,2015,2016,444,0,Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
2647,3552,"icarus post-operative intraperitoneal chemotherapy (epic) and hyperthermic intraperitoneal chemotherapy (hipec) after optimal cytoreductive surgery (crs) for neoplasms of the appendix, colon or rectum with isolated peritoneal metastasis",Recruiting,2,0,0,Appendix Cancer|Colorectal Cancer,drug or biologic,Early,282,All,AllOther,0,0,0,2013,2013,3471,0,Phase 2,1,NA,1,5.641907070938114,"(5,6]"
163,163,efficacy of doxycycline on metakaryote cell death in patients with resectable pancreatic cancer,"Active, not recruiting",1,0,0,Resectable Pancreatic Cancer,drug or biologic,Early,12,All,AllOther,0,NA,0,2016,2017,1824,0,Phase 2,1,efficacy,1,2.4849066497880004,"(2,3]"
3873,7131,safety and efficacy of gs-4774 in combination with tenofovir disoproxil fumarate (tdf) for the treatment of participants with chronic hepatitis b (chb) and who are currently not on treatment,Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Early,195,All,Industry&Combos,1,0,0,2014,2014,573,1,Phase 2,0,safety/efficacy,0,5.272999558563747,"(5,6]"
4034,7620,trial of iw-9179 in patients with diabetic gastroparesis (dgp),Completed,4,0,0,Diabetic Gastroparesis,drug or biologic,Early,90,All,Industry&Combos,1,0,0,2014,2014,426,1,Phase 2,4,NA,2,4.499809670330265,"(4,5]"
4004,7566,"safety, tolerability and efficacy of sofosbuvir, velpatasvir, and voxilaprevir in subjects with previous daa experience",Completed,4,1,1,Chronic Hepatitis C,drug or biologic,Early,77,All,Industry&Combos,0,NA,0,2016,2016,906,0,Phase 2,1,safety/efficacy,1,4.343805421853684,"(4,5]"
1456,1567,"a phase ii trial of the dna methyl transferase inhibitor, guadecitabine (sgi-110), in children and adults with wild type gist,pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and hlrcc-associated kidney cancer",Terminated,5,1,1,"Paraganglioma|Gastrointestinal Stromal Tumors|Carcinoma, Renal Cell|Renal Neoplasms|Pheochromocytoma",drug or biologic,Early,9,All,NIH&Combos,1,1,0,2017,2017,922,1,Phase 2,0,NA,0,2.1972245773362196,"(2,3]"
2655,3561,a study of ramucirumab (ly3009806) in combination with paclitaxel in participants with gastric cancer,Completed,4,1,1,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,245,All,Industry&Combos,1,0,0,2015,2015,746,1,Phase 2,0,NA,0,5.501258210544727,"(5,6]"
4097,8099,glecaprevir/pibrentasvir fixed-dose combination treatment for acute hepatitis c virus infection,"Active, not recruiting",1,0,0,Hepatitis C Infection|HIV Infection,drug or biologic,Early,50,All,IndustryNIHPartnership,0,NA,0,2019,2019,897,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
2670,3580,"cisplatin, carboplatin and etoposide or temozolomide and capecitabine in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that is metastatic or cannot be removed by surgery",Recruiting,2,0,0,Gastric Neuroendocrine Carcinoma|Intestinal Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Carcinoma,drug or biologic,Early,126,All,NIH&Combos,1,0,0,2015,2015,2978,1,Phase 2,0,NA,0,4.836281906951478,"(4,5]"
122,122,tumor subtypes in subjects on folfirinox with non-metastatic pancreatic cancer,Recruiting,2,0,0,"Pancreatic Ductal Adenocarcinoma (PDAC)|Cancer of Pancreas|Pancreatic Cancer, Adult|Pancreas Adenocarcinoma|Pancreatic Neoplasms|Pancreatic Cancer Non-resectable|Pancreatic Cancer Resectable",drug or biologic,Early,45,All,AllOther,0,NA,0,2019,2019,1268,0,Phase 2,1,NA,1,3.8066624897703196,"(3,4]"
2926,3927,"dosimetry-guided, peptide receptor radiotherapy (prrt) with 90y-dota- tyr3-octreotide (90y-dotatoc)",Unknown status,8,0,0,Neuroendocrine Tumors|Meningioma|Neuroblastoma|Medulloblastoma,drug or biologic,Early,46,All,NIH&Combos,0,NA,0,2017,2017,824,0,Phase 2,1,NA,1,3.828641396489095,"(3,4]"
288,293,rifaximin on visceral hypersensitivity,Recruiting,2,0,0,Visceral Hypersensitivity|Irritable Bowel Syndrome,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2018,2018,1096,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
1125,1195,fatty liver disease in obese children,"Active, not recruiting",1,0,0,Obesity|Nonalcoholic Fatty Liver Disease|Cardiovascular Disease,other,Others,14,All,AllOther,1,0,0,2014,2015,1096,1,Others,4,NA,2,2.6390573296152584,"(2,3]"
3479,5282,pegfilgrastim in patients with alcoholic hepatitis,Recruiting,2,0,0,Alcoholic Hepatitis,drug or biologic,Early,78,All,NIH&Combos,1,0,0,2016,2017,1257,1,Phase 2,0,NA,0,4.356708826689592,"(4,5]"
458,473,milk patch for eosinophilic esophagitis,Completed,4,1,1,Eosinophilic Esophagitis|Milk Allergy,drug or biologic,Early,20,All,Industry&Combos,1,0,0,2015,2015,811,1,Phase 2,4,NA,2,2.995732273553991,"(2,3]"
1972,2321,prevention of recurrence of crohn's disease by fecal microbiota therapy (fmt),Terminated,5,0,0,Crohn's Disease,drug or biologic,Early,30,All,AllOther,1,0,4,2015,2015,1983,1,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
3747,6342,safety and efficacy of sofosbuvir + velpatasvir with or without ribavirin in treatment-naive adults with chronic hcv infection,Completed,4,1,1,Hepatitis C,drug or biologic,Early,379,All,Industry&Combos,1,0,0,2013,2013,395,1,Phase 2,0,safety/efficacy,0,5.937536205082426,"(5,6]"
2951,3957,an extension study to evaluate the long-term safety and tolerability of uttr1147a in participants with moderate to severe ulcerative colitis or crohn's disease,Recruiting,2,0,0,Ulcerative Colitis|Crohn's Disease,drug or biologic,Early,320,All,Industry&Combos,0,NA,0,2018,2019,2234,0,Phase 2,1,safety,1,5.768320995793772,"(5,6]"
1664,1833,efficacy and safety of cannabidiol for gastroparesis and functional dyspepsia,Recruiting,2,0,0,Gastroparesis|Dyspepsia,drug or biologic,Early,96,All,AllOther,1,0,0,2019,2019,1732,1,Phase 2,2,safety/efficacy,2,4.564348191467836,"(4,5]"
3719,6217,a trial of a botanical drug containing east indian sandalwood oil (eiso) for the treatment of oral mucositis,Completed,4,0,0,Oral Mucositis,drug or biologic,Early,7,All,Industry&Combos,0,NA,1,2015,2015,594,0,Phase 2,1,NA,1,1.9459101490553132,"(1,2]"
4072,7848,efficacy and safety study of wtx101 (alxn1840) in adult wilson disease patients,Completed,4,0,0,Wilson Disease,drug or biologic,Early,28,All,Industry&Combos,0,NA,0,2014,2014,703,0,Phase 2,1,safety/efficacy,1,3.332204510175204,"(3,4]"
1195,1272,a phase ii study of minocycline and armodafinil for reducing the symptom burden produced by chemoradiation treatment for esophageal cancer,Completed,4,1,1,Esophageal Cancer,drug or biologic,Early,22,All,NIH&Combos,1,0,0,2012,2013,1430,1,Phase 2,2,NA,2,3.091042453358316,"(3,4]"
2717,3642,a study of regorafenib in advanced pancreatic cancer patients,Completed,4,1,1,Pancreatic Cancer,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2014,2014,1118,0,Phase 2,1,NA,1,2.995732273553991,"(2,3]"
4158,9131,a study to evaluate treatment of hepatitis c virus infection in pediatric subjects,Completed,4,0,0,Chronic Hepatitis C Infection,drug or biologic,Early,64,All,Industry&Combos,1,1,0,2015,2015,1849,1,Phase 2,0,NA,0,4.1588830833596715,"(4,5]"
1541,1678,"autologous tumor infiltrating lymphocytes mda-til in treating patients with recurrent or refractory ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma","Active, not recruiting",1,0,0,Malignant Solid Neoplasm|Metastatic Colorectal Adenocarcinoma|Metastatic Ovarian Carcinoma|Metastatic Pancreatic Ductal Adenocarcinoma|Platinum-Resistant Ovarian Carcinoma|Recurrent High Grade Ovarian Serous Adenocarcinoma|Recurrent Ovarian Carcinosarcoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,drug or biologic,Early,27,All,IndustryNIHPartnership,0,NA,0,2018,2018,1140,0,Phase 2,1,NA,1,3.295836866004329,"(3,4]"
607,633,proton therapy in reducing toxicity in anal cancer,"Active, not recruiting",1,0,0,Anus Neoplasms,drug or biologic,Early,14,All,AllOther,0,NA,0,2017,2017,1974,0,Phase 2,1,NA,1,2.6390573296152584,"(2,3]"
3012,4044,a phase ii study in patients with moderate to severe active ulcerative colitis.,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,164,All,Industry&Combos,1,0,0,2018,2019,597,1,Phase 2,2,NA,2,5.099866427824199,"(5,6]"
3944,7356,s1406 phase ii study of irinotecan and cetuximab with or without vemurafenib in braf mutant metastatic colorectal cancer,Completed,4,1,1,Colorectal Cancer,drug or biologic,Early,106,All,IndustryNIHPartnership,3,0,0,2014,2014,1108,3,Phase 2,0,NA,0,4.663439094112067,"(4,5]"
1358,1452,tas-102 and oxaliplatin for the treatment of refractory stage iv colon cancer,Recruiting,2,0,0,Metastatic Colorectal Carcinoma|Recurrent Colon Carcinoma|Refractory Colorectal Carcinoma|Stage IV Colon Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7,drug or biologic,Early,50,All,NIH&Combos,0,NA,0,2020,2019,1053,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
2692,3610,"a study to assess the safety, tolerability, pharmacokinetics and efficacy of edp-305 in subjects with primary biliary cholangitis",Completed,4,1,1,Primary Biliary Cholangitis,drug or biologic,Early,68,All,Industry&Combos,1,0,0,2018,2017,722,1,Phase 2,3,safety/efficacy,2,4.219507705176107,"(4,5]"
3531,5386,standard of care alone or in combination with ad-cea vaccine and avelumab in people with previously untreated metastatic colorectal cancer quilt-2.004,"Active, not recruiting",1,0,0,Colorectal Tumors|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Adenocarcinoma|Colorectal Cancer,drug or biologic,Early,30,All,NIH&Combos,NA,0,0,2017,2017,1944,NA,Phase 2,0,NA,0,3.4011973816621555,"(3,4]"
2830,3792,study to evaluate the efficacy and safety of elafibranor in patients with primary biliary cholangitis (pbc) and inadequate response to ursodeoxycholic acid,Completed,4,1,1,Primary Biliary Cholangitis (PBC),drug or biologic,Early,45,All,Industry&Combos,1,0,0,2017,2017,574,1,Phase 2,4,safety/efficacy,2,3.8066624897703196,"(3,4]"
1646,1810,use of a squatting assist device in patients with constipation,Recruiting,2,0,0,Constipation,device,Others,85,Female,AllOther,1,0,0,2016,2016,2676,1,Others,1,NA,1,4.442651256490317,"(4,5]"
3928,7318,tucatinib plus trastuzumab in patients with her2+ colorectal cancer,Recruiting,2,0,0,Metastatic Colorectal Adenocarcinoma,drug or biologic,Early,115,All,IndustryNIHPartnership,1,0,0,2017,2017,1803,1,Phase 2,0,NA,0,4.74493212836325,"(4,5]"
3268,4603,a study of the use of the medtronic pump and codman catheter to give chemotherapy to patients with colorectal carcinoma or cholangiocarcinoma,"Active, not recruiting",1,0,0,Colorectal Cancer|Cholangiocarcinoma,drug or biologic,Early,35,All,AllOther,0,NA,0,2018,2018,1414,0,Phase 2,1,NA,1,3.5553480614894135,"(3,4]"
2190,2663,gluten free diet in diminishing side effects patients with acute myeloid leukemia undergoing induction chemotherapy,Terminated,5,0,0,Acute Myeloid Leukemia,procedure,Others,1,All,NIH&Combos,1,0,4,2017,2017,110,1,Others,0,NA,0,0,NA
1021,1076,rifamycin in minimal hepatic encephalopathy,Recruiting,2,0,0,"Hepatic Encephalopathy|Cirrhosis, Liver",drug or biologic,Early,40,All,AllOther,1,0,0,2019,2019,745,1,Phase 2,4,NA,2,3.6888794541139363,"(3,4]"
1348,1440,flu vaccine response in patients on biologic therapies,Recruiting,2,0,0,Rheumatologic Disorder|Inflammatory Bowel Diseases|Immune Complex Diseases,drug or biologic,Early,54,All,AllOther,1,0,1,2017,2017,880,1,Phase 2,0,NA,0,3.9889840465642745,"(3,4]"
2805,3763,"gemcitabine, cisplatin, and nab-paclitaxel before surgery in patients with high-risk liver bile duct cancer",Recruiting,2,0,0,Resectable Cholangiocarcinoma|Stage IB Intrahepatic Cholangiocarcinoma AJCC v8|Stage II Intrahepatic Cholangiocarcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8,drug or biologic,Early,34,All,Industry&Combos,0,NA,0,2018,2018,1100,0,Phase 2,1,NA,1,3.5263605246161616,"(3,4]"
1963,2309,blood lipopolysaccharide (lps) rifaximin study,Completed,4,1,1,Obese|Insulin Resistance|Metabolic Syndrome,drug or biologic,Early,12,All,NIH&Combos,1,0,0,2014,2015,1552,1,Phase 2,2,NA,2,2.4849066497880004,"(2,3]"
3025,4063,an extension study to evaluate the long-term safety and durability of effect of lum001 in the treatment of cholestatic liver disease in pediatric subjects with alagille syndrome,Completed,4,1,1,Alagille Syndrome,drug or biologic,Early,34,All,Industry&Combos,0,NA,0,2014,2015,1904,0,Phase 2,1,safety,1,3.5263605246161616,"(3,4]"
3862,7076,"safety, tolerability and efficacy of 12-weeks of sovaprevir, ach-3102 and ribavirin in treatment-naive gt-1 hcv subjects",Completed,4,1,1,"Hepatitis C, Chronic",drug or biologic,Early,30,All,Industry&Combos,1,0,0,2013,2013,214,1,Phase 2,3,safety/efficacy,2,3.4011973816621555,"(3,4]"
2947,3953,"derazantinib in subjects with fgfr2 gene fusion-, mutation- or amplification- positive inoperable or advanced intrahepatic cholangiocarcinoma",Recruiting,2,0,0,Intrahepatic Cholangiocarcinoma|Combined Hepatocellular and Cholangiocarcinoma,drug or biologic,Early,143,All,Industry&Combos,0,NA,0,2017,2017,1421,0,Phase 2,1,NA,1,4.962844630259907,"(4,5]"
3925,7313,study of binimetinib + nivolumab plus or minus ipilimumab in patients with previously treated microsatellite-stable (mss) metastatic colorectal cancer with ras mutation,Completed,4,0,0,MSS|RAS-mutant Colorectal Cancer,drug or biologic,Early,77,All,Industry&Combos,1,1,0,2017,2017,1091,1,Phase 2,0,NA,0,4.343805421853684,"(4,5]"
2955,3962,"an investigational immuno-therapy study of nivolumab, and nivolumab in combination with other anti-cancer drugs, in colon cancer that has come back or has spread","Active, not recruiting",1,0,0,Microsatellite Unstable Colorectal Cancer|Microsatellite Stable Colorectal Cancer|Mismatch Repair Proficient Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer,drug or biologic,Early,340,All,Industry&Combos,1,1,0,2014,2014,3043,1,Phase 2,0,NA,0,5.8289456176102075,"(5,6]"
3267,4600,a study of idn-6556 in subjects with nafld and raised transaminases,Completed,4,1,1,Nonalcoholic Steatohepatitis|Non-alcoholic Fatty Liver Disease,drug or biologic,Early,38,All,Industry&Combos,1,0,0,2014,2014,365,1,Phase 2,2,NA,2,3.6375861597263857,"(3,4]"
2543,3417,erlotinib hydrochloride in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer,"Active, not recruiting",1,0,0,Attenuated Familial Adenomatous Polyposis|Familial Adenomatous Polyposis,drug or biologic,Early,46,All,NIH&Combos,0,NA,1,2016,2017,849,0,Phase 2,1,NA,1,3.828641396489095,"(3,4]"
2920,3915,gsk2982772 study in subjects with ulcerative colitis,Completed,4,1,1,"Colitis, Ulcerative",drug or biologic,Early,36,All,Industry&Combos,1,0,0,2016,2016,944,1,Phase 2,2,NA,2,3.58351893845611,"(3,4]"
2846,3817,a study evaluating the efficacy and safety of st-0529 in subjects with moderately to severely active ulcerative colitis,Terminated,5,0,0,"Colitis, Ulcerative",drug or biologic,Early,235,All,Industry&Combos,1,0,0,2019,2019,811,1,Phase 2,3,safety/efficacy,2,5.459585514144159,"(5,6]"
3080,4156,efficacy and safety trial of rpc1063 for moderate to severe crohn's disease,Completed,4,1,1,Crohn's Disease,drug or biologic,Early,69,All,Industry&Combos,0,NA,0,2015,2015,1434,0,Phase 2,1,safety/efficacy,1,4.23410650459726,"(4,5]"
1451,1561,tas-102 in treating advanced biliary tract cancers,"Active, not recruiting",1,1,1,Cholangiocarcinoma|Stage III Gallbladder Cancer AJCC v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IV Gallbladder Cancer AJCC v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVB Gallbladder Cancer AJCC v7,drug or biologic,Early,28,All,NIH&Combos,0,NA,0,2017,2017,406,0,Phase 2,1,NA,1,3.332204510175204,"(3,4]"
1153,1225,ponatinib hydrochloride in treating patients with advanced biliary cancer with fgfr2 fusions,Completed,4,1,1,Malignant Hepatobiliary Neoplasm,drug or biologic,Early,12,All,NIH&Combos,0,NA,0,2014,2014,1247,0,Phase 2,1,NA,1,2.4849066497880004,"(2,3]"
1948,2283,"combination of nivolumab and ipilimumab in breast, ovarian and gastric cancer patients",Terminated,5,0,0,Breast Cancer Female|Ovarian Cancer|Gastric Cancer,drug or biologic,Early,5,All,Industry&Combos,0,1,0,2017,2018,469,0,Phase 2,1,NA,1,1.6094379124341003,"(1,2]"
3778,6547,study of motilitone to treat functional dyspepsia,Completed,4,0,0,Dyspepsia,drug or biologic,Early,45,All,Industry&Combos,1,0,0,2015,2015,976,1,Phase 2,4,NA,2,3.8066624897703196,"(3,4]"
3599,5658,study to evaluate the efficacy and safety of oral pf-06651600 and pf-06700841 in subjects with moderate to severe crohn's disease,Recruiting,2,0,0,Crohn's Disease,drug or biologic,Early,250,All,Industry&Combos,1,0,0,2018,2018,1762,1,Phase 2,4,safety/efficacy,2,5.521460917862246,"(5,6]"
4019,7600,"phase 2b study of bms-986094 and daclatasvir, with or without ribavirin for the treatment of patients with chronic hepatitis c",Withdrawn,7,0,0,Hepatitis C Virus,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2012,2013,337,1,Phase 2,4,NA,2,NA,NA
1815,2051,"treatment of chronic delta hepatitis with lonafarnib, ritonavir and lambda interferon",Completed,4,0,0,Liver Disease|Hepatitis D,drug or biologic,Early,31,All,NIH&Combos,0,NA,0,2018,2018,831,0,Phase 2,1,NA,1,3.4339872044851463,"(3,4]"
687,718,folfox +/- ziv-aflibercept for esophageal and gastric cancer,Completed,4,1,1,Esophageal Cancer|Gastric Cancer,drug or biologic,Early,64,All,AllOther,1,0,0,2012,2013,1428,1,Phase 2,2,NA,2,4.1588830833596715,"(4,5]"
2194,2669,"sorafenib and nivolumab in treating participants with unresectable, locally advanced or metastatic liver cancer","Active, not recruiting",1,0,0,Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8,drug or biologic,Early,12,All,Industry&Combos,NA,1,0,2018,2018,1628,NA,Phase 2,0,NA,0,2.4849066497880004,"(2,3]"
3880,7153,ctla-4 /pd-l1 blockade following transarterial chemoembolization (deb-tace) in patients with intermediate stage of hcc (hepatocellular carcinoma) using durvalumab and tremelimumab,Recruiting,2,0,0,Intermediate Stage of Hepatocellular Carcinoma|Hepatocellular Carcinoma,drug or biologic,Early,30,All,Industry&Combos,1,1,0,2018,2019,1491,1,Phase 2,0,NA,0,3.4011973816621555,"(3,4]"
3957,7382,durvalumab and tremelimumab with or without high or low-dose radiation therapy in treating patients with metastatic colorectal or non-small cell lung cancer,"Active, not recruiting",1,0,0,Metastatic Colorectal Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,180,All,NIH&Combos,1,0,0,2016,2017,1669,1,Phase 2,0,NA,0,5.19295685089021,"(5,6]"
560,583,"pegph20 plus gemcitabine with radiotherapy in patients with localized, unresectable pancreatic cancer",Terminated,5,0,0,Pancreatic Adenocarcinoma Non-resectable,drug or biologic,Early,4,All,AllOther,0,NA,0,2016,2017,605,0,Phase 2,1,NA,1,1.3862943611198906,"(1,2]"
1484,1604,molecular phenotyping in predicting response in patients with stage ib-iii esophageal cancer receiving combination chemotherapy,Terminated,5,1,1,Stage IB Esophageal Adenocarcinoma|Stage IIA Esophageal Adenocarcinoma|Stage IIB Esophageal Adenocarcinoma|Stage IIIA Esophageal Adenocarcinoma|Stage IIIB Esophageal Adenocarcinoma|Stage IIIC Esophageal Adenocarcinoma,drug or biologic,Early,1,All,NIH&Combos,1,0,0,2015,2015,303,1,Phase 2,0,NA,0,0,NA
973,1026,randomized phase ii trial of pre-operative gemcitabine and nab paclitacel with or with out hydroxychloroquine,Completed,4,1,1,Pancreatic Cancer,drug or biologic,Early,104,All,AllOther,1,0,0,2013,2013,1558,1,Phase 2,0,NA,0,4.6443908991413725,"(4,5]"
3118,4231,"a study of rucaparib in patients with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (ariel2)","Active, not recruiting",1,0,0,Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,drug or biologic,Early,493,Female,Industry&Combos,0,NA,0,2013,2013,2197,0,Phase 2,1,NA,1,6.20050917404269,"(6,7]"
1623,1780,an open-label trial of losartan potassium in participants with eosinophilic esophagitis (eoe),Completed,4,1,1,Eosinophilic Esophagitis,drug or biologic,Early,15,All,NIH&Combos,1,1,0,2017,2017,790,1,Phase 2,0,NA,0,2.70805020110221,"(2,3]"
3788,6632,phase 2 study of ve303 for prevention of recurrent clostridium difficile infection,"Active, not recruiting",1,0,0,Clostridium Difficile Infection Recurrence|Clostridium Difficile Infection|Clostridium Difficile|CDI,drug or biologic,Early,146,All,Industry&Combos,1,0,1,2018,2019,844,1,Phase 2,4,NA,2,4.983606621708336,"(4,5]"
3946,7358,a study comparing the efficacy and safety of vanucizumab and folfox with bevacizumab and folfox in participants with untreated metastatic colorectal cancer,Terminated,5,1,1,Colorectal Cancer,drug or biologic,Early,197,All,Industry&Combos,1,0,0,2014,2014,760,1,Phase 2,2,safety/efficacy,2,5.2832037287379885,"(5,6]"
3388,5036,"a study to evaluate the safety, pharmacokinetics (pk) and pharmacodynamics (pd) for tak-906 in participants with diabetes mellitus and gastroparesis (dg) or with idiopathic gastroparesis (ig)",Completed,4,1,1,"Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis",drug or biologic,Early,51,All,Industry&Combos,1,0,4,2017,2017,164,1,Phase 2,3,safety,2,3.9318256327243257,"(3,4]"
3351,4876,dose-ranging study to assess safety and efficacy of sp-333 for the treatment of opioid-induced constipation (oic),Completed,4,0,0,Constipation,drug or biologic,Early,292,All,Industry&Combos,1,0,0,2013,2013,304,1,Phase 2,4,safety/efficacy,2,5.676753802268282,"(5,6]"
2630,3532,study to evaluate the efficacy and safety of vibegron administered orally for 12 weeks to women with irritable bowel syndrome,Completed,4,0,0,Irritable Bowel Syndrome,drug or biologic,Early,222,Female,Industry&Combos,1,0,0,2019,2018,634,1,Phase 2,3,safety/efficacy,2,5.402677381872279,"(5,6]"
209,212,1911gccc: galeterone or galeterone with gemcitabine for patients with metastatic pancreatic adenocarcinoma,Recruiting,2,0,0,Advanced Pancreatic Cancer,drug or biologic,Early,58,All,AllOther,1,0,0,2019,2019,1115,1,Phase 2,0,NA,0,4.060443010546419,"(4,5]"
2526,3380,autologous transplant targeted against crohn's,Withdrawn,7,0,0,Crohn's Disease,drug or biologic,Early,NA,All,AllOther,0,NA,0,2019,2019,1216,0,Phase 2,1,NA,1,NA,NA
2743,3678,a trial for new treatment of adult patients with irritable bowel syndrome,Completed,4,0,0,Irritable Bowel Syndrome,drug or biologic,Early,299,All,Industry&Combos,1,0,0,2018,2018,556,1,Phase 2,2,NA,2,5.700443573390687,"(5,6]"
4160,9135,study to evaluate safety and efficacy of vesatolimod for the treatment of chronic hepatitis b virus in virally-suppressed participants,Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Early,162,All,Industry&Combos,NA,0,0,2014,2014,681,NA,Phase 2,2,safety/efficacy,2,5.087596335232384,"(5,6]"
3359,4905,different doses of bi 1467335 compared to placebo in patients with clinical evidence of nash,Completed,4,1,1,Non-alcoholic Fatty Liver Disease,drug or biologic,Early,114,All,Industry&Combos,1,0,0,2017,2017,738,1,Phase 2,2,NA,2,4.736198448394496,"(4,5]"
2795,3752,study to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea in children.,Recruiting,2,0,0,Irritable Bowel Syndrome,drug or biologic,Early,120,All,Industry&Combos,1,0,0,2017,2017,1873,1,Phase 2,3,NA,2,4.787491742782046,"(4,5]"
3261,4586,safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination with or without ribavirin in participants with chronic genotype 1 hcv infection previously treated with a direct acting antiviral regimen,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,49,All,Industry&Combos,1,0,0,2015,2015,243,1,Phase 2,0,safety/efficacy,0,3.8918202981106265,"(3,4]"
678,709,pre-operative treatment for patients with untreated pancreatic cancer,"Active, not recruiting",1,0,0,Resectable Pancreatic Cancer|Unresectable Pancreatic Cancer|Pancreatic Adenocarcinoma|Neoadjuvant Pancreatic Cancer,drug or biologic,Early,24,All,AllOther,0,NA,0,2017,2017,1683,0,Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
784,821,study of gvax (with cy) and pembrolizumab in mmr-p advanced colorectal cancer,Completed,4,1,1,Metastatic Colorectal Cancer,drug or biologic,Early,17,All,Industry&Combos,0,NA,0,2016,2017,298,0,Phase 2,1,NA,1,2.833213344056216,"(2,3]"
2993,4011,pembrolizumab in treating patients with small bowel adenocarcinoma that is metastatic or locally advanced and cannot be removed by surgery,"Active, not recruiting",1,1,1,Metastatic Small Intestinal Adenocarcinoma|Recurrent Small Intestinal Carcinoma|Unresectable Small Intestinal Carcinoma,drug or biologic,Early,41,All,NIH&Combos,0,NA,0,2016,2017,678,0,Phase 2,1,NA,1,3.713572066704308,"(3,4]"
2858,3832,"a study to assess the antitumor activity, safety, pharmacokinetics and biomarkers of zolbetuximab (imab362) in participants with claudin (cldn) 18.2 positive, metastatic or advanced unresectable gastric and gastroesophageal junction (gej) adenocarcinoma","Active, not recruiting",1,0,0,Pharmacokinetics of Zolbetuximab|Gastric Cancer|Gastro-esophageal Junction (GEJ) Cancer|Pharmacokinetics of Oxaliplatin|Pharmacokinetics of Fluorouracil Bolus (5-FU),drug or biologic,Early,112,All,Industry&Combos,1,1,0,2018,2018,1463,1,Phase 2,2,safety,2,4.718498871295094,"(4,5]"
136,136,heated intraperitoneal chemotherapy and gastrectomy for gastric cancer with positive peritoneal cytology,Recruiting,2,0,0,Gastric Adenocarcinoma|Esophagogastric Junction|Gastric Cancer,drug or biologic,Early,40,All,NIH&Combos,0,NA,0,2017,2017,3040,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3445,5236,a study of mirikizumab (ly3074828) in participants with active crohn's disease,Completed,4,0,0,Crohn's Disease,drug or biologic,Early,151,All,Industry&Combos,1,0,0,2016,2016,727,1,Phase 2,2,NA,2,5.017279836814924,"(5,6]"
2098,2506,international multicentre study in advanced anal cancer comparing cisplatin plus 5 fu vs carboplatin plus weekly paclitaxel,Unknown status,8,0,0,Squamous Cell Carcinoma of the Anus,drug or biologic,Early,80,All,AllOther,1,0,0,2014,2013,1339,1,Phase 2,0,NA,0,4.382026634673881,"(4,5]"
3417,5169,savolitinib in treating patients with met amplified metastatic or unresectable colorectal cancer,Recruiting,2,0,0,Colorectal Carcinoma|Metastatic Colon Adenocarcinoma|Metastatic Rectal Adenocarcinoma|Stage III Colon Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Rectal Cancer AJCC v8|Stage IIIB Colon Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Rectal Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Rectal Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Rectal Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Rectal Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Rectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Rectal Adenocarcinoma,drug or biologic,Early,15,All,NIH&Combos,0,NA,0,2018,2019,1097,0,Phase 2,1,NA,1,2.70805020110221,"(2,3]"
2327,2945,fmt versus antimicrobials for initial treatment of recurrent cdi,Unknown status,8,0,0,Clostridium Difficile Infection,drug or biologic,Early,60,All,AllOther,1,0,0,2014,2015,1704,1,Phase 2,0,NA,0,4.0943445622221,"(4,5]"
2458,3208,a su2c catalyst Â® trial of a pd1 inhibitor with or without a vitamin d analog for the maintenance of pancreatic cancer,Completed,4,0,0,Pancreatic Cancer|Pancreas Adenocarcinoma|Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,24,All,Industry&Combos,1,0,0,2017,2017,915,1,Phase 2,4,NA,2,3.1780538303479458,"(3,4]"
172,173,"pegph20, gemicitabine and nab-paclitaxel for pancreatic ductal adenocarcinoma",Terminated,5,1,1,Adenocarcinoma,drug or biologic,Early,3,All,AllOther,0,1,0,2015,2015,1039,0,Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
3585,5589,"a long term extension trial of bi 655066/abbv-066 (risankizumab), in patients with moderately to severely active crohn's disease",Completed,4,1,1,Crohn Disease,drug or biologic,Early,65,All,Industry&Combos,0,NA,0,2015,2015,1372,0,Phase 2,1,NA,1,4.174387269895637,"(4,5]"
3255,4578,safety and tolerability of vk2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease,Completed,4,0,0,Hyperlipidemia|NAFLD,drug or biologic,Early,59,All,Industry&Combos,1,0,0,2016,2016,909,1,Phase 2,3,safety,2,4.07753744390572,"(4,5]"
1359,1453,vedolizumab post op study,Withdrawn,7,0,0,Crohn's Disease,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2016,2018,151,1,Phase 2,3,NA,2,NA,NA
195,197,azacitidine and pembrolizumab in pancreatic cancer,Recruiting,2,0,0,Pancreas Cancer,drug or biologic,Early,31,All,AllOther,0,NA,0,2017,2017,1552,0,Phase 2,1,NA,1,3.4339872044851463,"(3,4]"
1626,1783,study of lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors who are undergoing liver-directed radioembolization with yttrium-90 microspheres,"Active, not recruiting",1,0,0,Neuroendocrine Tumors|Gastrointestinal Neoplasms|Carcinoid Tumors,drug or biologic,Early,6,All,Industry&Combos,0,NA,0,2016,2017,1496,0,Phase 2,1,NA,1,1.791759469228055,"(1,2]"
3073,4139,sorafenib + mfolfox for hepatocellular carcinoma,Completed,4,1,1,Hepatocellular Cancer,drug or biologic,Early,40,All,AllOther,0,NA,0,2013,2013,2007,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3196,4433,safety and efficacy of relamorelin administered to participants with vomiting symptoms and moderate to severe diabetic gastroparesis,Completed,4,1,1,Diabetes Mellitus|Diabetes Mellitus Complications|Gastroparesis,drug or biologic,Early,393,All,Industry&Combos,1,0,0,2015,2015,497,1,Phase 2,4,safety/efficacy,2,5.973809611869261,"(5,6]"
3524,5378,dabrafenib + trametinib + pdr001 in colorectal cancer,Unknown status,8,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,25,All,Industry&Combos,0,NA,0,2018,2018,868,0,Phase 2,1,NA,1,3.2188758248682006,"(3,4]"
3195,4432,saroglitazar magnesium 4 mg in the treatment of nafld in women with pcos (evidences vii),Recruiting,2,0,0,Non-alcoholic Fatty Liver Disease in Women With PCOS,drug or biologic,Early,90,Female,Industry&Combos,1,0,0,2018,2018,971,1,Phase 2,4,NA,2,4.499809670330265,"(4,5]"
3889,7172,randomized phase ii trial of chemoembolization and sorafenib,Withdrawn,7,0,0,Hepatocellular Carcinoma,drug or biologic,Early,NA,All,AllOther,1,0,0,2016,2016,1461,1,Phase 2,0,NA,0,NA,NA
3884,7160,hypoxic changes in hepatocellular carcinoma (hcc) following trans arterial chemo embolization and stereotactic radiation: fluorine18 (18f) fluoromisonidazole (fmiso) imaging,Terminated,5,1,1,Hepatocellular Carcinoma,drug or biologic,Early,3,All,AllOther,0,NA,2,2017,2017,1164,0,Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
2933,3934,a study of experimental medication bms-986036 in adults with nonalcoholic steatohepatitis (nash) and liver cirrhosis,"Active, not recruiting",1,0,0,Hepatic Cirrhosis|Liver Fibrosis|Nonalcoholic Fatty Liver Disease (NAFLD)|Nonalcoholic Steatohepatitis,drug or biologic,Early,152,All,Industry&Combos,1,0,0,2018,2018,867,1,Phase 2,4,NA,2,5.0238805208462765,"(5,6]"
2258,2800,second-line study of pegph20 and pembro for ha high metastatic pdac,Unknown status,8,0,0,Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer|Pancreatic Neoplasms,drug or biologic,Early,35,All,Industry&Combos,0,NA,0,2018,2019,519,0,Phase 2,1,NA,1,3.5553480614894135,"(3,4]"
2883,3868,atezolizumab with or without cobimetinib in treating patients with metastatic bile duct cancer that cannot be removed by surgery or gallbladder cancer,"Active, not recruiting",1,0,0,Gallbladder Carcinoma|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Unresectable Cholangiocarcinoma,drug or biologic,Early,76,All,NIH&Combos,1,0,0,2017,2017,1651,1,Phase 2,0,NA,0,4.330733340286331,"(4,5]"
3371,4971,"study to evaluate the safety and efficacy of selonsertib, firsocostat, cilofexor, and combinations in participants with bridging fibrosis or compensated cirrhosis due to nonalcoholic steatohepatitis (nash)",Completed,4,1,1,Nonalcoholic Steatohepatitis,drug or biologic,Early,395,All,Industry&Combos,1,0,0,2018,2018,588,1,Phase 2,2,safety/efficacy,2,5.978885764901122,"(5,6]"
668,696,use of a novel drug in people with non-alcoholic steatohepatitis (nash) or non-alcoholic fatty liver disease (nafld),Unknown status,8,0,0,Non-alcoholic Fatty Liver Disease (NAFLD)|Non-alcoholic Steatohepatitis (NASH),drug or biologic,Early,100,All,Industry&Combos,1,0,0,2015,2015,1491,1,Phase 2,3,NA,2,4.605170185988092,"(4,5]"
1759,1970,regulation of endogenous glucose production by central katp channels,Suspended,6,0,0,"Type 2 Diabetes Mellitus|Glucose Metabolism Disorders|Glucose, High Blood",drug or biologic,Early,45,All,NIH&Combos,3,0,4,2018,2018,1339,3,Phase 2,1,NA,1,3.8066624897703196,"(3,4]"
2493,3304,cabozantinib and nivolumab for carcinoid tumors,Recruiting,2,0,0,Carcinoid Tumor|Carcinoid Tumor of GI System|Neuroendocrine Tumors,drug or biologic,Early,35,All,Industry&Combos,0,NA,0,2019,2019,731,0,Phase 2,1,NA,1,3.5553480614894135,"(3,4]"
2367,3023,optimizing immunosuppression drug dosing via phenotypic precision medicine,"Active, not recruiting",1,0,0,Liver Transplant|Kidney Transplant,drug or biologic,Early,64,All,NIH&Combos,1,0,4,2018,2018,620,1,Phase 2,1,NA,1,4.1588830833596715,"(4,5]"
3669,5853,study of sgm-1019 in patients with nonalcoholic steatohepatitis (nash),Terminated,5,0,0,Nonalcoholic Steatohepatitis,drug or biologic,Early,9,All,Industry&Combos,1,0,0,2018,2019,103,1,Phase 2,4,NA,2,2.1972245773362196,"(2,3]"
2810,3769,phase 2 dose-finding imu-838 for ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Early,240,All,Industry&Combos,1,0,0,2017,2018,1578,1,Phase 2,3,NA,2,5.480638923341991,"(5,6]"
1732,1925,tsr-022 (anti-tim-3 antibody) and tsr-042 (anti-pd-1 antibody) in patients with liver cancer,Recruiting,2,0,0,Adult Primary Liver Cancer|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer,drug or biologic,Early,42,All,Industry&Combos,0,NA,0,2018,2019,1062,0,Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
16,16,use of pancreatic enzymes in short bowel syndrome,Completed,4,1,1,Short Bowel Syndrome,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2017,2017,679,0,Phase 2,1,NA,1,2.772588722239781,"(2,3]"
2731,3659,phase ii trial of gemcitabine plus nab-paclitaxel +/- ogx-427 in patients with metastatic pancreatic cancer,Completed,4,1,1,Pancreatic Cancer,drug or biologic,Early,132,All,Industry&Combos,1,0,0,2013,2013,912,1,Phase 2,4,NA,2,4.882801922586371,"(4,5]"
1829,2083,a biomarker study in patients getting regorafenib for metastatic colorectal cancer,Terminated,5,1,1,Colon Cancer,drug or biologic,Early,10,All,Industry&Combos,0,NA,4,2015,2015,1004,0,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
44,44,ox bile- conjugated bile acids sodium in type ii diabetes mellitus,Completed,4,0,0,Type 2 Diabetes Mellitus|Obese|Overweight,drug or biologic,Early,24,All,AllOther,1,0,0,2016,2016,398,1,Phase 2,3,NA,2,3.1780538303479458,"(3,4]"
2005,2361,study of losartan in the treatment of nafld in children,Completed,4,1,1,"NAFLD",drug or biologic,Early,12,All,NIH&Combos,3,0,0,2013,2013,883,3,Phase 2,4,NA,2,2.4849066497880004,"(2,3]"
387,397,everolimus in patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery,Terminated,5,1,1,Gastrinoma|Glucagonoma|Insulinoma|Liver Metastases|Pancreatic Polypeptide Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma,drug or biologic,Early,2,All,NIH&Combos,1,0,0,2014,2014,1279,1,Phase 2,3,NA,2,0.6931471805599453,"(0,1]"
4169,9151,safety and efficacy of sofosbuvir + ribavirin in adolescents and children with genotype 2 or 3 chronic hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,106,All,Industry&Combos,1,1,0,2014,2014,1445,1,Phase 2,0,safety/efficacy,0,4.663439094112067,"(4,5]"
1178,1255,a study of the gut barrier and blood vessel inflammation in individuals with and without hiv,Completed,4,0,0,HIV,drug or biologic,Early,32,All,NIH&Combos,1,0,0,2015,2015,1512,1,Phase 2,4,NA,2,3.4657359027997265,"(3,4]"
3967,7452,"phase 2, randomized, double-blind, placebo-controlled of the efficacy and safety of cf102 in hepatocellular carcinoma (hcc)","Active, not recruiting",1,0,0,Hepatocellular Carcinoma,drug or biologic,Early,78,All,Industry&Combos,1,0,0,2014,2014,1887,1,Phase 2,3,safety/efficacy,2,4.356708826689592,"(4,5]"
2126,2549,kpt-330 to treat poorly differentiated lung and gastroenteropancreatic tumors,Completed,4,0,0,"Carcinoma, Neuroendocrine",drug or biologic,Early,14,All,Industry&Combos,0,NA,0,2014,2014,731,0,Phase 2,1,NA,1,2.6390573296152584,"(2,3]"
3097,4194,phase ii study of medi4736 monotherapy or in combinations with tremelimumab in metastatic pancreatic ductal carcinoma,Completed,4,1,1,Metastatic Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,65,All,Industry&Combos,1,0,0,2015,2015,577,1,Phase 2,0,NA,0,4.174387269895637,"(4,5]"
2807,3766,"study to evaluate safety, tolerability and efficacy of saroglitazar mg in patients with primary biliary cholangitis",Completed,4,0,0,Primary Biliary Cirrhosis,drug or biologic,Early,37,All,Industry&Combos,1,0,0,2017,2017,1085,1,Phase 2,3,safety/efficacy,2,3.6109179126442243,"(3,4]"
2835,3797,"study to compare oral pf-06651600, pf-06700841 and placebo in subjects with moderate to severe ulcerative colitis",Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,319,All,Industry&Combos,1,0,0,2016,2017,1557,1,Phase 2,2,NA,2,5.765191102784844,"(5,6]"
3732,6253,study of arc-520 in participants with hepatitis b virus e antigen (hbeag) positive chronic hepatitis b virus,Terminated,5,1,1,Chronic Hepatitis B,drug or biologic,Early,4,All,Industry&Combos,1,0,0,2015,2015,488,1,Phase 2,3,NA,2,1.3862943611198906,"(1,2]"
1182,1259,curcumin for pediatric nonalcoholic fatty liver disease,Recruiting,2,0,0,"NAFLD - Nonalcoholic Fatty Liver Disease|NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,30,All,Industry&Combos,1,0,0,2019,2019,323,1,Phase 2,3,NA,2,3.4011973816621555,"(3,4]"
2663,3572,"study to evaluate the efficacy, safety, and tolerability of bos-589 in the treatment of patients with diarrhea-predominant irritable bowel syndrome (ibs-d)",Completed,4,1,1,Diarrhea-predominant Irritable Bowel Syndrome,drug or biologic,Early,133,All,Industry&Combos,1,0,0,2019,2019,337,1,Phase 2,3,safety/efficacy,2,4.890349128221754,"(4,5]"
1798,2031,rucaparib in combination with nivolumab in patients with advanced or metastatic biliary tract cancer following platinum therapy,Recruiting,2,0,0,Biliary Tract Cancer,drug or biologic,Early,35,All,AllOther,0,NA,0,2018,2019,1010,0,Phase 2,1,NA,1,3.5553480614894135,"(3,4]"
2967,3980,evaluation of donor specific immune senescence and exhaustion as biomarkers of tolerance post liver transplantation,"Active, not recruiting",1,1,1,Liver Transplant|Liver Transplantation,drug or biologic,Early,100,All,IndustryNIHPartnership,0,NA,0,2015,2015,1518,0,Phase 2,1,NA,1,4.605170185988092,"(4,5]"
3250,4570,selinexor treatment of advanced relapsed/refractory squamous cell carcinomas,Terminated,5,1,1,Squamous Cell Carcinoma,drug or biologic,Early,45,All,Industry&Combos,1,1,0,2014,2014,444,1,Phase 2,0,NA,0,3.8066624897703196,"(3,4]"
3495,5299,"a study to evaluate opti-biomeÃ¢âÂ¢ bacillus subtilis mb40 on abdominal discomfort, gas and bloating in a healthy population",Unknown status,8,0,0,Bloating,other,Others,100,All,Industry&Combos,1,0,NA,2016,2016,151,1,Others,4,NA,2,4.605170185988092,"(4,5]"
1517,1647,"abemaciclib in treating patients with advanced, refractory, and unresectable digestive system neuroendocrine tumors",Recruiting,2,0,0,Advanced Digestive System Neuroendocrine Neoplasm|Digestive System Neuroendocrine Tumor|Foregut Carcinoid Tumor|Hindgut Carcinoid Tumor|Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm|Metastatic Digestive System Neuroendocrine Neoplasm|Midgut Neuroendocrine Tumor G1|Pancreatic Neuroendocrine Tumor|Refractory Digestive System Neuroendocrine Neoplasm,drug or biologic,Early,37,All,IndustryNIHPartnership,0,NA,0,2019,2019,1430,0,Phase 2,1,NA,1,3.6109179126442243,"(3,4]"
3771,6524,topical capsaicin for cyclical vomiting,Completed,4,0,0,Cyclical Vomiting,drug or biologic,Early,30,All,AllOther,1,0,0,2017,2017,593,1,Phase 2,4,NA,2,3.4011973816621555,"(3,4]"
3639,5762,pazopanib hydrochloride in treating patients with progressive carcinoid tumors,"Active, not recruiting",1,1,1,Atypical Carcinoid Tumor|Foregut Carcinoid Tumor|Hindgut Carcinoid Tumor|Metastatic Carcinoid Tumor|Metastatic Digestive System Neuroendocrine Tumor G1|Midgut Neuroendocrine Tumor G1|Recurrent Digestive System Neuroendocrine Tumor G1|Regional Digestive System Neuroendocrine Tumor G1,drug or biologic,Early,171,All,NIH&Combos,3,0,0,2013,2013,2083,3,Phase 2,2,NA,2,5.14166355650266,"(5,6]"
3272,4608,"emricasan, a caspase inhibitor, for evaluation in subjects with non-alcoholic steatohepatitis (nash) fibrosis",Completed,4,0,0,Non-alcoholic Steatohepatitis|Fibrosis|Liver Diseases,drug or biologic,Early,318,All,Industry&Combos,1,0,0,2016,2016,1099,1,Phase 2,3,NA,2,5.762051382780177,"(5,6]"
4171,9153,efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination and sofosbuvir + ribavirin for subjects with chronic hepatitis c virus (hcv) and inherited bleeding disorders,Completed,4,1,1,Chronic HCV Infection,drug or biologic,Early,122,All,Industry&Combos,1,1,0,2014,2014,487,1,Phase 2,0,safety/efficacy,0,4.804021044733257,"(4,5]"
2962,3974,"safety, tolerability, and efficacy of etrasimod (apd334) in patients with primary biliary cholangitis",Terminated,5,0,0,Primary Biliary Cholangitis,drug or biologic,Early,2,All,Industry&Combos,0,NA,0,2017,2017,412,0,Phase 2,1,safety/efficacy,1,0.6931471805599453,"(0,1]"
1500,1626,a phase ii trial of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy (hipec) with chemoradiation,Recruiting,2,0,0,Gastric Cancer|Stomach Cancer,drug or biologic,Early,29,All,AllOther,0,NA,0,2020,2018,1096,0,Phase 2,1,NA,1,3.367295829986474,"(3,4]"
4075,7867,"safety, tolerability and antiviral activity of selgantolimod in virally-suppressed adults with chronic hepatitis b",Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Early,48,All,Industry&Combos,1,0,0,2018,2018,350,1,Phase 2,2,safety,2,3.871201010907891,"(3,4]"
3919,7304,efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination for 8 weeks in subjects with chronic genotype 1 hcv and hiv-1 co-infection,Completed,4,0,0,Treatment of Hepatitis C,drug or biologic,Early,20,NA,AllOther,0,1,0,2015,2015,184,0,Phase 2,1,safety/efficacy,1,2.995732273553991,"(2,3]"
4090,8075,ledipasvir/sofosbuvir in adults with chronic hepatitis c virus (hcv) infection who are on dialysis for end stage renal disease,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,95,All,Industry&Combos,1,1,0,2017,2017,513,1,Phase 2,0,NA,0,4.553876891600541,"(4,5]"
1089,1151,naloxegol for opioid-related gastroparesis,Withdrawn,7,0,0,Gastroparesis|Opioid Use,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2017,2016,1005,1,Phase 2,4,NA,2,NA,NA
3836,6895,"encorafenib, binimetinib and cetuximab in subjects with previously untreated braf-mutant colorectal cancer","Active, not recruiting",1,0,0,BRAF V600E-mutant Metastatic Colorectal Cancer,drug or biologic,Early,95,All,Industry&Combos,0,NA,0,2018,2019,1077,0,Phase 2,1,NA,1,4.553876891600541,"(4,5]"
2100,2508,phase ii trial of natalizumab + prednisone for initial therapy of acute gi gvhd,Completed,4,1,1,Graft Versus Host Disease,drug or biologic,Early,21,All,Industry&Combos,0,NA,0,2014,2015,1492,0,Phase 2,1,NA,1,3.044522437723423,"(3,4]"
1577,1723,fecal microbiota transplantation for the treatment of diarrhea-predominant irritable bowel syndrome,Completed,4,1,1,Irritable Bowel Syndrome,drug or biologic,Early,48,All,AllOther,3,0,0,2014,2015,884,3,Phase 2,4,NA,2,3.871201010907891,"(3,4]"
2578,3467,losartan and nivolumab in combination with folfirinox and sbrt in localized pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,160,All,Industry&Combos,1,0,0,2018,2018,1239,1,Phase 2,0,NA,0,5.075173815233827,"(5,6]"
3823,6811,selonsertib in combination with prednisolone versus prednisolone alone in participants with severe alcoholic hepatitis (ah),Completed,4,1,1,Alcoholic Hepatitis (AH),drug or biologic,Early,104,All,Industry&Combos,1,0,0,2016,2016,533,1,Phase 2,2,NA,2,4.6443908991413725,"(4,5]"
2690,3608,an efficacy and safety study of lyc-30937-ec in subjects with active ulcerative colitis,Completed,4,1,1,"Colitis, Ulcerative",drug or biologic,Early,124,All,Industry&Combos,1,0,0,2016,2016,669,1,Phase 2,2,safety/efficacy,2,4.820281565605037,"(4,5]"
4094,8093,"a phase ii study of ramucirumab with somatostatin analog therapy in patients with advanced, progressive carcinoid tumors","Active, not recruiting",1,0,0,Carcinoid Tumors,drug or biologic,Early,44,All,Industry&Combos,0,NA,0,2016,2016,1631,0,Phase 2,1,NA,1,3.784189633918261,"(3,4]"
2988,4006,efficacy and safety study of ged-0507-34-levo for treatment of uc,Terminated,5,1,1,Ulcerative Colitis,drug or biologic,Early,19,All,AllOther,1,0,0,2016,2016,245,1,Phase 2,4,safety/efficacy,2,2.9444389791664403,"(2,3]"
2703,3626,an open label study of bavituximab and pembrolizumab in advanced gastric and gej cancer patients,Recruiting,2,0,0,Gastric Cancer|GastroEsophageal Cancer,drug or biologic,Early,80,All,Industry&Combos,0,NA,0,2019,2019,765,0,Phase 2,1,NA,1,4.382026634673881,"(4,5]"
3937,7337,safety study of pegylated interferon lambda plus single or 2 direct antiviral agents with ribavirin,Completed,4,0,0,Hepatitis C,drug or biologic,Early,165,All,Industry&Combos,0,NA,0,2013,2013,396,0,Phase 2,1,safety,1,5.10594547390058,"(5,6]"
3589,5611,sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma with disease progression on sorafenib,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma,drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2013,2013,3287,0,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
3,3,hepatic artery infusional floxuridine to treat pancreatic cancer liver metastases,Recruiting,2,0,0,Pancreatic Adenocarcinoma|Liver Metastases,drug or biologic,Early,15,All,AllOther,0,NA,0,2019,2019,1151,0,Phase 2,1,NA,1,2.70805020110221,"(2,3]"
1288,1375,methylprednisolone sodium succinate in treating patients with acute graft-versus-host disease of the gastrointestinal tract,Withdrawn,7,0,0,Acute Graft Versus Host Disease|Intestinal Graft Versus Host Disease,drug or biologic,Early,NA,All,NIH&Combos,0,NA,0,2015,2015,274,0,Phase 2,1,NA,1,NA,NA
1200,1278,durvalumab (medi4736) and tremelimumab and radiation therapy in hepatocellular carcinoma and biliary tract cancer,Recruiting,2,0,0,Hepatocellular Carcinoma|Biliary Tract Cancer,drug or biologic,Early,70,All,Industry&Combos,0,NA,0,2018,2018,1631,0,Phase 2,1,NA,1,4.248495242049359,"(4,5]"
3121,4235,study of tvb 2640 in subjects with non-alcoholic steatohepatitis (nash),Recruiting,2,0,0,Non-Alcoholic Fatty Liver Disease,drug or biologic,Early,141,All,Industry&Combos,1,0,0,2019,2019,924,1,Phase 2,1,NA,1,4.948759890378168,"(4,5]"
4111,8209,study to investigate the safety and efficacy of sofosbuvir/velpatasvir in adolescents and children with chronic hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,216,All,Industry&Combos,1,1,0,2017,2017,1027,1,Phase 2,0,safety/efficacy,0,5.375278407684165,"(5,6]"
710,744,fmt in ulcerative colitis-associated pouchitis,Completed,4,1,1,Ulcerative Colitis Associated Pouchitis,drug or biologic,Early,8,All,AllOther,0,NA,0,2014,2014,1311,0,Phase 2,1,NA,1,2.0794415416798357,"(2,3]"
2660,3567,efficacy and safety study of apremilast to treat active ulcerative colitis,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Early,170,All,Industry&Combos,1,0,0,2014,2015,991,1,Phase 2,4,safety/efficacy,2,5.135798437050262,"(5,6]"
2001,2354,a study of the safety and activity of liposomal irinotecan in combination with the 5-fu and oxaliplatin in the preoperative treatment of pancreatic adenocarcinoma,Recruiting,2,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,53,All,Industry&Combos,0,NA,0,2018,2018,1358,0,Phase 2,1,safety,1,3.970291913552122,"(3,4]"
309,314,study of durvalumab (medi4736) (anti-pd-l1) and trametinib (meki) in mss metastatic colon cancer,"Active, not recruiting",1,0,0,Malignant Neoplasms of Digestive Organs|Colorectal Cancer|Colon Cancer,drug or biologic,Early,29,All,Industry&Combos,0,NA,0,2018,2018,956,0,Phase 2,1,NA,1,3.367295829986474,"(3,4]"
542,564,lanreotide in the treatment of small bowel motility disorders,Completed,4,1,1,Gastrointestinal Motility Disorder|Intestinal Disease,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2017,2017,528,0,Phase 2,1,NA,1,2.4849066497880004,"(2,3]"
1147,1218,induction chemotherapy for locally advanced esophageal cancer,Recruiting,2,0,0,Esophageal Carcinoma,drug or biologic,Early,40,All,AllOther,NA,NA,0,2017,2017,1443,NA,Phase 2,0,NA,0,3.6888794541139363,"(3,4]"
830,869,"pembrolizumab, capecitabine, and radiation therapy in treating patients with mismatch-repair deficient and epstein-barr virus positive gastric cancer",Recruiting,2,0,0,Epstein-Barr Virus Positive|Gastric Adenocarcinoma|Mismatch Repair Protein Deficiency|Stage IB Gastric Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage IIA Gastric Cancer AJCC v7|Stage IIB Gastric Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage IIIA Gastric Cancer AJCC v7|Stage IIIB Gastric Cancer AJCC v7|Stage IIIC Gastric Cancer AJCC v7,drug or biologic,Early,40,All,NIH&Combos,0,NA,0,2017,2017,1919,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3601,5675,"a study to assess the safety, tolerability, pharmacokinetics and efficacy of edp-305 in subjects with non-alcoholic steatohepatitis",Completed,4,0,0,Non-Alcoholic Steatohepatitis,drug or biologic,Early,134,All,Industry&Combos,1,0,0,2018,2018,415,1,Phase 2,3,safety/efficacy,2,4.897839799950911,"(4,5]"
942,990,a pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (hcc) or biliary tract carcinomas (btc),Recruiting,2,0,0,Biliary Tract Neoplasms|Liver Cancer|Hepatocellular Carcinoma|Cholangiocarcinoma|Bile Duct Cancer,drug or biologic,Early,90,All,NIH&Combos,1,1,0,2016,2016,2005,1,Phase 2,0,NA,0,4.499809670330265,"(4,5]"
177,178,chemotherapy with or without radiation or surgery in treating participants with oligometastatic esophageal or gastric cancer,Recruiting,2,0,0,Gastric Adenocarcinoma|Oligometastasis|Stage IV Esophageal Adenocarcinoma AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7,drug or biologic,Early,100,All,NIH&Combos,1,0,0,2017,2018,1988,1,Phase 2,0,NA,0,4.605170185988092,"(4,5]"
3229,4526,open-label safety study of telaprevir and sofosbuvir in chronic hepatitis c genotype 1,Completed,4,1,1,"Hepatitis C, Chronic",drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2013,2013,121,0,Phase 2,1,safety,1,2.995732273553991,"(2,3]"
2164,2610,perflutren protein-type a microspheres and contrast-enhanced ultrasound in improving response to radioembolization therapy in patients with liver cancer,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Early,104,All,NIH&Combos,1,0,0,2017,2017,2202,1,Phase 2,1,NA,1,4.6443908991413725,"(4,5]"
4080,7899,cvm-1118 and sorafenib combination in subjects with advanced hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma|Advanced Cancer,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2018,2018,1389,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
97,97,sirolimus for cowden syndrome with colon polyposis,Recruiting,2,0,0,PTEN Gene Mutation|PTEN Hamartoma Tumor Syndrome|PTEN Hamartoma Syndrome|Cowden Syndrome|Bannayan Syndrome|Bannayan Zonana Syndrome|Polyposis,drug or biologic,Early,10,All,AllOther,0,NA,0,2019,2019,1050,0,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
3527,5382,chemotherapy and/or metastasectomy in treating patients with metastatic colorectal adenocarcinoma with lung metastases,Recruiting,2,0,0,Colorectal Adenocarcinoma|Colorectal Carcinoma Metastatic in the Lung|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,drug or biologic,Early,365,All,NIH&Combos,1,0,0,2018,2018,1674,1,Phase 2,0,NA,0,5.8998973535824915,"(5,6]"
3178,4371,simtuzumab (gs-6624) in the prevention of progression of liver fibrosis in adults with primary sclerosing cholangitis (psc),Completed,4,1,1,Primary Sclerosing Cholangitis (PSC),drug or biologic,Early,235,All,Industry&Combos,1,0,1,2012,2013,1253,1,Phase 2,3,NA,2,5.459585514144159,"(5,6]"
3963,7423,12 weeks of ledipasvir (ldv)/sofosbuvir (sof) with weight-based ribavirin vs. 24 weeks of ldv/sof,Terminated,5,1,1,HIV-1 Infection|Hepatitis C,drug or biologic,Early,7,All,NIH&Combos,1,0,0,2015,2016,338,1,Phase 2,0,NA,0,1.9459101490553132,"(1,2]"
2889,3874,phase 2 study of telomelysin (obp-301) in combination with pembrolizumab in esophagogastric adenocarcinoma,Recruiting,2,0,0,Esophagogastric Adenocarcinoma,drug or biologic,Early,41,All,Industry&Combos,0,NA,0,2019,2019,967,0,Phase 2,1,NA,1,3.713572066704308,"(3,4]"
4052,7683,"a study of faldaprevir, td-6450 and other antivirals in participants with genotype 1b hepatitis c virus infection",Completed,4,0,0,Hepatitis C Viral Infection|Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1,drug or biologic,Early,25,All,Industry&Combos,0,1,0,2016,2016,488,0,Phase 2,1,NA,1,3.2188758248682006,"(3,4]"
313,318,"magnetic resonance (mr) guided, dose-escalated radiation therapy (rt) + chemotherapy in pancreatic cancer",Recruiting,2,0,0,Unresectable Pancreatic Cancer,drug or biologic,Early,23,All,AllOther,0,NA,0,2013,2015,2214,0,Phase 2,1,NA,1,3.1354942159291497,"(3,4]"
937,985,metoclopramide versus placebo for gj placement,Completed,4,1,1,Radiation Exposure|Enteral Nutrition,drug or biologic,Early,110,All,AllOther,1,0,0,2017,2018,542,1,Phase 2,3,NA,2,4.700480365792417,"(4,5]"
2609,3507,bpm31510 administered intravenously with gemcitabine in advanced pancreatic cancer patients,Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,49,All,Industry&Combos,0,NA,0,2016,2016,1070,0,Phase 2,1,NA,1,3.8918202981106265,"(3,4]"
3515,5354,"folfoxiri plus panitumumab in metastatic ras wild-type, left-sided colorectal cancer",Recruiting,2,0,0,Colorectal Cancer Metastatic,drug or biologic,Early,35,All,Industry&Combos,0,NA,0,2019,2019,1004,0,Phase 2,1,NA,1,3.5553480614894135,"(3,4]"
11,11,study of pancreatic enzyme replacement on completion of adjuvant chemotherapy for resected pancreatic adenocarcinoma,Terminated,5,1,1,Pancreatic Cancer,drug or biologic,Early,4,All,Industry&Combos,0,NA,4,2018,2018,536,0,Phase 2,1,NA,1,1.3862943611198906,"(1,2]"
3461,5254,"a clinical trial of durvalumab and tremelimumab, administered with radiation therapy or ablation in patients with colorectal cancer",Completed,4,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,25,All,Industry&Combos,1,1,0,2017,2017,1465,1,Phase 2,0,NA,0,3.2188758248682006,"(3,4]"
3258,4582,combination therapy for chronic hepatitis c infection,Completed,4,1,1,"Hepatitis C, Chronic",drug or biologic,Early,229,All,NIH&Combos,1,1,0,2013,2013,942,1,Phase 2,0,NA,0,5.43372200355424,"(5,6]"
822,861,"pembrolizumab, a monoclonal antibody against pd-1, in combination with capecitabine and oxaliplatin (capox) in people with advanced biliary tract carcinoma (btc)","Active, not recruiting",1,1,1,Biliary Tract Neoplasms|Cholangiocarcinoma|Bile Duct Cancer|Liver Cancer|Gallbladder Cancer,drug or biologic,Early,11,All,NIH&Combos,0,NA,0,2017,2017,1134,0,Phase 2,1,NA,1,2.3978952727983707,"(2,3]"
3754,6387,trial of ire in cholangiocarcinoma,Recruiting,2,0,0,Cholangiocarcinoma,device,Others,20,All,AllOther,0,NA,0,2018,2018,1822,0,Others,1,NA,1,2.995732273553991,"(2,3]"
3290,4655,safety and efficacy of andecaliximab in participants with moderately to severely active crohn's disease,Terminated,5,1,1,Crohn's Disease,drug or biologic,Early,187,All,Industry&Combos,1,0,0,2015,2015,580,1,Phase 2,2,safety/efficacy,2,5.231108616854587,"(5,6]"
4113,8627,skin rash study before chemotherapy in colorectal & head and neck cancer patients,Recruiting,2,0,0,Colorectal Cancer|Head and Neck Cancer,drug or biologic,Early,100,All,AllOther,1,0,0,2013,2013,3287,1,Phase 2,0,NA,0,4.605170185988092,"(4,5]"
3846,6940,hydroxychloroquine and metabolic outcomes in patients undergoing tpait,Completed,4,0,0,Chronic Pancreatitis|Insulin Dependent Diabetes,drug or biologic,Early,9,All,AllOther,1,0,0,2017,2017,971,1,Phase 2,3,NA,2,2.1972245773362196,"(2,3]"
2709,3632,phase ii randomized trial of mfolfirinox +/- ramucirumab in advanced pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,95,All,Industry&Combos,1,0,0,2015,2016,1887,1,Phase 2,4,NA,2,4.553876891600541,"(4,5]"
2891,3876,dose ranging study of rpc4046 in eosinophilic esophagitis,Completed,4,0,0,Eosinophilic Esophagitis,drug or biologic,Early,100,All,Industry&Combos,1,0,0,2014,2014,535,1,Phase 2,4,NA,2,4.605170185988092,"(4,5]"
640,667,immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,10,All,AllOther,0,NA,0,2017,2017,1387,0,Phase 2,1,NA,1,2.302585092994046,"(2,3]"
4181,9366,"efficacy, safety, and pharmacokinetics (pk) study of ulimorelin in patients with enteral feeding intolerance (efi): the promote trial",Completed,4,0,0,Enteral Feeding Intolerance (EFI),drug or biologic,Early,120,All,Industry&Combos,1,0,0,2016,2016,516,1,Phase 2,2,safety/efficacy,2,4.787491742782046,"(4,5]"
1968,2315,perioperative therapy for resectable and borderline-resectable pancreatic adenocarcinoma with molecular correlates,Recruiting,2,0,0,Pancreatic Cancer|Pancreatic Adenocarcinoma|Pancreas Ductal Adenocarcinoma,drug or biologic,Early,50,All,Industry&Combos,1,1,0,2016,2016,1887,1,Phase 2,0,NA,0,3.912023005428146,"(3,4]"
481,499,prediction of nec with urinary ifabp,Withdrawn,7,0,0,Prematurity|Necrotizing Enterocolitis,other,Others,NA,All,AllOther,0,NA,2,2013,2014,608,0,Others,1,NA,1,NA,NA
3890,7173,lee001 and chemoembolization in patients with advanced hepatocellular carcinoma,Terminated,5,1,1,Hepatocellular Carcinoma,drug or biologic,Early,5,All,Industry&Combos,0,NA,0,2015,2016,1614,0,Phase 2,1,NA,1,1.6094379124341003,"(1,2]"
1504,1630,phase ii trial of dasatinib in patients with isocitrate dehydrogenase (idh)-mutant advanced intrahepatic cholangiocarcinoma,Completed,4,1,1,Cholangiocarcinoma,drug or biologic,Early,8,All,Industry&Combos,0,NA,0,2015,2015,1037,0,Phase 2,1,NA,1,2.0794415416798357,"(2,3]"
2012,2374,pravastatin intervention to delay hepatocellular carcinoma recurrence,Terminated,5,1,1,Hepatocellular Carcinoma|Liver Cirrhoses,drug or biologic,Early,1,All,NIH&Combos,1,0,1,2017,2018,68,1,Phase 2,3,NA,2,0,NA
1535,1667,gvax pancreas vaccine (with cy) in combination with nivolumab and sbrt for patients with borderline resectable pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2017,2018,1794,0,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
438,450,transdermal continuous oxygen therapy for infection prophylaxis in high- risk patients undergoing colon surgery,Withdrawn,7,0,0,Anorectal Surgeries,device,Others,NA,All,Industry&Combos,1,0,1,2015,2017,365,1,Others,0,NA,0,NA,NA
3782,6574,sequential and concurrent folfoxiri/bevacizumab regimens versus folfox/bevacizumab in first-line metastatic colorectal cancer,Terminated,5,1,1,Colorectal Neoplasms,drug or biologic,Early,280,All,Industry&Combos,1,0,0,2013,2013,1146,1,Phase 2,0,NA,0,5.634789603169249,"(5,6]"
3404,5125,microbiota restoration therapy for recurrent clostridium difficile infection,Completed,4,1,1,Clostridium Difficile Infection,drug or biologic,Early,272,All,Industry&Combos,1,1,0,2015,2015,609,1,Phase 2,0,NA,0,5.605802066295998,"(5,6]"
131,131,analyzing childhood recall antigens in patients with pancreatic cancer,Terminated,5,0,0,Pancreatic Cancer,drug or biologic,Early,9,All,AllOther,0,NA,4,2019,2017,843,0,Phase 2,1,NA,1,2.1972245773362196,"(2,3]"
2313,2909,ability of a dendritic cell vaccine to immunize melanoma or epithelial cancer patients against defined mutated neoantigens expressed by the autologous cancer,Terminated,5,1,1,Melanoma|Gastrointestinal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer,drug or biologic,Early,1,All,NIH&Combos,0,NA,0,2017,2018,454,0,Phase 2,1,NA,1,0,NA
3028,4068,a study of ramucirumab (ly3009806) or merestinib (ly2801653) in advanced or metastatic biliary tract cancer,"Active, not recruiting",1,1,1,Biliary Tract Cancer|Metastatic Cancer|Advanced Cancer,drug or biologic,Early,309,All,Industry&Combos,1,0,0,2016,2016,638,1,Phase 2,2,NA,2,5.733341276897746,"(5,6]"
2202,2690,continuous infusion terlipressin for patients with cirrhosis and refractory ascites,Completed,4,0,0,Cirrhosis|Ascites Hepatic,drug or biologic,Early,6,All,Industry&Combos,0,NA,0,2017,2017,625,0,Phase 2,1,NA,1,1.791759469228055,"(1,2]"
567,591,eosinophilic esophagitis clinical therapy comparison trial,Terminated,5,1,1,Eosinophilic Esophagitis,drug or biologic,Early,3,All,AllOther,1,0,0,2013,2013,1903,1,Phase 2,0,NA,0,1.0986122886681098,"(1,2]"
2525,3376,study to assess safety and efficacy of ifetroban for treatment of portal hypertension in cirrhotic patients,Completed,4,0,0,Portal Hypertension|Liver Cirrhosis,drug or biologic,Early,30,All,Industry&Combos,1,0,0,2016,2017,498,1,Phase 2,2,safety/efficacy,2,3.4011973816621555,"(3,4]"
2587,3480,"study of efficacy and safety of pdr001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (gi), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (gep-nec)",Completed,4,1,1,Well-differentiated Non-functional NET of Thoracic Origin|Well-differentiated Non-functional NET of Gastrointestinal Origin|Well-differentiated Non-functional NET of Pancreatic Origin|Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma,drug or biologic,Early,116,All,Industry&Combos,0,NA,0,2016,2017,542,0,Phase 2,1,safety/efficacy,1,4.7535901911063645,"(4,5]"
978,1031,"ramucirumab in treating patients with advanced or metastatic, previously treated biliary cancers that cannot be removed by surgery","Active, not recruiting",1,0,0,Cholangiocarcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Stage III Gallbladder Cancer AJCC v7|Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IV Gallbladder Cancer AJCC v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Gallbladder Carcinoma,drug or biologic,Early,61,All,NIH&Combos,0,NA,0,2015,2015,2194,0,Phase 2,1,NA,1,4.110873864173311,"(4,5]"
1351,1443,intratreatment fdg-pet during radiation therapy for gynecologic and gastrointestinal cancers,Recruiting,2,0,0,Cancer of the Cervix|Vulvar Cancer|Esophageal Cancer|Anal Canal Cancer,other,Others,130,All,AllOther,0,NA,4,2018,2018,1984,0,Others,1,NA,1,4.867534450455582,"(4,5]"
1514,1644,"an efficacy, safety and pharmacokinetics study of simeprevir, daclatasvir and sofosbuvir in participants with chronic hepatitis c virus genotype 1 or 4 infection and decompensated liver disease",Completed,4,1,1,"Hepatitis C, Chronic",drug or biologic,Early,40,All,Industry&Combos,1,1,0,2014,2014,317,1,Phase 2,0,safety/efficacy,0,3.6888794541139363,"(3,4]"
3137,4265,a phase 2a study of alxn1007 in participants with newly diagnosed acute lower gastrointestinal graft-versus-host disease,Terminated,5,1,1,Acute Graft-Versus-Host Disease|GIGVHD,drug or biologic,Early,25,All,Industry&Combos,NA,1,0,2014,2014,836,NA,Phase 2,0,NA,0,3.2188758248682006,"(3,4]"
1750,1959,the effectiveness of high resolution microendoscopy for people living with hiv,Recruiting,2,0,0,Anal High Grade Squamous Intraepithelial Lesion,other,Others,200,All,AllOther,0,NA,4,2020,2019,1249,0,Others,1,NA,1,5.298317366548036,"(5,6]"
2192,2666,nivolumab and ipilimumab in mucinous colorectal and appendiceal tumors,Completed,4,0,0,Mucinous Neoplasm|Colorectal Tumor|Appendiceal Tumor,drug or biologic,Early,16,All,AllOther,0,NA,0,2018,2019,689,0,Phase 2,1,NA,1,2.772588722239781,"(2,3]"
3965,7441,a study of smt19969 compared with vancomycin for the treatment of clostridium difficile-associated diarrhoea (cdad),Completed,4,0,0,Clostridium Difficile Infection,drug or biologic,Early,100,All,Industry&Combos,1,0,0,2014,2014,548,1,Phase 2,4,NA,2,4.605170185988092,"(4,5]"
3929,7319,a study to evaluate eft508 alone and in combination with avelumab in subjects with mss colorectal cancer,Completed,4,0,0,Microsatellite Stable Relapsed or Refractory Colorectal Cancer,drug or biologic,Early,56,All,Industry&Combos,1,0,0,2017,2017,554,1,Phase 2,0,NA,0,4.02535169073515,"(4,5]"
3192,4418,"paclitaxel and bevacizumab with or without emactuzumab in treating patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer","Active, not recruiting",1,0,0,Fallopian Tube Adenocarcinoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Malignant Ovarian Brenner Tumor|Ovarian Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma,drug or biologic,Early,9,Female,NIH&Combos,1,0,0,2016,2017,2948,1,Phase 2,0,NA,0,2.1972245773362196,"(2,3]"
788,825,akt inhibitor mk2206 in treating patients with previously treated colon or rectal cancer that is metastatic or locally advanced and cannot be removed by surgery,Completed,4,1,1,Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,drug or biologic,Early,18,All,NIH&Combos,0,NA,0,2013,2013,822,0,Phase 2,1,NA,1,2.8903717578961645,"(2,3]"
331,337,"non-alcoholic fatty liver disease, the hepatic response to oral glucose, and the effect of semaglutide (nafld heroes)",Recruiting,2,0,0,Non-Alcoholic Steatohepatitis|Non-Alcoholic Fatty Liver Disease,drug or biologic,Early,84,All,NIH&Combos,1,1,4,2019,2019,1287,1,Phase 2,0,NA,0,4.430816798843313,"(4,5]"
2849,3821,"a study to assess the antitumor activity and safety of imab362 in combination with nab-paclitaxel and gemcitabine (nab-p + gem) as first line treatment in subjects with claudin 18.2 (cldn18.2) positive, metastatic pancreatic adenocarcinoma",Recruiting,2,0,0,Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,141,All,Industry&Combos,1,0,0,2019,2019,1295,1,Phase 2,0,safety,0,4.948759890378168,"(4,5]"
948,997,dose escalated proton beam therapy or photon therapy for esophageal cancer,Withdrawn,7,0,0,Esophageal Cancer,drug or biologic,Early,NA,All,AllOther,1,1,0,2017,2017,407,1,Phase 2,0,NA,0,NA,NA
1156,1229,pelvic radiotherapy with concurrent neoadjuvant folfox for patients with newly diagnosed rectal adenocarcinoma,Terminated,5,0,0,Rectal Adenocarcinoma,drug or biologic,Early,3,All,AllOther,0,NA,0,2014,2015,1314,0,Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
2375,3034,"simvastatin in reducing pancreatitis in patients with recurrent, acute or chronic pancreatitis","Active, not recruiting",1,0,0,Acute Pancreatitis,drug or biologic,Early,8,All,NIH&Combos,1,0,1,2016,2016,1120,1,Phase 2,2,NA,2,2.0794415416798357,"(2,3]"
3003,4027,temozolomide with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors,"Active, not recruiting",1,0,0,Gastrinoma|Glucagonoma|Insulinoma|Islet Cell Carcinoma|Pancreatic Polypeptide Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma,drug or biologic,Early,145,All,NIH&Combos,1,0,0,2013,2013,3034,1,Phase 2,0,NA,0,4.976733742420574,"(4,5]"
2785,3741,combination chemotherapy with or without hypofractionated radiation therapy before surgery in treating patients with pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma|Borderline Resectable Adenocarcinoma of the Head of the Pancrease,drug or biologic,Early,126,All,NIH&Combos,1,0,0,2016,2016,2618,1,Phase 2,0,NA,0,4.836281906951478,"(4,5]"
3405,5127,"a study of abt-165 plus folfiri vs bevacizumab plus folfiri in subjects with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin and bevacizumab",Terminated,5,1,1,Cancer,drug or biologic,Early,70,All,Industry&Combos,1,0,0,2017,2018,638,1,Phase 2,0,NA,0,4.248495242049359,"(4,5]"
657,684,heated mitomycin and cisplatin during surgery in treating patients with stomach or gastroesophageal cancer,"Active, not recruiting",1,0,0,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Peritoneal Carcinomatosis,drug or biologic,Early,24,All,NIH&Combos,0,NA,0,2016,2016,1826,0,Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
3002,4026,a study to evaluate safety and pharmacodynamic efficacy of 0382 in obese subjects with nafld/nash.,Completed,4,0,0,Non-alcoholic Fatty Liver Disease (NAFLD)|Non-alcoholic Steatohepatitis (NASH),drug or biologic,Early,74,All,Industry&Combos,1,0,0,2019,2019,591,1,Phase 2,3,safety/efficacy,2,4.30406509320417,"(4,5]"
839,878,sitagliptin versus placebo in the treatment of non-alcoholic fatty liver disease,Completed,4,1,1,Non-alcoholic Fatty Liver Disease,drug or biologic,Early,50,All,AllOther,1,0,0,2013,2014,730,1,Phase 2,2,NA,2,3.912023005428146,"(3,4]"
3923,7310,ds-8201a in human epidermal growth factor receptor2 (her2)-expressing colorectal cancer (destiny-crc01),Completed,4,0,0,Colorectal Neoplasm,drug or biologic,Early,90,All,Industry&Combos,NA,1,0,2017,2018,532,NA,Phase 2,0,NA,0,4.499809670330265,"(4,5]"
845,886,phase 2 evaluation of multi-modality algorithm for non-metastatic adenocarcinoma of pancreas or ampulla,Terminated,5,1,1,Ductal Adenocarcinoma of Pancreas|Adenocarcinoma of Ampulla,drug or biologic,Early,11,All,AllOther,1,1,0,2015,2016,132,1,Phase 2,0,NA,0,2.3978952727983707,"(2,3]"
2420,3134,linaclotide in treating patients with stages 0-3 colorectal cancer,Recruiting,2,0,0,Colorectal Adenoma|Stage 0 Colorectal Cancer AJCC v8|Stage I Colorectal Cancer AJCC v8|Stage II Colorectal Cancer AJCC v8|Stage IIA Colorectal Cancer AJCC v8|Stage IIB Colorectal Cancer AJCC v8|Stage IIC Colorectal Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8,drug or biologic,Early,230,Female,AllOther,1,0,0,2019,2019,1067,1,Phase 2,2,NA,2,5.438079308923196,"(5,6]"
975,1028,study of pembrolizumab with or without defactinib following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma,Recruiting,2,0,0,Resectable Pancreatic Ductal Adenocarcinoma (PDAC)|Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,36,All,Industry&Combos,1,0,0,2018,2019,1434,1,Phase 2,0,NA,0,3.58351893845611,"(3,4]"
2025,2392,nivolumab with or without ipilimumab in treating patients with resectable liver cancer,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma|Resectable Hepatocellular Carcinoma,drug or biologic,Early,30,All,NIH&Combos,1,0,0,2017,2017,1828,1,Phase 2,0,NA,0,3.4011973816621555,"(3,4]"
2817,3776,study assessing safety and efficacy of combination of bl-8040 and pembrolizumab in metastatic pancreatic cancer patients (combat/keynote-202),"Active, not recruiting",1,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,80,All,Industry&Combos,1,1,0,2016,2016,1947,1,Phase 2,0,safety/efficacy,0,4.382026634673881,"(4,5]"
1557,1696,phase ii anetumab ravtansine in pre-treated mesothelin-expressing pancreatic cancer,Completed,4,1,1,Pancreatic Cancer,drug or biologic,Early,18,All,Industry&Combos,0,NA,0,2017,2017,817,0,Phase 2,1,NA,1,2.8903717578961645,"(2,3]"
2899,3888,rifaximin soluble solid dispersion (ssd) tablets plus lactulose for the treatment of overt hepatic encephalopathy (ohe),Completed,4,0,0,Overt Hepatic Encephalopathy,drug or biologic,Early,76,All,Industry&Combos,1,0,0,2018,2018,546,1,Phase 2,3,NA,2,4.330733340286331,"(4,5]"
2492,3296,phase ii study of spi-1620 in combination with docetaxel as a second-line to treat biliary cancer,Terminated,5,0,0,Biliary Cancer,drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2013,2013,883,0,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
3597,5653,efficacy and safety of orally administered ds102 in patients with acute alcoholic hepatitis,Suspended,6,0,0,Severe Acute Decompensated Alcoholic Hepatitis,drug or biologic,Early,120,All,Industry&Combos,1,0,0,2018,2018,367,1,Phase 2,2,safety/efficacy,2,4.787491742782046,"(4,5]"
2221,2732,dogs as probiotics,Completed,4,0,0,Health of the Human Microbiome,other,Others,20,All,AllOther,0,NA,NA,2015,2015,243,0,Others,1,NA,1,2.995732273553991,"(2,3]"
4168,9149,safety and efficacy of ledipasvir/sofosbuvir fixed dose combination +/- ribavirin in adolescents and children with chronic hcv-infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,226,All,Industry&Combos,1,1,0,2014,2014,1318,1,Phase 2,0,safety/efficacy,0,5.420534999272286,"(5,6]"
2105,2514,high resolution microendoscopy for the detection of esophageal squamous cell neoplasia,Recruiting,2,0,0,Suspected or Known Squamous Cell Neoplasia|Prior History of Squamous Cell Dysplasia and /or Neoplasia,drug or biologic,Early,1300,All,AllOther,1,0,4,2014,2014,2891,1,Phase 2,0,NA,0,7.170119543449628,"(7,13]"
728,762,resistant maltodextrin for gut microbiome in parkinson's disease: safety and tolerability study,Recruiting,2,0,0,Parkinson Disease|Intestinal Bacteria Flora Disturbance|Dietary Modification,other,Others,30,All,AllOther,1,0,0,2018,2018,967,1,Others,4,safety,2,3.4011973816621555,"(3,4]"
2116,2530,non-operative radiation management of adenocarcinoma of the lower rectum,Completed,4,1,1,"Cancer of Rectum|Cancer of the Rectum|Neoplasm, Rectum|Rectal Cancer|Rectum Cancer|Rectum Neoplasms|Adenocarcinoma of the Rectum",drug or biologic,Early,20,All,AllOther,0,NA,0,2015,2016,1348,0,Phase 2,1,NA,1,2.995732273553991,"(2,3]"
477,495,nivolumab + cabiralizumab + gemcitabine in patients with stage iv pancreatic cancer achieving disease control in response to first-line chemotherapy (gemcan trial).,Suspended,6,0,0,Pancreatic Cancer Stage IV,drug or biologic,Early,40,All,AllOther,0,NA,0,2018,2019,762,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
344,351,"disulfiram-copper gluconate in met pancreas cancer w rising ca19-9 on abraxane-gemzar, folfirinox or gemcitabine",Recruiting,2,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,42,All,Industry&Combos,1,1,0,2018,2019,411,1,Phase 2,0,NA,0,3.7376696182833684,"(3,4]"
321,326,"epacadostat, pembrolizumab, and crs-207, with or without cy/gvax pancreas in patients with metastatic pancreas cancer",Recruiting,2,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,44,All,Industry&Combos,NA,1,0,2016,2018,1470,NA,Phase 2,0,NA,0,3.784189633918261,"(3,4]"
107,107,a trial of systemic chemotherapy in combination with conventional transarterial chemoembolization in patients with advanced intra-hepatic cholangiocarcinoma,Terminated,5,1,1,Unresectable Intrahepatic Cholangiocarcinoma,drug or biologic,Early,1,All,AllOther,0,NA,0,2016,2017,503,0,Phase 2,1,NA,1,0,NA
2073,2467,"a study to assess the efficacy, safety and tolerability of oral lpcn 1144 in subjects with nonalcoholic steatohepatitis (nash)","Active, not recruiting",1,0,0,Nonalcoholic Steatohepatitis (NASH),drug or biologic,Early,56,Male,Industry&Combos,1,0,0,2019,2019,493,1,Phase 2,4,safety/efficacy,2,4.02535169073515,"(4,5]"
1423,1531,comparing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (crs-hipec) using mitomycin-c versus melphalan for colorectal peritoneal carcinomatosis,Recruiting,2,0,0,"Cancer, Appendiceal|ColoRectal Cancer",drug or biologic,Early,100,All,AllOther,1,0,0,2017,2017,2544,1,Phase 2,1,NA,1,4.605170185988092,"(4,5]"
892,936,trial using octreotide to enhance liver recovery after hepatectomy,"Active, not recruiting",1,0,0,Major Liver Resection,drug or biologic,Early,26,All,AllOther,1,0,4,2017,2017,950,1,Phase 2,3,NA,2,3.258096538021482,"(3,4]"
1258,1343,heal study (hepatic encephalopathy and albumin study),Recruiting,2,0,0,Cirrhosis|Hepatic Encephalopathy|Minimal Hepatic Encephalopathy|Covert Hepatic Encephalopathy,drug or biologic,Early,60,All,NA,1,0,0,2018,2018,1279,1,Phase 2,4,NA,2,4.0943445622221,"(4,5]"
3488,5291,evaluate the efficacy of medi4736 in immunological subsets of advanced colorectal cancer,Completed,4,1,1,Advanced Colorectal Cancer,drug or biologic,Early,16,All,Industry&Combos,0,NA,0,2014,2014,2036,0,Phase 2,1,efficacy,1,2.772588722239781,"(2,3]"
3187,4395,pharmacokinetic and pharmacodynamic study of idn-6556 in aclf,Terminated,5,1,1,Acute on Chronic Hepatic Failure|Acute Liver Failure|Liver Cirrhosis|Acute Alcoholic Hepatitis,drug or biologic,Early,23,All,Industry&Combos,1,0,0,2013,2013,487,1,Phase 2,3,NA,2,3.1354942159291497,"(3,4]"
1274,1360,envarsus xl immunosuppression following liver transplantation,Completed,4,0,0,Recipients of Liver Transplant,drug or biologic,Early,110,All,AllOther,0,0,0,2019,2019,640,0,Phase 2,1,NA,1,4.700480365792417,"(4,5]"
1042,1097,study of the combination of dkn-01 and nivolumab in previously treated patients with advanced biliary tract cancer (btc),Recruiting,2,0,0,Biliary Tract Cancer,drug or biologic,Early,30,All,Industry&Combos,1,1,0,2019,2019,1059,1,Phase 2,0,NA,0,3.4011973816621555,"(3,4]"
3629,5738,"study to assess efficacy, safety, tolerability and pharmacokinetics of simeprevir, daclatasvir and sofosbuvir in treatment-naive participants with chronic hepatitis c virus genotype 1 infection",Completed,4,1,1,Hepatitis C Virus,drug or biologic,Early,68,All,Industry&Combos,1,1,0,2015,2015,396,1,Phase 2,0,safety/efficacy,0,4.219507705176107,"(4,5]"
1324,1414,cisplatin and fluorouracil compared with carboplatin and paclitaxel in treating patients with inoperable locally recurrent or metastatic anal cancer,"Active, not recruiting",1,0,0,Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Squamous Cell Carcinoma|Metastatic Anal Canal Carcinoma|Recurrent Anal Canal Carcinoma|Stage IIIB Anal Canal Cancer|Stage IV Anal Canal Cancer,drug or biologic,Early,91,All,NIH&Combos,1,0,0,2015,2016,1673,1,Phase 2,0,NA,0,4.51085950651685,"(4,5]"
2837,3802,sapanisertib in treating patients with metastatic or refractory pancreatic neuroendocrine tumor that cannot be removed by surgery,"Active, not recruiting",1,0,0,Pancreatic Neuroendocrine Tumor G1|Pancreatic Neuroendocrine Tumor G2|Refractory Pancreatic Neuroendocrine Carcinoma,drug or biologic,Early,40,All,NIH&Combos,0,NA,0,2016,2017,1642,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3537,5404,"study of mk-3475 in patients with microsatellite unstable (msi) tumors (cohorts a, b and c)",Completed,4,1,1,MSI Positive Colorectal Cancer|MSI Negative Colorectal Cancer|MSI Positive Non-Colorectal Cancers,drug or biologic,Early,113,All,Industry&Combos,1,1,0,2013,2013,2160,1,Phase 2,0,NA,0,4.727387818712341,"(4,5]"
2777,3729,"an investigational immuno-therapy study of relatlimab plus nivolumab compared to various standard-of-care therapies in previously treated participants with recurrent, advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma",Withdrawn,7,0,0,Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2018,2019,850,1,Phase 2,0,NA,0,NA,NA
1114,1181,pembrolizumab after chemotherapy in treating patients with colorectal cancer that has spread to the liver and who are undergoing liver surgery,Suspended,6,0,0,Metastatic Malignant Neoplasm in the Liver|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,drug or biologic,Early,19,All,Industry&Combos,0,NA,0,2019,2019,1449,0,Phase 2,1,NA,1,2.9444389791664403,"(2,3]"
1754,1963,atezolizumab monotherapy vs atezolizumab plus cobimetinib in liver metastases from colorectal cancer,Withdrawn,7,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,NA,All,Industry&Combos,NA,1,4,2017,2018,1007,NA,Phase 2,0,NA,0,NA,NA
608,634,study of gemcitabine and abraxane for pancreas cancer,Terminated,5,0,0,Pancreatic Cancer,drug or biologic,Early,4,All,AllOther,0,NA,0,2014,2014,822,0,Phase 2,1,NA,1,1.3862943611198906,"(1,2]"
3483,5286,vorinostat plus hydroxychloroquine versus regorafenib in colorectal cancer,Completed,4,0,0,Colorectal Cancer,drug or biologic,Early,44,All,AllOther,3,0,0,2014,2015,1120,3,Phase 2,0,NA,0,3.784189633918261,"(3,4]"
2979,3994,a study to assess efficacy and safety of ser-287 in adults with active mild-to-moderate ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Early,201,All,Industry&Combos,1,0,0,2018,2018,895,1,Phase 2,3,safety/efficacy,2,5.303304908059076,"(5,6]"
2683,3600,a trial of iw-3718 for 8 weeks in patients with symptomatic gastroesophageal reflux disease (gerd),Completed,4,1,1,Gastroesophageal Reflux Disease,drug or biologic,Early,282,All,Industry&Combos,1,0,0,2015,2016,421,1,Phase 2,2,NA,2,5.641907070938114,"(5,6]"
3864,7084,tenofovir alafenamide (taf) in children and adolescents with chronic hepatitis b virus infection,Recruiting,2,0,0,Chronic Hepatitis B,drug or biologic,Early,150,All,Industry&Combos,1,0,0,2016,2016,3195,1,Phase 2,2,NA,2,5.0106352940962555,"(5,6]"
300,305,gtx-rt in borderline resectable pancreatic cancer,Terminated,5,1,1,Pancreatic Cancer,drug or biologic,Early,9,All,AllOther,0,NA,0,2012,2013,577,0,Phase 2,1,NA,1,2.1972245773362196,"(2,3]"
223,226,"study of crs-207, nivolumab, and ipilimumab with or without gvax pancreas vaccine (with cy) in patients with pancreatic cancer",Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,63,All,Industry&Combos,1,0,0,2017,2017,2117,1,Phase 2,0,NA,0,4.143134726391533,"(4,5]"
3270,4605,nitrate effect on exercise capacitance,Recruiting,2,0,0,Fontan,drug or biologic,Early,15,All,AllOther,0,NA,0,2020,2019,201,0,Phase 2,1,NA,1,2.70805020110221,"(2,3]"
3630,5739,"a study to evaluate the long-term efficacy, safety, and tolerability of repeated administration of upadacitinib (abt-494) in participants with crohn's disease","Active, not recruiting",1,0,0,Crohn's Disease (CD),drug or biologic,Early,107,All,Industry&Combos,1,1,0,2016,2016,3409,1,Phase 2,0,safety/efficacy,0,4.672828834461906,"(4,5]"
956,1006,lc bead lumi radio-opaque embolic beads to detect and characterize the vascularity of hepatic tumors during treatment with transarterial embolization (tae) alone or combined with thermal ablation,Enrolling by invitation,3,0,0,Hepatic Cancer|Liver Neoplasms|Hepatocellular Cancer|Liver Cancer,device,Others,19,All,NIH&Combos,0,NA,0,2016,2016,2164,0,Others,1,NA,1,2.9444389791664403,"(2,3]"
2977,3991,phase 2 study of ngm282 in patients with primary biliary cirrhosis,Completed,4,0,0,Primary Biliary Cirrhosis,drug or biologic,Early,45,All,Industry&Combos,2,0,0,2014,2014,303,1,Phase 2,2,NA,2,3.8066624897703196,"(3,4]"
2763,3712,study to evaluate the efficacy and safety of cc-90001 in participants with non-alcoholic steatohepatitis (nash) and liver fibrosis,Recruiting,2,0,0,Non-alcoholic Fatty Liver Disease|Liver Cirrhosis,drug or biologic,Early,195,All,Industry&Combos,1,0,0,2019,2019,1405,1,Phase 2,4,safety/efficacy,2,5.272999558563747,"(5,6]"
1452,1562,omega-3 fatty acid for the immune modulation of colorectal cancer,Recruiting,2,0,0,Colon Cancer,drug or biologic,Early,36,All,AllOther,1,0,0,2018,2019,641,1,Phase 2,4,NA,2,3.58351893845611,"(3,4]"
2946,3950,"a study to assess pharmacodynamics, safety and tolerability of pf-05221304 and pf-06865571 co-administered for 6 weeks in adults with non-alcoholic fatty liver disease.",Completed,4,1,1,Non-Alcoholic Fatty Liver Disease (NAFLD),drug or biologic,Early,99,All,Industry&Combos,1,0,0,2018,2019,248,1,Phase 2,3,safety,2,4.59511985013459,"(4,5]"
2143,2579,fecal microbiota transplantation (fmt) in recipients after allogeneic hematopoietic cell transplantation (hct),Terminated,5,0,0,Allogeneic Hematopoietic Cell Transplantation (HCT),drug or biologic,Early,8,All,AllOther,1,0,0,2018,2019,499,1,Phase 2,2,NA,2,2.0794415416798357,"(2,3]"
2756,3704,the hepquant shunt test for monitoring liver disease and treatment effects by measuring liver function and physiology,"Active, not recruiting",1,0,0,"NASH - Nonalcoholic Steatohepatitis",other,Others,17,All,Industry&Combos,0,NA,2,2017,2017,1605,0,Others,1,NA,1,2.833213344056216,"(2,3]"
3352,4885,a phase ll study of imm-124e for patients with non-alcoholic steatohepatitis,Completed,4,1,1,Non-alcoholic Steatohepatitis (NASH),drug or biologic,Early,133,All,Industry&Combos,1,0,0,2014,2014,1064,1,Phase 2,4,NA,2,4.890349128221754,"(4,5]"
1314,1403,gemcabene for the treatment of pediatric nafld,Terminated,5,1,1,Non-Alcoholic Fatty Liver Disease,drug or biologic,Early,6,All,AllOther,0,NA,0,2018,2018,516,0,Phase 2,1,NA,1,1.791759469228055,"(1,2]"
2802,3759,use of high-dose radiation therapy plus chemotherapy to improve the likelihood of surgical treatment in patients with locally advanced pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,48,All,AllOther,0,NA,0,2018,2018,1432,0,Phase 2,1,NA,1,3.871201010907891,"(3,4]"
4095,8094,inhaled tissue plasminogen activator for acute plastic bronchitis,Recruiting,2,0,0,Plastic Bronchitis|Protein-Losing Enteropathies|Healthy,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2014,2018,1595,0,Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
954,1004,bli4700-202: a pilot evaluation of bli4700 bowel preparation in adult subjects,Completed,4,0,0,Colonoscopy,drug or biologic,Early,17,All,Industry&Combos,0,NA,0,2017,2017,53,0,Phase 2,1,NA,1,2.833213344056216,"(2,3]"
1878,2171,safety study of regorafenib and sir-spheres Â® microspheres radioembolization in patients with refractory metastatic colorectal cancer with liver metastases,Completed,4,1,1,Colorectal Neoplasms,drug or biologic,Early,26,All,Industry&Combos,1,1,0,2014,2014,1069,1,Phase 2,0,safety,0,3.258096538021482,"(3,4]"
2507,3328,a safety and efficacy evaluation of bli400 laxative in constipated adolescent subjects,Completed,4,1,1,Constipation,drug or biologic,Early,33,All,Industry&Combos,0,NA,0,2016,2015,122,0,Phase 2,1,safety/efficacy,1,3.4965075614664802,"(3,4]"
2625,3526,a comparison of the effects of orp-101 versus placebo in adult patients with irritable bowel syndrome with diarrhea (ibs-d),Recruiting,2,0,0,Irritable Bowel Syndrome With Diarrhea,drug or biologic,Early,320,All,Industry&Combos,NA,0,0,2019,2019,740,NA,Phase 2,3,NA,2,5.768320995793772,"(5,6]"
803,840,trial of laparoscopic cholecystectomy vs. non-operative treatment for gallbladder dyskinesia,Unknown status,8,0,0,Gallbladder Dyskinesia,drug or biologic,Early,60,All,NIH&Combos,3,0,0,2014,2014,515,3,Phase 2,0,NA,0,4.0943445622221,"(4,5]"
4006,7578,ledipasvir/sofosbuvir fixed-dose combination for 12 or 24 weeks in genotype 1 or 4 hcv infected adults with sickle cell disease,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,10,All,Industry&Combos,1,1,0,2014,2015,413,1,Phase 2,0,NA,0,2.302585092994046,"(2,3]"
4140,8990,safety and immunogenicity of norovirus bivalent virus-like particle vaccine in healthy adults,Completed,4,1,1,Norovirus Prevention,drug or biologic,Early,454,All,Industry&Combos,1,0,1,2014,2014,601,1,Phase 2,4,safety,2,6.118097198041348,"(6,7]"
3157,4309,to evaluate the optimal dose of 68ga-ops202 as a pet (positron emission tomography) imaging agent in subjects with gastroenteropancreatic neuroendocrine tumour (gep-net),Completed,4,1,1,Gastro-Enteropancreatic Neuroendocrine Tumor,drug or biologic,Early,29,All,Industry&Combos,2,0,2,2017,2017,667,1,Phase 2,1,NA,1,3.367295829986474,"(3,4]"
3293,4665,a study of the efficacy and safety of pxl770 versus placebo after 12 weeks of treatment in patients with nafld,Completed,4,0,0,Nonalcoholic Fatty Liver,drug or biologic,Early,120,All,Industry&Combos,1,0,0,2018,2019,493,1,Phase 2,4,safety/efficacy,2,4.787491742782046,"(4,5]"
2881,3865,"a study to evaluate the efficacy, safety, and pharmacokinetics of uttr1147a compared with placebo and with vedolizumab in participants with moderate to severe ulcerative colitis (uc)","Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Early,195,All,Industry&Combos,1,0,0,2018,2018,1371,1,Phase 2,3,safety/efficacy,2,5.272999558563747,"(5,6]"
3546,5431,alisporivir with rbv in chronic hepatitis c genotype 2 and 3 participants for whom interferon is not an option,Completed,4,1,1,Hepatitis C|Liver Disease,drug or biologic,Early,52,All,Industry&Combos,1,0,0,2014,2014,396,1,Phase 2,0,NA,0,3.9512437185814275,"(3,4]"
816,854,"ultrasound-guided verteporfin photodynamic therapy for the treatment of unresectable solid pancreatic tumors or advanced pancreatic cancer, vertpac-02 study",Recruiting,2,0,0,Advanced Pancreatic Carcinoma|Locally Advanced Pancreatic Carcinoma|Metastatic Pancreatic Carcinoma|Pancreatic Neoplasm|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma,drug or biologic,Early,30,All,NIH&Combos,0,NA,0,2017,2016,1850,0,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
2720,3645,study to assess safety and efficacy of gkt137831 in patients with primary biliary cholangitis receiving ursodeoxycholic acid.,Completed,4,0,0,Primary Biliary Cirrhosis,drug or biologic,Early,111,All,Industry&Combos,1,0,0,2017,2017,654,1,Phase 2,3,safety/efficacy,2,4.709530201312334,"(4,5]"
2181,2646,"a study to testabi-009 in patients with metastatic, unresectable, low or intermediate grade neuroendocrine tumors of the lung or gastroenteropancreatic system",Terminated,5,1,1,Neuroendocrine Tumors,drug or biologic,Early,5,All,Industry&Combos,0,NA,0,2018,2018,788,0,Phase 2,1,NA,1,1.6094379124341003,"(1,2]"
254,258,neoadjuvant modified folfirinox and stereotactic body radiation therapy in borderline resectable pancreatic adenocarcinoma,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,9,All,AllOther,0,NA,0,2017,2017,1681,0,Phase 2,1,NA,1,2.1972245773362196,"(2,3]"
3755,6398,aspirin in preventing colorectal cancer in patients with colorectal adenoma,Recruiting,2,0,0,Colorectal Adenoma,drug or biologic,Early,90,All,NIH&Combos,1,0,1,2016,2018,1323,1,Phase 2,2,NA,2,4.499809670330265,"(4,5]"
3466,5265,ph 2 study of tas-102 / bevacizumab maintenance therapy post induction chemotherapy in metastatic colorectal cancer,Terminated,5,1,1,Metastatic Colorectal Cancer,drug or biologic,Early,4,All,AllOther,0,NA,0,2016,2016,639,0,Phase 2,1,NA,1,1.3862943611198906,"(1,2]"
21,21,mtt for children with asd who have gastrointestinal disorders,Recruiting,2,0,0,Autism Spectrum Disorder|Gastro-Intestinal Disorder|Constipation|Diarrhea,other,Others,70,All,AllOther,1,0,0,2019,2019,958,1,Others,4,NA,2,4.248495242049359,"(4,5]"
2989,4007,"randomized, double-blind, placebo-controlled phase 2 trial of bekinda (ondansetron 12 mg bimodal release tablets) for diarrhea predominant irritable bowel syndrome (ibs-d)",Completed,4,1,1,Irritable Bowel Syndrome With Diarrhea,drug or biologic,Early,127,All,Industry&Combos,1,0,0,2016,2016,393,1,Phase 2,3,NA,2,4.844187086458591,"(4,5]"
3760,6487,"study to evaluate safety, tolerability, and efficacy of gs-0976 in adults with nonalcoholic steatohepatitis",Completed,4,1,1,Nonalcoholic Steatohepatitis (NASH),drug or biologic,Early,127,All,Industry&Combos,NA,0,0,2016,2016,344,NA,Phase 2,2,safety/efficacy,2,4.844187086458591,"(4,5]"
3397,5081,"s1613, trastuzumab and pertuzumab or cetuximab and irinotecan hydrochloride in treating patients with locally advanced or metastatic her2/neu amplified colorectal cancer that cannot be removed by surgery",Recruiting,2,0,0,Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7,drug or biologic,Early,130,All,NIH&Combos,1,0,0,2017,2017,1635,1,Phase 2,0,NA,0,4.867534450455582,"(4,5]"
1966,2313,trial of nanopac Â® in subjects with locally advanced pancreatic adenocarcinoma,Recruiting,2,0,0,Locally Advanced Pancreatic Adenocarcinoma,drug or biologic,Early,65,All,Industry&Combos,NA,1,0,2017,2017,1461,NA,Phase 2,0,NA,0,4.174387269895637,"(4,5]"
2981,3996,extension study of apd334-003 in patients with moderately to severely active ulcerative colitis,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,118,All,Industry&Combos,1,0,0,2015,2015,1096,1,Phase 2,NA,NA,NA,4.770684624465665,"(4,5]"
2780,3733,a study of idn-6556 in subjects with liver cirrhosis,Completed,4,1,1,Liver Cirrhosis|Hepatic Cirrhosis,drug or biologic,Early,87,All,Industry&Combos,1,0,0,2014,2014,518,1,Phase 2,4,NA,2,4.465908118654584,"(4,5]"
1869,2152,enteral fish oil is superior to ursodeoxycholic acid (udca) and placebo for the treatment of cholestasis in infants,Withdrawn,7,0,0,Cholestasis|Liver Disease,drug or biologic,Early,NA,All,AllOther,1,0,0,2015,2016,0,1,Phase 2,0,NA,0,NA,NA
995,1050,transabdominal ultrasound with br55 for characterization of pancreatic lesions,Recruiting,2,0,0,Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,24,All,IndustryNIHPartnership,NA,1,2,2018,2018,1109,NA,Phase 2,0,NA,0,3.1780538303479458,"(3,4]"
733,767,botulinum toxin type a in preventing complications after surgery in patients with esophageal cancer,Recruiting,2,0,0,Esophageal Carcinoma,drug or biologic,Early,50,All,NIH&Combos,1,0,4,2016,2016,1643,1,Phase 2,2,NA,2,3.912023005428146,"(3,4]"
1071,1129,neoadjuvant folfox therapy with short course radiation and active surveillance in locally advanced rectal cancer,Recruiting,2,0,0,Advanced Rectal Cancer,drug or biologic,Early,40,All,AllOther,0,NA,0,2018,2019,1125,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3081,4158,"study to assess the efficacy, safety and tolerability of lcq908 in nafld patients",Completed,4,1,1,Non-alcoholic Fatty Liver Disease (NAFLD),drug or biologic,Early,52,All,Industry&Combos,1,0,0,2013,2013,457,1,Phase 2,4,safety/efficacy,2,3.9512437185814275,"(3,4]"
731,765,safety and tolerability study of an edible colon preparation,Completed,4,0,0,Bowel Preparation,drug or biologic,Early,69,All,Industry&Combos,1,0,4,2015,2015,397,1,Phase 2,1,safety,1,4.23410650459726,"(4,5]"
2056,2438,fluoroscopy or 3-d roadmap imaging software for liver tumor treatment,Completed,4,0,0,Image-Guided Surgery,other,Others,28,All,NIH&Combos,1,0,2,2013,2013,909,1,Others,0,NA,0,3.332204510175204,"(3,4]"
901,946,"liposomal irinotecan, fluorouracil and leucovorin in treating patients with refractory advanced high grade neuroendocrine cancer of gastrointestinal, unknown, or pancreatic origin",Recruiting,2,0,0,Locally Advanced Digestive System Neuroendocrine Carcinoma|Locally Advanced Pancreatic Neuroendocrine Carcinoma|Metastatic Digestive System Neuroendocrine Carcinoma|Metastatic Pancreatic Neuroendocrine Carcinoma|Refractory Digestive System Neuroendocrine Carcinoma|Refractory Pancreatic Neuroendocrine Carcinoma|Unresectable Digestive System Neuroendocrine Carcinoma|Unresectable Pancreatic Neuroendocrine Carcinoma,drug or biologic,Early,37,All,IndustryNIHPartnership,0,NA,0,2018,2019,1176,0,Phase 2,1,NA,1,3.6109179126442243,"(3,4]"
2980,3995,a study to evaluate the efficacy and safety of pf-06480605 in adult participants with moderate to severe ulcerative colitis,Recruiting,2,0,0,Moderate to Severe Ulcerative Colitis,drug or biologic,Early,240,All,Industry&Combos,1,0,0,2019,2019,1144,1,Phase 2,2,safety/efficacy,2,5.480638923341991,"(5,6]"
2285,2859,study of chemotherapy with or without hepatic arterial infusion for patients with unresectable metastatic colorectal cancer to the liver,Withdrawn,7,0,0,Colorectal Adenocarcinoma Metastatic to the Liver,drug or biologic,Early,NA,All,AllOther,1,0,0,2017,2017,807,1,Phase 2,0,NA,0,NA,NA
168,169,testing the combination of two approved chemotherapy drugs and radiation prior to surgery in localized pancreatic cancer,Recruiting,2,0,0,Pancreas Adenocarcinoma|Resectable Pancreatic Cancer,drug or biologic,Early,30,All,AllOther,0,NA,0,2018,2019,1902,0,Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
1170,1244,irinotecan -eluting lc bead-m1 (debiri-m1) for patients with liver metastases from colorectal cancer,Completed,4,1,1,Colorectal Cancer,drug or biologic,Early,14,All,AllOther,0,NA,0,2013,2014,486,0,Phase 2,1,NA,1,2.6390573296152584,"(2,3]"
525,546,minocycline study in pancreatic cancer patients,Completed,4,1,1,Pancreatic Cancer,drug or biologic,Early,80,All,NIH&Combos,1,0,0,2012,2013,2060,1,Phase 2,2,NA,2,4.382026634673881,"(4,5]"
2851,3824,"a phase 2, multi-center study to evaluate the efficacy and safety of ono-2952 in female subjects with diarrhea-predominant irritable bowel syndrome (ibs-d)",Completed,4,0,0,Irritable Bowel Syndrome (IBS),drug or biologic,Early,200,Female,Industry&Combos,1,0,0,2013,2013,456,1,Phase 2,2,safety/efficacy,2,5.298317366548036,"(5,6]"
3291,4660,"safety, tolerability, pharmacokinetics and efficacy of eyp001a in patients with nonalcoholic steatohepatitis (nash)",Recruiting,2,0,0,Non-alcoholic Steatohepatitis,drug or biologic,Early,160,All,Industry&Combos,1,0,0,2019,2019,873,1,Phase 2,3,safety/efficacy,2,5.075173815233827,"(5,6]"
3443,5234,"study of pembrolizumab, binimetinib, and bevacizumab in patients with refractory colorectal cancer",Recruiting,2,0,0,Colorectal Cancer|Metastatic Cancer,drug or biologic,Early,40,All,AllOther,0,0,0,2018,2018,1201,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3387,5033,"a study to evaluate the safety, tolerability & efficacy of msdc-0602k in patients with nash",Completed,4,1,1,Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis|NASH - Nonalcoholic Steatohepatitis,drug or biologic,Early,392,All,Industry&Combos,1,0,0,2016,2016,990,1,Phase 2,4,safety/efficacy,2,5.971261839790462,"(5,6]"
2008,2367,evaluate esophageal reinforcement with acell matristem surgical matrix: a degradable biologic scaffold material,"Active, not recruiting",1,0,0,Esophageal Adenocarcinoma,device,Others,78,All,Industry&Combos,0,NA,0,2013,2013,2905,0,Others,1,NA,1,4.356708826689592,"(4,5]"
3056,4108,a safety and efficacy study of xermelo Â® + first-line chemotherapy in patients with advanced biliary tract cancer,"Active, not recruiting",1,0,0,Biliary Tract Cancer,drug or biologic,Early,53,All,Industry&Combos,0,NA,0,2018,2019,1023,0,Phase 2,1,safety/efficacy,1,3.970291913552122,"(3,4]"
2030,2399,lgcp (laparoscopic greater curvature plication),Withdrawn,7,0,0,Obesity,procedure,Others,NA,All,AllOther,0,NA,0,2011,2013,913,0,Others,1,NA,1,NA,NA
3305,4699,phase ii trial of pembrolizumab with trastuzumab and chemotherapy in advanced her2 positive esophagogastric (eg) cancer,"Active, not recruiting",1,0,0,Esophageal Cancer|Gastric Cancer,drug or biologic,Early,37,All,AllOther,0,NA,0,2016,2016,1824,0,Phase 2,1,NA,1,3.6109179126442243,"(3,4]"
2688,3605,study to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease,"Active, not recruiting",1,0,0,Inflammatory Bowel Disease,drug or biologic,Early,250,Male,Industry&Combos,1,0,0,2017,2017,1116,1,Phase 2,2,safety,2,5.521460917862246,"(5,6]"
2898,3886,a study of mln0264 in participants with cancer of the stomach or gastroesophageal junction,Terminated,5,1,1,Adenocarcinoma of the Stomach|Gastroesophageal Junction Expressing Guanylyl Cyclase C,drug or biologic,Early,38,All,Industry&Combos,0,NA,0,2014,2014,529,0,Phase 2,1,NA,1,3.6375861597263857,"(3,4]"
2547,3422,"a safety and efficacy study of zw25 (zanidatamab) plus combination chemotherapy in her2-expressing gastrointestinal cancers, including gastroesophageal adenocarcinoma, biliary tract cancer, and colorectal cancer",Recruiting,2,0,0,"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",drug or biologic,Early,362,All,Industry&Combos,1,1,0,2019,2019,1310,1,Phase 2,0,safety/efficacy,0,5.8916442118257715,"(5,6]"
1405,1509,choosing the best antibiotic to protect friendly gut bacteria during the course of stem cell transplant,Recruiting,2,0,0,Intestinal Microbiome|Febrile Neutropenia,drug or biologic,Early,144,All,AllOther,1,0,0,2017,2017,1817,1,Phase 2,0,NA,0,4.969813299576001,"(4,5]"
1240,1324,gut microbiota changes after fecal microbiota transplantation,Unknown status,8,0,0,Clostridium Difficile Infection,drug or biologic,Early,6,All,AllOther,0,NA,0,2015,2015,274,0,Phase 2,1,NA,1,1.791759469228055,"(1,2]"
2783,3738,safety and efficacy study of ptg-100 in the treatment of moderate to severe ulcerative colitis,Terminated,5,1,1,Ulcerative Colitis,drug or biologic,Early,100,All,Industry&Combos,1,0,0,2016,2016,480,1,Phase 2,3,safety/efficacy,2,4.605170185988092,"(4,5]"
25,25,phase ii study of the effects of laparoscopic hyperthermic intraperitoneal chemotherapy (hipec) in patients with advanced gastric cancer,Recruiting,2,0,0,Gastric Cancer|Peritoneal Carcinomatosis,drug or biologic,Early,21,All,AllOther,0,NA,0,2019,2019,1298,0,Phase 2,1,NA,1,3.044522437723423,"(3,4]"
3330,4756,a trial of perioperative cv301 vaccination in combination with nivolumab and systemic chemotherapy for metastatic crc,"Active, not recruiting",1,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,78,All,Industry&Combos,1,0,0,2018,2018,1254,1,Phase 2,0,NA,0,4.356708826689592,"(4,5]"
2173,2630,"pembrolizumab, paclitaxel, and carboplatin in patients with advanced stage epithelial ovarian cancer (eoc).",Recruiting,2,0,0,Fallopian Tube Cancer|Peritoneum Cancer|Epithelial Ovarian Cancer,drug or biologic,Early,40,Female,Industry&Combos,0,NA,0,2016,2016,2170,0,Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
1865,2145,iv ibuprofen for the prevention of post-ercp pancreatitis,Terminated,5,1,1,Post-ERCP Acute Pancreatitis,drug or biologic,Early,69,All,AllOther,1,0,1,2014,2014,1461,1,Phase 2,3,NA,2,4.23410650459726,"(4,5]"
3044,4089,genotype-directed study of irinotecan dosing in folfiri + bevacizumabtreated metastatic colorectal cancer,"Active, not recruiting",1,0,0,Colon Cancer,drug or biologic,Early,100,All,AllOther,1,1,0,2014,2014,2557,1,Phase 2,0,NA,0,4.605170185988092,"(4,5]"
1390,1491,the use of hepatitis c positive livers in hepatitis c negative liver transplant recipients,Recruiting,2,0,0,Liver Transplant|Hepatitis C,drug or biologic,Early,20,All,AllOther,1,1,0,2019,2019,1721,1,Phase 2,0,NA,0,2.995732273553991,"(2,3]"
3123,4237,breathid octanoate breath test with or without methacetin breath test for correlation with biopsy in nash,Completed,4,1,1,Non-Alcoholic Steatohepatitis,device,Others,140,All,Industry&Combos,0,NA,2,2014,2015,823,0,Others,1,NA,1,4.941642422609304,"(4,5]"
216,219,palliative management of inoperable malignant bowel obstruction,Recruiting,2,0,0,Malignant Bowel Obstruction,drug or biologic,Early,59,All,NIH&Combos,0,NA,0,2019,2019,985,0,Phase 2,1,NA,1,4.07753744390572,"(4,5]"
869,912,hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid in treating patients with locally advanced pancreatic cancer,Recruiting,2,0,0,Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage I Pancreatic Cancer AJCC v6 and v7|Stage IA Pancreatic Cancer AJCC v6 and v7|Stage IB Pancreatic Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7,drug or biologic,Early,44,All,NIH&Combos,1,0,0,2017,2016,1902,1,Phase 2,0,NA,0,3.784189633918261,"(3,4]"
2826,3788,efficacy of crown in repair and maintenance of the intestinal mucosa in patients with cd receiving anti-tnf therapy,Terminated,5,0,0,Crohn's Disease,drug or biologic,Early,42,All,Industry&Combos,1,0,0,2016,2016,700,1,Phase 2,4,efficacy,2,3.7376696182833684,"(3,4]"
3076,4146,buspirone for early satiety and symptoms of gastroparesis,Recruiting,2,0,0,Gastroparesis,drug or biologic,Early,108,All,NIH&Combos,1,0,0,2018,2019,719,1,Phase 2,3,NA,2,4.68213122712422,"(4,5]"
421,433,pilot study of the effect of liraglutide on weight loss and gastric functions in obesity,Completed,4,1,1,Obesity,drug or biologic,Early,40,All,IndustryNIHPartnership,2,0,0,2016,2015,378,1,Phase 2,2,NA,2,3.6888794541139363,"(3,4]"
819,857,the impact of adjuvant liquid alginate on endoscopic ablation therapy of complicated barrett's esophagus,"Active, not recruiting",1,0,0,Barretts Esophagus With Dysplasia,drug or biologic,Early,24,All,AllOther,0,NA,0,2017,2017,1741,0,Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
2686,3603,a study of cabiralizumab given with nivolumab with and without chemotherapy in patients with advanced pancreatic cancer,"Active, not recruiting",1,0,0,Advanced Pancreatic Cancer,drug or biologic,Early,179,All,Industry&Combos,1,0,0,2017,2017,1095,1,Phase 2,0,NA,0,5.187385805840755,"(5,6]"
3433,5224,circulating cell-free tumor dna testing in guiding treatment for patients with advanced or metastatic colorectal cancer,Recruiting,2,0,0,Refractory Colorectal Carcinoma|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,drug or biologic,Early,100,All,NIH&Combos,1,0,0,2019,2019,945,1,Phase 2,0,NA,0,4.605170185988092,"(4,5]"
304,309,"study with cy, pembrolizumab, gvax, and sbrt in patients with locally advanced pancreatic cancer","Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,58,All,Industry&Combos,0,NA,0,2016,2016,1809,0,Phase 2,1,NA,1,4.060443010546419,"(4,5]"
2617,3516,clinical trial to evaluation the safety and efficacy of gr-md-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with nash cirrhosis,Completed,4,1,1,"Hypertension, Portal",drug or biologic,Early,162,All,Industry&Combos,1,0,0,2015,2015,853,1,Phase 2,4,safety/efficacy,2,5.087596335232384,"(5,6]"
466,481,a study of experimental medication bms-986263 in adults with advanced hepatic fibrosis after cure of hepatitis c,Completed,4,0,0,Hepatic Cirrhosis|Liver Fibrosis,drug or biologic,Early,61,All,Industry&Combos,1,0,0,2018,2018,299,1,Phase 2,4,NA,2,4.110873864173311,"(4,5]"
638,665,compassionate use of omegaven Â® for the treatment of intestinal failure associated liver disease in children,Completed,4,0,0,Total Parenteral Nutrition-Induced Cholestasis,drug or biologic,Early,6,All,AllOther,0,NA,0,2014,2015,952,0,Phase 2,1,NA,1,1.791759469228055,"(1,2]"
2508,3329,abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: big ten cancer research consortium btcrc-gi18-149,"Active, not recruiting",1,0,0,Gastroesophageal Cancer|Adenocarcinoma,drug or biologic,Early,3,All,Industry&Combos,0,NA,0,2019,2019,706,0,Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
2878,3859,efficacy and safety of bbt-401-1s in ulcerative colitis,Terminated,5,0,0,Ulcerative Colitis,drug or biologic,Early,16,All,Industry&Combos,1,0,0,2019,2019,392,1,Phase 2,4,safety/efficacy,2,2.772588722239781,"(2,3]"
2198,2679,"ziv-aflibercept followed by ziv-aflibercept, fluorouracil, and leucovorin calcium in treating patients with stage iv colorectal cancer",Withdrawn,7,0,0,Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,drug or biologic,Early,NA,All,NIH&Combos,0,NA,0,2014,2015,731,0,Phase 2,1,NA,1,NA,NA
2821,3781,study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in adults with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma,Completed,4,1,1,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,144,All,Industry&Combos,1,0,0,2016,2016,433,1,Phase 2,0,safety/efficacy,0,4.969813299576001,"(4,5]"
3645,5776,effect of over-the-counter toothpastes on chemotherapy-induced oral mucositis,Terminated,5,0,0,Mucositis|Neoplasms,drug or biologic,Early,1,All,Industry&Combos,1,0,0,2015,2018,251,1,Phase 2,1,NA,1,0,NA
2262,2804,vancomycin for c difficile naat+/eia- hematology oncology patients,Completed,4,0,0,Clostridium Difficile Infection|Hematologic Diseases|Bone Marrow Transplant|Oncologic Disorders,drug or biologic,Early,9,All,AllOther,1,0,0,2017,2018,760,1,Phase 2,3,NA,2,2.1972245773362196,"(2,3]"
1681,1854,"gemcitabine hydrochloride, cisplatin, and nab-paclitaxel in treating patients with advanced or metastatic biliary cancers",Completed,4,0,0,Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma,drug or biologic,Early,62,All,NIH&Combos,0,NA,0,2015,2015,1960,0,Phase 2,1,NA,1,4.127134385045092,"(4,5]"
2019,2385,vitamin c infusion for treatment in sepsis and alcoholic hepatitis,Recruiting,2,0,0,Alcoholic Hepatitis|Sepsis,drug or biologic,Early,20,All,NIH&Combos,1,0,0,2019,2019,960,1,Phase 2,4,NA,2,2.995732273553991,"(2,3]"
786,823,lanifibranor in patients with type 2 diabetes & nonalcoholic fatty liver disease,Recruiting,2,0,0,Nonalcoholic Fatty Liver Disease (NAFLD)|Type 2 Diabetes (T2DM),drug or biologic,Early,44,All,Industry&Combos,1,0,0,2018,2018,1326,1,Phase 2,4,NA,2,3.784189633918261,"(3,4]"
3130,4253,"study of efficacy, safety, tolerability, pharmacokinetic (pk) and pharmacodynamic (pd) of an anti-cd40 monoclonal antibody, cfz533, in liver transplant recipients with additional 12-month follow-up",Recruiting,2,0,0,Liver Transplant Rejection,drug or biologic,Early,128,All,Industry&Combos,1,0,0,2018,2019,998,1,Phase 2,0,safety/efficacy,0,4.852030263919617,"(4,5]"
2908,3898,"safety, tolerability, efficacy and dose-response of gsk2831781 in ulcerative colitis",Terminated,5,0,0,"Colitis, Ulcerative",drug or biologic,Early,104,All,Industry&Combos,1,0,0,2019,2019,742,1,Phase 2,2,safety/efficacy,2,4.6443908991413725,"(4,5]"
3757,6477,"evaluation of efficacy, safety and tolerability of aldafermin in a phase 2b, randomized, double-blind, placebo-controlled, multi-center study in subjects with nonalcoholic steatohepatitis and stage 2/3 fibrosis (alpine 2/3)","Active, not recruiting",1,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,152,All,Industry&Combos,1,0,0,2019,2019,792,1,Phase 2,4,safety/efficacy,2,5.0238805208462765,"(5,6]"
464,479,low dose naltrexone in symptomatic inflammatory bowel disease,Withdrawn,7,0,0,Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis,drug or biologic,Early,NA,All,AllOther,1,0,0,2013,2013,365,1,Phase 2,4,NA,2,NA,NA
3005,4030,a research study on how semaglutide works in people with fatty liver disease and liver damage,Completed,4,0,0,Non-alcoholic Steatohepatitis,drug or biologic,Early,65,All,Industry&Combos,1,0,0,2019,2019,674,1,Phase 2,4,NA,2,4.174387269895637,"(4,5]"
3092,4183,dose response study of gsk2330672 for the treatment of pruritus in participants with primary biliary cholangitis,Completed,4,1,1,Cholestasis,drug or biologic,Early,147,All,Industry&Combos,1,0,0,2016,2017,1190,1,Phase 2,2,NA,2,4.990432586778736,"(4,5]"
2923,3924,"a phase 2a, proof-of-concept study of gic-1001 in the management of visceral pain during sedation-free, full colonoscopy",Completed,4,1,1,Pain|Cancer|Colonic Diseases,drug or biologic,Early,308,All,Industry&Combos,1,0,1,2013,2013,243,1,Phase 2,4,NA,2,5.730099782973574,"(5,6]"
2958,3965,a study assessing the efficacy and safety of cbp-307 in subjects with moderate to severe ulcerative colitis (uc),Recruiting,2,0,0,Moderate to Severe Ulcerative Colitis,drug or biologic,Early,134,All,Industry&Combos,1,0,0,2021,2019,1008,1,Phase 2,4,safety/efficacy,2,4.897839799950911,"(4,5]"
253,257,study of neoadjuvent chemotherapy followed by sbrt in patients with resectable and borderline resectable pancreatic cancer,Withdrawn,7,0,0,Pancreatic Cancer|Pancreatic Adenocarcinoma,drug or biologic,Early,NA,All,AllOther,0,NA,0,2019,2019,915,0,Phase 2,1,NA,1,NA,NA
3951,7368,binimetinib and palbociclib or tas-102 in treating patients with kras and nras mutant metastatic or unresectable colorectal cancer,"Active, not recruiting",1,0,0,Metastatic Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Unresectable Carcinoma,drug or biologic,Early,101,All,NIH&Combos,3,0,0,2019,2019,483,3,Phase 2,0,NA,0,4.61512051684126,"(4,5]"
490,508,prebiotic to improve calcium absorption,Completed,4,0,0,Obesity,other,Others,20,Female,NA,1,0,4,2017,2017,801,1,Others,4,NA,2,2.995732273553991,"(2,3]"
2058,2442,mepo for eoe study,Recruiting,2,0,0,EoE|Eosinophilic Esophagitis,drug or biologic,Early,72,All,Industry&Combos,1,0,0,2018,2019,1169,1,Phase 2,3,NA,2,4.276666119016055,"(4,5]"
3555,5458,a study evaluating participants with moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn Disease,drug or biologic,Early,90,All,Industry&Combos,1,0,0,2019,2019,826,1,Phase 2,4,NA,2,4.499809670330265,"(4,5]"
926,973,fexofenadine use in gastroesophageal reflux symptoms,Terminated,5,1,1,Gastroesophageal Reflux,drug or biologic,Early,11,All,AllOther,3,0,0,2018,2018,335,3,Phase 2,2,NA,2,2.3978952727983707,"(2,3]"
3815,6761,olanzapine for nausea after surgery,Completed,4,1,1,Postoperative Nausea and Vomiting,drug or biologic,Early,180,Female,AllOther,1,0,1,2016,2016,1252,1,Phase 2,3,NA,2,5.19295685089021,"(5,6]"
3260,4585,study of safety and efficacy of tropifexor (ljn452) in patients with non-alcoholic steatohepatitis (nash),Completed,4,0,0,Non-alcoholic Steatohepatitis (NASH),drug or biologic,Early,351,All,Industry&Combos,1,0,0,2016,2016,1344,1,Phase 2,3,safety/efficacy,2,5.860786223465865,"(5,6]"
2405,3102,"study of the safety and efficacy of hydrocortisone acetate suppositories, 25 mg in the treatment of symptomatic internal hemorrhoids",Completed,4,0,0,Internal Hemorrhoids,drug or biologic,Early,103,All,Industry&Combos,1,0,0,2017,2019,752,1,Phase 2,4,safety/efficacy,2,4.634728988229636,"(4,5]"
286,291,acp-196 alone and in combination with pembrolizumab in subjects with advanced or metastatic pancreatic cancer,Completed,4,1,1,Metastatic Pancreatic Cancer,drug or biologic,Early,77,All,Industry&Combos,1,0,0,2015,2015,670,1,Phase 2,0,NA,0,4.343805421853684,"(4,5]"
2097,2505,efficacy of oral vancomycin prophylaxis for prevention of recurrent clostridium difficile infection,Recruiting,2,0,0,Recurrent Clostridium Difficile Infection|Clostridium Difficile Infection|CDI|C.Difficile Diarrhea|C. Diff Colitis|C.Difficile Colitis,drug or biologic,Early,150,All,AllOther,1,0,1,2018,2018,1136,1,Phase 2,2,efficacy,2,5.0106352940962555,"(5,6]"
157,157,molecularly tailored therapy to standard of care as second-line therapy in metastatic pancreatic cancer,Withdrawn,7,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2016,2016,667,1,Phase 2,0,NA,0,NA,NA
2984,4001,efficacy and safety of oral bt-11 in mild to moderate ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Early,198,All,Industry&Combos,1,0,0,2019,2019,687,1,Phase 2,3,safety/efficacy,2,5.288267030694535,"(5,6]"
3169,4336,a double-blind study to assess 2 doses of an investigational product for 16 weeks in participants with non-alcoholic fatty liver disease and type 2 diabetes mellitus,Completed,4,0,0,Non-alcoholic Steatohepatitis,drug or biologic,Early,164,All,Industry&Combos,1,0,4,2019,2019,593,1,Phase 2,2,NA,2,5.099866427824199,"(5,6]"
3942,7350,irinotecan and cetuximab with or without bevacizumab in treating patients with ras wild-type locally advanced or metastatic colorectal cancer that cannot be removed by surgery,Completed,4,1,1,Colorectal Adenocarcinoma|RAS Wild Type|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,36,All,NIH&Combos,1,0,0,2014,2014,1559,1,Phase 2,2,NA,2,3.58351893845611,"(3,4]"
3148,4281,treatment of septic shock by inhibiting autodigestion and preserving gut integrity with enteric lb1148,Terminated,5,1,1,Septic Shock,drug or biologic,Early,8,All,Industry&Combos,1,0,0,2014,2015,335,1,Phase 2,3,NA,2,2.0794415416798357,"(2,3]"
3053,4104,randomized embolization trial for neuroendocrine tumor metastases to the liver,Recruiting,2,0,0,"Neuroendocrine Tumor, Malignant|Liver Metastases",drug or biologic,Early,180,All,Industry&Combos,1,0,0,2016,2016,2556,1,Phase 2,0,NA,0,5.19295685089021,"(5,6]"
812,849,autologous stem cell transplant for crohn's disease,Recruiting,2,0,0,Crohn Disease,drug or biologic,Early,50,All,AllOther,0,NA,0,2017,2017,1846,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
3019,4054,"efficacy, safety and tolerability of pf-06687234 as add-on therapy to infliximab in active uc subjects not in remission.",Terminated,5,0,0,Ulcerative Colitis,drug or biologic,Early,20,All,Industry&Combos,1,0,0,2017,2017,1114,1,Phase 2,3,safety/efficacy,2,2.995732273553991,"(2,3]"
3733,6254,folfiri and panitumumab in treating patients with ras and braf wild-type metastatic colorectal cancer,Terminated,5,1,1,Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,drug or biologic,Early,1,All,NIH&Combos,0,NA,0,2015,2016,575,0,Phase 2,1,NA,1,0,NA
736,770,combination of tate and pd-1 inhibitor in liver cancer,Recruiting,2,0,0,Hepatocellular Carcinoma|Colorectal Neoplasms|Gastric Cancer|Lung Cancer,drug or biologic,Early,80,All,Industry&Combos,0,1,0,2017,2017,1644,0,Phase 2,1,NA,1,4.382026634673881,"(4,5]"
2938,3939,"study to evaluate the safety, tolerability, and efficacy of cilofexor in adults with primary biliary cholangitis without cirrhosis",Terminated,5,1,1,Primary Biliary Cholangitis,drug or biologic,Early,71,All,Industry&Combos,1,0,0,2016,2016,1007,1,Phase 2,2,safety/efficacy,2,4.2626798770413155,"(4,5]"
2443,3176,interventional bioremediation of microbiota in metabolic syndrome,Terminated,5,1,1,Pre-Diabetes,drug or biologic,Early,12,All,AllOther,1,0,0,2016,2016,579,1,Phase 2,2,NA,2,2.4849066497880004,"(2,3]"
1989,2340,a pilot evaluation of bli4900 bowel preparation in adult subjects,Completed,4,0,0,Colonoscopy,drug or biologic,Early,143,All,Industry&Combos,NA,1,0,2017,2017,733,NA,Phase 2,0,NA,0,4.962844630259907,"(4,5]"
4179,9236,safety and immunogenicity of norovirus gi.1/gii.4 bivalent virus-like particle vaccine in an elderly population,Completed,4,1,1,Norovirus,drug or biologic,Early,320,All,Industry&Combos,1,0,1,2016,2016,270,1,Phase 2,4,safety,2,5.768320995793772,"(5,6]"
746,781,pangea-imbbp: personalized antibodies for gastro-esophageal adenocarcinoma - a 1st pilot metastatic trial of biologics beyond progression,Completed,4,1,1,Adenocarcinoma,drug or biologic,Early,80,All,Industry&Combos,1,1,0,2014,2015,1838,1,Phase 2,0,NA,0,4.382026634673881,"(4,5]"
1108,1172,exist study of ly2157299 (galunisertib) in rectal cancer,Recruiting,2,0,0,Rectal Adenocarcinoma,drug or biologic,Early,50,All,Industry&Combos,0,NA,0,2016,2016,2009,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
1417,1524,palbociclib and cetuximab in metastatic colorectal cancer,Recruiting,2,0,0,"Cancer of the Colon|Colon Cancer|Colon Neoplasms|Colonic Cancer|Neoplasms, Colonic",drug or biologic,Early,57,All,Industry&Combos,0,NA,0,2018,2018,1767,0,Phase 2,1,NA,1,4.04305126783455,"(4,5]"
417,428,nivolumab and ipilimumab and radiation therapy in mss and msi high colorectal and pancreatic cancer,Recruiting,2,0,0,Microsatellite Stable Colorectal Cancer|Pancreatic Cancer|MSI High Colorectal Cancer,drug or biologic,Early,80,All,Industry&Combos,0,NA,0,2017,2017,1908,0,Phase 2,1,NA,1,4.382026634673881,"(4,5]"
2631,3534,"phase 2, nab paclitaxel/gemcitabine alone and in combination with acp-196 in subjects with metastatic pancreatic cancer",Terminated,5,1,1,Metastatic Pancreatic Cancer,drug or biologic,Early,3,All,Industry&Combos,1,0,0,2015,2015,171,1,Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
2619,3520,mrx-800: a long-term safety study of maralixibat in the treatment of cholestatic liver disease in subjects who previously participated in a maralixibat study,Enrolling by invitation,3,0,0,Cholestatic Liver Disease,drug or biologic,Early,124,All,Industry&Combos,0,NA,0,2019,2019,1780,0,Phase 2,1,safety,1,4.820281565605037,"(4,5]"
305,310,role of interim 18f-flt pet/ct for outcome prediction in pancreatic adenocarcinoma,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,6,All,AllOther,0,NA,2,2017,2017,1481,0,Phase 2,1,NA,1,1.791759469228055,"(1,2]"
1573,1716,docusate/senna for the treatment of diabetic gastroparesis,Terminated,5,1,1,Diabetic Gastroparesis,drug or biologic,Early,2,All,AllOther,1,0,0,2017,2018,137,1,Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
3209,4466,a phase 2b study of icosabutate in fatty liver disease,Recruiting,2,0,0,Non Alcoholic Steatohepatitis (NASH),drug or biologic,Early,264,All,Industry&Combos,1,0,0,2019,2019,719,1,Phase 2,4,NA,2,5.575949103146316,"(5,6]"
3176,4365,study on the effectiveness and safety of the combination of the two drugs regorafenib and nivolumab in patients with colorectal cancer (cancer of the colon or rectum classified as proficient mismatch repair and microsatellite stable),"Active, not recruiting",1,0,0,Colorectal Cancer,drug or biologic,Early,70,All,Industry&Combos,0,NA,0,2019,2019,394,0,Phase 2,1,safety,1,4.248495242049359,"(4,5]"
2148,2584,open-label study to evaluate mn-001 on hdl & triglyceride in nash & nafld subjects,Completed,4,0,0,Non-alcoholic Steatohepatitis|Hypertriglyceridemia|Non-alcoholic Fatty Liver Disease|Hypercholesterolemia,drug or biologic,Early,19,All,Industry&Combos,0,NA,0,2016,2016,820,0,Phase 2,1,NA,1,2.9444389791664403,"(2,3]"
886,930,"danvatirsen and durvalumab in treating patients with advanced and refractory pancreatic, non-small cell lung cancer, and mismatch repair deficient colorectal cancer","Active, not recruiting",1,0,0,Advanced Colorectal Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Lung Non-Small Cell Carcinoma|Mismatch Repair Deficiency|Refractory Colorectal Carcinoma|Refractory Lung Carcinoma|Refractory Pancreatic Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,drug or biologic,Early,53,All,IndustryNIHPartnership,0,NA,0,2016,2017,1490,0,Phase 2,1,NA,1,3.970291913552122,"(3,4]"
3587,5604,"phase 2 randomized, double-blind, placebo-controlled, parallel group trial of linaclotide administered to patients with opioid-induced constipation receiving chronic opioid treatment for non-cancer pain",Completed,4,1,1,Opioid-Induced Constipation,drug or biologic,Early,254,All,Industry&Combos,1,0,0,2014,2014,304,1,Phase 2,4,NA,2,5.537334267018537,"(5,6]"
124,124,"perioperative mvt-5873, a fully human monoclonal antibody against a ca 19-9 epitope, for operable ca 19-9 producing pancreatic cancers, cholangiocarcinomas, and metastatic colorectal cancers",Recruiting,2,0,0,Colon Cancer|Pancreatic Cancer|Cholangiocarcinoma|Mestatic Colon Carcinoma|Liver Metastasis,drug or biologic,Early,105,All,NIH&Combos,NA,1,0,2019,2019,1509,NA,Phase 2,0,NA,0,4.653960350157523,"(4,5]"
2649,3554,study of bgb-290 or placebo in participants with advanced or inoperable gastric cancer,"Active, not recruiting",1,0,0,Advanced or Inoperable Gastric Cancer,drug or biologic,Early,136,All,Industry&Combos,1,0,0,2018,2018,786,1,Phase 2,2,NA,2,4.912654885736052,"(4,5]"
994,1049,the effects of patiromer on serum potassium level and gut microbiome of esrd patients with hyperkalemia,Unknown status,8,0,0,ESRD|Hyperkalemia|End Stage Renal Disease,drug or biologic,Early,25,All,AllOther,3,1,0,2017,2017,516,3,Phase 2,0,NA,0,3.2188758248682006,"(3,4]"
3349,4864,rollover protocol for subjects who have responded on study 4218s - a phase 2 study,Completed,4,0,0,Neuroendocrine Tumors,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2014,2014,609,0,Phase 2,1,NA,1,1.9459101490553132,"(1,2]"
397,408,"durvalumab and ""booster"" radiation in metastatic adenocarcinoma of the pancreas","Active, not recruiting",1,0,0,Adenocarcinoma of the Pancreas,drug or biologic,Early,39,All,Industry&Combos,0,NA,0,2018,2018,2510,0,Phase 2,1,NA,1,3.6635616461296463,"(3,4]"
1267,1352,"safety, tolerability and efficacy of saroglitazar mg 4 mg in liver transplant recipients with nafld",Recruiting,2,0,0,Liver Transplant; Complications|NAFLD,drug or biologic,Early,15,All,Industry&Combos,0,NA,0,2018,2019,1010,0,Phase 2,1,safety/efficacy,1,2.70805020110221,"(2,3]"
1700,1881,the efficacy of probiotics to reduce antepartum group b streptococcus colonization.,"Active, not recruiting",1,0,0,Group B Streptococcus Carrier in Childbirth|Gastrointestinal Symptoms,drug or biologic,Early,116,Female,AllOther,2,0,1,2018,2019,880,1,Phase 2,3,efficacy,2,4.7535901911063645,"(4,5]"
2448,3188,a safety and efficacy study of dcl-101 compared to golytely,Completed,4,0,0,Bowel Preparation Before Colonoscopy,drug or biologic,Early,46,All,Industry&Combos,1,0,0,2016,2017,304,1,Phase 2,2,safety/efficacy,2,3.828641396489095,"(3,4]"
2564,3444,phase 2 study of amg 337 in met amplified gastric/esophageal adenocarcinoma or other solid tumors,Terminated,5,0,0,Stomach Neoplasms,drug or biologic,Early,60,All,Industry&Combos,0,NA,0,2013,2014,973,0,Phase 2,1,NA,1,4.0943445622221,"(4,5]"
2595,3491,"efficacy, safety, and pharmacokinetics of apt-1011 in subjects with eosinophilic esophagitis (eoe)",Completed,4,0,0,Eosinophilic Esophagitis,drug or biologic,Early,106,All,Industry&Combos,1,0,0,2017,2017,560,1,Phase 2,4,safety/efficacy,2,4.663439094112067,"(4,5]"
3375,4979,study of a monoclonal antibody khk4083 in moderate ulcerative colitis,Completed,4,1,1,"Ulcerative Colitis|Digestive System Diseases|Colitis, Ulcerative|Colitis|Gastrointestinal Diseases|Inflammatory Bowel Diseases|Intestinal Diseases|Colonic Diseases|Autoimmune Disease|Abdominal Pain",drug or biologic,Early,66,All,Industry&Combos,NA,0,0,2016,2016,822,NA,Phase 2,4,NA,2,4.189654742026425,"(4,5]"
1082,1142,"sequential, related donor partial liver transplantation followed by bone marrow transplantation for hepatocellular carcinoma (hcc)",Withdrawn,7,0,0,Fibrolamellar Hepatocellular Carcinoma|Hepatocellular Carcinoma (Fibrolamellar Variant)|Hepatocellular Carcinoma,drug or biologic,Early,NA,All,AllOther,0,NA,0,2016,2016,673,0,Phase 2,1,NA,1,NA,NA
2571,3457,trial of mfolfox6 + trastuzumab + avelumab in gastric and esophageal adenocarcinomas,"Active, not recruiting",1,0,0,Gastric Adenocarcinoma|Esophageal Adenocarcinoma|Metastasis|HER-2 Gene Amplification,drug or biologic,Early,18,Female,Industry&Combos,0,NA,0,2018,2019,596,0,Phase 2,1,NA,1,2.8903717578961645,"(2,3]"
3746,6329,linaclotide safety and efficacy in 2 to 5-year-old participants with functional constipation,Completed,4,0,0,Functional Constipation,drug or biologic,Early,35,All,Industry&Combos,NA,0,0,2019,2019,554,NA,Phase 2,3,safety/efficacy,2,3.5553480614894135,"(3,4]"
959,1009,efficacy and safety of bisacodyl and lactulose as a preparation for colonoscopy,Completed,4,1,1,Colonoscopy Preparation,drug or biologic,Early,32,All,Industry&Combos,0,1,0,2014,2014,122,0,Phase 2,1,safety/efficacy,1,3.4657359027997265,"(3,4]"
2108,2519,a randomized controlled clinical trial of thymoglobulin Â® after liver transplantation,Completed,4,1,1,Liver Failure,drug or biologic,Early,110,All,AllOther,1,0,0,2015,2015,938,1,Phase 2,0,NA,0,4.700480365792417,"(4,5]"
760,796,pilot study of fundamental modification of the gut microbiota in the treatment of refractory crohn's disease,Completed,4,0,0,Crohn Disease,drug or biologic,Early,10,All,NIH&Combos,1,0,0,2018,2018,903,1,Phase 2,4,NA,2,2.302585092994046,"(2,3]"
3026,4064,vedolizumab iv in pediatric participants with ulcerative colitis (uc) or crohn's disease (cd),Completed,4,1,1,Ulcerative Colitis|Crohn's Disease,drug or biologic,Early,89,All,Industry&Combos,1,0,0,2017,2017,874,1,Phase 2,3,NA,2,4.48863636973214,"(4,5]"
762,798,"tas 102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (gej) adenocarcinoma",Recruiting,2,0,0,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Gastric Cancer,drug or biologic,Early,25,All,AllOther,0,NA,0,2018,2018,1129,0,Phase 2,1,NA,1,3.2188758248682006,"(3,4]"
761,797,proton beam therapy in the treatment of esophageal cancer,Recruiting,2,0,0,Esophagus Cancer|Esophageal Cancer|Cancer of the Esophagus,other,Others,40,All,AllOther,1,1,0,2018,2018,1472,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
3563,5481,"study of 5-fu, oxaliplatin, & lapatinib combined with radiation therapy to treat her2 positive esophagogastric cancer",Terminated,5,1,1,HER2 Positive Esophagogastric Cancer,drug or biologic,Early,12,All,Industry&Combos,0,NA,0,2013,2013,365,0,Phase 2,1,NA,1,2.4849066497880004,"(2,3]"
3618,5706,p:ii above-label octreotide-lar with insufficiently controlled carcinoid syndrome,Terminated,5,1,1,Neuroendocrine Carcinoma,drug or biologic,Early,2,All,Industry&Combos,0,NA,0,2013,2013,243,0,Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
3617,5702,a study evaluating tas-102 plus nivolumab in patients with mss crc,Completed,4,0,0,Refractory Metastatic Colorectal Cancer,drug or biologic,Early,35,All,Industry&Combos,0,NA,0,2016,2016,459,0,Phase 2,1,NA,1,3.5553480614894135,"(3,4]"
3894,7187,open-label extension of cp101 trials evaluating oral full-spectrum microbiotaÃ¢âÂ¢ (cp101) in subjects with recurrence of clostridium difficile infection,"Active, not recruiting",1,0,0,Clostridium Difficile Infection|Recurrent Clostridium Difficile Infection|C. Diff|CDI|Recurrent C. Diff|rCDI|C. Difficile|Recurrent CDI|FMT|Fecal Microbiota|Fecal Transplant,drug or biologic,Early,70,All,Industry&Combos,0,NA,0,2018,2018,975,0,Phase 2,1,NA,1,4.248495242049359,"(4,5]"
4053,7684,study of idn-6556 in patients with severe alcoholic hepatitis and contraindications to steroid therapy,Terminated,5,1,1,Alcoholic Hepatitis,drug or biologic,Early,5,All,IndustryNIHPartnership,1,0,0,2013,2013,761,1,Phase 2,4,NA,2,1.6094379124341003,"(1,2]"
2714,3638,efficacy and safety of filgotinib in the treatment of small bowel crohn's disease (sbcd),Completed,4,0,0,Small Bowel Crohn's Disease,drug or biologic,Early,78,All,Industry&Combos,1,0,0,2017,2017,1196,1,Phase 2,2,safety/efficacy,2,4.356708826689592,"(4,5]"
2347,2979,"to assess safety, tolerability and efficacy of ljn452 in patients with primary bile acid diarrhea.",Completed,4,1,1,Primary Bile Acid Diarrhea,drug or biologic,Early,20,All,Industry&Combos,3,0,0,2016,2016,740,3,Phase 2,4,safety/efficacy,2,2.995732273553991,"(2,3]"
1614,1769,telotristat ethyl to promote weight stability in patients with advanced stage pancreatic cancer,Recruiting,2,0,0,Locally Advanced Unresectable Pancreatic Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8,drug or biologic,Early,80,All,Industry&Combos,1,0,4,2019,2019,898,1,Phase 2,0,NA,0,4.382026634673881,"(4,5]"
912,958,a safety and efficacy study of daikenchuto (tu-100) to relieve abdominal bloating in female subjects with irritable bowel syndrome,Completed,4,0,0,Irritable Bowel Syndrome in Females,drug or biologic,Early,101,Female,Industry&Combos,1,0,0,2014,2014,640,1,Phase 2,4,safety/efficacy,2,4.61512051684126,"(4,5]"
2014,2377,pilot trial of resistant starch in stage i-iii colorectal cancer survivors,Terminated,5,0,0,Colon Cancer|Rectal Cancer|Cancer Survivor|Colorectal Adenocarcinoma|Stage I Colorectal Cancer AJCC v8|Stage II Colorectal Cancer AJCC v8|Stage IIA Colorectal Cancer AJCC v8|Stage IIB Colorectal Cancer AJCC v8|Stage IIC Colorectal Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8,other,Others,7,All,NIH&Combos,1,0,1,2018,2019,513,1,Others,2,NA,2,1.9459101490553132,"(1,2]"
2687,3604,"a study to evaluate the safety, tolerability, and activity of tak-931 in participants with metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors",Completed,4,0,0,"Metastatic Pancreatic Cancer|Colorectal Cancer|Esophageal Neoplasms|Carcinoma, Non-small-cell Lung",drug or biologic,Early,101,All,Industry&Combos,0,NA,0,2017,2017,1034,0,Phase 2,1,safety,1,4.61512051684126,"(4,5]"
1039,1094,investigation of the gut microbiota in regulating nutrient absorption in humans,Completed,4,1,1,Obesity,drug or biologic,Early,27,All,NIH&Combos,3,0,1,2014,2014,1900,3,Phase 2,3,NA,2,3.295836866004329,"(3,4]"
301,306,low-dose radiation therapy to the whole liver with gemcitabine and cisplatin in ihc,Terminated,5,1,1,Intrahepatic Cholangiocarcinoma,drug or biologic,Early,6,All,AllOther,0,NA,0,2014,2014,731,0,Phase 2,1,NA,1,1.791759469228055,"(1,2]"
2685,3602,high or standard intensity radiation therapy after gemcitabine hydrochloride and nab-paclitaxel in treating patients with pancreatic cancer that cannot be removed by surgery,Terminated,5,1,1,Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer,drug or biologic,Early,20,All,NIH&Combos,1,0,0,2013,2013,1035,1,Phase 2,0,NA,0,2.995732273553991,"(2,3]"
367,375,treating anorectal dysfunction in ms,Terminated,5,1,1,Constipation|Fecal Incontinence|Multiple Sclerosis,drug or biologic,Early,11,All,AllOther,1,0,0,2015,2016,883,1,Phase 2,3,NA,2,2.3978952727983707,"(2,3]"
491,509,nivolumab in preventing colon adenomas in participants with lynch syndrome and a history of partial colectomy,"Active, not recruiting",1,0,0,Colon Adenoma|Colon Carcinoma|Lynch Syndrome|MLH1 Gene Mutation|MSH2 Gene Mutation,drug or biologic,Early,3,All,NIH&Combos,0,NA,1,2018,2018,863,0,Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
3416,5167,sofosbuvir (gs-7977) in combination with peg and ribavirin for 12 weeks in treatment experienced subjects with chronic hcv infection genotype 2 or 3,Completed,4,1,1,Hepatitis C,drug or biologic,Early,47,All,Industry&Combos,0,NA,0,2013,2013,212,0,Phase 2,1,NA,1,3.8501476017100584,"(3,4]"
905,950,paclitaxel protein bound plus cisplatin plus gemcitabine and paricalcitol for pancreatic adenocarcinoma (nabplagemd),"Active, not recruiting",1,0,0,Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma|Pancreatic Adenocarcinoma|Pancreas Metastases|Adenocarcinoma,drug or biologic,Early,14,All,AllOther,0,NA,0,2018,2018,1430,0,Phase 2,1,NA,1,2.6390573296152584,"(2,3]"
3710,6195,"safety, tolerability, and efficacy of gs-4997 alone or in combination with simtuzumab (sim) in adults with nonalcoholic steatohepatitis (nash) and fibrosis stages f2-f3",Completed,4,1,1,Non-Alcoholic Steatohepatitis (NASH),drug or biologic,Early,72,All,Industry&Combos,1,0,0,2015,2015,491,1,Phase 2,0,safety/efficacy,0,4.276666119016055,"(4,5]"
2265,2812,study to evaluate the safety and efficacy of oral cr845 (difelikefalin) in patients with primary biliary cholangitis (pbc) and moderate-to-severe pruritus,Recruiting,2,0,0,Cholestatic Pruritus,drug or biologic,Early,60,All,Industry&Combos,1,0,0,2019,2019,556,1,Phase 2,3,safety/efficacy,2,4.0943445622221,"(4,5]"
3227,4522,ledipasvir/sofosbuvir fixed-dose combination + ribavirin in subjects with chronic hcv with advanced liver disease or post-liver transplant,Completed,4,1,1,Chronic HCV Infection,drug or biologic,Early,339,All,Industry&Combos,1,0,0,2013,2013,487,1,Phase 2,0,NA,0,5.82600010738045,"(5,6]"
4071,7844,a study of abi-h0731 + nucleos(t)ide as finite treatment for chronic hepatitis b patients,Terminated,5,0,0,Chronic Hepatitis B,drug or biologic,Early,92,All,Industry&Combos,1,1,0,2018,2018,858,1,Phase 2,0,NA,0,4.5217885770490405,"(4,5]"
2114,2528,phase ii trial of neoadjuvant pembrolizumab for patients with early stage gastroesophageal adenocarcinoma,Recruiting,2,0,0,Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma|Esophageal Adenocarcinoma,drug or biologic,Early,33,All,AllOther,0,NA,0,2019,2019,1209,0,Phase 2,1,NA,1,3.4965075614664802,"(3,4]"
3332,4761,an efficacy and safety study of plecanatide in adolescents 12 to <18 years of age with chronic idiopathic constipation,Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Early,124,All,Industry&Combos,1,0,0,2017,2017,614,1,Phase 2,4,safety/efficacy,2,4.820281565605037,"(4,5]"
3014,4048,"lower-dose chemoradiation in treating patients with early-stage anal cancer, the decrease study",Recruiting,2,0,0,Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Canal Squamous Cell Carcinoma|Anal Margin Squamous Cell Carcinoma|Stage I Anal Cancer AJCC v8|Stage IIA Anal Cancer AJCC v8,drug or biologic,Early,252,All,NIH&Combos,1,0,0,2019,2019,2058,1,Phase 2,0,NA,0,5.529429087511423,"(5,6]"
4133,8971,a study to assess the efficacy and safety of enzalutamide in subjects with advanced hepatocellular carcinoma,Completed,4,1,1,Advanced Hepatocellular Carcinoma,drug or biologic,Early,165,All,Industry&Combos,1,0,0,2015,2015,693,1,Phase 2,2,safety/efficacy,2,5.10594547390058,"(5,6]"
3791,6657,a study of pf-05212384 plus irinotecan vs cetuximab plus irinotecan in patients with kras and nras wild type metastatic colorectal cancer,Terminated,5,1,1,Metastatic Colorectal Cancer,drug or biologic,Early,19,All,Industry&Combos,1,0,0,2013,2013,873,1,Phase 2,0,NA,0,2.9444389791664403,"(2,3]"
3826,6828,"study to evaluate the safety, tolerability, and efficacy of vesatolimod in combination with tenofovir disoproxil fumarate (tdf) in adults with chronic hepatitis b (chb) infection who are currently not being treated",Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Early,192,All,Industry&Combos,1,0,0,2015,2015,433,1,Phase 2,2,safety/efficacy,2,5.2574953720277815,"(5,6]"
276,281,confocal endoscopic microscopy for detection of early stage gastric cancer in subjects with hereditary diffuse gastric cancer syndrome,Terminated,5,1,1,Gastric Cancer|Gastric Neoplasms,device,Others,37,All,NIH&Combos,0,NA,2,2018,2019,434,0,Others,1,NA,1,3.6109179126442243,"(3,4]"
3978,7533,the use of hepatitis c positive kidneys in hepatitis c negative kidney transplant recipients,Enrolling by invitation,3,0,0,Kidney Transplantation|Hepatitis C,drug or biologic,Early,60,All,AllOther,1,1,0,2019,2019,1799,1,Phase 2,0,NA,0,4.0943445622221,"(4,5]"
2799,3756,a study of efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis,"Active, not recruiting",1,0,0,"Colitis, Ulcerative",drug or biologic,Early,214,All,Industry&Combos,1,0,0,2018,2018,742,1,Phase 2,2,safety/efficacy,2,5.365976015021851,"(5,6]"
3982,7540,a study of the use of hepatitis c positive donors for hepatitis c negative lung transplant recipients with post-transplant treatment with mavyret,Completed,4,0,0,Hepatitis C,drug or biologic,Early,20,All,AllOther,0,NA,0,2018,2018,843,0,Phase 2,1,NA,1,2.995732273553991,"(2,3]"
2068,2461,study of pembrolizumab in locally advanced esophageal adenocarcinoma,Recruiting,2,0,0,Esophageal Adenocarcinoma,drug or biologic,Early,46,All,Industry&Combos,1,0,0,2016,2017,1577,1,Phase 2,0,NA,0,3.828641396489095,"(3,4]"
1945,2279,a study evaluating safety and efficacy of niraparib in patients with previously treated metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma,Recruiting,2,0,0,Esophageal Cancer|Gastric Cancer|Adenocarcinoma,drug or biologic,Early,43,All,Industry&Combos,0,NA,0,2019,2019,662,0,Phase 2,1,safety/efficacy,1,3.7612001156935624,"(3,4]"
3086,4170,a phase 2 study of elobixibat in adults with nafld or nash,Completed,4,0,0,"NAFLD|NASH",drug or biologic,Early,47,All,Industry&Combos,1,0,0,2019,2019,386,1,Phase 2,3,NA,2,3.8501476017100584,"(3,4]"
3927,7317,safety and efficacy of vicriviroc (mk-7690) in combination with pembrolizumab (mk-3475) in participants with advanced/metastatic microsatellite stable (mss) colorectal cancer (crc) (mk-7690-046),Completed,4,0,0,Colorectal Neoplasms,drug or biologic,Early,42,All,Industry&Combos,1,0,0,2018,2018,988,1,Phase 2,0,safety/efficacy,0,3.7376696182833684,"(3,4]"
1911,2225,challenge study of an etec vaccine,Completed,4,0,0,"Enteritis; Escherichia Coli, Enterotoxigenic",drug or biologic,Early,56,All,AllOther,1,1,1,2013,2013,870,1,Phase 2,0,NA,0,4.02535169073515,"(4,5]"
2210,2699,add-on peginterferon following nucleos(t)ide analogue treatment,Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Early,14,All,NIH&Combos,1,1,0,2015,2015,1192,1,Phase 2,0,NA,0,2.6390573296152584,"(2,3]"
2764,3713,an active and placebo-controlled study of brazikumab in participants with moderately to severely active ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis|Colitis|Ulcerative|IBD,drug or biologic,Early,225,All,Industry&Combos,1,0,0,2018,2018,1589,1,Phase 2,3,NA,2,5.41610040220442,"(5,6]"
896,940,pre-operative trial (pgha vs. pgh) for resectable pancreatic cancer,Terminated,5,1,1,Pancreatic Cancer Resectable,drug or biologic,Early,32,Female,IndustryNIHPartnership,1,0,0,2017,2017,503,1,Phase 2,0,NA,0,3.4657359027997265,"(3,4]"
3396,5079,"study of the safety, pharmacodynamics, efficacy, and pk of timp-glia in subjects with celiac disease",Completed,4,1,1,Celiac Disease,drug or biologic,Early,34,All,Industry&Combos,1,0,0,2018,2018,225,1,Phase 2,4,safety/efficacy,2,3.5263605246161616,"(3,4]"
2615,3514,s1505: combination chemotherapy or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma,drug or biologic,Early,112,All,NIH&Combos,1,0,0,2015,2015,1704,1,Phase 2,0,NA,0,4.718498871295094,"(4,5]"
469,485,"ph 2 trial of vitamin c & g-flip (low doses gemcitabine, 5fu, leucovorin, irinotecan, oxaliplatin) for pancreatic cancer",Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,34,All,AllOther,1,0,0,2013,2014,2010,1,Phase 2,0,NA,0,3.5263605246161616,"(3,4]"
2331,2950,vgx-3100 and electroporation in treating patients with hiv-positive high-grade anal lesions,Recruiting,2,0,0,Anal Intraepithelial Neoplasia|High Grade Squamous Intraepithelial Neoplasia|HIV Positivity|Human Papillomavirus-16 Positive|Human Papillomavirus-18 Positive,drug or biologic,Early,80,All,IndustryNIHPartnership,0,NA,0,2018,2018,1430,0,Phase 2,1,NA,1,4.382026634673881,"(4,5]"
3623,5718,nivolumab and metformin in patients with treatment refractory mss colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Adenocarcinoma|Metastatic Microsatellite Stable Colorectal Carcinoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer|Stage IVC Colorectal Cancer|Colorectal Cancer Metastatic,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2019,2019,1112,0,Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
1558,1697,fecal microbiota transplant (fmt) in melanoma patients,Recruiting,2,0,0,Melanoma,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2017,2018,2029,0,Phase 2,1,NA,1,2.995732273553991,"(2,3]"
3071,4136,apx005m with concurrent chemoradiation for resectable esophageal and gastroesophageal junction cancers,Recruiting,2,0,0,Esophageal Cancer|GastroEsophageal Cancer,drug or biologic,Early,26,All,Industry&Combos,0,NA,0,2017,2017,1364,0,Phase 2,1,NA,1,3.258096538021482,"(3,4]"
623,650,"napoli-2: fluorouracil, leucovorin, and nanoliposomal irinotecan in biliary cancer",Recruiting,2,0,0,Advanced Biliary Tract Cancer,drug or biologic,Early,44,All,Industry&Combos,0,NA,0,2019,2019,733,0,Phase 2,1,NA,1,3.784189633918261,"(3,4]"
3265,4597,phase 2b study in nash to assess iva337,Completed,4,1,1,Non-Alcoholic Steatohepatitis (NASH),drug or biologic,Early,247,All,Industry&Combos,1,0,0,2017,2017,1108,1,Phase 2,4,NA,2,5.5093883366279774,"(5,6]"
3467,5267,"a study of type-1 polarized dendritic cell ( Â±dc1) vaccine in combination with tumor-selective chemokine modulation (interferon- Â±2b, rintatolimod, and celecoxib) in subjects with chemo-refractory metastatic colorectal cancer",Withdrawn,7,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2015,2016,822,0,Phase 2,1,NA,1,NA,NA
602,628,olaparib in treating patients with stage iv pancreatic cancer,"Active, not recruiting",1,0,0,Metastatic Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v6 and v7,drug or biologic,Early,34,All,IndustryNIHPartnership,0,NA,0,2016,2016,1845,0,Phase 2,1,NA,1,3.5263605246161616,"(3,4]"
3557,5466,study of neratinib +trastuzumab or neratinib + cetuximab in patients with kras/nras/braf/pik3ca wild-type metastatic colorectal cancer by her2 status,Recruiting,2,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,35,All,Industry&Combos,1,1,0,2018,2018,1293,1,Phase 2,0,NA,0,3.5553480614894135,"(3,4]"
2121,2539,treatment of chronic delta hepatitis with lonafarnib and ritonavir,Completed,4,1,1,Hepatitis D,drug or biologic,Early,22,All,NIH&Combos,1,0,0,2015,2015,575,1,Phase 2,3,NA,2,3.091042453358316,"(3,4]"
588,614,"antibiotic ""dysbiosis"" in preterm infants",Completed,4,0,0,"Enterocolitis, Necrotizing|Bacteremia|Bronchopulmonary Dysplasia|Intraventricular Hemorrhage|Periventricular Leukomalacia|Chronic Lung Disease|Ileal Perforation",drug or biologic,Early,186,All,NIH&Combos,3,0,0,2016,2017,968,3,Phase 2,0,NA,0,5.225746673713202,"(5,6]"
1658,1826,vitamin e for nash treatment in hiv infected individuals,Recruiting,2,0,0,"NAFLD|NASH - Nonalcoholic Steatohepatitis|HIV Infections",drug or biologic,Early,56,All,AllOther,1,0,0,2018,2019,1126,1,Phase 2,3,NA,2,4.02535169073515,"(4,5]"
2530,3392,a study of ak002 in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis,Completed,4,0,0,Eosinophilic Gastritis|Eosinophilic Gastroenteritis,drug or biologic,Early,65,All,Industry&Combos,1,0,0,2018,2018,341,1,Phase 2,4,NA,2,4.174387269895637,"(4,5]"
960,1010,gut decontamination in pediatric allogeneic hematopoietic,"Active, not recruiting",1,0,0,Hematopoietic Stem Cell Transplantation (HSCT)|Acute GVH Disease,drug or biologic,Early,24,All,AllOther,1,0,1,2015,2016,2101,1,Phase 2,0,NA,0,3.1780538303479458,"(3,4]"
3786,6584,"a six week efficacy, safety and tolerability study of v565 in crohn's disease",Unknown status,8,0,0,Crohn's Disease,drug or biologic,Early,126,All,Industry&Combos,1,0,0,2016,2016,730,1,Phase 2,2,safety/efficacy,2,4.836281906951478,"(4,5]"
753,789,perioperative ketamine for pain with gastric bypass,Completed,4,1,1,Laparoscopic Gastric Bypass Surgery|Ketamine,drug or biologic,Early,34,All,AllOther,1,0,0,2018,2018,633,1,Phase 2,0,NA,0,3.5263605246161616,"(3,4]"
1550,1689,yf476 in barrett's esophagus,Completed,4,1,1,Barrett's Esophagus,drug or biologic,Early,27,All,Industry&Combos,1,0,0,2015,2013,1658,1,Phase 2,4,NA,2,3.295836866004329,"(3,4]"
2406,3103,"sucralfate to improve oral intake in children with infectious oral ulcers: a randomized, double-blind, placebo-controlled trial",Enrolling by invitation,3,0,0,"Herpangina|Gingivostomatitis|Hand, Foot and Mouth Disease",drug or biologic,Early,100,All,AllOther,1,0,4,2017,2017,627,1,Phase 2,4,NA,2,4.605170185988092,"(4,5]"
3392,5062,a study of efruxifermin in subjects with histologically confirmed nonalcoholic steatohepatitis (nash),"Active, not recruiting",1,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,110,All,Industry&Combos,1,0,0,2019,2019,624,1,Phase 2,4,NA,2,4.700480365792417,"(4,5]"
695,727,a clinical trial of entinostat in combination with nivolumab for patients with previously treated unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma,"Active, not recruiting",1,0,0,Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Cancer|Cholangiocarcinoma|Pancreatic Cancer|Metastatic Pancreatic Cancer,drug or biologic,Early,44,All,Industry&Combos,1,1,0,2017,2017,1120,1,Phase 2,0,NA,0,3.784189633918261,"(3,4]"
2279,2840,an evaluation of the safety and efficacy of ntz on collagen turnover in nash patients with fibrosis,Completed,4,0,0,"Non-alcoholic Steatohepatitis|Fatty Liver|Fibrosis, Liver|Compensated Cirrhosis",drug or biologic,Early,16,All,AllOther,0,NA,0,2018,2018,711,0,Phase 2,1,safety/efficacy,1,2.772588722239781,"(2,3]"
3681,6043,a study to evaluate the efficacy and safety of tak-906 in adult participants with symptomatic idiopathic or diabetic gastroparesis,"Active, not recruiting",1,0,0,Diabetic Gastroparesis|Idiopathic Gastroparesis,drug or biologic,Early,242,All,Industry&Combos,1,0,0,2018,2018,971,1,Phase 2,4,safety/efficacy,2,5.488937726156687,"(5,6]"
461,476,folfox-6 induction chemotherapy followed by esophagectomy and post-operative chemoradiotherapy in patients with esophageal adenocarcinoma,"Active, not recruiting",1,0,0,Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Adenocarcinoma of the Gastric Cardia|Stage IIIA Esophageal Cancer|Stage IIIB Esophageal Cancer|Stage IIIC Esophageal Cancer,drug or biologic,Early,63,All,AllOther,1,1,0,2014,2014,2797,1,Phase 2,0,NA,0,4.143134726391533,"(4,5]"
1112,1178,lipiodol as an imaging biomarker in patients with primary and metastatic liver cancer,Completed,4,1,1,Liver Cancer,drug or biologic,Early,39,All,Industry&Combos,0,NA,4,2013,2013,2497,0,Phase 2,1,NA,1,3.6635616461296463,"(3,4]"
1217,1295,cabozantinib and erlotinib for patients with egfr and c-met co-expressing metastatic pancreatic adenocarcinoma,Terminated,5,1,1,Pancreatic Adenocarcinoma Metastatic,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2017,2017,549,0,Phase 2,1,NA,1,1.9459101490553132,"(1,2]"
2929,3930,a trial of idn-6556 in post orthotopic liver transplant for chronic hcv,Completed,4,1,1,Liver Fibrosis|Hepatic Fibrosis|Liver Cirrhosis|Hepatic Cirrhosis,drug or biologic,Early,64,All,Industry&Combos,1,0,0,2014,2014,1386,1,Phase 2,4,NA,2,4.1588830833596715,"(4,5]"
4047,7665,"nivolumab in treating patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis",Terminated,5,1,1,"Hepatomegaly|Myelofibrosis Transformation in Essential Thrombocythemia|Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase|Primary Myelofibrosis|Splenomegaly",drug or biologic,Early,8,All,NIH&Combos,0,NA,0,2015,2015,1065,0,Phase 2,1,NA,1,2.0794415416798357,"(2,3]"
2754,3699,study of durvalumab (medi4736) after chemo-radiation for microsatellite stable stage ii-iv rectal cancer,Recruiting,2,0,0,Rectal Cancer,drug or biologic,Early,47,All,AllOther,0,NA,0,2017,2018,749,0,Phase 2,1,NA,1,3.8501476017100584,"(3,4]"
2337,2960,safety and efficacy of imm 124-e for patients with severe alcoholic hepatitis,Completed,4,1,1,"Hepatitis, Alcoholic",drug or biologic,Early,57,All,IndustryNIHPartnership,1,0,0,2013,2014,1482,1,Phase 2,4,safety/efficacy,2,4.04305126783455,"(4,5]"
3319,4735,nnits-nitazoxanide for norovirus in transplant patients study,Recruiting,2,0,0,Gastroenteritis Norovirus,drug or biologic,Early,160,All,NIH&Combos,1,0,0,2018,2018,1052,1,Phase 2,2,NA,2,5.075173815233827,"(5,6]"
3926,7314,ledipasvir/sofosbuvir fixed-dose combination and vedroprevir with or without ribavirin in treatment-experienced participants with chronic genotype 1 hcv infection and cirrhosis,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Early,47,All,Industry&Combos,1,0,0,2014,2014,215,1,Phase 2,0,NA,0,3.8501476017100584,"(3,4]"
1241,1325,phase 2 rct of alvimopan vs. placebo after crs/hipec,Terminated,5,1,1,Ileus,drug or biologic,Early,84,All,AllOther,1,0,0,2017,2018,782,1,Phase 2,3,NA,2,4.430816798843313,"(4,5]"
2431,3159,simvastatin in preventing liver cancer in patients with liver cirrhosis,Recruiting,2,0,0,Cirrhosis,drug or biologic,Early,80,All,NIH&Combos,1,0,1,2016,2017,1593,1,Phase 2,2,NA,2,4.382026634673881,"(4,5]"
3462,5255,regorafenib plus 5-fluorouracil/leucovorin beyond progression in mcrc,Suspended,6,0,0,Colorectal Cancer,drug or biologic,Early,2,All,AllOther,0,NA,0,2017,2017,970,0,Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
239,242,efficacy and safety of syn-010 in ibs-c,Terminated,5,0,0,Irritable Bowel Syndrome With Constipation,drug or biologic,Early,59,All,Industry&Combos,1,0,0,2018,2018,655,1,Phase 2,4,safety/efficacy,2,4.07753744390572,"(4,5]"
2707,3630,"efficacy and safety of abgn-168h in patients with moderate to severe active, anti-tnf alpha and/or anti-integrin refractory ulcerative colitis",Completed,4,0,0,Ulcerative Colitis,drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2017,2018,727,0,Phase 2,1,safety/efficacy,1,3.1780538303479458,"(3,4]"
4176,9176,ledipasvir/sofosbuvir fixed-dose combination  Â± ribavirin in participants with chronic genotype 1 hcv who participated in a prior gilead-sponsored hcv treatment study,Completed,4,1,1,HCV Infection,drug or biologic,Early,100,All,Industry&Combos,1,1,0,2013,2014,488,1,Phase 2,0,NA,0,4.605170185988092,"(4,5]"
2696,3615,effects of intravenous gc4419 on the incidence and severity of esophagitis due to chemoradiotherapy for lung cancer,Recruiting,2,0,0,Esophagitis,drug or biologic,Early,60,All,Industry&Combos,0,NA,0,2020,2019,713,0,Phase 2,1,NA,1,4.0943445622221,"(4,5]"
3839,6902,phase 2 study of ngm282 in patients with primary sclerosing cholangitis,Completed,4,0,0,Primary Sclerosing Cholangitis,drug or biologic,Early,62,All,Industry&Combos,1,0,0,2016,2016,457,1,Phase 2,2,NA,2,4.127134385045092,"(4,5]"
696,728,evaluating the effect of itraconazole on pathologic complete response rates in esophageal cancer,Recruiting,2,0,0,Esophagus Adenocarcinoma|Esophagus Squamous Cell Carcinoma|Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,78,All,AllOther,0,NA,0,2019,2019,1096,0,Phase 2,1,NA,1,4.356708826689592,"(4,5]"
2727,3653,ph2a study to evaluate iw-3718 in patients with gastroesophageal reflux not completely responsive to proton pump inhibitors,Completed,4,0,0,Gastroesophageal Reflux,drug or biologic,Early,93,All,Industry&Combos,1,0,0,2014,2014,303,1,Phase 2,4,NA,2,4.532599493153256,"(4,5]"
3034,4076,ramucirumab and paclitaxel or folfiri in advanced small bowel cancers,Recruiting,2,0,0,Metastatic Small Intestinal Adenocarcinoma|Stage III Small Intestinal Adenocarcinoma AJCC v8|Stage IIIA Small Intestinal Adenocarcinoma AJCC v8|Stage IIIB Small Intestinal Adenocarcinoma AJCC v8|Stage IV Small Intestinal Adenocarcinoma AJCC v8,drug or biologic,Early,94,All,NIH&Combos,1,0,0,2019,2019,1216,1,Phase 2,0,NA,0,4.543294782270004,"(4,5]"
2999,4023,"a multi-part, double blind study to assess safety, tolerability and efficacy of tropifexor (ljn452) in pbc patients",Completed,4,1,1,Primary Biliary Cholangitis,drug or biologic,Early,61,All,Industry&Combos,1,0,0,2015,2015,1058,1,Phase 2,3,safety/efficacy,2,4.110873864173311,"(4,5]"
3091,4181,"neo: neoadjuvant chemotherapy, excision and observation for early rectal cancer","Active, not recruiting",1,0,0,Rectal Cancer,drug or biologic,Early,58,All,AllOther,0,NA,0,2017,2017,1682,0,Phase 2,1,NA,1,4.060443010546419,"(4,5]"
3579,5561,"study to evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of nimacimab in patients with diabetic gastroparesis","Active, not recruiting",1,0,0,Diabetic Gastroparesis,drug or biologic,Early,6,All,Industry&Combos,NA,1,0,2019,2019,153,NA,Phase 2,1,safety/efficacy,1,1.791759469228055,"(1,2]"
2601,3498,safety and efficacy of combination listeria/gvax pancreas vaccine in the pancreatic cancer setting,Completed,4,1,1,"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer",drug or biologic,Early,303,All,Industry&Combos,1,0,0,2013,2014,695,1,Phase 2,0,safety/efficacy,0,5.713732805509369,"(5,6]"
2911,3902,safety and efficacy of bms-986165 in participants with moderate to severe ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Early,120,All,Industry&Combos,1,0,0,2019,2019,813,1,Phase 2,3,safety/efficacy,2,4.787491742782046,"(4,5]"
2675,3587,a phase 2 study of mm-141 plus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,drug or biologic,Early,88,All,Industry&Combos,1,0,0,2015,2015,1188,1,Phase 2,4,NA,2,4.477336814478207,"(4,5]"
1745,1952,epacadostat and pembrolizumab in patients with gist,Completed,4,0,0,Gastrointestinal Stromal Tumors,drug or biologic,Early,1,All,AllOther,0,NA,0,2017,2018,903,0,Phase 2,1,NA,1,0,NA
3368,4935,proclaim -- misoprostol in the prevention of recurrent cdi prevent recurrence of clostridium difficile infection with misoprostol,Recruiting,2,0,0,Clostridium Difficile,drug or biologic,Early,440,All,NIH&Combos,1,0,1,2018,2018,1436,1,Phase 2,4,NA,2,6.0867747269123065,"(6,7]"
3383,5017,"a study to evaluate the safety, and tolerability, and efficacy of seladelpar in patients with psc",Completed,4,0,0,Primary Sclerosing Cholangitis,drug or biologic,Early,1,All,Industry&Combos,1,0,0,2019,2019,58,1,Phase 2,4,safety/efficacy,2,0,NA
2996,4017,a study to investigate how well ravagalimab (abbv-323) works and how safe it is in participants with moderate to severe ulcerative colitis who failed prior therapy,"Active, not recruiting",1,0,0,Ulcerative Colitis (UC),drug or biologic,Early,42,All,Industry&Combos,0,NA,0,2018,2019,1007,0,Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
4038,7629,ledipasvir/sofosbuvir fixed-dose combination in adults with nosocomial genotype 1 hcv infection,Completed,4,1,1,Hepatitis C,drug or biologic,Early,5,All,Industry&Combos,0,NA,0,2013,2013,304,0,Phase 2,1,NA,1,1.6094379124341003,"(1,2]"
2135,2562,mechanism of microbiome-induced insulin resistance in humans (aim 1),Unknown status,8,0,0,Insulin Sensitivity,drug or biologic,Early,20,All,AllOther,3,0,0,2014,2014,1825,3,Phase 2,3,NA,2,2.995732273553991,"(2,3]"
564,588,elobixibat colonic motor function study,Withdrawn,7,0,0,Chronic Idiopathic Constipation,drug or biologic,Early,NA,All,Industry&Combos,1,0,4,2015,2015,366,1,Phase 2,2,NA,2,NA,NA
3199,4438,a pk/pd study of cm4620-ie in patients with acute pancreatitis,Completed,4,0,0,Acute Pancreatitis,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2018,2019,60,0,Phase 2,1,NA,1,1.9459101490553132,"(1,2]"
3551,5447,"lenvatinib and everolimus in treating patients with advanced, unresectable carcinoid tumors",Recruiting,2,0,0,Advanced Carcinoid Tumor|Digestive System Neuroendocrine Neoplasm|Multiple Endocrine Neoplasia Type 1|Neuroendocrine Neoplasm|Unresectable Carcinoid Tumor,drug or biologic,Early,32,All,NIH&Combos,0,NA,0,2019,2019,647,0,Phase 2,1,NA,1,3.4657359027997265,"(3,4]"
1749,1958,"vgx-3100 delivered intramuscularly (im) followed by electroporation (ep) for the treatment of hpv-16 and/or hpv-18 related anal or anal/peri-anal, high grade squamous intraepithelial lesion (hsil) in individuals seronegative for human immunodeficiency virus (hiv)-1/2",Completed,4,0,0,Anal Neoplasm,drug or biologic,Early,22,All,Industry&Combos,0,NA,0,2018,2018,775,0,Phase 2,1,NA,1,3.091042453358316,"(3,4]"
3334,4770,a phase 2 study of cin-102 in adults with idiopathic and diabetic gastroparesis,Completed,4,0,0,Gastroparesis,drug or biologic,Early,73,All,Industry&Combos,NA,0,0,2019,2019,463,NA,Phase 2,3,NA,2,4.290459441148391,"(4,5]"
676,707,bruog 292: folfox-a for metastatic pancreatic cancer: a phase ii brown university oncology research group trial,"Active, not recruiting",1,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,50,All,AllOther,0,NA,0,2014,2014,1987,0,Phase 2,1,NA,1,3.912023005428146,"(3,4]"
3478,5281,combination chemotherapy and bevacizumab with or without pri-724 in treating patients with newly diagnosed metastatic colorectal cancer,Withdrawn,7,0,0,Colorectal Adenocarcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,drug or biologic,Early,NA,All,IndustryNIHPartnership,1,0,0,2015,2015,731,1,Phase 2,0,NA,0,NA,NA
3100,4198,a study of tislelizumab (bgb-a317) versus chemotherapy as second line treatment in participants with advanced esophageal squamous cell carcinoma,"Active, not recruiting",1,0,0,Esophageal Squamous Cell Carcinoma (ESCC),drug or biologic,Late,513,All,Industry&Combos,1,0,0,2018,2018,1040,1,Phase 3,0,NA,0,6.240275845170769,"(6,7]"
2657,3564,52-week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea (ibs-d),Terminated,5,1,1,Irritable Bowel Syndrome With Diarrhea,drug or biologic,Late,558,Female,Industry&Combos,1,0,0,2014,2014,638,1,Phase 3,4,safety/efficacy,2,6.324358962381311,"(6,7]"
3338,4788,lubiprostone for children with constipation,Completed,4,1,1,Constipation - Functional,drug or biologic,Late,419,All,Industry&Combos,0,NA,0,2014,2014,1160,0,Phase 3,1,NA,1,6.037870919922137,"(6,7]"
3968,7457,a study of glecaprevir (gle)/pibrentasvir (pib) in treatment-naive adults with chronic hepatitis c virus (hcv) genotype 1-6 infection and compensated cirrhosis,Completed,4,1,1,Hepatitis C Virus (HCV),drug or biologic,Late,343,All,Industry&Combos,0,NA,0,2017,2017,824,0,Phase 3,1,NA,1,5.8377304471659395,"(5,6]"
2983,3999,pentoxifylline treatment in acute pancreatitis (ap),Completed,4,1,1,Acute Pancreatitis (AP)|Gallstone Pancreatitis|Alcoholic Pancreatitis|Trauma Acute Pancreatitis|Hypertriglyceridemia Acute Pancreatitis|Idiopathic (Unknown) Acute Pancreatitis|Medication Induced Acute Pancreatitis|Cancer Acute Pancreatitis|Miscellaneous (i.e. Acute on Chronic Pancreatitis),drug or biologic,Late,83,All,NIH&Combos,1,0,0,2015,2015,730,1,Phase 3,4,NA,2,4.418840607796598,"(4,5]"
3706,6164,tenofovir alafenamide versus tenofovir disoproxil fumarate for treatment of hepatitis b e antigen-positive hepatitis b,"Active, not recruiting",1,1,1,HBV|Chronic HBV Infection,drug or biologic,Late,875,All,Industry&Combos,1,0,0,2013,2013,791,1,Phase 3,2,NA,2,6.774223886357614,"(6,7]"
3666,5841,evaluating the safety and efficacy of tradipitant vs. placebo in idiopathic and diabetic gastroparesis,Recruiting,2,0,0,Idiopathic Gastroparesis|Diabetic Gastroparesis|Gastroparesis,drug or biologic,Late,250,All,Industry&Combos,1,0,0,2019,2019,743,1,Phase 3,4,safety/efficacy,2,5.521460917862246,"(5,6]"
2806,3765,a maintenance study of mirikizumab in participants with moderately to severely active ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Late,1044,All,Industry&Combos,1,0,0,2018,2018,1132,1,Phase 3,2,NA,2,6.950814768442584,"(6,7]"
1735,1935,comparison of smoflipid to soy-based lipid reduction for cholestasis prevention in surgical neonates,Recruiting,2,0,0,Cholestasis of Parenteral Nutrition,drug or biologic,Late,50,All,AllOther,1,0,1,2018,2018,944,1,Phase 3,0,NA,0,3.912023005428146,"(3,4]"
4089,8066,safety and efficacy of pembrolizumab (mk-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (hcc) and complete radiological response after surgical resection or local ablation (mk-3475-937 / keynote-937),Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Late,950,All,Industry&Combos,1,0,0,2019,2019,2225,1,Phase 3,2,safety/efficacy,2,6.856461984594587,"(6,7]"
2879,3861,long-term safety and efficacy study of teduglutide in pediatric participants with short bowel syndrome (sbs),Completed,4,0,0,Short Bowel Syndrome,drug or biologic,Late,60,All,Industry&Combos,0,NA,0,2016,2017,1396,0,Phase 3,1,safety/efficacy,1,4.0943445622221,"(4,5]"
2713,3637,"tislelizumab in combination with chemotherapy as first-line treatment in adults with inoperable, locally advanced or metastatic gastric, or gastroesophageal junction carcinoma",Recruiting,2,0,0,"Gastric, or Gastroesophageal Junction Adenocarcinoma",drug or biologic,Late,980,All,Industry&Combos,1,0,0,2018,2018,1327,1,Phase 3,3,NA,2,6.887552571664617,"(6,7]"
3764,6507,vitamin d3 with chemotherapy and bevacizumab in treating patients with advanced or metastatic colorectal cancer,Recruiting,2,0,0,Colorectal Adenocarcinoma,drug or biologic,Late,400,All,NIH&Combos,1,0,0,2019,2019,944,1,Phase 3,2,NA,2,5.991464547107982,"(5,6]"
3040,4084,a phase 3 study to evaluate the safety and biomarkers of resmetirom (mgl-3196) in non alcoholic fatty liver disease (nafld) patients,Recruiting,2,0,0,Non-Alcoholic Fatty Liver Disease,drug or biologic,Late,700,All,Industry&Combos,1,0,0,2019,2019,716,1,Phase 3,4,safety,2,6.551080335043404,"(6,7]"
3048,4097,evaluation of long term safety and efficacy of glepaglutide in treatment of sbs,Recruiting,2,0,0,Short Bowel Syndrome,drug or biologic,Late,145,All,Industry&Combos,1,0,0,2019,2019,1278,1,Phase 3,4,safety/efficacy,2,4.976733742420574,"(4,5]"
1944,2278,telaprevir plus standard of care (soc) in hcv associated hepatocellular carcinoma (hcc),Terminated,5,1,1,Infection,drug or biologic,Late,1,All,Industry&Combos,0,NA,0,2013,2013,306,0,Phase 3,1,NA,1,0,NA
2553,3430,demonstrate noninferiority in efficacy and to assess safety of ct-p13 in patients with active crohn's disease,Completed,4,1,1,Crohn's Disease,drug or biologic,Late,220,All,Industry&Combos,1,0,0,2014,2014,479,1,Phase 3,2,safety/efficacy,2,5.393627546352362,"(5,6]"
3163,4321,assess safety and efficacy of elad (extracorporeal liver assist system) in subjects with alcohol-induced liver failure,Completed,4,1,1,Acute Alcoholic Hepatitis,drug or biologic,Late,203,All,Industry&Combos,1,0,0,2011,2013,699,1,Phase 3,0,safety/efficacy,0,5.313205979041787,"(5,6]"
4130,8968,hepatocellular carcinoma study comparing vaccinia virus based immunotherapy plus sorafenib vs sorafenib alone,Completed,4,1,1,Hepatocellular Carcinoma (HCC),drug or biologic,Late,459,All,Industry&Combos,1,0,0,2015,2015,1735,1,Phase 3,0,NA,0,6.129050210060545,"(6,7]"
1103,1167,averting complications of proton pump inhibitor therapy by effervescent calcium magnesium citrate,"Active, not recruiting",1,0,0,Osteoporosis|Hypomagnesemia,drug or biologic,Late,62,All,AllOther,1,0,1,2019,2019,1094,1,Phase 3,4,NA,2,4.127134385045092,"(4,5]"
3625,5720,multicenter study to evaluate the efficacy and safety of metoclopramide nasal spray in women with diabetic gastroparesis,Completed,4,1,1,Diabetic Gastroparesis,drug or biologic,Late,205,Female,Industry&Combos,1,0,0,2014,2014,792,1,Phase 3,2,safety/efficacy,2,5.3230099791384085,"(5,6]"
3572,5523,a study of ramucirumab (ly3009806) versus placebo in participants with hepatocellular carcinoma and elevated baseline alpha-fetoprotein,Recruiting,2,1,1,Hepatocellular Carcinoma,drug or biologic,Late,292,All,Industry&Combos,1,0,0,2015,2015,969,1,Phase 3,2,NA,2,5.676753802268282,"(5,6]"
3323,4744,an investigational immuno-therapy study of nivolumab or placebo in participants with resected esophageal or gastroesophageal junction cancer,"Active, not recruiting",1,1,1,Advanced Cancer,drug or biologic,Late,794,All,Industry&Combos,1,0,0,2016,2016,1398,1,Phase 3,2,NA,2,6.677083461247136,"(6,7]"
3379,4988,a placebo-controlled study of oral ozanimod as maintenance therapy for moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn Disease,drug or biologic,Late,485,All,Industry&Combos,1,0,0,2018,2018,2191,1,Phase 3,4,NA,2,6.184148890937483,"(6,7]"
2620,3521,a study of ruxolitinib in pancreatic cancer patients,Terminated,5,1,1,Pancreatic Cancer,drug or biologic,Late,86,All,Industry&Combos,1,0,0,2014,2014,610,1,Phase 3,2,NA,2,4.454347296253507,"(4,5]"
2788,3744,study evaluating efficacy and safety of ffx versus combination of cpi-613 with mffx in patients with metastatic adenocarcinoma of the pancreas,"Active, not recruiting",1,0,0,Pancreatic Cancer Metastatic,drug or biologic,Late,528,All,Industry&Combos,1,0,0,2018,2018,1118,1,Phase 3,0,safety/efficacy,0,6.269096283706261,"(6,7]"
4116,8701,clostridium difficile vaccine 2-dose versus 3-dose study,Completed,4,0,0,Clostridium Difficile Associated Disease,drug or biologic,Late,2004,All,Industry&Combos,1,0,1,2019,2019,631,1,Phase 3,3,NA,2,7.602900462204755,"(7,13]"
1222,1300,rectal indomethacin to prevent post-endoscopic retrograde cholangiopancreatography (ercp) pancreatitis,Terminated,5,1,1,Post-ERCP Acute Pancreatitis,drug or biologic,Late,449,All,AllOther,1,0,1,2013,2013,699,1,Phase 3,4,NA,2,6.1070228877422545,"(6,7]"
2770,3719,safety and efficacy trial of rpc1063 for moderate to severe ulcerative colitis,Completed,4,0,0,Ulcerative Colitis,drug or biologic,Late,1012,All,Industry&Combos,1,0,0,2015,2015,1745,1,Phase 3,4,safety/efficacy,2,6.919683849847411,"(6,7]"
1411,1517,a study of colesevelam in fecal incontinence,Recruiting,2,0,0,Fecal Incontinence|Bile Acid Malabsorption,drug or biologic,Late,60,Female,AllOther,1,0,0,2015,2015,2404,1,Phase 3,3,NA,2,4.0943445622221,"(4,5]"
230,233,assessing how the viscosity of submucosal gel injections helps with endoscopic mucosal resections,Recruiting,2,0,0,Gastric Cancer|Colon Cancer,drug or biologic,Late,32,All,AllOther,0,NA,0,2015,2014,2709,0,Phase 3,1,NA,1,3.4657359027997265,"(3,4]"
4144,9029,immunogenicity and safety of sci-b-vac Â® to engerix-b Â® in adults,Completed,4,1,1,Hepatitis B Vaccines,drug or biologic,Late,1607,All,Industry&Combos,1,0,1,2018,2017,481,1,Phase 3,3,safety,2,7.382124365737512,"(7,13]"
3427,5208,efficacy and safety study of pdt using photofrin in unresectable advanced perihilar cholangiocarcinoma (opus),Terminated,5,1,1,Hilar Cholangiocarcinoma,drug or biologic,Late,28,All,Industry&Combos,1,0,0,2014,2014,792,1,Phase 3,1,safety/efficacy,1,3.332204510175204,"(3,4]"
4164,9144,safety and efficacy of sof/vel/vox fdc for 12 weeks and sof/vel for 12 weeks in daa-experienced adults with chronic hcv infection who have not received an ns5a inhibitor,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,333,All,Industry&Combos,1,0,0,2015,2015,287,1,Phase 3,0,safety/efficacy,0,5.808142489980444,"(5,6]"
1273,1359,vedolizumab monotherapy vs combination therapy with tacrolimus in uc,Terminated,5,1,1,Ulcerative Colitis,drug or biologic,Late,4,All,Industry&Combos,1,0,0,2016,2017,623,1,Phase 3,2,NA,2,1.3862943611198906,"(1,2]"
4151,9039,sofosbuvir/velpatasvir fixed dose combination for 12 weeks in adults with chronic hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,741,All,Industry&Combos,1,0,0,2014,2014,335,1,Phase 3,4,NA,2,6.608000625296087,"(6,7]"
2539,3409,effect of glp-1 receptor agonism after sleeve gastrectomy,Recruiting,2,0,0,Obesity,drug or biologic,Late,75,All,Industry&Combos,1,0,4,2017,2017,1623,1,Phase 3,3,NA,2,4.31748811353631,"(4,5]"
2725,3650,a study of the efficacy and safety of etrolizumab in participants with ulcerative colitis who have been previously exposed to tumor necrosis factor (tnf) inhibitors,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Late,609,All,Industry&Combos,1,0,0,2014,2014,2157,1,Phase 3,2,safety/efficacy,2,6.411818267709897,"(6,7]"
3237,4545,a study of dcc-2618 vs sunitinib in advanced gist patients after treatment with imatinib,"Active, not recruiting",1,0,0,Gastrointestinal Stromal Tumors,drug or biologic,Late,426,All,Industry&Combos,1,0,0,2018,2019,841,1,Phase 3,0,NA,0,6.054439346269371,"(6,7]"
3795,6673,"multi-center, randomized, open-label study of g/p +/- rbv for ns5a + sof previously treated gt1 hcv subjects",Completed,4,1,1,Hepatitis C|HCV,drug or biologic,Late,177,All,Industry&Combos,1,0,0,2017,2017,617,1,Phase 3,0,NA,0,5.176149732573829,"(5,6]"
3423,5199,"a study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5 fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer","Active, not recruiting",1,0,0,Colo-rectal Cancer,drug or biologic,Late,490,All,Industry&Combos,1,0,0,2018,2018,1048,1,Phase 3,1,efficacy,1,6.194405391104672,"(6,7]"
2823,3785,safety and efficacy of mmx mesalamine/mesalazine in pediatric subjects with mild to moderate ulcerative colitis,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Late,107,All,Industry&Combos,1,0,0,2014,2014,1447,1,Phase 3,4,safety/efficacy,2,4.672828834461906,"(4,5]"
4069,7831,study of cabozantinib (xl184) vs placebo in subjects with hepatocellular carcinoma who have received prior sorafenib,Completed,4,1,1,Hepatocellular Carcinoma,drug or biologic,Late,707,All,Industry&Combos,1,0,0,2013,2013,1481,1,Phase 3,4,NA,2,6.561030665896573,"(6,7]"
3106,4215,efficacy and safety of everolimus in liver transplant recipients of living donor liver transplants,Completed,4,1,1,Liver Transplantation,drug or biologic,Late,285,All,Industry&Combos,1,0,0,2013,2013,1120,1,Phase 3,1,safety/efficacy,1,5.652489180268651,"(5,6]"
4073,7858,contrast-enhanced ultrasound evaluation of chemoembolization,Recruiting,2,0,0,"Hepatocellular Carcinoma|Chemoembolization, Therapeutic",drug or biologic,Late,210,All,IndustryNIHPartnership,0,NA,2,2016,2016,1917,0,Phase 3,1,NA,1,5.3471075307174685,"(5,6]"
3899,7210,telotristat etiprate for carcinoid syndrome therapy,Completed,4,1,1,Carcinoid Syndrome,drug or biologic,Late,76,All,Industry&Combos,1,0,0,2014,2014,749,1,Phase 3,3,NA,2,4.330733340286331,"(4,5]"
2869,3847,topical or ablative treatment in preventing anal cancer in patients with hiv and anal high-grade squamous intraepithelial lesions,Recruiting,2,0,0,Anal Cancer|High-grade Squamous Intraepithelial Lesion|HIV Infection|Human Papilloma Virus Infection,drug or biologic,Late,5058,All,IndustryNIHPartnership,1,0,1,2014,2014,4297,1,Phase 3,0,NA,0,8.52872642722991,"(7,13]"
4147,9034,safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in adults with chronic hcv infection who have previously received treatment with direct-acting antiviral therapy,Completed,4,1,1,Hepatitis C,drug or biologic,Late,416,All,Industry&Combos,1,0,0,2015,2015,334,1,Phase 3,2,safety/efficacy,2,6.030685260261263,"(6,7]"
3859,7067,phase 3 study of bulevirtide in patients with chd,"Active, not recruiting",1,0,0,"Hepatitis D, Chronic",drug or biologic,Late,150,All,Industry&Combos,1,0,0,2019,2019,2144,1,Phase 3,0,NA,0,5.0106352940962555,"(5,6]"
3659,5818,randomized trial of crenolanib in subjects with d842v mutated gist,"Active, not recruiting",1,0,0,GIST With D842V Mutated PDGFRA Gene,drug or biologic,Late,120,All,Industry&Combos,1,0,0,2016,2016,1826,1,Phase 3,4,NA,2,4.787491742782046,"(4,5]"
2871,3849,"a phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of linaclotide administered orally for 12 weeks to patients with irritable bowel syndrome with constipation (ibs-c)",Completed,4,1,1,Irritable Bowel Syndrome With Constipation (IBS-C),drug or biologic,Late,1722,All,Industry&Combos,1,0,0,2013,2013,669,1,Phase 3,2,safety/efficacy,2,7.451241684987676,"(7,13]"
2260,2802,evaluation of the length of treatment with pd-1/pd-l1 inhibitors in patients with advanced solid tumors,Recruiting,2,0,0,Advanced Solid Tumors|NSCLC|Bladder Cancer|HNSCC|Renal Cancer|Melanoma|Anal Cancer|Colorectal Cancer|Cholangiocarcinoma|Gastric Cancer|Hepatocellular Carcinoma,drug or biologic,Late,578,All,AllOther,1,0,0,2019,2019,2147,1,Phase 3,0,NA,0,6.359573868672378,"(6,7]"
3220,4500,sorafenib tosylate with or without stereotactic body radiation therapy in treating patients with liver cancer,"Active, not recruiting",1,0,0,Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer,drug or biologic,Late,193,All,NIH&Combos,1,0,0,2012,2013,4079,1,Phase 3,1,NA,1,5.262690188904886,"(5,6]"
2853,3827,"a phase 3 efficacy, safety and tolerability study of zolbetuximab (experimental drug) plus mfolfox6 chemotherapy compared to placebo plus mfolfox6 as treatment for gastric and gastroesophageal junction (gej) cancer",Recruiting,2,0,0,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer|Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer|Metastatic Gastric Adenocarcinoma or Cancer|Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,drug or biologic,Late,550,All,Industry&Combos,1,0,0,2018,2018,1348,1,Phase 3,2,safety/efficacy,2,6.309918278226516,"(6,7]"
4178,9210,randomised study of interferon-free treatment for recently acquired hepatitis c in pwid and people with hiv coinfection.,Completed,4,0,0,Hepatitis C,drug or biologic,Late,222,All,AllOther,0,0,0,2015,2017,1110,0,Phase 3,1,NA,1,5.402677381872279,"(5,6]"
3626,5727,multicenter study to evaluate the efficacy and safety of metoclopramide nasal spray in men with diabetic gastroparesis,Completed,4,1,1,Diabetic Gastroparesis,drug or biologic,Late,53,Male,Industry&Combos,1,0,0,2014,2014,853,1,Phase 3,2,safety/efficacy,2,3.970291913552122,"(3,4]"
2790,3746,an extension study for treatment of moderately to severely active ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Late,702,All,Industry&Combos,0,NA,0,2019,2019,2872,0,Phase 3,1,NA,1,6.553933404025811,"(6,7]"
2843,3811,short bowel syndrome research study for children up to 17 years of age on parenteral nutrition,Completed,4,1,1,Short Bowel Syndrome,drug or biologic,Late,59,All,Industry&Combos,0,0,0,2016,2016,421,0,Phase 3,1,NA,1,4.07753744390572,"(4,5]"
3134,4258,safety and efficacy study of oral ferric maltol compared to intravenous iron to treat iron deficiency anaemia in ibd,Completed,4,1,1,"Anemia, Iron-Deficiency|Inflammatory Bowel Disease|Crohn's Disease",drug or biologic,Late,250,All,Industry&Combos,1,0,0,2016,2016,1004,1,Phase 3,0,safety/efficacy,0,5.521460917862246,"(5,6]"
2828,3790,a study comparing the efficacy and safety of etrolizumab with adalimumab and placebo in participants with moderate to severe ulcerative colitis (uc) in participants naive to tumor necrosis factor (tnf) inhibitors,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Late,358,All,Industry&Combos,1,0,0,2014,2014,1935,1,Phase 3,2,safety/efficacy,2,5.8805329864007,"(5,6]"
3590,5618,lubiprostone in children with functional constipation,Completed,4,1,1,Constipation - Functional,drug or biologic,Late,606,All,Industry&Combos,1,0,0,2014,2013,957,1,Phase 3,2,NA,2,6.406879986069314,"(6,7]"
2991,4009,"a study of zolbetuximab (imab362) plus capox compared with placebo plus capox as first-line treatment of subjects with claudin (cldn) 18.2-positive, her2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (gej) adenocarcinoma",Recruiting,2,0,0,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer|Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer|Metastatic Gastric Adenocarcinoma or Cancer|Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,drug or biologic,Late,500,All,Industry&Combos,1,0,0,2018,2018,1373,1,Phase 3,2,NA,2,6.214608098422191,"(6,7]"
2862,3838,long-term study of teduglutide in pediatric subjects with short bowel syndrome who completed the ted-c13-003 study,Completed,4,1,1,Short Bowel Syndrome,drug or biologic,Late,29,All,Industry&Combos,0,NA,0,2016,2016,1313,0,Phase 3,1,NA,1,3.367295829986474,"(3,4]"
3066,4126,treatment of thrombocytopenia in patients with chronic liver diseaseundergoing an elective procedure,Completed,4,1,1,Thrombocytopenia Associated With Liver Disease,drug or biologic,Late,231,All,Industry&Combos,1,0,0,2013,2014,1090,1,Phase 3,4,NA,2,5.442417710521793,"(5,6]"
3969,7464,a phase 3 study to evaluate combination therapy with daclatasvir and sofosbuvir in the treatment of hiv and hepatitis c virus coinfection.,Completed,4,1,1,Hepatitis C,drug or biologic,Late,238,All,Industry&Combos,1,0,0,2014,2014,242,1,Phase 3,0,NA,0,5.472270673671475,"(5,6]"
3941,7347,performance of sgm-101 for the delineation of primary and recurrent tumor and metastases in patients undergoing surgery for colorectal cancer,Recruiting,2,0,0,Colorectal Neoplasms,drug or biologic,Late,300,All,Industry&Combos,1,0,4,2018,2019,868,1,Phase 3,0,NA,0,5.703782474656201,"(5,6]"
2650,3555,efficacy and safety study of shp647 as induction therapy in participants with moderate to severe ulcerative colitis,Terminated,5,1,1,Ulcerative Colitis,drug or biologic,Late,279,All,Industry&Combos,1,0,0,2017,2017,953,1,Phase 3,2,safety/efficacy,2,5.631211781821365,"(5,6]"
824,863,a phase iii trial of hmpl-004 in patients with mild to moderate active ulcerative colitis,Terminated,5,1,1,Ulcerative Colitis,drug or biologic,Late,201,All,Industry&Combos,1,0,0,2013,2013,579,1,Phase 3,4,NA,2,5.303304908059076,"(5,6]"
4091,8079,efficacy and safety evaluation of a regimen consisting of peginterferon lambda-1a + ribavirin + daclatasvir (lambda + rbv + dcv) in hcv genotype 1b treatment na Â¯ve patients or prior relapsers to peginterferon alfa + ribavirin (alfa + rbv) therapy,Completed,4,0,0,Hepatitis C,drug or biologic,Late,444,All,Industry&Combos,1,0,0,2012,2013,638,1,Phase 3,0,safety/efficacy,0,6.095824562432225,"(6,7]"
1134,1204,comparison of two needle aspiration techniques for endoscopic ultrasound-guided fine needle aspiration (eus-fna) in solid pancreatic lesions,Completed,4,1,1,Pancreatic Solid Lesions|Pancreatic Mass,device,Others,121,All,Industry&Combos,1,0,2,2013,2013,730,1,Others,1,NA,1,4.795790545596741,"(4,5]"
2684,3601,a study of pertuzumab in combination with trastuzumab and chemotherapy in participants with human epidermal growth factor receptor 2 (her2)-positive metastatic gastroesophageal junction or gastric cancer,Completed,4,1,1,Gastric Cancer,drug or biologic,Late,780,All,Industry&Combos,1,0,0,2013,2013,1278,1,Phase 3,2,NA,2,6.659293919683638,"(6,7]"
3938,7338,safety and efficacy of ledipasvir/sofosbuvir fixed-dose combination  Â± ribavirin in treatment-experienced subjects with genotype 1 hcv infection,Completed,4,1,1,Chronic Hepatitis C Virus,drug or biologic,Late,441,All,Industry&Combos,1,0,0,2013,2013,304,1,Phase 3,0,safety/efficacy,0,6.089044875446846,"(6,7]"
4117,8710,efficacy and safety study of simeprevir in combination with sofosbuvir in participants with chronic hepatitis c virus infection without cirrhosis,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,310,All,Industry&Combos,1,0,0,2014,2014,275,1,Phase 3,0,safety/efficacy,0,5.736572297479192,"(5,6]"
2742,3675,glufosfamide versus 5-fu in second line metastatic pancreatic cancer,Recruiting,2,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Late,480,All,Industry&Combos,1,0,0,2013,2014,3166,1,Phase 3,0,NA,0,6.173786103901937,"(6,7]"
2716,3641,controlling anal incontinence by performing anal exercises with biofeedback or loperamide (capable),Completed,4,1,1,Fecal Incontinence,drug or biologic,Late,300,Female,NIH&Combos,2,0,0,2013,2014,820,1,Phase 3,4,NA,2,5.703782474656201,"(5,6]"
4125,8953,a study of nivolumab in combination with ipilimumab in participants with advanced hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Late,650,All,Industry&Combos,1,0,0,2019,2019,1288,1,Phase 3,0,NA,0,6.476972362889683,"(6,7]"
3292,4663,"randomized, open-label, multicenter, controlled, pivotal study to assess safety and efficacy of elad in subjects w/ aild",Terminated,5,1,1,Acute Alcoholic Hepatitis,drug or biologic,Late,151,All,Industry&Combos,0,0,0,2015,2016,790,0,Phase 3,1,safety/efficacy,1,5.017279836814924,"(5,6]"
2659,3566,12-week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea (ibs-d),Completed,4,1,1,Irritable Bowel Syndrome With Diarrhea,drug or biologic,Late,535,Female,Industry&Combos,1,0,0,2014,2014,457,1,Phase 3,4,safety/efficacy,2,6.282266746896006,"(6,7]"
1835,2090,the effect of naloxegol on refractory constipation in the intensive care unit,Withdrawn,7,0,0,Constipation|Critical Illness,drug or biologic,Late,NA,All,Industry&Combos,1,0,0,2016,2017,700,1,Phase 3,3,NA,2,NA,NA
4070,7837,a study of pegylated interferon alfa-2a in combination with lamivudine or entecavir compared with untreated control group in children with hepatitis b envelope antigen (hbeag)-positive chronic hepatitis b (chb) in the immune-tolerant phase,Completed,4,1,1,Pediatric Immuno-Tolerant Chronic Hepatitis B,drug or biologic,Late,62,All,Industry&Combos,1,0,0,2014,2014,2053,1,Phase 3,0,NA,0,4.127134385045092,"(4,5]"
3699,6140,low dose oral methotrexate in pediatric crohn's disease patients initiating anti-tumor necrosis factor (anti-tnf) therapy,Recruiting,2,0,0,Pediatric Crohn's Disease,drug or biologic,Late,425,All,NIH&Combos,1,0,0,2016,2016,1826,1,Phase 3,3,NA,2,6.052089168924417,"(6,7]"
3193,4424,a study of nivolumab in participants with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablation,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma|Liver Cancer,drug or biologic,Late,530,All,Industry&Combos,1,0,0,2017,2018,1734,1,Phase 3,4,NA,2,6.272877006546167,"(6,7]"
3685,6069,efficacy and safety study of ontamalimab as maintenance treatment in participants with moderate to severe crohn's disease (carmen cd 307),"Active, not recruiting",1,0,0,Crohn's Disease,drug or biologic,Late,40,All,Industry&Combos,1,0,0,2018,2019,999,1,Phase 3,2,safety/efficacy,2,3.6888794541139363,"(3,4]"
3684,6064,a study of daclatasvir and sofosbuvir with ribavirin in subjects with cirrhosis and genotype 3 hepatitis c infection,Completed,4,1,1,Hepatitis C,drug or biologic,Late,106,All,Industry&Combos,0,NA,0,2016,2016,352,0,Phase 3,1,NA,1,4.663439094112067,"(4,5]"
3401,5118,telestar (telotristat etiprate for somatostatin analogue not adequately controlled carcinoid syndrome),Completed,4,1,1,Carcinoid Syndrome,drug or biologic,Late,135,All,Industry&Combos,1,0,0,2012,2013,1168,1,Phase 3,4,NA,2,4.90527477843843,"(4,5]"
2562,3441,a study evaluating regorafenib following completion of standard chemotherapy for patients with colon cancer,Terminated,5,0,0,Stage III (IIIB or IIIC) Colon Cancer,drug or biologic,Late,34,All,Industry&Combos,1,0,0,2016,2016,1217,1,Phase 3,4,NA,2,3.5263605246161616,"(3,4]"
2638,3542,efficacy and safety study of shp647 as induction therapy in participants with moderate to severe ulcerative colitis,Terminated,5,1,1,Ulcerative Colitis,drug or biologic,Late,380,All,Industry&Combos,1,0,0,2017,2018,894,1,Phase 3,2,safety/efficacy,2,5.940171252720432,"(5,6]"
2046,2421,"a randomized, open-label, comparative, parallel-group, multicenter study of sparc1507",Withdrawn,7,0,0,Advanced Biliary Tract Cancer,drug or biologic,Late,NA,All,Industry&Combos,1,0,0,2015,2018,90,1,Phase 3,3,NA,2,NA,NA
2588,3481,a safety and efficacy comparison of bli4700 bowel prep versus an fda-approved comparator in adults prior to colonoscopy,Completed,4,0,0,Colonoscopy,drug or biologic,Late,620,All,Industry&Combos,1,0,0,2018,2018,180,1,Phase 3,1,safety/efficacy,1,6.429719478039138,"(6,7]"
3113,4225,tenofovir alafenamide in preventing liver complications in participants with current or past hepatitis b virus who are receiving anti-cancer therapy for solid tumors,"Active, not recruiting",1,0,0,Hepatitis B Virus Positive|Malignant Solid Neoplasm,drug or biologic,Late,444,All,NIH&Combos,1,0,1,2019,2019,2192,1,Phase 3,1,NA,1,6.095824562432225,"(6,7]"
2935,3936,study to assess the efficacy and safety of ntra-2112 on intestinal malabsorption in preterm infants,"Active, not recruiting",1,0,0,Premature Birth of Newborn|Intestinal Malabsorption,drug or biologic,Late,530,All,Industry&Combos,1,0,0,2015,2016,881,1,Phase 3,4,safety/efficacy,2,6.272877006546167,"(6,7]"
3052,4103,efficacy and safety evaluation of glepaglutide in treatment of sbs,Recruiting,2,0,0,Short Bowel Syndrome,drug or biologic,Late,129,All,Industry&Combos,1,0,0,2018,2018,1122,1,Phase 3,4,safety/efficacy,2,4.859812404361672,"(4,5]"
2715,3640,a study of pegylated recombinant human hyaluronidase in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in participants with hyaluronan-high stage iv previously untreated pancreatic ductal adenocarcinoma,Terminated,5,1,1,Pancreatic Ductal Carcinoma,drug or biologic,Late,492,All,Industry&Combos,1,0,0,2016,2016,1330,1,Phase 3,2,NA,2,6.198478716492308,"(6,7]"
1676,1847,brain and gut plasticity in mild tbi following growth hormone therapy,"Active, not recruiting",1,0,0,Traumatic Brain Injury|Fatigue|Cognitive Impairment,drug or biologic,Late,54,All,AllOther,1,1,0,2018,2018,1172,1,Phase 3,0,NA,0,3.9889840465642745,"(3,4]"
2750,3692,study to evaluate the efficacy and safety of filgotinib in the induction and maintenance of remission in adults with moderately to severely active ulcerative colitis,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Late,1351,All,Industry&Combos,1,0,0,2016,2016,1233,1,Phase 3,2,safety/efficacy,2,7.208600337960199,"(7,13]"
1751,1960,encopresis & mie (dod #2),Recruiting,2,0,0,Encopresis|Autism Spectrum Disorder,other,Others,112,All,AllOther,1,0,0,2017,2017,1437,1,Others,1,NA,1,4.718498871295094,"(4,5]"
3543,5418,long-term follow-up study with darvadstrocel in the treatment of complex perianal fistula,Recruiting,2,0,0,Crohn's Disease|Complex Perianal Fistula,drug or biologic,Late,150,All,Industry&Combos,0,NA,4,2019,2019,1577,0,Phase 3,1,NA,1,5.0106352940962555,"(5,6]"
3841,6913,safety and tolerability extension trial for patients with chronic idiopathic constipation,Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,411,All,Industry&Combos,0,NA,0,2013,2013,607,0,Phase 3,1,safety,1,6.018593214496234,"(6,7]"
3898,7200,study of thermodox with standardized radiofrequency ablation (rfa) for treatment of hepatocellular carcinoma (hcc),Completed,4,0,0,Hepatocellular Carcinoma,drug or biologic,Late,556,All,Industry&Combos,1,0,0,2014,2014,1552,1,Phase 3,4,NA,2,6.320768294250582,"(6,7]"
2662,3571,simplicity: studying impacts on malabsorption with liprotamase in cystic fibrosis,Completed,4,1,1,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,drug or biologic,Late,15,All,Industry&Combos,0,1,0,2016,2016,183,0,Phase 3,1,NA,1,2.70805020110221,"(2,3]"
2704,3627,"effect of tumor treating fields (ttfields, 150 khz) as front-line treatment of locally-advanced pancreatic adenocarcinoma concomitant with gemcitabine and nab-paclitaxel (panova-3)",Recruiting,2,0,0,Pancreas Adenocarcinoma,drug or biologic,Late,556,All,Industry&Combos,1,0,0,2017,2018,1940,1,Phase 3,0,NA,0,6.320768294250582,"(6,7]"
2582,3472,trial of iw-3718 for 8 weeks in patients with persistent gastroesophageal reflux disease (gerd) receiving proton pump inhibitors,Completed,4,0,0,Gastroesophageal Reflux Disease (GERD),drug or biologic,Late,609,All,Industry&Combos,1,0,0,2018,2018,785,1,Phase 3,2,NA,2,6.411818267709897,"(6,7]"
2701,3621,endotag-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on folfirinox treatment,"Active, not recruiting",1,0,0,Metastatic Pancreas Cancer|Locally Advanced Pancreatic Cancer|Pancreatic Adenocarcinoma,drug or biologic,Late,218,All,Industry&Combos,1,0,0,2017,2018,1116,1,Phase 3,0,NA,0,5.384495062789089,"(5,6]"
2566,3447,a study of regorafenib in refractory advanced gastro-oesophageal cancer,Recruiting,2,0,0,Gastro-Oesophageal Cancer,drug or biologic,Late,350,All,AllOther,1,0,0,2016,2016,2038,1,Phase 3,3,NA,2,5.857933154483459,"(5,6]"
3574,5538,a study of atezolizumab plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation,Recruiting,2,0,0,"Carcinoma, Hepatocellular",drug or biologic,Late,662,All,Industry&Combos,1,0,0,2019,2019,1186,1,Phase 3,0,NA,0,6.495265555937008,"(6,7]"
3125,4247,one year study of rifaximin delayed release (dr) tablets in crohn's disease,Terminated,5,1,1,Crohn's Disease,drug or biologic,Late,80,All,Industry&Combos,1,0,0,2014,2014,1091,1,Phase 3,4,NA,2,4.382026634673881,"(4,5]"
3403,5123,"bi 695501 versus humira in patients with active crohn's disease: a trial comparing efficacy, endoscopic improvement, safety, and immunogenicity",Completed,4,1,1,Crohn Disease,drug or biologic,Late,147,All,Industry&Combos,1,0,0,2016,2016,944,1,Phase 3,2,safety/efficacy,2,4.990432586778736,"(4,5]"
3544,5421,microbiota restoration therapy for recurrent clostridium difficile infection (punchcd3),Completed,4,0,0,Clostridium Difficile Infection,drug or biologic,Late,267,All,Industry&Combos,1,0,0,2017,2017,976,1,Phase 3,3,NA,2,5.58724865840025,"(5,6]"
1328,1418,intravenous fat emulsion comprised of fish oil in the treatment of parenteral nutrition induced liver injury in infants,Completed,4,0,0,Total Parenteral Nutrition-induced Cholestasis,drug or biologic,Late,2,All,AllOther,0,NA,0,2015,2015,1339,0,Phase 3,1,NA,1,0.6931471805599453,"(0,1]"
2992,4010,pembrolizumab (mk-3475) plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin for first-line advanced and/or unresectable biliary tract carcinoma (btc) (mk-3475-966/keynote-966),"Active, not recruiting",1,0,0,Biliary Tract Carcinoma,drug or biologic,Late,1048,All,Industry&Combos,1,0,0,2019,2019,1437,1,Phase 3,3,NA,2,6.954638864880987,"(6,7]"
1234,1313,reversal of hepatic impairment in patients with hepatitis c virus (hcv) and early decompensation of cirrhosis,"Active, not recruiting",1,0,0,Hepatitis C,drug or biologic,Late,9,All,Industry&Combos,0,NA,4,2015,2015,2041,0,Phase 3,1,NA,1,2.1972245773362196,"(2,3]"
3955,7378,the safety and efficacy of methylene blue mmx Â® modified release tablets administered to subjects undergoing screening or surveillance colonoscopy,Completed,4,1,1,Colorectal Cancer,drug or biologic,Late,1249,All,Industry&Combos,1,0,4,2012,2013,1126,1,Phase 3,2,safety/efficacy,2,7.130098510125578,"(7,13]"
2832,3794,a study of ramucirumab (ly3009806) in combination with capecitabine and cisplatin in participants with stomach cancer,Completed,4,1,1,Metastatic Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,drug or biologic,Late,645,All,Industry&Combos,1,0,0,2014,2015,728,1,Phase 3,2,NA,2,6.4692503167957724,"(6,7]"
2901,3890,"mesalamine 4 g sachet for the induction of remission in active, mild to moderate ulcerative colitis (uc)",Completed,4,1,1,Ulcerative Colitis,drug or biologic,Late,228,All,Industry&Combos,1,0,0,2015,2015,859,1,Phase 3,4,NA,2,5.429345628954441,"(5,6]"
2774,3725,etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Late,433,All,Industry&Combos,1,0,0,2019,2019,933,1,Phase 3,2,NA,2,6.07073772800249,"(6,7]"
3835,6893,a study to evaluate the efficacy and safety of abt-493/abt-530 in combination with sofosbuvir and ribavirin in participants with hepatitis c virus who did not respond to treatment in a previous abbvie clinical study,"Active, not recruiting",1,0,0,Hepatitis C Virus Infection,drug or biologic,Late,50,All,Industry&Combos,1,1,0,2016,2016,1515,1,Phase 3,0,safety/efficacy,0,3.912023005428146,"(3,4]"
3851,7012,unity 2: a study of an investigational treatment regimen of dcv+asv+bms-791325 in a fixed dose combination (the dcv 3daa (direct acting antiviral) regimen) with or without rbv for 12 weeks for the treatment of chronic hepatitis c virus(hcv)genotype 1 infection in subjects with compensated cirrhosis,Completed,4,0,0,Hepatitis C,drug or biologic,Late,202,All,Industry&Combos,1,0,0,2013,2013,243,1,Phase 3,3,NA,2,5.308267697401205,"(5,6]"
2668,3578,an efficacy and safety study of ontamalimab as maintenance therapy in participants with moderate to severe ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Late,366,All,Industry&Combos,1,0,0,2017,2018,1238,1,Phase 3,2,safety/efficacy,2,5.902633333401366,"(5,6]"
3129,4252,the evarrest Â® fibrin sealant patch liver study,Completed,4,1,1,Hemorrhage,drug or biologic,Late,102,All,Industry&Combos,1,0,0,2013,2013,273,1,Phase 3,0,NA,0,4.624972813284271,"(4,5]"
3058,4111,civacir Â® polyclonal immune globulin (igg) to prevent hepatitis c virus (hcv) recurrence in liver transplant patients.,Completed,4,0,0,"Hepatitis C Infection|Viruses|Hepatocellular Carcinoma|Hepatitis, Viral, Human|Liver Cirrhosis",drug or biologic,Late,80,All,Industry&Combos,1,0,1,2013,2013,975,1,Phase 3,0,NA,0,4.382026634673881,"(4,5]"
2616,3515,a study to evaluate the safety and efficacy of ustekinumab induction and maintenance therapy in participants with moderately to severely active ulcerative colitis,"Active, not recruiting",1,1,1,"Colitis, Ulcerative|Inflammatory Bowel Diseases",drug or biologic,Late,961,All,Industry&Combos,1,0,NA,2015,2015,1127,1,Phase 3,2,safety/efficacy,2,6.8679744089702925,"(6,7]"
171,172,a multicenter study of active specific immunotherapy with oncovax Â® in patients with stage ii colon cancer,Recruiting,2,0,0,Stage II Colon Cancer,drug or biologic,Late,550,All,Industry&Combos,1,0,0,2015,2015,1888,1,Phase 3,0,NA,0,6.309918278226516,"(6,7]"
2732,3661,comparing nuc-1031 plus cisplatin to gemcitabine plus cisplatin in patients with advanced biliary tract cancer,Recruiting,2,0,0,Biliary Tract Cancer,drug or biologic,Late,828,All,AllOther,1,0,0,2019,2019,1438,1,Phase 3,1,NA,1,6.71901315438526,"(6,7]"
2623,3524,study of ruxolitinib in pancreatic cancer patients (janus 1),Terminated,5,1,1,Pancreatic Cancer,drug or biologic,Late,321,All,Industry&Combos,1,0,0,2014,2014,702,1,Phase 3,2,NA,2,5.771441123130016,"(5,6]"
2563,3442,"multicenter randomized parallel group phase iii study comparing the bowel cleansing efficacy, safety and tolerability of ner1006 versus trisulfate solution using 2-day split-dosing regimen in adults",Completed,4,1,1,Colon Cancer|Colorectal Carcinoma|Colon Cleansing,drug or biologic,Late,621,All,Industry&Combos,1,0,4,2014,2014,273,1,Phase 3,1,safety/efficacy,1,6.431331081933479,"(6,7]"
2677,3589,ibp-9414 for the prevention of necrotizing enterocolitis - the connection study,Recruiting,2,0,0,Necrotizing Enterocolitis,drug or biologic,Late,2158,All,Industry&Combos,1,0,1,2019,2019,1185,1,Phase 3,4,NA,2,7.67693714581808,"(7,13]"
3854,7047,study of cabozantinib in combination with atezolizumab versus sorafenib in subjects with advanced hcc who have not received previous systemic anticancer therapy,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Late,740,All,Industry&Combos,1,0,0,2018,2018,904,1,Phase 3,0,NA,0,6.606650186198215,"(6,7]"
3917,7300,preventive treatment of oxaliplatin induced peripheral neuropathy in metastatic colorectal cancer (polar-m),Completed,4,0,0,Colorectal Cancer|Chemotherapy-induced Peripheral Neuropathy,drug or biologic,Late,291,All,Industry&Combos,1,0,1,2018,2018,700,1,Phase 3,3,NA,2,5.673323267171493,"(5,6]"
3311,4710,nintedanib (bibf 1120) vs placebo in refractory metastatic colorectal cancer (lume-colon 1),Completed,4,1,1,Colorectal Neoplasms,drug or biologic,Late,768,All,Industry&Combos,1,0,0,2014,2014,596,1,Phase 3,2,NA,2,6.643789733147672,"(6,7]"
629,656,cardiox liver function test pivotal trial,Withdrawn,7,0,0,Hepatic Failure|Liver Failure,drug or biologic,Late,NA,All,Industry&Combos,0,1,2,2015,2015,182,0,Phase 3,1,NA,1,NA,NA
2861,3837,filgotinib in long-term extension study of adults with ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Late,1173,All,Industry&Combos,1,1,0,2016,2017,2442,1,Phase 3,2,NA,2,7.067319848653476,"(7,13]"
4079,7890,eradicate hp2 - treating helicobacter pylori with rhb-105 compared to active comparator,Completed,4,1,1,Helicobacter Pylori Infection|Dyspepsia,drug or biologic,Late,455,All,Industry&Combos,1,0,0,2017,2017,493,1,Phase 3,3,NA,2,6.12029741895095,"(6,7]"
2734,3663,combination chemotherapy with or without atezolizumab in treating patients with stage iii colon cancer and deficient dna mismatch repair,Recruiting,2,0,0,Colon Adenocarcinoma|DNA Repair Disorder|Lynch Syndrome|Stage III Colon Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7,drug or biologic,Late,700,All,NIH&Combos,1,0,0,2016,2017,2394,1,Phase 3,0,NA,0,6.551080335043404,"(6,7]"
3127,4249,long term safety study of plecanatide,Completed,4,1,1,Irritable Bowel Syndrome,drug or biologic,Late,2272,All,Industry&Combos,0,NA,0,2016,2016,486,0,Phase 3,1,safety,1,7.7284157798410416,"(7,13]"
2844,3812,"study of ibrutinib vs placebo, in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma (resolve)",Completed,4,1,1,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Late,430,All,Industry&Combos,1,0,0,2015,2015,1249,1,Phase 3,2,NA,2,6.063785208687608,"(6,7]"
1824,2075,everolimus plus mycophenolic acid for kidney preservation in liver transplant recipients with impaired kidney function,Recruiting,2,0,0,Kidney Failure,drug or biologic,Late,104,All,AllOther,1,0,1,2020,2019,3300,1,Phase 3,0,NA,0,4.6443908991413725,"(4,5]"
3415,5156,a maintenance and long-term extension study of the efficacy and safety of upadacitinib (abt-494) in participants with crohn's disease who completed the studies m14-431 or m14-433,Enrolling by invitation,3,0,0,Crohn's Disease,drug or biologic,Late,747,All,Industry&Combos,1,0,0,2017,2018,3434,1,Phase 3,4,safety/efficacy,2,6.616065185132817,"(6,7]"
3906,7265,safety and efficacy of lenvatinib (e7080/mk-7902) in combination with pembrolizumab (mk-3475) versus lenvatinib as first-line therapy in participants with advanced hepatocellular carcinoma (mk-7902-002/e7080-g000-311/leap-002),"Active, not recruiting",1,0,0,"Carcinoma, Hepatocellular",drug or biologic,Late,750,All,Industry&Combos,1,0,0,2018,2018,1229,1,Phase 3,2,safety/efficacy,2,6.620073206530356,"(6,7]"
2641,3545,avelumab in first-line maintenance gastric cancer (javelin gastric 100),Completed,4,0,0,"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction",drug or biologic,Late,499,All,Industry&Combos,1,0,0,2015,2015,1359,1,Phase 3,0,NA,0,6.212606095751519,"(6,7]"
3936,7335,safety and efficacy of ledipasvir/sofosbuvir fixed-dose combination  Â± ribavirin for the treatment of hcv (ion-3),Completed,4,1,1,Chronic Hepatitis C Virus,drug or biologic,Late,647,All,Industry&Combos,1,0,0,2013,2013,214,1,Phase 3,0,safety/efficacy,0,6.472346294500901,"(6,7]"
2970,3984,first-line esophageal carcinoma study with chemo vs. chemo plus pembrolizumab (mk-3475-590/keynote-590),"Active, not recruiting",1,1,1,Esophageal Neoplasms,drug or biologic,Late,749,All,Industry&Combos,1,0,0,2017,2017,1073,1,Phase 3,2,NA,2,6.618738983517219,"(6,7]"
3083,4161,early palliative care with standard care or standard care alone in improving quality of life of patients with incurable lung or non-colorectal gastrointestinal cancer and their family caregivers,Completed,4,1,1,Liver Cancer|Anxiety Disorder|Depression|Small Cell Lung Cancer|Extrahepatic Bile Duct Cancer|Malignant Mesothelioma|Pancreatic Cancer|Esophageal Cancer|Gastric Cancer|Non-small Cell Lung Cancer,other,Others,405,All,NIH&Combos,1,0,4,2015,2015,824,1,Others,0,NA,0,6.003887067106539,"(6,7]"
2969,3982,a 12-week study with a 4-week randomized withdrawal period to evaluate the efficacy and safety of tenapanor for the treatment of ibs-c,Completed,4,1,1,Constipation Predominant Irritable Bowel Syndrome,drug or biologic,Late,606,All,Industry&Combos,1,0,0,2015,2015,517,1,Phase 3,4,safety/efficacy,2,6.406879986069314,"(6,7]"
3560,5472,a study to evaluate efficacy and safety of ustekinumab re-induction therapy in participants with moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn Disease,drug or biologic,Late,200,All,Industry&Combos,1,0,0,2018,2018,1286,1,Phase 3,4,safety/efficacy,2,5.298317366548036,"(5,6]"
3054,4105,"imiquimod, fluorouracil, or observation in treating hiv-positive patients with high-grade anal squamous skin lesions",Recruiting,2,0,0,Anal Intraepithelial Neoplasia|High-grade Squamous Intraepithelial Lesion|HIV Infection,drug or biologic,Late,150,All,IndustryNIHPartnership,3,0,0,2014,2015,2012,3,Phase 3,1,NA,1,5.0106352940962555,"(5,6]"
3857,7060,an open label study of chronic use of bli400 laxative in constipated adults,Completed,4,1,1,Constipation|Chronic Idiopathic Constipation|CIC,drug or biologic,Late,330,All,Industry&Combos,0,NA,0,2016,2016,426,0,Phase 3,1,NA,1,5.799092654460526,"(5,6]"
3429,5218,a study to assess whether etrolizumab is a safe and efficacious treatment for participants with moderately to severely active crohn's disease,"Active, not recruiting",1,0,0,Crohn Disease,drug or biologic,Late,1150,All,Industry&Combos,1,0,0,2015,2015,2325,1,Phase 3,2,NA,2,7.047517221357296,"(7,13]"
3680,6041,study to evaluate the safety and efficacy of relamorelin in patients with diabetic gastroparesis study 02,Terminated,5,0,0,Gastroparesis|Diabetes Mellitus,drug or biologic,Late,311,All,Industry&Combos,1,0,0,2018,2018,932,1,Phase 3,2,safety/efficacy,2,5.739792912179234,"(5,6]"
3027,4067,study of nivolumab in unresectable advanced or recurrent esophageal cancer,Completed,4,0,0,Esophageal Cancer,drug or biologic,Late,419,All,Industry&Combos,1,0,0,2015,2015,1775,1,Phase 3,0,NA,0,6.037870919922137,"(6,7]"
4086,8023,study to confirm efficacy and safety of terlipressin in hepatorenal syndrome (hrs) type 1,Completed,4,0,0,Hepatorenal Syndrome,drug or biologic,Late,300,All,Industry&Combos,1,0,0,2016,2016,1106,1,Phase 3,2,safety/efficacy,2,5.703782474656201,"(5,6]"
2679,3595,a study of the efficacy and safety of upadacitinib (abt-494) in participants with moderately to severely active ulcerative colitis,Completed,4,0,0,Ulcerative Colitis (UC),drug or biologic,Late,522,All,Industry&Combos,1,0,0,2018,2018,794,1,Phase 3,4,safety/efficacy,2,6.257667587882639,"(6,7]"
4163,9143,safety and efficacy of sof/vel/vox fdc for 8 weeks and sof/vel for 12 weeks in adults chronic genotype 3 hcv infection and cirrhosis,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,220,All,Industry&Combos,1,0,0,2015,2015,294,1,Phase 3,0,safety/efficacy,0,5.393627546352362,"(5,6]"
2240,2762,transarterial chemoembolization compared with stereotactic body radiation therapy or stereotactic ablative radiation therapy in treating patients with residual or recurrent liver cancer undergone initial transarterial chemoembolization,"Active, not recruiting",1,0,0,Child-Pugh Class A|Child-Pugh Class B|Recurrent Hepatocellular Carcinoma,drug or biologic,Late,13,All,NIH&Combos,1,0,0,2016,2016,2469,1,Phase 3,0,NA,0,2.5649493574615367,"(2,3]"
3675,5931,a study of onco-dox in locally advanced hepatocellular carcinoma,Terminated,5,1,1,Hepatocellular Carcinoma|Hepatoma|Liver Cell Carcinoma,drug or biologic,Late,2,All,Industry&Combos,1,0,0,2015,2015,582,1,Phase 3,0,NA,0,0.6931471805599453,"(0,1]"
3586,5591,a long-term active treatment study of mongersen (ged-0301) in subjects with crohn's disease,Terminated,5,1,1,Crohn's Disease,drug or biologic,Late,310,All,Industry&Combos,1,0,0,2015,2016,528,1,Phase 3,4,NA,2,5.736572297479192,"(5,6]"
2762,3711,long-term safety and efficacy study of adalimumab in pediatric subjects with ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Late,101,All,Industry&Combos,0,NA,0,2015,2015,3457,0,Phase 3,1,safety/efficacy,1,4.61512051684126,"(4,5]"
1208,1286,alvimopan versus placebo in patients undergoing radical cystectomy on an enhanced recovery protocol,Recruiting,2,0,0,Bladder Cancer,drug or biologic,Late,136,All,Industry&Combos,1,0,0,2017,2018,823,1,Phase 3,2,NA,2,4.912654885736052,"(4,5]"
3738,6282,tenofovir alafenamide versus tenofovir disoproxil fumarate for treatment of hepatitis b e antigen-negative hepatitis b,"Active, not recruiting",1,1,1,HBV|Chronic HIV Infection,drug or biologic,Late,426,All,Industry&Combos,1,0,0,2013,2013,730,1,Phase 3,2,NA,2,6.054439346269371,"(6,7]"
2558,3437,"study of romiplostim for chemotherapy-induced thrombocytopenia in adult subjects with gastrointestinal, pancreatic, or colorectal cancer",Recruiting,2,0,0,Chemotherapy-induced Thrombocytopenia,drug or biologic,Late,162,All,Industry&Combos,1,0,0,2017,2019,1217,1,Phase 3,0,NA,0,5.087596335232384,"(5,6]"
4180,9314,a phase iii study of the efficacy and safety of remimazolam compared to placebo and midazolam in colonoscopy patients,Completed,4,1,1,Colonoscopy,drug or biologic,Late,461,All,Industry&Combos,1,0,0,2014,2015,368,1,Phase 3,2,safety/efficacy,2,6.133398042996649,"(6,7]"
3384,5022,a study of the efficacy and safety of upadacitnib (abt-494) in participants with moderately to severely active crohn's disease who have inadequately responded to or are intolerant to conventional and/or biologic therapies,Recruiting,2,0,0,Crohn's Disease,drug or biologic,Late,501,All,Industry&Combos,1,0,0,2017,2017,1377,1,Phase 3,4,safety/efficacy,2,6.2166061010848646,"(6,7]"
2907,3897,long-term safety of linaclotide in pediatric participants with fc or ibs-c,Enrolling by invitation,3,0,0,Irritable Bowel Syndrome With Constipation|Functional Constipation,drug or biologic,Late,120,All,Industry&Combos,1,1,0,2019,2019,1486,1,Phase 3,0,safety,0,4.787491742782046,"(4,5]"
2903,3892,the plecanatide irritable bowel syndrome with constipation study (ibs-c),Completed,4,1,1,Irritable Bowel Syndrome Characterized by Constipation,drug or biologic,Late,1054,All,Industry&Combos,1,0,0,2015,2014,731,1,Phase 3,3,NA,2,6.960347729101308,"(6,7]"
2882,3866,second plecanatide study in irritable bowel syndrome with constipation (ibs-c),Completed,4,1,1,Irritable Bowel Syndrome Characterized by Constipation,drug or biologic,Late,1135,All,Industry&Combos,1,0,0,2015,2015,519,1,Phase 3,3,NA,2,7.034387929915503,"(7,13]"
3897,7198,open-label extension study of brazikumab in crohn's disease,Enrolling by invitation,3,0,0,Crohn's Disease,drug or biologic,Late,1000,All,Industry&Combos,1,1,0,2019,2019,2156,1,Phase 3,0,NA,0,6.907755278982137,"(6,7]"
3243,4552,trial of eflornithine plus sulindac in patients with familial adenomatous polyposis (fap),Completed,4,1,1,Familial Adenomatous Polyposis,drug or biologic,Late,171,All,Industry&Combos,1,0,0,2011,2013,1857,1,Phase 3,3,NA,2,5.14166355650266,"(5,6]"
3411,5147,(voyager) study of avapritinib vs regorafenib in patients with locally advanced unresectable or metastatic gist,"Active, not recruiting",1,1,1,GIST,drug or biologic,Late,476,All,Industry&Combos,1,0,0,2018,2018,714,1,Phase 3,0,NA,0,6.16541785423142,"(6,7]"
1362,1456,lactated ringers with or without rectal indomethacin to prevent post-ercp pancreatitis,Completed,4,1,1,Post-ERCP Acute Pancreatitis,drug or biologic,Late,192,All,AllOther,1,0,1,2015,2014,609,1,Phase 3,4,NA,2,5.2574953720277815,"(5,6]"
2768,3717,andecaliximab with mfolfox6 as first line treatment for advanced gastric or gastroesophageal junction adenocarcinoma,Completed,4,1,1,Gastric Adenocarcinoma,drug or biologic,Late,432,All,Industry&Combos,1,0,0,2015,2015,1310,1,Phase 3,2,NA,2,6.068425588244111,"(6,7]"
3331,4760,safety and efficacy of selonsertib in adults with nonalcoholic steatohepatitis (nash) and bridging (f3) fibrosis,Terminated,5,1,1,Nonalcoholic Steatohepatitis,drug or biologic,Late,808,All,Industry&Combos,1,0,0,2017,2017,856,1,Phase 3,2,safety/efficacy,2,6.694562058521095,"(6,7]"
1340,1432,a long-term safety study of tenapanor for the treatment of ibs-c,Completed,4,1,1,Constipation Predominant Irritable Bowel Syndrome,drug or biologic,Late,312,All,Industry&Combos,0,NA,0,2016,2016,579,0,Phase 3,1,safety,1,5.7430031878094825,"(5,6]"
2965,3978,"s0820, adenoma and second primary prevention trial",Recruiting,2,0,0,Colorectal Neoplasms,drug or biologic,Late,1340,All,IndustryNIHPartnership,2,0,1,2011,2013,4505,1,Phase 3,3,NA,2,7.200424892944957,"(7,13]"
2698,3618,pembrolizumab/placebo plus trastuzumab plus chemotherapy in human epidermal growth factor receptor 2 positive (her2+) advanced gastric or gastroesophageal junction (gej) adenocarcinoma (mk-3475-811/keynote-811),Recruiting,2,0,0,Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma,drug or biologic,Late,732,All,Industry&Combos,1,0,0,2018,2018,1700,1,Phase 3,4,NA,2,6.595780513961311,"(6,7]"
179,180,endoscopic biliary co-axial stent placement plus/minus use of radiofrequency ablation (rfa) for clearance of occluded self expandable metal stents (sems) in patients with distal biliary obstruction from unresectable biliary-pancreatic malignancies,Completed,4,1,1,Pancreatic Cancer|Unresectable Biliary-pancreatic Malignancies,device,Others,24,All,AllOther,1,0,0,2015,2015,1765,1,Others,0,NA,0,3.1780538303479458,"(3,4]"
2748,3688,an efficacy and safety study of vedolizumab intravenous (iv) compared to adalimumab subcutaneous (sc) in participants with ulcerative colitis,Completed,4,1,1,"Colitis, Ulcerative",drug or biologic,Late,771,All,Industry&Combos,1,0,0,2015,2015,1185,1,Phase 3,2,safety/efficacy,2,6.647688373563329,"(6,7]"
3395,5078,assess efficacy and safety of durvalumab alone or combined with bevacizumab in high risk of recurrence hcc patients after curative treatment,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Late,888,All,Industry&Combos,1,0,0,2019,2019,1493,1,Phase 3,4,safety/efficacy,2,6.78897174299217,"(6,7]"
4082,7913,phase iiib study of apd421 in combination as ponv prophylaxis,Completed,4,1,1,PONV,drug or biologic,Late,1147,All,Industry&Combos,1,0,1,2015,2015,212,1,Phase 3,4,NA,2,7.044905117129371,"(7,13]"
3803,6702,efficacy of alicaforsen in pouchitis patients who have failed to respond to at least one course of antibiotics,Completed,4,1,1,Pouchitis,drug or biologic,Late,138,All,Industry&Combos,1,0,0,2015,2015,949,1,Phase 3,3,efficacy,2,4.927253685157205,"(4,5]"
2567,3448,bekinda (ondansetron 24 mg bimodal release tablets) for vomiting due to presumed acute gastroenteritis or gastritis,Completed,4,1,1,Gastroenteritis|Gastritis,drug or biologic,Late,330,All,Industry&Combos,1,0,0,2014,2014,798,1,Phase 3,4,NA,2,5.799092654460526,"(5,6]"
3112,4223,the evarrest Â® pediatric mild or moderate liver and soft tissue bleeding study,Recruiting,2,0,0,Controlling Mild to Moderate Bleeding During Surgery,drug or biologic,Late,35,All,Industry&Combos,0,NA,0,2017,2018,1716,0,Phase 3,1,NA,1,3.5553480614894135,"(3,4]"
1823,2074,alvimopan as rescue in post op ileus,Unknown status,8,0,0,Colorectal Surgery|Ileus,drug or biologic,Late,142,All,Industry&Combos,1,0,0,2016,2016,700,1,Phase 3,0,NA,0,4.955827057601261,"(4,5]"
3554,5456,a study of mirikizumab (ly3074828) in participants with crohn's disease,Recruiting,2,0,0,Crohn's Disease,drug or biologic,Late,1150,All,Industry&Combos,1,0,0,2019,2019,1249,1,Phase 3,3,NA,2,7.047517221357296,"(7,13]"
1804,2039,everolimus monotherapy as immunosuppression after liver transplant,Recruiting,2,0,0,Kidney Failure,drug or biologic,Late,104,All,AllOther,1,0,1,2019,2019,3128,1,Phase 3,0,NA,0,4.6443908991413725,"(4,5]"
4104,8163,"efficacy and safety study of pegylated interferon lambda-1a with ribavirin and daclatasvir, to treat na Â¯ve subjects with chronic hcv genotypes 1, 2, 3, and 4 who are co-infected with hiv",Completed,4,0,0,Chronic Hepatitis C Infection,drug or biologic,Late,453,All,Industry&Combos,1,1,0,2013,2013,777,1,Phase 3,0,safety/efficacy,0,6.115892125483034,"(6,7]"
3511,5339,filgotinib in the induction and maintenance of remission in adults with moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn's Disease,drug or biologic,Late,1320,All,Industry&Combos,1,0,0,2016,2016,2192,1,Phase 3,2,NA,2,7.1853870155804165,"(7,13]"
3845,6939,"safety study of 2 formulations of gsk's human rotavirus (hrv) vaccine (444563), in healthy infants starting at age 6-12 weeks",Completed,4,1,1,"Infections, Rotavirus",drug or biologic,Late,1351,All,Industry&Combos,1,0,1,2019,2019,500,1,Phase 3,4,safety,2,7.208600337960199,"(7,13]"
2607,3505,study of tas-102 or placebo plus bsc in patients with metastatic gastric cancer,Completed,4,0,0,Refractory Metastatic Gastric Cancer,drug or biologic,Late,506,All,Industry&Combos,1,0,0,2015,2015,731,1,Phase 3,4,NA,2,6.226536669287466,"(6,7]"
2912,3903,durvalumab or placebo in combination with gemcitabine/cisplatin in patients with 1st line advanced biliary tract cancer (topaz-1),Recruiting,2,0,0,Biliary Tract Neoplasms,drug or biologic,Late,757,All,Industry&Combos,1,0,0,2019,2019,1171,1,Phase 3,4,NA,2,6.6293632534374485,"(6,7]"
3818,6779,study of a candidate clostridium difficile toxoid vaccine in subjects at risk for c. difficile infection,Terminated,5,1,1,Clostridium Difficile Infection,drug or biologic,Late,9302,All,Industry&Combos,1,0,1,2013,2013,1778,1,Phase 3,3,NA,2,9.137984709784043,"(7,13]"
1544,1682,"comparison of adenoma detection rate among water, carbon dioxide and air methods of minimal sedation colonoscopy",Terminated,5,0,0,Screening Colonoscopy,procedure,Others,450,All,AllOther,1,0,4,2013,2013,758,1,Others,1,NA,1,6.1092475827643655,"(6,7]"
1856,2131,a clinical study to evaluate the efficacy and safety of aramchol in subjects with nash (armor),Recruiting,2,0,0,Nonalcoholic Steatohepatitis (NASH),drug or biologic,Late,2000,All,Industry&Combos,1,0,0,2019,2019,1896,1,Phase 3,4,safety/efficacy,2,7.600902459542082,"(7,13]"
4157,9130,a study of of glecaprevir/pibrentasvir in adults with chronic hepatitis c virus (hcv) genotype 5 or 6 infection,Completed,4,1,1,Hepatitis C Virus (HCV),drug or biologic,Late,84,All,Industry&Combos,0,1,0,2016,2017,497,0,Phase 3,1,NA,1,4.430816798843313,"(4,5]"
1095,1159,"hepatic dysfunction, vitamin d status, and glycemic control in diabetes",Completed,4,0,0,Type 2 Diabetes|Nonalcoholic Fatty Liver Disease|Vitamin D Deficiency,other,Others,12,All,AllOther,1,0,0,2014,2014,945,1,Others,4,NA,2,2.4849066497880004,"(2,3]"
3173,4350,phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (nash),Terminated,5,0,0,Nonalcoholic Steatohepatitis (NASH) With Fibrosis,drug or biologic,Late,2157,All,Industry&Combos,1,0,0,2016,2016,1702,1,Phase 3,4,safety/efficacy,2,7.676473646389156,"(7,13]"
3313,4716,does cefoxitin or piperacillin-tazobactam prevent postoperative surgical site infections after pancreatoduodenectomy?,Recruiting,2,0,0,Pancreatic Cancer|Pancreas Cancer|Pancreatic Diseases,drug or biologic,Late,100,All,AllOther,1,0,0,2017,2017,1461,1,Phase 3,0,NA,0,4.605170185988092,"(4,5]"
2624,3525,a safety extension study of ontamalimab in participants with moderate to severe ulcerative colitis or crohn's disease (aida),Recruiting,2,0,0,Crohn's Disease|Ulcerative Colitis,drug or biologic,Late,451,All,Industry&Combos,1,0,0,2017,2018,2133,1,Phase 3,2,safety,2,6.111467339502679,"(6,7]"
3507,5323,trial of linaclotide in patients with chronic idiopathic constipation,Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,1223,All,Industry&Combos,1,0,0,2014,2014,304,1,Phase 3,4,NA,2,7.109062135687172,"(7,13]"
2730,3658,a study comparing the efficacy and safety of etrolizumab with adalimumab and placebo in participants with moderate to severe ulcerative colitis (uc) in participants naive to tumor necrosis factor (tnf) inhibitors,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Late,358,All,Industry&Combos,1,0,0,2014,2014,1933,1,Phase 3,2,safety/efficacy,2,5.8805329864007,"(5,6]"
3428,5214,a safety and efficacy evaluation of bli400 laxative in constipated adults,Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,459,All,Industry&Combos,1,0,0,2015,2015,184,1,Phase 3,2,safety/efficacy,2,6.129050210060545,"(6,7]"
3581,5577,efficacy and safety study of mongersen (ged-0301) for the treatment of subjects with active crohn's disease,Terminated,5,1,1,Crohn Disease,drug or biologic,Late,701,All,Industry&Combos,1,0,0,2015,2015,759,1,Phase 3,4,safety/efficacy,2,6.55250788703459,"(6,7]"
3678,6024,a study to evaluate long-term outcomes following treatment with abt-450/ritonavir/abt-267 (abt-450/r/abt-267) and abt-333 with or without ribavirin (rbv) in adults with genotype 1 chronic hepatitis c virus (hcv) infection,Completed,4,0,0,Chronic Hepatitis C Virus (HCV) Infection Genotype 1,drug or biologic,Late,615,All,Industry&Combos,0,NA,0,2014,2014,2527,0,Phase 3,1,NA,1,6.421622267806518,"(6,7]"
2786,3742,a study to investigate the safety and efficacy of lt-02 in patients with mesalamine refractory ulcerative colitis (uc),Terminated,5,0,0,Ulcerative Colitis,drug or biologic,Late,25,All,Industry&Combos,1,0,0,2016,2016,973,1,Phase 3,4,safety/efficacy,2,3.2188758248682006,"(3,4]"
3167,4330,"colorectal cancer treated with adjuvant regorafenib versus placebo after curative treatment of liver metastases in a randomized, double-blind, placebo-controlled phase-iii study",Terminated,5,1,1,Colorectal Neoplasms,drug or biologic,Late,25,All,Industry&Combos,1,0,0,2013,2013,1001,1,Phase 3,4,NA,2,3.2188758248682006,"(3,4]"
3039,4083,long term safety & efficacy study evaluating the effect of a4250 in children with pfic,Recruiting,2,0,0,Progressive Familial Intrahepatic Cholestasis,drug or biologic,Late,120,All,Industry&Combos,0,NA,0,2018,2018,1160,0,Phase 3,1,safety/efficacy,1,4.787491742782046,"(4,5]"
3284,4635,effect of intravenous (iv) vedolizumab on mucosal healing in crohn's disease,Completed,4,1,1,Crohn's Disease,drug or biologic,Late,101,All,Industry&Combos,0,NA,0,2015,2015,795,0,Phase 3,1,NA,1,4.61512051684126,"(4,5]"
3637,5759,induction study #2 of oral ozanimod as induction therapy for moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn Disease,drug or biologic,Late,600,All,Industry&Combos,1,0,0,2018,2018,1861,1,Phase 3,4,NA,2,6.396929655216146,"(6,7]"
2676,3588,efficacy and safety trial of apatinib plus best supportive care compared to placebo plus best supportive care in patients with gastric cancer,Completed,4,0,0,Gastric Cancer|Gastric Adenocarcinoma,drug or biologic,Late,460,All,Industry&Combos,1,0,0,2017,2017,718,1,Phase 3,3,safety/efficacy,2,6.131226489483141,"(6,7]"
3523,5371,is end tidal co2 level elevation during upper endoscopy with co2 gas insufflation physiologically significant,Recruiting,2,0,0,Endoscopy,drug or biologic,Late,230,All,AllOther,1,0,0,2020,2019,621,1,Phase 3,2,NA,2,5.438079308923196,"(5,6]"
2681,3598,avelumab in third-line gastric cancer (javelin gastric 300),Completed,4,1,1,"Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Gastric Cancer Third Line",drug or biologic,Late,371,All,Industry&Combos,1,0,0,2015,2015,626,1,Phase 3,0,NA,0,5.916202062607435,"(5,6]"
391,402,a study of cisplatin or carboplatin with gemcitabine versus gemcitabine alone as adjuvant therapy in patients with resected or ablation intra-hepatic cholangiocarcinoma,Withdrawn,7,0,0,Intrahepatic Cholangiocarcinoma,drug or biologic,Late,NA,All,AllOther,1,0,0,2017,2017,1711,1,Phase 3,0,NA,0,NA,NA
2922,3922,a study to evaluate the safety and efficacy of upadacitinib (abt-494) for induction and maintenance therapy in participants with moderately to severely active ulcerative colitis (uc),"Active, not recruiting",1,0,0,Ulcerative Colitis (UC),drug or biologic,Late,844,All,Industry&Combos,1,0,0,2016,2016,1905,1,Phase 3,4,safety/efficacy,2,6.7381524945959574,"(6,7]"
1017,1072,accelerating gastrointestinal recovery,Completed,4,1,1,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,drug or biologic,Late,146,Female,Industry&Combos,1,0,1,2012,2013,942,1,Phase 3,3,NA,2,4.983606621708336,"(4,5]"
3988,7547,a study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma [imbrave150],"Active, not recruiting",1,0,0,"Carcinoma, Hepatocellular",drug or biologic,Late,558,All,Industry&Combos,1,0,0,2018,2018,1175,1,Phase 3,0,NA,0,6.324358962381311,"(6,7]"
1872,2165,use of epidurals intraoperatively for patients undergoing pancreas resection,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Late,336,All,AllOther,1,0,0,2018,2018,1797,1,Phase 3,1,NA,1,5.817111159963204,"(5,6]"
3099,4197,comparing proton therapy to photon radiation therapy for esophageal cancer,Recruiting,2,0,0,Clinical Stage I Esophageal Adenocarcinoma AJCC v8|Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage I Esophageal Adenocarcinoma AJCC v8|Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Thoracic Esophagus Squamous Cell Carcinoma,drug or biologic,Late,300,All,NIH&Combos,1,0,0,2019,2019,2880,1,Phase 3,0,NA,0,5.703782474656201,"(5,6]"
1613,1768,charm ii: chemotherapy for ablation and resolution of mucinous pancreatic cysts,Recruiting,2,0,0,Pancreatic Cyst|EUS-FNA,drug or biologic,Late,100,All,NIH&Combos,1,0,0,2017,2019,1450,1,Phase 3,2,NA,2,4.605170185988092,"(4,5]"
3419,5178,a study of the efficacy and safety of upadacitinib (abt-494) in participants with moderately to severely active crohn's disease who have inadequately responded to or are intolerant to biologic therapy,"Active, not recruiting",1,0,0,Crohn's Disease,drug or biologic,Late,645,All,Industry&Combos,1,0,0,2017,2017,1408,1,Phase 3,4,safety/efficacy,2,6.4692503167957724,"(6,7]"
3852,7032,comparison of ridinilazole versus vancomycin treatment for clostridium difficile infection,Recruiting,2,0,0,Clostridioides Difficile Infection,drug or biologic,Late,680,All,Industry&Combos,1,0,0,2018,2019,855,1,Phase 3,4,NA,2,6.522092798170152,"(6,7]"
3262,4588,study to evaluate efficacy and safety of two drug regimens in subjects with moderate to severe crohn's disease,Completed,4,1,1,Crohn's Disease,drug or biologic,Late,514,All,Industry&Combos,1,0,0,2014,2014,2100,1,Phase 3,4,safety/efficacy,2,6.2422232654551655,"(6,7]"
3381,5004,"combination chemotherapy, bevacizumab, and/or atezolizumab in treating patients with deficient dna mismatch repair metastatic colorectal cancer, the commit study",Recruiting,2,0,0,Metastatic Colorectal Adenocarcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Late,231,All,NIH&Combos,1,0,0,2016,2017,1635,1,Phase 3,0,NA,0,5.442417710521793,"(5,6]"
4148,9035,"efficacy and safety of ledipasvir/sofosbuvir, with or without ribavirin, in hcv infected participants who have failed prior treatment with sofosbuvir-based therapies",Terminated,5,1,1,Hepatitis C Virus Infection,drug or biologic,Late,87,All,Industry&Combos,1,0,0,2015,2015,496,1,Phase 3,0,safety/efficacy,0,4.465908118654584,"(4,5]"
3641,5765,a study of efficacy and safety of mongersen (ged-0301) for the treatment of adult and adolescent subjects with active crohn's disease,Withdrawn,7,0,0,Crohn Disease,drug or biologic,Late,NA,All,Industry&Combos,1,0,0,2016,2017,351,1,Phase 3,4,safety/efficacy,2,NA,NA
3282,4631,efficacy and safety of 177lu-edotreotide prrt in gep-net patients,Recruiting,2,0,0,Neuroendocrine Tumors,drug or biologic,Late,300,All,Industry&Combos,1,0,0,2017,2017,2676,1,Phase 3,0,safety/efficacy,0,5.703782474656201,"(5,6]"
4150,9038,comparison of sofosbuvir/velpatasvir fixed dose combination for 12 weeks with sofosbuvir and ribavirin for 24 weeks in adults with chronic genotype 3 hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,558,All,Industry&Combos,1,0,0,2014,2014,427,1,Phase 3,0,NA,0,6.324358962381311,"(6,7]"
3580,5562,"study to assess efficacy and safety of cx601, adult allogeneic expanded adipose-derived stem cells (easc) for the treatment of complex perianal fistula(s) in participants with crohn's disease (cd)",Recruiting,2,0,0,Crohn's Disease,drug or biologic,Late,554,All,Industry&Combos,1,0,0,2017,2017,1811,1,Phase 3,4,safety/efficacy,2,6.317164686747284,"(6,7]"
3568,5507,a study of the efficacy and safety of risankizumab in participants with moderately to severely active crohn's disease,Completed,4,0,0,Crohn's Disease,drug or biologic,Late,931,All,Industry&Combos,1,0,0,2017,2017,1279,1,Phase 3,2,safety/efficacy,2,6.836259277277067,"(6,7]"
2816,3775,stent vs. indomethacin for preventing post-ercp pancreatitis,Recruiting,2,0,0,Post-ERCP Pancreatitis,other,Others,2180,All,NIH&Combos,1,0,1,2015,2015,2769,1,Others,4,NA,2,7.687080155783135,"(7,13]"
3677,6018,open label efficacy and safety of anti-map (mycobacterium avium ssp. paratuberculosis) therapy in adult crohn's disease,Completed,4,1,1,Crohn Disease,drug or biologic,Late,54,All,Industry&Combos,1,1,0,2017,2017,605,1,Phase 3,0,safety/efficacy,0,3.9889840465642745,"(3,4]"
3565,5501,12-week study of plecanatide for cic (the national cic3 study),Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,1410,All,Industry&Combos,1,0,0,2014,2014,395,1,Phase 3,4,NA,2,7.251344983372214,"(7,13]"
2123,2542,four quadrants transverse abdominus plane (4q-tap) block with plain and liposomal bupivacaine vs. thoracic epidermal analgesia (tea) in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (crs-hipec) on an enhanced recovery pathway,Completed,4,0,0,Peritoneal Cancer,drug or biologic,Late,75,All,AllOther,1,0,0,2017,2017,1093,1,Phase 3,0,NA,0,4.31748811353631,"(4,5]"
3370,4957,radiation therapy with protons or photons in treating patients with liver cancer,Recruiting,2,0,0,Unrectable or Locally Recurrent Hepatocellular Carcinoma,other,Others,186,All,NIH&Combos,1,0,0,2017,2017,2565,1,Others,0,NA,0,5.225746673713202,"(5,6]"
3638,5761,a safety and efficacy study of relamorelin in diabetic gastroparesis 01,Terminated,5,0,0,Gastroparesis|Diabetes Mellitus,drug or biologic,Late,336,All,Industry&Combos,1,0,0,2017,2017,1072,1,Phase 3,2,safety/efficacy,2,5.817111159963204,"(5,6]"
3238,4546,efficacy and safety study of ontamalimab as induction therapy in participants with moderate to severe crohn's disease (carmen cd 306),Terminated,5,1,1,Crohn's Disease,drug or biologic,Late,34,All,Industry&Combos,1,0,0,2018,2018,763,1,Phase 3,2,safety/efficacy,2,3.5263605246161616,"(3,4]"
3033,4074,standard lipid therapy vs ivfe minimization for prevention of pnald,Completed,4,1,1,Cholestasis,drug or biologic,Late,22,All,AllOther,1,0,1,2015,2016,509,1,Phase 3,0,NA,0,3.091042453358316,"(3,4]"
2868,3846,a study of the efficacy and safety of etrolizumab treatment in maintenance of disease remission in ulcerative colitis (uc) participants who are naive to tumor necrosis factor (tnf) inhibitors,Completed,4,1,1,"Colitis, Ulcerative",drug or biologic,Late,359,All,Industry&Combos,1,0,0,2014,2014,2064,1,Phase 3,2,safety/efficacy,2,5.883322388488279,"(5,6]"
3792,6665,study of regorafenib after sorafenib in patients with hepatocellular carcinoma,Completed,4,1,1,"Carcinoma, Hepatocellular",drug or biologic,Late,573,All,Industry&Combos,1,0,0,2013,2013,1021,1,Phase 3,4,NA,2,6.35088571671474,"(6,7]"
3245,4554,phase 3 study of dcc-2618 vs placebo in advanced gist patients who have been treated with prior anticancer therapies,"Active, not recruiting",1,1,1,Gastrointestinal Stromal Tumors,drug or biologic,Late,129,All,Industry&Combos,1,0,0,2017,2018,458,1,Phase 3,4,NA,2,4.859812404361672,"(4,5]"
4153,9057,trientine tetrahydrochloride (teta 4hcl) for the treatment of wilson's disease,"Active, not recruiting",1,0,0,Wilson Disease,drug or biologic,Late,55,All,Industry&Combos,1,0,0,2018,2018,807,1,Phase 3,0,NA,0,4.007333185232471,"(4,5]"
1926,2248,high dose interval vitamin d supplementation in patients with ibd receiving remicade,Completed,4,0,0,IBD|Ulcerative Colitis|Crohn Disease,drug or biologic,Late,50,All,AllOther,0,NA,0,2017,2017,1218,0,Phase 3,1,NA,1,3.912023005428146,"(3,4]"
3369,4944,efficacy and safety trial of elobixibat in patients with chronic idiopathic constipation,Terminated,5,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,314,All,Industry&Combos,1,0,0,2013,2013,334,1,Phase 3,2,safety/efficacy,2,5.749392985908253,"(5,6]"
976,1029,evaluation of oral simethicone with low volume polyethylene glycol bowel preparation during colonoscopy,Completed,4,0,0,Colonoscopy,drug or biologic,Late,250,All,AllOther,1,0,2,2018,2018,295,1,Phase 3,3,NA,2,5.521460917862246,"(5,6]"
4060,7763,study to evaluate the efficacy and safety of larazotide acetate for the relief of ced symptoms,Recruiting,2,0,0,Celiac Disease,drug or biologic,Late,630,All,Industry&Combos,1,0,0,2018,2019,795,1,Phase 3,3,safety/efficacy,2,6.4457198193855785,"(6,7]"
3606,5681,diabetic gastroparesis study 05,Terminated,5,0,0,Gastroparesis,drug or biologic,Late,202,All,Industry&Combos,0,NA,0,2018,2018,655,0,Phase 3,1,NA,1,5.308267697401205,"(5,6]"
3408,5137,"evaluation of the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo",Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,552,All,Industry&Combos,1,0,0,2017,2017,157,1,Phase 3,4,bio-equivalence,2,6.313548046277095,"(6,7]"
4172,9160,sof (sovaldi Â®) +rbv for 16 or 24 weeks and sof+rbv+peg-ifn for 12 weeks in adults with genotype 2 or 3 chronic hcv infection,Completed,4,1,1,Hepatitis C,drug or biologic,Late,601,All,Industry&Combos,1,0,0,2013,2013,470,1,Phase 3,0,NA,0,6.398594934535208,"(6,7]"
2994,4014,nivolumab after combined modality therapy in treating patients with high risk stage ii-iiib anal cancer,Recruiting,2,0,0,Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Margin Squamous Cell Carcinoma|Stage IIB Anal Cancer AJCC v8|Stage III Anal Cancer AJCC v8|Stage IIIA Anal Cancer AJCC v8|Stage IIIB Anal Cancer AJCC v8|Stage IIIC Anal Cancer AJCC v8,drug or biologic,Late,344,All,NIH&Combos,1,0,0,2017,2018,1357,1,Phase 3,0,NA,0,5.840641657373398,"(5,6]"
3520,5368,an extension study of oral ozanimod for moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn Disease,drug or biologic,Late,1200,All,Industry&Combos,0,NA,0,2018,2018,2865,0,Phase 3,1,NA,1,7.090076835776092,"(7,13]"
980,1033,hmpl-004 maintenance treatment in subjects with mild to moderate ulcerative colitis,Terminated,5,1,1,Ulcerative Colitis,drug or biologic,Late,66,All,Industry&Combos,1,0,0,2013,2013,487,1,Phase 3,4,NA,2,4.189654742026425,"(4,5]"
3089,4174,a study of tislelizumab (bgb-a317) in combination with chemotherapy as first line treatment in participants with advanced esophageal squamous cell carcinoma,"Active, not recruiting",1,0,0,Esophageal Squamous Cell Carcinoma (ESCC),drug or biologic,Late,649,All,Industry&Combos,1,0,0,2018,2018,1297,1,Phase 3,2,NA,2,6.47543271670409,"(6,7]"
3017,4052,a open label extension study for subjects that complete study mp-101-cl-001,Withdrawn,7,0,0,Short Bowel Syndrome|Short Gut Syndrome|SBS|Short Gut,drug or biologic,Late,NA,All,Industry&Combos,0,1,0,2014,2015,1096,0,Phase 3,1,NA,1,NA,NA
3809,6748,comparison of sofosbuvir/velpatasvir fixed dose combination for 12 weeks with sofosbuvir and ribavirin for 12 weeks in adults with chronic genotype 2 hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,269,All,Industry&Combos,1,0,0,2014,2014,303,1,Phase 3,0,NA,0,5.594711379601839,"(5,6]"
1570,1713,genotype-tailored treatment of symptomatic acid-reflux in children with uncontrolled asthma,Recruiting,2,0,0,Asthma|Gastroesophageal Reflux,drug or biologic,Late,110,All,AllOther,1,0,0,2017,2017,1553,1,Phase 3,2,NA,2,4.700480365792417,"(4,5]"
2875,3854,gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel in treating patients with newly diagnosed advanced biliary tract cancers,Recruiting,2,0,0,Stage III Distal Bile Duct Cancer AJCC v8|Stage III Gallbladder Cancer AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Distal Bile Duct Cancer AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Distal Bile Duct Cancer AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Distal Bile Duct Cancer AJCC v8|Stage IV Gallbladder Cancer AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Gallbladder Cancer AJCC v8|Stage IVB Gallbladder Cancer AJCC v8|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma,drug or biologic,Late,268,All,NIH&Combos,1,0,0,2018,2018,1855,1,Phase 3,0,NA,0,5.5909869805108565,"(5,6]"
2081,2477,a randomized controlled pilot trial of indomethacin in acute pancreatitis,Completed,4,1,1,Acute Pancreatitis,drug or biologic,Late,42,All,AllOther,1,0,0,2016,2013,2209,1,Phase 3,4,NA,2,3.7376696182833684,"(3,4]"
3972,7503,to compare ridinilazole versus vancomycin treatment for clostridium difficile infection,Recruiting,2,0,0,Clostridioides Difficile Infection,drug or biologic,Late,680,All,Industry&Combos,1,0,0,2018,2019,855,1,Phase 3,4,NA,2,6.522092798170152,"(6,7]"
3322,4742,to assess safety/efficacy of elad in subjects w/ severe acute alcoholic hepatitis (saah) and lille score failure,Terminated,5,1,1,Severe Acute Alcoholic Hepatitis,drug or biologic,Late,18,All,Industry&Combos,1,0,0,2013,2014,548,1,Phase 3,0,safety/efficacy,0,2.8903717578961645,"(2,3]"
2639,3543,study to evaluate the safety and efficacy of two adalimumab dosing regimens in subjects with moderate to severe ulcerative colitis,Completed,4,1,1,Ulcerative Colitis (UC),drug or biologic,Late,952,All,Industry&Combos,1,0,0,2014,2014,1988,1,Phase 3,4,safety/efficacy,2,6.858565034791365,"(6,7]"
3150,4287,efficacy evaluation of therasphere to treat inoperable liver cancer with blockage of the portal vein,Terminated,5,1,1,Hepatocellular Carcinoma,drug or biologic,Late,36,All,Industry&Combos,1,0,0,2013,2014,1181,1,Phase 3,0,efficacy,0,3.58351893845611,"(3,4]"
3230,4528,ct-p13 (infliximab) subcutaneous administration in patients with moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn's Disease,drug or biologic,Late,600,All,Industry&Combos,1,0,0,2019,2019,582,1,Phase 3,3,NA,2,6.396929655216146,"(6,7]"
3576,5557,12-week study of plecanatide for cic (the cic3 study),Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,1394,All,Industry&Combos,1,0,0,2013,2013,516,1,Phase 3,4,NA,2,7.2399325913204695,"(7,13]"
2693,3611,study of pegilodecakin (ly3500518) with folfox compared to folfox alone second-line tx in participants with metastatic pancreatic cancer,Completed,4,1,1,Pancreatic Cancer,drug or biologic,Late,567,All,Industry&Combos,1,0,0,2016,2017,922,1,Phase 3,0,NA,0,6.340359303727752,"(6,7]"
3750,6361,"open-label, single arm trial of bi 695502 in patients with previously untreated metastatic colorectal cancer",Completed,4,1,1,Colorectal Neoplasms,drug or biologic,Late,123,All,Industry&Combos,0,NA,0,2016,2016,847,0,Phase 3,1,NA,1,4.812184355372417,"(4,5]"
2953,3959,aurora: phase 3 study for the efficacy and safety of cvc for the treatment of liver fibrosis in adults with nash,Terminated,5,0,0,Nonalcoholic Steatohepatitis,drug or biologic,Late,1779,All,Industry&Combos,1,0,0,2017,2017,1363,1,Phase 3,2,safety/efficacy,2,7.483806687665835,"(7,13]"
3333,4765,safety and efficacy of selonsertib in adults with compensated cirrhosis due to nonalcoholic steatohepatitis (nash),Terminated,5,1,1,Nonalcoholic Steatohepatitis,drug or biologic,Late,883,All,Industry&Combos,1,0,0,2017,2017,826,1,Phase 3,2,safety/efficacy,2,6.78332520060396,"(6,7]"
4128,8959,study of durvalumab and tremelimumab as first-line treatment in patients with advanced hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Late,1504,All,Industry&Combos,1,0,0,2017,2017,1541,1,Phase 3,0,NA,0,7.315883504509785,"(7,13]"
3087,4171,short-term survival of subjects with acute-on-chronic liver failure after plasma exchange with human serum albumin 5%,Recruiting,2,0,0,Acute-On-Chronic Liver Failure,drug or biologic,Late,380,All,Industry&Combos,1,0,0,2018,2019,1014,1,Phase 3,0,NA,0,5.940171252720432,"(5,6]"
1796,2029,bismuth subsalicylate's role in the prevention of travelers' diarrhea,Unknown status,8,0,0,Diarrhea Travelers|Antibiotic Resistant Infection,drug or biologic,Late,488,All,Industry&Combos,1,0,1,2018,2018,712,1,Phase 3,4,NA,2,6.1903154058531475,"(6,7]"
2585,3477,a trial of iw-3718 for 8 weeks in patients with persistent gastroesophageal reflux disease (gerd) receiving proton pump inhibitors,Terminated,5,0,0,Gastroesophageal Reflux Disease (GERD),drug or biologic,Late,495,All,Industry&Combos,1,0,0,2018,2018,863,1,Phase 3,2,NA,2,6.20455776256869,"(6,7]"
2593,3487,a safety and efficacy comparison of bli4700 bowel preparation versus an fda-approved comparator in adult subjects prior to colonoscopy,Completed,4,0,0,Colonoscopy,drug or biologic,Late,450,All,Industry&Combos,1,0,0,2017,2017,230,1,Phase 3,1,safety/efficacy,1,6.1092475827643655,"(6,7]"
2895,3880,study for participants with ulcerative colitis previously enrolled in etrolizumab phase ii/iii studies,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Late,1822,All,Industry&Combos,0,NA,0,2014,2014,3988,0,Phase 3,1,NA,1,7.507690077819904,"(7,13]"
2982,3998,a 26-week study to evaluate the efficacy and safety of tenapanor in ibs-c,Completed,4,1,1,Constipation Predominant Irritable Bowel Syndrome,drug or biologic,Late,593,All,Industry&Combos,1,0,0,2016,2015,609,1,Phase 3,4,safety/efficacy,2,6.385194398997726,"(6,7]"
3787,6597,unity 1: a study of an investigational treatment regimen of daclatasvir (dcv) + asunaprevir (asv) + bms-791325 in a fixed dose combination (the dcv 3daa (direct acting antiviral) regimen) for 12 weeks for the treatment of chronic hepatitis c virus (hcv) genotype 1 infection in non-cirrhotic subjects,Completed,4,0,0,Hepatitis C,drug or biologic,Late,416,All,Industry&Combos,1,1,0,2013,2013,243,1,Phase 3,0,NA,0,6.030685260261263,"(6,7]"
3409,5140,study evaluating the efficacy and safety of obeticholic acid in subjects with compensated cirrhosis due to nonalcoholic steatohepatitis,"Active, not recruiting",1,0,0,Compensated Cirrhosis|Nonalcoholic Steatohepatitis,drug or biologic,Late,919,All,Industry&Combos,1,0,0,2018,2017,1401,1,Phase 3,4,safety/efficacy,2,6.823286122355687,"(6,7]"
3594,5636,a safety and efficacy study of relamorelin in diabetic gastroparesis study 03,Terminated,5,0,0,Gastroparesis|Diabetes Mellitus,drug or biologic,Late,467,All,Industry&Combos,1,0,0,2018,2018,985,1,Phase 3,3,safety/efficacy,2,6.1463292576688975,"(6,7]"
2026,2393,gemcitabine and nab-paclitaxel combined with momelotinib in participants with previously untreated metastatic pancreatic ductal adenocarcinoma,Terminated,5,1,1,Metastatic Pancreatic Ductal Adenocarcinoma,drug or biologic,Late,25,All,Industry&Combos,1,1,0,2014,2014,1043,1,Phase 3,4,NA,2,3.2188758248682006,"(3,4]"
3362,4917,safety and efficacy of adalimumab versus ustekinumab for one year,Completed,4,0,0,Crohn Disease,drug or biologic,Late,386,All,Industry&Combos,1,0,0,2018,2018,992,1,Phase 3,4,safety/efficacy,2,5.955837369464831,"(5,6]"
3425,5204,a study of napabucasin (bbi-608) in combination with folfiri in adult patients with previously treated metastatic colorectal cancer,Completed,4,0,0,Colorectal Cancer,drug or biologic,Late,1253,All,Industry&Combos,1,0,0,2016,2016,1792,1,Phase 3,0,NA,0,7.133295954896068,"(7,13]"
2811,3770,"result: reliable, emergent solution using liprotamase treatment",Unknown status,8,0,0,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,drug or biologic,Late,140,All,Industry&Combos,1,0,0,2017,2017,306,1,Phase 3,0,NA,0,4.941642422609304,"(4,5]"
3449,5240,5-fu based maintenance therapy in ras wild type metastatic colorectal cancer after induction with folfox plus panitumumab,Terminated,5,0,0,Colorectal Adenocarcinoma|RAS Wild Type|Stage III Colorectal Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Late,4,All,IndustryNIHPartnership,1,0,0,2017,2018,583,1,Phase 3,0,NA,0,1.3862943611198906,"(1,2]"
2733,3662,phase 3 trial of 90y-clivatuzumab tetraxetan & gemcitabine vs placebo & gemcitabine in metastatic pancreatic cancer,Terminated,5,0,0,Metastatic Pancreatic Cancer|Pancreatic Cancer,drug or biologic,Late,334,All,Industry&Combos,1,0,0,2013,2013,1066,1,Phase 3,3,NA,2,5.811140992976701,"(5,6]"
4085,7964,clostridium difficile vaccine efficacy trial,"Active, not recruiting",1,0,0,Clostridium Difficile Infection,drug or biologic,Late,17525,All,Industry&Combos,1,0,1,2017,2017,1623,1,Phase 3,4,efficacy,2,9.771383711902791,"(7,13]"
2930,3931,a trial of linaclotide 290  Â¼g in patients with irritable bowel syndrome with constipation (ibs-c),Completed,4,1,1,Irritable Bowel Syndrome Characterized by Constipation,drug or biologic,Late,614,All,Industry&Combos,1,0,0,2018,2018,266,1,Phase 3,2,NA,2,6.419994928147142,"(6,7]"
3105,4214,testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors,Recruiting,2,0,0,Atypical Carcinoid Tumor|Carcinoid Tumor|Functioning Pancreatic Neuroendocrine Tumor|Intermediate Grade Lung Neuroendocrine Neoplasm|Locally Advanced Pancreatic Neuroendocrine Tumor|Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm|Low Grade Lung Neuroendocrine Neoplasm|Lung Atypical Carcinoid Tumor|Lung Carcinoid Tumor|Metastatic Digestive System Neuroendocrine Neoplasm|Metastatic Digestive System Neuroendocrine Tumor G1|Metastatic Pancreatic Neuroendocrine Tumor|Metastatic Thymic Neuroendocrine Neoplasm|Neuroendocrine Neoplasm|Non-Functioning Pancreatic Neuroendocrine Tumor|Pancreatic Serotonin-Producing Neuroendocrine Tumor|Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7|Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7|Stage IV Digestive System Neuroendocrine Tumor AJCC v7,drug or biologic,Late,395,All,NIH&Combos,1,0,0,2017,2018,2632,1,Phase 3,2,NA,2,5.978885764901122,"(5,6]"
2885,3870,a study of long-term effects of vedolizumab subcutaneous in adults with ulcerative colitis and crohn's disease,"Active, not recruiting",1,0,0,"Colitis, Ulcerative|Crohn's Disease",drug or biologic,Late,746,All,Industry&Combos,1,1,0,2015,2016,2577,1,Phase 3,0,NA,0,6.61472560020376,"(6,7]"
2729,3657,an extension study to evaluate maintenance of efficacy and long-term treatment effect of oral budesonide suspension (obs) in adults and adolescents with eosinophilic esophagitis (eoe),Completed,4,1,1,Eosinophilic Esophagitis (EoE),drug or biologic,Late,219,All,Industry&Combos,1,0,0,2016,2016,1320,1,Phase 3,2,efficacy,2,5.389071729816501,"(5,6]"
2689,3607,pembrolizumab (mk-3475) plus chemotherapy versus placebo plus chemotherapy in participants gastric or gastroesophageal junction (gej) adenocarcinoma (mk-3475-859/keynote-859),"Active, not recruiting",1,0,0,Stomach Neoplasms,drug or biologic,Late,1542,All,Industry&Combos,1,0,0,2018,2018,2151,1,Phase 3,2,NA,2,7.340835554123275,"(7,13]"
2976,3990,study of eryaspase in combination with chemotherapy versus chemotherapy alone as 2nd-line treatment in pac,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma,drug or biologic,Late,500,All,Industry&Combos,1,0,0,2018,2018,1051,1,Phase 3,0,NA,0,6.214608098422191,"(6,7]"
4124,8888,urea breath test (ubt) with breath hp system /breathid hp lab system pediatrics,Completed,4,1,1,Helicobacter Pylori Infection,drug or biologic,Late,54,All,Industry&Combos,0,NA,2,2016,2017,165,0,Phase 3,1,NA,1,3.9889840465642745,"(3,4]"
3911,7280,entecavir to taf switch,"Active, not recruiting",1,0,0,Hepatitis B,drug or biologic,Late,27,All,Industry&Combos,0,NA,4,2018,2017,1003,0,Phase 3,1,NA,1,3.295836866004329,"(3,4]"
1350,1442,cimzia versus cimzia plus azathioprine in the treatment of active crohn's disease,Unknown status,8,0,0,Crohn's Disease,drug or biologic,Late,65,All,Industry&Combos,1,0,0,2013,2013,457,1,Phase 3,3,NA,2,4.174387269895637,"(4,5]"
3486,5289,induction study #1 of oral ozanimod as induction therapy for moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn Disease,drug or biologic,Late,600,All,Industry&Combos,1,0,0,2018,2018,1946,1,Phase 3,4,NA,2,6.396929655216146,"(6,7]"
3627,5735,phase 3 study of tislelizumab versus sorafenib in participants with unresectable hcc,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma (HCC),drug or biologic,Late,674,All,Industry&Combos,1,0,0,2018,2017,1270,1,Phase 3,0,NA,0,6.513230110912307,"(6,7]"
3126,4248,one year study of rifaximin delayed release (dr) in crohn's disease,Terminated,5,1,1,Crohn's Disease,drug or biologic,Late,81,All,Industry&Combos,1,0,0,2014,2014,1074,1,Phase 3,4,NA,2,4.394449154672439,"(4,5]"
506,527,ketotifen for children with functional dyspepsia in association with duodenal eosinophilia,Recruiting,2,0,0,Functional Dyspepsia,drug or biologic,Late,40,All,AllOther,3,0,0,2015,2015,3500,3,Phase 3,3,NA,2,3.6888794541139363,"(3,4]"
4096,8097,eradicate hp - treating helicobacter pylori with rhb-105,Completed,4,1,1,Dyspepsia|Helicobacter Pylori Infection,drug or biologic,Late,119,All,Industry&Combos,1,0,0,2013,2013,577,1,Phase 3,3,NA,2,4.77912349311153,"(4,5]"
3858,7061,bli400-302: a safety and efficacy evaluation of bli400 laxative in constipated adults,Completed,4,1,1,Constipation|Chronic Idiopathic Constipation|CIC,drug or biologic,Late,1020,All,Industry&Combos,1,0,0,2016,2016,365,1,Phase 3,4,safety/efficacy,2,6.927557906278317,"(6,7]"
365,373,randomized trial of glutamine in patients with mucositis or esophagitis,Terminated,5,0,0,Advanced Cancers,drug or biologic,Late,77,All,AllOther,1,0,4,2013,2014,2428,1,Phase 3,2,NA,2,4.343805421853684,"(4,5]"
2781,3734,conventional or hypofractionated radiation therapy in treating patients with prostate cancer,Recruiting,2,0,0,Stage I Prostate Cancer AJCC v8|Stage II Prostate Cancer AJCC v8|Stage IIA Prostate Cancer AJCC v8|Stage IIB Prostate Cancer AJCC v8|Stage IIC Prostate Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8,other,Others,176,Male,NIH&Combos,1,0,0,2019,2019,1616,1,Others,0,NA,0,5.170483995038151,"(5,6]"
1601,1752,use of post operative loperamide in colorectal patients after diverting ileostomies,Terminated,5,1,1,"Dehydration, Diverting Ileostomy, Loperamide",drug or biologic,Late,40,All,AllOther,1,0,1,2014,2014,816,1,Phase 3,0,NA,0,3.6888794541139363,"(3,4]"
3798,6690,safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination for 12 weeks in adults who participated in a prior gilead-sponsored hcv treatment study,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,31,All,Industry&Combos,0,NA,0,2017,2017,328,0,Phase 3,1,safety/efficacy,1,3.4339872044851463,"(3,4]"
2348,2981,"phase iii daclatasvir, sofosbuvir, and ribavirin in cirrhotic participants and participants post-liver transplant",Completed,4,1,1,Hepatitis C,drug or biologic,Late,116,All,Industry&Combos,1,1,0,2014,2014,245,1,Phase 3,0,NA,0,4.7535901911063645,"(4,5]"
3765,6510,phase iii daclatasvir and sofosbuvir for genotype 3 chronic hcv,Completed,4,1,1,Hepatitis C,drug or biologic,Late,173,All,Industry&Combos,1,1,0,2014,2014,243,1,Phase 3,0,NA,0,5.153291594497779,"(5,6]"
3993,7553,study to evaluate efficacy and safety of switching from tdf to taf in adults with chronic hepatitis b who are virologically suppressed,Completed,4,1,1,Chronic Hepatitis B,drug or biologic,Late,490,All,Industry&Combos,1,0,0,2016,2016,620,1,Phase 3,2,safety/efficacy,2,6.194405391104672,"(6,7]"
2724,3649,seladelpar in subjects with primary biliary cholangitis (pbc),Recruiting,2,0,0,Primary Biliary Cirrhosis,drug or biologic,Late,500,All,Industry&Combos,1,1,0,2017,2017,2546,1,Phase 3,0,NA,0,6.214608098422191,"(6,7]"
2722,3647,solution: study of oral liprotamase unit-matched therapy of non-porcine origin in patients with cystic fibrosis,Completed,4,1,1,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,drug or biologic,Late,128,All,Industry&Combos,1,0,0,2014,2015,488,1,Phase 3,0,NA,0,4.852030263919617,"(4,5]"
3517,5357,filgotinib in long-term extension study of adults with crohn's disease,Enrolling by invitation,3,0,0,Crohn's Disease,drug or biologic,Late,1000,All,Industry&Combos,1,1,0,2016,2017,2967,1,Phase 3,2,NA,2,6.907755278982137,"(6,7]"
4093,8092,evaluation of the safety of lubiprostone in pediatric participants aged Ã¢â°Â¥ 6 years to < 18 years with functional constipation,Completed,4,1,1,Constipation - Functional,drug or biologic,Late,87,All,Industry&Combos,0,NA,0,2016,2016,206,0,Phase 3,1,safety,1,4.465908118654584,"(4,5]"
2682,3599,a study to evaluate the efficacy and safety of maralixibat in subjects with progressive familial intrahepatic cholestasis (march-pfic),Recruiting,2,0,0,Progressive Familial Intrahepatic Cholestasis (PFIC),drug or biologic,Late,30,All,Industry&Combos,1,0,0,2019,2019,723,1,Phase 3,4,safety/efficacy,2,3.4011973816621555,"(3,4]"
2893,3878,"a pharmacokinetic, safety, and pharmacodynamic study of teduglutide in pediatric subjects with short bowel syndrome",Completed,4,1,1,Short Bowel Syndrome,drug or biologic,Late,42,All,Industry&Combos,0,1,0,2013,2013,421,0,Phase 3,1,safety,1,3.7376696182833684,"(3,4]"
3751,6362,a study to evaluate the efficacy and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis c virus genotype 1 - 6 infection and renal impairment,Completed,4,1,1,Hepatitis C Virus (HCV),drug or biologic,Late,101,All,Industry&Combos,1,1,0,2017,2017,329,1,Phase 3,0,safety/efficacy,0,4.61512051684126,"(4,5]"
3516,5355,open-label extension and safety study for participants with crohn's disease previously enrolled in the etrolizumab phase iii study ga29144,Recruiting,2,0,0,Crohn Disease,drug or biologic,Late,900,All,Industry&Combos,0,0,0,2015,2015,4000,0,Phase 3,1,safety,1,6.802394763324311,"(6,7]"
2678,3593,a study to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (lucent 3),Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Late,960,All,Industry&Combos,0,NA,0,2018,2018,1862,0,Phase 3,1,safety/efficacy,1,6.866933284461882,"(6,7]"
3716,6213,"caphosol study: prevention of oral mucositis in children, adolescents and young adults receiving chemotherapy",Terminated,5,1,1,Oral Mucositis,drug or biologic,Late,1,All,AllOther,1,0,1,2015,2016,152,1,Phase 3,0,NA,0,0,NA
3591,5619,efficacy and safety of vedolizumab subcutaneous (sc) as maintenance therapy in crohn's disease (cd),Completed,4,1,1,Crohn's Disease,drug or biologic,Late,644,All,Industry&Combos,1,0,0,2015,2016,1218,1,Phase 3,4,safety/efficacy,2,6.467698726104354,"(6,7]"
2705,3628,efficacy and safety of vedolizumab subcutaneously (sc) as maintenance therapy in ulcerative colitis,Completed,4,1,1,"Colitis, Ulcerative",drug or biologic,Late,383,All,Industry&Combos,1,0,0,2015,2015,894,1,Phase 3,4,safety/efficacy,2,5.948034989180646,"(5,6]"
3373,4974,26 week efficacy and safety trial for patients with chronic idiopathic constipation,Terminated,5,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,376,All,Industry&Combos,1,0,0,2013,2013,334,1,Phase 3,2,safety/efficacy,2,5.929589143389895,"(5,6]"
4177,9192,"this study will evaluate the immunogenicity, reactogenicity and safety of the routine infant vaccines pediarix Â®, hiberix Â® and prevenar 13 Â® when co-administered with glaxosmithkline (gsk) biologicals' liquid human rotavirus vaccine (hrv) as compared to gsk's licensed lyophilized vaccine",Completed,4,1,1,Rotavirus Infection|Rotavirus Vaccines,drug or biologic,Late,1280,All,Industry&Combos,1,0,1,2017,2017,390,1,Phase 3,1,safety,1,7.154615356913663,"(7,13]"
4092,8085,efficacy and safety of e/c/f/taf (genvoya Â®) in hiv-1/hepatitis b co-infected adults,Completed,4,1,1,HIV|HBV,drug or biologic,Late,79,All,Industry&Combos,1,1,0,2014,2014,332,1,Phase 3,0,safety/efficacy,0,4.3694478524670215,"(4,5]"
2950,3956,sintilimab or placebo with chemotherapy in esophageal squamous cell carcinoma,Recruiting,2,0,0,Esophageal Squamous Cell Carcinoma,drug or biologic,Late,676,All,Industry&Combos,1,0,0,2018,2018,944,1,Phase 3,4,NA,2,6.516193076042964,"(6,7]"
3256,4579,"safety, tolerability, and efficacy of cilofexor in non-cirrhotic adults with primary sclerosing cholangitis",Recruiting,2,0,0,Primary Sclerosing Cholangitis,drug or biologic,Late,400,All,Industry&Combos,1,0,0,2019,2019,1588,1,Phase 3,2,safety/efficacy,2,5.991464547107982,"(5,6]"
3522,5370,safety and efficacy of remimazolam in asa iii and iv patients undergoing colonoscopy,Completed,4,1,1,Colonoscopy,drug or biologic,Late,79,All,Industry&Combos,1,0,4,2015,2015,396,1,Phase 3,2,safety/efficacy,2,4.3694478524670215,"(4,5]"
4175,9170,safety and efficacy study in subjects with chronic hcv and underlying hemophilia,Completed,4,1,1,Hepatitis C Virus,drug or biologic,Late,71,Male,Industry&Combos,1,1,0,2012,2013,671,1,Phase 3,0,safety/efficacy,0,4.2626798770413155,"(4,5]"
1433,1542,assessing repeat fit testing for crc,Completed,4,0,0,Colo-rectal Cancer,behavioral,Others,220,All,AllOther,1,0,4,2017,2015,1151,1,Others,0,NA,0,5.393627546352362,"(5,6]"
3643,5768,a safety and efficacy study of relamorelin in diabetic gastroparesis study 04,Terminated,5,0,0,Gastroparesis|Diabetes Mellitus,drug or biologic,Late,451,All,Industry&Combos,1,0,0,2017,2018,977,1,Phase 3,3,safety/efficacy,2,6.111467339502679,"(6,7]"
3790,6647,a study to investigate the safety and efficacy of fidaxomicin (oral suspension or tablets) and vancomycin (oral liquid or capsules) in pediatric subjects with clostridium difficile-associated diarrhea (cdad),Completed,4,1,1,Clostridium Difficile-associated Diarrhea (CDAD),drug or biologic,Late,148,All,Industry&Combos,1,0,0,2014,2015,1153,1,Phase 3,1,safety/efficacy,1,4.997212273764115,"(4,5]"
2910,3900,a safety and efficacy study of a bowel cleansing preparation (bli800) in pediatric subjects undergoing colonoscopy,Completed,4,1,1,Colonoscopy,drug or biologic,Late,91,All,Industry&Combos,1,0,0,2016,2016,664,1,Phase 3,1,safety/efficacy,1,4.51085950651685,"(4,5]"
1515,1645,carvedilol vs band ligation vs combination therapy for primary prophylaxis of variceal bleeding,Withdrawn,7,0,0,Portal Hypertension Related to Cirrhosis,drug or biologic,Late,NA,All,AllOther,1,0,0,2014,2018,243,1,Phase 3,0,NA,0,NA,NA
2798,3755,an induction study of mirikizumab in participants with moderately to severely active ulcerative colitis (lucent 1),Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Late,1160,All,Industry&Combos,1,0,0,2018,2018,1043,1,Phase 3,2,NA,2,7.05617528410041,"(7,13]"
3855,7058,ecospor iii - ser-109 versus placebo in the treatment of adults with recurrent clostridium difficile infection,Completed,4,0,0,Clostridium Difficile Infection,drug or biologic,Late,182,All,Industry&Combos,1,0,0,2017,2017,1089,1,Phase 3,2,NA,2,5.204006687076795,"(5,6]"
3914,7295,"a study of nivolumab, nivolumab plus ipilimumab, or investigator's choice chemotherapy for the treatment of participants with deficient mismatch repair (dmmr)/microsatellite instability high (msi-h) metastatic colorectal cancer (mcrc)",Recruiting,2,0,0,Metastatic Colorectal Cancer,drug or biologic,Late,748,All,Industry&Combos,1,0,0,2019,2019,2199,1,Phase 3,0,NA,0,6.617402977974478,"(6,7]"
2865,3842,study to determine the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis (eoe),"Active, not recruiting",1,0,0,Eosinophilic Esophagitis,drug or biologic,Late,321,All,Industry&Combos,1,0,0,2018,2018,1088,1,Phase 3,4,safety/efficacy,2,5.771441123130016,"(5,6]"
3570,5510,efficacy and safety of anti-map therapy in adult crohn's disease,Completed,4,1,1,Crohn's Disease,drug or biologic,Late,331,All,Industry&Combos,1,0,0,2013,2013,1703,1,Phase 3,2,safety/efficacy,2,5.802118375377063,"(5,6]"
3391,5061,effects of long-term administration of human albumin in subjects with decompensated cirrhosis and ascites,Recruiting,2,0,0,Decompensated Cirrhosis and Ascites,drug or biologic,Late,410,All,Industry&Combos,1,1,0,2018,2018,1165,1,Phase 3,0,NA,0,6.016157159698354,"(6,7]"
1890,2189,patient controlled epidural analgesia versus intravenous patient controlled analgesia for post-operative pain control in patients undergoing elective liver resection,"Active, not recruiting",1,0,0,Liver Cancer|Pain Management,other,Others,231,All,AllOther,1,0,0,2015,2015,2192,1,Others,0,NA,0,5.442417710521793,"(5,6]"
3819,6781,a global study to evaluate transarterial chemoembolization (tace) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Late,710,All,Industry&Combos,1,0,0,2018,2018,1400,1,Phase 3,4,NA,2,6.565264970035361,"(6,7]"
3856,7059,bezlotoxumab (mk-6072) versus placebo in children with clostridium difficile infection (cdi) (mk-6072-001),Recruiting,2,0,0,Clostridium Difficile Infection,drug or biologic,Late,192,All,Industry&Combos,1,0,1,2017,2018,1504,1,Phase 3,3,NA,2,5.2574953720277815,"(5,6]"
3609,5690,predictors of physical activity maintenance in colorectal cancer survivors,Recruiting,2,0,0,Colorectal Cancer,behavioral,Others,60,All,NIH&Combos,1,0,4,2018,2019,1343,1,Others,2,NA,2,4.0943445622221,"(4,5]"
2575,3464,"a study comparing the sodium picosulfate, magnesium oxide and anhydrous citric acid oral solution with prepopik Â® for colon cleansing in preparation for colonoscopy",Completed,4,1,1,Bowel Preparation,drug or biologic,Late,917,All,Industry&Combos,1,0,4,2017,2017,207,1,Phase 3,1,NA,1,6.821107472256465,"(6,7]"
4136,8979,"a multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (e7080) versus sorafenib in first-line treatment of participants with unresectable hepatocellular carcinoma",Completed,4,1,1,Hepatocellular Carcinoma (HCC),drug or biologic,Late,954,All,Industry&Combos,1,0,0,2013,2013,1353,1,Phase 3,0,safety/efficacy,0,6.860663671448287,"(6,7]"
2586,3479,a study of napabucasin plus nab-paclitaxel with gemcitabine in adult patients with metastatic pancreatic adenocarcinoma,Completed,4,1,1,"Carcinoma, Pancreatic Ductal",drug or biologic,Late,1134,All,Industry&Combos,1,0,0,2016,2016,1186,1,Phase 3,0,NA,0,7.033506484287697,"(7,13]"
4056,7721,study of the efficacy and safety of lonafarnib / ritonavir with and without pegylated interferon -alfa-2a,Recruiting,2,0,0,Hepatitis Delta Virus,drug or biologic,Late,400,All,Industry&Combos,1,0,0,2018,2018,852,1,Phase 3,4,safety/efficacy,2,5.991464547107982,"(5,6]"
3784,6578,telotristat etiprate - expanded treatment for patients with carcinoid syndrome symptoms,Completed,4,1,1,Carcinoid Syndrome,drug or biologic,Late,124,All,Industry&Combos,1,1,0,2014,2014,1702,1,Phase 3,0,NA,0,4.820281565605037,"(4,5]"
3953,7372,a phase iii study of xilonix in patients with advanced colorectal cancer,Terminated,5,1,1,Metastatic Colorectal Cancer,drug or biologic,Late,643,All,Industry&Combos,1,0,0,2013,2013,1552,1,Phase 3,4,NA,2,6.466144724237619,"(6,7]"
3687,6078,long term safety of naldemedine,Completed,4,1,1,Opioid-induced Constipation,drug or biologic,Late,1246,All,Industry&Combos,1,0,0,2013,2013,840,1,Phase 3,4,safety,2,7.1276936993473985,"(7,13]"
2589,3482,efficacy study of nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy in stomach cancer or stomach/esophagus junction cancer,"Active, not recruiting",1,0,0,Gastric Cancer|Gastroesophageal Junction Cancer,drug or biologic,Late,2031,All,Industry&Combos,1,0,0,2016,2016,1323,1,Phase 3,0,efficacy,0,7.616283561580385,"(7,13]"
2863,3840,a study to evaluate the long-term safety and efficacy of upadacitinib (abt-494) in participants with ulcerative colitis (uc),Enrolling by invitation,3,0,0,Ulcerative Colitis (UC),drug or biologic,Late,950,All,Industry&Combos,1,1,0,2016,2017,2766,1,Phase 3,4,safety/efficacy,2,6.856461984594587,"(6,7]"
3542,5417,microbiota restoration therapy for recurrent clostridium difficile infection (punch cd3-ols),Recruiting,2,0,0,Clostridium Difficile Infection|Infection|Communicable Diseases,drug or biologic,Late,500,All,Industry&Combos,0,NA,0,2019,2019,945,0,Phase 3,1,NA,1,6.214608098422191,"(6,7]"
4084,7946,exalenz lab mode system compared to biopsy for h.pylori detection,Completed,4,1,1,Helicobacter Pylori Infection,device,Others,282,All,Industry&Combos,1,1,2,2015,2015,244,1,Others,1,NA,1,5.641907070938114,"(5,6]"
2760,3708,enhance: seladelpar in subjects with primary biliary cholangitis (pbc) and an inadequate response to or an intolerance to ursodeoxycholic acid (udca),Completed,4,0,0,Primary Biliary Cholangitis,drug or biologic,Late,265,All,Industry&Combos,1,0,0,2018,2018,503,1,Phase 3,2,NA,2,5.579729825986222,"(5,6]"
4118,8711,efficacy and safety study of simeprevir in combination with sofosbuvir in participants with genotype 1 chronic hepatitis c virus infection and cirrhosis,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,103,All,Industry&Combos,0,NA,0,2014,2014,275,0,Phase 3,1,safety/efficacy,1,4.634728988229636,"(4,5]"
2819,3778,calprotectin-directed humira Â® maintenance therapy (cadhum),Withdrawn,7,0,0,Crohn's Disease,drug or biologic,Late,NA,All,Industry&Combos,1,0,0,2012,2013,882,1,Phase 3,3,NA,2,NA,NA
3143,4274,folfox6m plus sir-spheres microspheres vs folfox6m alone in patients with liver mets from primary colorectal cancer,Completed,4,1,1,Colorectal Cancer Metastatic,drug or biologic,Late,209,All,Industry&Combos,1,0,0,2012,2013,1332,1,Phase 3,0,NA,0,5.342334251964811,"(5,6]"
3043,4088,randomized global phase 3 study to evaluate the impact on nash with fibrosis of obeticholic acid treatment,"Active, not recruiting",1,0,0,Non Alcoholic Steatohepatitis (NASH),drug or biologic,Late,2480,All,Industry&Combos,1,0,0,2015,2015,3632,1,Phase 3,4,NA,2,7.8160138391590275,"(7,13]"
2308,2903,"a phase iii study to evaluate the efficacy, safety, and pharmacokinetics of investigational product mp-101 in subjects with short bowel syndrome who have had an inadequate response to anti-diarrheals",Withdrawn,7,0,0,Short Bowel Syndrome|Short Gut Syndrome|SBS|Short Bowel|Short Gut,drug or biologic,Late,NA,All,Industry&Combos,3,0,0,2014,2014,1096,3,Phase 3,3,safety/efficacy,2,NA,NA
3772,6529,sofosbuvir/velpatasvir fixed-dose combination in adults with chronic hcv infection and child-pugh class b cirrhosis,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,268,All,Industry&Combos,1,0,0,2014,2014,396,1,Phase 3,0,NA,0,5.5909869805108565,"(5,6]"
2927,3928,intra-arterial gemcitabine vs. iv gemcitabine and nab-paclitaxel following radiotherapy for lapc,Recruiting,2,0,0,Locally Advanced Pancreatic Cancer,drug or biologic,Late,320,All,Industry&Combos,1,0,0,2017,2018,1634,1,Phase 3,0,NA,0,5.768320995793772,"(5,6]"
1522,1654,"trial of carbon ion versus photon radiotherapy for locally advanced, unresectable pancreatic cancer",Withdrawn,7,0,0,Locally Advanced Pancreatic Adenocarcinoma,other,Others,NA,All,AllOther,1,0,0,2018,2019,764,1,Others,0,NA,0,NA,NA
2600,3497,efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis,"Active, not recruiting",1,0,0,Erosive Esophagitis,drug or biologic,Late,1027,All,Industry&Combos,1,0,0,2019,2019,636,1,Phase 3,4,safety/efficacy,2,6.934397209928558,"(6,7]"
2583,3473,evaluation of efficacy and safety of neoadjuvant treatment with pamrevlumab in combination with chemotherapy (either gemcitabine plus nab-paclitaxel or folfirinox) in locally advanced pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer Non-resectable,drug or biologic,Late,280,All,Industry&Combos,1,0,0,2019,2019,1239,1,Phase 3,4,safety/efficacy,2,5.634789603169249,"(5,6]"
4149,9036,sofosbuvir/velpatasvir fixed-dose combination in adults with chronic hcv infection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,111,All,Industry&Combos,0,NA,0,2015,2015,394,0,Phase 3,1,NA,1,4.709530201312334,"(4,5]"
3184,4389,efficacy and safety of lifesealÃ¢âÂ¢ kit for colorectal staple line sealing,Unknown status,8,0,0,Rectal Cancer|Anastomotic Leak,device,Others,736,All,Industry&Combos,1,0,0,2016,2016,485,1,Others,1,safety/efficacy,1,6.601230118728877,"(6,7]"
3057,4109,radiation therapy vs. observation following gemcitabine and cisplatin for inoperable localized liver cancer,Terminated,5,1,1,Stage III Intrahepatic Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma,other,Others,1,All,NIH&Combos,1,0,0,2014,2014,1372,1,Others,0,NA,0,0,NA
3065,4125,treatment of thrombocytopenia in patients with chronic liver disease undergoing an elective procedure,Completed,4,1,1,Thrombocytopenia Associated With Liver Disease,drug or biologic,Late,204,All,Industry&Combos,1,0,0,2013,2013,1186,1,Phase 3,4,NA,2,5.318119993844216,"(5,6]"
3569,5508,a study to assess the efficacy and safety of risankizumab in participants with moderately to severely active crohn's disease who failed prior biologic treatment,Completed,4,0,0,Crohn's Disease,drug or biologic,Late,618,All,Industry&Combos,1,0,0,2017,2017,1078,1,Phase 3,2,safety/efficacy,2,6.42648845745769,"(6,7]"
3346,4851,"pharmacodynamic, pharmacokinetic, and tolerability study of a liquid form of lubiprostone in adult subjects with chronic idiopathic constipation",Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,164,All,Industry&Combos,1,0,0,2013,2013,92,1,Phase 3,3,NA,2,5.099866427824199,"(5,6]"
3663,5833,efficacy and safety of cadazolid versus vancomycin in subjects with clostridium difficile-associated diarrhea,Completed,4,1,1,Clostridium Difficile Infection,drug or biologic,Late,631,All,Industry&Combos,1,0,0,2013,2013,1183,1,Phase 3,2,safety/efficacy,2,6.447305862541213,"(6,7]"
2738,3667,efficacy and safety of adalimumab in pediatric subjects with moderate to severe ulcerative colitis,Completed,4,1,1,Ulcerative Colitis,drug or biologic,Late,101,All,Industry&Combos,1,0,0,2014,2014,1943,1,Phase 3,4,safety/efficacy,2,4.61512051684126,"(4,5]"
3893,7185,efficacy and safety of 8-weeks of glecaprevir/pibrentasvir in treatment-na Â¯ve adults with hcv genotype 1-6 and aspartate aminotransferase to platelet ratio index (apri) Ã¢â°Â¤1,Completed,4,1,1,Hepatitis C Virus (HCV),drug or biologic,Late,230,All,Industry&Combos,0,NA,0,2017,2017,371,0,Phase 3,1,safety/efficacy,1,5.438079308923196,"(5,6]"
3662,5832,efficacy and safety of cadazolid versus vancomycin in subjects with clostridium difficile - associated diarrhea,Completed,4,1,1,Clostridium Difficile Infection,drug or biologic,Late,632,All,Industry&Combos,1,0,0,2013,2014,1067,1,Phase 3,2,safety/efficacy,2,6.448889394146858,"(6,7]"
2815,3774,a study to assess the efficacy and safety of golimumab in pediatric participants with moderately to severely active ulcerative colitis,Recruiting,2,0,0,"Colitis, Ulcerative",drug or biologic,Late,100,All,Industry&Combos,1,0,0,2018,2018,1150,1,Phase 3,0,safety/efficacy,0,4.605170185988092,"(4,5]"
3611,5694,a study of the efficacy and safety of risankizumab in participants with crohn's disease,"Active, not recruiting",1,0,0,Crohn's Disease,drug or biologic,Late,1250,All,Industry&Combos,1,0,0,2017,2018,2983,1,Phase 3,4,safety/efficacy,2,7.1308988302963465,"(7,13]"
4143,9028,lot-to-lot consistency of sci-b-vacÃ¢âÂ¢ in adults,Completed,4,1,1,Hepatitis B Vaccines,drug or biologic,Late,2838,All,Industry&Combos,1,0,1,2018,2017,656,1,Phase 3,3,NA,2,7.950854857719988,"(7,13]"
2580,3469,a study of bbi608 plus weekly paclitaxel to treat gastric and gastro-esophageal junction cancer,Completed,4,1,1,Gastric Cancer|Gastroesophageal Junction Cancer,drug or biologic,Late,714,All,Industry&Combos,1,0,0,2014,2014,1085,1,Phase 3,4,NA,2,6.570882962339584,"(6,7]"
2602,3500,immunotherapy study in borderline resectable or locally advanced unresectable pancreatic cancer,Terminated,5,0,0,Pancreatic Cancer|Pancreatic Carcinoma Non-resectable|Locally Advanced Malignant Neoplasm,drug or biologic,Late,302,All,Industry&Combos,1,0,0,2013,2013,1185,1,Phase 3,0,NA,0,5.71042701737487,"(5,6]"
2642,3546,"linaclotide safety and efficacy in pediatric participants, 6 to 17 years of age, with irritable bowel syndrome with constipation (ibs-c) or functional constipation (fc)",Recruiting,2,0,0,Functional Constipation|Irritable Bowel Syndrome With Constipation,drug or biologic,Late,426,All,Industry&Combos,1,0,0,2019,2019,1379,1,Phase 3,4,safety/efficacy,2,6.054439346269371,"(6,7]"
2758,3706,a study in adolescents and adults with eosinophilic esophagitis (eoe) measuring histologic response and determine if reduction in dysphagia is achieved,Completed,4,1,1,Eosinophilic Esophagitis (EoE),drug or biologic,Late,318,All,Industry&Combos,1,0,0,2015,2015,1144,1,Phase 3,4,NA,2,5.762051382780177,"(5,6]"
2302,2891,chemotherapy before & after surgery in patients with resectable gallbladder cancer,Withdrawn,7,0,0,Stage I Gallbladder Cancer AJCC v8|Stage II Gallbladder Cancer AJCC v8|Stage IIA Gallbladder Cancer AJCC v8|Stage IIB Gallbladder Cancer AJCC v8|Stage III Gallbladder Cancer AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8,drug or biologic,Late,NA,All,AllOther,1,0,0,2018,2019,425,1,Phase 3,0,NA,0,NA,NA
4146,9033,safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/velpatasvir in adults with chronic hcv infection who have not previously received treatment with direct-acting antiviral therapy,Completed,4,1,1,Hepatitis C,drug or biologic,Late,943,All,Industry&Combos,1,0,0,2015,2015,329,1,Phase 3,0,safety/efficacy,0,6.849066282633458,"(6,7]"
2794,3751,open-label extension of rpc1063 as therapy for moderate to severe ulcerative colitis,"Active, not recruiting",1,0,0,Ulcerative Colitis,drug or biologic,Late,871,All,Industry&Combos,0,NA,0,2015,2015,2280,0,Phase 3,1,NA,1,6.769641976852503,"(6,7]"
650,677,l-menthol infusion as a novel technique during colonoscopy,Terminated,5,0,0,Colonic Polyps|Colon Cancer,drug or biologic,Late,82,All,AllOther,1,0,2,2015,2019,0,1,Phase 3,2,NA,2,4.406719247264253,"(4,5]"
4102,8127,bag mode breathid hp validation versus endoscopy in detection of helicobacter pylori,Completed,4,0,0,Helicobacter Pylori Infection,other,Others,193,All,Industry&Combos,0,NA,2,2013,2014,396,0,Others,1,NA,1,5.262690188904886,"(5,6]"
3023,4060,mesalamine 2 g sachet for the maintenance of clinical and endoscopic remission in ulcerative colitis (uc),Completed,4,0,0,Ulcerative Colitis,drug or biologic,Late,276,All,Industry&Combos,1,0,0,2015,2016,961,1,Phase 3,4,NA,2,5.62040086571715,"(5,6]"
4173,9161,trial of simplified treatment monitoring for 8 weeks glecaprevir/pibrentasvir in chronic hepatitis c patients,Completed,4,1,1,"Hepatitis C, Chronic",drug or biologic,Late,380,All,AllOther,1,0,0,2017,2017,485,1,Phase 3,0,NA,0,5.940171252720432,"(5,6]"
4043,7647,open-label extension (ole) study of plecanatide for chronic idiopathic constipation (cic),Completed,4,1,1,Chronic Idiopathic Constipation,drug or biologic,Late,2370,All,Industry&Combos,1,1,0,2013,2013,883,1,Phase 3,0,NA,0,7.7706452341291765,"(7,13]"
2740,3669,phase iii folfirinox (mffx) +/- sbrt in locally advanced pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Late,27,All,AllOther,1,0,0,2013,2013,2953,1,Phase 3,0,NA,0,3.295836866004329,"(3,4]"
4129,8967,an investigational immuno-therapy study of nivolumab compared to sorafenib as a first treatment in patients with advanced hepatocellular carcinoma,"Active, not recruiting",1,1,1,Hepatocellular Carcinoma,drug or biologic,Late,743,All,Industry&Combos,1,0,0,2015,2015,1270,1,Phase 3,0,NA,0,6.610696044717759,"(6,7]"
3001,4025,a phase 3 study to evaluate the efficacy and safety of mgl-3196 (resmetirom) in patients with nash and fibrosis,Recruiting,2,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Late,2000,All,Industry&Combos,1,0,0,2019,2019,979,1,Phase 3,4,safety/efficacy,2,7.600902459542082,"(7,13]"
3175,4357,study comparing efficacy and safety of defibrotide vs best supportive care in the prevention of hepatic veno-occlusive disease in adult and pediatric patients,Completed,4,0,0,Veno-occlusive Disease,drug or biologic,Late,373,All,Industry&Combos,1,0,1,2016,2016,1503,1,Phase 3,0,safety/efficacy,0,5.921578419643816,"(5,6]"
3556,5460,study comparing rifaximin with xifaxan 200 mg in traveler's diarrhea,Completed,4,1,1,Diarrhea,drug or biologic,Late,739,All,Industry&Combos,1,0,0,2015,2016,419,1,Phase 3,3,NA,2,6.6052979209482015,"(6,7]"
3959,7391,gastroschisis outcomes of delivery (good) study,Recruiting,2,0,0,Gastroschisis,other,Others,800,Female,AllOther,1,0,0,2016,2018,2776,1,Others,0,NA,0,6.684611727667927,"(6,7]"
2814,3773,a study to assess the efficacy and safety of risankizumab in participants with ulcerative colitis,Enrolling by invitation,3,0,0,Ulcerative Colitis (UC),drug or biologic,Late,942,All,Industry&Combos,1,0,0,2018,2018,1935,1,Phase 3,3,safety/efficacy,2,6.848005274576363,"(6,7]"
2860,3835,continuation study with budesonide oral suspension (bos) for adolescent and adult participants with eosinophilic esophagitis (eoe),"Active, not recruiting",1,0,0,Eosinophilic Esophagitis (EoE),drug or biologic,Late,133,All,Industry&Combos,0,NA,0,2017,2017,2216,0,Phase 3,1,NA,1,4.890349128221754,"(4,5]"
1308,1397,a randomized comparison of rifaximin versus lactulose in hospitalized cirrhotic patients with renal failure,Withdrawn,7,0,0,Hepatic Encephalopathy,drug or biologic,Late,NA,All,AllOther,1,0,0,2014,2015,427,1,Phase 3,0,NA,0,NA,NA
3226,4520,efficacy and safety study of ontamalimab as induction therapy in participants with moderate to severe crohn's disease (carmen cd 305),Terminated,5,1,1,Crohn's Disease,drug or biologic,Late,30,All,Industry&Combos,1,0,0,2018,2018,678,1,Phase 3,2,safety/efficacy,2,3.4011973816621555,"(3,4]"
4159,9132,efficacy and safety of sofosbuvir/velpatasvir fixed dose combination for 12 weeks in adults with chronic hepatitis c virus (hcv) and human immunodeficiency virus (hiv)-1 coinfection,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,107,All,Industry&Combos,0,NA,0,2015,2015,303,0,Phase 3,1,safety/efficacy,1,4.672828834461906,"(4,5]"
2852,3825,study of pembrolizumab (mk-3475) plus chemotherapy versus placebo plus chemotherapy in participants with gastric or gastroesophageal junction (gej) adenocarcinoma (mk-3475-585/keynote-585),"Active, not recruiting",1,0,0,Gastric Cancer|Gastroesophageal Junction Cancer,drug or biologic,Late,1007,All,Industry&Combos,1,0,0,2017,2017,2454,1,Phase 3,4,NA,2,6.914730892718563,"(6,7]"
3702,6149,aprepitant- and olanzapine- containing anti-emetic regimens with high dose melphalan,Unknown status,8,0,0,Nausea|Vomiting,drug or biologic,Late,429,All,AllOther,1,0,4,2016,2017,1135,1,Phase 3,0,NA,0,6.061456918928017,"(6,7]"
2906,3895,"nab-paclitaxel and gemcitabine vs gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer (the ""apact"" study)","Active, not recruiting",1,1,1,"Pancreatic Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Neoplasms|Endocrine Gland Neoplasms|Pancreatic Diseases|Digestive System Diseases|Endocrine System Diseases|Gemcitabine|Antimetabolites, Antineoplastic",drug or biologic,Late,866,All,Industry&Combos,1,0,0,2013,2014,1739,1,Phase 3,0,NA,0,6.763884908562435,"(6,7]"
424,436,thoracic epidural analgesia or four-quadrant transversus abdominus plane block in reducing pain in patients undergoing liver surgery,Recruiting,2,0,0,Liver and Intrahepatic Bile Duct Disorder,drug or biologic,Late,96,All,NIH&Combos,1,0,4,2017,2017,1792,1,Phase 3,0,NA,0,4.564348191467836,"(4,5]"
2579,3468,phase 4 study of obeticholic acid evaluating clinical outcomes in patients with primary biliary cholangitis,Recruiting,2,0,0,"Liver Cirrhosis, Biliary",drug or biologic,Late,428,All,Industry&Combos,1,0,0,2014,2014,3653,1,Phase 4,4,NA,2,6.059123195581797,"(6,7]"
546,568,changes in oral contraceptive hormones after gastric bypass surgery,Withdrawn,7,0,0,Bariatric Surgery Candidate|Contraception,drug or biologic,Late,NA,Female,AllOther,0,NA,0,2013,2013,1710,0,Phase 4,1,NA,1,NA,NA
3905,7258,efficacy of metronidazole prophylaxis against clostridium difficile-associated diarrhea in high risk adult patients,Terminated,5,1,1,Clostridium Difficile Diarrhea,drug or biologic,Late,76,All,AllOther,1,0,1,2014,2014,578,1,Phase 4,1,efficacy,1,4.330733340286331,"(4,5]"
1597,1747,comparing the effectiveness of iv bezlotoxumab versus placebo in decreasing morbidity and mortality in patients with fulminant c. diff requiring surgery.,Recruiting,2,0,0,Clostridia Difficile Colitis|Clostridium; Sepsis,drug or biologic,Late,100,All,Industry&Combos,1,0,0,2018,2019,682,1,Phase 4,3,NA,2,4.605170185988092,"(4,5]"
32,32,comparison of clenpiq vs golytely bowel preparation,Terminated,5,1,1,Bowel Preparation Solutions,drug or biologic,Late,14,All,Industry&Combos,1,0,2,2017,2018,258,1,Phase 4,0,NA,0,2.6390573296152584,"(2,3]"
1952,2289,rifaximin therapy in chronic kidney disease,Completed,4,0,0,Chronic Kidney Disease,drug or biologic,Late,30,All,AllOther,1,0,1,2015,2015,1400,1,Phase 4,3,NA,2,3.4011973816621555,"(3,4]"
540,562,reduction of postoperative gastrointestinal dysmotility following total laparoscopic hysterectomy.,Completed,4,0,0,Postoperative Passage of Flatus|Postoperative Bowel Movement,drug or biologic,Late,81,Female,AllOther,0,0,1,2019,2018,543,0,Phase 4,1,NA,1,4.394449154672439,"(4,5]"
511,532,eoe rct fluticasone and omeprazole vs fluticasone alone,Recruiting,2,0,0,Eosinophilic Esophagitis,drug or biologic,Late,100,All,AllOther,1,0,4,2018,2018,731,1,Phase 4,4,NA,2,4.605170185988092,"(4,5]"
1427,1536,hpv vaccine therapy in interrupting progression in patients with high-grade vulvar or anal lesions,Recruiting,2,0,0,High Grade Anal Canal Intraepithelial Neoplasia|Vulvar High Grade Squamous Intraepithelial Lesion,drug or biologic,Late,220,All,NIH&Combos,1,0,0,2017,2017,1603,1,Phase 4,3,NA,2,5.393627546352362,"(5,6]"
4048,7666,community-based treatment of chronic hepatitis c monoinfection and coinfection with hiv in the district of columbia,Completed,4,1,1,HCV HIV,drug or biologic,Late,600,All,NIH&Combos,0,NA,0,2015,2015,525,0,Phase 4,1,NA,1,6.396929655216146,"(6,7]"
3124,4245,a single-arm evaluation of the effect of hcv treatment on cardiovascular disease risk,Withdrawn,7,0,0,Hepatitis C,drug or biologic,Late,NA,All,Industry&Combos,0,NA,4,2018,2018,304,0,Phase 4,1,NA,1,NA,NA
2626,3527,an efficacy and safety study of infliximab dose escalation in pediatric participants with inflammatory bowel disease,Terminated,5,1,1,Inflammatory Bowel Diseases,drug or biologic,Late,53,All,Industry&Combos,1,1,0,2015,2016,1186,1,Phase 4,0,safety/efficacy,0,3.970291913552122,"(3,4]"
4100,8111,real world study: genotype 1 chronic hepatitis c virus treatment and evaluation of real world svr and pro,Completed,4,1,1,"Hepatitis C, Chronic",drug or biologic,Late,200,All,Industry&Combos,1,1,0,2015,2015,700,1,Phase 4,0,NA,0,5.298317366548036,"(5,6]"
2085,2486,pharmacokinetic study of bupropion hydrochloride products with different release patterns,Completed,4,1,1,Depression,drug or biologic,Late,34,All,AllOther,3,0,4,2014,2014,945,3,Phase 4,1,NA,1,3.5263605246161616,"(3,4]"
1339,1431,hope - a study to evaluate the effect of a prehabilitation program on gi cancer patients planning to undergo surgery,Unknown status,8,0,0,Pancreatic Cancer|Esophageal Cancer|Gastric Cancer,behavioral,Others,60,All,AllOther,1,1,0,2018,2018,122,1,Others,0,NA,0,4.0943445622221,"(4,5]"
3132,4256,safety and efficacy of everolimus treatment in liver transplantation for liver cancer,"Active, not recruiting",1,0,0,"Carcinoma, Hepatocellular",drug or biologic,Late,336,All,AllOther,1,0,0,2014,2014,2498,1,Phase 4,0,safety/efficacy,0,5.817111159963204,"(5,6]"
2086,2488,a pilot study to treat patients with chronic hepatitis c virus (hcv) genotype 1 and end-stage renal disease (esrd),Unknown status,8,0,0,Chronic Hepatitis C|End Stage Renal Disease,drug or biologic,Late,20,All,Industry&Combos,0,NA,0,2012,2013,365,0,Phase 4,1,NA,1,2.995732273553991,"(2,3]"
3355,4892,screening to prophylax against clostridium difficile infection -,Recruiting,2,0,0,Clostridium Difficile Infection,drug or biologic,Late,2500,All,AllOther,1,0,1,2016,2016,1857,1,Phase 4,3,NA,2,7.824046010856292,"(7,13]"
3122,4236,prevention of de novo hcv with antiviral hcv therapy post-liver and post-kidney transplant,Completed,4,1,1,Hepatitis C|Transplantation Disease Transmission,drug or biologic,Late,122,All,AllOther,0,NA,4,2018,2018,524,0,Phase 4,1,NA,1,4.804021044733257,"(4,5]"
779,816,reduction in symptomatic esophageal stricture formation,Terminated,5,1,1,Esophageal Stenosis,drug or biologic,Late,3,All,AllOther,1,0,1,2014,2014,337,1,Phase 4,3,NA,2,1.0986122886681098,"(1,2]"
1967,2314,an alternate dosing schedule for pentavalent rotavirus vaccine (rotateq),Completed,4,1,1,Diarrhea|Gastroenteritis,drug or biologic,Late,66,All,Industry&Combos,1,1,1,2013,2014,668,1,Phase 4,0,NA,0,4.189654742026425,"(4,5]"
2554,3432,smv + sof with/without rbv for ifn-ii patients with chc,Completed,4,1,1,Hepatitis C,drug or biologic,Late,24,All,Industry&Combos,1,0,0,2014,2014,609,1,Phase 4,0,NA,0,3.1780538303479458,"(3,4]"
1001,1056,"an open-label, non-randomized, parallel group study in subjects with mild and moderate hepatic insufficiency and healthy volunteers",Completed,4,1,1,Hepatic Impairment,drug or biologic,Late,21,All,Industry&Combos,1,1,NA,2013,2013,455,1,Phase 4,0,NA,0,3.044522437723423,"(3,4]"
3998,7559,maraviroc efficacy for hepatitis c,Completed,4,0,0,Hepatitis C|Human Immunodeficiency Virus,drug or biologic,Late,10,All,Industry&Combos,3,0,0,2016,2017,664,3,Phase 4,0,efficacy,0,2.302585092994046,"(2,3]"
953,1003,minocycline administration during human liver transplantation,Withdrawn,7,0,0,Liver Disease,drug or biologic,Late,NA,All,AllOther,1,0,0,2016,2016,0,1,Phase 4,2,NA,2,NA,NA
2184,2651,impact of oral antibiotic treatment on c. difficile,Completed,4,1,1,C. Difficile|Diarrhea|Enterocolitis,drug or biologic,Late,33,All,AllOther,1,0,0,2014,2014,1113,1,Phase 4,0,NA,0,3.4965075614664802,"(3,4]"
3337,4779,"prea, pk and safety pass study of iv pantoprazole in pediatric subjects",Recruiting,2,0,0,Gastroesophageal Reflux Disease,drug or biologic,Late,24,All,Industry&Combos,0,NA,0,2015,2017,3633,0,Phase 4,1,safety,1,3.1780538303479458,"(3,4]"
654,681,study of abatacept (orencia) to treat primary biliary cirrhosis,Completed,4,1,1,Primary Biliary Cirrhosis,drug or biologic,Late,16,All,Industry&Combos,0,NA,0,2014,2014,1491,0,Phase 4,1,NA,1,2.772588722239781,"(2,3]"
578,602,switch from calcineurin inhibitor to belatacept in pancreas transplant recipients,Completed,4,1,1,Nephrotoxicity,drug or biologic,Late,6,All,AllOther,0,NA,0,2014,2014,639,0,Phase 4,1,NA,1,1.791759469228055,"(1,2]"
2456,3202,investigation of microbiomes of postmenopausal women looking for outcomes and response to estrogen therapy,Completed,4,0,0,Female Urogenital Diseases|Vaginal Atrophy|Postmenopausal Atrophic Vaginitis|Genitourinary Disease|Postmenopausal Symptoms,drug or biologic,Late,25,Female,AllOther,1,1,4,2019,2019,532,1,Phase 4,0,NA,0,3.2188758248682006,"(3,4]"
2400,3093,live-c-free: early and late treatment of hepatitis c with sofosbuvir/ledipasvir in liver transplant recipients,Completed,4,1,1,Hepatitis C,drug or biologic,Late,32,All,AllOther,1,0,0,2015,2016,728,1,Phase 4,0,NA,0,3.4657359027997265,"(3,4]"
1932,2255,anti-inflammatory therapy to improve outcomes after tpiat,"Active, not recruiting",1,0,0,"Pancreatitis, Chronic; Diabetes; Transplant",drug or biologic,Late,45,All,NIH&Combos,1,0,0,2016,2016,1492,1,Phase 4,0,NA,0,3.8066624897703196,"(3,4]"
1225,1303,daa treatment in donor hcv-positive to recipient hcv-negative liver transplant,Terminated,5,0,0,End Stage Liver Disease|Hepatitis C,drug or biologic,Late,35,All,AllOther,0,NA,1,2017,2017,1291,0,Phase 4,1,NA,1,3.5553480614894135,"(3,4]"
2936,3937,transanastomotic tube for proximal esophageal atresia with distal tracheoesophageal fistula repair,Unknown status,8,0,0,Esophageal Atresia|Tracheoesophageal Fistula,device,Others,150,All,AllOther,1,0,0,2018,2018,721,1,Others,0,NA,0,5.0106352940962555,"(5,6]"
4009,7582,"sofosbuvir, ribavirin, for the treatment of chronic hepatitis c virus genotype 1 in hiv-coinfected patients receiving fixed dose co-formulation emtricitabine/ tenofovir/cobicistat/elvitegravir: a pilot study",Completed,4,0,0,Hepatitis C Infection|HIV Infection,drug or biologic,Late,10,All,AllOther,0,NA,0,2014,2014,396,0,Phase 4,1,NA,1,2.302585092994046,"(2,3]"
3837,6899,multi-center study to transplant hepatitis-c infected kidneys,"Active, not recruiting",1,1,1,Renal Failure Chronic|Hepatitis C,drug or biologic,Late,30,All,Industry&Combos,0,NA,1,2018,2019,345,0,Phase 4,1,NA,1,3.4011973816621555,"(3,4]"
1969,2317,antibiotics to decrease post ercp cholangitis,Unknown status,8,0,0,Cholangitis,drug or biologic,Late,200,All,AllOther,1,0,0,2017,2017,1427,1,Phase 4,2,NA,2,5.298317366548036,"(5,6]"
3814,6759,designing optimal prevention and management of postoperative nausea and emesis for patients undergoing laparoscopic sleeve gastrectomy,Unknown status,8,0,0,Post-operative Nausea and Vomiting|Laparoscopic Sleeve Gastrectomy,drug or biologic,Late,82,All,AllOther,1,0,1,2018,2017,722,1,Phase 4,1,NA,1,4.406719247264253,"(4,5]"
1009,1064,defining predictors of rt response to vedolizumab in ibd,Recruiting,2,0,0,Crohn Disease of Small Intestine,drug or biologic,Late,80,All,AllOther,0,NA,0,2017,2018,1089,0,Phase 4,1,NA,1,4.382026634673881,"(4,5]"
176,177,pre-operative bowel preparation prior to minimally invasive sacral colpopexy,Completed,4,0,0,Pelvic Organ Prolapse|Prolapse,other,Others,95,Female,AllOther,1,0,0,2013,2013,1642,1,Others,3,NA,2,4.553876891600541,"(4,5]"
3093,4184,hcv-rna kinetics during sorafenib for hepatocellular carcinoma (hcc),Terminated,5,1,1,Hepatocellular Cancer,drug or biologic,Late,3,All,AllOther,0,NA,0,2013,2013,1310,0,Phase 4,1,NA,1,1.0986122886681098,"(1,2]"
3289,4650,preemptive zepatier treatment in donor hcv positive to recipient hcv negative cardiac transplant,Withdrawn,7,0,0,Cardiac Transplant Disorder|Hepatitis C,drug or biologic,Late,NA,All,Industry&Combos,0,NA,1,2017,2018,883,0,Phase 4,1,NA,1,NA,NA
1939,2268,ultrasound evaluation of crohn's disease,Enrolling by invitation,3,0,0,Crohn Disease,drug or biologic,Late,100,All,AllOther,0,NA,2,2017,2017,1902,0,Phase 4,1,NA,1,4.605170185988092,"(4,5]"
4028,7612,study to investigate the efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination for 12 weeks in subjects with chronic genotype 1 and 4 hcv infection with autoimmune disease,Unknown status,8,0,0,Chronic Hepatitis C,drug or biologic,Late,40,All,Industry&Combos,0,NA,0,2016,2016,366,0,Phase 4,1,safety/efficacy,1,3.6888794541139363,"(3,4]"
2261,2803,an open-label preference evaluation of bli800,Completed,4,0,0,Colonoscopy,drug or biologic,Late,40,All,Industry&Combos,0,NA,0,2020,2019,58,0,Phase 4,1,NA,1,3.6888794541139363,"(3,4]"
2610,3509,a study of tofacitinib in patients with ulcerative colitis in stable remission,"Active, not recruiting",1,1,1,Ulcerative Colitis,drug or biologic,Late,141,All,Industry&Combos,1,0,0,2017,2017,820,1,Phase 4,4,NA,2,4.948759890378168,"(4,5]"
1587,1737,efficacy of rectal infiltration of exparel for analgesic benefit following hemorrhoidectomy,Terminated,5,1,1,Hemorrhoid,drug or biologic,Late,11,All,AllOther,1,0,0,2014,2014,640,1,Phase 4,2,efficacy,2,2.3978952727983707,"(2,3]"
2450,3190,oral hepatitis c treatment for indolent lymphoma (optimal) study,Terminated,5,1,1,Liver Disease,drug or biologic,Late,1,All,AllOther,1,1,0,2016,2016,466,1,Phase 4,0,NA,0,0,NA
1766,1979,investigation of cannabinoid receptor agonist dronabinol in patients with functional chest pain,Withdrawn,7,0,0,Esophageal Diseases,drug or biologic,Late,NA,All,AllOther,1,0,0,2015,2017,771,1,Phase 4,2,NA,2,NA,NA
2551,3428,comparison of 24-hours versus 72-hours of octreotide infusion in preventing early rebleed from esophageal varices,Recruiting,2,0,0,Esophageal Varices|Liver Cirrhoses|Bleeding Esophageal Varices|Upper Gastrointestinal Bleeding,drug or biologic,Late,160,All,AllOther,1,0,0,2018,2018,2265,1,Phase 4,1,NA,1,5.075173815233827,"(5,6]"
3916,7297,intravenous lidocaine randomized comparative effectiveness trial,Completed,4,1,1,Abdominal Pain,drug or biologic,Late,154,All,AllOther,1,0,0,2017,2018,218,1,Phase 4,4,NA,2,5.0369526024136295,"(5,6]"
3984,7542,toward elimination of hepatitis c virus (hcv): a pilot study,Unknown status,8,0,0,Hepatitis C|Addict Heroin,drug or biologic,Late,30,All,Industry&Combos,0,NA,0,2017,2018,229,0,Phase 4,1,NA,1,3.4011973816621555,"(3,4]"
2759,3707,vedolizumab intravenous (iv) dose optimization in ulcerative colitis,Completed,4,0,0,"Colitis, Ulcerative",drug or biologic,Late,278,All,Industry&Combos,1,0,0,2017,2017,1212,1,Phase 4,4,NA,2,5.627621113690637,"(5,6]"
1674,1845,"phase 4, vedolizumab-4002 post-marketing, disease-drug-drug interaction study",Withdrawn,7,0,0,"Colitis, Ulcerative|Crohn Disease",drug or biologic,Late,NA,All,Industry&Combos,1,1,0,2016,2016,1369,1,Phase 4,4,NA,2,NA,NA
3380,5002,pilot study to assess dimethyl fumarate related gi symptom mitigation,Terminated,5,1,1,Relapsing Remitting Multiple Sclerosis,drug or biologic,Late,5,All,Industry&Combos,1,0,0,2014,2014,335,1,Phase 4,0,NA,0,1.6094379124341003,"(1,2]"
802,839,anal dysplasia study of men who have sex with men living with hiv,Withdrawn,7,0,0,Anal Dysplasia|Human Papilloma Virus|HIV,drug or biologic,Late,NA,Male,AllOther,0,0,0,2012,2015,214,0,Phase 4,1,NA,1,NA,NA
4013,7587,the sim-sof trial for hepatitis c,Completed,4,1,1,Chronic Hepatitis C,drug or biologic,Late,93,All,AllOther,1,0,0,2014,2013,365,1,Phase 4,0,NA,0,4.532599493153256,"(4,5]"
949,998,deliver: direct acting antiviral effects on the liver,Completed,4,1,1,HCV Coinfection|Liver Disease|HIV,drug or biologic,Late,15,All,AllOther,1,0,0,2016,2017,1002,1,Phase 4,0,NA,0,2.70805020110221,"(2,3]"
4011,7585,a study of the safety and effectiveness of simeprevir and sofosbuvir for patients with hiv and hepatitis c,Withdrawn,7,0,0,"Hepatitis C, Chronic|HIV CDC Category A1",drug or biologic,Late,NA,All,Industry&Combos,0,NA,0,2014,2014,396,0,Phase 4,1,safety,1,NA,NA
2345,2973,sofosbuvir/velpatasvir in postpartum women with opioid use disorder and chronic hepatitis c infection,Recruiting,2,0,0,"Hepatitis C, Chronic|Opioid-use Disorder",drug or biologic,Late,75,Female,AllOther,0,NA,4,2017,2018,1248,0,Phase 4,1,NA,1,4.31748811353631,"(4,5]"
1934,2258,"antibiotic resistance and microbiome in children aged 6-59 months in nouna, burkina faso",Completed,4,0,0,Child Development,drug or biologic,Late,252,All,AllOther,1,0,0,2017,2017,789,1,Phase 4,4,NA,2,5.529429087511423,"(5,6]"
1833,2087,does clinical response correlate with serum certolizumab levels?,Unknown status,8,0,0,Crohn's Disease,drug or biologic,Late,20,All,Industry&Combos,0,NA,0,2015,2015,912,0,Phase 4,1,NA,1,2.995732273553991,"(2,3]"
366,374,prospective evaluation of stent patency in patients with benign biliary obstruction of the wing biliary stent (viaductÃ¢âÂ¢),Unknown status,8,0,0,Bile Duct Stricture,other,Others,50,All,AllOther,0,NA,0,2013,2013,365,0,Others,1,NA,1,3.912023005428146,"(3,4]"
2248,2773,hepatitis c virus post-exposure prophylaxis for health care workers,Withdrawn,7,0,0,Viral Hepatitis C,drug or biologic,Late,NA,All,AllOther,0,NA,1,2013,2013,395,0,Phase 4,1,NA,1,NA,NA
3748,6345,"monitoring sof/vel in treatment na Â¯ve, hcv participants with active infection","Active, not recruiting",1,0,0,Hepatitis C|HIV-1-infection|Liver Diseases,drug or biologic,Late,400,All,NIH&Combos,0,NA,0,2018,2018,659,0,Phase 4,1,NA,1,5.991464547107982,"(5,6]"
1736,1937,peripheral pharmacodynamics of phentermine-topiramate in obese patients,Completed,4,1,1,Obesity,drug or biologic,Late,24,All,NIH&Combos,1,0,0,2013,2013,334,1,Phase 4,3,NA,2,3.1780538303479458,"(3,4]"
2112,2523,gadolinium contrast-enhanced abbreviated mri (amri) vs. standard ultrasound for hepatocellular carcinoma (hcc) surveillance in patients with cirrhosis,Recruiting,2,0,0,Liver Cancer|Liver Cirrhoses|Liver Carcinoma,drug or biologic,Late,150,All,Industry&Combos,0,NA,4,2020,2018,1344,0,Phase 4,1,NA,1,5.0106352940962555,"(5,6]"
3372,4973,a comparison of fidaxomicin and vancomycin in patients with cdi receiving antibiotics for concurrent infections,Completed,4,0,0,Clostridium Difficile Infection (CDI),drug or biologic,Late,147,All,Industry&Combos,1,0,0,2016,2017,1483,1,Phase 4,0,NA,0,4.990432586778736,"(4,5]"
4112,8422,citicoline for alcohol dependence,Completed,4,1,1,Alcohol Dependence,drug or biologic,Late,62,All,AllOther,1,0,0,2014,2014,914,1,Phase 4,3,NA,2,4.127134385045092,"(4,5]"
1168,1242,prospective analysis of value of contrast-enhanced sonography during biopsies of focal liver masses,Terminated,5,1,1,Liver Biopsy,drug or biologic,Late,83,All,AllOther,1,1,2,2017,2016,555,1,Phase 4,1,NA,1,4.418840607796598,"(4,5]"
2031,2401,use of a novel diet (uc diet) for treatment of mild to moderate active pediatric ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis (UC),drug or biologic,Late,20,All,AllOther,0,1,0,2015,2015,2283,0,Phase 4,1,NA,1,2.995732273553991,"(2,3]"
2127,2550,efficacy and safety of combination ambrisentan and tadalafil in patients with portopulmonary hypertension,Withdrawn,7,0,0,"Portopulmonary Hypertension|Pulmonary Hypertension|Cirrhosis, Liver",drug or biologic,Late,NA,All,Industry&Combos,0,NA,0,2017,2017,385,0,Phase 4,1,safety/efficacy,1,NA,NA
79,79,pancreatic enzyme supplementation for celiac disease,Terminated,5,1,1,Celiac Disease,drug or biologic,Late,21,All,Industry&Combos,3,0,0,2015,2015,1492,3,Phase 4,2,NA,2,3.044522437723423,"(3,4]"
3393,5076,bezlotoxumab (bezlo) in addition to standard of care (soc) vancomycin for the treatment of multi-recurrent clostridium difficile infection,Recruiting,2,0,0,Clostridium Difficile Infection Recurrence,drug or biologic,Late,12,All,Industry&Combos,0,NA,0,2019,2019,471,0,Phase 4,1,NA,1,2.4849066497880004,"(2,3]"
3654,5805,standard bupivacaine vs liposomal bupivacaine in colorectal patients,Terminated,5,1,1,"Opioid Use|Pain, Postoperative|Colectomy|Colorectal Surgery",drug or biologic,Late,63,All,AllOther,1,0,4,2018,2018,247,1,Phase 4,2,NA,2,4.143134726391533,"(4,5]"
3353,4886,oral vancomycin to prevent recurrent c difficile infection with antibiotics,"Active, not recruiting",1,0,0,Clostridium Difficile Infection,drug or biologic,Late,104,All,AllOther,1,0,1,2018,2018,1073,1,Phase 4,0,NA,0,4.6443908991413725,"(4,5]"
2476,3255,prospective trial of oral vancomycin therapy vs. placebo for prevention of cdi,Withdrawn,7,0,0,CDI,drug or biologic,Late,NA,All,AllOther,1,0,1,2020,2019,76,1,Phase 4,2,NA,2,NA,NA
1510,1638,a comparison of sustained and extended release bupropion following bariatric surgery,Completed,4,0,0,Roux en Y Gastric Bypass,drug or biologic,Late,20,All,AllOther,3,0,NA,2014,2014,245,3,Phase 4,0,NA,0,2.995732273553991,"(2,3]"
3159,4315,study of montelukast on gastrointestinal tolerability in patients with relapsing forms of multiple sclerosis receiving tecfidera,Completed,4,1,1,Multiple Sclerosis,drug or biologic,Late,102,All,Industry&Combos,1,0,0,2015,2015,707,1,Phase 4,3,NA,2,4.624972813284271,"(4,5]"
3242,4551,triple combination therapy in high risk crohn's disease (cd),"Active, not recruiting",1,0,0,Crohn Disease,drug or biologic,Late,55,All,Industry&Combos,0,NA,0,2016,2017,1198,0,Phase 4,1,NA,1,4.007333185232471,"(4,5]"
3763,6506,vedolizumab iv 300 mg in the treatment of fistulizing crohn's disease,Completed,4,1,1,Crohn's Disease,drug or biologic,Late,34,All,Industry&Combos,1,0,0,2015,2016,755,1,Phase 4,4,NA,2,3.5263605246161616,"(3,4]"
2252,2785,use of bismuth subsalicylate in clostridium difficile colitis,Withdrawn,7,0,0,Clostridium Difficile Infection,drug or biologic,Late,NA,All,AllOther,1,0,0,2018,2018,122,1,Phase 4,0,NA,0,NA,NA
1731,1924,naloxegol to prevent lower gastrointestinal paralysis in critically ill adults administered opioids,Terminated,5,0,0,Constipation,drug or biologic,Late,12,All,AllOther,1,0,1,2016,2017,1011,1,Phase 4,4,NA,2,2.4849066497880004,"(2,3]"
2364,3019,botulinum toxin pyloroplasty to reduce postoperative nausea and vomiting after sleeve gastrectomy,Unknown status,8,0,0,Bariatric Surgery|Postoperative Nausea and Vomiting,drug or biologic,Late,104,All,Industry&Combos,1,0,0,2018,2019,450,1,Phase 4,4,NA,2,4.6443908991413725,"(4,5]"
3096,4193,single arm post-marketing study of sc20 colonoscope,Terminated,5,0,0,Gentle Colonoscopy,device,Others,2,All,Industry&Combos,0,NA,4,2014,2014,365,0,Others,1,NA,1,0.6931471805599453,"(0,1]"
3813,6758,does iv ondansetron prevent pruritus after intrathecal morphine in pediatric patients?,Terminated,5,1,1,Pruritus|Nausea/Vomiting,drug or biologic,Late,46,All,AllOther,1,0,1,2017,2017,621,1,Phase 4,4,NA,2,3.828641396489095,"(3,4]"
3991,7550,impact of hepatitis c therapy and bone health,Terminated,5,0,0,Human Immunodeficiency Virus|Hepatitis C,drug or biologic,Late,6,Male,Industry&Combos,1,1,0,2017,2017,455,1,Phase 4,0,NA,0,1.791759469228055,"(1,2]"
898,943,single-dose linaclotide for capsule endoscopy preparation,Completed,4,0,0,Crohn's|Ulcerative Colitis|Gastrointestinal Bleeding,drug or biologic,Late,30,All,AllOther,0,NA,0,2015,2015,486,0,Phase 4,1,NA,1,3.4011973816621555,"(3,4]"
470,486,effect of exenatide in obese patients with accelerated gastric emptying,Completed,4,1,1,Obesity,drug or biologic,Late,20,All,NIH&Combos,1,0,0,2014,2014,273,1,Phase 4,4,NA,2,2.995732273553991,"(2,3]"
1353,1447,an open label single-arm phase 4 study of vedolizumab in subjects with newly diagnosed active ulcerative colitis,Withdrawn,7,0,0,Ulcerative Colitis,drug or biologic,Late,NA,All,NA,0,NA,0,2017,2017,580,0,Phase 4,1,NA,1,NA,NA
532,554,shingrix vaccine in patients with moderate to severe ulcerative colitis on tofacitinib,Recruiting,2,0,0,Inflammatory Bowel Diseases,drug or biologic,Late,100,All,AllOther,1,1,4,2018,2019,854,1,Phase 4,0,NA,0,4.605170185988092,"(4,5]"
1950,2286,comparative efficacy of water & indigo carmine vs. water or air method on adenoma detection rate (adr) - a randomized controlled trial (rct),Completed,4,1,1,Colorectal Neoplasms,drug or biologic,Late,480,All,AllOther,1,0,0,2012,2013,1506,1,Phase 4,1,efficacy,1,6.173786103901937,"(6,7]"
2442,3175,carat: canagliflozin vs. placebo for post bariatric patients with persistent type 2 diabetes,Terminated,5,1,1,"Diabetes Mellitus, Type 2|Obesity",drug or biologic,Late,16,All,Industry&Combos,1,0,0,2016,2017,560,1,Phase 4,3,NA,2,2.772588722239781,"(2,3]"
3994,7555,transplanting hepatitis c positive thoracic organs,Recruiting,2,0,0,Hepatitis C|Awaiting Organ Transplant,drug or biologic,Late,100,All,AllOther,1,1,0,2017,2017,1371,1,Phase 4,0,NA,0,4.605170185988092,"(4,5]"
1260,1345,botox or botox with esophageal dilation in patients with achalasia,Enrolling by invitation,3,0,0,Achalasia,drug or biologic,Late,50,All,AllOther,1,0,0,2018,2019,1480,1,Phase 4,1,NA,1,3.912023005428146,"(3,4]"
100,100,short bowel syndrome and teduglutide versus placebo,Completed,4,1,1,Short Bowel Syndrome,drug or biologic,Late,8,All,AllOther,3,0,0,2014,2014,424,3,Phase 4,4,NA,2,2.0794415416798357,"(2,3]"
4030,7614,pilot treatment as prevention for hcv among persons who actively inject drugs,Completed,4,0,0,Chronic Hepatitis C,other,Others,31,All,NIH&Combos,1,0,0,2015,2015,852,1,Others,0,NA,0,3.4339872044851463,"(3,4]"
4023,7605,effects of ledipasvir/sofosbuvir on the pharmacokinetics and renal safety of tenofovir alafenamide (taf),Completed,4,1,1,Hepatitis C|HIV Coinfection,drug or biologic,Late,10,All,AllOther,0,NA,4,2017,2018,550,0,Phase 4,1,safety,1,2.302585092994046,"(2,3]"
1553,1692,a comparison of eleview versus hetastarch as injectate for emr,Completed,4,1,1,Procedural Bleeding|Delayed Bleeding|Post-Polypectomy Syndrome|Post Procedural Complication,drug or biologic,Late,160,All,AllOther,1,0,0,2017,2017,455,1,Phase 4,1,NA,1,5.075173815233827,"(5,6]"
940,988,an exploratory study on the effects of repeat doses of albiglutide compared to exenatide on gastric myoelectrical activity and gastric emptying in type 2 diabetes mellitus subjects,Terminated,5,1,1,"Diabetes Mellitus, Type 2",drug or biologic,Late,4,All,Industry&Combos,1,0,0,2016,2016,171,1,Phase 4,0,NA,0,1.3862943611198906,"(1,2]"
3924,7312,study to evaluate the safety and efficacy of daclatasvir/sofosbuvir/ribavirin for 16 versus 24 weeks for hcv genotype 3 cirrhotics,Completed,4,1,1,Hepatitis C|Cirrhosis,drug or biologic,Late,39,All,AllOther,1,0,0,2014,2015,943,1,Phase 4,0,safety/efficacy,0,3.6635616461296463,"(3,4]"
3701,6148,acupuncture point p6 stimulation for reduction of nausea and vomiting during cesarean,Completed,4,1,1,Nausea|Vomiting|Satisfaction,drug or biologic,Late,180,Female,AllOther,1,0,1,2016,2015,244,1,Phase 4,0,NA,0,5.19295685089021,"(5,6]"
198,200,effects of gastric acid on colonic microbiome,Completed,4,0,0,Clostridium Difficile,drug or biologic,Late,12,Male,AllOther,0,NA,4,2013,2013,577,0,Phase 4,1,NA,1,2.4849066497880004,"(2,3]"
1444,1553,comparison of volumen and breeza oral contrast agents in pediatric patients,Completed,4,0,0,Inflammatory Bowel Diseases,other,Others,66,All,AllOther,1,0,2,2016,2016,365,1,Others,2,NA,2,4.189654742026425,"(4,5]"
2995,4015,postmarketing vedolizumab milk-only lactation study in lactating women with active ulcerative colitis or crohn's disease,Completed,4,1,1,"Colitis, Ulcerative|Crohn's Disease",drug or biologic,Late,11,Female,Industry&Combos,0,NA,0,2015,2017,450,0,Phase 4,1,NA,1,2.3978952727983707,"(2,3]"
1313,1402,intrathoracic esophagogastric anastomosis after robot assisted minimally invasive esophagectomy using stratafix,Unknown status,8,0,0,Esophageal Cancer,device,Others,30,All,Industry&Combos,0,NA,0,2015,2015,487,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
2349,2982,perioperative intravenous lidocaine infusion for patients undergoing laparoscopic and open pancreatectomies,Completed,4,1,1,Pancreatectomy,drug or biologic,Late,48,All,AllOther,1,0,0,2015,2016,762,1,Phase 4,4,NA,2,3.871201010907891,"(3,4]"
1819,2068,corticosteroid dosage for crohn's disease flare,Terminated,5,1,1,Crohn's Disease|Inflammatory Bowel Disease,drug or biologic,Late,15,All,AllOther,1,0,0,2015,2015,659,1,Phase 4,0,NA,0,2.70805020110221,"(2,3]"
1927,2250,patient satisfaction with propofol for out patient colonoscopy,Completed,4,1,1,Colon Cancer|IBS|Polyps,drug or biologic,Late,600,All,AllOther,1,0,4,2016,2013,851,1,Phase 4,2,NA,2,6.396929655216146,"(6,7]"
1656,1823,steady-state pharmacokinetics of rifaximin 550 mg tablets in healthy and hepatically impaired subjects,Recruiting,2,0,0,Severe Hepatic Impairment,drug or biologic,Late,18,All,Industry&Combos,0,NA,0,2019,2018,1488,0,Phase 4,1,pharmacokinetics only,1,2.8903717578961645,"(2,3]"
3723,6229,ropinirole for the treatment of muscle cramps in patients with cirrhosis,Enrolling by invitation,3,0,0,Muscle Cramp|Cirrhosis,drug or biologic,Late,60,All,AllOther,3,0,4,2017,2016,2098,3,Phase 4,0,NA,0,4.0943445622221,"(4,5]"
1264,1349,quality of life and nutritional improvements in cirrhotic patients,Terminated,5,0,0,Liver Cirrhosis|Hepatic Encephalopathy|Portal Hypertension,drug or biologic,Late,4,All,AllOther,1,0,0,2013,2013,395,1,Phase 4,3,NA,2,1.3862943611198906,"(1,2]"
1789,2018,genetic analysis-guided irinotecan hydrochloride dosing of mfolfirinox in treating patients with locally advanced gastroesophageal or stomach cancer,Recruiting,2,0,0,Esophageal Adenocarcinoma|Gastric Adenocarcinoma|Stage IIB Gastric Cancer|Stage IIIA Esophageal Adenocarcinoma|Stage IIIA Gastric Cancer|Stage IIIB Esophageal Adenocarcinoma|Stage IIIB Gastric Cancer|Stage IIIC Esophageal Adenocarcinoma|Stage IIIC Gastric Cancer,drug or biologic,Late,36,All,NIH&Combos,0,NA,0,2015,2014,3021,0,Phase 4,1,NA,1,3.58351893845611,"(3,4]"
2057,2439,unilateral tap block for laparoscopic gastric sleeve surgery,Recruiting,2,0,0,Laparoscopic Sleeve Gastrectomy|Subcostal Transversus Abdominis Plane Block,drug or biologic,Late,90,All,AllOther,1,0,4,2019,2018,1026,1,Phase 4,3,NA,2,4.499809670330265,"(4,5]"
3902,7239,tox neg trial: clostridium difficile diagnosis and treatment,"Active, not recruiting",1,0,0,Clostridium Difficile Infection|Diarrhea,drug or biologic,Late,80,All,AllOther,1,0,4,2018,2017,1463,1,Phase 4,4,NA,2,4.382026634673881,"(4,5]"
3376,4981,trial of high dose vitamin d in patient's with crohn's disease,Terminated,5,1,1,Crohn's Disease|Vitamin D Deficiency,drug or biologic,Late,11,All,AllOther,0,0,0,2014,2015,366,0,Phase 4,1,NA,1,2.3978952727983707,"(2,3]"
3700,6146,post-operative therapy for nausea or vomiting,Terminated,5,1,1,Vomiting|Nausea,drug or biologic,Late,300,All,AllOther,1,0,0,2017,2016,165,1,Phase 4,0,NA,0,5.703782474656201,"(5,6]"
2396,3085,exparel vs. standard bupivicaine for abdominoplasty,Terminated,5,1,1,"Pain, Postoperative",drug or biologic,Late,4,All,AllOther,1,0,0,2013,2013,426,1,Phase 4,1,NA,1,1.3862943611198906,"(1,2]"
1660,1828,venlafaxine pk following bariatric surgery,Completed,4,0,0,Roux en Y Gastric Bypass|Sleeve Gastrectomy,drug or biologic,Late,12,All,AllOther,3,0,NA,2013,2013,455,3,Phase 4,0,NA,0,2.4849066497880004,"(2,3]"
1286,1373,a longitudinal study to identify ibs phenotypes using fecal microbiota and hydrogen breath testing,Recruiting,2,0,0,Irritable Bowel Syndrome,drug or biologic,Late,64,All,AllOther,1,0,0,2017,2018,1387,1,Phase 4,0,NA,0,4.1588830833596715,"(4,5]"
1144,1215,c. difficile and ursodiol,"Active, not recruiting",1,1,1,Diarrhea,drug or biologic,Late,9,All,AllOther,0,NA,0,2016,2017,975,0,Phase 4,1,NA,1,2.1972245773362196,"(2,3]"
2362,3008,assessing the efficacy of steroid treatment of achalasia,Enrolling by invitation,3,0,0,Achalasia,drug or biologic,Late,10,All,AllOther,0,NA,0,2013,2013,3136,0,Phase 4,1,efficacy,1,2.302585092994046,"(2,3]"
1325,1415,evaluation of health costs and resource utilization,Terminated,5,0,0,Ulcerative Colitis|Crohn's Disease,drug or biologic,Late,51,All,Industry&Combos,1,0,4,2013,2014,395,1,Phase 4,2,NA,2,3.9318256327243257,"(3,4]"
3399,5113,"comparative efficacy of fixed-dose combination sofosbuvir + ledipasvir, 8 vs. 12 weeks in chronic hepatitis c genotype 6",Completed,4,1,1,PT-NANBH,drug or biologic,Late,60,All,Industry&Combos,1,1,0,2015,2015,488,1,Phase 4,0,efficacy,0,4.0943445622221,"(4,5]"
2559,3438,study of oca evaluating pharmacokinetics and safety in patients with pbc and hepatic impairment,"Active, not recruiting",1,0,0,"Liver Cirrhosis, Biliary",drug or biologic,Late,50,All,Industry&Combos,1,0,0,2018,2018,1623,1,Phase 4,4,safety,2,3.912023005428146,"(3,4]"
3321,4740,a pilot study comparing tolerance of oral heme iron polypeptide with oral ionic iron,Withdrawn,7,0,0,Iron Deficiency,drug or biologic,Late,NA,All,AllOther,3,0,0,2013,2016,121,3,Phase 4,0,NA,0,NA,NA
2896,3884,easy: extended access to sollpura over years,Completed,4,1,1,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,drug or biologic,Late,25,All,Industry&Combos,0,NA,0,2016,2016,546,0,Phase 4,1,NA,1,3.2188758248682006,"(3,4]"
3831,6848,hepatitis c virus(hcv) heart and lung study,Completed,4,1,1,"Hepatitis C, Chronic|Heart Failure|Pulmonary Disease, Chronic Obstructive|Lung Diseases, Interstitial",drug or biologic,Late,15,All,Industry&Combos,1,1,0,2016,2016,861,1,Phase 4,0,NA,0,2.70805020110221,"(2,3]"
826,865,prunes for gastrointestinal function after gynecologic surgery,Terminated,5,1,1,Constipation,drug or biologic,Late,77,Female,AllOther,1,0,1,2018,2017,943,1,Phase 4,0,NA,0,4.343805421853684,"(4,5]"
667,695,folic acid in pediatric inflammatory bowel disease,Unknown status,8,0,0,Inflammatory Bowel Diseases,drug or biologic,Late,100,All,AllOther,0,NA,0,2019,2018,476,0,Phase 4,1,NA,1,4.605170185988092,"(4,5]"
3646,5777,dysphagia following anterior cervical spine surgery; single dose steroid vs saline (dysdexvssal),Recruiting,2,0,0,Dysphagia,drug or biologic,Late,80,All,AllOther,1,0,1,2018,2018,1424,1,Phase 4,2,NA,2,4.382026634673881,"(4,5]"
1367,1462,conversion from mpa to zortress (everolimus) for gi toxicity post-renal transplantation,Terminated,5,1,1,"Kidney Transplant Rejection|Gastrointestinal Disorder, Functional",drug or biologic,Late,1,All,Industry&Combos,1,1,0,2016,2016,1034,1,Phase 4,0,NA,0,0,NA
688,719,evaluation of intravenous and intraperitoneal pharmacokinetics of dalbavancin in peritoneal dialysis patients,Completed,4,1,1,Infectious Peritonitis,drug or biologic,Late,10,All,AllOther,3,1,4,2016,2017,413,3,Phase 4,0,pharmacokinetics only,0,2.302585092994046,"(2,3]"
2952,3958,the safety/efficacy of rifaximin with/without lactulose in participants with a history of recurrent hepatic encephalopathy,Completed,4,1,1,Hepatic Encephalopathy|Cirrhosis,drug or biologic,Late,222,All,Industry&Combos,1,0,0,2013,2013,708,1,Phase 4,0,safety/efficacy,0,5.402677381872279,"(5,6]"
4017,7593,"hcv seek, test and rapid treatment for young pwid",Recruiting,2,0,0,Hepatitis C|Drug Use,drug or biologic,Late,72,All,Industry&Combos,1,0,0,2018,2018,1391,1,Phase 4,0,NA,0,4.276666119016055,"(4,5]"
4003,7564,determine the efficacy and safety of harvoni in genotype 1 chronic hepatitis c infected people who are alcoholics,"Active, not recruiting",1,0,0,Genotype 1 Hepatitis C Virus,drug or biologic,Late,30,All,AllOther,0,NA,0,2016,2016,1461,0,Phase 4,1,safety/efficacy,1,3.4011973816621555,"(3,4]"
3995,7556,curing hcv in incarcerated patients,Unknown status,8,0,0,"Hepatitis C, Chronic",drug or biologic,Late,100,All,Industry&Combos,0,NA,0,2017,2017,364,0,Phase 4,1,NA,1,4.605170185988092,"(4,5]"
1157,1230,intraductal secretin stimulation test: what is the proper collection time?,Recruiting,2,0,0,"Cholangiopancreatography, Endoscopic Retrograde",drug or biologic,Late,36,All,AllOther,0,NA,2,2017,2017,1826,0,Phase 4,1,NA,1,3.58351893845611,"(3,4]"
1467,1581,ketamine vs hydromorphone,Completed,4,1,1,"Laparoscopic Gastric Bypass|Obesity|Pain, Postoperative",drug or biologic,Late,54,All,AllOther,1,0,4,2016,2017,667,1,Phase 4,1,NA,1,3.9889840465642745,"(3,4]"
1382,1482,ketamine and propofol combination versus propofol for upper gastrointestinal endoscopy,Terminated,5,1,1,Obesity|Bariatrics|Sleep Apnea Syndromes|Gastric Bypass|Endoscopy,drug or biologic,Late,22,All,AllOther,1,0,4,2015,2016,1100,1,Phase 4,2,NA,2,3.091042453358316,"(3,4]"
1959,2303,radial reload laparoscopic lar case series,Terminated,5,1,1,Colorectal Cancer,device,Others,8,All,Industry&Combos,0,NA,0,2012,2013,214,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
2613,3512,the caliber study randomized controlled trial of linx versus double-dose proton pump inhibitor therapy for reflux disease,Completed,4,1,1,GERD Gastroesophageal Reflux Disease,drug or biologic,Late,152,All,Industry&Combos,3,0,0,2015,2015,853,3,Phase 4,0,NA,0,5.0238805208462765,"(5,6]"
3838,6900,study of oral treatments for hepatitis c,Completed,4,1,1,Chronic Hepatitis C,drug or biologic,Late,1275,All,Industry&Combos,1,0,0,2016,2016,1107,1,Phase 4,0,NA,0,7.150701457592526,"(7,13]"
2867,3844,"efficacy, safety, and pharmacokinetics of rifaximin in subjects with severe hepatic impairment and hepatic encephalopathy",Recruiting,2,0,0,Hepatic Encephalopathy,drug or biologic,Late,100,All,Industry&Combos,1,0,0,2013,2013,3346,1,Phase 4,4,safety/efficacy,2,4.605170185988092,"(4,5]"
3989,7548,a pilot study of treating hcv at a psychiatrist-staffed outpatient addiction clinic,Completed,4,1,1,"Hepatitis C, Chronic|Hepatitis C|Opiate Dependence",drug or biologic,Late,11,All,Industry&Combos,0,NA,0,2017,2017,715,0,Phase 4,1,NA,1,2.3978952727983707,"(2,3]"
2404,3099,"safety, tolerability, and efficacy of 24 weeks simeprevir+sofosbuvir for chronic hepatitis c genotype 1",Withdrawn,7,0,0,PT-NANBH,drug or biologic,Late,NA,All,Industry&Combos,0,NA,0,2015,2015,122,0,Phase 4,1,safety/efficacy,1,NA,NA
2225,2739,apixaban pharmacokinetics in bariatric patients (apb),Completed,4,1,1,Bariatric Surgery|Obesity,drug or biologic,Late,33,All,AllOther,0,1,4,2015,2017,927,0,Phase 4,1,pharmacokinetics only,1,3.4965075614664802,"(3,4]"
3773,6531,minimizing nausea and vomiting during spinals for cs,Terminated,5,1,1,Nausea|Vomiting,drug or biologic,Late,22,Female,AllOther,1,0,0,2016,2015,565,1,Phase 4,4,NA,2,3.091042453358316,"(3,4]"
4032,7618,effects of persistent innate immune activation on vaccine efficacy,Terminated,5,1,1,Hepatitis C Infection,drug or biologic,Late,24,All,NIH&Combos,1,1,4,2015,2015,1273,1,Phase 4,0,efficacy,0,3.1780538303479458,"(3,4]"
2365,3020,early diuresis following colorectal surgery,Completed,4,1,1,Colorectal Disorders,drug or biologic,Late,123,All,AllOther,1,0,0,2015,2015,425,1,Phase 4,0,NA,0,4.812184355372417,"(4,5]"
544,566,prophylactic octreotide to prevent post duodenal emr and ampullectomy bleeding,Terminated,5,0,0,Adenoma,drug or biologic,Late,33,All,AllOther,0,0,1,2014,2014,1580,0,Phase 4,1,NA,1,3.4965075614664802,"(3,4]"
1600,1751,pilot study to investigate the association between acid control and heartburn symptoms after proton pump inhibitor treatment,Completed,4,1,1,Heartburn,drug or biologic,Late,55,All,Industry&Combos,1,0,4,2016,2016,91,1,Phase 4,4,NA,2,4.007333185232471,"(4,5]"
3812,6756,effects of ondansetron dose and timing on post-operative nausea and vomiting,Completed,4,1,1,Post-operative Nausea and Vomiting,drug or biologic,Late,141,All,AllOther,2,0,1,2017,2017,529,1,Phase 4,3,NA,2,4.948759890378168,"(4,5]"
601,627,a prospective evaluation of the strattice-lift to treat anal fistula,Unknown status,8,0,0,Anal Fistula|Rectal Fistula|Fistula in Ano|Transsphincteric Fistula,device,Others,15,All,AllOther,0,NA,0,2015,2015,672,0,Others,1,NA,1,2.70805020110221,"(2,3]"
3418,5173,oral vancomycin for secondary prophylaxis of clostridium difficile infection (cdi),Unknown status,8,0,0,Clostridium Difficile Infection|Clostridium Difficile Infection Recurrence,drug or biologic,Late,130,All,AllOther,1,0,1,2019,2019,303,1,Phase 4,4,NA,2,4.867534450455582,"(4,5]"
381,391,oral cromolyn sodium for the treatment of eosinophilic esophagitis,Completed,4,0,0,Eosinophilic Esophagitis,drug or biologic,Late,16,All,AllOther,1,0,0,2015,2014,943,1,Phase 4,3,NA,2,2.772588722239781,"(2,3]"
1922,2241,intraoperative tap block with bupivacaine/dexamethasone against liposomal bupivacaine (exparel Â®),Completed,4,1,1,"Pain, Postoperative|Crohn Disease|Inflammatory Bowel Diseases|Colorectal Cancer|Gastrointestinal Cancer|Gastrointestinal Disease|Digestive System Disease|Pain|Pain, Neuropathic|Intestinal Disease",drug or biologic,Late,102,All,AllOther,1,0,0,2018,2018,371,1,Phase 4,0,NA,0,4.624972813284271,"(4,5]"
907,953,evaluation of gallbladder contractility using both cck and milk consecutively,Completed,4,1,1,Abdominal Pain,drug or biologic,Late,50,All,AllOther,0,NA,2,2016,2016,772,0,Phase 4,1,NA,1,3.912023005428146,"(3,4]"
677,708,budesonide versus fluticasone for treatment of eosinophilic esophagitis,Completed,4,1,1,Eosinophilic Esophagitis,drug or biologic,Late,129,All,NIH&Combos,1,0,0,2013,2015,1216,1,Phase 4,2,NA,2,4.859812404361672,"(4,5]"
1190,1267,evaluation of glycerin suppositories to improve bowel function in gastroschisis,Terminated,5,0,0,Gastroschisis,drug or biologic,Late,16,All,AllOther,1,0,0,2017,2017,1096,1,Phase 4,1,NA,1,2.772588722239781,"(2,3]"
1128,1198,treating disrupted sleep in individuals with inflammatory bowel disease,Completed,4,1,1,Sleep Disturbance|Fatigue|Inflammatory Bowel Disease,drug or biologic,Late,99,All,AllOther,2,1,0,2014,2013,1095,1,Phase 4,0,NA,0,4.59511985013459,"(4,5]"
3400,5115,a study to evaluate the efficacy and safety of vedolizumab in the treatment of chronic pouchitis,Completed,4,1,1,Pouchitis,drug or biologic,Late,102,All,Industry&Combos,1,0,0,2016,2016,1338,1,Phase 4,4,safety/efficacy,2,4.624972813284271,"(4,5]"
2095,2501,pain control in colorectal surgery: liposomal bupivacaine block versus intravenous lidociane,Unknown status,8,0,0,Colorectal Disorders,drug or biologic,Late,70,All,AllOther,1,0,0,2019,2018,730,1,Phase 4,1,NA,1,4.248495242049359,"(4,5]"
1659,1827,multimodal narcotic limited perioperative pain control with colorectal surgery,Unknown status,8,0,0,"Colon Cancer|Colon Diverticulosis|Colonic Neoplasms|Colonic Diverticulitis|Pain, Postoperative|Ileus|Ileus Paralytic|Ileus; Mechanical|Constipation Drug Induced|Constipation|Rectum Cancer|Rectum Neoplasm",drug or biologic,Late,80,All,AllOther,1,0,4,2016,2017,334,1,Phase 4,0,NA,0,4.382026634673881,"(4,5]"
3690,6097,cimzia versus mesalamine for crohn's recurrence,Terminated,5,1,1,Crohn's Disease,drug or biologic,Late,10,All,Industry&Combos,1,0,0,2012,2013,1216,1,Phase 4,0,NA,0,2.302585092994046,"(2,3]"
3997,7558,hcv treatment immune response with grazoprevir/elbasvir before or after renal transplant,Recruiting,2,0,0,"Hepatitis C|Renal Insufficiency, Chronic|Disorder of Transplanted Kidney",drug or biologic,Late,25,All,AllOther,0,NA,0,2016,2017,1187,0,Phase 4,1,NA,1,3.2188758248682006,"(3,4]"
2504,3322,viekira pak or mavyret treatment for patient with chronic kidney disease and hepatitis c,"Active, not recruiting",1,0,0,Chronic Kidney Disease|Chronic Hepatitis C,drug or biologic,Late,24,All,Industry&Combos,0,1,0,2016,2017,1611,0,Phase 4,1,NA,1,3.1780538303479458,"(3,4]"
291,296,ability of mayo clinic high-performance liquid chromatography (hplc) method to measure fecal bile acids,Completed,4,1,1,Diarrhea Predominant Irritable Bowel Syndrome,drug or biologic,Late,13,All,NIH&Combos,0,NA,0,2014,2014,122,0,Phase 4,1,NA,1,2.5649493574615367,"(2,3]"
1973,2323,ramelteon for treatment of insomnia in cirrhosis,Completed,4,1,1,Cirrhosis,drug or biologic,Late,10,All,NIH&Combos,0,NA,0,2017,2017,607,0,Phase 4,1,NA,1,2.302585092994046,"(2,3]"
852,893,clinical efficacy and safety of using 3.0mg liraglutide to treat weight regain after roux-en-y gastric bypass surgery,"Active, not recruiting",1,0,0,Obesity,drug or biologic,Late,132,All,Industry&Combos,1,0,0,2017,2017,1379,1,Phase 4,2,safety/efficacy,2,4.882801922586371,"(4,5]"
3308,4703,direct acting antiviral therapy in donor hcv-positive to recipient hcv-negative kidney transplant,Withdrawn,7,0,0,Kidney Failure|Kidney Diseases|Hepatitis C,drug or biologic,Late,NA,All,AllOther,0,NA,1,2018,2019,685,0,Phase 4,1,NA,1,NA,NA
2857,3831,"an open-label, long-term study to assess the immunogenicity of linzess Â® (linaclotide) administered orally to adult participants with irritable bowel syndrome with constipation or chronic idiopathic constipation",Completed,4,1,1,Irritable Bowel Syndrome With Constipation|Chronic Idiopathic Constipation,drug or biologic,Late,828,All,Industry&Combos,1,0,0,2015,2015,827,1,Phase 4,0,NA,0,6.71901315438526,"(6,7]"
4001,7562,exploring renal transplants using hepatitis c infected donors for hcv-negative recipients,Completed,4,1,1,End-Stage Renal Disease|Hepatitis C,drug or biologic,Late,10,All,Industry&Combos,1,1,0,2016,2016,287,1,Phase 4,0,NA,0,2.302585092994046,"(2,3]"
1896,2200,effect of obesity on proton pump inhibitors,Recruiting,2,0,0,Pediatric Obesity|NAFLD|GERD,drug or biologic,Late,150,All,AllOther,2,1,0,2020,2018,2373,1,Phase 4,0,NA,0,5.0106352940962555,"(5,6]"
4170,9152,efficacy and safety of sofosbuvir+ribavirin in genotype 2 hcv-infected u.s. veterans with cirrhosis,Completed,4,1,1,Hepatitis C Virus Infection,drug or biologic,Late,66,All,Industry&Combos,0,NA,0,2014,2014,365,0,Phase 4,1,safety/efficacy,1,4.189654742026425,"(4,5]"
371,379,gastric acid suppression and probiotic colonization,Completed,4,1,1,Probiotics,drug or biologic,Late,39,All,AllOther,1,0,4,2017,2018,285,1,Phase 4,4,NA,2,3.6635616461296463,"(3,4]"
2185,2652,budesonide in patients with immune mediated enteropathies,Recruiting,2,0,0,Enteropathy|Celiac Disease|CVID Enteropathy|Collagenous Sprue|Autoimmune Enteropathy,drug or biologic,Late,20,All,AllOther,1,0,0,2019,2019,722,1,Phase 4,0,NA,0,2.995732273553991,"(2,3]"
1508,1636,stress ulcer prophylaxis versus placebo in critically ill infants with congenital heart disease,Recruiting,2,0,0,Congenital Heart Disease|Upper Gastrointestinal Bleeding|Stress Ulcer|Infection,drug or biologic,Late,100,All,AllOther,1,0,4,2018,2019,843,1,Phase 4,4,NA,2,4.605170185988092,"(4,5]"
3709,6186,the efficacy of stabilized chlorine dioxide rinse as a chemical adjuvant for treatment of per-implant mucositis,Completed,4,0,0,Peri-implant Mucositis,drug or biologic,Late,54,All,Industry&Combos,1,0,0,2021,2018,671,1,Phase 4,3,efficacy,2,3.9889840465642745,"(3,4]"
2055,2435,potential mechanisms for intussusception after rotavirus vaccine-pilot study,Completed,4,1,1,Intussusception|Rotavirus Infections,drug or biologic,Late,144,All,AllOther,1,0,4,2015,2015,547,1,Phase 4,2,NA,2,4.969813299576001,"(4,5]"
3817,6777,isopropyl alcohol vs ondansetron for nausea in the emergency department,Completed,4,1,1,Nausea,drug or biologic,Late,122,All,AllOther,1,0,0,2016,2016,670,1,Phase 4,3,NA,2,4.804021044733257,"(4,5]"
3357,4897,harmonic ace Â®+7 shears in laparoscopic colectomy,Completed,4,1,1,Benign or Malignant Disease Indicated for Colectomy,device,Others,40,All,Industry&Combos,0,NA,0,2014,2014,184,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
437,449,does a preoperative bowel regimen change time to first bowel movement after robotic sacral colpopexy,Recruiting,2,0,0,Constipation|Post-Op Complication,drug or biologic,Late,100,Female,AllOther,1,0,0,2019,2019,731,1,Phase 4,0,NA,0,4.605170185988092,"(4,5]"
1707,1891,effects of crofelemer on the gut microbiome in healthy volunteers and in hiv+ patients with non-infectious diarrhea,Recruiting,2,0,0,Acquired Immunodeficiency Syndrome|Healthy Volunteers|HIV/AIDS|HIV Diarrhea|Human Immunodeficiency Virus,drug or biologic,Late,24,All,Industry&Combos,1,1,0,2019,2019,162,1,Phase 4,0,NA,0,3.1780538303479458,"(3,4]"
2695,3614,efficacy of eluxadoline in the treatment of irritable bowel syndrome with diarrhea in patients with inadequate control of symptoms with prior loperamide use,Completed,4,1,1,Irritable Bowel Syndrome With Diarrhea,drug or biologic,Late,346,All,Industry&Combos,1,0,0,2016,2016,454,1,Phase 4,4,efficacy,2,5.846438775057725,"(5,6]"
856,897,probiotics to promote intestinal health,Completed,4,0,0,Communicable Diseases|Infection|Anti-Infective Agents|Therapeutic Uses|Pharmacologic Actions,other,Others,87,All,AllOther,1,0,1,2014,2014,638,1,Others,4,NA,2,4.465908118654584,"(4,5]"
1306,1395,postpartum perineal pain after obstetric anal sphincter injuries,Recruiting,2,0,0,Pain|Postpartum Depression,drug or biologic,Late,160,Female,AllOther,1,0,1,2018,2018,1648,1,Phase 4,3,NA,2,5.075173815233827,"(5,6]"
2341,2967,effect iv ibuprofen and inflammatory responses,Completed,4,1,1,Gallbladder Disease,drug or biologic,Late,60,All,AllOther,1,0,0,2013,2013,457,1,Phase 4,3,NA,2,4.0943445622221,"(4,5]"
1810,2045,smoflipid in patients who are intralipid intolerant,Withdrawn,7,0,0,Home Parenteral Nutrition|Short Bowel Syndrome,drug or biologic,Late,NA,All,AllOther,1,0,0,2017,2017,412,1,Phase 4,1,NA,1,NA,NA
3975,7528,the kentucky viral hepatitis treatment study,Recruiting,2,0,0,Hepatitis C|Opioid-Related Disorders|Injection Drug Use,drug or biologic,Late,900,All,IndustryNIHPartnership,0,1,0,2019,2019,1073,0,Phase 4,1,NA,1,6.802394763324311,"(6,7]"
900,945,evaluation of the dpp-4 inhibitor sitagliptin in the treatment of non-alcoholic fatty liver disease using mri,Withdrawn,7,0,0,Type 2 Diabetes|Non-alcoholic Fatty Liver Disease,drug or biologic,Late,NA,All,AllOther,0,NA,0,2014,2014,640,0,Phase 4,1,NA,1,NA,NA
2468,3239,"pharmacokinetic,safety and exploratory efficacy of rectiv Â® in adolescents with chronic anal fissure",Withdrawn,7,0,0,Anal Fissure,drug or biologic,Late,NA,All,Industry&Combos,0,NA,0,2013,2013,638,0,Phase 4,1,safety/efficacy,1,NA,NA
2069,2462,efficacy of linaclotide in type ii diabetics with chronic constipation,"Active, not recruiting",1,0,0,Chronic Constipation|Diabete Mellitus,drug or biologic,Late,23,All,AllOther,3,0,0,2017,2015,2251,3,Phase 4,2,efficacy,2,3.1354942159291497,"(3,4]"
263,267,chronotherapy in inflammatory bowel disease,Recruiting,2,0,0,Inflammatory Bowel Diseases,drug or biologic,Late,128,All,AllOther,1,0,0,2020,2016,1802,1,Phase 4,0,NA,0,4.852030263919617,"(4,5]"
2247,2772,hepatitis c treatment in pwids: mat or syringe exchange assisted-therapy vs standard of care,Completed,4,1,1,"Hepatitis C|Substance Use Disorders|Substance Abuse, Intravenous",drug or biologic,Late,100,All,AllOther,1,1,0,2017,2017,737,1,Phase 4,0,NA,0,4.605170185988092,"(4,5]"
806,843,a research study to bank samples for future evaluation to identify biomarkers that predispose crohn's disease and ulcerative colitis patients to develop hepatosplenic t-cell lymphoma (hstcl),Completed,4,1,1,Hepatosplenic T-Cell Lymphoma,drug or biologic,Late,1,All,Industry&Combos,0,NA,4,2013,2013,2535,0,Phase 4,1,NA,1,0,NA
4044,7652,cardiovascular disease in hiv and hepatitis c: risk outcomes after hepatitis c eradication,Recruiting,2,0,0,Cardiovascular Diseases|Hepatitis C|Hiv,drug or biologic,Late,90,All,IndustryNIHPartnership,1,1,4,2019,2018,956,1,Phase 4,0,NA,0,4.499809670330265,"(4,5]"
196,198,eluxadoline bile acid malabsorption (bam) study,Completed,4,1,1,Irritable Bowel Syndrome With Diarrhea,drug or biologic,Late,24,All,Industry&Combos,1,1,0,2018,2018,795,1,Phase 4,0,NA,0,3.1780538303479458,"(3,4]"
1368,1463,glucagon use in colonoscopies,Completed,4,1,1,Colon Cancer,drug or biologic,Late,100,All,AllOther,1,0,2,2014,2014,1491,1,Phase 4,2,NA,2,4.605170185988092,"(4,5]"
931,978,rtpa in in the prevention of cvad-associated thrombosis and infection in pediatric patients with short bowel syndrome,Completed,4,1,1,Short Bowel Syndrome,drug or biologic,Late,8,All,AllOther,0,NA,1,2015,2015,580,0,Phase 4,1,NA,1,2.0794415416798357,"(2,3]"
1502,1628,cvd 37000: immunity and microbiome studies at intestinal and systemic sites in ty21a vaccinated adults,Recruiting,2,0,0,Typhoid Vaccination,drug or biologic,Late,260,All,AllOther,1,1,4,2019,2013,3902,1,Phase 4,0,NA,0,5.560681631015528,"(5,6]"
984,1038,noninvasive subharmonic aided pressure estimation of portal hypertension,Completed,4,0,0,Liver Diseases|Portal Hypertension,drug or biologic,Late,178,All,NIH&Combos,0,NA,2,2015,2015,1455,0,Phase 4,1,NA,1,5.181783550292085,"(5,6]"
3312,4715,daa treatment in donor hcv-positive to recipient hcv-negative heart transplant,Terminated,5,0,0,End Stage Heart Disease|Hepatitis C,drug or biologic,Late,40,All,AllOther,0,NA,1,2017,2017,1243,0,Phase 4,1,NA,1,3.6888794541139363,"(3,4]"
1443,1552,implementation of ppi medication pgx testing,Completed,4,1,1,Gastroesophageal Reflux,drug or biologic,Late,28,All,AllOther,0,NA,0,2016,2016,186,0,Phase 4,1,NA,1,3.332204510175204,"(3,4]"
3307,4702,pan-genotypic direct acting antiviral therapy in donor hcv-positive to recipient hcv-negative lung transplant,Enrolling by invitation,3,0,0,Respiratory Failure|Hepatitis C,drug or biologic,Late,25,All,AllOther,0,NA,1,2018,2019,1060,0,Phase 4,1,NA,1,3.2188758248682006,"(3,4]"
3386,5031,efficacy of pharmacotherapy to enhance weight loss following sleeve gastrectomy,Suspended,6,0,0,Obesity,drug or biologic,Late,110,All,AllOther,1,0,0,2018,2019,976,1,Phase 4,0,efficacy,0,4.700480365792417,"(4,5]"
1821,2072,methylnaltrexone use for opioid-induced postoperative constipation,Completed,4,0,0,Constipation,drug or biologic,Late,60,All,AllOther,1,0,0,2013,2013,730,1,Phase 4,0,NA,0,4.0943445622221,"(4,5]"
425,437,trial of high dose vs. standard dose influenza vaccine in inflammatory bowel disease patients,Completed,4,1,1,Inflammatory Bowel Disease (IBD),drug or biologic,Late,81,All,AllOther,1,0,1,2015,2016,608,1,Phase 4,4,NA,2,4.394449154672439,"(4,5]"
1447,1556,a within subjects comparison of two antegrade flushing regimens in children,Completed,4,1,1,Fecal Incontinence|Neurogenic Bowel,drug or biologic,Late,5,All,AllOther,3,0,4,2015,2016,413,3,Phase 4,0,NA,0,1.6094379124341003,"(1,2]"
829,868,fatty liver study in patients with type ii diabetes,Terminated,5,1,1,Type II Diabetes|Nonalcoholic Fatty Liver,drug or biologic,Late,5,All,AllOther,1,0,0,2015,2013,1340,1,Phase 4,0,NA,0,1.6094379124341003,"(1,2]"
3300,4682,immunologic effects of hcv therapy with harvoni in hcv genotype 1 chronically mono-infected active and former idus,Completed,4,1,1,Hepatitis C,drug or biologic,Late,34,All,NIH&Combos,1,1,0,2015,2016,0,1,Phase 4,0,NA,0,3.5263605246161616,"(3,4]"
4045,7653,b/f/taf switch study for hiv-hbv coinfection,Recruiting,2,0,0,HIV-1-infection|Hepatitis B,drug or biologic,Late,60,All,Industry&Combos,0,NA,0,2019,2019,977,0,Phase 4,1,NA,1,4.0943445622221,"(4,5]"
3510,5335,enhanced algorithm for crohn's treatment incorporating early combination therapy,Completed,4,0,0,Crohn's Disease,other,Others,1095,All,AllOther,1,0,0,2012,2014,2211,1,Others,0,NA,0,6.9985096422506015,"(6,7]"
3350,4875,to evaluate patient preference of movantik and polyethylene glycol 3350 for opioid induced constipation,Completed,4,1,1,Opioid Induced Constipation,drug or biologic,Late,276,All,Industry&Combos,3,0,0,2017,2017,174,3,Phase 4,0,NA,0,5.62040086571715,"(5,6]"
3712,6205,impact of oral hygiene gels on peri-implant mucositis,Completed,4,0,0,Mucositis,other,Others,21,All,AllOther,1,0,0,2017,2017,205,1,Others,3,NA,2,3.044522437723423,"(3,4]"
1050,1105,a study evaluating the effect of albiglutide on gallbladder emptying in healthy subjects,Completed,4,1,1,"Diabetes Mellitus, Type 2",drug or biologic,Late,20,All,Industry&Combos,3,0,0,2015,2015,124,3,Phase 4,4,NA,2,2.995732273553991,"(2,3]"
2230,2745,corticosteroids with vedolizumab in crohn's disease,Terminated,5,1,1,Crohn's Disease,drug or biologic,Late,1,All,Industry&Combos,1,0,0,2014,2016,678,1,Phase 4,4,NA,2,0,NA
2096,2503,study to investigate prucalopride vs. polyethylene glycol 3350 on colon activity,Completed,4,1,1,Chronic Constipation,drug or biologic,Late,13,All,Industry&Combos,3,0,0,2012,2013,273,3,Phase 4,0,NA,0,2.5649493574615367,"(2,3]"
3811,6754,pharmacogenomics and post-operative nausea and vomiting,Completed,4,1,1,Postoperative Nausea,drug or biologic,Late,92,All,AllOther,1,1,0,2018,2018,607,1,Phase 4,0,NA,0,4.5217885770490405,"(4,5]"
2197,2677,prospective study assessing patient satisfaction of symptom control with proton pump inhibitor dosing regimen,Unknown status,8,0,0,Heartburn,drug or biologic,Late,150,All,AllOther,1,0,0,2015,2014,700,1,Phase 4,0,NA,0,5.0106352940962555,"(5,6]"
2778,3731,study of a prebiotic supplement to mitigate excessive weight gain among physicians in residency,Completed,4,0,0,Weight Gain Trajectory|Metabolic Syndrome,other,Others,11,All,AllOther,1,0,1,2020,2018,137,1,Others,1,NA,1,2.3978952727983707,"(2,3]"
3647,5781,comparison of voice therapy and antireflex therapy in lpr,Withdrawn,7,0,0,Laryngopharyngeal Reflux,drug or biologic,Late,NA,All,AllOther,2,0,0,2015,2016,457,1,Phase 4,0,NA,0,NA,NA
1632,1794,spironolactone after liver transplant,Completed,4,1,1,"Transplant, Liver",drug or biologic,Late,30,All,AllOther,1,0,0,2016,2014,1127,1,Phase 4,0,NA,0,3.4011973816621555,"(3,4]"
3177,4369,sofosbuvir based daa therapy in hiv/hcv coinfected pre or post liver transplant,Completed,4,1,1,HIV|Hepatitis C|Cirrhosis,drug or biologic,Late,68,All,NIH&Combos,0,NA,0,2015,2016,1247,0,Phase 4,1,NA,1,4.219507705176107,"(4,5]"
2489,3282,efficacy and safety of vibrant capsule vs. vibrant placebo for the treatment of chronic idiopathic constipation (cic),Completed,4,0,0,Chronic Idiopathic Constipation,drug or biologic,Late,59,All,Industry&Combos,1,0,4,2020,2018,165,1,Phase 4,1,safety/efficacy,1,4.07753744390572,"(4,5]"
1302,1391,impact of everolimus on hiv persistence post kidney or liver transplant,Completed,4,1,1,HIV|Kidney Transplant|Liver Transplant,drug or biologic,Late,10,All,Industry&Combos,0,NA,4,2015,2016,707,0,Phase 4,1,NA,1,2.302585092994046,"(2,3]"
633,660,immunogenicity of herpes zoster subunit vaccine in inflammatory bowel disease patients treated with vedolizumab,Recruiting,2,0,0,Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Herpes Zoster,drug or biologic,Late,30,All,AllOther,1,1,4,2019,2019,1069,1,Phase 4,0,NA,0,3.4011973816621555,"(3,4]"
821,860,effect of simethicone on screening colonoscopy,Completed,4,1,1,Adenoma Colon,drug or biologic,Late,268,All,AllOther,1,0,4,2017,2017,756,1,Phase 4,2,NA,2,5.5909869805108565,"(5,6]"
1421,1529,iv acetaminophen for post-operative pain management in enhanced recovery after surgery (eras) population,Completed,4,1,1,Abdominal Wall Hernia|Pancreatic Diseases|Bowel Disease|Gastric Disease,drug or biologic,Late,180,All,Industry&Combos,1,0,0,2017,2018,409,1,Phase 4,4,NA,2,5.19295685089021,"(5,6]"
1578,1724,yield of diagnostic tests and effects of crofelemer for chronic idiopathic diarrhea in non-hiv patients,Recruiting,2,0,0,Chronic Diarrhea of Unknown Origin,drug or biologic,Late,100,All,Industry&Combos,0,NA,0,2019,2019,1096,0,Phase 4,1,NA,1,4.605170185988092,"(4,5]"
3980,7536,renal transplants in hepatitis c negative recipients with nucleic acid positive donors,Completed,4,1,1,End Stage Renal Disease|Hepatitis C,drug or biologic,Late,11,All,AllOther,0,NA,0,2018,2018,450,0,Phase 4,1,NA,1,2.3978952727983707,"(2,3]"
3358,4900,vancomycin prophylaxis in recurrent clostridium difficile infection,Unknown status,8,0,0,Clostridium Difficile Infection,drug or biologic,Late,140,All,AllOther,0,NA,1,2014,2014,731,0,Phase 4,1,NA,1,4.941642422609304,"(4,5]"
274,278,comparative effectiveness of split-dose colonoscopy bowel preparation regimens,Recruiting,2,0,0,Colorectal Cancer,drug or biologic,Late,10000,All,AllOther,1,0,4,2017,2018,1022,1,Phase 4,1,NA,1,9.210340371976184,"(7,13]"
510,531,prospective randomized controlled trial of an enhanced recovery protocol for anorectal surgery,Recruiting,2,0,0,Anorectal Disorder,other,Others,88,All,AllOther,1,0,0,2018,2018,948,1,Others,1,NA,1,4.477336814478207,"(4,5]"
142,142,effect of octreotide on the colonic motility in pediatric patients,Completed,4,1,1,Colonic Motility Index|Constipation,drug or biologic,Late,13,All,AllOther,0,NA,4,2013,2013,304,0,Phase 4,1,NA,1,2.5649493574615367,"(2,3]"
3287,4645,hcv post-exposure prophylaxis for health care workers,Withdrawn,7,0,0,Hepatitis C,drug or biologic,Late,NA,All,Industry&Combos,0,NA,1,2017,2019,141,0,Phase 4,1,NA,1,NA,NA
939,987,bowel function after minimally invasive hysterectomy,Recruiting,2,0,0,Constipation,drug or biologic,Late,101,Female,AllOther,1,0,1,2020,2019,672,1,Phase 4,0,NA,0,4.61512051684126,"(4,5]"
3983,7541,administration of zepatier (grazoprevir plus elbasvir) in chronic hemodialysis (hd) patients with hepatitis c,Completed,4,0,0,Hepatitis C|Hemodialysis|Nosocomial Infection,drug or biologic,Late,6,All,Industry&Combos,0,1,0,2017,2019,222,0,Phase 4,1,NA,1,1.791759469228055,"(1,2]"
1624,1781,fecal microbiota transplant,Enrolling by invitation,3,0,0,Clostridium Difficile Infection,procedure,Others,50,All,AllOther,0,NA,0,2019,2018,2188,0,Others,1,NA,1,3.912023005428146,"(3,4]"
1261,1346,preoperative pain control in gastric bypass surgery patients,Completed,4,0,0,Post-operative Pain,drug or biologic,Late,80,All,AllOther,0,0,0,2013,2013,1033,0,Phase 4,1,NA,1,4.382026634673881,"(4,5]"
3985,7543,"anti-hepatitis a virus, pharmacokinetics, and safety of immune globulin (human)",Completed,4,1,1,Anti-Hepatitis A Antibody Levels in Heathy Subjects,drug or biologic,Late,28,All,Industry&Combos,0,NA,1,2017,2017,178,0,Phase 4,1,safety,1,3.332204510175204,"(3,4]"
1271,1357,efficacy of exparel (tm) on post-operative pain after laparoscopic gastric bypass using circular eea stapler,Recruiting,2,0,0,Post-operative Pain Management,drug or biologic,Late,150,All,AllOther,1,0,0,2017,2017,1491,1,Phase 4,1,efficacy,1,5.0106352940962555,"(5,6]"
45,45,gut microbiome modulation to enable efficacy of checkpoint-based immunotherapy in pancreatic adenocarcinoma,Withdrawn,7,0,0,Pancreatic Cancer,drug or biologic,Late,NA,All,AllOther,0,NA,0,2019,2019,342,0,Phase 4,1,efficacy,1,NA,NA
741,775,cystic fibrosis and gut dysmotility: the effect of polyethylene glycol (peg) on intestinal transit,Recruiting,2,0,0,Cystic Fibrosis Gastrointestinal Disease,drug or biologic,Late,15,All,AllOther,0,NA,0,2019,2019,549,0,Phase 4,1,NA,1,2.70805020110221,"(2,3]"
1174,1249,esophageal food impaction,Completed,4,0,0,Esophageal Food Bolus Obstruction,drug or biologic,Late,20,All,AllOther,0,NA,0,2017,2017,587,0,Phase 4,1,NA,1,2.995732273553991,"(2,3]"
4020,7601,lung transplantation in chronic hcv infection with post transplant epclusa treatment,Terminated,5,1,1,"Hepatitis C, Chronic|Lung Transplant",drug or biologic,Late,1,All,AllOther,0,NA,0,2017,2017,556,0,Phase 4,1,NA,1,0,NA
1694,1875,"study to gather information on the acceptability of a new flavor system with increasing levels of 2, 4, 6 g or higher of mannitol for peg 3350 in subjects having infrequent bowel movements.",Completed,4,1,1,Constipation,drug or biologic,Late,50,All,Industry&Combos,1,1,0,2020,2013,34,1,Phase 4,0,NA,0,3.912023005428146,"(3,4]"
444,456,evaluation of the efficacy of contrast enhanced ultrasound compared to mri for differentiation of hepatic lesions,Recruiting,2,0,0,Hepatic Disease,drug or biologic,Late,40,All,AllOther,0,NA,2,2018,2019,1284,0,Phase 4,1,efficacy,1,3.6888794541139363,"(3,4]"
2272,2831,comparison of diuretic effect with furosemide alone versus the combination of furosemide and albumin in cirrhotic patients,Recruiting,2,0,0,"Cirrhosis, Liver|Volume Overload|Fluid Overload",drug or biologic,Late,150,All,AllOther,1,0,0,2020,2019,347,1,Phase 4,0,NA,0,5.0106352940962555,"(5,6]"
3820,6782,outcome of iv acetaminophen use in laparoscopic cholecystectomies in patients at risk of osa,Withdrawn,7,0,0,Cholecystitis|Cholelithiasis|Obstructive Sleep Apnea,drug or biologic,Late,NA,All,AllOther,1,0,0,2014,2014,120,1,Phase 4,1,NA,1,NA,NA
2369,3026,a trial of the cost effectiveness of iv acetaminophen in bariatric surgery,Completed,4,0,0,Hospital Costs|Length of Stay|Postoperative Pain Score|Patient Satisfaction,drug or biologic,Late,113,All,AllOther,1,0,0,2014,2013,334,1,Phase 4,3,NA,2,4.727387818712341,"(4,5]"
4141,9009,fgf401 in hcc and solid tumors characterized by positive fgfr4 and klb expression,Completed,4,1,1,Hepatocellular Carcinoma (HCC)|Solid Malignancies,drug or biologic,Early,172,All,Industry&Combos,1,1,0,2014,2014,1613,1,Phase 1|Phase 2,0,NA,0,5.147494476813453,"(5,6]"
835,874,"a study of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan in metastatic pancreatic cancer",Recruiting,2,0,0,"Adenocarcinoma|Pancreatic Neoplasms|Neoplasm, Glandular|Neoplasms|Neoplasms Pancreatic|Digestive System Neoplasm|Endocrine Gland Neoplasms|Digestive System Disease|Pancreatic Diseases|Endocrine System Diseases",drug or biologic,Early,86,All,AllOther,NA,1,0,2018,2018,1076,NA,Phase 1|Phase 2,0,NA,0,4.454347296253507,"(4,5]"
3244,4553,a study of bms-813160 in combination with chemotherapy or nivolumab in participants with advanced solid tumors,"Active, not recruiting",1,0,0,Colorectal Cancer|Pancreatic Cancer,drug or biologic,Early,332,All,Industry&Combos,1,0,0,2017,2017,2029,1,Phase 1|Phase 2,0,NA,0,5.805134968916488,"(5,6]"
847,888,tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma,Terminated,5,1,1,Pancreatic Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer,drug or biologic,Early,16,All,AllOther,0,1,0,2015,2015,781,0,Phase 1|Phase 2,1,NA,1,2.772588722239781,"(2,3]"
2287,2866,early fmt for c.difficile,Completed,4,1,1,Clostridium Difficile,device,Others,13,All,AllOther,1,0,0,2015,2015,519,1,Others,0,NA,0,2.5649493574615367,"(2,3]"
3726,6236,regorafenib and pembrolizumab in treating participants with advanced or metastatic colorectal cancer,Recruiting,2,0,0,Colorectal Cancer|Colorectal Cancer Metastatic,drug or biologic,Early,75,All,NIH&Combos,0,NA,0,2018,2019,1096,0,Phase 1|Phase 2,1,NA,1,4.31748811353631,"(4,5]"
3378,4987,a multiple ascending dose study of bio89-100 in subjects with biopsy confirmed nash or nafld and at high risk of nash,"Active, not recruiting",1,0,0,"NASH",drug or biologic,Early,81,All,Industry&Combos,1,0,0,2019,2019,369,1,Phase 1|Phase 2,2,NA,2,4.394449154672439,"(4,5]"
1198,1276,"pembrolizumab, combination chemotherapy, and radiation therapy before surgery in treating adult patients with locally advanced gastroesophageal junction or gastric cardia cancer that can be removed by surgery",Suspended,6,0,0,Gastric Cardia Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Stage IB Gastric Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage IIA Gastric Cancer AJCC v7|Stage IIB Gastric Cancer AJCC v7|Stage IIIA Gastric Cancer AJCC v7|Stage IIIB Gastric Cancer AJCC v7,drug or biologic,Early,68,All,NIH&Combos,0,NA,0,2016,2016,2107,0,Phase 1|Phase 2,1,NA,1,4.219507705176107,"(4,5]"
2928,3929,genetic analysis-guided dosing of folfirabrax in treating patients with advanced gastrointestinal cancer,Completed,4,0,0,Adenocarcinoma of Unknown Primary|Adult Cholangiocarcinoma|Gallbladder Carcinoma|Gastric Adenocarcinoma|Malignant Gastrointestinal Neoplasm|Metastatic Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage III Ampulla of Vater Cancer|Stage III Pancreatic Cancer|Stage IIIA Gallbladder Cancer|Stage IIIA Gastric Cancer|Stage IIIB Gallbladder Cancer|Stage IIIB Gastric Cancer|Stage IV Ampulla of Vater Cancer|Stage IV Gallbladder Cancer|Stage IV Gastric Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,19,All,NIH&Combos,0,NA,0,2015,2014,1096,0,Phase 1|Phase 2,1,NA,1,2.9444389791664403,"(2,3]"
3860,7074,mgd007 combined with mga012 in relapsed/refractory metastatic colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Cancer Metastatic,drug or biologic,Early,52,All,Industry&Combos,0,NA,0,2018,2018,667,0,Phase 1|Phase 2,1,NA,1,3.9512437185814275,"(3,4]"
2275,2834,positron emission tomography (pet) imaging studies with nis reporter,Terminated,5,1,1,Myeloma|Endometrial Cancer,drug or biologic,Early,8,All,AllOther,2,1,2,2016,2016,456,1,Phase 1|Phase 2,0,NA,0,2.0794415416798357,"(2,3]"
2204,2693,"evaluation of safety, tolerability, and antiviral activity of chlorcyclizine hcl in patients with chronic hepatitis c",Completed,4,1,1,Chronic Hepatitis C,drug or biologic,Early,24,All,NIH&Combos,1,0,0,2014,2014,0,1,Phase 1|Phase 2,0,safety,0,3.1780538303479458,"(3,4]"
1057,1112,trial of ascorbic acid (aa) + nanoparticle paclitaxel protein bound + cisplatin + gemcitabine (aa nabplagem),"Active, not recruiting",1,0,0,Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreas Metastases,drug or biologic,Early,27,All,AllOther,0,NA,0,2018,2017,1293,0,Phase 1|Phase 2,1,NA,1,3.295836866004329,"(3,4]"
1107,1171,resveratrol and human hepatocyte function in cancer,Withdrawn,7,0,0,Liver Cancer,drug or biologic,Early,NA,All,AllOther,1,0,4,2014,2015,183,1,Phase 1|Phase 2,1,NA,1,NA,NA
3327,4750,ph 1-2 study adi-peg 20 plus folfox in subjects with advanced gi malignancies focusing on hepatocellular carcinoma,Terminated,5,0,0,Advanced Gastrointestinal (GI) Malignancies|Hepatocellular Carcinoma|Gastric Cancer|Colorectal Cancer,drug or biologic,Early,140,All,Industry&Combos,0,NA,0,2014,2014,1918,0,Phase 1|Phase 2,1,NA,1,4.941642422609304,"(4,5]"
3069,4133,study of nivolumab plus chemotherapy in patients with advanced cancer (nivoplus),Terminated,5,0,0,Advanced Cancer|Pancreatic Cancer|Renal Cell Cancer|Non Small Cell Lung Cancer|Colorectal Carcinoma|Endometrial|Uterine,drug or biologic,Early,33,All,AllOther,0,1,0,2015,2015,945,0,Phase 1|Phase 2,1,NA,1,3.4965075614664802,"(3,4]"
3072,4137,study of peposertib in combination with capecitabine and rt in rectal cancer,"Active, not recruiting",1,0,0,Locally Advanced Rectal Cancer,drug or biologic,Early,160,All,Industry&Combos,1,0,0,2018,2019,1569,1,Phase 1|Phase 2,3,NA,2,5.075173815233827,"(5,6]"
2462,3216,neoadjuvant chemoradiotherapy with crlx-101 and capecitabine for rectal cancer,Terminated,5,1,1,Rectal Cancer,drug or biologic,Early,32,All,Industry&Combos,0,1,0,2013,2013,1020,0,Phase 1|Phase 2,1,NA,1,3.4657359027997265,"(3,4]"
3892,7178,phase 1-2 trial hcq plus tace in unresectable hcc,Terminated,5,1,1,Hepatocellular Carcinoma,drug or biologic,Early,8,All,AllOther,0,NA,0,2013,2013,1826,0,Phase 1|Phase 2,1,NA,1,2.0794415416798357,"(2,3]"
1971,2320,vaginal microbiome seeding and health outcomes in cesarean-delivered neonates.,Recruiting,2,0,0,"Cesarean Delivery Affecting Newborn|Obesity, Childhood|Intestinal Microbiome",drug or biologic,Early,600,All,AllOther,1,0,1,2017,2018,1826,1,Phase 1|Phase 2,3,NA,2,6.396929655216146,"(6,7]"
1913,2228,combination probiotic: bb-12 with lgg (different doses) in treating children with autism spectrum disorder,Recruiting,2,0,0,Autism Spectrum Disorder|Gastrointestinal Symptoms,drug or biologic,Early,70,All,NIH&Combos,1,0,0,2018,2016,3410,1,Phase 1|Phase 2,3,NA,2,4.248495242049359,"(4,5]"
234,237,quilt-3.039: nant pancreatic cancer vaccine: combination immunotherapy in subjects with pancreatic cancer who have progressed on or after standard-of-care therapy,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,3,All,Industry&Combos,0,NA,0,2017,2017,1205,0,Phase 1|Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
4126,8954,a study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Early,42,All,Industry&Combos,NA,NA,0,2019,2019,671,NA,Phase 1|Phase 2,0,NA,0,3.7376696182833684,"(3,4]"
3962,7408,study of wnt974 in combination with lgx818 and cetuximab in patients with braf-mutant metastatic colorectal cancer (mcrc) and wnt pathway mutations,Completed,4,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2014,2014,547,0,Phase 1|Phase 2,1,NA,1,2.995732273553991,"(2,3]"
3948,7365,safety and efficacy study of neratinib and cetuximab to treat patients with quadruple wild-type metastatic colorectal cancer,Withdrawn,7,0,0,Colorectal Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2013,2013,1016,0,Phase 1|Phase 2,1,safety/efficacy,1,NA,NA
1482,1601,dose-defining study of tirapazamine combined with embolization in liver cancer,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma|Gastrointestinal Cancer Metastatic|Neuroendocrine Tumors,drug or biologic,Early,63,All,Industry&Combos,0,NA,0,2014,2014,2678,0,Phase 1|Phase 2,1,NA,1,4.143134726391533,"(4,5]"
2808,3767,a study of multiple immunotherapy-based treatment combinations in participants with metastatic pancreatic ductal adenocarcinoma (morpheus-pancreatic cancer),Recruiting,2,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,290,All,Industry&Combos,1,0,0,2017,2017,1960,1,Phase 1|Phase 2,0,NA,0,5.66988092298052,"(5,6]"
842,882,"study of iv vts-270 for infantile liver disease associated with niemann-pick disease, type c","Active, not recruiting",1,0,0,"Niemann-Pick Disease, Type C",drug or biologic,Early,3,All,NIH&Combos,0,NA,0,2018,2019,1075,0,Phase 1|Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
1008,1063,Â±dc1 vaccine + chemokine modulatory regimen (ckm) as adjuvant treatment of peritoneal surface malignancies,Completed,4,1,1,Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface|Malignant Peritoneal Mesothelioma|Peritoneal Carcinomatosis,drug or biologic,Early,64,All,NIH&Combos,0,NA,0,2014,2014,1693,0,Phase 1|Phase 2,1,NA,1,4.1588830833596715,"(4,5]"
4161,9139,an open-label study of the effect of telaprevir in combination with peginterferon alfa-2b and ribavirin in pediatric subjects infected with hepatitis c virus,Terminated,5,1,1,Hepatitis C,drug or biologic,Early,42,All,Industry&Combos,0,NA,0,2012,2013,820,0,Phase 1|Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
734,768,study of tas-102 plus radiation therapy for the treatment of the liver in patients with hepatic metastases from colorectal cancer,Recruiting,2,0,0,Colorectal Cancer,drug or biologic,Early,56,All,Industry&Combos,0,NA,0,2017,2017,1936,0,Phase 1|Phase 2,1,NA,1,4.02535169073515,"(4,5]"
606,632,phase i nab-paclitaxel plus gemcitabine with proton therapy for locally advanced pancreatic cancer (lapc),Recruiting,2,0,0,Locally Advanced Pancreatic Cancer,drug or biologic,Early,24,All,AllOther,0,NA,0,2018,2019,1004,0,Phase 1|Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
2834,3796,efficacy and safety of prepopik Â® in children for overall colon cleansing in preparation for colonoscopy,Completed,4,1,1,Need for Bowel Preparation,drug or biologic,Early,78,All,Industry&Combos,1,0,0,2013,2014,988,1,Phase 1|Phase 2,1,safety/efficacy,1,4.356708826689592,"(4,5]"
1375,1474,cpi-613 in treating patients with advanced or metastatic bile duct cancer that cannot be removed by surgery,Completed,4,1,1,Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Cholangiocarcinoma of the Gallbladder|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Unresectable Extrahepatic Bile Duct Cancer,drug or biologic,Early,17,All,NIH&Combos,NA,1,0,2013,2013,1796,NA,Phase 1|Phase 2,0,NA,0,2.833213344056216,"(2,3]"
1545,1683,l-dos47 plus doxorubicin in advanced pancreatic cancer,Recruiting,2,0,0,Pancreas Cancer,drug or biologic,Early,20,All,Industry&Combos,NA,NA,0,2019,2019,690,NA,Phase 1|Phase 2,0,NA,0,2.995732273553991,"(2,3]"
2767,3716,gb1275 monotherapy and in combination with an anti-pd1 antibody in patients with specified advanced solid tumors or in combination with standard of care in patients with metastatic pancreatic adenocarcinoma,Recruiting,2,0,0,Pancreatic Adenocarcinoma|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Triple Negative Breast Cancer|Castration-resistant Prostate Cancer|Microsatellite Stable Colorectal Cancer|Non-small Cell Lung Cancer|Small-cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Urothelial Carcinoma|Renal Cell Carcinoma|Hepatocellular Carcinoma,drug or biologic,Early,242,All,Industry&Combos,NA,1,0,2019,2019,1296,NA,Phase 1|Phase 2,0,NA,0,5.488937726156687,"(5,6]"
2115,2529,bms-986205 and nivolumab as first or second line therapy in treating patients with liver cancer,"Active, not recruiting",1,0,0,Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma,drug or biologic,Early,8,All,IndustryNIHPartnership,0,NA,0,2018,2018,770,0,Phase 1|Phase 2,1,NA,1,2.0794415416798357,"(2,3]"
153,153,paricalcitol plus gemcitabine and nab-paclitaxel in metastatic pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,112,All,AllOther,1,0,0,2018,2018,1091,1,Phase 1|Phase 2,3,NA,2,4.718498871295094,"(4,5]"
233,236,"c-met inhibitor amg 337, oxaliplatin, leucovorin calcium, and fluorouracil in treating patients with advanced stomach or esophageal cancer",Withdrawn,7,0,0,Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Gastrointestinal Cancer|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Stage IIIA Esophageal Cancer|Stage IIIA Gastric Cancer|Stage IIIB Esophageal Cancer|Stage IIIB Gastric Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer,drug or biologic,Early,NA,All,NIH&Combos,1,0,0,2015,2015,1096,1,Phase 1|Phase 2,2,NA,2,NA,NA
1471,1585,"taladegib, paclitaxel, carboplatin, and radiation therapy in treating patients with localized esophageal or gastroesophageal junction cancer","Active, not recruiting",1,0,0,Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Adenocarcinoma AJCC v7|Stage II Esophageal Adenocarcinoma AJCC v7|Stage IIA Esophageal Adenocarcinoma AJCC v7|Stage IIB Esophageal Adenocarcinoma AJCC v7|Stage IIIA Esophageal Adenocarcinoma AJCC v7|Stage IIIB Esophageal Adenocarcinoma AJCC v7,drug or biologic,Early,66,All,NIH&Combos,1,1,0,2015,2017,2215,1,Phase 1|Phase 2,0,NA,0,4.189654742026425,"(4,5]"
2079,2475,tas102 in combination with nal-iri in advanced gi cancers,Recruiting,2,0,0,Colorectal Adenocarcinoma|Gastric Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Non-Resectable Cholangiocarcinoma|Stage IV Colorectal Cancer|Stage IV Gastric Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer|Stage III Colorectal Cancer|Stage III Gastric Cancer|Stage III Pancreatic Cancer|Unresectable Digestive System Adenocarcinoma|Unresectable Pancreatic Carcinoma,drug or biologic,Early,64,All,Industry&Combos,0,NA,0,2017,2018,1398,0,Phase 1|Phase 2,1,NA,1,4.1588830833596715,"(4,5]"
2277,2836,paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride with or without wee1 inhibitor mk-1775 in treating patients with previously untreated pancreatic cancer that is metastatic or cannot be removed by surgery,"Active, not recruiting",1,0,0,Metastatic Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma,drug or biologic,Early,2,All,NIH&Combos,1,0,0,2014,2014,2529,1,Phase 1|Phase 2,2,NA,2,0.6931471805599453,"(0,1]"
2481,3264,"safety, tolerability and pharmacodynamics of synb1020",Terminated,5,1,1,Cirrhosis,drug or biologic,Early,23,All,Industry&Combos,1,0,0,2018,2018,487,1,Phase 1|Phase 2,4,safety,2,3.1354942159291497,"(3,4]"
2433,3161,intravenous lidocaine infusion in the management of post-operative pain in colorectal patients,Withdrawn,7,0,0,Colorectal Disorders,drug or biologic,Early,NA,All,AllOther,1,0,0,2013,2015,1155,1,Phase 1|Phase 2,3,NA,2,NA,NA
3082,4160,study of gns561 in patients with liver cancer,Recruiting,2,0,0,"Hepatocellular Carcinoma|Cholangiocarcinoma, Intrahepatic",drug or biologic,Early,50,All,Industry&Combos,NA,1,0,2017,2018,1017,NA,Phase 1|Phase 2,0,NA,0,3.912023005428146,"(3,4]"
3552,5448,a study of emibetuzumab in combination with ramucirumab (ly3009806) in participants with advanced cancer,Completed,4,1,1,Advanced Cancer|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Hepatocellular Cancer|Renal Cell Carcinoma|Non-Small Cell Lung Cancer,drug or biologic,Early,97,All,Industry&Combos,1,1,0,2014,2014,1369,1,Phase 1|Phase 2,0,NA,0,4.574710978503383,"(4,5]"
3454,5245,novel pet/ct imaging biomarkers of cb-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory ras wildtype colorectal cancer,Recruiting,2,0,0,Colorectal Cancer|Metastatic Colorectal Cancer|RAS Wild Type Colorectal Cancer|Refractory Colorectal Cancer,drug or biologic,Early,40,All,IndustryNIHPartnership,0,NA,0,2017,2017,1926,0,Phase 1|Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3164,4322,"phase 1b study to evaluate atp128, with or without bi 754091, in patients with stage iv colorectal cancer",Recruiting,2,0,0,Colorectal Cancer|MSS|Stage IV Colon Cancer|Stage IV Rectal Cancer|Metastatic Colorectal Cancer|Liver Metastasis Colon Cancer,drug or biologic,Early,32,All,Industry&Combos,1,1,0,2019,2019,724,1,Phase 1|Phase 2,0,NA,0,3.4657359027997265,"(3,4]"
3930,7322,a study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (morpheus-crc),Recruiting,2,0,0,Colorectal Cancer,drug or biologic,Early,382,All,Industry&Combos,1,0,0,2018,2018,1676,1,Phase 1|Phase 2,0,safety/efficacy,0,5.945420608606575,"(5,6]"
3031,4071,erlotinib hydrochloride in preventing liver cancer in patients with cirrhosis of the liver,"Active, not recruiting",1,0,0,Cirrhosis|Hepatocellular Carcinoma,drug or biologic,Early,25,All,NIH&Combos,0,NA,1,2014,2014,1905,0,Phase 1|Phase 2,1,NA,1,3.2188758248682006,"(3,4]"
3119,4233,bgj398 in combination with imatinib mesylate in patients with untreated advanced gastrointestinal stromal tumor (gist),Completed,4,1,1,Advanced Gastrointestinal Stromal Tumor (GIST),drug or biologic,Early,16,All,AllOther,0,NA,0,2014,2014,1635,0,Phase 1|Phase 2,1,NA,1,2.772588722239781,"(2,3]"
813,850,"does weight loss surgery and probiotic supplementation lead to a ""lean"" gut microbiota?",Completed,4,0,0,Obesity,other,Others,18,All,AllOther,1,0,0,2013,2013,852,1,Others,2,NA,2,2.8903717578961645,"(2,3]"
3881,7154,quilt-3.072: nant hepatocellular carcinoma (hcc) vaccine,Withdrawn,7,0,0,Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2018,2018,455,1,Phase 1|Phase 2,0,NA,0,NA,NA
2253,2787,initial feasibility study to treat borderline resectable pancreatic cancer with a planar ldr source,Recruiting,2,0,0,Pancreatic Cancer,device,Others,80,All,Industry&Combos,0,NA,0,2016,2017,1857,0,Others,1,NA,1,4.382026634673881,"(4,5]"
908,954,lee011 plus everolimus in patients with metastatic pancreatic adenocarcinoma refractory to chemotherapy,"Active, not recruiting",1,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,44,All,Industry&Combos,0,1,0,2016,2017,1307,0,Phase 1|Phase 2,1,NA,1,3.784189633918261,"(3,4]"
4119,8757,phase 1b/2 study of oprozomib in combination with sorafenib in subjects with advanced hepatocellular carcinoma,Withdrawn,7,0,0,Advanced Hepatocellular Carcinoma,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2014,2014,90,1,Phase 1|Phase 2,0,NA,0,NA,NA
2103,2511,fecal microbiota transplantation to treat recurrent c. difficile associated diarrhea via retention enema or oral route,Completed,4,1,1,C. Difficile,drug or biologic,Early,69,All,AllOther,1,0,0,2015,2015,990,1,Phase 1|Phase 2,1,NA,1,4.23410650459726,"(4,5]"
3607,5684,polypepi1018 vaccine and cdx for the treatment of metastatic colorectal cancer (oberto),Completed,4,0,0,Colorectal Cancer,drug or biologic,Early,11,All,Industry&Combos,0,NA,0,2018,2018,464,0,Phase 1|Phase 2,1,NA,1,2.3978952727983707,"(2,3]"
2836,3799,study evaluating the effect of tc-6499 on gastric emptying time in diabetic subjects with gastroparesis,Completed,4,0,0,Gastroparesis,drug or biologic,Early,80,All,Industry&Combos,3,0,0,2014,2014,214,3,Phase 1|Phase 2,2,NA,2,4.382026634673881,"(4,5]"
3168,4335,"a study to test the safety and effectiveness of nivolumab combined with daratumumab in patients with pancreatic, non-small cell lung or triple negative breast cancers, that have advanced or have spread","Active, not recruiting",1,0,0,Advanced Cancer,drug or biologic,Early,120,All,Industry&Combos,0,NA,0,2017,2017,1132,0,Phase 1|Phase 2,1,safety,1,4.787491742782046,"(4,5]"
2207,2696,study of gemcabene in adults with fpld,Completed,4,1,1,Familial Partial Lipodystrophy|Hypertriglyceridemia|Fatty Liver|NASH - Nonalcoholic Steatohepatitis,drug or biologic,Early,5,All,AllOther,2,0,0,2018,2018,505,1,Phase 1|Phase 2,0,NA,0,1.6094379124341003,"(1,2]"
2070,2463,pembrolizumab with or without elbasvir/grazoprevir and ribavirin in treating patients with advanced refractory liver cancer,"Active, not recruiting",1,0,0,BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Hepatitis C Infection|Refractory Liver Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7,drug or biologic,Early,30,All,NIH&Combos,1,1,0,2016,2016,1848,1,Phase 1|Phase 2,0,NA,0,3.4011973816621555,"(3,4]"
3943,7353,study of magrolimab (hu5f9-g4) in combination with cetuximab in participants with solid tumors and advanced colorectal cancer,Completed,4,1,1,Solid Tumor|Colorectal Cancer,drug or biologic,Early,78,All,Industry&Combos,NA,1,0,2016,2016,1195,NA,Phase 1|Phase 2,0,NA,0,4.356708826689592,"(4,5]"
3547,5439,safety study of itacitinib (incb039110) in combination with gemcitabine and nab-paclitaxel in subjects with advanced solid tumors,Completed,4,0,0,Solid Tumors|Pancreatic Cancer,drug or biologic,Early,55,All,Industry&Combos,0,NA,0,2013,2013,975,0,Phase 1|Phase 2,1,safety,1,4.007333185232471,"(4,5]"
1575,1719,nab-pac+cis+gem in pts w previously untreated metastatic pda,Completed,4,1,1,Stage IV Pancreatic Cancer,drug or biologic,Early,25,All,AllOther,0,NA,0,2013,2013,1066,0,Phase 1|Phase 2,1,NA,1,3.2188758248682006,"(3,4]"
3302,4688,safety and efficacy study of amg 820 and pembrolizumab combination in select advanced solid tumor cancer,Completed,4,1,1,Pancreatic Cancer|Colorectal Cancer|Non-Small Cell Lung Cancer,drug or biologic,Early,117,All,Industry&Combos,0,NA,0,2016,2016,993,0,Phase 1|Phase 2,1,safety/efficacy,1,4.762173934797756,"(4,5]"
2150,2586,gl-onc1 oncolytic immunotherapy in patients with recurrent or refractory ovarian cancer,"Active, not recruiting",1,0,0,Ovarian Cancer|Peritoneal Carcinomatosis|Fallopian Tube Cancer,drug or biologic,Early,64,Female,Industry&Combos,0,NA,0,2016,2016,1705,0,Phase 1|Phase 2,1,NA,1,4.1588830833596715,"(4,5]"
3456,5248,a phase i/ii study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Cancer|Colorectal Carcinoma|Colorectal Adenocarcinoma|Refractory Cancer|Colorectal Neoplasms,drug or biologic,Early,34,All,NIH&Combos,NA,1,0,2017,2017,1022,NA,Phase 1|Phase 2,0,NA,0,3.5263605246161616,"(3,4]"
2162,2606,fecal microbiota transplantation for the treatment of primary sclerosing cholangitis.,Completed,4,1,1,Sclerosing Cholangitis,drug or biologic,Early,10,All,AllOther,0,NA,0,2015,2016,576,0,Phase 1|Phase 2,1,NA,1,2.302585092994046,"(2,3]"
594,620,m7824 (msb0011359c) in combination with gemcitabine in adults with previously treated advanced adenocarcinoma of the pancreas,Terminated,5,1,1,Cancer of Pancreas|Pancreas Cancer|Pancreatic Adenocarcinoma|Pancreatic Cancer|Pancreatic Neoplasms,drug or biologic,Early,7,All,NIH&Combos,NA,1,0,2018,2018,719,NA,Phase 1|Phase 2,0,NA,0,1.9459101490553132,"(1,2]"
2483,3268,trial to evaluate safety and tolerability of gp-2250 in combination with gemcitabine,Recruiting,2,0,0,"Pancreatic Cancer, Adult",drug or biologic,Early,54,All,Industry&Combos,0,NA,0,2019,2019,1082,0,Phase 1|Phase 2,1,safety,1,3.9889840465642745,"(3,4]"
90,90,feasibility of the lum imaging system for detection of gastrointestinal cancers,Recruiting,2,0,0,Colorectal Cancer|Pancreatic Cancer|Esophageal Cancer|Gastric Cancer,drug or biologic,Early,66,All,IndustryNIHPartnership,1,1,2,2015,2016,1915,1,Phase 1|Phase 2,0,NA,0,4.189654742026425,"(4,5]"
722,756,bispecific antibody armed activated t-cells with aldesleukin and sargramostim in treating patients with locally advanced or metastatic pancreatic cancer,"Active, not recruiting",1,0,0,Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,drug or biologic,Early,2,All,NIH&Combos,0,NA,0,2015,2015,2192,0,Phase 1|Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
1774,1994,contrast-enhanced ultrasound in human crohn's disease,Withdrawn,7,0,0,Crohn's Disease,drug or biologic,Early,NA,All,AllOther,0,NA,2,2014,2015,700,0,Phase 1|Phase 2,1,NA,1,NA,NA
1063,1119,ibrutinib combined with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer,Completed,4,1,1,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,18,All,AllOther,1,1,0,2015,2015,1495,1,Phase 1|Phase 2,0,NA,0,2.8903717578961645,"(2,3]"
964,1015,"trial to test safety and efficacy of vaccination for incurable hpv 16-related oropharyngeal, cervical and anal cancer","Active, not recruiting",1,0,0,Cancer of Head and Neck|Cancer of Cervix|Cancer of Anus,drug or biologic,Early,11,All,AllOther,0,NA,0,2016,2016,1461,0,Phase 1|Phase 2,1,safety/efficacy,1,2.3978952727983707,"(2,3]"
3189,4409,"safety, tolerability and host response to lactobacillus johnsonii",Completed,4,1,1,Healthy,drug or biologic,Early,42,All,AllOther,1,0,4,2015,2015,488,1,Phase 1|Phase 2,2,safety,2,3.7376696182833684,"(3,4]"
2408,3106,fecal microbiota transplant for improvement of metabolism,Completed,4,1,1,Obesity,drug or biologic,Early,24,All,AllOther,1,0,0,2015,2016,756,1,Phase 1|Phase 2,2,NA,2,3.1780538303479458,"(3,4]"
916,962,fmt in cirrhosis and hepatic encephalopathy,Recruiting,2,0,0,Cirrhosis|Hepatic Encephalopathy,drug or biologic,Early,100,All,AllOther,1,0,4,2019,2019,1403,1,Phase 1|Phase 2,3,NA,2,4.605170185988092,"(4,5]"
635,662,study of ngm282 in subjects with functional constipation and healthy individuals,Completed,4,0,0,Functional Constipation,drug or biologic,Early,31,All,Industry&Combos,1,0,0,2016,2015,397,1,Phase 1|Phase 2,2,NA,2,3.4339872044851463,"(3,4]"
303,308,effect of tu-100 in patients with irritable bowel syndrome (ibs),Completed,4,0,0,Irritable Bowel Syndrome|Digestive System Diseases|Gastrointestinal Diseases|Intestinal Diseases|Abdominal Pain,drug or biologic,Early,40,All,Industry&Combos,1,0,0,2013,2013,577,1,Phase 1|Phase 2,4,NA,2,3.6888794541139363,"(3,4]"
585,611,niraparib + ipilimumab or nivolumab in progression free pancreatic adenocarcinoma after platinum-based chemotherapy,Recruiting,2,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,84,All,Industry&Combos,1,0,0,2018,2018,1490,1,Phase 1|Phase 2,0,NA,0,4.430816798843313,"(4,5]"
357,365,nivolumab in combination with chemotherapy before surgery in treating patients with borderline resectable pancreatic cancer,Recruiting,2,0,0,Borderline Resectable Pancreatic Adenocarcinoma|Resectable Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,36,All,Industry&Combos,0,NA,0,2019,2019,996,0,Phase 1|Phase 2,1,NA,1,3.58351893845611,"(3,4]"
1415,1521,avelumab with chemoradiation for stage ii/iii resectable esophageal and gastroesophageal cancer,Recruiting,2,0,0,Resectable Esophageal Cancer|GastroEsophageal Cancer,drug or biologic,Early,24,All,AllOther,1,1,0,2018,2018,1372,1,Phase 1|Phase 2,0,NA,0,3.1780538303479458,"(3,4]"
3534,5393,cetuximab and pembrolizumab in treating patients with colorectal cancer that is metastatic or cannot be removed by surgery,"Active, not recruiting",1,0,0,Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer,drug or biologic,Early,44,All,IndustryNIHPartnership,0,NA,0,2016,2016,1453,0,Phase 1|Phase 2,1,NA,1,3.784189633918261,"(3,4]"
3870,7113,"study to explore the safety, tolerability and efficacy of mk-3475 in combination with incb024360 in participants with selected cancers",Completed,4,1,1,Microsatellite-instability (MSI) High Colorectal Cancer (CRC)|Endometrial Cancer|Head and Neck Cancer|Hepatocellular Carcinoma (HCC)|Gastric Cancer|Lung Cancer|Lymphoma|Renal Cell Carcinoma (RCC)|Ovarian Cancer|Solid Tumors|UC (Urothelial Cancer)|Melanoma|Bladder Cancer|Triple Negative Breast Cancer (TNBC),drug or biologic,Early,444,All,Industry&Combos,1,1,0,2014,2014,1593,1,Phase 1|Phase 2,0,safety/efficacy,0,6.095824562432225,"(6,7]"
2621,3522,quilt-3.010: a study of gemcitabine and nab-paclitaxel with or without npc-1c to treat patients with pancreatic cancer,Terminated,5,0,0,"Pancreatic Cancer, Adult",drug or biologic,Early,81,All,Industry&Combos,1,0,0,2013,2013,1442,1,Phase 1|Phase 2,0,NA,0,4.394449154672439,"(4,5]"
2522,3365,a study of ft 4101 in overweight/obese participants with nash,Terminated,5,0,0,Nonalcoholic Steatohepatitis (NASH)|Overweight or Obesity,drug or biologic,Early,14,All,Industry&Combos,1,0,0,2019,2019,248,1,Phase 1|Phase 2,2,NA,2,2.6390573296152584,"(2,3]"
2661,3569,"study of nanoliposomal irinotecan (nal-iri)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma","Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,56,All,Industry&Combos,0,NA,0,2015,2015,2127,0,Phase 1|Phase 2,1,NA,1,4.02535169073515,"(4,5]"
2694,3613,"a phase 1b/2 study of medi4736 with tremelimumab, medi4736 or tremelimumab monotherapy in gastric or gej adenocarcinoma",Completed,4,1,1,Gastric or Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,114,All,Industry&Combos,1,0,0,2015,2015,1490,1,Phase 1|Phase 2,0,NA,0,4.736198448394496,"(4,5]"
3055,4107,safety and efficacy of fecal microbiome transplantation (fmt) in the treatment of antibiotic dependent pouchitis (adp),Terminated,5,1,1,Pouchitis,drug or biologic,Early,6,All,Industry&Combos,1,0,0,2016,2017,550,1,Phase 1|Phase 2,4,safety/efficacy,2,1.791759469228055,"(1,2]"
2193,2667,tivozanib in treating patients with liver cancer that is metastatic or cannot be removed by surgery,Completed,4,1,1,Advanced Adult Hepatocellular Carcinoma|Non-Resectable Hepatocellular Carcinoma,drug or biologic,Early,33,All,IndustryNIHPartnership,NA,1,0,2013,2013,1992,NA,Phase 1|Phase 2,0,NA,0,3.4965075614664802,"(3,4]"
4135,8977,study of dalantercept and sorafenib in patients with advanced hepatocellular carcinoma,Completed,4,1,1,Advanced Adult Hepatocellular Carcinoma,drug or biologic,Early,21,All,Industry&Combos,NA,1,0,2013,2014,1066,NA,Phase 1|Phase 2,0,NA,0,3.044522437723423,"(3,4]"
3471,5273,"phase i/ii study of the anti-programmed death ligand-1 antibody medi4736 in combination with olaparib and/or cediranib for advanced solid tumors and advanced or recurrent ovarian, triple negative breast, lung, prostate and colorectal cancers",Recruiting,2,0,0,Colorectal Neoplasms|Breast Neoplasms,drug or biologic,Early,384,All,NIH&Combos,NA,1,0,2015,2015,2406,NA,Phase 1|Phase 2,0,NA,0,5.950642552587727,"(5,6]"
4078,7889,proof of concept study to determine the safety and antiviral effect of bzf961 with or without ritonavir boosting in hepatitis c virus infected patients,Completed,4,0,0,Hepatitis C,drug or biologic,Early,54,All,Industry&Combos,2,0,0,2013,2013,640,1,Phase 1|Phase 2,2,safety,2,3.9889840465642745,"(3,4]"
2518,3353,a study evaluating the safety and efficacy of curcumin in patients with primary sclerosing cholangitis (psc),Completed,4,1,1,Primary Sclerosing Cholangitis,drug or biologic,Early,15,All,Industry&Combos,0,NA,0,2016,2017,525,0,Phase 1|Phase 2,1,safety/efficacy,1,2.70805020110221,"(2,3]"
1401,1504,tremelimumab with chemoembolization or ablation for liver cancer,Completed,4,1,1,Heptocellular Cancer|Biliary Tract Neoplasms|Liver Cancer|Hepatocellular Carcinoma|Biliary Cancer,drug or biologic,Early,61,All,NIH&Combos,NA,1,0,2013,2013,1497,NA,Phase 1|Phase 2,0,NA,0,4.110873864173311,"(4,5]"
2447,3186,bruog 379 phase ib/ii trial onc201 + nivolumab in mss mcrc,"Active, not recruiting",1,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,13,All,Industry&Combos,0,1,0,2019,2019,579,0,Phase 1|Phase 2,1,NA,1,2.5649493574615367,"(2,3]"
200,203,quilt-3.070:pancreatic cancer vaccine: subjects with pancreatic cancer who have progressed on or after standard-of-care therapy,Unknown status,8,0,0,Pancreatic Cancer,drug or biologic,Early,173,All,Industry&Combos,0,NA,0,2017,2018,698,0,Phase 1|Phase 2,1,NA,1,5.153291594497779,"(5,6]"
1609,1761,the icon study: outcomes after fmt for patients with ibd and cdi,Completed,4,1,1,Inflammatory Bowel Diseases|Clostridium Difficile Infection,drug or biologic,Early,50,All,AllOther,0,NA,0,2017,2017,980,0,Phase 1|Phase 2,1,NA,1,3.912023005428146,"(3,4]"
3344,4835,phase ib/ii study of medi4736 evaluated in different combinations in metastatic pancreatic ductal carcinoma,Completed,4,1,1,Metastatic Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,23,All,Industry&Combos,1,1,0,2015,2016,836,1,Phase 1|Phase 2,0,NA,0,3.1354942159291497,"(3,4]"
2344,2972,use of f-652 in patients with alcoholic hepatitis,Completed,4,1,1,Alcoholic Hepatitis,drug or biologic,Early,18,All,AllOther,NA,NA,0,2016,2016,880,NA,Phase 1|Phase 2,0,NA,0,2.8903717578961645,"(2,3]"
2323,2935,"encorafenib, cetuximab, and nivolumab in treating patients with microsatellite stable, brafv600e mutated unresectable or metastatic colorectal cancer",Recruiting,2,0,0,BRAF NP_004324.2:p.V600E|Metastatic Colon Adenocarcinoma|Metastatic Microsatellite Stable Colorectal Carcinoma|Metastatic Rectal Adenocarcinoma|Progressive Disease|Recurrent Colorectal Carcinoma|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Rectal Adenocarcinoma,drug or biologic,Early,38,All,NIH&Combos,0,NA,0,2019,2019,1843,0,Phase 1|Phase 2,1,NA,1,3.6375861597263857,"(3,4]"
3063,4121,a study of bbi608 in combination with standard chemotherapies in adult patients with advanced gastrointestinal cancer,Completed,4,0,0,Advanced Gastrointestinal Cancer,drug or biologic,Early,495,All,Industry&Combos,0,1,0,2013,2014,1885,0,Phase 1|Phase 2,1,NA,1,6.20455776256869,"(6,7]"
2633,3536,safety study of intravenous immunoglobulin (ivig) post-portoenterostomy in infants with biliary atresia,Completed,4,1,1,Biliary Atresia,drug or biologic,Early,30,All,NIH&Combos,0,NA,0,2013,2013,1004,0,Phase 1|Phase 2,1,safety,1,3.4011973816621555,"(3,4]"
2418,3128,microbiota intervention to change the response of parkinson's disease,Recruiting,2,0,0,Parkinson Disease,drug or biologic,Early,86,All,Industry&Combos,1,0,0,2018,2019,595,1,Phase 1|Phase 2,4,NA,2,4.454347296253507,"(4,5]"
3739,6290,phase i/ii study of sgi-110 with irinotecan versus regorafenib or tas-102 in metastatic colorectal cancer,Completed,4,1,1,Previously Treated Metastatic Colorectal Cancer,drug or biologic,Early,118,All,Industry&Combos,1,0,0,2013,2013,2133,1,Phase 1|Phase 2,0,NA,0,4.770684624465665,"(4,5]"
2291,2871,"an open-label, proof of consent study of vorinostat for the treatment of mdoerate-to-severe crohn s disease and maintenance therapy with ustekinumab",Recruiting,2,0,0,Crohn's Disease,drug or biologic,Early,35,All,NIH&Combos,0,1,0,2017,2017,1339,0,Phase 1|Phase 2,1,NA,1,3.5553480614894135,"(3,4]"
732,766,study of gemcitabine/taxotere/xeloda (gtx) in combination with cisplatin and irinotecan in subjects with metastatic pancreatic cancer,Completed,4,1,1,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,47,All,AllOther,1,1,0,2014,2015,1581,1,Phase 1|Phase 2,0,NA,0,3.8501476017100584,"(3,4]"
2894,3879,cgt9486 (formerly known as plx9486) as a single agent and in combination with plx3397 (pexidartinib) or sunitinib in participants with advanced solid tumors,Completed,4,0,0,Gastrointestinal Stromal Tumors,drug or biologic,Early,51,All,Industry&Combos,NA,1,0,2015,2015,1893,NA,Phase 1|Phase 2,0,NA,0,3.9318256327243257,"(3,4]"
2167,2613,sorafenib tosylate and pembrolizumab in treating patients with advanced or metastatic liver cancer,Recruiting,2,0,0,Advanced Adult Hepatocellular Carcinoma|Child-Pugh Class A|Stage III Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma,drug or biologic,Early,27,All,Industry&Combos,0,NA,0,2017,2017,1826,0,Phase 1|Phase 2,1,NA,1,3.295836866004329,"(3,4]"
3918,7301,onvansertib in combination with folfiri and bevacizumab for second line treatment of metastatic colorectal cancer patients with a kras mutation,Recruiting,2,0,0,Metastatic Colorectal Cancer|KRAS Gene Mutation,drug or biologic,Early,44,All,Industry&Combos,NA,NA,0,2019,2019,1091,NA,Phase 1|Phase 2,0,NA,0,3.784189633918261,"(3,4]"
332,338,"bats treatment for pancreatic cancer, phase ib/ii",Recruiting,2,0,0,Locally Advanced Pancreatic Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,22,All,AllOther,0,NA,0,2017,2017,1769,0,Phase 1|Phase 2,1,NA,1,3.091042453358316,"(3,4]"
2666,3576,study of ido inhibitor in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer,Completed,4,0,0,Metastatic Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer,drug or biologic,Early,157,All,Industry&Combos,0,NA,0,2014,2014,1265,0,Phase 1|Phase 2,1,NA,1,5.056245805348308,"(5,6]"
188,190,pembrolizumab + poly-iclc in mrp colon cancer,Recruiting,2,0,0,Metastatic Colon Cancer|Solid Tumor,drug or biologic,Early,42,All,Industry&Combos,0,1,0,2016,2018,1087,0,Phase 1|Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
302,307,chemotherapy with nab-paclitaxel/germcitabine/cisplatin +/- bgb324 with pancreatic cancer,Recruiting,2,0,0,Cancer of Pancreas,drug or biologic,Early,74,All,Industry&Combos,1,0,0,2018,2019,910,1,Phase 1|Phase 2,0,NA,0,4.30406509320417,"(4,5]"
1052,1107,bms-813160 with nivolumab and gemcitabine and nab-paclitaxel in borderline resectable and locally advanced pancreatic ductal adenocarcinoma (pdac),Recruiting,2,0,0,Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,53,All,IndustryNIHPartnership,NA,1,0,2018,2018,2345,NA,Phase 1|Phase 2,0,NA,0,3.970291913552122,"(3,4]"
1280,1367,imaging with [89zr]panitumumab-pet/mri in patients with newly diagnosed colorectal cancer,Recruiting,2,0,0,Metastatic Colon Cancer,drug or biologic,Early,10,All,AllOther,0,NA,2,2018,2019,2120,0,Phase 1|Phase 2,1,NA,1,2.302585092994046,"(2,3]"
3139,4268,topical irrigation therapy for crs,Terminated,5,1,1,Rhinitis|Sinusitis,drug or biologic,Early,10,All,AllOther,1,0,0,2015,2015,581,1,Phase 1|Phase 2,2,NA,2,2.302585092994046,"(2,3]"
1880,2174,"bms-986156, ipilimumab, and nivolumab with or without stereotactic body radiation therapy in treating patients with advanced or metastatic lung/chest or liver cancers",Recruiting,2,0,0,Advanced Malignant Solid Neoplasm|Metastatic Carcinoma in the Liver|Metastatic Carcinoma in the Lung|Metastatic Malignant Neoplasm in the Thoracic Cavity|Metastatic Malignant Solid Neoplasm,drug or biologic,Early,60,All,NIH&Combos,1,1,0,2019,2019,1471,1,Phase 1|Phase 2,0,NA,0,4.0943445622221,"(4,5]"
3658,5816,study of cx-4945 in combination with gemcitabine and cisplatin for frontline treatment of cholangiocarcinoma,"Active, not recruiting",1,0,0,Cholangiocarcinoma,drug or biologic,Early,127,All,Industry&Combos,1,0,0,2014,2014,2319,1,Phase 1|Phase 2,0,NA,0,4.844187086458591,"(4,5]"
2445,3181,determine function of antroquinonol in combination with soc in first line metastatic pancreatic cancer,Recruiting,2,0,0,Pancreatic Neoplasm,drug or biologic,Early,52,All,Industry&Combos,0,NA,0,2017,2017,1307,0,Phase 1|Phase 2,1,NA,1,3.9512437185814275,"(3,4]"
863,905,fmt in pediatric crohn's disease,Completed,4,0,0,Crohn Disease|Pediatric Crohns Disease,drug or biologic,Early,9,All,AllOther,0,NA,4,2017,2017,629,0,Phase 1|Phase 2,1,NA,1,2.1972245773362196,"(2,3]"
1892,2191,donor alloantigen reactive tregs (dartregs) for calcineurin inhibitor (cni) reduction,Completed,4,1,1,Liver Transplant Recipient|Living Donor (of the Respective Liver Transplant Recipient),drug or biologic,Early,15,All,IndustryNIHPartnership,0,NA,0,2015,2016,1288,0,Phase 1|Phase 2,1,NA,1,2.70805020110221,"(2,3]"
71,71,"use of autologous, adult adipose-derived stem/stromal cells in inflammatory bowel disease",Enrolling by invitation,3,0,0,Inflammatory Bowel Diseases,procedure,Others,100,All,Industry&Combos,1,1,0,2016,2016,1826,1,Others,1,NA,1,4.605170185988092,"(4,5]"
966,1017,a study of ly2090314 and chemotherapy in participants with metastatic pancreatic cancer,Terminated,5,1,1,Pancreatic Cancer,drug or biologic,Early,13,All,Industry&Combos,1,1,0,2012,2013,822,1,Phase 1|Phase 2,0,NA,0,2.5649493574615367,"(2,3]"
1252,1337,mek162 in combination with imatinib mesylate in patients with untreated advanced gastrointestinal stromal tumor (gist),Recruiting,2,0,0,Gastrointestinal Stromal Tumor (GIST),drug or biologic,Early,76,All,AllOther,0,NA,0,2013,2013,3287,0,Phase 1|Phase 2,1,NA,1,4.330733340286331,"(4,5]"
2423,3142,delivering a diuretic into the liver artery followed by plugging up the artery to starve out liver cancer cells,Recruiting,2,0,0,Unresectable Hepatocellular Carcinoma,drug or biologic,Early,36,All,AllOther,0,NA,0,2017,2017,1826,0,Phase 1|Phase 2,1,NA,1,3.58351893845611,"(3,4]"
1568,1711,study of pi3kinase inhibition (copanlisib) and anti-pd-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (mss) colorectal cancer,Recruiting,2,0,0,Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer|Colon Cancer,drug or biologic,Early,54,All,Industry&Combos,NA,1,0,2018,2019,1080,NA,Phase 1|Phase 2,0,NA,0,3.9889840465642745,"(3,4]"
3698,6131,safety and efficacy of ky1044 and atezolizumab in advanced cancer,Recruiting,2,0,0,Squamous Cell Carcinoma of Head and Neck|Non-small Cell Lung Cancer|Hepatocellular Carcinoma|Esophageal Cancer|Gastric Cancer|Melanoma|Renal Cell Carcinoma|Pancreatic Cancer|Cervical Cancer|Triple Negative Breast Cancer|Advanced Cancer|Metastatic Cancer,drug or biologic,Early,412,All,Industry&Combos,NA,1,0,2019,2019,1554,NA,Phase 1|Phase 2,0,safety/efficacy,0,6.021023349349527,"(6,7]"
519,540,a pilot evaluation of bli4700 bowel preparation in adult subjects,Completed,4,0,0,Colonoscopy,drug or biologic,Early,120,All,Industry&Combos,0,NA,0,2017,2016,365,0,Phase 1|Phase 2,1,NA,1,4.787491742782046,"(4,5]"
3206,4461,carbon monoxide-saturated medium for islet isolation,Completed,4,0,0,Chronic Pancreatitis,other,Others,16,All,AllOther,1,0,4,2015,2015,1369,1,Others,2,NA,2,2.772588722239781,"(2,3]"
1233,1311,tas-ox for refractory metastatic colon cancer,Completed,4,0,0,Colorectal Neoplasms,drug or biologic,Early,43,All,AllOther,0,NA,0,2016,2016,1310,0,Phase 1|Phase 2,1,NA,1,3.7612001156935624,"(3,4]"
3667,5845,a phase 1/2 study of incb001158 in combination with chemotherapy in subjects with solid tumors,"Active, not recruiting",1,0,0,Biliary Tract Cancer (BTC)|Colorectal Cancer (CRC)|Endometrial Cancer|Gastroesophageal Cancer (GC)|Ovarian Cancer|Solid Tumors,drug or biologic,Early,149,All,Industry&Combos,0,1,0,2017,2017,1416,0,Phase 1|Phase 2,1,NA,1,5.003946305945459,"(5,6]"
1729,1922,administering peripheral blood lymphocytes transduced with a murine t-cell receptor recognizing the g12v variant of mutated ras in hla-a*11:01 patients,Suspended,6,0,0,Pancreatic Cancer|Gastric Cancer|Gastrointestinal Cancer|Colon Cancer|Rectal Cancer,drug or biologic,Early,6,All,NIH&Combos,NA,1,0,2017,2017,3568,NA,Phase 1|Phase 2,0,NA,0,1.791759469228055,"(1,2]"
3030,4070,testing the combination of new anti-cancer drug peposertib with avelumab and radiation therapy for advanced/metastatic solid tumors and hepatobiliary malignancies,Recruiting,2,0,0,Locally Advanced Cholangiocarcinoma|Locally Advanced Gallbladder Carcinoma|Locally Advanced Malignant Solid Neoplasm|Metastatic Cholangiocarcinoma|Metastatic Gallbladder Carcinoma|Metastatic Malignant Solid Neoplasm|Refractory Cholangiocarcinoma|Refractory Gallbladder Carcinoma|Refractory Malignant Solid Neoplasm|Stage III Gallbladder Cancer AJCC v8|Stage III Hilar Cholangiocarcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIA Hilar Cholangiocarcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8|Stage IIIB Hilar Cholangiocarcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIC Hilar Cholangiocarcinoma AJCC v8|Stage IV Gallbladder Cancer AJCC v8|Stage IV Hilar Cholangiocarcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Gallbladder Cancer AJCC v8|Stage IVA Hilar Cholangiocarcinoma AJCC v8|Stage IVB Gallbladder Cancer AJCC v8|Stage IVB Hilar Cholangiocarcinoma AJCC v8|Unresectable Cholangiocarcinoma|Unresectable Gallbladder Carcinoma|Unresectable Malignant Solid Neoplasm,drug or biologic,Early,30,All,NIH&Combos,1,0,0,2019,2019,1076,1,Phase 1|Phase 2,0,NA,0,3.4011973816621555,"(3,4]"
1639,1802,lipidome and microbiome profile of acne,"Active, not recruiting",1,0,0,Acne Vulgaris,drug or biologic,Early,30,All,AllOther,0,1,4,2016,2016,3958,0,Phase 1|Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
2699,3619,a study of nab-paclitaxel and gemcitabine with or without olaratumab (ly3012207) in participants with metastatic pancreatic cancer,"Active, not recruiting",1,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,186,All,Industry&Combos,1,0,0,2017,2017,1293,1,Phase 1|Phase 2,2,NA,2,5.225746673713202,"(5,6]"
1542,1679,high dose ascorbic acid (aa) + nanoparticle paclitaxel protein bound + cisplatin + gemcitabine (aa nabplagem) in patients who have metastatic pancreatic cancer,Withdrawn,7,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,NA,All,AllOther,0,NA,0,2019,2019,1096,0,Phase 1|Phase 2,1,NA,1,NA,NA
767,803,immune checkpoint inhibition (tremelimumab and/or medi4736) in combination with radiation therapy in patients with unresectable pancreatic cancer,Completed,4,1,1,Pancreatic Neoplasms|Pancreatic Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer,drug or biologic,Early,65,All,NIH&Combos,NA,1,0,2014,2015,1673,NA,Phase 1|Phase 2,0,NA,0,4.174387269895637,"(4,5]"
1088,1150,cabozantinib in combination with durvalumab in patients with gastroesophageal cancer and other gastrointestinal malignancies,Recruiting,2,0,0,Gastric Cancer|Esophageal Adenocarcinoma|Hepatocellular Carcinoma|Colorectal Cancer,drug or biologic,Early,93,All,Industry&Combos,0,NA,0,2018,2018,1385,0,Phase 1|Phase 2,1,NA,1,4.532599493153256,"(4,5]"
63,63,pert for treatment of exocrine pancreatic insufficiency in patients with unresectable pancreatic cancer,Terminated,5,1,1,Pancreatic Insufficiency|Pancreatic Cancer|Pancreatic Enzyme Abnormality,drug or biologic,Early,16,All,Industry&Combos,3,0,0,2016,2016,851,3,Phase 1|Phase 2,4,NA,2,2.772588722239781,"(2,3]"
3439,5230,quilt 3.071: nant colorectal cancer (crc) vaccine,"Active, not recruiting",1,0,0,Colorectal Cancer Metastatic|mCRC,drug or biologic,Early,332,All,Industry&Combos,1,0,0,2018,2018,1315,1,Phase 1|Phase 2,0,NA,0,5.805134968916488,"(5,6]"
2787,3743,study of ngm120 in subjects with advanced solid tumors and pancreatic cancer using combination therapy,Recruiting,2,0,0,Pancreatic Cancer|Metastatic Castration-resistant Prostate Cancer|Bladder Cancer|Melanoma|Non-small Cell Lung Cancer|Colorectal Cancer|Gastric Cancer|Esophageal Cancer|Ovarian Cancer|Head Neck Squamous Cell Carcinoma,drug or biologic,Early,90,All,Industry&Combos,NA,0,0,2019,2019,1173,NA,Phase 1|Phase 2,4,NA,2,4.499809670330265,"(4,5]"
454,469,fecal microbiota transplant (fmt) in pediatric active ulcerative colitis and pediatric active crohn's colitis,Completed,4,0,0,Inflammatory Bowel Diseases|Ulcerative Colitis|Crohn Disease,drug or biologic,Early,15,All,AllOther,1,0,0,2015,2015,1254,1,Phase 1|Phase 2,4,NA,2,2.70805020110221,"(2,3]"
3364,4926,fecal microbial transplant in pediatric crohn's disease,Completed,4,0,0,Crohn's Disease,drug or biologic,Early,7,All,AllOther,1,0,0,2014,2015,639,1,Phase 1|Phase 2,3,NA,2,1.9459101490553132,"(1,2]"
1006,1061,"first line gemcitabine, cisplatin and mek162 in advanced biliary tract carcinoma",Completed,4,1,1,Advanced Biliary Tract Carcinoma,drug or biologic,Early,42,All,Industry&Combos,0,NA,0,2013,2013,2250,0,Phase 1|Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
3046,4091,pen-221 in somatostatin receptor 2 expressing advanced cancers including neuroendocrine and small cell lung cancers,Completed,4,0,0,"Neuroendocrine Tumors|Carcinoma, Small Cell Lung|Neuroendocrine Carcinoma",drug or biologic,Early,89,All,Industry&Combos,0,NA,0,2016,2016,1331,0,Phase 1|Phase 2,1,NA,1,4.48863636973214,"(4,5]"
2416,3126,dose escalation trial of stereotactic body radiation therapy (sbrt) in combination with gc4419 in pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer|Stereotactic Body Radiation Therapy,drug or biologic,Early,48,All,Industry&Combos,1,0,0,2017,2018,926,1,Phase 1|Phase 2,4,NA,2,3.871201010907891,"(3,4]"
768,804,dose escalation trial of azd1775 and gemcitabine (+radiation) for unresectable adenocarcinoma of the pancreas,Completed,4,1,1,Adenocarcinoma of the Pancreas,drug or biologic,Early,34,All,AllOther,0,NA,0,2014,2014,1673,0,Phase 1|Phase 2,1,NA,1,3.5263605246161616,"(3,4]"
2761,3710,safety and efficacy of apx005m with gemcitabine and nab-paclitaxel with or without nivolumab in patients with previously untreated metastatic pancreatic adenocarcinoma,"Active, not recruiting",1,0,0,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,129,All,Industry&Combos,1,0,0,2017,2017,1342,1,Phase 1|Phase 2,0,safety/efficacy,0,4.859812404361672,"(4,5]"
2775,3726,"a phase 1/2 study to investigate the safety, biologic and anti-tumor activity of oncos-102 in combination with durvalumab in subjects with advanced peritoneal malignancies","Active, not recruiting",1,0,0,Colorectal Cancer|Platinum-resistant Ovarian Cancer|Appendiceal Cancer,drug or biologic,Early,67,All,Industry&Combos,1,1,0,2016,2017,1546,1,Phase 1|Phase 2,0,safety,0,4.204692619390966,"(4,5]"
1498,1623,"dec-205/ny-eso-1 fusion protein cdx-1401, poly iclc, and ido1 inhibitor incb024360 in treating patients with ovarian, fallopian tube, or primary peritoneal cancer in remission","Active, not recruiting",1,0,0,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Carcinoma,drug or biologic,Early,40,Female,IndustryNIHPartnership,1,0,0,2014,2014,2141,1,Phase 1|Phase 2,0,NA,0,3.6888794541139363,"(3,4]"
805,842,load703 oncolytic virus therapy for pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,43,All,Industry&Combos,NA,1,0,2016,2016,1795,NA,Phase 1|Phase 2,0,NA,0,3.7612001156935624,"(3,4]"
1677,1850,"irx-2, cyclophosphamide, and pembrolizumab in treating participants with recurrent or metastatic gastric or gastroesophageal junction cancer",Suspended,6,0,0,Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Recurrent Gastric Adenocarcinoma|Recurrent Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,20,All,NIH&Combos,0,NA,0,2019,2019,1037,0,Phase 1|Phase 2,1,NA,1,2.995732273553991,"(2,3]"
3455,5247,"phase i/ii trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer",Completed,4,0,0,Colorectal Cancer,drug or biologic,Early,27,All,AllOther,0,NA,0,2017,2017,973,0,Phase 1|Phase 2,1,NA,1,3.295836866004329,"(3,4]"
2521,3359,study of et140202 t cells in adults with advanced hepatocellular carcinoma,Terminated,5,0,0,Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasm|Metastatic Liver Cancer,drug or biologic,Early,2,All,Industry&Combos,NA,NA,0,2019,2019,581,NA,Phase 1|Phase 2,0,NA,0,0.6931471805599453,"(0,1]"
3885,7162,study of tocilizumab in patients with hepatocellular carcinoma (hcc) undergoing transarterial chemoembolization (tace),Withdrawn,7,0,0,Hepatocellular Carcinoma,drug or biologic,Early,NA,All,AllOther,0,NA,0,2016,2017,1096,0,Phase 1|Phase 2,1,NA,1,NA,NA
2845,3813,"s1313, pegph20 in treating patients with newly diagnosed metastatic pancreatic cancer","Active, not recruiting",1,1,1,Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,126,All,IndustryNIHPartnership,1,0,0,2013,2014,1916,1,Phase 1|Phase 2,0,NA,0,4.836281906951478,"(4,5]"
2855,3829,olaparib and ramucirumab in treating patients with metastatic or locally recurrent gastric or gastroesophageal junction cancer that cannot be removed by surgery,Recruiting,2,0,0,Metastatic Esophageal Carcinoma|Metastatic Gastric Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Gastroesophageal Junction Adenocarcinoma|Stage III Esophageal Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIA Gastric Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIB Gastric Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7|Stage IIIC Gastric Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Unresectable Esophageal Carcinoma|Unresectable Gastric Carcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,49,All,NIH&Combos,0,NA,0,2017,2017,1696,0,Phase 1|Phase 2,1,NA,1,3.8918202981106265,"(3,4]"
2604,3502,rx-3117 in combination with abraxane Â® in subjects with metastatic pancreatic cancer,Completed,4,0,0,Metastatic Pancreatic Cancer,drug or biologic,Early,46,All,Industry&Combos,0,NA,0,2017,2017,729,0,Phase 1|Phase 2,1,NA,1,3.828641396489095,"(3,4]"
135,135,endoscopic pancreatic duct stenting for relief of obstructive pain in patients with pancreatic cancer,Withdrawn,7,0,0,Pancreatic Cancer,device,Others,NA,All,AllOther,0,NA,4,2013,2014,670,0,Others,1,NA,1,NA,NA
235,238,quilt-3.060: nant pancreatic cancer vaccine: molecularly informed integrated immunotherapy in subjects with pancreatic cancer who have progressed on or after standard-of-care therapy,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,80,All,Industry&Combos,0,NA,0,2017,2017,1121,0,Phase 1|Phase 2,1,NA,1,4.382026634673881,"(4,5]"
3651,5795,a dose ranging study evaluating efficacy and safety of ni-03,Recruiting,2,0,0,Chronic Pancreatitis,drug or biologic,Early,260,All,Industry&Combos,1,0,0,2016,2015,2069,1,Phase 1|Phase 2,3,safety/efficacy,2,5.560681631015528,"(5,6]"
1155,1228,"study of safety, tolerability, and efficacy of ustekinumab for symptomatic gastrointestinal inflammation associated with common variable immunodeficiency",Completed,4,1,1,Gastrointestinal Inflammation Associated With CVID|CVID Enteropathy,drug or biologic,Early,5,All,NIH&Combos,1,1,0,2014,2015,1397,1,Phase 1|Phase 2,0,safety/efficacy,0,1.6094379124341003,"(1,2]"
794,831,"ipilimumab and local radiation therapy in treating patients with recurrent melanoma, non-hodgkin lymphoma, colon, or rectal cancer",Terminated,5,1,1,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Colon Cancer|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Melanoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Rectal Cancer|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|WaldenstrÃ¶m Macroglobulinemia,drug or biologic,Early,3,All,NIH&Combos,0,1,0,2013,2013,638,0,Phase 1|Phase 2,1,NA,1,1.0986122886681098,"(1,2]"
987,1041,safety study of bmx-001 (radio-protector) in patients with newly diagnosed anal cancer,Recruiting,2,0,0,"Anal Cancer, Squamous Cell Carcinoma|Radiation Exposure",drug or biologic,Early,24,All,Industry&Combos,0,NA,0,2017,2017,1464,0,Phase 1|Phase 2,1,safety,1,3.1780538303479458,"(3,4]"
1193,1270,weekly vitamin d in pediatric ibd,Completed,4,0,0,Inflammatory Bowel Diseases|Skin Pigmentation,other,Others,34,All,AllOther,1,0,0,2014,2013,365,1,Others,1,NA,1,3.5263605246161616,"(3,4]"
2700,3620,"a phase 1/2 trial of gemcitabine plus nab-paclitaxel with or without fg-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer","Active, not recruiting",1,0,0,Pancreatic Cancer (Unresectable),drug or biologic,Early,37,All,Industry&Combos,1,0,0,2014,2014,2710,1,Phase 1|Phase 2,0,NA,0,3.6109179126442243,"(3,4]"
2178,2641,cb-839 + capecitabine in solid tumors and fluoropyrimidine resistant pik3ca mutant colorectal cancer,Suspended,6,0,0,Colorectal Cancer|Colon Cancer|Rectal Cancer|Solid Tumor,drug or biologic,Early,53,All,AllOther,0,NA,0,2016,2016,1845,0,Phase 1|Phase 2,1,NA,1,3.970291913552122,"(3,4]"
1538,1674,"liposomal irinotecan, fluorouracil, leucovorin calcium, and rucaparib in treating patients with metastatic pancreatic, colorectal, gastroesophageal, or biliary cancer",Recruiting,2,0,0,Metastatic Biliary Tract Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Digestive System Neoplasm|Metastatic Pancreatic Adenocarcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,drug or biologic,Early,110,All,NIH&Combos,0,NA,0,2017,2018,2197,0,Phase 1|Phase 2,1,NA,1,4.700480365792417,"(4,5]"
285,290,treatment of hepatic encephalopathy with flumazenil and change in cortical gaba levels in mrs,Withdrawn,7,0,0,Hepatic Encephalopathy|Liver Cirrhosis,drug or biologic,Early,NA,All,NIH&Combos,3,0,4,2014,2014,1218,3,Phase 1|Phase 2,2,NA,2,NA,NA
1199,1277,genistein in treatment of metastatic colorectal cancer,Completed,4,1,1,Colon Cancer|Rectal Cancer|Colorectal Cancer,drug or biologic,Early,13,All,Industry&Combos,0,NA,0,2013,2013,1175,0,Phase 1|Phase 2,1,NA,1,2.5649493574615367,"(2,3]"
1859,2134,m7824 in patients with metastatic colorectal cancer or with advanced solid tumors with microsatellite instability,Recruiting,2,0,0,Colon Adenocarcinoma|High-Frequency Microsatellite Instability|Metastatic Malignant Solid Neoplasm|Rectal Adenocarcinoma|Refractory Colorectal Carcinoma|Stage IV Colon Cancer AJCC v8|Stage IV Rectal Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Rectal Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Rectal Cancer AJCC v8,drug or biologic,Early,74,All,NIH&Combos,0,NA,0,2018,2018,1335,0,Phase 1|Phase 2,1,NA,1,4.30406509320417,"(4,5]"
3900,7213,abx196 in combination with nivolumab in patients with hepatocellular carcinoma,Recruiting,2,0,0,"Carcinoma, Hepatocellular",drug or biologic,Early,48,All,Industry&Combos,0,NA,0,2019,2019,670,0,Phase 1|Phase 2,1,NA,1,3.871201010907891,"(3,4]"
2015,2381,"gemcitabine, nab-paclitaxel and kpt-330 in advanced pancreatic cancer",Recruiting,2,0,0,Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage IV Pancreatic Cancer,drug or biologic,Early,56,All,NIH&Combos,1,0,0,2014,2014,2983,1,Phase 1|Phase 2,0,NA,0,4.02535169073515,"(4,5]"
436,448,mesothelin-targeted immunotoxin lmb-100 alone or in combination with nab-paclitaxel in people with previously treated metastatic and/or locally advanced pancreatic ductal adenocarcinoma and mesothelin expressing solid tumors,"Active, not recruiting",1,1,1,Neoplasms|Pancreatic Neoplasms,drug or biologic,Early,40,All,NIH&Combos,NA,1,0,2016,2016,882,NA,Phase 1|Phase 2,0,NA,0,3.6888794541139363,"(3,4]"
2540,3410,a study of multiple immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer (g/gej) or esophageal cancer (morpheus-gastric and esophageal cancer),Recruiting,2,0,0,Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma,drug or biologic,Early,410,All,Industry&Combos,1,0,0,2017,2017,2675,1,Phase 1|Phase 2,0,NA,0,6.016157159698354,"(6,7]"
2414,3122,[68ga]dotatate-pet/mri in hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,other,Others,30,All,AllOther,1,1,2,2018,2019,1066,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
3971,7502,trial of trc105 and sorafenib in patients with hcc,Completed,4,1,1,Hepatocellular Carcinoma,drug or biologic,Early,27,All,Industry&Combos,0,NA,0,2015,2016,1003,0,Phase 1|Phase 2,1,NA,1,3.295836866004329,"(3,4]"
3708,6181,mln0128 compared to sorafenib in advanced or metastatic hepatocellular carcinoma,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma|Liver Cancer|HCC,drug or biologic,Early,11,All,Industry&Combos,1,0,0,2015,2016,1704,1,Phase 1|Phase 2,0,NA,0,2.3978952727983707,"(2,3]"
3608,5686,phase 1b/2 study of rivoceranib and trifluridine/tipiracil for metastatic colorectal cancer,Recruiting,2,0,0,CRC,drug or biologic,Early,127,All,Industry&Combos,1,0,0,2019,2019,379,1,Phase 1|Phase 2,0,NA,0,4.844187086458591,"(4,5]"
3961,7399,"a study of edp1503 in patients with colorectal cancer, breast cancer, and checkpoint inhibitor relapsed tumors",Recruiting,2,0,0,Colorectal Cancer Metastatic|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Bladder Cancer|GastroEsophageal Cancer|Renal Cell Carcinoma|MSI-H,drug or biologic,Early,120,All,Industry&Combos,1,1,0,2018,2018,731,1,Phase 1|Phase 2,0,NA,0,4.787491742782046,"(4,5]"
408,419,cpi-613 in combination with modified folfirinox in locally advanced pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,33,All,AllOther,0,NA,0,2018,2018,879,0,Phase 1|Phase 2,1,NA,1,3.4965075614664802,"(3,4]"
2997,4019,"durvalumab, an anti-pdli antibody, and tremelimumab, an anti-ctla4 antibody, and chemoradiation before surgery for esophageal cancer",Recruiting,2,0,0,Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,drug or biologic,Early,78,All,Industry&Combos,0,NA,0,2016,2016,2556,0,Phase 1|Phase 2,1,NA,1,4.356708826689592,"(4,5]"
3950,7367,a study of pf-05212384 plus folfiri versus bevacizumab plus folfiri in metastatic colorectal cancer,Terminated,5,1,1,Metastatic Colorectal Carcinoma,drug or biologic,Early,18,All,Industry&Combos,0,0,0,2013,2014,546,0,Phase 1|Phase 2,1,NA,1,2.8903717578961645,"(2,3]"
1044,1099,smoflipid to lessen the severity of neonatal cholestasis,Terminated,5,1,1,"Cholestasis|Jaundice, Obstructive",drug or biologic,Early,2,All,AllOther,0,NA,4,2016,2016,214,0,Phase 1|Phase 2,1,NA,1,0.6931471805599453,"(0,1]"
4122,8876,"phase ib/2, multicenter, dose escalation study of dcr-myc in patients with hepatocellular carcinoma",Terminated,5,1,1,Hepatocellular Carcinoma,drug or biologic,Early,21,All,Industry&Combos,0,NA,0,2014,2015,623,0,Phase 1|Phase 2,1,NA,1,3.044522437723423,"(3,4]"
1086,1147,probiotics and gut health,Recruiting,2,0,0,Metabolic Syndrome,drug or biologic,Early,40,All,AllOther,3,0,0,2018,2018,1251,3,Phase 1|Phase 2,2,NA,2,3.6888794541139363,"(3,4]"
752,788,effect of secretin in functional dyspepsia and healthy subjects,Completed,4,1,1,Dyspepsia|Healthy,drug or biologic,Early,20,All,NIH&Combos,3,0,0,2018,2018,236,3,Phase 1|Phase 2,2,NA,2,2.995732273553991,"(2,3]"
2656,3563,efficacy and tolerability of nm-bl in patients with exocrine pancreatic insufficiency due to cystic fibrosis,Completed,4,0,0,Pancreatic Insufficiency|Cystic Fibrosis|Digestive System Diseases|Lung Diseases|Respiratory Tract Diseases,drug or biologic,Early,35,All,Industry&Combos,3,0,0,2012,2013,426,3,Phase 1|Phase 2,4,efficacy,2,3.5553480614894135,"(3,4]"
2175,2632,nintedanib and capecitabine in treating patients with refractory metastatic colorectal cancer,Completed,4,1,1,Colon Adenocarcinoma|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,drug or biologic,Early,42,All,IndustryNIHPartnership,0,1,0,2015,2015,908,0,Phase 1|Phase 2,1,NA,1,3.7376696182833684,"(3,4]"
3824,6822,"a study of bbi608 in combination with sorafenib, or bbi503 in combination with sorafenib in adult patients with hepatocellular carcinoma",Completed,4,0,0,Hepatocellular Carcinoma,drug or biologic,Early,99,All,Industry&Combos,1,0,0,2014,2014,1673,1,Phase 1|Phase 2,0,NA,0,4.59511985013459,"(4,5]"
509,530,study of nintedanib and chemotherapy for advanced pancreatic cancer,Recruiting,2,0,0,Cancer of Pancreas,drug or biologic,Early,20,All,Industry&Combos,0,NA,0,2016,2017,1363,0,Phase 1|Phase 2,1,NA,1,2.995732273553991,"(2,3]"
2449,3189,high dose ascorbic acid and nanoparticle paclitaxel protein bound and cisplatin and gemcitabine (aa nabplagem) in patients who have metastatic pancreatic cancer,Withdrawn,7,0,0,Metastatic Pancreatic Cancer|Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreatic Metastasis,drug or biologic,Early,NA,All,AllOther,0,NA,0,2019,2019,1096,0,Phase 1|Phase 2,1,NA,1,NA,NA
3868,7106,a study of ly3499446 in participants with advanced solid tumors with kras g12c mutation,Terminated,5,0,0,Advanced Solid Tumor|Non-Small Cell Lung Cancer|Colorectal Cancer,drug or biologic,Early,5,All,Industry&Combos,1,0,0,2019,2019,337,1,Phase 1|Phase 2,0,NA,0,1.6094379124341003,"(1,2]"
1386,1486,pilot and feasibility study of 2'-fl as a dietary supplement in ibd patients receiving stable maintenance anti-tnf therapy,Recruiting,2,0,0,Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis,drug or biologic,Early,216,All,AllOther,NA,0,0,2019,2019,1258,NA,Phase 1|Phase 2,4,NA,2,5.375278407684165,"(5,6]"
528,549,high dose ascorbic acid (aa) + nanoparticle paclitaxel protein bound + cisplatin + gemcitabine (aa nabplagem) in patients who have metastatic pancreatic cancer,Withdrawn,7,0,0,Metastatic Pancreatic Cancer|Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreatic Metastasis,drug or biologic,Early,NA,All,AllOther,0,NA,0,2018,2019,914,0,Phase 1|Phase 2,1,NA,1,NA,NA
3160,4318,an investigational immuno-therapy study of nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread,Recruiting,2,0,0,Colorectal Cancer|Colorectal Tumors|Colorectal Carcinoma|Colorectal Neoplasm,drug or biologic,Early,232,All,Industry&Combos,1,0,0,2017,2018,1810,1,Phase 1|Phase 2,0,NA,0,5.44673737166631,"(5,6]"
3878,7146,68 ga psma pet/mri for hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,drug or biologic,Early,10,All,AllOther,0,NA,2,2019,2019,705,0,Phase 1|Phase 2,1,NA,1,2.302585092994046,"(2,3]"
2634,3537,"combination margetuximab and pembrolizumab for advanced, metastatic her2(+) gastric or gastroesophageal junction cancer","Active, not recruiting",1,0,0,Gastric Cancer|Stomach Cancer|Esophageal Cancer,drug or biologic,Early,95,All,Industry&Combos,0,NA,0,2016,2016,1858,0,Phase 1|Phase 2,1,NA,1,4.553876891600541,"(4,5]"
243,246,quilt-3.080: nant pancreatic cancer vaccine,Unknown status,8,0,0,Pancreatic Cancer,drug or biologic,Early,173,All,Industry&Combos,0,NA,0,2018,2018,491,0,Phase 1|Phase 2,1,NA,1,5.153291594497779,"(5,6]"
2307,2902,phase ib/ii trial of nal-irinotecan and nivolumab as second-line treatment in patients with advanced biliary tract cancer,Recruiting,2,0,0,Biliary Tract Cancer,drug or biologic,Early,40,All,Industry&Combos,0,NA,0,2018,2019,1440,0,Phase 1|Phase 2,1,NA,1,3.6888794541139363,"(3,4]"
3632,5741,a combination clinical study of plx3397 and pembrolizumab to treat advanced melanoma and other solid tumors,Terminated,5,1,1,Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Gastrointestinal Stromal Tumor (GIST)|Ovarian Cancer,drug or biologic,Early,78,All,Industry&Combos,0,1,0,2015,2015,1142,0,Phase 1|Phase 2,1,NA,1,4.356708826689592,"(4,5]"
628,655,aspirin for the treatment of nonalcoholic fatty liver disease,Recruiting,2,0,0,Nonalcoholic Fatty Liver|Nonalcoholic Steatohepatitis,drug or biologic,Early,80,All,AllOther,1,0,0,2019,2019,1572,1,Phase 1|Phase 2,4,NA,2,4.382026634673881,"(4,5]"
3679,6040,columbia-1: novel oncology therapies in combination with chemotherapy and bevacizumab as first- line therapy in mss-crc,"Active, not recruiting",1,0,0,Metastatic Microsatellite-stable Colorectal Cancer,drug or biologic,Early,61,All,Industry&Combos,1,0,0,2019,2019,1623,1,Phase 1|Phase 2,0,NA,0,4.110873864173311,"(4,5]"
2110,2521,pembrolizumab and monoclonal antibody therapy in advanced cancer,Terminated,5,1,1,Advanced Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer,drug or biologic,Early,16,All,AllOther,1,1,0,2014,2014,1400,1,Phase 1|Phase 2,0,NA,0,2.772588722239781,"(2,3]"
3707,6167,gen1029 (hexabody Â®-dr5/dr5) safety trial in patients with malignant solid tumors,Recruiting,2,0,0,Colorectal Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Renal Cell Carcinoma|Gastric Cancer|Pancreatic Cancer|Urothelial Cancer,drug or biologic,Early,520,All,Industry&Combos,0,NA,0,2018,2018,1304,0,Phase 1|Phase 2,1,safety,1,6.253828811575473,"(6,7]"
3458,5250,epacadostat in combination with pembrolizumab and azacitidine in subjects with metastatic colorectal cancer,Withdrawn,7,0,0,Metastatic Colorectal Cancer,drug or biologic,Early,NA,All,Industry&Combos,0,NA,0,2017,2018,303,0,Phase 1|Phase 2,1,NA,1,NA,NA
2887,3872,"testing the combination of anetumab ravtansine with either nivolumab, nivolumab and ipilimumab, or gemcitabine and nivolumab in advanced pancreatic cancer",Recruiting,2,0,0,Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Adenocarcinoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma,drug or biologic,Early,64,All,NIH&Combos,1,1,0,2019,2019,1129,1,Phase 1|Phase 2,0,NA,0,4.1588830833596715,"(4,5]"
643,670,"nivolumab, ipilimumab and chemoradiation in treating patients with resectable gastric cancer",Recruiting,2,0,0,Clinical Stage 0 Gastric Cancer AJCC v8|Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage I Gastric Cancer AJCC v8|Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Gastric Cancer AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Gastric Adenocarcinoma|Localized Gastric Carcinoma|Localized Gastroesophageal Junction Adenocarcinoma|Pathologic Stage 0 Gastric Cancer AJCC v8|Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage I Gastric Cancer AJCC v8|Pathologic Stage IA Gastric Cancer AJCC v8|Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Gastric Cancer AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastric Cancer AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastric Cancer AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8,drug or biologic,Early,30,All,NIH&Combos,0,NA,0,2018,2019,1089,0,Phase 1|Phase 2,1,NA,1,3.4011973816621555,"(3,4]"
3954,7377,sym004 in combination with folfiri in metastatic colorectal cancer patients,Terminated,5,1,1,Metastatic Colorectal Cancer,drug or biologic,Early,10,All,Industry&Combos,NA,1,0,2015,2016,426,NA,Phase 1|Phase 2,0,NA,0,2.302585092994046,"(2,3]"
435,447,panitumumab-irdye800 in patients with pancreatic cancer undergoing surgery,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma,drug or biologic,Early,15,All,NIH&Combos,NA,1,2,2017,2018,1455,NA,Phase 1|Phase 2,0,NA,0,2.70805020110221,"(2,3]"
3776,6537,alpha-1 antitrypsin (aat) enhances islet autograft survival in patients with chronic pancreatitis,"Active, not recruiting",1,0,0,Chronic Pancreatitis,drug or biologic,Early,48,All,AllOther,1,0,1,2016,2016,1857,1,Phase 1|Phase 2,4,NA,2,3.871201010907891,"(3,4]"
2325,2938,immune checkpoint therapy with nivolumab esophageal squamous cell carcinoma,"Active, not recruiting",1,0,0,Esophageal Squamous Cell Carcinoma,drug or biologic,Early,10,All,AllOther,0,NA,0,2017,2017,1435,0,Phase 1|Phase 2,1,NA,1,2.302585092994046,"(2,3]"
2395,3083,ga-68 dota-toc of somatostatin positive malignancies,Terminated,5,1,1,Neuroendocrine Tumor|Paraganglioma|Carcinoid Tumors|Neuroblastoma,drug or biologic,Early,300,All,AllOther,0,NA,2,2014,2014,1141,0,Phase 1|Phase 2,1,NA,1,5.703782474656201,"(5,6]"
1519,1650,taa specific cytotoxic t lymphocytes in patients with pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,45,All,AllOther,1,1,0,2017,2018,1199,1,Phase 1|Phase 2,0,NA,0,3.8066624897703196,"(3,4]"
1803,2038,"pembrolizumab in combination with ibrutinib for advanced, refractory colorectal cancers","Active, not recruiting",1,1,1,Colon Cancer|Colorectal Cancer|Colorectal Carcinoma|Colon Disease,drug or biologic,Early,40,All,Industry&Combos,NA,NA,0,2017,2018,680,NA,Phase 1|Phase 2,0,NA,0,3.6888794541139363,"(3,4]"
693,725,hepatocyte transplantation in liver failure,Withdrawn,7,0,0,Liver Failure,drug or biologic,Early,NA,All,AllOther,0,NA,0,2008,2014,731,0,Phase 1|Phase 2,1,NA,1,NA,NA
2351,2988,study of pembrolizumab with lanreotide depot for gastroenteropancreatic neuroendocrine tumors,"Active, not recruiting",1,0,0,Gastroenteropancreatic Neuroendocrine Tumors,drug or biologic,Early,22,All,Industry&Combos,0,NA,0,2017,2017,1523,0,Phase 1|Phase 2,1,NA,1,3.091042453358316,"(3,4]"
3295,4668,administering peripheral blood lymphocytes transduced with a cd70-binding chimeric antigen receptor to people with cd70 expressing cancers,Suspended,6,0,0,Pancreatic Cancer|Renal Cell Cancer|Breast Cancer|Melanoma|Ovarian Cancer,drug or biologic,Early,2,All,NIH&Combos,NA,1,0,2016,2017,3557,NA,Phase 1|Phase 2,0,NA,0,0.6931471805599453,"(0,1]"
1622,1777,"a phase i/ii evaluation of adxs11-001, mitomycin, 5-fluorouracil (5-fu) and imrt for anal cancer",Terminated,5,1,1,Anal Cancer,drug or biologic,Early,11,All,AllOther,0,NA,0,2012,2013,1826,0,Phase 1|Phase 2,1,NA,1,2.3978952727983707,"(2,3]"
459,474,durvalumab plus cv301 with maintenance chemotherapy in metastatic colorectal or pancreatic adenocarcinoma,"Active, not recruiting",1,0,0,Metastatic Colorectal Cancer|Colorectal Adenocarcinoma|Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer,drug or biologic,Early,8,All,IndustryNIHPartnership,NA,1,0,2017,2018,1211,NA,Phase 1|Phase 2,0,NA,0,2.0794415416798357,"(2,3]"
1777,1999,spironolactone therapy in young women with nash,Recruiting,2,0,0,"NASH - Nonalcoholic Steatohepatitis",drug or biologic,Early,30,Female,AllOther,1,0,4,2018,2019,1269,1,Phase 1|Phase 2,4,NA,2,3.4011973816621555,"(3,4]"
2502,3319,safety and efficacy of fmt in individuals with one or more recurrences of clostridium difficile associated disease (cdad),Terminated,5,0,0,Clostridial Infection|Dysbiosis|Probiotic Therapy,drug or biologic,Early,10,All,NIH&Combos,NA,0,0,2018,2018,901,NA,Phase 1|Phase 2,2,safety/efficacy,2,2.302585092994046,"(2,3]"
138,138,pre-operative stereotactic body radiation therapy for pancreatic adenocarcinoma with or without ccx872-b,Withdrawn,7,0,0,Adenocarcinoma of the Pancreas|Pancreas Cancer,drug or biologic,Early,NA,All,AllOther,1,1,0,2018,2019,30,1,Phase 1|Phase 2,0,NA,0,NA,NA
114,114,neoadjuvant/adjuvant gvax pancreas vaccine (with cy) with or without nivolumab and urelumab trial for surgically resectable pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,62,All,IndustryNIHPartnership,1,0,0,2015,2016,2256,1,Phase 1|Phase 2,0,NA,0,4.127134385045092,"(4,5]"
2439,3170,safety and immunological effect of pembrolizumab in resectable or borderline resectable pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,drug or biologic,Early,68,All,AllOther,1,0,0,2014,2015,2832,1,Phase 1|Phase 2,0,safety,0,4.219507705176107,"(4,5]"
1303,1392,liver transplantation with tregs at mgh,Recruiting,2,0,0,Liver Transplant,drug or biologic,Early,9,All,NIH&Combos,0,NA,0,2018,2019,2164,0,Phase 1|Phase 2,1,NA,1,2.1972245773362196,"(2,3]"
1167,1241,delayed infusion of dcreg in living donor liver transplantation,Enrolling by invitation,3,0,0,Living Donor Liver Transplantation,drug or biologic,Early,24,All,AllOther,0,NA,4,2019,2019,1414,0,Phase 1|Phase 2,1,NA,1,3.1780538303479458,"(3,4]"
4139,8987,a safety and efficacy study of cc-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (hcc),Completed,4,1,1,"Carcinoma, Hepatocellular",drug or biologic,Early,21,All,Industry&Combos,0,NA,0,2016,2016,1284,0,Phase 1|Phase 2,1,safety/efficacy,1,3.044522437723423,"(3,4]"
1957,2298,fecal microbiota transplant for primary cdi,Terminated,5,0,0,Clostridium Difficile Infection,drug or biologic,Early,5,All,AllOther,1,1,0,2019,2019,511,1,Phase 1|Phase 2,0,NA,0,1.6094379124341003,"(1,2]"
27,27,pancreatic islets and parathyroid gland co-transplantation for treatment of type 1 diabetes,Recruiting,2,0,0,Type 1 Diabetes,other,Others,8,All,AllOther,0,NA,0,2019,2019,1309,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
1767,1980,effects of probiotic on inflammation and microbiota in patients with nash,Terminated,5,0,0,Non-Alcoholic Fatty Liver Disease|Probiotics MeSH Descriptor Data 2018|Interleukin-17 MeSH Descriptor Data 2018,drug or biologic,Early,6,All,AllOther,0,NA,4,2018,2018,213,0,Phase 1|Phase 2,1,NA,1,1.791759469228055,"(1,2]"
1377,1477,dcreg in living donor liver transplantation,"Active, not recruiting",1,0,0,Living Donor Liver Transplantation,drug or biologic,Early,16,All,AllOther,0,NA,4,2017,2017,2101,0,Phase 1|Phase 2,1,NA,1,2.772588722239781,"(2,3]"
1056,1111,vegfr/pdgfr dual kinase inhibitor x-82 and everolimus for treating patients with pancreatic neuroendocrine tumors,Terminated,5,1,1,Adenocarcinoma|Pancreatic Neoplasms,drug or biologic,Early,23,All,Industry&Combos,NA,1,0,2013,2013,2665,NA,Phase 1|Phase 2,0,NA,0,3.1354942159291497,"(3,4]"
463,478,"quilt-2.022 nant-008 in combination w/ 5-fluorouracil, bevacizumab, leucovorin & oxaliplatin in subjects with pancreatic cancer",Suspended,6,0,0,Pancreatic Adenocarcinoma Metastatic,drug or biologic,Early,64,All,Industry&Combos,0,NA,0,2017,2018,2469,0,Phase 1|Phase 2,1,NA,1,4.1588830833596715,"(4,5]"
2782,3736,medi9447(oleclumab) pancreatic chemotherapy combination study.,Recruiting,2,0,0,Carcinoma|Metastatic Pancreatic Adenocarcinoma,drug or biologic,Early,339,All,Industry&Combos,1,0,0,2018,2018,1653,1,Phase 1|Phase 2,0,NA,0,5.82600010738045,"(5,6]"
1407,1511,manipulating the gut microbiome study,Terminated,5,0,0,Urea Cycle Disorder,drug or biologic,Early,4,All,AllOther,3,0,0,2017,2017,438,3,Phase 1|Phase 2,0,NA,0,1.3862943611198906,"(1,2]"
3861,7075,abi-009 (nab-rapamycin) in combination with folfox and bevacizumab as first-line therapy in patients with advanced or metastatic colorectal cancer,Recruiting,2,0,0,Colorectal Cancer Metastatic,drug or biologic,Early,43,All,Industry&Combos,0,1,0,2018,2018,1249,0,Phase 1|Phase 2,1,NA,1,3.7612001156935624,"(3,4]"
1431,1540,safety and efficacy of ecoactive on intestinal adherent invasive e. coli in patients with inactive crohn's disease,Recruiting,2,0,0,Crohn Disease,drug or biologic,Early,30,All,Industry&Combos,1,0,0,2019,2019,580,1,Phase 1|Phase 2,2,safety/efficacy,2,3.4011973816621555,"(3,4]"
389,399,trial of neoadjuvant and adjuvant nivolumab and bms-813160 with or without gvax for locally advanced pancreatic ductal adenocarcinomas.,Recruiting,2,0,0,Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)|Pancreatic Ductal Adenocarcinoma,drug or biologic,Early,30,All,Industry&Combos,NA,0,0,2018,2019,817,NA,Phase 1|Phase 2,0,NA,0,3.4011973816621555,"(3,4]"
3729,6244,safety and efficacy study of single doses of tt-034 in patients with chronic hepatitis c,Completed,4,0,0,Hepatitis C,drug or biologic,Early,9,All,Industry&Combos,0,NA,0,2013,2014,974,0,Phase 1|Phase 2,1,safety/efficacy,1,2.1972245773362196,"(2,3]"
1320,1410,"a study of the efficacy of cannabidiol in patients with multiple myeloma, glioblastoma multiforme, and gi malignancies",Unknown status,8,0,0,"Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer, Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme",drug or biologic,Early,160,All,Industry&Combos,3,0,0,2018,2019,532,3,Phase 1|Phase 2,4,efficacy,2,5.075173815233827,"(5,6]"
3575,5541,"safety, pharmacokinetics and preliminary anti-tumor activity of intravenous tkm-080301 in subjects with advanced hepatocellular carcinoma",Completed,4,0,0,"Hepatocellular Carcinoma|Hepatoma|Liver Cancer, Adult|Liver Cell Carcinoma, Adult",drug or biologic,Early,43,All,Industry&Combos,0,NA,0,2014,2014,700,0,Phase 1|Phase 2,1,safety,1,3.7612001156935624,"(3,4]"
1928,2251,"fresh, frozen or lyophilized fecal microbiota transplantation for multiple recurrent c. difficile associated diarrhea",Completed,4,1,1,Recurrent C. Difficile Associated Diarrhea,drug or biologic,Early,79,All,AllOther,1,0,0,2014,2013,1704,1,Phase 1|Phase 2,0,NA,0,4.3694478524670215,"(4,5]"
1724,1917,administering peripheral blood lymphocytes transduced with a murine t-cell receptor recognizing the g12d variant of mutated ras in hla-a*11:01 patients,Suspended,6,0,0,Gastrointestinal Cancer|Pancreatic Cancer|Gastric Cancer|Colon Cancer|Rectal Cancer,drug or biologic,Early,4,All,NIH&Combos,NA,1,0,2018,2019,3121,NA,Phase 1|Phase 2,0,NA,0,1.3862943611198906,"(1,2]"
3665,5840,a safety and efficacy evaluation of bli801 laxative in adults experiencing non-idiopathic constipation,Completed,4,0,0,Constipation,drug or biologic,Early,435,All,Industry&Combos,1,0,0,2016,2016,304,1,Phase 2|Phase 3,4,safety/efficacy,2,6.075346031088684,"(6,7]"
2820,3780,a study of guselkumab in participants with moderately to severely active ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis,drug or biologic,Early,950,All,Industry&Combos,1,0,0,2019,2019,1007,1,Phase 2|Phase 3,2,NA,2,6.856461984594587,"(6,7]"
3084,4163,study of quadruple therapy with eltrombopag for chronic hepatitis c,Terminated,5,1,1,Thrombocytopenia|Hepatitis C,drug or biologic,Early,7,All,Industry&Combos,0,NA,0,2013,2013,730,0,Phase 2|Phase 3,1,NA,1,1.9459101490553132,"(1,2]"
3867,7105,antibiotic safety (scamp),Completed,4,1,1,Complicated Intra Abdominal Infections,drug or biologic,Early,260,All,Industry&Combos,1,0,0,2013,2013,1141,1,Phase 2|Phase 3,0,safety,0,5.560681631015528,"(5,6]"
3672,5887,a study of the efficacy and safety of guselkumab in participants with moderately to severely active crohn's disease,Recruiting,2,0,0,Crohn's Disease,drug or biologic,Early,2000,All,Industry&Combos,1,0,0,2018,2018,1512,1,Phase 2|Phase 3,2,safety/efficacy,2,7.600902459542082,"(7,13]"
2006,2363,the efficacy of azd1722 in constipation predominant irritable bowel syndrome (ibs-c),Completed,4,1,1,Constipation Predominant Irritable Bowel Syndrome,drug or biologic,Early,356,All,Industry&Combos,1,0,0,2013,2013,426,1,Phase 2|Phase 3,4,efficacy,2,5.87493073085203,"(5,6]"
3276,4617,cisplatin and combination chemotherapy in treating children and young adults with hepatoblastoma or liver cancer after surgery,Recruiting,2,0,0,"Childhood Hepatocellular Carcinoma|Childhood Malignant Liver Neoplasm|Fibrolamellar Carcinoma|Hepatoblastoma|Hepatocellular Malignant Neoplasm, Not Otherwise Specified",drug or biologic,Early,1220,All,NIH&Combos,1,0,0,2018,2018,2595,1,Phase 2|Phase 3,0,NA,0,7.106606137727303,"(7,13]"
1066,1122,study on the use of low dose ketamine after gastric bypass and gastrectomy,Completed,4,1,1,Pain|Postoperative Depression,drug or biologic,Early,90,All,AllOther,1,0,0,2015,2014,925,1,Phase 2|Phase 3,3,NA,2,4.499809670330265,"(4,5]"
1491,1615,compassionate use of omegaven in children,Completed,4,1,1,"Total Parenteral Nutrition-induced Cholestasis|Cholestasis|Short Bowel Syndrome|Gastroschisis|Intestinal Atresia|Infant, Premature, Diseases|Cholestasis of Parenteral Nutrition",drug or biologic,Early,63,All,AllOther,0,NA,0,2015,2015,1214,0,Phase 2|Phase 3,1,NA,1,4.143134726391533,"(4,5]"
61,61,the bihormonal ilet bionic pancreas feasibility study,Completed,4,1,1,Type 1 Diabetes Mellitus,drug or biologic,Early,12,All,Industry&Combos,3,0,0,2019,2019,49,3,Phase 2|Phase 3,0,NA,0,2.4849066497880004,"(2,3]"
609,635,cirten-simultaneous pancreas-kidney transplant recipients,Recruiting,2,0,0,Kidney Pancreas Transplantation,drug or biologic,Early,30,All,Industry&Combos,0,NA,0,2018,2019,1342,0,Phase 2|Phase 3,1,NA,1,3.4011973816621555,"(3,4]"
2800,3757,varlitinib in combination with capecitabine for advanced or metastatic biliary tract cancer,"Active, not recruiting",1,0,0,Biliary Tract Cancer,drug or biologic,Early,490,All,AllOther,1,0,0,2017,2017,727,1,Phase 2|Phase 3,2,NA,2,6.194405391104672,"(6,7]"
2672,3582,efficacy and safety of reparixin in pancreatic islet auto-transplantation,Completed,4,1,1,Pancreatectomy for Chronic Pancreatitis,drug or biologic,Early,104,All,Industry&Combos,1,0,0,2013,2014,1430,1,Phase 2|Phase 3,2,safety/efficacy,2,4.6443908991413725,"(4,5]"
3421,5191,efficacy of rifaximin in preventing campylobacteriosis,Completed,4,1,1,Dysentery|Diarrhea|Enteric Campylobacteriosis,drug or biologic,Early,30,All,AllOther,1,0,1,2014,2014,678,1,Phase 2|Phase 3,4,efficacy,2,3.4011973816621555,"(3,4]"
797,834,liver and fat regulation in overweight adolescent girls,"Active, not recruiting",1,0,0,Hepatic Steatosis|Polycystic Ovarian Syndrome|Obesity,drug or biologic,Early,105,Female,AllOther,0,1,4,2014,2014,2679,0,Phase 2|Phase 3,1,NA,1,4.653960350157523,"(4,5]"
34,34,tissue analysis after thermal ablation for colon cancer liver metastases leading to immediate retreatment,Recruiting,2,0,0,Colorectal Cancer Liver Metastases,procedure,Others,100,All,AllOther,0,NA,2,2019,2019,1437,0,Others,1,NA,1,4.605170185988092,"(4,5]"
3596,5652,vitamin d + telaprevir + peginterferon + ribavirin for of hepatitis c genotype 1,Withdrawn,7,0,0,Hepatitis C,drug or biologic,Early,NA,All,Industry&Combos,1,0,0,2013,2013,791,1,Phase 2|Phase 3,0,NA,0,NA,NA
2919,3914,safety and efficacy of andecaliximab (gs-5745) in adults with moderately to severely active ulcerative colitis,Terminated,5,1,1,Ulcerative Colitis,drug or biologic,Early,165,All,Industry&Combos,1,0,0,2015,2015,366,1,Phase 2|Phase 3,2,safety/efficacy,2,5.10594547390058,"(5,6]"
3979,7534,utilization of hepatitis c positive kidneys in negative recipients,Recruiting,2,0,0,Kidney Transplant|Hepatitis C|HCV,drug or biologic,Early,25,All,AllOther,0,NA,0,2019,2019,723,0,Phase 2|Phase 3,1,NA,1,3.2188758248682006,"(3,4]"
167,168,circulating tumor dna testing in predicting treatment for patients with stage iia colon cancer after surgery,Recruiting,2,0,0,Colon Adenocarcinoma|Stage IIA Colon Cancer AJCC v8,drug or biologic,Early,1408,All,NIH&Combos,1,0,0,2019,2019,928,1,Phase 2|Phase 3,0,NA,0,7.249925536717988,"(7,13]"
2654,3560,"combination margetuximab, incmga00012, mgd013, and chemotherapy phase 2/3 trial in her2+ gastric/gej cancer (mahogany)",Recruiting,2,0,0,Gastric Cancer|Gastroesophageal Junction Cancer|HER2-positive Gastric Cancer,other,Others,860,All,Industry&Combos,1,0,0,2019,2019,1675,1,Others,0,NA,0,6.756932389247553,"(6,7]"
3614,5699,behavioral and pharmacologic treatment of binge eating and obesity: acute treatment,"Active, not recruiting",1,0,0,Binge-eating Disorder|Obesity,drug or biologic,Early,136,All,NIH&Combos,1,0,0,2017,2017,2499,1,Phase 2|Phase 3,2,NA,2,4.912654885736052,"(4,5]"
358,366,effect of ranolazine on gastrointestinal motor function and pain in patients with ibs-d,Terminated,5,1,1,Diarrhea Predominant Irritable Bowel Syndrome,drug or biologic,Early,5,All,AllOther,1,0,0,2014,2014,365,1,Phase 2|Phase 3,3,NA,2,1.6094379124341003,"(1,2]"
702,736,somatostatin analogues with perioperative antibiotics versus prolonged antibiotics,Enrolling by invitation,3,0,0,Pancreatic Diseases,drug or biologic,Early,400,All,AllOther,1,0,0,2020,2019,899,1,Phase 2|Phase 3,1,NA,1,5.991464547107982,"(5,6]"
3135,4259,nivolumab and ipilimumab in treating patients with esophageal and gastroesophageal junction adenocarcinoma undergoing surgery,Recruiting,2,0,0,Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8,drug or biologic,Early,278,All,NIH&Combos,1,0,0,2018,2019,1809,1,Phase 2|Phase 3,0,NA,0,5.627621113690637,"(5,6]"
3264,4594,a health intervention to prevent depression hepatitis c patients,Terminated,5,0,0,Hepatitis C|Major Depressive Disorder,behavioral,Others,1,All,AllOther,1,0,1,2013,2013,852,1,Others,1,NA,1,0,NA
99,99,acetic acid chromoendoscopy in barrett's esophagus surveillance,Terminated,8,1,1,Barrett's Esophagus,drug or biologic,Early,60,All,AllOther,1,0,NA,2015,2017,507,1,Phase 2|Phase 3,1,NA,1,4.0943445622221,"(4,5]"
1802,2037,probiotic (visbiome) for gulf war illness,Unknown status,8,0,0,Gulf War Illness,drug or biologic,Early,60,All,AllOther,1,0,0,2017,2013,1721,1,Phase 2|Phase 3,3,NA,2,4.0943445622221,"(4,5]"
3649,5787,a study to assess resistance and durability of response to abt-493 and/or abt-530,Completed,4,1,1,Hepatitis C,drug or biologic,Early,384,All,Industry&Combos,0,NA,4,2015,2015,1576,0,Phase 2|Phase 3,1,NA,1,5.950642552587727,"(5,6]"
3111,4222,a clinical trial to evaluate the efficacy and safety of two aramchol doses versus placebo in patients with nash,Completed,4,0,0,Fatty Liver,drug or biologic,Early,247,All,Industry&Combos,1,0,0,2014,2015,1237,1,Phase 2|Phase 3,4,safety/efficacy,2,5.5093883366279774,"(5,6]"
327,333,secretin infusion to prevent pancreatic leaks following pancreatic resection,Completed,4,1,1,Injury of Body of Pancreas,drug or biologic,Early,170,All,AllOther,1,0,0,2014,2014,1969,1,Phase 2|Phase 3,3,NA,2,5.135798437050262,"(5,6]"
1355,1449,probiotic (vsl #3) for gulf war illness,Terminated,5,1,1,Gulf War Illness,drug or biologic,Early,29,All,AllOther,1,0,0,2013,2013,1034,1,Phase 2|Phase 3,3,NA,2,3.367295829986474,"(3,4]"
1392,1493,evaluate the clinical benefits of envarsusxr in post liver transplant,"Active, not recruiting",1,0,0,Post Liver Transplant,drug or biologic,Early,35,All,Industry&Combos,1,0,1,2017,2017,1479,1,Phase 2|Phase 3,0,NA,0,3.5553480614894135,"(3,4]"
3194,4429,cancer associated thrombosis and isoquercetin (catiq),Completed,4,1,1,Thromboembolism of Vein VTE in Colorectal Cancer|Thromboembolism of Vein in Pancreatic Cancer|Thromboembolism of Vein in Non-small Cell Lung Cancer,drug or biologic,Early,64,All,IndustryNIHPartnership,NA,1,0,2014,2015,1430,NA,Phase 2|Phase 3,0,NA,0,4.1588830833596715,"(4,5]"
3162,4320,safety and efficacy study in infant with sbs,Terminated,5,0,0,Short Bowel Syndrome,drug or biologic,Early,2,All,Industry&Combos,1,0,0,2016,2017,367,1,Phase 2|Phase 3,4,safety/efficacy,2,0.6931471805599453,"(0,1]"
2452,3194,rectal indomethacin in the prevention of post-ercp pancreatitis,Completed,4,1,1,Post-ERCP Pancreatitis,drug or biologic,Early,1037,All,AllOther,1,0,1,2013,2013,1735,1,Phase 2|Phase 3,4,NA,2,6.9440872082295275,"(6,7]"
117,117,benralizumab for eosinophilic gastritis,"Active, not recruiting",1,0,0,Eosinophilic Gastritis or Gastroenteritis,drug or biologic,Early,26,All,Industry&Combos,1,0,0,2018,2018,815,1,Phase 2|Phase 3,3,NA,2,3.258096538021482,"(3,4]"
2796,3753,impact of emergency department probiotic (lgg) treatment of pediatric gastroenteritis,Completed,4,1,1,Gastroenteritis,drug or biologic,Early,971,All,AllOther,1,0,0,2013,2014,1492,1,Phase 2|Phase 3,4,NA,2,6.878326468291325,"(6,7]"
2237,2758,microbiota or placebo after antimicrobial therapy for recurrent c. difficile at home (match),Recruiting,2,0,0,Clostridium Difficile Infection,drug or biologic,Early,390,All,AllOther,1,0,1,2016,2018,1292,1,Phase 2|Phase 3,3,NA,2,5.966146739123692,"(5,6]"
2749,3690,bi655130 (spesolimab) induction treatment in patients with moderate-to-severe ulcerative colitis,Completed,4,1,1,"Colitis, Ulcerative",drug or biologic,Early,98,All,Industry&Combos,1,0,0,2018,2018,783,1,Phase 2|Phase 3,2,NA,2,4.584967478670572,"(4,5]"
3999,7560,efficacy of all-oral anti-viral therapy for symptomatic hepatitis c virus infection-related cryoglobulinemia,Completed,4,1,1,Hepatitis C|Cryoglobulinemia,drug or biologic,Early,10,All,Industry&Combos,0,NA,0,2016,2016,1264,0,Phase 2|Phase 3,1,efficacy,1,2.302585092994046,"(2,3]"
3361,4916,sirt followed by cis-gem chemotherapy versus cis-gem chemotherapy alone as 1st line treatment of patients with unresectable intrahepatic cholangiocarcinoma,"Active, not recruiting",1,0,0,Intrahepatic Cholangiocarcinoma,drug or biologic,Early,89,All,Industry&Combos,1,0,0,2016,2017,1612,1,Phase 2|Phase 3,0,NA,0,4.48863636973214,"(4,5]"
4103,8158,"a study to evaluate the pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in pediatric subjects with genotypes 1-6 chronic hepatitis c virus (hcv) infection","Active, not recruiting",1,0,0,Hepatitis C Virus (HCV),drug or biologic,Early,110,All,Industry&Combos,1,1,0,2017,2017,1165,1,Phase 2|Phase 3,0,safety/efficacy,0,4.700480365792417,"(4,5]"
2818,3777,"a multicenter, randomized, double-blind, placebo controlled induction study to evaluate the efficacy and safety of risankizumab in participants with moderately to severely active ulcerative colitis",Recruiting,2,0,0,Ulcerative Colitis (UC),drug or biologic,Early,1547,All,Industry&Combos,1,0,0,2018,2018,1661,1,Phase 2|Phase 3,2,safety/efficacy,2,7.344072850573066,"(7,13]"
3921,7307,an investigational immunotherapy study of nivolumab with standard of care therapy vs standard of care therapy for first-line treatment of colorectal cancer that has spread,"Active, not recruiting",1,0,0,Colorectal Cancer,drug or biologic,Early,180,All,Industry&Combos,1,0,0,2018,2018,1279,1,Phase 2|Phase 3,0,NA,0,5.19295685089021,"(5,6]"
1853,2125,treating bacterial overgrowth in parkinson's disease,Completed,4,0,0,Parkinson's Disease|Small Intestinal Bacterial Overgrowth,drug or biologic,Early,24,All,AllOther,1,0,0,2015,2015,609,1,Phase 2|Phase 3,2,NA,2,3.1780538303479458,"(3,4]"
2838,3804,efficacy & safety of td-1473 in ulcerative colitis,Recruiting,2,0,0,Ulcerative Colitis (UC),drug or biologic,Early,880,All,Industry&Combos,1,0,0,2018,2019,2274,1,Phase 2|Phase 3,4,safety/efficacy,2,6.779921907472252,"(6,7]"
2909,3899,gemcitabine plus cisplatin with or without bintrafusp alfa (m7824) in participants with 1l biliary tract cancer (btc),Recruiting,2,0,0,Biliary Tract Cancer|Cholangiocarcinoma|Gallbladder Cancer,drug or biologic,Early,512,All,Industry&Combos,1,0,0,2019,2019,1161,1,Phase 2|Phase 3,4,NA,2,6.238324625039508,"(6,7]"
3901,7229,comparison of cadazolid versus vancomycin in children with clostridium difficile-associated diarrhea (cdad),Terminated,5,1,1,Clostridium Difficile Infection,drug or biologic,Early,1,All,Industry&Combos,1,0,0,2017,2017,368,1,Phase 2|Phase 3,1,NA,1,0,NA
160,160,individualizing automated closed loop glucose control through pharmacokinetic profiling in an insulin-only bionic pancreas,Enrolling by invitation,3,0,0,Type 1 Diabetes Mellitus,drug or biologic,Early,45,All,AllOther,3,0,0,2017,2019,988,3,Phase 2|Phase 3,1,NA,1,3.8066624897703196,"(3,4]"
2305,2897,"efficacy study of anakinra, pentoxifylline, and zinc compared to methylprednisolone in severe acute alcoholic hepatitis",Completed,4,1,1,Acute Alcoholic Hepatitis,drug or biologic,Early,104,All,NIH&Combos,1,0,0,2013,2013,1856,1,Phase 2|Phase 3,3,efficacy,2,4.6443908991413725,"(4,5]"
3612,5697,behavioral and pharmacologic treatment of binge eating and obesity: specialist treatment,Enrolling by invitation,3,0,0,Binge-Eating Disorder|Obesity,drug or biologic,Early,72,All,NIH&Combos,1,0,0,2017,2017,2217,1,Phase 2|Phase 3,1,NA,1,4.276666119016055,"(4,5]"
3514,5349,an active and placebo-controlled study of brazikumab in participants with moderately to severely active crohn's disease,"Active, not recruiting",1,0,0,Crohn's Disease|IBD,drug or biologic,Early,1140,All,Industry&Combos,1,0,0,2018,2018,1441,1,Phase 2|Phase 3,3,NA,2,7.038783541388542,"(7,13]"
467,482,eosinophilic esophagitis intervention trial-1 food vs. 4 food elimination diet followed by swallowed glucocorticoids,Completed,4,1,1,Eosinophilic Esophagitis|Eosinophilic Gastrointestinal Disorders (EGIDs),drug or biologic,Early,67,All,AllOther,3,0,0,2015,2016,786,3,Phase 2|Phase 3,0,NA,0,4.204692619390966,"(4,5]"
2856,3830,sofeed: six food vs. one food eosinophilic esophagitis diet study,Completed,4,1,1,Eosinophilic Gastrointestinal Disorders (EGIDs)|Eosinophilic Esophagitis (EoE),drug or biologic,Early,129,All,NIH&Combos,3,0,0,2016,2016,1062,3,Phase 2|Phase 3,0,NA,0,4.859812404361672,"(4,5]"
645,672,sacral neuromodulation (snm) with interstimtm for bowel dysfunction following surgery for rectal cancers with sphincter preservation,Terminated,5,1,1,Rectal Cancer|for Bowel Dysfunction Following Surgery for Rectal Cancers,device,Others,4,All,AllOther,3,0,0,2014,2014,923,3,Others,1,NA,1,1.3862943611198906,"(1,2]"
1572,1715,percutaneous hepatic perfusion vs. cisplatin/gemcitabine in patients with intrahepatic cholangiocarcinoma,"Active, not recruiting",1,0,0,Bile Duct Cancer|Intrahepatic Cholangiocarcinoma,drug or biologic,Early,295,All,Industry&Combos,1,0,0,2017,2018,1727,1,Phase 2|Phase 3,0,NA,0,5.68697535633982,"(5,6]"
15,15,the role of secondary bile acids in intestinal inflammation,Recruiting,2,0,0,Ulcerative Colitis|Pouchitis,drug or biologic,Early,15,All,AllOther,0,NA,0,2018,2019,2289,0,Phase 2|Phase 3,1,NA,1,2.70805020110221,"(2,3]"
811,848,use of omegaven for treatment with parenteral nutrition associated liver disease,Completed,4,1,1,Parenteral Nutrition-related Hepatitis,drug or biologic,Early,2,All,AllOther,0,NA,0,2021,2013,2040,0,Phase 2|Phase 3,1,NA,1,0.6931471805599453,"(0,1]"
2422,3138,naloxegol and opioid-induced constipation,Recruiting,2,0,0,Constipation|Constipation Drug Induced,drug or biologic,Early,280,All,AllOther,1,0,0,2017,2017,1121,1,Phase 2|Phase 3,2,NA,2,5.634789603169249,"(5,6]"
2942,3944,13c-methacetin breath test for the prediction of outcome in in ali or alf,Completed,4,1,1,Acute Liver Failure,drug or biologic,Early,76,All,IndustryNIHPartnership,0,NA,2,2016,2016,1195,0,Phase 2|Phase 3,1,NA,1,4.330733340286331,"(4,5]"
4156,9127,adcc mediated b-cell depletion and baff-r blockade,Recruiting,2,0,0,Autoimmune Hepatitis,drug or biologic,Early,80,All,Industry&Combos,1,0,0,2017,2018,2696,1,Phase 2|Phase 3,4,NA,2,4.382026634673881,"(4,5]"
1701,1882,hyperbaric oxygen for ulcerative colitis,Terminated,5,0,0,Ulcerative Colitis,procedure,Others,18,All,AllOther,1,0,0,2014,2013,1188,1,Others,4,NA,2,2.8903717578961645,"(2,3]"
3252,4574,high volume lactated ringer's solution and pancreatitis,Terminated,5,1,1,Pancreatitis,other,Others,26,All,AllOther,1,0,1,2014,2014,730,1,Others,0,NA,0,3.258096538021482,"(3,4]"
3613,5698,behavioral and pharmacologic treatment of binge eating and obesity: maintenance therapy,Enrolling by invitation,3,0,0,Binge-Eating Disorder|Obesity,drug or biologic,Early,88,All,NIH&Combos,1,0,0,2017,2017,2225,1,Phase 2|Phase 3,3,NA,2,4.477336814478207,"(4,5]"
3805,6730,"efficacy, safety, and tolerability study of rp-g28 in subjects with lactose intolerance",Completed,4,0,0,Lactose Intolerance,drug or biologic,Early,377,All,Industry&Combos,1,0,0,2016,2016,243,1,Phase 2|Phase 3,2,safety/efficacy,2,5.932245187448011,"(5,6]"
2627,3528,a randomized phase 2/3 multi-center study of sm-88 in patients with metastatic pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,drug or biologic,Early,250,All,Industry&Combos,NA,0,0,2018,2018,1375,NA,Phase 2|Phase 3,0,NA,0,5.521460917862246,"(5,6]"
141,141,pilot study of the liver live donor champion program,Enrolling by invitation,3,0,0,End Stage Liver Disease,behavioral,Others,100,All,AllOther,0,NA,4,2018,2018,1017,0,Others,1,NA,1,4.605170185988092,"(4,5]"
1346,1438,effects of chemoradiation and surgery on cardiopulmonary fitness and tumor neoplastic phenotype in gastrointestinal malignancies,Terminated,5,0,0,Pathologically Proven Gastrointestinal Malignancy|Plan of Care Must Include Chemoradiation,other,Others,8,All,AllOther,0,NA,4,2014,2014,521,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
3116,4229,y90 radioembolization dose delivery and radiation exposure assessment,Unknown status,8,0,0,Hepatocellular Carcinoma|Radiation Exposure,other,Others,20,All,Industry&Combos,1,1,4,2018,2018,364,1,Others,0,NA,0,2.995732273553991,"(2,3]"
31,31,feasibility and effectiveness of colonic irrigation,Terminated,5,0,0,Colonic Irrigation,procedure,Others,36,All,AllOther,0,NA,2,2016,2016,1468,0,Others,1,NA,1,3.58351893845611,"(3,4]"
2312,2908,"caffeinated gum to prevent post-operative ileus: a prospective, randomized, placebo-controlled trial",Withdrawn,7,0,0,C.Surgical Procedure; Digestive System,behavioral,Others,NA,All,AllOther,1,0,4,2014,2017,1216,1,Others,4,NA,2,NA,NA
3114,4226,fluorescent cholangiography vs white light for bile ducts identification,Completed,4,0,0,Cholecystitis|Cholelithiasis,procedure,Others,1000,All,AllOther,1,0,2,2016,2016,639,1,Others,1,NA,1,6.907755278982137,"(6,7]"
1159,1232,stage 3 fontan operation liver ultrasound study,Completed,4,1,1,Fontan Operation,device,Others,21,All,AllOther,0,NA,2,2014,2014,578,0,Others,1,NA,1,3.044522437723423,"(3,4]"
2090,2493,carolina-colowrap Â® in colonoscopy performance and outcomes study,Completed,4,0,0,Performance and Tolerance of Colonoscopy,device,Others,350,All,Industry&Combos,1,0,1,2014,2014,334,1,Others,1,NA,1,5.857933154483459,"(5,6]"
1030,1085,"influences of high-fiber, organic whole-food formula on the gut microbiome in critically ill children",Recruiting,2,0,0,Critical Illness|Dysbiosis|Pediatric ALL,other,Others,40,All,AllOther,1,0,4,2018,2018,1276,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
1478,1594,safety evaluation of a diet and nutritional supplementation program- purify 2.0,Completed,4,0,0,Gastrointestinal Symptoms,other,Others,38,All,Industry&Combos,0,NA,0,2018,2017,41,0,Others,1,safety,1,3.6375861597263857,"(3,4]"
3808,6739,assessing neurocognitive effects of gluten exposure,Terminated,5,0,0,Celiac Disease|Neurobehavioral Manifestations,other,Others,2,All,AllOther,3,0,4,2012,2015,853,3,Others,2,NA,2,0.6931471805599453,"(0,1]"
340,346,outcomes of ablation of unresectable pancreatic cancer using the nanoknife irreversible electroporation (ire) system,Recruiting,2,0,0,Unresectable Pancreatic Cancer,device,Others,12,All,AllOther,0,NA,0,2014,2014,2801,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
648,675,use of a novel synbiotic to change human gut bacteria and improve health in obese adults,Completed,4,0,0,Intestinal Microbiota and Barrier Function,other,Others,151,All,AllOther,1,0,0,2015,2013,791,1,Others,3,NA,2,5.017279836814924,"(5,6]"
3745,6328,human challenge model refinement with enterotoxigenic escherichia coli strain b7a,Completed,4,1,1,Healthy Volunteer,drug or biologic,NA,47,All,AllOther,1,0,1,2016,2016,244,1,NA,1,NA,1,3.8501476017100584,"(3,4]"
1529,1661,mediterranean diet and protein-sparing modified diet for metabolic syndrome in liver transplant recipients,Terminated,5,0,0,Liver Transplantation|Metabolic Syndrome X|Obesity,other,Others,25,All,AllOther,1,0,0,2014,2014,214,1,Others,0,NA,0,3.2188758248682006,"(3,4]"
2328,2947,effects of global osteopathic manual treatments in patients with idiopathic gastroparesis,Unknown status,8,0,0,Idiopathic Gastroparesis,other,Others,12,All,AllOther,3,1,NA,2014,2014,303,3,Others,0,NA,0,2.4849066497880004,"(2,3]"
1265,1350,early cycle ergometry for critically-ill liver failure patients in a transplant intensive care unit,Recruiting,2,0,0,Liver Cirrhoses|Liver Failure|ICU Acquired Weakness,device,Others,201,All,AllOther,1,0,0,2019,2019,813,1,Others,1,NA,1,5.303304908059076,"(5,6]"
1466,1580,feasibility of insomnia tracking and treatment in ibd,Completed,4,0,0,Inflammatory Bowel Diseases|Insomnia,behavioral,Others,39,All,AllOther,0,NA,0,2019,2019,556,0,Others,1,NA,1,3.6635616461296463,"(3,4]"
831,870,vagal nerve stimulation for gastroparesis,"Active, not recruiting",1,0,0,Gastroparesis,device,Others,45,All,AllOther,0,NA,0,2017,2017,1461,0,Others,1,NA,1,3.8066624897703196,"(3,4]"
3328,4754,vancomycin for the treatment of naat(+)/toxin(-) c. difficile,Recruiting,2,0,0,Clostridium Difficile Infection,drug or biologic,NA,30,All,AllOther,1,0,0,2019,2019,685,1,NA,3,NA,2,3.4011973816621555,"(3,4]"
691,722,comparison of on-site versus off-site evaluation of cholangioscopy-guided biopsies of the bile duct,"Active, not recruiting",1,0,0,Bile Duct Stricture,other,Others,62,All,AllOther,1,0,2,2013,2013,2616,1,Others,1,NA,1,4.127134385045092,"(4,5]"
1336,1428,an interdisciplinary approach to the treatment of encopresis in children with autism spectrum disorders,Completed,4,1,1,Encopresis|Autistic Disorder,drug or biologic,NA,22,All,AllOther,1,0,0,2015,2015,700,1,NA,1,NA,1,3.091042453358316,"(3,4]"
1041,1096,a web-based tailored health behavior intervention for breast and colon cancer survivors (ewellness),Completed,4,0,0,Nutrition|Physical Activity,behavioral,Others,49,All,AllOther,1,0,4,2019,2017,493,1,Others,1,NA,1,3.8918202981106265,"(3,4]"
306,311,fiber blends and gut microbiota (fb),Completed,4,0,0,Gut Microbiome,other,Others,14,All,AllOther,0,NA,4,2019,2019,87,0,Others,1,NA,1,2.6390573296152584,"(2,3]"
3233,4535,exercise to reduce chemotherapy-induced peripheral neuropathy,Completed,4,0,0,Gastrointestinal Cancer|Colorectal Cancer|Pancreatic Cancer|Gastric Cancer|Stomach Cancer|Esophageal Cancer,behavioral,Others,54,All,AllOther,1,0,4,2018,2018,376,1,Others,0,NA,0,3.9889840465642745,"(3,4]"
3540,5409,study of the kono-s anastomosis versus the side-to-side functional end anastomosis,Recruiting,2,0,0,Crohn's Disease,other,Others,88,All,AllOther,1,0,1,2017,2014,3063,1,Others,0,NA,0,4.477336814478207,"(4,5]"
1292,1379,effect of milk oligosaccharides and bifidobacteria on the intestinal microflora of children with autism,Completed,4,1,1,Autism,other,Others,11,All,AllOther,3,0,4,2014,2014,528,3,Others,3,NA,2,2.3978952727983707,"(2,3]"
514,535,treatment with the specific carbohydrate diet for children with active crohns disease and ulcerative colitis,Completed,4,0,0,Crohn's Disease|Ulcerative Colitis,other,Others,9,All,AllOther,0,NA,0,2014,2014,1188,0,Others,1,NA,1,2.1972245773362196,"(2,3]"
420,432,neoadjuvant stereotactic body radiation therapy for resectable adenocarcinoma of the pancreatic head and/or body,Completed,4,0,0,Pancreatic Cancer,other,Others,18,All,AllOther,0,NA,0,2014,2014,1141,0,Others,1,NA,1,2.8903717578961645,"(2,3]"
129,129,rfa rct for pancreatic or bile duct cancer,Terminated,5,0,0,Unresectable Pancreatic Cancer|Cholangiocarcinoma Non-resectable,procedure,Others,8,All,AllOther,1,0,0,2014,2014,1081,1,Others,0,NA,0,2.0794415416798357,"(2,3]"
1094,1158,novel blood test to predict safe foods for infants and toddlers with food protein-induced enterocolitis syndrome (fpies),Enrolling by invitation,3,0,0,Food Protein-Induced Enterocolitis Syndrome|Allergies|Pediatric Disorder,other,Others,20,All,AllOther,0,NA,2,2020,2019,1089,0,Others,1,NA,1,2.995732273553991,"(2,3]"
3151,4288,point-of-care ultrasonography for intussusception,Unknown status,8,0,0,Intussusception|Emergencies,other,Others,800,All,AllOther,1,0,2,2017,2017,776,1,Others,0,NA,0,6.684611727667927,"(6,7]"
1130,1200,"single center comparison of 4 fda approved, commercially available bowel purgatives for colonoscopy",Withdrawn,7,0,0,Patients Undergoing Screening or Surveillance Colonoscopy,drug or biologic,NA,NA,All,AllOther,1,0,4,2014,2014,61,1,NA,1,NA,1,NA,NA
3335,4771,blood and stool molecular biomarkers longitudinal detection study in crohn's disease (cd) patients,Terminated,5,0,0,Crohn's Disease,procedure,Others,41,All,Industry&Combos,0,NA,4,2018,2018,329,0,Others,1,NA,1,3.713572066704308,"(3,4]"
3842,6914,oral care protocol for the management of chemotherapy and radiation therapy-induced oral mucositis,Completed,4,1,1,Oral Mucositis|Oral Cancer,procedure,Others,19,All,AllOther,1,0,0,2015,2014,549,1,Others,1,NA,1,2.9444389791664403,"(2,3]"
3865,7089,effectiveness of an mhealth colorectal cancer screening intervention,Completed,4,0,0,Colorectal Neoplasms,behavioral,Others,450,All,NIH&Combos,1,0,4,2014,2014,700,1,Others,1,NA,1,6.1092475827643655,"(6,7]"
1744,1951,advancing nutritional science for children with functional dyspepsia,Recruiting,2,0,0,Dyspepsia,other,Others,40,All,AllOther,3,0,4,2019,2019,853,3,Others,2,NA,2,3.6888794541139363,"(3,4]"
3222,4507,a clinical study of precision tace (p-tace) with surefire,Withdrawn,7,0,0,Unresectable Hepatocellular Carcinoma,device,Others,NA,All,Industry&Combos,1,0,NA,2017,2018,1096,1,Others,1,NA,1,NA,NA
1758,1969,parastomal hernia repair utilizing the retromuscular sugarbaker versus keyhole mesh techniques,Recruiting,2,0,0,Parastomal Hernia,procedure,Others,142,All,AllOther,1,0,0,2019,2019,1461,1,Others,1,NA,1,4.955827057601261,"(4,5]"
1598,1748,endoscopic direct-peg placement in patients unable to undergo pull-peg procedure,"Active, not recruiting",1,0,0,Head and Neck Neoplasm|Gastrostomy|Esophageal Stenosis and Obstruction,procedure,Others,45,All,AllOther,0,1,0,2019,2019,734,0,Others,1,NA,1,3.8066624897703196,"(3,4]"
1383,1483,using addiction comprehensive health enhancement support system (achess) in an alcoholic liver disease population,Recruiting,2,0,0,"Liver Diseases, Alcoholic",device,Others,30,All,AllOther,0,NA,4,2018,2018,997,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
1995,2347,treatment of adenocarcinoma of the rectum with transanal local excision for complete responders,Recruiting,2,0,0,Rectal Cancer,procedure,Others,15,All,AllOther,0,NA,0,2019,2016,3232,0,Others,1,NA,1,2.70805020110221,"(2,3]"
2653,3559,evolution Â® biliary stent system-fully covered,Completed,4,0,0,Carcinomas/Neoplasms,device,Others,90,All,Industry&Combos,0,NA,4,2014,2014,669,0,Others,1,NA,1,4.499809670330265,"(4,5]"
853,894,esophageal balloon measurements to better characterize thoraco-abdominal interrelationship mechanics.,"Active, not recruiting",1,0,0,Surgery,other,Others,50,All,AllOther,1,0,0,2018,2018,1724,1,Others,0,NA,0,3.912023005428146,"(3,4]"
3849,6992,pharyngeal electrical stimulation evaluation for dysphagia after stroke,Completed,4,0,0,Dysphagia Following Cerebral Infarction,device,Others,50,All,Industry&Combos,1,0,0,2017,2018,671,1,Others,1,NA,1,3.912023005428146,"(3,4]"
1311,1400,the role of microbiome reprogramming on liver fat accumulation,Recruiting,2,0,0,"NAFLD",other,Others,40,All,AllOther,1,0,4,2019,2019,925,1,Others,2,NA,2,3.6888794541139363,"(3,4]"
1366,1461,gut flora metabolite reduction after dietary intervention (grady),Recruiting,2,0,0,Dietary Modification|Cardiovascular Risk Factor,behavioral,Others,90,All,AllOther,1,0,0,2013,2014,2798,1,Others,0,NA,0,4.499809670330265,"(4,5]"
2880,3862,oropharyngeal administration of mother's colostrum for premature infants,"Active, not recruiting",1,0,0,"Infection|Enterocolitis, Necrotizing|Ventilator-associated Pneumonia",other,Others,260,All,AllOther,1,0,1,2014,2013,2536,1,Others,3,NA,2,5.560681631015528,"(5,6]"
1495,1619,narrow band imaging for gastric neoplasia,Unknown status,8,0,0,Gastric Cancer|Gastric Metaplasia|Gastric Dysplasia,procedure,Others,220,All,AllOther,0,NA,2,2014,2014,2345,0,Others,1,NA,1,5.393627546352362,"(5,6]"
4014,7588,dvd-based hiv/hcv prevention intervention for drug-involved latino criminal justice clients,Completed,4,0,0,Human Immunodeficiency Virus|Acquired Immunodeficiency Syndrome|Hepatitis C,behavioral,Others,201,All,NIH&Combos,1,0,1,2014,2014,670,1,Others,0,NA,0,5.303304908059076,"(5,6]"
1093,1155,a pilot study on the efficacy and safety of olanzapine in gastroparesis,Terminated,5,1,1,Idiopathic Gastroparesis,drug or biologic,NA,3,All,AllOther,0,NA,0,2012,2013,2342,0,NA,1,safety/efficacy,1,1.0986122886681098,"(1,2]"
554,576,garden-fresh produce and exercise reduce colon cancer risk,Unknown status,8,0,0,Garden-fresh Produce and Exercise (GFPE),behavioral,Others,21,All,AllOther,0,NA,1,2019,2019,135,0,Others,1,NA,1,3.044522437723423,"(3,4]"
2925,3926,assessing portal hypertension with methacetin breath test,Completed,4,1,1,Patients With Compensated Liver Cirrhosis,device,Others,246,All,Industry&Combos,0,NA,2,2014,2014,1491,0,Others,1,NA,1,5.5053315359323625,"(5,6]"
58,58,polyethylene glycol cleansing in patients at high risk for poor bowel preparation,Recruiting,2,0,0,Colonoscopy,drug or biologic,NA,270,All,AllOther,1,0,4,2017,2017,1430,1,NA,1,NA,1,5.598421958998375,"(5,6]"
170,171,sems placement before surgery in unblocking bile duct in patients with periampullary pancreatic cancer with severe obstructive jaundice,Terminated,5,1,1,Pancreatic Cancer,procedure,Others,4,All,AllOther,1,0,4,2019,2017,326,1,Others,0,NA,0,1.3862943611198906,"(1,2]"
876,920,alcohol related impairment and reinforcement: pre to post roux en y gastric bypass surgery,Unknown status,8,0,0,Bariatric Surgery Candidate,other,Others,60,All,AllOther,0,NA,NA,2015,2015,1369,0,Others,1,NA,1,4.0943445622221,"(4,5]"
261,265,randomized control trial comparing prokinetics and their influence on endoscopy outcomes for upper gi bleed.,Terminated,5,1,1,Upper Gastrointestinal Bleeding,drug or biologic,NA,4,All,AllOther,2,0,0,2013,2014,92,1,NA,2,NA,2,1.3862943611198906,"(1,2]"
3830,6838,"milk in life conditions (milc): bacterial composition of human milk pumped and stored in ""real-life"" conditions",Completed,4,1,1,Human Milk Microbiome|Bacterial Growth,device,Others,52,Female,NIH&Combos,3,0,4,2017,2017,133,3,Others,0,NA,0,3.9512437185814275,"(3,4]"
3816,6765,real-time decision support for postoperative nausea and vomiting (ponv) prophylaxis,Completed,4,1,1,Postoperative Nausea and Vomiting,drug or biologic,NA,27034,All,AllOther,0,NA,1,2015,2016,489,0,NA,1,NA,1,10.204850612043773,"(7,13]"
3174,4356,prader-willi syndrome macronutrient study,Completed,4,0,0,Prader Willi Syndrome|Syndromic Obesity|Childhood Obesity,other,Others,10,All,AllOther,3,1,NA,2013,2014,731,3,Others,0,NA,0,2.302585092994046,"(2,3]"
675,705,treating ibd with inulin,Recruiting,2,0,0,Inflammatory Bowel Diseases,other,Others,200,All,Industry&Combos,1,0,0,2018,2018,1068,1,Others,4,NA,2,5.298317366548036,"(5,6]"
252,256,effect of bacillus subtilis de111 Â® on daily bowel movements,Completed,4,0,0,Bowel Movement Regulation|Occasional Constipation|Occasional Diarrhea,other,Others,50,All,Industry&Combos,1,0,4,2019,2016,364,1,Others,4,NA,2,3.912023005428146,"(3,4]"
952,1001,"effect of protein from complementary foods on infant growth, body composition and gut health",Completed,4,0,0,Infant Growth|Infant Body Fat|Infant Gut Microbiome,behavioral,Others,75,All,NIH&Combos,1,0,4,2014,2014,1614,1,Others,0,NA,0,4.31748811353631,"(4,5]"
28,28,molecular detection of advanced neoplasia in pancreatic cysts,Recruiting,2,0,0,Pancreas Cyst,procedure,Others,800,All,AllOther,1,1,2,2019,2018,2060,1,Others,0,NA,0,6.684611727667927,"(6,7]"
944,992,the effect of a probiotic strain on aspirin-induced gi damage,Terminated,5,0,0,Reduction of Small Intestinal Ulceration Risk,other,Others,30,All,Industry&Combos,1,0,1,2019,2019,104,1,Others,4,NA,2,3.4011973816621555,"(3,4]"
2384,3060,probiotics effect on the female urinary microbiome profum trial (probiotics effect on the female urinary microbiome),Completed,4,0,0,Healthy,other,Others,8,Female,AllOther,1,0,4,2017,2017,333,1,Others,4,NA,2,2.0794415416798357,"(2,3]"
2477,3256,examining the effects of juice fasting,Completed,4,0,0,Epigenetics|Microbiome,behavioral,Others,24,All,AllOther,1,0,4,2018,2018,244,1,Others,1,NA,1,3.1780538303479458,"(3,4]"
3006,4031,choline supplementation and cardiovascular health,Recruiting,2,0,0,Cardiovascular Risk Factor,other,Others,12,All,AllOther,3,0,1,2018,2018,1315,3,Others,1,NA,1,2.4849066497880004,"(2,3]"
2040,2411,ieat 2.0 open trial,Completed,4,0,0,Gastrointestinal Disorders,behavioral,Others,15,All,AllOther,0,NA,0,2017,2017,512,0,Others,1,NA,1,2.70805020110221,"(2,3]"
3347,4853,endoscopic pyloromyotomy for refractory gastroparesis,Completed,4,0,0,Gastroparesis,procedure,Others,42,All,AllOther,3,0,0,2017,2017,1119,3,Others,2,NA,2,3.7376696182833684,"(3,4]"
550,572,stimulation for colonic motility,Enrolling by invitation,3,0,0,Neurogenic Bowel Dysfunction,other,Others,10,All,AllOther,0,NA,0,2015,2019,1095,0,Others,1,NA,1,2.302585092994046,"(2,3]"
2166,2612,"latinos cares (colorectal cancer awareness, research, education and screening)","Active, not recruiting",1,0,0,Colorectal Cancer|Colorectal Carcinoma,behavioral,Others,159,All,AllOther,1,0,4,2017,2014,808,1,Others,0,NA,0,5.0689042022202315,"(5,6]"
1714,1905,blackberry flavonoid absorption and effects on intestinal bacteria,Completed,4,0,0,Metabolic Syndrome,other,Others,46,All,NA,3,0,NA,2013,2013,212,3,Others,2,NA,2,3.828641396489095,"(3,4]"
697,729,"gut permeability, sensitivity and symptomatology","Active, not recruiting",1,0,0,Irritable Bowel Syndrome|Visceral Hypersensitivity,procedure,Others,39,All,AllOther,1,1,2,2015,2015,2373,1,Others,0,NA,0,3.6635616461296463,"(3,4]"
947,996,structured mobile technology based lifestyle program vs usual care for patients with non-alcoholic fatty liver disease,Suspended,6,0,0,Non-Alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis,other,Others,120,All,AllOther,1,0,0,2019,2019,896,1,Others,0,NA,0,4.787491742782046,"(4,5]"
1581,1728,impact of weight loss surgery in adolescents with nafld,"Active, not recruiting",1,0,0,"NAFLD|Obesity, Adolescent",other,Others,11,All,NIH&Combos,0,NA,1,2016,2014,2663,0,Others,1,NA,1,2.3978952727983707,"(2,3]"
1038,1093,"the effect of bariatric surgery on metabolism, the metabolome and microbiome in patients with type 2 diabetes",Recruiting,2,0,0,Type 2 Diabetes Mellitus|Obesity,drug or biologic,NA,30,All,AllOther,1,0,4,2016,2016,2101,1,NA,0,NA,0,3.4011973816621555,"(3,4]"
573,597,using spectrally encoded confocal microscopy (secm) to image the esophagus,"Active, not recruiting",1,0,0,Eosinophilic Esophagitis,device,Others,84,All,NIH&Combos,0,NA,4,2014,2013,2983,0,Others,1,NA,1,4.430816798843313,"(4,5]"
42,42,"the effects of gastric or duodenal nutrient infusion on food intake, obesity and comorbidities in obese individuals",Completed,4,0,0,Obesity,other,Others,8,All,AllOther,1,0,4,2016,2016,852,1,Others,1,NA,1,2.0794415416798357,"(2,3]"
2234,2753,stereotactic magnetic resonance guided radiation therapy,Recruiting,2,0,0,Pancreas Cancer|Lung Cancer|Renal Cancer|Adrenal Metastases|Prostate Cancer|Liver Metastases|Oligoprogressive Nodal Metastases|Metachronous Nodal Metastases|Synchronous Nodal Metastases,other,Others,1000,All,AllOther,1,1,0,2019,2019,1684,1,Others,0,NA,0,6.907755278982137,"(6,7]"
1007,1062,fit mailing protocol-for cancer screening navigation,Unknown status,8,0,0,Colorectal Neoplasms,behavioral,Others,13392,All,AllOther,1,0,4,2016,2015,427,1,Others,0,NA,0,9.502412792729256,"(7,13]"
3720,6218,milk fat intake and metabolic health markers,Unknown status,8,0,0,Insulin Sensitivity|Type 2 Diabetes,other,Others,21,All,AllOther,3,0,1,2016,2014,851,3,Others,3,NA,2,3.044522437723423,"(3,4]"
2292,2872,interindividual variation in excretion of curcumin,Completed,4,0,0,Metabolites|Gut Microbiota,other,Others,8,All,AllOther,0,NA,0,2018,2018,181,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
630,657,endoscopic suturing of the gastric pylorus to delay gastric emptying and treat obesity,Terminated,5,0,0,Obesity|Over Weight,procedure,Others,8,All,AllOther,0,NA,0,2014,2013,1547,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
1146,1217,text messaging to reduce alcohol relapse in liver transplant patients,Completed,4,0,0,Alcoholic Liver Disease,behavioral,Others,15,All,AllOther,1,0,0,2018,2013,368,1,Others,1,NA,1,2.70805020110221,"(2,3]"
4042,7646,hepatitis c-video vs. brochure education delivery,Completed,4,0,0,Hepatitis C,other,Others,176,All,AllOther,1,1,1,2019,2019,339,1,Others,0,NA,0,5.170483995038151,"(5,6]"
2960,3969,integrative personal omics profiling for dynamic molecular phenotypes monitoring during fiber supplementation,Completed,4,0,0,Prebiotics,other,Others,18,All,AllOther,NA,NA,4,2021,2014,1031,NA,Others,1,NA,1,2.8903717578961645,"(2,3]"
40,40,plastic vs. fully covered self expanding stents (fcsems) for treatment of anastomotic bile leaks,Enrolling by invitation,3,0,0,Bile Leak,device,Others,64,All,AllOther,1,0,0,2017,2018,1828,1,Others,0,NA,0,4.1588830833596715,"(4,5]"
2138,2570,trial of low residue diet versus clear liquids following elective colorectal surgery,Completed,4,1,1,Nausea/Vomiting,device,Others,100,All,AllOther,1,0,0,2017,2017,349,1,Others,0,NA,0,4.605170185988092,"(4,5]"
570,594,evaluation of 3d overlay during transjugular intrahepatic portosystemic shunt (tips) procedure,Completed,4,0,0,Portal Hypertension,procedure,Others,20,All,Industry&Combos,0,NA,0,2014,2014,856,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1022,1077,potato fiber and gastrointestinal function: phase 3,Completed,4,0,0,Gastrointestinal Symptoms|Gastrointestinal Transit Time|Stool Frequency,other,Others,90,All,AllOther,3,0,4,2013,2014,90,3,Others,2,NA,2,4.499809670330265,"(4,5]"
1331,1421,beyond confounders: addressing source of measurement variability and error in shear wave elastography,Completed,4,1,1,Liver Fibrosis|Liver Diseases,device,Others,30,All,Industry&Combos,0,NA,2,2017,2017,411,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
2496,3309,effectiveness of changing dietary fat on weight loss,Completed,4,0,0,Overweight,behavioral,Others,60,All,AllOther,1,0,4,2016,2017,351,1,Others,0,NA,0,4.0943445622221,"(4,5]"
428,440,a study of cognitive-behavioral therapy for rumination disorder,Unknown status,8,0,0,Rumination Disorder,behavioral,Others,7,All,AllOther,0,NA,0,2017,2017,640,0,Others,1,NA,1,1.9459101490553132,"(1,2]"
1230,1308,impact of juiceplus+ on the health status of an overweight stressed population,Unknown status,8,0,0,Inflammation,other,Others,80,Female,AllOther,1,0,4,2015,2015,365,1,Others,2,NA,2,4.382026634673881,"(4,5]"
1034,1089,personalized dietary intervention in managing bowel dysfunction and improving quality of life in stage i-iii rectosigmoid cancer survivors,"Active, not recruiting",1,0,0,Cancer Survivor|Stage I Rectosigmoid Cancer|Stage II Rectosigmoid Cancer|Stage III Rectosigmoid Cancer,behavioral,Others,10,All,NIH&Combos,0,NA,4,2017,2017,1705,0,Others,1,NA,1,2.302585092994046,"(2,3]"
3257,4580,impact of feeding on pro-inflammatory cytokine response in neonates receiving a rbc transfusion,Terminated,5,0,0,Transfusions,other,Others,12,All,AllOther,1,0,1,2013,2013,852,1,Others,0,NA,0,2.4849066497880004,"(2,3]"
3444,5235,promoting colorectal cancer screening in rural emergency departments,Unknown status,8,0,0,Colorectal Cancer,behavioral,Others,191,All,AllOther,1,0,4,2018,2014,1300,1,Others,0,NA,0,5.25227342804663,"(5,6]"
1980,2330,a pilot study of oncosilÃ¢âÂ¢ given to patients with pancreatic cancer treated with gemcitabine +/- nab-paclitaxel.,"Active, not recruiting",1,0,0,Unresectable Locally Advanced Pancreatic Carcinoma,device,Others,9,All,Industry&Combos,0,NA,0,2017,2017,1249,0,Others,1,NA,1,2.1972245773362196,"(2,3]"
4008,7581,development and pilot testing of a phci for emergency department patients who decline rapid hiv/ hcv screening,Recruiting,2,0,0,Hiv|Hepatitis C,behavioral,Others,200,All,AllOther,1,0,4,2019,2019,474,1,Others,0,NA,0,5.298317366548036,"(5,6]"
2413,3121,optimization of the bowel preparation regimen for the pillcam Â® colon 2 capsule endoscopy procedure,Completed,4,1,1,Colorectal Cancer Screening,drug or biologic,NA,122,All,Industry&Combos,1,0,2,2015,2015,245,1,NA,0,NA,0,4.804021044733257,"(4,5]"
2499,3313,mindfulness-based exercise video in educating hispanic/latino patients with colorectal cancer and their caregivers,Terminated,5,0,0,Anxiety Disorder|Colon Cancer|Depression|Fatigue|Rectal Cancer,procedure,Others,94,All,NIH&Combos,1,0,4,2014,2014,1037,1,Others,0,NA,0,4.543294782270004,"(4,5]"
1893,2195,using data-driven implementation strategies to improve the quality of cirrhosis care,Enrolling by invitation,3,0,0,"Cirrhosis, Liver",other,Others,12,All,AllOther,0,1,4,2019,2019,1095,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
2104,2513,"comparison of methods to distend the colon during insertion: co2, air insufflation, water-aided colonoscopy",Completed,4,0,0,Pain|Colorectal Adenomas|Colorectal Cancer,other,Others,624,All,AllOther,1,0,0,2013,2013,243,1,Others,2,NA,2,6.436150368369428,"(6,7]"
3224,4517,iron supplement to improve iron status following bariatric surgery,Recruiting,2,0,0,"Anemia, Iron Deficiency",other,Others,64,Female,AllOther,1,0,0,2015,2014,1856,1,Others,1,NA,1,4.1588830833596715,"(4,5]"
208,211,esophageal absorption in eoe,Terminated,5,0,0,Eosinophilic Esophagitis,other,Others,14,All,AllOther,0,NA,4,2014,2014,669,0,Others,1,NA,1,2.6390573296152584,"(2,3]"
2917,3911,non-complex biliary stones dsc vs erc,Recruiting,2,0,0,Biliary Stones,device,Others,298,All,Industry&Combos,1,0,0,2018,2018,1897,1,Others,1,NA,1,5.697093486505405,"(5,6]"
1636,1799,improving treatment of nontuberculous mycobacterial infection in cystic fibrosis,Completed,4,1,1,Cystic Fibrosis,drug or biologic,NA,31,All,AllOther,3,0,0,2015,2014,609,3,NA,0,NA,0,3.4339872044851463,"(3,4]"
2182,2649,the effect of a 30-day automated text messaging intervention on hospital based acute care encounters following ileostomy,Terminated,5,0,0,Ileostomy; Complications|Ileostomy - Stoma|Ileostomy Malfunction|Ileostomy Underactive|Complication of Surgical Procedure,behavioral,Others,9,All,Industry&Combos,0,NA,1,2018,2018,395,0,Others,1,NA,1,2.1972245773362196,"(2,3]"
1020,1075,effect of surefire infusion device on tumor response to regional intra-arterial therapy for primary liver malignancies,Recruiting,2,0,0,Liver Cancer,drug or biologic,NA,10,All,Industry&Combos,1,0,0,2016,2016,2191,1,NA,0,NA,0,2.302585092994046,"(2,3]"
1412,1518,genotype-supported versus conventional proton pump inhibitor dosing,Completed,4,1,1,Gastroesophageal Reflux Disease,other,Others,185,All,NIH&Combos,1,0,4,2016,2016,958,1,Others,0,NA,0,5.220355825078324,"(5,6]"
2576,3465,novel endoluminal clinical treatment of reflux,"Active, not recruiting",1,0,0,GERD,drug or biologic,NA,100,All,Industry&Combos,3,0,0,2017,2017,1338,3,NA,2,NA,2,4.605170185988092,"(4,5]"
559,582,using spectrally encoded confocal microscopy (secm) to visualise the esophagus using an secm probe,Completed,4,1,1,Barrett's Esophagus,device,Others,6,All,AllOther,0,NA,4,2014,2014,183,0,Others,1,NA,1,1.791759469228055,"(1,2]"
312,317,efficacy of a whole cell algae fermentate on gut health and overall immune function in healthy adults with mild gastrointestinal issues,Completed,4,0,0,Healthy|Gastrointestinal Dysfunction|Cold Symptom|Flu Symptom,other,Others,70,All,Industry&Combos,3,0,4,2021,2019,274,3,Others,4,efficacy,2,4.248495242049359,"(4,5]"
1332,1424,effects of freeze dried strawberry powder supplementation on cardiovascular risk factors and gut microbiome,Recruiting,2,0,0,Cardiovascular Risk Factor,other,Others,50,All,AllOther,3,0,1,2018,2019,396,3,Others,2,NA,2,3.912023005428146,"(3,4]"
2113,2526,clinical food study to evaluate the effect of kb174 on the gut microbiome in subjects with well-compensated cirrhosis,Completed,4,0,0,Early Cirrhosis,other,Others,40,All,Industry&Combos,1,0,4,2019,2019,216,1,Others,2,NA,2,3.6888794541139363,"(3,4]"
307,312,a pilot study of a home-based walking intervention for pancreatic cancer patients,Completed,4,0,0,Cancer of Pancreas,behavioral,Others,50,All,AllOther,1,0,4,2015,2013,2578,1,Others,0,NA,0,3.912023005428146,"(3,4]"
2463,3225,validation of the genepoc gbs assay for the detection of the cfb gene from streptococcus agalactiae strains,Completed,4,1,1,Streptococcus Agalactiae Infection,device,Others,771,Female,Industry&Combos,0,NA,2,2016,2016,181,0,Others,1,NA,1,6.647688373563329,"(6,7]"
246,249,resection versus microwave ablation for resectable colorectal cancer liver metastases,Terminated,5,0,0,Colorectal Neoplasms|Neoplasm Metastasis|Hepatic Neoplasms,procedure,Others,1,All,AllOther,1,0,0,2016,2016,549,1,Others,1,NA,1,0,NA
3314,4722,evaluation of mf4637 for correcting the omega-3 nutritional deficiency in nafld patients,Completed,4,0,0,Non Alcoholic Fatty Liver,other,Others,172,All,Industry&Combos,1,0,0,2016,2015,792,1,Others,4,NA,2,5.147494476813453,"(5,6]"
2220,2731,effect of feed warming method on feeding tolerance in the preterm infant born at less than 30 weeks gestation,Unknown status,8,0,0,Enteral Feeding,other,Others,86,All,Industry&Combos,1,0,1,2014,2013,730,1,Others,0,NA,0,4.454347296253507,"(4,5]"
555,577,using virtual reality for patients with gastrointestinal disease,Unknown status,8,0,0,Gastrointestinal Disease|Inflammatory Bowel Diseases,other,Others,200,All,AllOther,1,0,4,2018,2017,699,1,Others,0,NA,0,5.298317366548036,"(5,6]"
2455,3200,improving care after chemotherapy,Completed,4,0,0,Non-small Cell Lung Cancer|Colorectal Cancer|Breast Cancer,other,Others,120,All,AllOther,1,0,4,2013,2013,426,1,Others,0,NA,0,4.787491742782046,"(4,5]"
325,330,non-endoscopic surveillance for barrett's esophagus following ablative therapy,Completed,4,1,1,Barrett's Esophagus,device,Others,138,All,IndustryNIHPartnership,1,1,2,2014,2014,1380,1,Others,0,NA,0,4.927253685157205,"(4,5]"
1135,1205,capsule marking using an ofdi capsule,"Active, not recruiting",1,0,0,Barrett's Esophagus,device,Others,130,All,NIH&Combos,0,NA,4,2015,2014,2679,0,Others,1,NA,1,4.867534450455582,"(4,5]"
818,856,effects of pitavastatin on insulin sensitivity and liver fat,Completed,4,1,1,"Obesity|Fatty Liver, Nonalcoholic",drug or biologic,NA,50,Male,AllOther,1,0,0,2014,2015,1155,1,NA,4,NA,2,3.912023005428146,"(3,4]"
796,833,palliative care in improving quality of life and symptoms in patients with stage iii-iv pancreatic or ovarian cancer,Withdrawn,7,0,0,Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IIIA Ovarian Epithelial Cancer|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIB Ovarian Epithelial Cancer|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIC Ovarian Epithelial Cancer|Stage IIIC Ovarian Germ Cell Tumor|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer,procedure,Others,NA,All,NIH&Combos,1,0,4,2013,2014,1035,1,Others,0,NA,0,NA,NA
660,687,a pilot study to evaluate radiotherapy-induced anti-tumor immunity in metastatic carcinoma of the pancreas,Completed,4,1,1,Histological or Cytological Diagnosis of Pancreatic Carcinoma,device,Others,4,All,AllOther,0,NA,2,2013,2013,792,0,Others,1,NA,1,1.3862943611198906,"(1,2]"
123,123,eoe(eosinophilic esophagitis),Completed,4,0,0,Eosinophilic Esophagitis|Dysphagia,procedure,Others,10,All,AllOther,0,NA,2,2013,2014,821,0,Others,1,NA,1,2.302585092994046,"(2,3]"
1032,1087,magnamosis first-in-human study of feasibility and safety,Recruiting,2,0,0,Intestinal Anastomosis Complication,device,Others,10,All,AllOther,0,NA,0,2014,2014,3136,0,Others,1,safety,1,2.302585092994046,"(2,3]"
763,799,precision pain self-management in young adults with irritable bowel syndrome,Completed,4,0,0,Irritable Bowel Syndrome,behavioral,Others,80,All,NIH&Combos,1,0,4,2017,2016,821,1,Others,1,NA,1,4.382026634673881,"(4,5]"
1850,2121,capsule endoscopy for hemorrhage in the er,Unknown status,8,0,0,Upper Gastrointestinal Bleeding,device,Others,100,All,Industry&Combos,1,0,2,2018,2018,379,1,Others,1,NA,1,4.605170185988092,"(4,5]"
116,116,radiopaque hydrogel in patients undergoing radiotherapy for pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma,device,Others,21,All,Industry&Combos,0,NA,0,2017,2018,1274,0,Others,1,NA,1,3.044522437723423,"(3,4]"
1295,1382,intestinal sweet taste receptor function and adaptation to dietary sugars and sweeteners,Completed,4,0,0,Diabetes,other,Others,10,All,AllOther,0,NA,4,2016,2014,518,0,Others,1,NA,1,2.302585092994046,"(2,3]"
191,193,aspiration of residual gastric contents,Completed,4,0,0,"Infant, Premature|Nutrition, Enteral",procedure,Others,146,All,NIH&Combos,1,0,4,2013,2013,1255,1,Others,0,NA,0,4.983606621708336,"(4,5]"
735,769,phase i trial of imrt using a contralateral esophagus sparing technique (cest) in locally advanced lung cancer,"Active, not recruiting",1,1,1,Non-small Cell Lung Carcinoma|Small Cell Lung Carcinoma,other,Others,27,All,AllOther,0,NA,0,2015,2015,1341,0,Others,1,NA,1,3.295836866004329,"(3,4]"
1381,1481,the utility of timed segmental withdrawal during screening colonoscopy,Completed,4,0,0,Colonoscopy,procedure,Others,326,All,AllOther,1,0,4,2014,2014,699,1,Others,1,NA,1,5.786897381366708,"(5,6]"
871,914,spray cryotherapy for esophageal cancer (ice-cancer),Terminated,5,1,1,Esophageal Cancer,device,Others,1,All,AllOther,0,NA,0,2013,2013,548,0,Others,1,NA,1,0,NA
1710,1897,"plant based diet, ethnicity, and the gut microbiome",Completed,4,0,0,Diet Modification|Microbial Colonization,other,Others,38,Female,AllOther,0,NA,4,2017,2017,674,0,Others,1,NA,1,3.6375861597263857,"(3,4]"
3279,4626,"performance, efficacy and safety of vibrating capsule in aiding constipated individuals",Completed,4,0,0,Chronic Idiopathic Constipation,device,Others,144,All,Industry&Combos,1,0,0,2014,2014,549,1,Others,3,safety/efficacy,2,4.969813299576001,"(4,5]"
1149,1220,hair loss prevention study for pancreatic cancer,Recruiting,2,0,0,Alopecia,device,Others,10,All,AllOther,0,NA,4,2020,2019,596,0,Others,1,NA,1,2.302585092994046,"(2,3]"
412,423,hiatal interrogation in sleeve gastrectomy,Recruiting,2,0,0,Sleeve Gastrectomy,procedure,Others,50,All,AllOther,1,0,1,2018,2018,1184,1,Others,1,NA,1,3.912023005428146,"(3,4]"
1393,1494,validation of capsovision capsocam Â® sv-3 capsule endoscopy system,Completed,4,0,0,Intestinal Disease|Inflammatory Bowel Diseases|Crohn Disease|Ulcer|Celiac Disease,device,Others,84,All,Industry&Combos,0,NA,2,2020,2015,1715,0,Others,1,NA,1,4.430816798843313,"(4,5]"
316,321,endoscopic ultrasound (eus) guided fine needle aspiration (fna) eus-fna of solid pancreatic mass lesions using a novel corkscrew technique: a pilot study,Terminated,5,1,1,Pancreatic Cancer,device,Others,4,All,AllOther,0,NA,2,2014,2014,761,0,Others,1,NA,1,1.3862943611198906,"(1,2]"
2809,3768,"study of gemcitabine, nab-paclitaxel, pegph20 and rivaroxaban for advanced pancreatic adenocarcinoma","Active, not recruiting",1,0,0,Pancreatic Cancer|Advanced Pancreatic Ductal Adenocarcinoma,drug or biologic,NA,110,All,Industry&Combos,1,1,0,2016,2016,1826,1,NA,0,NA,0,4.700480365792417,"(4,5]"
456,471,esophageal dysmotility - prospective study evaluating methods for esophageal dilation,Terminated,5,1,1,Esophageal Dysmotility,device,Others,10,All,AllOther,1,0,0,2018,2014,835,1,Others,1,NA,1,2.302585092994046,"(2,3]"
1067,1123,characterization of bile acid pathway in obesity,Recruiting,2,0,0,Obesity,other,Others,20,All,AllOther,1,1,4,2017,2017,1597,1,Others,0,NA,0,2.995732273553991,"(2,3]"
1084,1144,improving knowledge of medication in ulcerative colitis with an iphone application,Completed,4,0,0,Ulcerative Colitis,other,Others,39,All,AllOther,1,0,4,2014,2014,1216,1,Others,1,NA,1,3.6635616461296463,"(3,4]"
1364,1458,outcome analysis of poem and endoluminal therapies,Enrolling by invitation,3,0,0,Achalasia|Gastric Fistula|Weight Gain After Primary Weight Loss Surgery|Marginal Ulcer|Stenoses|Gastric Nec,procedure,Others,500,All,AllOther,0,NA,0,2017,2016,3927,0,Others,1,NA,1,6.214608098422191,"(6,7]"
2512,3341,rapid hepatitis c elimination trial- a pilot study of daclatasvir/asunaprevir/bms-791325 with or without ribavirin to treat hepatitis c virus,Completed,4,0,0,Hepatitis C,drug or biologic,NA,25,All,NA,1,1,0,2014,2014,580,1,NA,0,NA,0,3.2188758248682006,"(3,4]"
3325,4747,soda and milk study,Completed,4,0,0,Obesity|Dyslipidemia,other,Others,30,Male,AllOther,3,0,1,2014,2014,884,3,Others,1,NA,1,3.4011973816621555,"(3,4]"
758,794,sleep position may reduce acid reflux symptoms at night,Terminated,5,0,0,Extra-esophageal Reflux,other,Others,10,All,Industry&Combos,0,NA,0,2014,2014,821,0,Others,1,NA,1,2.302585092994046,"(2,3]"
1684,1859,educational intervention - improving knowledge and screening rates for colorectal cancer,"Active, not recruiting",1,0,0,Colorectal Carcinoma,other,Others,200,All,NIH&Combos,0,NA,4,2017,2017,175,0,Others,1,NA,1,5.298317366548036,"(5,6]"
3728,6243,tte and dysphagia in anterior cervical surgery,Recruiting,2,0,0,Dysphagia,other,Others,150,All,AllOther,1,0,1,2014,2014,2557,1,Others,1,NA,1,5.0106352940962555,"(5,6]"
2314,2911,feeling and body investigators,"Active, not recruiting",1,0,0,Functional Abdominal Pain,behavioral,Others,126,All,AllOther,0,NA,0,2014,2014,2376,0,Others,1,NA,1,4.836281906951478,"(4,5]"
2293,2873,volumetric laser endomicroscopy with intelligent real-time image segmentation (iris),"Active, not recruiting",1,0,0,"Barrett's Esophagus Without Dysplasia|Barrett's Esophagus With Dysplasia|Barrett's Esophagus With Low Grade Dysplasia|Barrett's Esophagus With High Grade Dysplasia|Barrett's Esophagus With Dysplasia, Unspecified",other,Others,148,All,Industry&Combos,1,0,2,2019,2019,494,1,Others,0,NA,0,4.997212273764115,"(4,5]"
1806,2041,diet as essential therapy (diet) for inflammatory bowel disease,Unknown status,8,0,0,Crohn Disease,other,Others,32,All,AllOther,1,0,0,2017,2017,973,1,Others,4,NA,2,3.4657359027997265,"(3,4]"
683,714,assessment of novel mri quantification free breathing technique in evaluation of liver lesions,Completed,4,1,1,Hepatocellular Carcinoma,device,Others,52,All,AllOther,1,1,2,2014,2013,2193,1,Others,0,NA,0,3.9512437185814275,"(3,4]"
2146,2582,contrast-enhanced ultrasound in diagnosing patients with liver cancer undergoing yttrium-90 radioembolization,Withdrawn,7,0,0,Hepatocellular Carcinoma,drug or biologic,NA,NA,All,NIH&Combos,0,NA,2,2017,2017,730,0,NA,1,NA,1,NA,NA
492,510,comparing early capsule deployment to current standard of care for management of gastrointestinal bleeding,Completed,4,1,1,Melena|Gastrointestinal Hemorrhage,device,Others,87,All,Industry&Combos,1,0,2,2015,2015,805,1,Others,0,NA,0,4.465908118654584,"(4,5]"
378,387,ds vs sips-bariatric surgery comparasion,Recruiting,2,0,0,Bariatric Surgery Candidate,procedure,Others,110,All,AllOther,1,0,4,2017,2017,2221,1,Others,0,NA,0,4.700480365792417,"(4,5]"
642,669,effect of a comprehensive nutrition support product on the nutritional status of adults with inflammatory bowel disease,Completed,4,0,0,"Colitis, Ulcerative|Crohn's Disease",other,Others,10,All,AllOther,0,NA,4,2016,2016,198,0,Others,1,NA,1,2.302585092994046,"(2,3]"
3558,5468,laparoscopic tap block for sleeve gastrectomy: does timing matter,Suspended,6,0,0,"Obesity|Pain, Postoperative",procedure,Others,200,All,AllOther,1,0,4,2021,2019,364,1,Others,1,NA,1,5.298317366548036,"(5,6]"
2340,2966,survivorship care plan in promoting physical activity in breast or colorectal cancer survivors in wisconsin,Completed,4,0,0,Cancer Survivor|Healthy Subject|Stage I Colorectal Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIA Colorectal Cancer|Stage IIB Breast Cancer|Stage IIB Colorectal Cancer|Stage IIC Colorectal Cancer|Stage IIIA Breast Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Breast Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Breast Cancer|Stage IIIC Colorectal Cancer,device,Others,100,All,AllOther,1,0,4,2016,2016,572,1,Others,0,NA,0,4.605170185988092,"(4,5]"
3722,6226,motor imagery exercise and tongue strength,Unknown status,8,0,0,Dysphagia,behavioral,Others,40,All,AllOther,1,0,0,2018,2017,712,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
280,285,hepatitis c virus (hcv) positive liver grafts in hcv negative recipients,Enrolling by invitation,3,0,0,Liver Failure,procedure,Others,100,All,AllOther,0,NA,0,2018,2018,1095,0,Others,1,NA,1,4.605170185988092,"(4,5]"
3964,7425,way to cure hcv adherence,"Active, not recruiting",1,0,0,Hepatitis C,behavioral,Others,60,All,AllOther,1,0,4,2015,2015,914,1,Others,0,NA,0,4.0943445622221,"(4,5]"
1464,1577,a study evaluating a proprietary amino acid mixture (enterade Â®)- for maintaining bowel regularity in patients with gi toxicity from any combination of therapy including tyrosine kinase inhibitors (tki),Terminated,5,0,0,Diarrhea,other,Others,7,All,AllOther,1,0,0,2015,2015,303,1,Others,0,NA,0,1.9459101490553132,"(1,2]"
2427,3149,prebiotic in preterm infants,Recruiting,2,0,0,"Preterm Infant|Development, Infant|Nutrition",other,Others,90,All,AllOther,1,0,4,2017,2018,1277,1,Others,4,NA,2,4.499809670330265,"(4,5]"
1047,1102,diet reintroduction study in irritable bowel syndrome,Completed,4,0,0,Irritable Bowel Syndrome,other,Others,20,All,AllOther,1,0,0,2017,2017,1022,1,Others,3,NA,2,2.995732273553991,"(2,3]"
2557,3436,wallflex pancreatic metal stent for pancreatic duct strictures,"Active, not recruiting",1,0,0,Chronic Pancreatitis,device,Others,67,All,Industry&Combos,0,NA,0,2016,2017,1680,0,Others,1,NA,1,4.204692619390966,"(4,5]"
1811,2046,tool to improve treatment adherence and outcomes at grady liver clinic,Completed,4,0,0,Hepatitis C,behavioral,Others,100,All,AllOther,1,0,4,2019,2017,330,1,Others,0,NA,0,4.605170185988092,"(4,5]"
1834,2089,b-mode ultrasound imaging in detecting early liver cancer,Suspended,6,0,0,Cirrhosis|Early Hepatocellular Carcinoma|Fibrosis|Stage I Hepatocellular Carcinoma|Stage II Hepatocellular Carcinoma,other,Others,45,All,AllOther,0,NA,2,2016,2016,1510,0,Others,1,NA,1,3.8066624897703196,"(3,4]"
1740,1947,standard colonoscopy versus colonoscopy with endocuff vision,Completed,4,1,1,Colorectal Polyp|Colorectal Adenoma|Colon Cancer,device,Others,200,All,AllOther,1,0,4,2017,2017,128,1,Others,0,NA,0,5.298317366548036,"(5,6]"
3303,4694,perioperative active warming techniques in colorectal surgeries,Terminated,5,1,1,Normothermia,device,Others,50,All,AllOther,1,0,0,2009,2017,617,1,Others,1,NA,1,3.912023005428146,"(3,4]"
637,664,treatment of vitamin d deficiency in intestinal rehabilitation clinic patients with a portable ultraviolet b lamp,Completed,4,0,0,Vitamin D Deficiency|Short Bowel Syndrome,device,Others,70,All,AllOther,1,0,0,2013,2013,608,1,Others,0,NA,0,4.248495242049359,"(4,5]"
568,592,effect of location of feeding on glycemic control in critically ill patients (elf),Unknown status,8,0,0,Glucose Metabolism Disorders|Critical Illness,procedure,Others,170,All,Industry&Combos,1,0,0,2018,2017,426,1,Others,2,NA,2,5.135798437050262,"(5,6]"
1709,1896,high-resolution anoscopy perceived discomfort study,Completed,4,0,0,Pain|Anal Cancer,procedure,Others,54,All,AllOther,1,0,4,2019,2019,486,1,Others,0,NA,0,3.9889840465642745,"(3,4]"
880,924,serum-derived bovine immunoglobulin /protein isolate (sbi) 5.0 g bid on nutritional status in subjects with ibs-d,Completed,4,0,0,Diarrhea-predominant Irritable Bowel Syndrome,other,Others,15,All,AllOther,0,NA,4,2014,2014,884,0,Others,1,NA,1,2.70805020110221,"(2,3]"
2464,3227,"intake-dependent effect of cocoa flavanol absorption, metabolism and excretion in humans",Completed,4,0,0,Healthy,other,Others,14,Male,Industry&Combos,3,0,4,2017,2013,54,3,Others,4,NA,2,2.6390573296152584,"(2,3]"
259,263,prospective trial evaluating the effect of closed suction drainage versus straight drainage after distal pancreatectomy,Terminated,5,0,0,Pancreatic Fistula,device,Others,150,All,AllOther,1,0,0,2015,2013,2936,1,Others,0,NA,0,5.0106352940962555,"(5,6]"
1183,1260,validation of hepafat-scan for noninvasive measurement of steatosis in youth,Completed,4,0,0,Non-alcoholic Fatty Liver Disease,procedure,Others,50,All,Industry&Combos,1,0,2,2015,2015,625,1,Others,0,NA,0,3.912023005428146,"(3,4]"
1889,2187,radial reload open lar case series,Terminated,5,1,1,Low Anterior Resection|Proctosigmoid Resection|Rectal Cancer,device,Others,8,All,Industry&Combos,0,NA,0,2012,2013,184,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
968,1019,efficacy and tolerability of suprep with and without simethicone for routine colonoscopy for colorectal cancer screening,Withdrawn,7,0,0,Colorectal Cancer,drug or biologic,NA,NA,All,AllOther,1,0,4,2015,2016,640,1,NA,3,efficacy,2,NA,NA
460,475,the effects of dietary fiber on the gut microbiome and hdl particles of human subjects,Completed,4,0,0,Gut Microbiota,other,Others,20,All,AllOther,3,0,4,2018,2019,222,3,Others,2,NA,2,2.995732273553991,"(2,3]"
1075,1134,cleans technique for the treatment of esophageal food impaction,Unknown status,8,0,0,Esophageal Food Impaction,device,Others,40,All,Industry&Combos,0,NA,0,2018,2018,92,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
682,713,evaluating heat transfer with the esophageal cooling device,Completed,4,0,0,Non-cardiac Surgery,device,Others,19,All,AllOther,0,0,NA,2016,2016,275,0,Others,1,NA,1,2.9444389791664403,"(2,3]"
256,260,the role of hif-2a in the pathogenesis of reflux esophagitis,Completed,4,0,0,Esophagitis|Reflux Esophagitis|Gastroesophageal Reflux Disease,other,Others,12,All,NA,0,NA,4,2012,2013,910,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
3448,5239,child-physician recommendation on parental adherence to colorectal cancer screening,Completed,4,0,0,Colorectal Cancer,other,Others,59,All,AllOther,0,NA,4,2017,2017,242,0,Others,1,NA,1,4.07753744390572,"(4,5]"
3430,5219,cancer communication within hispanic social networks,Completed,4,0,0,Colorectal Carcinoma,other,Others,57,All,NIH&Combos,0,NA,4,2020,2014,154,0,Others,1,NA,1,4.04305126783455,"(4,5]"
1343,1435,a role for fgf21 in postprandial nutrient homeostasis after rygb,"Active, not recruiting",1,0,0,Obesity,procedure,Others,24,All,NIH&Combos,1,1,4,2017,2017,1771,1,Others,0,NA,0,3.1780538303479458,"(3,4]"
1080,1140,the effect of the reflux bandÃ¢âÂ¢ upper esophageal sphincter (ues) assist device on reflux for lung transplant recipients,Recruiting,2,0,0,Lung Transplant|GERD,device,Others,20,All,AllOther,0,NA,1,2019,2019,1019,0,Others,1,NA,1,2.995732273553991,"(2,3]"
7,7,feasibility of laryngeal mask airway gastro on patients undergoing endoscopic retrograde cholangiopancreatography for pancreas and bile duct disorders,Completed,4,1,1,Bile Duct Disorder|Endocrine Pancreas Disorder,device,Others,33,All,NIH&Combos,0,NA,4,2018,2019,460,0,Others,1,NA,1,3.4965075614664802,"(3,4]"
2874,3852,endorotor den (direct endoscopic necrosectomy)trial,Completed,4,0,0,Acute Pancreatic Necrosis|Acute Pancreatitis|Necrotizing Pancreatitis,device,Others,30,All,Industry&Combos,0,NA,0,2018,2018,280,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
351,359,magnetic resonance imaging of the brain and stomach in healthy volunteers and gastroparesis,Recruiting,2,0,0,Gastroparesis,other,Others,70,All,NIH&Combos,1,1,4,2020,2019,1248,1,Others,0,NA,0,4.248495242049359,"(4,5]"
2573,3460,randomized control trial (rct) of early palliative care for hcc,Recruiting,2,0,0,"Carcinoma, Hepatocellular",behavioral,Others,72,All,AllOther,1,0,4,2015,2019,883,1,Others,0,NA,0,4.276666119016055,"(4,5]"
1998,2350,perineal self-acupressure,Completed,4,0,0,Chronic Constipation|Constipation|Hemorrhoids,behavioral,Others,100,All,AllOther,1,0,0,2013,2013,365,1,Others,0,NA,0,4.605170185988092,"(4,5]"
3218,4495,quality of life in adults impaired functioning - a randomized controlled trial of bidet vs usual toileting,Terminated,5,0,0,Toileting in Adults With Impaired Functional Status|Caregiver Burden for Those Who Care for Adults With Impaired Functional Status|UTI in Adults With Impaired Functional Status,behavioral,Others,28,All,AllOther,1,0,1,2014,2015,730,1,Others,0,NA,0,3.332204510175204,"(3,4]"
613,639,cap assisted balloon enteroscopy versus conventional balloon enteroscopy in the evaluation of obscure gastrointestinal bleeding: a randomized controlled trial,Terminated,5,0,0,Obscure Gastrointestinal Bleeding,procedure,Others,87,All,AllOther,1,0,2,2014,2014,1246,1,Others,1,NA,1,4.465908118654584,"(4,5]"
445,457,response to supplement and placebo in gerd,Completed,4,1,1,Gastroesophageal Reflux Disease (GERD)|Heartburn|Dyspepsia,drug or biologic,NA,24,All,AllOther,2,0,0,2013,2013,304,1,NA,4,NA,2,3.1780538303479458,"(3,4]"
341,347,comparison of colon adenoma detection rate using two distal colonoscope attachments,Completed,4,1,1,Colon Cancer Screening|Colon Polyps|Colon Adenomas|Water Exchange Colonoscopy,device,Others,126,All,AllOther,1,0,1,2016,2016,397,1,Others,1,NA,1,4.836281906951478,"(4,5]"
1753,1962,cap assisted colonoscopy enhances quality based competency in colonoscopy among trainees,Completed,4,1,1,"Endoscopy, Gastrointestinal",device,Others,219,All,AllOther,1,0,2,2015,2015,62,1,Others,0,NA,0,5.389071729816501,"(5,6]"
14,14,confocal endomicroscopy for permeability of esophageal wall in refractory gastroesophageal reflux disease (gerd),Unknown status,8,0,0,Gastro Esophageal Reflux|Barrett Esophagus|Erosive Esophagitis,procedure,Others,60,All,AllOther,1,1,2,2017,2017,399,1,Others,1,NA,1,4.0943445622221,"(4,5]"
2048,2423,probability ramp control of propofol for egd,Completed,4,1,1,Gastrointestinal Disease,device,Others,40,All,AllOther,1,0,0,2013,2013,61,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
403,414,the affect of low-volume bowel preparation for hospitalized patients colonoscopies,Terminated,5,1,1,Colonoscopy,drug or biologic,NA,32,All,AllOther,1,0,2,2013,2013,2007,1,NA,1,NA,1,3.4657359027997265,"(3,4]"
4024,7606,increasing uptake of evidence-based screening services through chw-led multi-modality intervention,Completed,4,0,0,Human Papillomavirus|Human Immunodeficiency Virus|Hepatitis C|ColoRectal Cancer,device,Others,752,All,NIH&Combos,1,0,4,2016,2017,1298,1,Others,1,NA,1,6.62273632394984,"(6,7]"
3407,5134,nutritional therapy study in pediatric crohn's disease,Completed,4,0,0,Crohn's Disease,other,Others,18,All,AllOther,2,0,0,2015,2015,1126,1,Others,3,NA,2,2.8903717578961645,"(2,3]"
270,274,effect of use of straw on tolerability and quality of split dose 4l-peg preparation,Terminated,5,0,0,Colon Cancer,other,Others,20,All,AllOther,1,0,NA,2014,2014,335,1,Others,1,NA,1,2.995732273553991,"(2,3]"
1680,1853,efficacy of pea hull fiber - phase 2,Recruiting,2,0,0,Healthy,other,Others,50,All,AllOther,3,0,4,2017,2017,1708,3,Others,4,efficacy,2,3.912023005428146,"(3,4]"
1884,2182,financial incentives to increase colorectal cancer screening in priority populations,Completed,4,0,0,Colorectal Cancer,behavioral,Others,898,All,AllOther,1,0,4,2017,2017,589,1,Others,1,NA,1,6.8001700683022,"(6,7]"
251,255,pancreatic duct stent for acute necrotizing pancreatitis,Recruiting,2,0,0,Necrotizing Pancreatitis|Walled Off Necrosis,device,Others,28,All,AllOther,1,0,0,2017,2016,1492,1,Others,1,NA,1,3.332204510175204,"(3,4]"
92,92,extracorporeal shock wave lithotripsy versus single operator pancreatoscopy and intraductal lithotripsy for the treatment of pancreatic duct stones,Recruiting,2,0,0,Chronic Pancreatitis|Pancreatic Duct Stone,device,Others,60,All,AllOther,1,0,0,2019,2019,1084,1,Others,0,NA,0,4.0943445622221,"(4,5]"
878,922,hepatic energy fluxes in nash and nas patients,Recruiting,2,0,0,"NASH - Nonalcoholic Steatohepatitis|NAS|Overweight or Obesity|Weight Loss|Bariatric Surgery Candidate",procedure,Others,18,All,AllOther,0,NA,0,2019,2019,730,0,Others,1,NA,1,2.8903717578961645,"(2,3]"
3660,5830,celiac disease screening,Terminated,5,0,0,Celiac Disease,other,Others,14,All,AllOther,1,0,4,2013,2013,212,1,Others,4,NA,2,2.6390573296152584,"(2,3]"
3573,5528,evaluating a shared decision making program for crohn's disease,Completed,4,0,0,Crohn's Disease,behavioral,Others,204,All,AllOther,1,0,4,2014,2014,1279,1,Others,0,NA,0,5.318119993844216,"(5,6]"
3385,5023,probiotic on psychological and cognitive effects,Completed,4,0,0,Aging,other,Others,200,All,AllOther,1,0,4,2017,2017,699,1,Others,3,NA,2,5.298317366548036,"(5,6]"
1450,1560,sponge and eosinophil peroxidase (epo) staining,Recruiting,2,0,0,Eosinophilic Esophagitis,device,Others,25,All,AllOther,0,NA,2,2017,2017,1819,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
2244,2767,"a comparison of air insufflation, water immersion and water exchange colonoscopy in crc screening",Completed,4,0,0,Pain|Colorectal Adenomas|Colorectal Cancer,other,Others,288,All,AllOther,1,0,0,2013,2013,245,1,Others,1,NA,1,5.662960480135946,"(5,6]"
1992,2343,endoscopic suturing for primary obesity treatment,Completed,4,1,1,Obesity|Body Weight|Overweight,device,Others,20,All,Industry&Combos,0,NA,0,2012,2013,819,0,Others,1,NA,1,2.995732273553991,"(2,3]"
748,784,modulation of the intestinal microbiome by a high protein diet,Recruiting,2,0,0,Obesity,other,Others,216,All,AllOther,1,0,4,2021,2018,1914,1,Others,0,NA,0,5.375278407684165,"(5,6]"
1817,2064,conversion to everolimus from calcineurin inhibitor with mycophenolic acid: impact on long term renal function in liver transplantation.,Completed,4,1,1,Immunosuppression|Renal Failure,drug or biologic,NA,24,All,Industry&Combos,1,0,1,2013,2013,2053,1,NA,0,NA,0,3.1780538303479458,"(3,4]"
1187,1264,comparison of captivator tissue cassettes vs. no cassettes for endoscopic mucosal resection in esophageal carcinoma,Completed,4,0,0,Esophageal Neoplasms,device,Others,30,All,AllOther,1,0,4,2016,2016,912,1,Others,1,NA,1,3.4011973816621555,"(3,4]"
126,126,defining the role of the gut microbiome in mediating the effects of obesity on intestinal stem cells,"Active, not recruiting",1,0,0,Obesity,procedure,Others,4,All,AllOther,0,NA,4,2016,2017,1672,0,Others,1,NA,1,1.3862943611198906,"(1,2]"
1505,1632,integrated behavioral health innovations in childhood chronic illness care delivery systems,Withdrawn,7,0,0,Inflammatory Bowel Disease,behavioral,Others,NA,All,AllOther,1,0,0,2016,2016,699,1,Others,1,NA,1,NA,NA
1251,1336,interactions of human gut microbiota with intestinal sweet taste receptors,"Active, not recruiting",1,0,0,Obesity,other,Others,90,All,AllOther,1,0,4,2017,2017,419,1,Others,2,NA,2,4.499809670330265,"(4,5]"
320,325,diet and exercise after pancreatic cancer,Recruiting,2,0,0,Pancreatic Cancer,behavioral,Others,50,All,AllOther,1,0,4,2017,2017,1366,1,Others,0,NA,0,3.912023005428146,"(3,4]"
486,504,transcutaneous electroacupuncture for gastric complications of scleroderma,Completed,4,0,0,Scleroderma|Gastroparesis,device,Others,23,All,AllOther,3,0,0,2017,2017,874,3,Others,3,NA,2,3.1354942159291497,"(3,4]"
1816,2057,noninvasive markers of gluten ingestion in celiac disease patients,Completed,4,0,0,Adult Form of Celiac Disease,other,Others,5,All,AllOther,0,0,2,2015,2015,365,0,Others,1,NA,1,1.6094379124341003,"(1,2]"
1761,1972,study of new software used during ablations,Completed,4,0,0,"Liver Cancer|Neoplasms, Liver|Hepatic Neoplasms|Hepatic Cancer",procedure,Others,13,All,NIH&Combos,0,NA,2,2013,2013,677,0,Others,1,NA,1,2.5649493574615367,"(2,3]"
214,217,evaluation of sequential stent addition vs. incremental dilation & stent exchange for management of anastomotic biliary strictures after liver transplantation,Recruiting,2,0,0,Anastomotic Stenosis|Biliary Stricture,procedure,Others,100,All,AllOther,1,0,0,2017,2017,1096,1,Others,0,NA,0,4.605170185988092,"(4,5]"
2949,3955,personalized research on diet in ulcerative colitis and crohn's disease,"Active, not recruiting",1,0,0,Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Indeterminate Colitis,other,Others,54,All,AllOther,3,0,0,2017,2018,967,3,Others,0,NA,0,3.9889840465642745,"(3,4]"
1254,1339,remote ischemic conditioning (ric) in recipients of brain death donor livers - a feasibility and safety study,Completed,4,1,1,"Liver Failure|Carcinoma, Hepatocellular",device,Others,31,All,AllOther,0,NA,0,2015,2015,730,0,Others,1,safety,1,3.4339872044851463,"(3,4]"
324,329,multi-modality therapy for untreated patients with resectable or marginally resectable pancreatic cancer,Terminated,5,0,0,Pancreatic Cancer,other,Others,6,All,AllOther,1,1,0,2013,2013,546,1,Others,0,NA,0,1.791759469228055,"(1,2]"
3210,4470,cpb versus sham treatment for pain management in small duct chronic pancreatitis,Completed,4,1,1,Chronic Pancreatitis,procedure,Others,5,All,AllOther,1,0,0,2014,2013,730,1,Others,1,NA,1,1.6094379124341003,"(1,2]"
3528,5383,the c-span coalition: colorectal cancer screening and patient navigation,Completed,4,0,0,Colorectal Cancer,behavioral,Others,7711,All,AllOther,1,0,4,2017,2017,191,1,Others,0,NA,0,8.95040315983296,"(7,13]"
681,712,electronic neurocognitive tools in screening for mental capability in patients undergoing liver surgery,Unknown status,8,0,0,Liver and Intrahepatic Bile Duct Disorder,procedure,Others,100,All,NIH&Combos,1,0,NA,2018,2018,501,1,Others,0,NA,0,4.605170185988092,"(4,5]"
231,234,imaging the duodenum using an optical frequency domain imaging ofdi capsule,Recruiting,2,0,0,Celiac Disease|Healthy,device,Others,24,All,AllOther,0,NA,4,2014,2013,2526,0,Others,1,NA,1,3.1780538303479458,"(3,4]"
520,541,multi-tracer pet prediction and assessment of response to gemcitabine in pancreatic cancer patients,Completed,4,1,1,Pancreatic Cancer,device,Others,9,All,AllOther,0,NA,2,2014,2014,853,0,Others,1,NA,1,2.1972245773362196,"(2,3]"
1000,1055,genetic education risk assessment and testing study,"Active, not recruiting",1,0,0,Candidates for Hereditary Pancreatic Cancer Testing,other,Others,1000,All,AllOther,1,0,4,2018,2019,1211,1,Others,0,NA,0,6.907755278982137,"(6,7]"
446,458,biomarkers of liver pathology in patients with presumed non-alcoholic steatohepatitis following bariatric surgery,"Active, not recruiting",1,1,1,"NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease",device,Others,14,All,AllOther,0,1,4,2017,2018,520,0,Others,1,NA,1,2.6390573296152584,"(2,3]"
2213,2708,"calcium: magnesium balance, microbiota, and necroptosis and inflammation","Active, not recruiting",1,0,0,Colorectal Cancer,other,Others,240,All,AllOther,2,0,1,2020,2017,2125,1,Others,3,NA,2,5.480638923341991,"(5,6]"
4077,7886,birth-cohort evaluation to advance screening and testing for hepatitis c,Completed,4,0,0,Hepatitis C|Chronic Hepatitis C,other,Others,29607,All,AllOther,3,0,4,2014,2013,393,3,Others,0,NA,0,10.295766098840117,"(7,13]"
1566,1707,a food additive removal diet for pediatric eosinophilic esophagitis,Recruiting,2,0,0,Eosinophilic Esophagitis,other,Others,72,All,AllOther,1,0,0,2018,2018,1145,1,Others,0,NA,0,4.276666119016055,"(4,5]"
2310,2906,mivideo - video visit summary for cancer patients,Completed,4,0,0,Colorectal Cancer,other,Others,58,All,AllOther,0,NA,4,2014,2014,90,0,Others,1,NA,1,4.060443010546419,"(4,5]"
3200,4443,lactated ringer's versus normal saline for acute pancreatitis,Unknown status,8,0,0,"Pancreatitis, Acute",other,Others,119,All,AllOther,1,0,0,2018,2018,525,1,Others,2,NA,2,4.77912349311153,"(4,5]"
3050,4100,contrast-enhanced ultrasound imaging in diagnosing liver cancer in patients with cirrhosis,Recruiting,2,0,0,Liver Cirrhosis,procedure,Others,640,All,IndustryNIHPartnership,0,NA,2,2017,2018,1259,0,Others,1,NA,1,6.461468176353717,"(6,7]"
1970,2318,impact of oral carbohydrate consumption prior to cesarean section,Completed,4,0,0,Dehydration,other,Others,134,Female,AllOther,2,0,4,2016,2016,728,1,Others,3,NA,2,4.897839799950911,"(4,5]"
1048,1103,evaluating the efficacy of cpap therapy for the treatment of fatty liver,Withdrawn,7,0,0,Non-alcoholic Fatty Liver Disease,device,Others,NA,All,NIH&Combos,1,0,0,2013,2019,0,1,Others,0,efficacy,0,NA,NA
1923,2243,a randomized controlled trial investigating if antibiotic use in the first 48 hours of life adversely impacts the preterm infant microbiome,Completed,4,1,1,"Premature Birth of Newborn|Enterocolitis, Necrotizing",drug or biologic,NA,27,All,AllOther,1,0,1,2015,2015,1431,1,NA,3,NA,2,3.295836866004329,"(3,4]"
631,658,stereotactic body radiation therapy or conventionally fractionated concurrent chemotherapy and radiation therapy preoperatively for resectable or borderline resectable pancreatic adenocarcinoma,Recruiting,2,0,0,Pancreatic Cancer,other,Others,102,All,AllOther,1,0,0,2018,2018,1136,1,Others,0,NA,0,4.624972813284271,"(4,5]"
3564,5495,brief intervention by community health workers for unhealthy drinking in latinos,"Active, not recruiting",1,0,0,Drinking Heavy|Drinking Behavior|Drinking Excessive,behavioral,Others,237,All,AllOther,1,0,0,2017,2018,986,1,Others,0,NA,0,5.4680601411351315,"(5,6]"
2550,3427,"safety, tolerability, and sustained weight loss of endoscopic sleeve gastroplasty with diet modification and exercise","Active, not recruiting",1,0,0,Obesity,procedure,Others,60,All,AllOther,1,0,0,2017,2017,2009,1,Others,0,safety,0,4.0943445622221,"(4,5]"
571,595,evaluating active esophageal cooling during cardiac ablation procedures,Recruiting,2,0,0,Atrial Fibrillation,device,Others,20,All,Industry&Combos,0,NA,1,2019,2019,592,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1016,1071,"sucralose, stevia, gut microbiome and glucose metabolism",Completed,4,0,0,Impaired Glucose Tolerance,other,Others,40,All,AllOther,0,1,4,2016,2017,393,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
2091,2495,a trial comparing transversus abdominis plane catheter versus epidural after esophagectomy,Unknown status,8,0,0,"Esophageal Cancer|Pain, Postoperative",procedure,Others,90,All,AllOther,NA,0,0,2018,2018,1096,NA,Others,0,NA,0,4.499809670330265,"(4,5]"
3138,4267,multi-center clinical study to evaluate the c2 cryoballoon focal ablation system,"Active, not recruiting",1,0,0,Barrett Esophagus,device,Others,150,All,Industry&Combos,0,NA,0,2015,2016,1887,0,Others,1,NA,1,5.0106352940962555,"(5,6]"
4051,7680,comparing brief alcohol interventions for hiv-hcv co-infected persons,"Active, not recruiting",1,0,0,HIV|Hepatitis C,behavioral,Others,300,All,AllOther,1,0,1,2014,2015,1978,1,Others,1,NA,1,5.703782474656201,"(5,6]"
897,941,effects of fermented vegetables on gut microflora and inflammation in women,"Active, not recruiting",1,0,0,Inflammation|Women's Health|Gastrointestinal Microbiome,other,Others,34,Female,AllOther,1,0,1,2018,2018,967,1,Others,2,NA,2,3.5263605246161616,"(3,4]"
3583,5583,cycling in preventing colorectal cancer in participants with lynch syndrome,"Active, not recruiting",1,0,0,High-Frequency Microsatellite Instability|Mismatch Repair Gene Mutation|Mutation-Negative Lynch Syndrome|Mutation-Positive Lynch Syndrome,device,Others,21,All,NIH&Combos,0,NA,1,2018,2018,1092,0,Others,1,NA,1,3.044522437723423,"(3,4]"
777,814,a study to assess the effect of y-90 therapy on non-target/background liver,Terminated,5,1,1,HCC|Liver Cancer,other,Others,20,All,AllOther,0,NA,2,2016,2017,697,0,Others,1,NA,1,2.995732273553991,"(2,3]"
186,187,investigation of linaclotide's effect on the bi-directional brain and gut axis in ibs-c patients,Completed,4,0,0,Irritable Bowel Syndrome With Constipation (IBS-C),drug or biologic,NA,39,All,Industry&Combos,1,0,4,2014,2014,1341,1,NA,2,NA,2,3.6635616461296463,"(3,4]"
1099,1163,hepatic encephalopathy: lactulose or polyethylene glycol (h.e.l.p.),Withdrawn,7,0,0,Hepatic Encephalopathy|HE|Cirrhosis|Altered Mental Status|AMS,drug or biologic,NA,NA,All,AllOther,1,0,0,2013,2013,365,1,NA,0,NA,0,NA,NA
1460,1572,"sacral nerve stimulation in treating low anterior resection syndrome or fecal incontinence in patients with locally advanced rectal cancer or other pelvic cancer, the restore study",Recruiting,2,0,0,Fecal Incontinence|Low Anterior Resection Syndrome|Malignant Anal Neoplasm|Malignant Bladder Neoplasm|Malignant Cervical Neoplasm|Malignant Ovarian Neoplasm|Malignant Pelvic Neoplasm|Malignant Prostate Neoplasm|Malignant Uterine Neoplasm|Malignant Vaginal Neoplasm|Malignant Vulvar Neoplasm|Rectal Adenocarcinoma|Stage III Rectal Cancer AJCC v8|Stage IIIA Rectal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Rectal Cancer AJCC v8|Stage IV Rectal Cancer AJCC v8|Stage IVA Rectal Cancer AJCC v8|Stage IVB Rectal Cancer AJCC v8|Stage IVC Rectal Cancer AJCC v8,device,Others,60,All,NIH&Combos,0,NA,4,2019,2019,2302,0,Others,1,NA,1,4.0943445622221,"(4,5]"
268,272,mychart in patients with inflammatory bowel disease.,Completed,4,0,0,Inflammatory Bowel Diseases,behavioral,Others,128,All,AllOther,1,0,0,2017,2017,431,1,Others,0,NA,0,4.852030263919617,"(4,5]"
228,231,gastric emptying ultrasound research study,Completed,4,0,0,Gastric Emptying,procedure,Others,48,All,AllOther,1,0,4,2016,2016,365,1,Others,1,NA,1,3.871201010907891,"(3,4]"
1342,1434,splenic embolization for portal hypertension,Recruiting,2,0,0,Portal Hypertension,device,Others,30,All,AllOther,1,0,0,2018,2018,973,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
1800,2033,nutrition intervention during chemotherapy,"Active, not recruiting",1,0,0,Cancer Patients Receiving Chemotherapy or Chemoradiotherapy,other,Others,31,All,AllOther,1,0,4,2013,2013,2740,1,Others,2,NA,2,3.4339872044851463,"(3,4]"
2446,3184,microgreen consumption for healthy aging,Completed,4,0,0,Aging|Menopause|Healthy,other,Others,26,All,AllOther,3,0,4,2020,2019,129,3,Others,1,NA,1,3.258096538021482,"(3,4]"
1179,1256,development of 'emma'--a pediatric ibd quiz,Completed,4,0,0,Ulcerative Colitis|Crohn's Disease|Inflammatory Bowel Disease,other,Others,116,All,AllOther,0,NA,4,2014,2014,1064,0,Others,1,NA,1,4.7535901911063645,"(4,5]"
3656,5808,gluten sensor device to promote gluten free diet adherence and quality of life in patients with celiac disease,Completed,4,0,0,Celiac Disease,other,Others,30,All,AllOther,1,0,0,2017,2018,302,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
334,340,postprandial liver and spleen stiffness measurements in the noninvasive diagnosis of cirrhosis,Completed,4,0,0,Chronic Liver Disease,device,Others,22,All,AllOther,0,NA,2,2017,2017,242,0,Others,1,NA,1,3.091042453358316,"(3,4]"
140,140,the effect of probiotic intake on intestinal permeability in healthy adults,Completed,4,0,0,Intestinal Barrier Function,other,Others,39,All,Industry&Combos,3,0,4,2018,2018,236,3,Others,3,NA,2,3.6635616461296463,"(3,4]"
2417,3127,trial comparing pla to higrt (prove-hcc),Completed,4,0,0,Hepatocellular Carcinoma,procedure,Others,12,All,AllOther,1,0,4,2018,2018,351,1,Others,0,NA,0,2.4849066497880004,"(2,3]"
1440,1549,safety of endoscopic resection of large colorectal polyps: a randomized trial.,"Active, not recruiting",1,1,1,Colon Polyps,procedure,Others,1257,All,NA,1,0,0,2013,2013,1644,1,Others,0,safety,0,7.136483208590247,"(7,13]"
2789,3745,microbiome individuality and stability over time,Completed,4,0,0,Diet,other,Others,21,All,AllOther,0,NA,4,2021,2018,189,0,Others,1,NA,1,3.044522437723423,"(3,4]"
1363,1457,diet / gut microbiome interaction and influence on inflammatory disease in hiv patients,Recruiting,2,0,0,HIV,other,Others,98,All,AllOther,1,0,4,2015,2016,2101,1,Others,0,NA,0,4.584967478670572,"(4,5]"
2454,3197,continuous vs bolus nasogastric feeding in mechanically ventilated pediatric patients 2,Completed,4,0,0,Dietary Modification,other,Others,147,All,AllOther,1,0,0,2015,2015,1126,1,Others,0,NA,0,4.990432586778736,"(4,5]"
583,609,use of goggle balloon to improve cecal intubation during colonoscopy,Withdrawn,7,0,0,Redundant Colon,device,Others,NA,All,AllOther,1,0,0,2015,2014,1001,1,Others,1,NA,1,NA,NA
1579,1725,wells and enteric disease transmission trial (wet - trial),Recruiting,2,0,0,Gastrointestinal Infection|Respiratory Viral Infection,device,Others,30,All,AllOther,1,0,1,2020,2019,686,1,Others,3,NA,2,3.4011973816621555,"(3,4]"
1321,1411,laryngopharyngeal reflux before and after cricopharyngeal myotomy,Recruiting,2,0,0,Laryngopharyngeal Reflux|Zenker's Diverticulum,device,Others,30,All,AllOther,0,NA,2,2013,2013,3226,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
1309,1398,influence of freeze dried strawberry consumption on gut microbiota and cardiovascular health.,Recruiting,2,0,0,Microbial Colonization|Cardiovascular Diseases|Obesity,other,Others,20,All,AllOther,3,0,4,2017,2017,1613,3,Others,3,NA,2,2.995732273553991,"(2,3]"
2276,2835,prospr project 1: identifying and tracking personalized crc screening regimens for patients in clinical settings,"Active, not recruiting",1,0,0,ColoRectal Cancer,other,Others,9865,All,AllOther,0,NA,4,2018,2013,2186,0,Others,1,NA,1,9.196748418456716,"(7,13]"
3850,7011,the impact of high-flow nasal cannula on swallow function,Completed,4,0,0,Swallowing Disorder|Respiratory Insufficiency,device,Others,19,All,AllOther,0,NA,4,2018,2018,527,0,Others,1,NA,1,2.9444389791664403,"(2,3]"
3602,5676,food and alcohol behavior study: meaningful enhancement,"Active, not recruiting",1,0,0,Binge Drinking|Folate Deficiency,other,Others,20,Female,AllOther,1,0,0,2019,2019,428,1,Others,1,NA,1,2.995732273553991,"(2,3]"
669,697,a trial of radiofrequency ablation for anal intraepithelial neoplasia using the halo ablation system,Completed,4,1,1,HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial Lesions,device,Others,22,All,Industry&Combos,0,NA,0,2013,2013,822,0,Others,1,NA,1,3.091042453358316,"(3,4]"
535,557,effects of beverages containing orange or apple pomace on digestive health in adults,Completed,4,0,0,Digestive Health,other,Others,90,All,Industry&Combos,3,0,4,2018,2018,319,3,Others,2,NA,2,4.499809670330265,"(4,5]"
2961,3970,vitora: clinical study to evaluate the effect of kb109 on the gut microbiome in subjects whose gastrointestinal tracts are colonized with multiple drug-resistant organisms,Terminated,5,0,0,"Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects",other,Others,3,All,Industry&Combos,1,0,4,2019,2019,355,1,Others,0,NA,0,1.0986122886681098,"(1,2]"
2154,2592,functional dyspepsia hypnosis,Enrolling by invitation,3,0,0,Functional Dyspepsia,behavioral,Others,23,All,AllOther,0,NA,0,2019,2019,578,0,Others,1,NA,1,3.1354942159291497,"(3,4]"
3068,4132,preoperative biliary drainage in resectable pancreatic or periampullary cancer,Recruiting,2,0,0,Pancreatic Carcinoma,device,Others,294,All,Industry&Combos,1,0,0,2013,2013,2962,1,Others,0,NA,0,5.683579767338681,"(5,6]"
363,371,medication adherence in patients with inflammatory bowel disease (ibd),Completed,4,0,0,Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis,behavioral,Others,77,All,AllOther,0,1,4,2015,2015,519,0,Others,1,NA,1,4.343805421853684,"(4,5]"
4145,9032,"assessing long-term ctn 0049 outcomes, hcv prevalence and progression along the hcv care continuum among hiv/hcv co-infected substance users in the u.s.",Completed,4,0,0,Hepatitis C|HIV|AIDS|Substance Use,behavioral,Others,422,All,IndustryNIHPartnership,1,0,0,2015,2015,890,1,Others,0,NA,0,6.045005314036012,"(6,7]"
3640,5763,pilot: feasibility of intermittent enteral feeding in ventilated micu patients,Completed,4,0,0,Nutrition,other,Others,14,All,AllOther,NA,1,0,2019,2019,121,NA,Others,0,NA,0,2.6390573296152584,"(2,3]"
192,194,intraluminal endosonography for examination of the structural changes of the stomach in gastroparetic patients,Completed,4,0,0,Idiopathic Gastroparesis|Diabetic Gastroparesis,procedure,Others,11,All,AllOther,0,NA,2,2013,2013,549,0,Others,1,NA,1,2.3978952727983707,"(2,3]"
3062,4117,wp01 - normothermic liver preservation,Completed,4,0,0,Liver Transplantation,device,Others,267,All,Industry&Combos,1,0,0,2016,2016,1219,1,Others,0,NA,0,5.58724865840025,"(5,6]"
2134,2561,"educate, assess risk and overcoming barriers to colorectal screening among african americans",Recruiting,2,0,0,Colorectal Cancer,behavioral,Others,150,All,AllOther,0,NA,1,2018,2019,917,0,Others,1,NA,1,5.0106352940962555,"(5,6]"
719,753,comparing two types of diets on psychological and gastrointestinal symptoms,Completed,4,0,0,Irritable Bowel Syndrome,other,Others,40,All,AllOther,1,0,0,2017,2018,708,1,Others,4,NA,2,3.6888794541139363,"(3,4]"
3280,4629,multivitamin adherence following bariatric surgery,Completed,4,1,1,Obesity,behavioral,Others,24,All,AllOther,1,0,4,2014,2014,731,1,Others,1,NA,1,3.1780538303479458,"(3,4]"
3459,5251,small media interventions to increase colorectal cancer screening among chinese americans,Completed,4,0,0,Colorectal Cancer|Cancer Screening,behavioral,Others,1707,All,AllOther,1,0,4,2017,2017,441,1,Others,0,NA,0,7.442492722794441,"(7,13]"
529,550,application of a novel allergen-specific immune signature directed approach to dietary elimination therapy in patients with eosinophilic esophagitis (idiet),Completed,4,1,1,Eosinophilic Esophagitis,device,Others,24,All,NIH&Combos,0,NA,0,2016,2016,710,0,Others,1,NA,1,3.1780538303479458,"(3,4]"
4027,7611,nurse case management to improve hepatitis c care in hiv co-infection,Completed,4,1,1,"HIV|Hepatitis C, Chronic",behavioral,Others,68,All,AllOther,1,0,4,2016,2016,639,1,Others,1,NA,1,4.219507705176107,"(4,5]"
2027,2395,omegaven Â® as parenteral nutrition,Unknown status,8,0,0,Cholestasis,drug or biologic,NA,25,All,AllOther,0,NA,0,2015,2013,1369,0,NA,1,NA,1,3.2188758248682006,"(3,4]"
2117,2532,a crohn's disease diet to reduce symptoms of crohn's disease,Withdrawn,7,0,0,Crohn's Disease,other,Others,NA,All,AllOther,1,0,0,2013,2013,365,1,Others,2,NA,2,NA,NA
792,829,compassionate use of omegaven in the treatment of parenteral nutrition induced hepatic injury,Completed,4,0,0,Liver Disease|Impaired Liver Function|Parenteral Nutrition Associated Liver Disease,drug or biologic,NA,15,All,AllOther,0,NA,4,2013,2013,2014,0,NA,1,NA,1,2.70805020110221,"(2,3]"
1876,2169,the small intestine bacterial overgrowth study pilot,Recruiting,2,0,0,Systemic Sclerosis|Small Intestinal Bacterial Overgrowth,other,Others,500,All,AllOther,1,0,2,2018,2019,776,1,Others,1,NA,1,6.214608098422191,"(6,7]"
3007,4034,the microbiome and resilience to sleep and circadian disruption,Recruiting,2,0,0,Sleep Deprivation|Circadian Dysregulation|Stress,behavioral,Others,50,All,AllOther,3,0,4,2018,2015,2019,3,Others,2,NA,2,3.912023005428146,"(3,4]"
376,385,health coaching as a tool for improving medication adherence in adult patients with inflammatory bowel disease,"Active, not recruiting",1,0,0,Inflammatory Bowel Diseases,behavioral,Others,43,All,Industry&Combos,3,0,4,2018,2019,1116,3,Others,0,NA,0,3.7612001156935624,"(3,4]"
187,189,"the ilet introduction study: a feasibility study of the ilet, a fully integrated bihormonal bionic pancreas",Terminated,5,1,1,Diabetes Mellitus Type 1,drug or biologic,NA,20,All,AllOther,3,0,0,2016,2016,791,3,NA,0,NA,0,2.995732273553991,"(2,3]"
596,622,genetic-specific effects of fructose on liver lipogenesis,Recruiting,2,0,0,"NAFLD|Non-Alcoholic Fatty Liver Disease",other,Others,48,All,NIH&Combos,1,1,4,2018,2019,1041,1,Others,0,NA,0,3.871201010907891,"(3,4]"
3506,5317,insertion technique in large volume paracentesis,Completed,4,0,0,Cirrhosis,procedure,Others,72,All,AllOther,1,0,0,2014,2013,335,1,Others,1,NA,1,4.276666119016055,"(4,5]"
1828,2082,tae and mwa combination therapy in early-stage hepatocellular carcinoma,Terminated,5,0,0,"Hepatocellular Carcinoma|Hepatoma|Liver Cancer, Adult|Liver Cell Carcinoma|Liver Cell Carcinoma, Adult",device,Others,12,All,AllOther,1,0,0,2016,2016,671,1,Others,0,NA,0,2.4849066497880004,"(2,3]"
1298,1385,myfortic in high meld liver transplantation,Withdrawn,7,0,0,High Model for End-Stage Liver Disease (MELD) Score,drug or biologic,NA,NA,All,AllOther,1,0,0,2013,2013,852,1,NA,0,NA,0,NA,NA
2612,3511,endoscopic surgery for bariatric revision after weight loss failure,Recruiting,2,0,0,Morbid Obesity|Weight Loss,device,Others,20,All,AllOther,0,NA,0,2013,2014,3256,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2824,3786,clinical management with spm system and validation of the spm 5 hour cutoff in patients with symptoms of gastroparesis,Terminated,5,1,1,Gastroparesis,device,Others,167,All,Industry&Combos,0,NA,2,2013,2014,1155,0,Others,1,NA,1,5.117993812416755,"(5,6]"
576,600,determining risk factors for successful ppi weaning,Terminated,5,0,0,Gastroesophageal Reflux,behavioral,Others,5,All,AllOther,0,NA,1,2017,2016,760,0,Others,1,NA,1,1.6094379124341003,"(1,2]"
1216,1294,"biospecimen collection and testing for the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal and vulvar dysplasia and cancer",Recruiting,2,0,0,"Cervical Adenocarcinoma|Cervical Adenocarcinoma In Situ|Cervical Intraepithelial Neoplasia|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Cervical Squamous Intraepithelial Neoplasia|Early Invasive Cervical Adenocarcinoma|Early Invasive Cervical Squamous Cell Carcinoma|High Grade Cervical Squamous Intraepithelial Neoplasia|High Grade Vaginal Intraepithelial Neoplasia|Low Grade Vaginal Intraepithelial Neoplasia|Stage I Cervical Cancer AJCC v8|Stage I Vaginal Cancer AJCC v8|Stage I Vulvar Cancer AJCC v8|Stage IA Cervical Cancer AJCC v8|Stage IA Vaginal Cancer AJCC v8|Stage IA Vulvar Cancer AJCC v8|Stage IA1 Cervical Cancer AJCC v8|Stage IA2 Cervical Cancer AJCC v8|Stage IB Cervical Cancer AJCC v8|Stage IB Vaginal Cancer AJCC v8|Stage IB Vulvar Cancer AJCC v8|Stage IB1 Cervical Cancer AJCC v8|Stage IB2 Cervical Cancer AJCC v8|Stage II Cervical Cancer AJCC v8|Stage II Vaginal Cancer AJCC v8|Stage II Vulvar Cancer AJCC v8|Stage IIA Cervical Cancer AJCC v8|Stage IIA Vaginal Cancer AJCC v8|Stage IIA1 Cervical Cancer AJCC v8|Stage IIA2 Cervical Cancer AJCC v8|Stage IIB Cervical Cancer AJCC v8|Stage IIB Vaginal Cancer AJCC v8|Stage III Cervical Cancer AJCC v8|Stage III Vaginal Cancer AJCC v8|Stage III Vulvar Cancer AJCC v8|Stage IIIA Cervical Cancer AJCC v8|Stage IIIA Vulvar Cancer AJCC v8|Stage IIIB Cervical Cancer AJCC v8|Stage IIIB Vulvar Cancer AJCC v8|Stage IIIC Vulvar Cancer AJCC v8|Stage IV Cervical Cancer AJCC v8|Stage IV Vaginal Cancer AJCC v8|Stage IV Vulvar Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Vaginal Cancer AJCC v8|Stage IVA Vulvar Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Vaginal Cancer AJCC v8|Stage IVB Vulvar Cancer AJCC v8|Vaginal Adenocarcinoma|Vulvar Adenocarcinoma|Vulvar High Grade Squamous Intraepithelial Lesion|Vulvar Intraepithelial Neoplasia|Vulvar Squamous Cell Carcinoma|Vulvar Squamous Intraepithelial Lesion",procedure,Others,500,Female,NIH&Combos,0,NA,4,2014,2014,2926,0,Others,1,NA,1,6.214608098422191,"(6,7]"
2434,3162,social media listening in improving clinical trial recruitment in patients with cancer,Withdrawn,7,0,0,Breast Carcinoma|Colon Carcinoma|Kidney Carcinoma|Lymphoma|Non-Small Cell Lung Carcinoma|Prostate Carcinoma,other,Others,NA,All,NIH&Combos,0,NA,4,2018,2017,418,0,Others,1,NA,1,NA,NA
2132,2558,mobility and activity training (mat) to optimize outcomes for older adult abdominal surgery patients,Withdrawn,7,0,0,Gastrointestinal Malignancy,behavioral,Others,NA,All,AllOther,1,0,4,2013,2013,944,1,Others,0,NA,0,NA,NA
1612,1767,evaluation of jarro-dophilus eps Â® probiotic formulations,Completed,4,0,0,Healthy,other,Others,75,All,Industry&Combos,1,0,4,2016,2016,31,1,Others,3,NA,2,4.31748811353631,"(4,5]"
1734,1932,self-monitoring and reminder texts to increase physical activity after cancer ii,Completed,4,0,0,Colorectal Cancer|Colon Cancer|Rectal Cancer,behavioral,Others,44,All,AllOther,1,0,4,2018,2018,899,1,Others,0,NA,0,3.784189633918261,"(3,4]"
946,994,eoe food desensitization,Recruiting,2,0,0,Eosinophilic Esophagitis,other,Others,5,All,AllOther,0,NA,4,2016,2018,1727,0,Others,1,NA,1,1.6094379124341003,"(1,2]"
4105,8177,digimeds to optimize adherence in patients with hepatitis c and increased risk for nonadherence,Unknown status,8,0,0,"Hepatitis C, Chronic|Nonadherence, Patient",device,Others,253,All,Industry&Combos,0,NA,0,2017,2017,648,0,Others,1,NA,1,5.53338948872752,"(5,6]"
2239,2760,hepatitis c alcohol reduction treatment,Completed,4,0,0,"Hepatitis C, Chronic; AUD",behavioral,Others,182,All,AllOther,1,0,4,2014,2014,1460,1,Others,0,NA,0,5.204006687076795,"(5,6]"
3016,4050,perianal operating scope feasibliity,Withdrawn,7,0,0,Transanal Endoscopic Surgery,device,Others,NA,All,AllOther,0,NA,4,2016,2017,365,0,Others,1,NA,1,NA,NA
1277,1364,efficacy of open label placebo in children with fgids,Unknown status,8,0,0,Functional Abdominal Pain|Functional Dyspepsia|Irritable Bowel Syndrome|Functional Gastrointestinal Disorders,drug or biologic,NA,80,All,AllOther,3,0,0,2015,2014,1614,3,NA,0,efficacy,0,4.382026634673881,"(4,5]"
2249,2777,diet intervention for crohn's disease patient,Recruiting,2,0,0,Crohn Disease,behavioral,Others,300,All,AllOther,1,1,4,2019,2019,1053,1,Others,0,NA,0,5.703782474656201,"(5,6]"
350,358,tolerance of an oral nutritional supplement(ons),Completed,4,0,0,Gastro-Intestinal Tolerance,other,Others,25,All,Industry&Combos,0,NA,NA,2013,2013,31,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
2392,3073,gluten free diet in preventing graft versus host disease in patients undergoing donor stem cell transplant,Terminated,5,0,0,Graft Versus Host Disease|Hematopoietic Cell Transplantation Recipient,other,Others,7,All,NIH&Combos,0,NA,1,2017,2017,293,0,Others,1,NA,1,1.9459101490553132,"(1,2]"
858,900,mayo clinic ibd biobank,Enrolling by invitation,3,0,0,Inflammatory Bowel Diseases,procedure,Others,1000,All,AllOther,1,1,4,2018,2018,17197,1,Others,0,NA,0,6.907755278982137,"(6,7]"
2353,2991,educational-medical-behavioral treatment of fecal incontinence,Terminated,5,1,1,Fecal Incontinence,drug or biologic,NA,31,All,AllOther,1,0,0,2012,2013,789,1,NA,2,NA,2,3.4339872044851463,"(3,4]"
874,917,surrogate markers of portal pressure,Completed,4,0,0,Portal Hypertension|Cirrhosis,drug or biologic,NA,41,All,AllOther,0,1,2,2015,2014,1552,0,NA,1,NA,1,3.713572066704308,"(3,4]"
1166,1240,evaluation of low-dose irinotecan and cyberknife Â® sbrt to treat colorectal cancer with limited liver metastasis,Withdrawn,7,0,0,Colorectal Cancer,drug or biologic,NA,NA,All,AllOther,0,NA,0,2013,2013,2557,0,NA,1,NA,1,NA,NA
2409,3108,infant fecal insult study,Completed,4,0,0,Dermatitis,other,Others,24,Female,Industry&Combos,0,NA,4,2016,2016,86,0,Others,1,NA,1,3.1780538303479458,"(3,4]"
355,363,use of adjustable gastric band in adolescents,Withdrawn,7,0,0,OBESITY,device,Others,NA,All,AllOther,0,NA,0,2013,2016,0,0,Others,1,NA,1,NA,NA
2945,3947,evaluation of pcls using three eus-fna needles,Completed,4,1,1,Pancreatic Cystic Lesions,device,Others,250,All,Industry&Combos,1,0,2,2012,2013,1610,1,Others,0,NA,0,5.521460917862246,"(5,6]"
1345,1437,online health assessment to support comprehensive care,Withdrawn,7,0,0,Chronic Pancreatitis,device,Others,NA,All,NIH&Combos,0,NA,4,2014,2014,761,0,Others,1,NA,1,NA,NA
1592,1742,the influence of gonadal hormone suppression on adipocyte lineage and the microbiome,Enrolling by invitation,3,0,0,Adipose Tissue|Microbiome|Menopause,other,Others,20,Female,AllOther,0,NA,4,2018,2018,1815,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2366,3022,tace with or without sbrt as bridging therapy for pre-transplant hcc patients,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma,other,Others,40,All,AllOther,1,0,0,2013,2013,3075,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
3075,4145,strategies and opportunities to stop colon cancer in priority populations,Completed,4,1,1,Colorectal Cancer,other,Others,62155,All,NIH&Combos,1,0,4,2012,2013,1126,1,Others,0,NA,0,11.037386544225816,"(7,13]"
1695,1876,exercise intervention in liver transplant patients,Completed,4,0,0,End Stage Liver Disease|Sarcopenia|Liver Cirrhoses,behavioral,Others,83,All,AllOther,1,0,0,2015,2016,1248,1,Others,0,NA,0,4.418840607796598,"(4,5]"
57,57,utility of bowel ultrasound in diagnosing necrotizing eneterocolitis in congenital heart disease,Withdrawn,7,0,0,"Enterocolitis, Necrotizing|Congenital Heart Disease",device,Others,NA,All,AllOther,1,0,2,2017,2017,364,1,Others,0,NA,0,NA,NA
2186,2653,perioperative palliative care surrounding cancer surgery for patients & their family members,Recruiting,2,0,0,Gastrointestinal Cancer,other,Others,380,All,AllOther,1,0,4,2018,2018,860,1,Others,0,NA,0,5.940171252720432,"(5,6]"
1031,1086,follow-up yttrium-90 internal pair production pet/ct vs brehmsstrahlung imaging in patients with primary/metastatic liver tumors,Completed,4,1,1,Liver Cancer|Hepatic Tumors,device,Others,9,All,AllOther,0,NA,4,2014,2013,1279,0,Others,1,NA,1,2.1972245773362196,"(2,3]"
1246,1330,a trial of thickened feeds to treat gastroesophageal reflux in children admitted after choking spell,Terminated,5,0,0,Apparent Life Threatening Event|Gastroesophageal Reflux|Aspiration,other,Others,3,All,AllOther,1,0,0,2017,2017,1439,1,Others,0,NA,0,1.0986122886681098,"(1,2]"
2094,2500,acupuncture for unintentional weight loss and anorexia with gi cancer,Completed,4,0,0,Malignant Neoplasm of Gastrointestinal Tract,device,Others,45,All,AllOther,1,0,4,2014,2014,578,1,Others,1,NA,1,3.8066624897703196,"(3,4]"
1404,1507,use of radiofrequency ablation for rgb salvage,Completed,4,1,1,Obesity,device,Others,25,All,Industry&Combos,0,NA,0,2013,2013,914,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
257,261,correlation and comparison of the hepquant Â® disease severity index (dsi) with hepatic venous pressure gradient (hvpg),Completed,4,1,1,Liver Disease,drug or biologic,NA,20,All,AllOther,0,NA,2,2015,2016,359,0,NA,1,NA,1,2.995732273553991,"(2,3]"
3203,4451,assessing the utility of cognitive behavioral therapy for pain control in patients with chronic pancreatitis,Completed,4,0,0,Chronic Pancreatitis,behavioral,Others,9,All,AllOther,1,0,4,2017,2017,929,1,Others,0,NA,0,2.1972245773362196,"(2,3]"
1520,1651,pulmonary rehabilitation in end-stage liver disease,Recruiting,2,0,0,End Stage Liver Disease,behavioral,Others,50,All,AllOther,1,0,4,2017,2018,1367,1,Others,0,NA,0,3.912023005428146,"(3,4]"
1435,1544,pilot study of triphala and rubia cordifolia on gut microbiome and skin,Completed,4,0,0,Sebum Production|Stool Microbiome|Transepidermal Water Loss|Facial Brrightness|Erythema|Wrinkles|Facial Shine,other,Others,35,All,AllOther,1,0,4,2018,2018,157,1,Others,4,NA,2,3.5553480614894135,"(3,4]"
2317,2914,virtual reality alternative to pharmacological sedation during colonoscopy,Recruiting,2,0,0,Colonoscopy,device,Others,25,All,AllOther,0,NA,0,2020,2019,633,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
1053,1108,srl (sirolimus) withdrawal,Completed,4,0,0,Acute Rejection of Liver Transplant|Effects of Immunosuppressant Therapy,drug or biologic,NA,25,All,AllOther,0,NA,2,2014,2013,2679,0,NA,1,NA,1,3.2188758248682006,"(3,4]"
2319,2922,internet based cognitive behavioral therapy in pediatric chronic pancreatitis,Recruiting,2,0,0,Chronic Pancreatitis|Acute Recurrent Pancreatitis,behavioral,Others,260,All,Industry&Combos,1,0,0,2018,2019,1377,1,Others,4,NA,2,5.560681631015528,"(5,6]"
3694,6122,smartphone based adot treatment with fixed-dose elbasvir and grazoprevir in pwids,Unknown status,8,0,0,Hepatitis C|Medication Adherence,behavioral,Others,75,All,Industry&Combos,1,0,0,2017,2017,365,1,Others,0,NA,0,4.31748811353631,"(4,5]"
958,1008,"a patient portal tool, e-assist, for supporting crc screening","Active, not recruiting",1,0,0,Colorectal Cancer,behavioral,Others,1826,All,NIH&Combos,1,0,4,2016,2017,1199,1,Others,2,NA,2,7.509883061154913,"(7,13]"
1083,1143,the beans to enrich the gut microbiome vs. obesity's negative effects (be gone) trial,"Active, not recruiting",1,0,0,Colorectal Cancer Prevention,other,Others,80,All,AllOther,3,0,1,2016,2016,3263,3,Others,0,NA,0,4.382026634673881,"(4,5]"
201,204,gastric artery embolization trial for lessening appetite nonsurgically,Unknown status,8,0,0,Arterial Embolization|Other Surgical Procedures|Obesity,device,Others,5,All,AllOther,0,NA,0,2014,2014,1126,0,Others,1,NA,1,1.6094379124341003,"(1,2]"
1965,2311,whole grain and fiber addition study,Completed,4,0,0,Healthy,other,Others,29,All,Industry&Combos,3,0,4,2018,2018,301,3,Others,0,NA,0,3.367295829986474,"(3,4]"
1141,1212,advanced mr imaging for early biologic tumor changes to neoadjuvant chemoradiation treatment for rectal cancer,Completed,4,0,0,Rectal Cancer,procedure,Others,28,All,AllOther,3,0,2,2013,2013,1533,3,Others,0,NA,0,3.332204510175204,"(3,4]"
1232,1310,serial sms reminders and an opt-out mailed fit kits to improve colorectal screening participation: a single center rct,Completed,4,0,0,Bowel Cancer|Colon Cancer,behavioral,Others,440,All,AllOther,1,0,4,2018,2018,85,1,Others,1,NA,1,6.0867747269123065,"(6,7]"
2156,2597,effect of heavy alcohol consumption on farnesoid x receptor (fxr) signaling,Recruiting,2,0,0,Alcohol Consumption,drug or biologic,NA,45,All,IndustryNIHPartnership,1,0,4,2016,2016,1948,1,NA,4,NA,2,3.8066624897703196,"(3,4]"
2741,3674,ocs liver protect trial: preserving and assessing donor livers for transplantation,"Active, not recruiting",1,0,0,Liver Transplantation|Liver Preservation for Transplant,device,Others,300,All,Industry&Combos,1,0,0,2015,2016,1357,1,Others,0,NA,0,5.703782474656201,"(5,6]"
1900,2205,water immersion and polyp detection: a randomized controlled trial,Completed,4,1,1,Adenoma|Colonic Neoplasms,procedure,Others,121,All,AllOther,3,0,4,2017,2017,548,3,Others,0,NA,0,4.795790545596741,"(4,5]"
4016,7591,abatacept vs placebo in ra patients with hepatitis b on entecavir background,Withdrawn,7,0,0,Rheumatoid Arthritis|Chronic Hepatitis B,drug or biologic,NA,NA,All,AllOther,3,0,0,2014,2014,1442,3,NA,4,NA,2,NA,NA
2394,3078,a pilot study of individualized adaptive radiation therapy for hepatocellular carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,other,Others,80,All,NIH&Combos,0,NA,0,2015,2016,2287,0,Others,1,NA,1,4.382026634673881,"(4,5]"
3037,4081,a trial of percutaneous vs. endoscopic drainage of suspected klatskin tumors,Terminated,5,0,0,Cholangiocarcinoma|Hilar Lymphadenopathy|Biliary Stricture,procedure,Others,13,All,AllOther,1,0,0,2017,2017,600,1,Others,0,NA,0,2.5649493574615367,"(2,3]"
161,161,randomized trial of wire and sphincterotome systems for biliary cannulation,Completed,4,0,0,"Cholestasis, Extrahepatic",other,Others,498,All,AllOther,2,0,0,2014,2016,0,1,Others,1,NA,1,6.210600077024653,"(6,7]"
3235,4540,improving mental and physical health and decreasing hospital readmission after pancreatectomy through enhanced patient and caregiver education and engagement,Terminated,5,0,0,Pancreatectomy,other,Others,91,All,AllOther,1,0,4,2015,2016,988,1,Others,0,NA,0,4.51085950651685,"(4,5]"
3402,5121,trial of the effect of timing of cholecystectomy during initial admission for mild gallstone pancreatitis,Completed,4,0,0,Pancreatitis,procedure,Others,100,All,AllOther,1,0,0,2016,2016,757,1,Others,0,NA,0,4.605170185988092,"(4,5]"
1690,1868,sensorimotor dysfunction in achalasia,Withdrawn,7,0,0,Achalasia,device,Others,NA,All,AllOther,0,NA,2,2015,2018,166,0,Others,1,NA,1,NA,NA
626,653,ct perfusion images in assessing treatment response in patients with pancreatic cancer,Enrolling by invitation,3,0,0,Pancreatic Ductal Adenocarcinoma,device,Others,150,All,NIH&Combos,0,NA,4,2017,2017,3022,0,Others,1,NA,1,5.0106352940962555,"(5,6]"
622,649,nutritional impact of serum-derived bovine immunoglobulin protein isolate in subjects with ipaa,Completed,4,0,0,Pouchitis|Irritable Pouch Syndrome,other,Others,6,All,Industry&Combos,0,NA,0,2016,2016,335,0,Others,1,NA,1,1.791759469228055,"(1,2]"
1836,2091,"young, empowered & strong (yes): the young women's breast cancer study 2- focus on intervention pilot",Completed,4,0,0,Breast Cancer,other,Others,30,Female,AllOther,1,1,4,2019,2019,119,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
1287,1374,"an assessment of the glyconutrient ambrotoseÃ¢âÂ¢ on immunity, gut health, and safety in men and women",Completed,4,0,0,Healthy,other,Others,75,All,AllOther,1,0,4,2020,2018,212,1,Others,2,safety,2,4.31748811353631,"(4,5]"
10,10,use of a colon irrigation device as a preparation for a colon visualization procedure,Completed,4,0,0,Screening Colonoscopy,device,Others,10,All,Industry&Combos,0,NA,NA,2018,2019,206,0,Others,1,NA,1,2.302585092994046,"(2,3]"
778,815,pre-emptive analgesia in ano-rectal surgery,Completed,4,0,0,Hemorrhoids|Fissure in Ano|Rectal Fistula|Anal Condyloma,drug or biologic,NA,90,All,AllOther,1,0,0,2015,2014,1065,1,NA,4,NA,2,4.499809670330265,"(4,5]"
3451,5242,promoting cancer screening among medicaid recipients in minnesota,Completed,4,0,0,Colorectal Cancer|Breast Cancer,behavioral,Others,10000,All,AllOther,1,0,4,2017,2014,160,1,Others,2,NA,2,9.210340371976184,"(7,13]"
197,199,a prospectivetrial comparing thunderbeat to the ligasure energy device during laparoscopic colon surgery,Completed,4,1,1,Colon Cancer,device,Others,73,All,Industry&Combos,1,0,4,2015,2016,1170,1,Others,0,NA,0,4.290459441148391,"(4,5]"
2622,3523,pre-operative biliary sems rct during neoadjuvant therapy,Completed,4,1,1,Pancreatic Cancer,device,Others,119,All,Industry&Combos,1,0,0,2014,2015,1065,1,Others,0,NA,0,4.77912349311153,"(4,5]"
81,81,[impedance measurement for non-erosive reflux disease,Withdrawn,7,0,0,GERD|Healthy,device,Others,NA,All,AllOther,0,NA,2,2016,2016,690,0,Others,1,NA,1,NA,NA
1586,1736,anal cytology collection procedures in predicting high-grade anal dysplasia in men who have sex with men,"Active, not recruiting",1,0,0,Anal Carcinoma|HIV Infection|Human Papillomavirus Infection,procedure,Others,415,Male,NIH&Combos,0,NA,4,2016,2013,2921,0,Others,1,NA,1,6.028278520230698,"(6,7]"
927,974,analgesic efficacy of intravenous ibuprofen in biliary colic,Completed,4,1,1,Biliary Colic,drug or biologic,NA,22,All,AllOther,1,0,0,2014,2014,1016,1,NA,2,efficacy,2,3.091042453358316,"(3,4]"
1857,2132,nash fitness intervention in thrombosis trial (nashfit),Terminated,5,0,0,Liver Diseases|Blood Disorder|Digestive System Disease,behavioral,Others,27,All,AllOther,1,0,0,2018,2018,1027,1,Others,0,NA,0,3.295836866004329,"(3,4]"
443,455,probiotics and the gut microbiome in obese hispanic youth,Terminated,5,0,0,"Obesity, Abdominal|Adiposity",other,Others,22,All,AllOther,1,0,4,2017,2015,317,1,Others,4,NA,2,3.091042453358316,"(3,4]"
3465,5264,pain coping skills for colorectal cancer survivors,Completed,4,0,0,Colorectal Cancer,behavioral,Others,29,All,AllOther,1,0,0,2016,2016,822,1,Others,0,NA,0,3.367295829986474,"(3,4]"
1301,1390,examining the change in microbiome diversity and urine metabolites after lignite extract use,Unknown status,8,0,0,Microbiome,other,Others,20,All,Industry&Combos,1,0,4,2017,2017,59,1,Others,2,NA,2,2.995732273553991,"(2,3]"
3103,4212,ablation confirmation study,Recruiting,2,0,0,"Cancer of the Liver|Liver Cancer|Neoplasms, Liver",device,Others,100,All,Industry&Combos,0,NA,0,2018,2019,1089,0,Others,1,NA,1,4.605170185988092,"(4,5]"
928,975,changes in intestinal permeability 4 hours after gluten challenge,Completed,4,0,0,Celiac Disease|Wheat Hypersensitivity|Gluten Sensitivity|Gluten Enteropathy|Immune System and Related Disorders|Duodenal Diseases,other,Others,60,All,AllOther,1,0,4,2017,2017,385,1,Others,3,NA,2,4.0943445622221,"(4,5]"
2171,2628,texas hepatocellular carcinoma consortium (thccc) project 5,"Active, not recruiting",1,0,0,"Carcinoma, Hepatocellular|Liver Neoplasms",behavioral,Others,2871,All,AllOther,1,0,4,2015,2018,1589,1,Others,2,NA,2,7.962415680121064,"(7,13]"
1768,1981,assessing a endoscopic mucosal resection site using different endoscopic imaging methods,Completed,4,1,1,Post-endoscopic Mucosal Resection of Colon Polyps,device,Others,230,All,Industry&Combos,0,NA,2,2016,2016,1004,0,Others,1,NA,1,5.438079308923196,"(5,6]"
1891,2190,evaluation of liver cancer with magnetic resonance imaging (mri),Completed,4,1,1,Hepatocellular Carcinoma|HCC,device,Others,84,All,AllOther,0,1,2,2013,2013,1707,0,Others,1,NA,1,4.430816798843313,"(4,5]"
388,398,pilot study to assess safety and feasibility of normothermic machine preservation in human liver transplantation,Completed,4,0,0,Liver Transplantation,device,Others,25,All,AllOther,0,1,0,2015,2016,1485,0,Others,1,safety,1,3.2188758248682006,"(3,4]"
3872,7128,acceptance of a partially-hydrolyzed infant formula,Completed,4,0,0,Stool,other,Others,100,All,Industry&Combos,1,0,4,2017,2017,497,1,Others,3,NA,2,4.605170185988092,"(4,5]"
3634,5743,one step versus two step approach for gestational diabetes mellitus screening,Unknown status,8,0,0,Gestational Diabetes,other,Others,284,Female,AllOther,1,0,2,2017,2016,273,1,Others,0,NA,0,5.648974238161206,"(5,6]"
838,877,ketogenic diet in non-alcoholic fatty liver disease,Recruiting,2,0,0,"Fatty Liver, Nonalcoholic|Liver Diseases",other,Others,24,All,AllOther,1,0,0,2018,2019,1025,1,Others,0,NA,0,3.1780538303479458,"(3,4]"
3664,5834,emst and swallowing in long-term survivors of hnca,Recruiting,2,0,0,Head and Neck Neoplasms|Deglutition Disorders,behavioral,Others,20,All,AllOther,1,0,4,2019,2018,1847,1,Others,1,NA,1,2.995732273553991,"(2,3]"
3198,4436,protein supplementation post bariatric surgery,Completed,4,0,0,Bariatric Surgery Candidate,other,Others,48,All,AllOther,1,0,4,2016,2016,853,1,Others,1,NA,1,3.871201010907891,"(3,4]"
3481,5284,effect of formula on infant behavior,Completed,4,0,0,Gastrointestinal Tolerance,other,Others,69,All,Industry&Combos,0,NA,4,2016,2016,183,0,Others,1,NA,1,4.23410650459726,"(4,5]"
1387,1487,effect of gut-cued eating on bmi and efficacy of open-label placebo to augment weight loss,Completed,4,0,0,Eating Behavior|Obesity|Body Weight|Hunger,behavioral,Others,31,All,AllOther,1,0,4,2019,2019,248,1,Others,0,efficacy,0,3.4339872044851463,"(3,4]"
1886,2184,self-monitoring and reminder texts to increase physical activity after cancer: a pilot randomized controlled trial,Completed,4,0,0,Colon Cancer|Rectum Cancer,behavioral,Others,42,All,AllOther,1,0,4,2016,2014,1054,1,Others,0,NA,0,3.7376696182833684,"(3,4]"
825,864,the inflammatory bowel disease - anti-inflammatory diet (ibd-aid),Completed,4,0,0,Inflammatory Bowel Diseases,other,Others,38,All,AllOther,0,NA,0,2021,2017,730,0,Others,1,NA,1,3.6375861597263857,"(3,4]"
1663,1832,choice architecture and colorectal cancer screening outreach,Completed,4,0,0,Cancer of Colon,behavioral,Others,423,All,AllOther,1,0,4,2017,2017,120,1,Others,1,NA,1,6.0473721790462776,"(6,7]"
4002,7563,a peer-based mobile-health intervention to increase access & adherence to hepatitis c treatment & hiv viral suppression,"Active, not recruiting",1,0,0,Hepatitis C|HIV|Risk Reduction Behavior,behavioral,Others,300,All,AllOther,1,0,4,2016,2016,1321,1,Others,2,NA,2,5.703782474656201,"(5,6]"
832,871,response of the gut microbiome and circulating metabolome to diet in children: ancillary study to kidfit (nct03405246),Enrolling by invitation,3,0,0,Gastrointestinal Microbiome|Metabolome|Pediatric Obesity|Dietary Approaches to Stop Hypertension,behavioral,Others,112,All,NIH&Combos,1,0,1,2018,2018,814,1,Others,1,NA,1,4.718498871295094,"(4,5]"
674,704,palliative care in improving quality of life in patients with newly diagnosed pancreatic cancer,Completed,4,0,0,Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,procedure,Others,10,All,NIH&Combos,0,NA,4,2014,2014,181,0,Others,1,NA,1,2.302585092994046,"(2,3]"
2336,2958,controlled trial of wls vs. cli for severely obese adolescents with nash,"Active, not recruiting",1,0,0,Obesity|Nonalcoholic Steatohepatitis|Nonalcoholic Fatty Liver Disease,behavioral,Others,62,All,AllOther,1,1,0,2015,2015,2253,1,Others,0,NA,0,4.127134385045092,"(4,5]"
945,993,temperature monitoring with innersense esophageal temperature sensor/feeding tube after birth through stabilization in vlbw infants,Completed,4,1,1,Body Temperature,device,Others,52,All,Industry&Combos,1,0,1,2014,2014,517,1,Others,0,NA,0,3.9512437185814275,"(3,4]"
1589,1739,vegetable intake effect on heterocyclic amine metabolism,Terminated,5,0,0,Colon Cancer,other,Others,25,All,AllOther,3,0,1,2021,2013,711,3,Others,0,NA,0,3.2188758248682006,"(3,4]"
1090,1152,optical imaging of gastrointestinal biopsy samples and their correlation with histology,Enrolling by invitation,3,0,0,Gastrointestinal Disease|Gastrointestinal Dysfunction,device,Others,200,All,AllOther,0,NA,NA,2020,2016,2472,0,Others,1,NA,1,5.298317366548036,"(5,6]"
465,480,a study to assess the efficacy and safety of salix probiotic blend in participants with functional gastrointestinal disturbances,Completed,4,0,0,Functional Gastrointestinal Disorders,other,Others,188,All,Industry&Combos,0,NA,4,2019,2019,126,0,Others,1,safety/efficacy,1,5.236441962829949,"(5,6]"
46,46,hrim vs mucosal impedance in gerd participants,Withdrawn,7,0,0,Gastro-esophageal Reflux Disease (GERD),device,Others,NA,All,AllOther,0,NA,2,2016,2016,1156,0,Others,1,NA,1,NA,NA
1124,1194,human milk and infant intestinal microbiome study,Completed,4,0,0,Breast Feeding|Human Microbiome,other,Others,6,All,AllOther,1,0,4,2017,2017,511,1,Others,2,NA,2,1.791759469228055,"(1,2]"
2467,3232,watermelon focused dietary inflammatory index intervention,Unknown status,8,0,0,Inflammation|Diet Modification,behavioral,Others,30,All,AllOther,1,1,1,2017,2017,92,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
1588,1738,yogic breathing and ibs,Completed,4,0,0,IBS - Irritable Bowel Syndrome,behavioral,Others,14,All,AllOther,1,0,0,2020,2019,292,1,Others,1,NA,1,2.6390573296152584,"(2,3]"
1738,1940,3-tesla mri response to tace in hcc (liver cancer),Terminated,5,1,1,Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Stage A Adult Primary Liver Cancer (BCLC)|Stage B Adult Primary Liver Cancer (BCLC),drug or biologic,NA,2,All,NIH&Combos,0,NA,2,2014,2014,656,0,NA,1,NA,1,0.6931471805599453,"(0,1]"
536,558,food effects on the gut microbiota,Completed,4,0,0,Gut Microbial Responses to Dietary Fiber,other,Others,24,Female,Industry&Combos,0,NA,4,2017,2017,630,0,Others,1,NA,1,3.1780538303479458,"(3,4]"
620,647,implementing a low fodmap diet in irritable bowel syndrome patients,Enrolling by invitation,3,0,0,IBS - Irritable Bowel Syndrome,other,Others,100,All,AllOther,1,0,4,2019,2019,731,1,Others,0,NA,0,4.605170185988092,"(4,5]"
24,24,comparison of duodenal stenting vs transpyloric and duodenal stenting for malignant obstruction,Completed,4,0,0,Duodenal Obstruction,device,Others,17,All,AllOther,0,0,0,2017,2017,902,0,Others,1,NA,1,2.833213344056216,"(2,3]"
3413,5150,enhanced recovery after surgery in laparoscopic sleeve gastrectomy,Completed,4,0,0,Obesity,other,Others,132,All,AllOther,1,0,4,2018,2019,369,1,Others,1,NA,1,4.882801922586371,"(4,5]"
3584,5584,weight management and health behavior intervention in lowering cancer risk for brca positive and lynch syndrome families,Recruiting,2,0,0,Hereditary Breast Carcinoma|Hereditary Ovarian Carcinoma|Lynch Syndrome|Mutation Carrier,behavioral,Others,384,All,NIH&Combos,2,0,1,2019,2017,1647,1,Others,0,NA,0,5.950642552587727,"(5,6]"
747,782,sentinel lymph node mapping in rectal cancer,Unknown status,8,0,0,Rectal Neoplasms,procedure,Others,26,All,AllOther,0,NA,2,2016,2016,942,0,Others,1,NA,1,3.258096538021482,"(3,4]"
1560,1699,capsule endoscopy versus conservative therapy for obscure gastrointestinal bleeding,Withdrawn,7,0,0,Hemorrhage|Anemia,device,Others,NA,All,AllOther,1,0,4,2013,2013,0,1,Others,0,NA,0,NA,NA
647,674,to investigate the effect of arabinogalactan on the gut microbiome in adults,Completed,4,0,0,Gut Microbiota,other,Others,30,All,Industry&Combos,3,0,4,2020,2019,135,3,Others,3,NA,2,3.4011973816621555,"(3,4]"
2866,3843,enhanced recovery after surgery: a rct of perioperative management of gynecologic patients,Completed,4,0,0,Laparotomy|Gynecologic Diseases,other,Others,40,Female,AllOther,1,0,0,2015,2014,934,1,Others,1,NA,1,3.6888794541139363,"(3,4]"
727,761,the effect of concord grape polyphenol-soy protein isolate complex (gp-spi) on gut microbiota,Unknown status,8,0,0,"Mechanisms, Defense",other,Others,30,All,AllOther,0,NA,4,2019,2019,214,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
37,37,bionic pancreas in children with hyperinsulinism and post-pancreatectomy diabetes,Completed,4,1,1,Hyperinsulinism|Diabetes|Pancreatic Diseases|Pancreatectomy; Hyperglycemia,device,Others,10,All,AllOther,3,0,0,2017,2018,539,3,Others,0,NA,0,2.302585092994046,"(2,3]"
451,464,effect of a probiotic mixture on the gut microbiome and fatigue in patients with quiescent inflammatory bowel disease,Recruiting,2,0,0,Inflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis,other,Others,100,All,Industry&Combos,1,0,2,2017,2017,1479,1,Others,3,NA,2,4.605170185988092,"(4,5]"
1703,1886,per-oral endoscopic myotomy for esophageal swallowing disorders,"Active, not recruiting",1,0,0,Achalasia,procedure,Others,20,All,AllOther,0,NA,4,2015,2014,3867,0,Others,1,NA,1,2.995732273553991,"(2,3]"
260,264,"study of a lumen- apposing, covered, self-expanding metal stent (axiosÃ¢âÂ¢) versus multiple double pigtail stents",Terminated,5,1,1,Pancreatic Necrosis,device,Others,5,All,AllOther,1,0,0,2016,2016,686,1,Others,1,NA,1,1.6094379124341003,"(1,2]"
166,166,abnormal food timing and circadian dyssynchrony in alcohol induced colon carcinogenesis,Recruiting,2,0,0,Colorectal Cancer,drug or biologic,NA,44,All,AllOther,3,0,4,2019,2016,2109,3,NA,0,NA,0,3.784189633918261,"(3,4]"
1752,1961,a prospective trial of an endoscopic quality improvement project,Completed,4,0,0,Colon Polyps,other,Others,10,All,AllOther,3,0,4,2014,2013,638,3,Others,1,NA,1,2.302585092994046,"(2,3]"
1723,1916,prehabilitation of frail surgical cancer patients using remote ischemic preconditioning,Recruiting,2,0,0,Colon Cancer|Fragility|Prehabilitaiton|Surgery,procedure,Others,96,All,AllOther,1,0,0,2019,2019,1095,1,Others,3,NA,2,4.564348191467836,"(4,5]"
3281,4630,intervention to improve hcv treatment uptake and adherence in hiv/hcv coinfection,Completed,4,0,0,HIV|Hepatitis C|Co-Infection,behavioral,Others,85,All,NIH&Combos,1,0,4,2014,2013,1244,1,Others,1,NA,1,4.442651256490317,"(4,5]"
1322,1412,radioembolization of primary and secondary liver malignancies and the effect on the immune system,Recruiting,2,0,0,Hepatocellular Carcinoma|Secondary Malignant Neoplasm of Liver,other,Others,30,All,AllOther,0,NA,4,2019,2018,1757,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
248,252,effectiveness and safety of the endoscopic removal of large and flat colonic polyps with lumenr retractortm,Completed,4,0,0,Colonic Adenomatous Polyps,device,Others,60,All,AllOther,1,0,0,2014,2013,1675,1,Others,0,safety,0,4.0943445622221,"(4,5]"
1255,1340,short duration 6fed sponge for eoe patients,Withdrawn,7,0,0,Eosinophilic Esophagitis,device,Others,NA,All,AllOther,0,NA,4,2017,2017,487,0,Others,1,NA,1,NA,NA
1940,2270,"egesta - emergent gi therapy for severe, complicated cdi using fecal microbiota transplant",Withdrawn,7,0,0,C.Difficile Colitis,drug or biologic,NA,NA,All,Industry&Combos,0,NA,0,2016,2016,425,0,NA,1,NA,1,NA,NA
721,755,comparing methods to biopsy pancreas mass,Completed,4,0,0,Pancreas Mass Diagnosis,procedure,Others,59,All,AllOther,1,0,2,2012,2015,427,1,Others,0,NA,0,4.07753744390572,"(4,5]"
1110,1176,study of inspiratory muscle training for patients undergoing esophageal surgery,Withdrawn,7,0,0,"Cancer of Esophagus|Cancer of the Esophagus|Esophageal Cancer|Esophagus Cancer|Esophagus Neoplasm|Neoplasms, Esophageal",behavioral,Others,NA,All,AllOther,0,NA,1,2016,2016,365,0,Others,1,NA,1,NA,NA
3718,6216,vibrent smartphone mobile application,"Active, not recruiting",1,0,0,Mucositis,other,Others,48,All,AllOther,0,NA,4,2015,2016,833,0,Others,1,NA,1,3.871201010907891,"(3,4]"
130,130,improving tolerability of bowel preparation laxative for colonoscopy,Completed,4,0,0,Colonoscopy|Bowel Preparation,other,Others,313,All,AllOther,1,0,4,2014,2014,344,1,Others,1,NA,1,5.746203190540153,"(5,6]"
1941,2271,standard endoscopic hemostasis versus ovesco severe non-variceal ugi hemorrhage,Recruiting,2,0,0,Upper Gastrointestinal Hemorrhage,device,Others,65,All,AllOther,1,0,0,2017,2015,2222,1,Others,2,NA,2,4.174387269895637,"(4,5]"
139,139,outcomes of esophageal self dilation for benign refractory esophageal stricture management,Recruiting,2,0,0,Esophageal Stricture|Esophageal Dilation,device,Others,30,All,AllOther,1,0,0,2018,2018,1471,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
1719,1912,bridge device for post-operative pain control,Suspended,6,0,0,"Liver Failure|Liver Diseases, Alcoholic|Liver Diseases|Pain, Postoperative|Transplant; Failure, Liver|Liver Cirrhosis, Biliary",device,Others,50,All,AllOther,1,0,0,2017,2018,3884,1,Others,0,NA,0,3.912023005428146,"(3,4]"
2473,3247,casad for severe diarrhea in the emergency department,Terminated,5,1,1,Cancer|Diarrhea,drug or biologic,NA,2,All,Industry&Combos,1,0,0,2013,2013,243,1,NA,2,NA,2,0.6931471805599453,"(0,1]"
219,222,exercise and colon cancer,Completed,4,0,0,Stage II Colon Cancer|Stage III Colon Cancer,other,Others,44,All,AllOther,0,NA,0,2014,2015,31,0,Others,1,NA,1,3.784189633918261,"(3,4]"
1055,1110,a carbohydrate-restricted diet to reverse fatty liver in adolescents with obesity,Completed,4,0,0,Non-alcoholic Fatty Liver Disease|Childhood Obesity|Insulin Resistance,other,Others,27,All,AllOther,1,0,0,2016,2016,700,1,Others,1,NA,1,3.295836866004329,"(3,4]"
2041,2413,comparing the effects of lactated ringers and normal saline in acute pancreatitis,Unknown status,8,0,0,Pancreatitis,other,Others,80,All,AllOther,1,0,0,2017,2014,2008,1,Others,0,NA,0,4.382026634673881,"(4,5]"
2569,3454,sunfiber and the microbiota,Completed,4,0,0,Diet Modification,other,Others,30,All,AllOther,3,0,1,2018,2019,148,3,Others,2,NA,2,3.4011973816621555,"(3,4]"
1730,1923,utility of ultrasound assessment of the inferior vena cava in patients with sepsis and dehydration,Suspended,6,0,0,Sepsis|Gastroenteritis|Dehydration,device,Others,564,All,AllOther,1,0,2,2015,2015,2039,1,Others,0,NA,0,6.335054251498059,"(6,7]"
356,364,understanding the pathophysiology and effects of diaphragmatic breathing in upright gastroesophageal reflux,Completed,4,0,0,GERD,behavioral,Others,60,All,AllOther,1,0,0,2016,2017,1213,1,Others,1,NA,1,4.0943445622221,"(4,5]"
3365,4929,eus guided transduodenal biopsy using the 19g flex,Unknown status,8,0,0,Abdominal Neoplasms,device,Others,200,All,AllOther,0,NA,2,2014,2013,638,0,Others,1,NA,1,5.298317366548036,"(5,6]"
1347,1439,a dietary intervention study on the microbiome in crohn's disease patients,Recruiting,2,0,0,Crohn Disease,other,Others,60,All,NIH&Combos,1,0,4,2019,2019,790,1,Others,0,NA,0,4.0943445622221,"(4,5]"
569,593,precision approach to ppi therapy in gastroesophageal reflux disease,Recruiting,2,0,0,Gastroesophageal Reflux|Laryngopharyngeal Reflux,device,Others,200,All,AllOther,0,NA,2,2018,2018,1083,0,Others,1,NA,1,5.298317366548036,"(5,6]"
1307,1396,prehabilitation intervention to maximize early recovery (primer) in liver transplantation,"Active, not recruiting",1,0,0,Liver Diseases|End Stage Liver Disease|Frailty,device,Others,30,All,AllOther,1,0,0,2018,2018,1676,1,Others,1,NA,1,3.4011973816621555,"(3,4]"
1648,1812,nutritional drink in gastroparesis,Recruiting,2,0,0,Gastroparesis,other,Others,20,All,AllOther,0,NA,0,2018,2019,1301,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2208,2697,quality of life in patients with primary sclerosing cholangitis,Completed,4,0,0,Primary Sclerosing Cholangitis,other,Others,102,All,AllOther,0,NA,4,2016,2016,813,0,Others,1,NA,1,4.624972813284271,"(4,5]"
1398,1501,eus-cnb versus eus-sink for diagnosis of upper gastrointestinal (ugi) subepithelial tumors,Terminated,5,1,1,Esophageal Subepithelial Lesions,device,Others,56,All,AllOther,1,0,2,2014,2014,1219,1,Others,1,NA,1,4.02535169073515,"(4,5]"
3827,6830,study of psyllium 6.8 g versus placebo on satiety in healthy volunteers,Completed,4,0,0,Hunger,other,Others,45,All,Industry&Combos,3,0,4,2013,2013,31,3,Others,3,NA,2,3.8066624897703196,"(3,4]"
3620,5712,increasing colorectal cancer (crc) screening among hispanic primary care patients,Completed,4,1,1,Colorectal Cancer,behavioral,Others,400,All,AllOther,1,0,1,2014,2014,842,1,Others,0,NA,0,5.991464547107982,"(5,6]"
879,923,accelerated recovery pathway for discharge after surgery in patients with pancreatic cancer,Completed,4,1,1,Pancreatic Carcinoma,procedure,Others,98,All,AllOther,1,0,4,2015,2015,949,1,Others,0,NA,0,4.584967478670572,"(4,5]"
3493,5297,efficacy of ostom-i alert system at decreasing dehydration related complications,Terminated,5,1,1,Ileostomy - Stoma,device,Others,3,All,AllOther,0,NA,0,2016,2017,580,0,Others,1,efficacy,1,1.0986122886681098,"(1,2]"
1977,2327,diet and fecal incontinence in senior women,Completed,4,0,0,Accidental Bowel Leakage|Fecal Incontinence|Incontinence|Bowel Incontinence,behavioral,Others,55,Female,AllOther,0,NA,0,2018,2018,1034,0,Others,1,NA,1,4.007333185232471,"(4,5]"
2461,3214,a pilot study to assess the efficacy and safety of various vibrating capsule modes,Completed,4,0,0,Constipation,device,Others,63,All,Industry&Combos,1,0,0,2017,2017,136,1,Others,4,safety/efficacy,2,4.143134726391533,"(4,5]"
3992,7551,accessible hcv care intervention for people who inject illicit drugs (pwid),"Active, not recruiting",1,0,0,Hepatitis C|People Who Inject Drugs|PWID|HCV Coinfection,other,Others,300,All,NIH&Combos,1,0,0,2017,2017,1471,1,Others,0,NA,0,5.703782474656201,"(5,6]"
1702,1884,the gut-brain axis in food reward and alcohol consumption,Completed,4,0,0,Impulsivity|Alcohol Consumption,other,Others,29,All,NIH&Combos,1,0,4,2013,2013,488,1,Others,2,NA,2,3.367295829986474,"(3,4]"
2519,3354,intragastric balloon in obese adolescents with comorbidities,Recruiting,2,0,0,Obesity,device,Others,12,All,AllOther,0,NA,0,2017,2017,1497,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
3920,7306,drug interaction potential between dolutegravir and simeprevir in hiv/hcv seronegative volunteers,Completed,4,1,1,HIV|Hepatitis C,drug or biologic,NA,25,All,AllOther,3,0,4,2015,2016,243,3,NA,0,NA,0,3.2188758248682006,"(3,4]"
754,790,prospective study to compare the efficacy of e.g.scan to detect barrett's esophagus compared with standard endoscopy,Completed,4,1,1,Barrett's Esophagus,device,Others,100,All,Industry&Combos,1,1,2,2014,2014,579,1,Others,0,efficacy,0,4.605170185988092,"(4,5]"
1975,2325,oxaliplatin microdosing assay in predicting exposure and sensitivity to oxaliplatin-based chemotherapy,Completed,4,1,1,Colon Adenocarcinoma,drug or biologic,NA,6,All,NIH&Combos,0,NA,0,2015,2015,917,0,NA,1,NA,1,1.791759469228055,"(1,2]"
2118,2533,rescuing the microbiome effectively with different doses of b. infantis in infants,Completed,4,0,0,Gut Microbiome,other,Others,40,All,Industry&Combos,1,0,4,2018,2018,362,1,Others,3,NA,2,3.6888794541139363,"(3,4]"
1223,1301,automated navigation to improve outpatient colonoscopy adherence,Completed,4,0,0,"Adherence, Patient|Colonoscopy|Text Messaging",behavioral,Others,752,All,AllOther,1,0,4,2018,2018,296,1,Others,3,NA,2,6.62273632394984,"(6,7]"
95,95,evaluation of the ability to detect bowel gas during laparoscopic surgery,Completed,4,0,0,Intestinal Perforation,device,Others,8,All,AllOther,0,NA,NA,2016,2016,121,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
3508,5330,impact of a patient-centered program for low anterior resection syndrome a multicenter randomized controlled trial,Recruiting,2,0,0,Rectal Cancer|Surgery|Patient Activation|Low Anterior Resection|Low Anterior Resection Syndrome,other,Others,128,All,AllOther,1,0,4,2019,2019,639,1,Others,1,NA,1,4.852030263919617,"(4,5]"
2283,2853,counseling hepatitis c virus (hcv) positive patients for cardiovascular disease risk factors,Enrolling by invitation,3,0,0,Hepatitis C|Atherosclerosis,behavioral,Others,250,All,AllOther,1,0,0,2018,2019,1095,1,Others,1,NA,1,5.521460917862246,"(5,6]"
89,89,plant exosomes +/- curcumin to abrogate symptoms of inflammatory bowel disease,Recruiting,2,0,0,Irritable Bowel Disease,procedure,Others,90,All,AllOther,1,0,0,2021,2018,1403,1,Others,0,NA,0,4.499809670330265,"(4,5]"
913,959,a randomized controlled trial of an advanced care planning video decision support tool for patients with end-stage liver disease,Completed,4,0,0,End Stage Liver Disease,behavioral,Others,50,All,AllOther,1,0,4,2018,2018,522,1,Others,0,NA,0,3.912023005428146,"(3,4]"
3908,7274,effectiveness of electrical neurostimulation in cyclic vomiting syndrome.,Suspended,6,0,0,Cyclic Vomiting Syndrome,device,Others,3,All,AllOther,0,0,0,2021,2019,284,0,Others,1,NA,1,1.0986122886681098,"(1,2]"
800,837,trial on impact of healthpromise mobile app on inflammatory bowel disease care and quality of life,Completed,4,0,0,Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis,other,Others,320,All,AllOther,1,0,4,2014,2015,1814,1,Others,1,NA,1,5.768320995793772,"(5,6]"
3616,5701,examining reach and implementation of an evidence-based weight loss program in rural primary care,"Active, not recruiting",1,0,0,Obesity,behavioral,Others,98,All,AllOther,0,NA,0,2018,2018,575,0,Others,1,NA,1,4.584967478670572,"(4,5]"
2529,3389,clinical trial to evaluate the endoscopic ultrasound guided celiac plexus block for treatment of pain in chronic pancreatitis,Completed,4,0,0,"Pancreatitis, Chronic|Abdominal Pain",procedure,Others,29,All,AllOther,1,0,4,2017,2017,918,1,Others,3,NA,2,3.367295829986474,"(3,4]"
3204,4452,urine trypsinogen 2 dipstick for the early detection of post-ercp pancreatitis,Recruiting,2,0,0,Post-ERCP Acute Pancreatitis,device,Others,1825,All,AllOther,0,NA,2,2017,2017,1487,0,Others,1,NA,1,7.509335266016592,"(7,13]"
1164,1238,the role of the gut microbiota in estrogen metabolism and dietary flax as a potential modulator.,"Active, not recruiting",1,0,0,Menopause,other,Others,30,Female,AllOther,1,0,4,2017,2017,1490,1,Others,1,NA,1,3.4011973816621555,"(3,4]"
17,17,predict recurrence of barrett's esophagus after complete eradication of intestinal metaplasia,Recruiting,2,0,0,Barrett Esophagus,device,Others,50,All,AllOther,0,NA,1,2018,2018,1517,0,Others,1,NA,1,3.912023005428146,"(3,4]"
398,409,dietary carbohydrate and gerd in veterans,Recruiting,2,0,0,Gastroesophageal Reflux Disease|Obesity,other,Others,200,All,AllOther,1,0,0,2015,2016,2075,1,Others,1,NA,1,5.298317366548036,"(5,6]"
2726,3651,the effect of convective pre-warming on intra-operative thermoregulatory capabilities,Recruiting,2,0,0,"Temperature Change, Body",device,Others,40,All,AllOther,1,0,0,2019,2017,1497,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
413,424,therasphere & treatment of unresectable primary or unresectable secondary liver cancer,Recruiting,2,0,0,"Liver, Cancer of, Non-Resectable",device,Others,500,All,AllOther,0,NA,0,2019,2014,3997,0,Others,1,NA,1,6.214608098422191,"(6,7]"
266,270,bacteriophage for gastrointestinal health 2 study,Completed,4,0,0,Mild Gastrointestinal Symptoms in Healthy Adults,other,Others,93,All,AllOther,1,0,4,2020,2018,395,1,Others,3,NA,2,4.532599493153256,"(4,5]"
2157,2598,crohn disease exclusion diet after single medication de-escalation,Completed,4,1,1,Crohn Disease,other,Others,19,All,AllOther,1,1,0,2015,2015,1369,1,Others,0,NA,0,2.9444389791664403,"(2,3]"
1380,1480,strength for health,Withdrawn,7,0,0,Colon Cancer,behavioral,Others,NA,All,AllOther,1,0,4,2013,2013,92,1,Others,1,NA,1,NA,NA
2523,3368,swap-meat: study with appetizing plant food - meat eating alternatives trial,Completed,4,0,0,Microbiome|Immune Function|Cardiovascular Diseases,behavioral,Others,38,All,AllOther,3,0,1,2018,2019,322,3,Others,2,NA,2,3.6375861597263857,"(3,4]"
3588,5608,intensive models of hcv care for injection drug users,Completed,4,0,0,Hepatitis C|Medication Adherence,other,Others,150,All,AllOther,1,0,0,2013,2013,1247,1,Others,0,NA,0,5.0106352940962555,"(5,6]"
1206,1284,efficacy of audio recorded guided imagery vs deep breathing exercises on functional gastrointestinal pain disorders,"Active, not recruiting",1,0,0,Abdominal Pain|Functional Gastrointestinal Disorders,device,Others,48,All,AllOther,1,0,0,2017,2016,1918,1,Others,2,efficacy,2,3.871201010907891,"(3,4]"
1936,2262,effect of strawberry consumption on the microbiome,Completed,4,0,0,Microbiome,other,Others,30,All,AllOther,1,0,4,2020,2018,163,1,Others,1,NA,1,3.4011973816621555,"(3,4]"
1666,1836,yttrium y 90 glass microspheres pet/ct in imaging patients with liver tumors,"Active, not recruiting",1,0,0,Primary Malignant Liver Neoplasm,device,Others,39,All,AllOther,0,NA,2,2017,2017,1108,0,Others,1,NA,1,3.6635616461296463,"(3,4]"
330,336,head to head comparison of two needles eus guided fnb,Withdrawn,7,0,0,Pancreatic Tumor,device,Others,NA,All,AllOther,3,0,2,2015,2016,61,3,Others,1,NA,1,NA,NA
3501,5308,improving rates of colorectal cancer screening among never screened patients,Completed,4,0,0,Colorectal Neoplasms,behavioral,Others,420,All,AllOther,1,0,4,2012,2013,455,1,Others,2,NA,2,6.040254711277414,"(6,7]"
810,847,comparison of back-loaded vs preloaded fiducial needles in eus-guided fiducial marker placement in pancreatic cancer.,Completed,4,1,1,Pancreatic Cancer,device,Others,44,All,Industry&Combos,1,0,0,2015,2016,606,1,Others,1,NA,1,3.784189633918261,"(3,4]"
1060,1116,cardiometabolic benefits of potatoes mediated along the gut-vessel axis in adults with metabolic syndrome,Recruiting,2,0,0,Cardiovascular Diseases|Endotoxemia|Endothelial Dysfunction|Postprandial Hyperglycemia|Gut Health,other,Others,30,All,AllOther,3,0,1,2018,2018,686,3,Others,1,NA,1,3.4011973816621555,"(3,4]"
877,921,human gut microbiota and prebiotic response,Completed,4,0,0,Healthy Gut Microbiota,other,Others,41,All,AllOther,3,0,4,2018,2018,383,3,Others,1,NA,1,3.713572066704308,"(3,4]"
925,972,early intervention and prevention of non-alcoholic fatty liver disease in adolescents,Completed,4,0,0,Non-alcoholic Fatty Liver Disease,behavioral,Others,28,All,AllOther,1,0,1,2014,2014,822,1,Others,0,NA,0,3.332204510175204,"(3,4]"
3505,5314,bovine lactoferrin in reducing taste disturbances in patients with colorectal cancer receiving oxaliplatin-based chemotherapy,Completed,4,0,0,Colorectal Cancer|Dysgeusia|Oral Complications of Chemotherapy,procedure,Others,12,All,NIH&Combos,0,NA,4,2012,2013,942,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
714,748,"kv-cbct and ultrasound imaging in guiding radiation therapy in patients with prostate, liver, or pancreatic cancer",Completed,4,1,1,Adult Liver Carcinoma|Malignant Pancreatic Neoplasm|Prostate Carcinoma,device,Others,30,All,AllOther,0,NA,2,2015,2015,1544,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
1518,1648,"a randomized, pilot study comparing cost effectiveness on two commercially available gastric feeding tubes",Recruiting,2,0,0,Long Term Enteral Tube Feeding,device,Others,40,All,AllOther,1,0,4,2019,2019,1527,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
2170,2626,endorings colonoscopy vs standard colonoscopy,Completed,4,1,1,Colorectal Adenoma|Colorectal Polyp|Colon Cancer,device,Others,592,All,Industry&Combos,1,0,4,2018,2018,237,1,Others,0,NA,0,6.3835066348840055,"(6,7]"
2326,2941,trans-incisional vs laparoscopic guided rectus sheath block for pediatric single incision laparoscopic cholecystectomy,Completed,4,1,1,"Pain, Postoperative",drug or biologic,NA,48,All,AllOther,1,0,4,2015,2015,1218,1,NA,3,NA,2,3.871201010907891,"(3,4]"
1238,1321,localized therapeutics for the treatment of gastrointestinal disorders,Completed,4,0,0,Healthy Adults,other,Others,18,All,AllOther,3,0,4,2014,2015,241,3,Others,4,NA,2,2.8903717578961645,"(2,3]"
666,694,cryotherapy for malignant dysphagia in patients with advanced esophageal cancer,Unknown status,8,0,0,Esophageal Adenocarcinoma,procedure,Others,15,All,AllOther,0,1,4,2015,2015,943,0,Others,1,NA,1,2.70805020110221,"(2,3]"
282,287,eus fiducial for pancreas surgery,Unknown status,8,0,0,Pancreatic Neoplasms,device,Others,20,All,AllOther,0,NA,0,2016,2016,1165,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2017,2383,web-based management of pediatric functional abdominal pain,Completed,4,0,0,"Gastrointestinal Disorders, Functional",behavioral,Others,344,All,AllOther,1,0,0,2014,2014,1751,1,Others,1,NA,1,5.840641657373398,"(5,6]"
2374,3032,conventional direct laryngoscopy vs. video laryngoscopy with the c-mac for pyloromyotomy,Enrolling by invitation,3,0,0,"Pyloric Stenosis|Intubation, Pediatric",device,Others,72,All,AllOther,1,0,4,2016,2013,3743,1,Others,0,NA,0,4.276666119016055,"(4,5]"
1210,1288,efficacy of ear neurostimulation for adolescents with functional abdominal pain,Completed,4,1,1,Functional Disorder of Intestine|Nausea Persistent,device,Others,115,All,AllOther,1,0,0,2015,2015,457,1,Others,4,efficacy,2,4.74493212836325,"(4,5]"
3762,6501,melatonin in pediatric fd population,Completed,4,0,0,Dyspepsia,other,Others,14,All,AllOther,3,0,0,2020,2014,243,3,Others,4,NA,2,2.6390573296152584,"(2,3]"
2435,3163,telemedicine follow-up for bariatric surgery patients: what do patients prefer,Terminated,5,0,0,Obesity,other,Others,24,All,AllOther,1,0,4,2021,2019,531,1,Others,2,NA,2,3.1780538303479458,"(3,4]"
2216,2725,cytosponge adequacy study evaluation ii,Completed,4,1,1,Barrett's Esophagus|GERD,device,Others,191,All,Industry&Combos,0,1,2,2015,2015,997,0,Others,1,NA,1,5.25227342804663,"(5,6]"
1285,1372,"long-term, substantial weight loss and insulin regulation of lipolysis",Recruiting,2,0,0,"Obesity, Morbid",procedure,Others,30,All,AllOther,0,NA,4,2019,2019,1369,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
646,673,covered vs uncovered metal stents for palliative biliary decompression in inoperable malignant distal bile duct obstruction,Completed,4,0,0,Distal Bile Duct Obstruction,device,Others,5,All,AllOther,1,0,4,2013,2017,1119,1,Others,0,NA,0,1.6094379124341003,"(1,2]"
991,1045,vitamin d repletion and maintenance in ibd: how much and how often,Withdrawn,7,0,0,Inflammatory Bowel Diseases|Vitamin D Deficiency,other,Others,NA,All,AllOther,1,0,0,2017,2017,649,1,Others,0,NA,0,NA,NA
4076,7885,prevention support for people leaving jail,Recruiting,2,0,0,"HIV Infections|Sexually Transmitted Diseases, Bacterial|Hepatitis C|Substance Use Disorders",behavioral,Others,300,Male,AllOther,1,0,1,2019,2019,767,1,Others,0,NA,0,5.703782474656201,"(5,6]"
616,642,mri to assess fibrosis in eosinophilic esophagitis patients,Recruiting,2,0,0,Eosinophilic Esophagitis,device,Others,20,All,AllOther,0,NA,4,2018,2017,1781,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1397,1498,endoscopic mucosal resection and cellular matrix,Enrolling by invitation,3,0,0,Barretts Esophagus With High Grade Dysplasia|Barrett Adenocarcinoma,device,Others,20,All,AllOther,1,0,1,2017,2017,1843,1,Others,0,NA,0,2.995732273553991,"(2,3]"
1728,1921,vacuum assisted therapy in emergent contaminated abdominal surgeries,Completed,4,0,0,Gastrointestinal Injury|Complicated Diverticulitis,device,Others,20,All,Industry&Combos,0,NA,0,2014,2014,1096,0,Others,1,NA,1,2.995732273553991,"(2,3]"
653,680,laser versus mechanical lithotripsy of bile duct stones,Completed,4,0,0,Choledocholithiasis,procedure,Others,60,All,AllOther,1,0,0,2013,2013,1155,1,Others,1,NA,1,4.0943445622221,"(4,5]"
1194,1271,transcutaneous vns to treat pediatric ibd,Recruiting,2,0,0,Crohn Disease|Ulcerative Colitis,device,Others,30,All,AllOther,1,0,0,2019,2019,1051,1,Others,1,NA,1,3.4011973816621555,"(3,4]"
1528,1660,neuroimaging and biomarkers in chronic visceral pain,Completed,4,0,0,Irritable Bowel Syndrome,behavioral,Others,119,All,NIH&Combos,0,NA,0,2012,2013,1174,0,Others,1,NA,1,4.77912349311153,"(4,5]"
3800,6694,enteral formula tolerance in pediatric patients,Completed,4,0,0,Enteral Nutrition,other,Others,22,All,Industry&Combos,0,NA,NA,2016,2016,153,0,Others,1,NA,1,3.091042453358316,"(3,4]"
221,224,evaluation of the gastrointestinal manifestation of fabry's disease,Recruiting,2,0,0,Fabry's Disease,device,Others,50,All,AllOther,0,1,2,2016,2016,1857,0,Others,1,NA,1,3.912023005428146,"(3,4]"
1256,1341,contrast-enhanced mri in detecting benign and malignant liver lesions,Recruiting,2,0,0,Hepatocellular Carcinoma|Liver and Intrahepatic Bile Duct Disorder|Metastatic Malignant Neoplasm in the Liver|Primary Malignant Liver Neoplasm,drug or biologic,NA,100,All,NIH&Combos,0,NA,2,2014,2014,2575,0,NA,1,NA,1,4.605170185988092,"(4,5]"
1868,2149,comparison of fcsems and plastic stents,Completed,4,0,0,Infected Pancreatic Necrosis|Acute Pancreatic Fluid Collection|Pancreatic and Peripancreatic Necrosis|Pancreatic Collection|Symptomatic Pancreatic Necrosis,device,Others,60,All,AllOther,1,0,0,2016,2016,879,1,Others,1,NA,1,4.0943445622221,"(4,5]"
1712,1900,effects of the anti-hiv pill truvada on gene transcription in the gastrointestinal tract of hiv-uninfected individuals,Completed,4,0,0,HIV,drug or biologic,NA,9,Male,AllOther,0,NA,4,2015,2015,731,0,NA,1,NA,1,2.1972245773362196,"(2,3]"
577,601,effects of low fodmap diet on leaky gut,Recruiting,2,0,0,Irritable Bowel Syndrome,other,Others,40,All,AllOther,0,NA,4,2020,2019,743,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
220,223,pilot study to image the esophagus using a secm tethered endoscopic capsule,Completed,4,1,1,Healthy|Barrett's Esophagus|Gastric Acid Reflux,device,Others,3,All,NIH&Combos,0,NA,NA,2015,2014,762,0,Others,1,NA,1,1.0986122886681098,"(1,2]"
2032,2402,perioperative geriatrics intervention for older cancer patients undergoing surgical resection,"Active, not recruiting",1,0,0,Pancreatic Cancer|Esophageal Cancer|Gastric Cancer|Rectal Cancer|Hepatobiliary Cancer|Colon Cancer,other,Others,160,All,AllOther,1,0,4,2016,2016,2191,1,Others,0,NA,0,5.075173815233827,"(5,6]"
64,64,slowly digestible carbohydrates and the ileal brake,Completed,4,0,0,"Obesity|Diabetes Mellitus, Type 2|Appetitive Behavior",other,Others,20,All,Industry&Combos,3,0,4,2018,2015,59,3,Others,2,NA,2,2.995732273553991,"(2,3]"
70,70,immunonutrition in ulcerative colitis,Unknown status,8,0,0,Ulcerative Colitis,other,Others,30,All,AllOther,1,0,4,2018,2018,245,1,Others,1,NA,1,3.4011973816621555,"(3,4]"
3217,4494,"cosmesis, patient satisfaction and quality of life after da vinci single site and multiport laparoscopic cholecystectomy",Completed,4,0,0,Symptomatic Gallbladder Disease,procedure,Others,136,All,Industry&Combos,1,0,0,2013,2013,1187,1,Others,0,NA,0,4.912654885736052,"(4,5]"
651,678,transforming non-invasive liver disease detection by mre: the hepatogram,Recruiting,2,0,0,Obesity|Fatty Liver,device,Others,80,All,AllOther,0,NA,2,2015,2015,2314,0,Others,1,NA,1,4.382026634673881,"(4,5]"
1137,1207,efficacy of linaclotide to senna for cic,Terminated,5,1,1,Chronic Idiopathic Constipation,drug or biologic,NA,9,All,AllOther,1,0,0,2014,2014,639,1,NA,2,efficacy,2,2.1972245773362196,"(2,3]"
80,80,ultrasound monitoring of abdominal soft tissue,Suspended,6,0,0,Pancreatic Cancer|Liver Cancer,drug or biologic,NA,65,All,NIH&Combos,1,1,2,2016,2015,2801,1,NA,0,NA,0,4.174387269895637,"(4,5]"
1352,1446,method to measure protein digestion & absorption,"Active, not recruiting",1,0,0,"Chronic Heart Failure|Pulmonary Disorder, Chronic Obstructive",other,Others,74,All,AllOther,0,1,4,2014,2014,2284,0,Others,1,NA,1,4.30406509320417,"(4,5]"
3731,6251,the effects of cold liquids on the swallowing mechanism in preterm infants,Completed,4,0,0,Dysphagia,other,Others,10,All,AllOther,0,NA,4,2013,2013,730,0,Others,1,NA,1,2.302585092994046,"(2,3]"
1497,1622,"the sonic incytes liver incyte system, assessment of liver fibrosis and steatosis",Recruiting,2,0,0,Liver Fibrosis|Liver Steatosis,device,Others,200,All,Industry&Combos,0,NA,2,2019,2019,790,0,Others,1,NA,1,5.298317366548036,"(5,6]"
1780,2003,comparing the digestion of milk with different beta-casein protein content by dairy intolerant persons,Recruiting,2,0,0,Dairy Intolerance,other,Others,200,All,AllOther,3,0,4,2018,2018,1079,3,Others,1,NA,1,5.298317366548036,"(5,6]"
2228,2743,cold snare endoscopic mucosal resection trial,Recruiting,2,0,0,Colonic Polyp|Colonoscopy|Complication|Recurrence,procedure,Others,870,All,NA,2,0,0,2019,2019,1187,1,Others,4,NA,2,6.76849321164863,"(6,7]"
1430,1539,ipod games in hepatic encephalopathy,Completed,4,0,0,Hepatic Encephalopathy|Cirrhosis,behavioral,Others,30,All,AllOther,0,NA,0,2014,2013,1277,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
54,54,evaluation of efficacy and safety of goff transpancreatic septotomy vs. double wire technique for achieving biliary access in technically challenging ercps,Completed,4,0,0,Biliary Obstruction|Biliary Stones,procedure,Others,1600,All,AllOther,1,0,0,2017,2016,1191,1,Others,0,safety/efficacy,0,7.3777589082278725,"(7,13]"
2581,3470,gluten ingestion biomarkers in patients w gluten sensitivity and healthy controls peptides in patients with non-celiac gluten sensitivity and healthy patients: a placebo-controlled study,Completed,4,0,0,Non Celiac Gluten Sensitivity,other,Others,90,All,AllOther,3,0,2,2016,2016,730,3,Others,3,NA,2,4.499809670330265,"(4,5]"
3297,4672,tolerance of healthy infants fed infant formulas,Completed,4,0,0,Gastrointestinal Tolerance,other,Others,126,All,Industry&Combos,1,0,NA,2015,2015,153,1,Others,4,NA,2,4.836281906951478,"(4,5]"
1814,2050,consumer-based activity monitor in evaluating and measuring activity of older patients with abdominal cancer undergoing surgery,Completed,4,1,1,Malignant Gastrointestinal Neoplasm|Malignant Peritoneal Neoplasm,device,Others,34,All,NIH&Combos,0,NA,4,2015,2015,580,0,Others,1,NA,1,3.5263605246161616,"(3,4]"
1437,1546,safety and tolerability of serum derived bovine immunoglobulin in children with diarrhea predominant ibs,Completed,4,0,0,Diarrhea Predominant Irritable Bowel Syndrome,other,Others,20,All,AllOther,1,0,4,2015,2014,351,1,Others,1,safety,1,2.995732273553991,"(2,3]"
3004,4028,growth and tolerance of infants fed milk-based infant formula,Completed,4,0,0,Gastro-Intestinal Tolerance,other,Others,189,All,Industry&Combos,1,0,4,2019,2019,356,1,Others,4,NA,2,5.241747015059643,"(5,6]"
2497,3310,gender- and culturally-sensitive weight loss intervention for hispanic males,Completed,4,0,0,Overweight|Obesity,behavioral,Others,50,Male,AllOther,1,0,0,2016,2016,276,1,Others,1,NA,1,3.912023005428146,"(3,4]"
1708,1895,development and validation of the automated evaluation of gastrointestinal symptoms (aegis) platform,Completed,4,0,0,Abdominal Pain|Deglutition Disorders|Fecal Incontinence|Nausea|Diarrhea|Constipation|Gastroesophageal Reflux,other,Others,255,All,NIH&Combos,1,1,4,2015,2014,518,1,Others,0,NA,0,5.541263545158426,"(5,6]"
1548,1687,exalt: exercise attenuates liver tumors trial,Recruiting,2,0,0,Hepatocellular Carcinoma,behavioral,Others,21,All,AllOther,1,0,0,2019,2019,1428,1,Others,0,NA,0,3.044522437723423,"(3,4]"
495,514,evaluating the impact of automated evaluation of gastrointestinal symptoms (aegis) on clinical outcomes,Completed,4,0,0,Abdominal Pain|Deglutition Disorders|Fecal Incontinence|Nausea|Diarrhea|Constipation|Gastroesophageal Reflux,other,Others,610,All,AllOther,1,1,4,2015,2017,303,1,Others,0,NA,0,6.413458957167357,"(6,7]"
2538,3405,blood flow monitoring to prevent post-polypectomy induced ulcer bleeding,Recruiting,2,0,0,Delayed Post-Polypectomy Induced Ulcer Hemorrhage,device,Others,264,All,AllOther,1,0,0,2016,2017,2340,1,Others,2,NA,2,5.575949103146316,"(5,6]"
2466,3231,exercise and nutrition on obese microbiome,Completed,4,0,0,Overweight and Obesity,other,Others,31,All,AllOther,1,0,4,2019,2019,61,1,Others,1,NA,1,3.4339872044851463,"(3,4]"
184,185,impact of slowly digestible carbohydrates on gastric emptying rates,"Active, not recruiting",1,0,0,"Obesity|Diabetes Mellitus, Type 2|Appetitive Behavior",other,Others,32,All,AllOther,NA,0,4,2018,2019,837,NA,Others,1,NA,1,3.4657359027997265,"(3,4]"
1171,1246,effects and tolerability with clenpiq and low residue diet,Recruiting,2,0,0,Colonoscopy Preparation,other,Others,150,All,Industry&Combos,1,0,4,2019,2019,72,1,Others,1,NA,1,5.0106352940962555,"(5,6]"
93,93,exploring the effects of a high chlorophyll dietary intervention to reduce colon cancer risk in adults,Completed,4,0,0,Colon Cancer Prevention,behavioral,Others,50,All,AllOther,3,0,1,2018,2018,142,3,Others,0,NA,0,3.912023005428146,"(3,4]"
2591,3484,nitrous oxide for endoscopic ablation of refractory barrett's esophagus (no fear-be),Suspended,6,0,0,Barrett Esophagus|Intestinal Metaplasia|Esophageal Dysplasia,device,Others,70,All,AllOther,0,NA,0,2018,2018,1184,0,Others,1,NA,1,4.248495242049359,"(4,5]"
3253,4576,endoscopic ultrasound (eus) fine needle biopsy (fnb) submucosal nodule,Withdrawn,7,0,0,GI Lesions,device,Others,NA,All,AllOther,1,0,2,2017,2017,726,1,Others,2,NA,2,NA,NA
498,518,"pancreatic resection, malnutrition and readmission",Completed,4,0,0,Pancreatic Cancer|Malnutrition,other,Others,38,All,AllOther,0,NA,4,2013,2013,913,0,Others,1,NA,1,3.6375861597263857,"(3,4]"
1215,1293,biomarkers predicting successful tacrolimus withdrawal and everolimus (zortress) monotherapy early after liver transplantation,Completed,4,0,0,Liver Transplantation,drug or biologic,NA,30,All,Industry&Combos,0,NA,0,2016,2016,1826,0,NA,1,NA,1,3.4011973816621555,"(3,4]"
323,328,methods to detect liver fibrosis,Terminated,5,0,0,Liver Fibroses|Hepatic Steatosis,device,Others,6,All,AllOther,1,1,2,2017,2017,703,1,Others,2,NA,2,1.791759469228055,"(1,2]"
1104,1168,using patients' social contact to improve out-patient endoscopy among blacks,Completed,4,0,0,Compliance|Colon Cancer,behavioral,Others,812,All,AllOther,1,0,4,2015,2014,985,1,Others,0,NA,0,6.699500340161678,"(6,7]"
2130,2554,mindfulness - based stress reduction and the relationship on inflammation in autoimmune hepatitis,Completed,4,0,0,Autoimmune Hepatitis,behavioral,Others,21,All,AllOther,0,NA,0,2016,2017,365,0,Others,1,NA,1,3.044522437723423,"(3,4]"
2235,2755,"daily imaging, target identification, and simulated computed tomography-based stereotactic adaptive radiotherapy workflow in a novel ring gantry radiotherapy device",Recruiting,2,0,0,Cancer of Pancreas|Cancer of Pelvis|Cancer of Abdomen|Cancer of Thorax,device,Others,32,All,Industry&Combos,0,NA,NA,2019,2019,908,0,Others,1,NA,1,3.4657359027997265,"(3,4]"
83,83,prospective evaluation of mri biomarkers in pancreatic ductal adenocarcinoma,"Active, not recruiting",1,0,0,Pancreatic Adenocarcinoma,other,Others,70,All,AllOther,1,1,2,2016,2013,4048,1,Others,0,NA,0,4.248495242049359,"(4,5]"
795,832,a study of the effect of probiotics on gastrointestinal function during pregnancy,"Active, not recruiting",1,0,0,Pregnancy Early|Nausea Gravidarum|Vomiting of Pregnancy,other,Others,39,Female,AllOther,0,NA,4,2017,2018,1543,0,Others,1,NA,1,3.6635616461296463,"(3,4]"
1073,1131,"nectar study: nectar (honey) effects on comfort, thoughts, and regularity",Recruiting,2,0,0,Gastrointestinal Dysfunction|Physiological Stress|Cognition - Other,other,Others,60,All,AllOther,3,0,4,2019,2019,366,3,Others,2,NA,2,4.0943445622221,"(4,5]"
855,896,yoga for youth with ibd: a pilot feasibility study,Completed,4,0,0,Inflammatory Bowel Diseases|Yoga|Adolescents|Crohn Disease|Ulcerative Colitis,behavioral,Others,9,All,AllOther,0,NA,0,2021,2017,150,0,Others,1,NA,1,2.1972245773362196,"(2,3]"
338,344,multicenter prospective randomized controlled trial of plicated laparoscopic adjustable gastric banding,Terminated,5,1,1,Morbid Obesity,device,Others,17,All,Industry&Combos,1,0,0,2012,2013,577,1,Others,1,NA,1,2.833213344056216,"(2,3]"
2482,3265,confirming proper replacement of dislodged gastrostomy tubes in pediatric patients,Completed,4,0,0,Gastrostomy Tube Site Complication|Gastrostomy Complications,other,Others,50,All,AllOther,0,NA,2,2020,2019,475,0,Others,1,NA,1,3.912023005428146,"(3,4]"
110,110,retracting the esophagus during af ablation,Unknown status,8,0,0,Atrial Fibrillation|Esophageal Fistula|Cardiac Arrhythmia,device,Others,40,All,Industry&Combos,1,0,1,2016,2016,731,1,Others,1,NA,1,3.6888794541139363,"(3,4]"
1552,1691,eus-fna with and without suction,Completed,4,0,0,Solid Pancreatic Mass Lesions,procedure,Others,72,All,AllOther,1,0,2,2014,2014,120,1,Others,1,NA,1,4.276666119016055,"(4,5]"
1905,2215,"microbiome, exercise tracking study (mets)",Unknown status,8,0,0,Colorectal Cancer,behavioral,Others,20,All,AllOther,0,NA,1,2016,2015,641,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1964,2310,effect of video monitor size on adenoma detection rate,Completed,4,1,1,Colon Adenoma,device,Others,1805,All,AllOther,1,0,2,2013,2013,426,1,Others,1,NA,1,7.498315870766981,"(7,13]"
867,909,comparing speedlyte and iv rehydration treating children with gastroenteritis in a pediatric emergency department (ed),Terminated,5,0,0,Dehydration|Acute Gastroenteritis,other,Others,5,All,AllOther,1,0,0,2018,2018,570,1,Others,3,NA,2,1.6094379124341003,"(1,2]"
1049,1104,alternate day fasting combined and nafld for the treatment of non-alcoholic fatty liver disease (nafld),Enrolling by invitation,3,0,0,Non-Alcoholic Fatty Liver Disease|Obesity|Pre-diabetes,other,Others,180,All,AllOther,1,0,0,2019,2019,1461,1,Others,1,NA,1,5.19295685089021,"(5,6]"
1908,2220,poem anterior versus posterior approach,Completed,4,0,0,Achalasia,procedure,Others,150,All,AllOther,1,0,0,2015,2015,670,1,Others,1,NA,1,5.0106352940962555,"(5,6]"
2485,3273,exploratory/proof of principle microbiota study,Completed,4,0,0,Fecal Microbiota,other,Others,78,All,Industry&Combos,1,0,4,2015,2015,731,1,Others,3,NA,2,4.356708826689592,"(4,5]"
3213,4486,antiviral pharmacology and adherence in drug users,"Active, not recruiting",1,0,0,"HEPATITIS C|Virus, Human Immunodeficiency",behavioral,Others,60,All,IndustryNIHPartnership,1,0,4,2015,2015,1582,1,Others,0,NA,0,4.0943445622221,"(4,5]"
4099,8107,developing individualized strategies to prevent nausea and vomiting,Withdrawn,7,0,0,Postoperative Nausea and Vomiting|Genetic Polymorphisms,drug or biologic,NA,NA,All,NIH&Combos,2,0,1,2011,2013,365,1,NA,4,NA,2,NA,NA
1633,1795,reducing up-set stomach and vomiting after surgery using essential oils,Completed,4,0,0,Nausea,other,Others,143,All,AllOther,1,0,0,2017,2018,110,1,Others,3,NA,2,4.962844630259907,"(4,5]"
146,146,trial to assess the effects of an antimicrobial mouthwash on the esophageal microbiome,Completed,4,0,0,Esophageal Adenocarcinoma|Barrett's Esophagus|Reflux Esophagitis,drug or biologic,NA,21,All,AllOther,1,0,0,2015,2015,853,1,NA,0,NA,0,3.044522437723423,"(3,4]"
3777,6543,"proof of concept: ""bottom's up"" seat to treat constipation",Completed,4,1,1,Constipation Aggravated|Pelvic Floor; Incompetency,device,Others,12,All,AllOther,0,NA,0,2015,2015,610,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
1,1,single anastomosis duodenal ileal bypass (sadi) for sleeve revision,Recruiting,2,0,0,Bariatric Surgery Candidate|Severe Obesity,procedure,Others,50,All,AllOther,0,NA,0,2019,2019,2269,0,Others,1,NA,1,3.912023005428146,"(3,4]"
1059,1115,the effect of acetaminophen on non-alcoholic fatty liver disease patients,Withdrawn,7,0,0,Non-alcoholic Fatty Liver Disease (NAFLD),drug or biologic,NA,NA,All,AllOther,1,1,4,2014,2014,291,1,NA,0,NA,0,NA,NA
1742,1949,human breastmilk in young children with norovirus infection of the gut,Terminated,5,0,0,Norovirus Infections,other,Others,4,All,AllOther,0,NA,4,2015,2014,640,0,Others,1,NA,1,1.3862943611198906,"(1,2]"
1764,1976,fecal microbiota transplantation for c diff infection,Recruiting,2,0,0,Clostridium Difficile Infection,drug or biologic,NA,100,All,AllOther,0,NA,0,2013,2013,2922,0,NA,1,NA,1,4.605170185988092,"(4,5]"
3713,6209,low-level laser therapy for prevention of oral mucositis,Unknown status,8,0,0,Mucositis,device,Others,25,All,NIH&Combos,0,NA,1,2016,2016,486,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
1399,1502,electronic record assimilation and subsequent eradication of hepatitis c,Completed,4,0,0,Hepatitis C|Liver Diseases,behavioral,Others,1600,All,Industry&Combos,1,0,4,2021,2019,365,1,Others,0,NA,0,7.3777589082278725,"(7,13]"
883,927,change in reward system activation and gut microbiota following rygb and sleeve gastrectomy for weight loss vs. control-heads up ancillary,Completed,4,0,0,Bariatric Surgery Candidate,procedure,Others,6,All,AllOther,1,1,2,2016,2016,579,1,Others,0,NA,0,1.791759469228055,"(1,2]"
1189,1266,translumbosacral neuromodulation for fi,Recruiting,2,0,0,Fecal Incontinence,device,Others,132,All,NIH&Combos,1,0,0,2019,2019,1337,1,Others,4,NA,2,4.882801922586371,"(4,5]"
2021,2387,super heroes: searching how the extract rebaudioside occludes excess steatosis,Recruiting,2,0,0,Non-Alcoholic Fatty Liver Disease,other,Others,60,All,AllOther,1,0,0,2019,2019,859,1,Others,0,NA,0,4.0943445622221,"(4,5]"
1521,1652,feasibility study to evaluate safety of envizion medicalÃ¢âÂ¢ envueÃ¢âÂ¢ system,Completed,4,1,1,Enteral Nutrition,device,Others,48,All,Industry&Combos,0,NA,4,2018,2018,103,0,Others,1,safety,1,3.871201010907891,"(3,4]"
1473,1589,a clinical study to assess the effect of novel glycans on nitrogen metabolism of the gut in healthy subjects,Completed,4,0,0,Healthy,other,Others,47,All,Industry&Combos,1,0,4,2020,2017,71,1,Others,3,NA,2,3.8501476017100584,"(3,4]"
1537,1671,assessment of immune activation and tolerance in celiac disease during gluten challenge,Completed,4,1,1,Celiac Disease,other,Others,16,All,Industry&Combos,1,0,4,2018,2018,373,1,Others,4,NA,2,2.772588722239781,"(2,3]"
1812,2047,effect of a synbiotic supplement on a high-protein diet,Unknown status,8,0,0,Obesity,other,Others,40,All,AllOther,1,0,4,2017,2017,152,1,Others,2,NA,2,3.6888794541139363,"(3,4]"
2053,2433,transcutaneous electrical acupoint stimulation (teas) for chronic constipation,Recruiting,2,0,0,Constipation - Functional,device,Others,100,All,AllOther,1,0,0,2017,2017,1584,1,Others,4,NA,2,4.605170185988092,"(4,5]"
3633,5742,appendectomy versus non-operative treatment for acute non-perforated appendicitis in children,Recruiting,2,0,0,Appendicitis,procedure,Others,978,All,AllOther,1,0,0,2016,2016,2192,1,Others,0,NA,0,6.885509670034818,"(6,7]"
267,271,"changes in gut hormones, body composition and energy expenditure after roux-en-y",Completed,4,0,0,Obesity|Weight Loss,other,Others,57,All,AllOther,1,1,4,2014,2014,424,1,Others,0,NA,0,4.04305126783455,"(4,5]"
1461,1573,sulfur colloid spect/ct in measuring liver function in patients with primary or metastatic liver cancer undergoing radiation therapy or surgery,Recruiting,2,0,0,Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma|Stage IV Liver Cancer|Stage IVA Liver Cancer|Stage IVB Liver Cancer|Vascular Thrombosis,drug or biologic,NA,60,All,NIH&Combos,0,NA,2,2016,2016,1988,0,NA,1,NA,1,4.0943445622221,"(4,5]"
4,4,ct perfusion scans in detecting changes in blood flow to the liver after portal vein embolization,Recruiting,2,0,0,Liver and Intrahepatic Bile Duct Carcinoma,procedure,Others,22,All,NIH&Combos,0,NA,2,2019,2018,1259,0,Others,1,NA,1,3.091042453358316,"(3,4]"
1123,1193,randomized trial of outpatient vs. inpatient management of low-risk patients with upper gastrointestinal bleeding.,Terminated,5,0,0,Upper Gastrointestinal Bleeding,other,Others,17,All,AllOther,1,0,0,2013,2013,913,1,Others,0,NA,0,2.833213344056216,"(2,3]"
1739,1942,prebiotic effects of isomalto-oligosaccharide,Completed,4,0,0,Microbiota,other,Others,54,All,AllOther,1,0,4,2015,2015,214,1,Others,2,NA,2,3.9889840465642745,"(3,4]"
318,323,stereotactic body radiotherapy dose escalation in pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer,other,Others,40,All,AllOther,1,1,4,2015,2014,2751,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
2322,2934,dietary soy isoflavones in chronic pancreatitis,Completed,4,0,0,Chronic Pancreatitis,other,Others,11,All,AllOther,0,1,0,2015,2015,731,0,Others,1,NA,1,2.3978952727983707,"(2,3]"
556,578,liver fibrosis evaluation using ultrasound shear wave imaging,"Active, not recruiting",1,0,0,Liver Fibrosis,device,Others,325,All,AllOther,0,NA,4,2018,2018,1105,0,Others,1,NA,1,5.783825182329737,"(5,6]"
1283,1370,endoscopic necrosectomy versus step-up endoscopic intervention,Recruiting,2,0,0,Pancreatic Necrosis|Necrosis Pancreas,procedure,Others,70,All,AllOther,1,0,0,2019,2019,735,1,Others,1,NA,1,4.248495242049359,"(4,5]"
1493,1617,efficacy of pea hull fibre supplementation,Completed,4,0,0,Healthy,other,Others,35,All,AllOther,3,0,4,2016,2016,395,3,Others,3,efficacy,2,3.5553480614894135,"(3,4]"
3156,4302,study of the safety and tolerability of axa1125 and axa1957 in subjects with non-alcoholic fatty liver disease (nafld),Completed,4,1,1,"NAFLD",other,Others,112,All,Industry&Combos,1,0,4,2019,2018,484,1,Others,1,safety,1,4.718498871295094,"(4,5]"
1506,1634,defining adolescent nausea through brain imaging and neurostimulation response,Recruiting,2,0,0,Functional Gastrointestinal Disorders,device,Others,110,All,NIH&Combos,1,0,0,2018,2018,1500,1,Others,4,NA,2,4.700480365792417,"(4,5]"
743,777,gut microbiome & gastrointestinal toxicities as determinants of response to neoadjuvant chemo for advanced breast cancer,"Active, not recruiting",1,0,0,Breast Cancer,other,Others,40,Female,AllOther,0,NA,4,2016,2016,2191,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
2902,3891,"a clinical evaluation of the eclipseÃ¢âÂ¢ system, a vaginal bowel control (vbc) therapy for fecal incontinence in women",Completed,4,1,1,Fecal Incontinence,device,Others,137,Female,Industry&Combos,0,NA,0,2015,2015,1160,0,Others,1,NA,1,4.919980925828125,"(4,5]"
3756,6402,efficacy and safety of vibrant capsule vs. placebo for the treatment of chronic idiopathic constipation,Recruiting,2,0,0,Chronic Idiopathic Constipation,device,Others,250,All,Industry&Combos,1,0,0,2019,2019,853,1,Others,1,safety/efficacy,1,5.521460917862246,"(5,6]"
600,626,fermented soy and heartburn symptom relief,Completed,4,0,0,Heartburn|Acid Regurgitation,other,Others,51,All,AllOther,1,0,0,2019,2019,100,1,Others,2,NA,2,3.9318256327243257,"(3,4]"
2872,3850,axios stent with electrocautery enhanced delivery system,Completed,4,1,1,Pancreatic Pseudocyst(s),device,Others,30,All,Industry&Combos,0,NA,0,2014,2014,214,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
3530,5385,voices in pain care,"Active, not recruiting",1,0,0,Chronic Pain,other,Others,983,All,AllOther,1,0,4,2017,2017,778,1,Others,0,NA,0,6.890609120147166,"(6,7]"
3424,5200,theranostics of radiolabeled somatostatin antagonists 68ga-dota-jr11 and 177lu-dota-jr11 in patients with neuroendocrine tumors,Completed,4,0,0,Neuroendocrine Tumors,device,Others,20,All,AllOther,0,NA,0,2015,2015,1854,0,Others,1,NA,1,2.995732273553991,"(2,3]"
67,67,the set-point study for type 2 diabetes: evaluating the use of an insulin only bionic pancreas system in type 2 diabetes,Completed,4,1,1,Type 2 Diabetes Mellitus,device,Others,16,All,AllOther,3,0,0,2018,2017,244,3,Others,0,NA,0,2.772588722239781,"(2,3]"
1722,1915,computer aided detection of polyps during colonoscopy procedures,Completed,4,0,0,Colo-rectal Cancer|Polyp of Colon|Adenomatous Polyps,device,Others,300,All,Industry&Combos,0,NA,4,2019,2019,137,0,Others,1,NA,1,5.703782474656201,"(5,6]"
2411,3115,cryoballoon ablation for treatment of duodenal adenomas,Enrolling by invitation,3,0,0,Duodenal Adenomas|Familial Adenomatous Polyposis,device,Others,50,All,Industry&Combos,1,1,0,2019,2019,1084,1,Others,0,NA,0,3.912023005428146,"(3,4]"
2985,4002,tr Â«freeze Â® palliative esophageal cancer,"Active, not recruiting",1,0,0,Esophageal Cancer,device,Others,51,All,Industry&Combos,0,NA,4,2017,2017,1456,0,Others,1,NA,1,3.9318256327243257,"(3,4]"
3909,7276,ehealth partnered evaluation initiative - evaluation of the initial deployment of va's annie texting system,Completed,4,1,1,Hepatitis C,other,Others,750,All,AllOther,2,0,4,2019,2015,730,1,Others,2,NA,2,6.620073206530356,"(6,7]"
2438,3169,reducing binge eating to prevent weight gain in black women,Recruiting,2,0,0,Binge Eating|Weight Loss|Weight Gain Prevention,behavioral,Others,40,Female,NIH&Combos,1,0,0,2018,2019,901,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
1861,2140,minimally invasive surgery vs. endoscopy randomized (miser) trial for necrotizing pancreatitis,Completed,4,0,0,Necrosis of Pancreas|Infected Pancreatic Necrosis,procedure,Others,69,All,AllOther,1,0,0,2014,2014,1370,1,Others,0,NA,0,4.23410650459726,"(4,5]"
2371,3028,patient-centered care and asian americans,Completed,4,0,0,Hepatitis B|Hepatitis C|Liver Disease,behavioral,Others,431,All,AllOther,1,0,4,2014,2014,1242,1,Others,2,NA,2,6.066108090103747,"(6,7]"
293,298,developing viability index for machine perfused livers,Recruiting,2,0,0,Liver Cirrhoses,other,Others,60,All,AllOther,0,NA,2,2018,2018,1096,0,Others,1,NA,1,4.0943445622221,"(4,5]"
997,1052,gastrointestinal tract recovery in patients undergoing open ventral hernia repair,Terminated,5,1,1,Ventral Hernia,drug or biologic,NA,10,All,Industry&Combos,1,0,0,2015,2015,1065,1,NA,4,NA,2,2.302585092994046,"(2,3]"
1904,2213,nasal bridles and repeat endoscopic procedures for endoscopic nasoenteric tubes,Recruiting,2,0,0,Feeding Disorders,device,Others,100,All,AllOther,1,0,1,2019,2019,1076,1,Others,2,NA,2,4.605170185988092,"(4,5]"
801,838,effect of vibrant capsule on gastric emptying and antropyloroduodenal motility in healthy volunteers,Completed,4,0,0,Gastroparesis,device,Others,24,All,Industry&Combos,1,0,NA,2016,2016,275,1,Others,3,NA,2,3.1780538303479458,"(3,4]"
382,392,rct of the double wire technique for sphincterotomy,Terminated,5,0,0,"Cholangiopancreatography, Endoscopic Retrograde|Sphincterotomy, Endoscopic|VATER'S AMPULLA",procedure,Others,16,All,AllOther,1,0,0,2013,2013,1369,1,Others,0,NA,0,2.772588722239781,"(2,3]"
2594,3489,eradicating barrett's esophagus using radiofrequency ablation or a novel hybrid argon plasma coagulation technique,Terminated,5,0,0,Barrett's Esophagus|High-grade Dysplasia in Barrett Esophagus|Low Grade Dysplasia in Barrett Esophagus,device,Others,41,All,Industry&Combos,1,0,0,2018,2019,651,1,Others,1,NA,1,3.713572066704308,"(3,4]"
462,477,pain and infection after transvaginal colectomy,Unknown status,8,0,0,Colonic Resection Procedures,procedure,Others,110,All,AllOther,1,0,0,2013,2013,1826,1,Others,0,NA,0,4.700480365792417,"(4,5]"
780,817,64cu dota-trastuzumab pet/ct in studying patients with gastric cancer,"Active, not recruiting",1,1,1,Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Gastric Cancer|Stage IA Gastric Cancer|Stage IB Gastric Cancer|Stage IIA Gastric Cancer|Stage IIB Gastric Cancer|Stage IIIA Gastric Cancer|Stage IIIB Gastric Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer,device,Others,8,All,AllOther,0,NA,2,2013,2014,2598,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
287,292,gemcitabine/nab-paclitaxel with higrt in resectable pancreatic cancer,"Active, not recruiting",1,1,1,Resectable Pancreatic Cancers,drug or biologic,NA,40,All,AllOther,0,NA,0,2014,2015,1359,0,NA,1,NA,1,3.6888794541139363,"(3,4]"
1867,2147,crural dissection in sleeve gastrectomy,Enrolling by invitation,3,0,0,Sleeve Gastrectomy,procedure,Others,250,All,AllOther,1,0,0,2019,2019,1135,1,Others,1,NA,1,5.521460917862246,"(5,6]"
3952,7369,effects of chronic viral infection on immune response to zoster vaccination,Terminated,5,1,1,Hepatitis C,drug or biologic,NA,14,All,NIH&Combos,1,1,4,2015,2015,647,1,NA,0,NA,0,2.6390573296152584,"(2,3]"
374,383,gastrointestinal microbiome study of appendiceal cancer,Recruiting,2,0,0,"Pseudomyxoma Peritonei|Appendiceal Neoplasm|Cancer, Appendiceal",other,Others,24,All,AllOther,0,NA,4,2015,2015,2557,0,Others,1,NA,1,3.1780538303479458,"(3,4]"
1530,1662,assessment of vertebral fracture risk for first time liver transplant candidates,Recruiting,2,0,0,Metabolic Bone Disease|Transplant-Related Disorder|Secondary Osteoporosis,other,Others,50,All,AllOther,0,NA,1,2019,2019,956,0,Others,1,NA,1,3.912023005428146,"(3,4]"
772,809,value of patch testing in direct diet therapy for eosinophilic esophagitis,Completed,4,1,1,Eosinophilic Esophagitis,device,Others,8,All,AllOther,0,NA,2,2014,2014,1127,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
3042,4086,study to intervene with nutrition for gastroparesis,Recruiting,2,0,0,Gastroparesis,other,Others,30,All,AllOther,0,NA,4,2019,2019,668,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
429,441,two stage study of single dose pegph20 and cetuximab in patients with pancreatic adenocarcinoma prior to surgical resection,Completed,4,1,1,Pancreatic Cancer,drug or biologic,NA,2,All,AllOther,0,NA,0,2014,2014,732,0,NA,1,NA,1,0.6931471805599453,"(0,1]"
2441,3174,pilot study of annie text messaging for depression treatment adherence,Completed,4,0,0,Depression,behavioral,Others,52,All,AllOther,1,0,4,2019,2019,345,1,Others,0,NA,0,3.9512437185814275,"(3,4]"
3117,4230,health it generated pros to improve outcomes in cirrhosis,Enrolling by invitation,3,0,0,Cirrhosis,other,Others,900,All,AllOther,1,0,1,2018,2018,1459,1,Others,0,NA,0,6.802394763324311,"(6,7]"
1192,1269,educational brochure in preparing patients with gastric cancer and their caregivers for recovery after surgery,Withdrawn,7,0,0,Anxiety|Gastric Carcinoma|Stress,procedure,Others,NA,All,NIH&Combos,1,1,4,2015,2015,243,1,Others,0,NA,0,NA,NA
1326,1416,staging of superficial eac using vle,Enrolling by invitation,3,0,0,Esophageal Cancer,other,Others,60,All,AllOther,0,NA,2,2017,2017,1549,0,Others,1,NA,1,4.0943445622221,"(4,5]"
173,174,esophagectomy with or without prior ischemic gastric preconditioning,Terminated,5,0,0,Esophageal Cancer,procedure,Others,1,All,AllOther,1,0,0,2015,2015,550,1,Others,0,NA,0,0,NA
3487,5290,enhancing prevention pathways toward tribal colorectal health,"Active, not recruiting",1,0,0,Colorectal Neoplasm,behavioral,Others,22,All,NIH&Combos,1,0,4,2016,2016,2160,1,Others,2,NA,2,3.091042453358316,"(3,4]"
2044,2419,comparing epidural versus general anesthesia for less cholecystectomies,Unknown status,8,0,0,Cholelithiasis,procedure,Others,70,All,AllOther,1,0,4,2017,2015,1399,1,Others,1,NA,1,4.248495242049359,"(4,5]"
531,553,clinical and financial impact of an evidenced-based adhesive small bowel obstruction management protocol,Withdrawn,7,0,0,Intestinal Obstruction,drug or biologic,NA,NA,All,AllOther,1,0,0,2016,2015,743,1,NA,4,NA,2,NA,NA
439,451,supportive care intervention-pancreas,Completed,4,0,0,Advanced Pancreatic Cancer,behavioral,Others,60,All,AllOther,1,0,4,2013,2013,761,1,Others,0,NA,0,4.0943445622221,"(4,5]"
3504,5312,quell opioid reduction and pain relief in patients with cancer,Terminated,5,1,1,Pain|Metastatic Breast Cancer|Prostate Cancer|Colorectal Cancer,device,Others,33,All,Industry&Combos,1,0,4,2016,2016,396,1,Others,2,NA,2,3.4965075614664802,"(3,4]"
1026,1081,physical activity in gastrointestinal cancer,Completed,4,0,0,Metastatic Gastrointestinal Cancer|Physical Activity,other,Others,20,All,AllOther,0,NA,4,2017,2017,417,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1746,1953,testing how well magnesium citrate capsules work as preparation for a colonoscopy,Completed,4,0,0,Colonoscopy,other,Others,62,All,AllOther,1,0,4,2017,2017,994,1,Others,1,NA,1,4.127134385045092,"(4,5]"
1445,1554,microbiota diversity and composition and polyphenol bioavailability,Completed,4,0,0,Fecal Microbiota,other,Others,11,All,AllOther,3,0,4,2016,2015,62,3,Others,3,NA,2,2.3978952727983707,"(2,3]"
2259,2801,study of flat polyp detection using new narrow band imaging (nbi) compared to white light colonoscopy - the find flat colonoscopy study,Completed,4,1,1,Colorectal Neoplasms|Colonic Polyps|Colorectal Cancer,device,Others,281,All,AllOther,1,0,2,2011,2013,1216,1,Others,1,NA,1,5.638354669333745,"(5,6]"
84,84,feasibility evaluation of an artificial pancreas with glucose prediction trust index,Completed,4,0,0,Type 1 Diabetes Mellitus,device,Others,15,All,AllOther,0,NA,0,2017,2017,275,0,Others,1,NA,1,2.70805020110221,"(2,3]"
3673,5927,measurements of water in breath and saliva,"Active, not recruiting",1,0,0,Human Energy Expenditure,procedure,Others,60,All,NIH&Combos,0,NA,2,2017,2018,1098,0,Others,1,NA,1,4.0943445622221,"(4,5]"
23,23,acceptability and efficacy of the zemedy app for irritable bowel syndrome,Completed,4,1,1,Irritable Bowel Syndrome,behavioral,Others,146,All,Industry&Combos,3,0,0,2019,2019,336,3,Others,0,efficacy,0,4.983606621708336,"(4,5]"
1096,1160,bridge to orthotopic liver transplantation (olt) - surefire precision vs endhole embolization with debtace,Terminated,5,0,0,Hepatocellular Carcinoma of the Liver|Subjects Eligible for Liver Transplantation,device,Others,11,All,Industry&Combos,0,NA,0,2017,2017,517,0,Others,1,NA,1,2.3978952727983707,"(2,3]"
386,396,adherence to colon cancer screening (accs),Completed,4,0,0,Colon Cancer|Rectal Cancer,other,Others,1900,All,AllOther,1,0,4,2014,2013,2312,1,Others,0,NA,0,7.549609165154532,"(7,13]"
1219,1297,participatory research to advance colon cancer prevention,"Active, not recruiting",1,0,0,Colorectal Cancer,other,Others,15000,All,AllOther,3,0,4,2017,2017,1029,3,Others,0,NA,0,9.615805480084347,"(7,13]"
3254,4577,bcaa supplemental study,Completed,4,0,0,Cirrhosis,other,Others,26,All,AllOther,1,0,4,2017,2017,623,1,Others,0,NA,0,3.258096538021482,"(3,4]"
1227,1305,evaluate if response to infliximab or adalimumab may be regained with an immunomodulator,Terminated,5,1,1,Inflammatory Bowel Disease|Ulcerative Colitis|Crohn's Disease,drug or biologic,NA,3,All,AllOther,0,NA,0,2015,2015,1007,0,NA,1,NA,1,1.0986122886681098,"(1,2]"
3304,4695,"evaluation of closed-loop tiva propofol, sufentanil and ketamine guided by bis monitor",Completed,4,0,0,Acute Cholecystitis|Chronic Cholecystitis,procedure,Others,4,All,AllOther,1,0,NA,2013,2013,212,1,Others,1,NA,1,1.3862943611198906,"(1,2]"
180,181,ultrasound elastography assessment of spleen and liver stiffness before and after transjugular intrahepatic portosystemic shunt (tips) procedure,Recruiting,2,0,0,Portal Hypertension,procedure,Others,100,All,AllOther,0,NA,1,2018,2017,1323,0,Others,1,NA,1,4.605170185988092,"(4,5]"
1619,1774,copper cu 64 anti-cea monoclonal antibody m5a pet in diagnosing patients with cea positive cancer,"Active, not recruiting",1,0,0,"Breast Cancer|Colon Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Liver and Intrahepatic Biliary Tract Cancer|Lung Cancer|Metastatic Cancer|Pancreatic Cancer|Rectal Cancer|Thyroid Gland Medullary Carcinoma|Unspecified Adult Solid Tumor, Protocol Specific",drug or biologic,NA,20,All,NIH&Combos,0,NA,2,2014,2015,2039,0,NA,1,NA,1,2.995732273553991,"(2,3]"
1679,1852,transpyloric stenting as a predictor for g-poem for refractory gastroparesis,Recruiting,2,0,0,Gastroparesis,device,Others,36,All,AllOther,1,0,0,2020,2019,962,1,Others,2,NA,2,3.58351893845611,"(3,4]"
3567,5505,behavioral science and hepatitis c screening outreach,Completed,4,0,0,Hepatitis C,behavioral,Others,21493,All,AllOther,1,0,4,2018,2019,580,1,Others,2,NA,2,9.975482579707275,"(7,13]"
65,65,assessment of a serious illness conversation guide (sicg) in advanced gastro-intestinal cancers,Suspended,6,0,0,"Gastrointestinal Cancer|Colorectal Cancer|Pancreatic Adenocarcinoma|Gastric Cancer|Esophageal Cancer|Cholangiocarcinoma|Hepatocellular Carcinoma|Neuroendocrine Tumors|GIST, Malignant",behavioral,Others,68,All,AllOther,1,0,4,2019,2019,958,1,Others,0,NA,0,4.219507705176107,"(4,5]"
1463,1575,pilot study for evaluation of cryobiopsy and correlation with standard forceps biopsy,Enrolling by invitation,3,0,0,Gastrointestinal Disease,device,Others,20,All,AllOther,0,NA,NA,2018,2018,1121,0,Others,1,NA,1,2.995732273553991,"(2,3]"
723,757,tethered capsule endoscope in screening patients with barrett esophagus,Completed,4,0,0,Barrett Esophagus,device,Others,1,All,NIH&Combos,0,NA,NA,2016,2016,371,0,Others,1,NA,1,0,NA
3029,4069,a nutritional management algorithm in older patients with locally advanced esophageal cancer,"Active, not recruiting",1,0,0,Localized Stage I-III Esophageal Cancer|Gastroesophageal Junction Cancer,other,Others,26,All,AllOther,0,NA,4,2014,2013,2900,0,Others,1,NA,1,3.258096538021482,"(3,4]"
836,875,procurement of leukapheresis products from end stage liver disease (esld) patients for immunological studies,Terminated,5,1,1,End Stage Liver Disease,procedure,Others,1,All,AllOther,0,NA,4,2015,2014,731,0,Others,1,NA,1,0,NA
1389,1490,analyzing ibs to identify biomarkers and microbiome signatures,Completed,4,0,0,Diarrhoea Predominant Irritable Bowel Syndrome|IBS,procedure,Others,26,All,AllOther,0,1,4,2015,2015,591,0,Others,1,NA,1,3.258096538021482,"(3,4]"
3715,6211,low-level laser therapy for prevention of oral mucositis,Completed,4,0,0,Mucositis,device,Others,50,All,AllOther,0,NA,1,2016,2016,1614,0,Others,1,NA,1,3.912023005428146,"(3,4]"
1979,2329,computer aided detection of polyps in the colon,Recruiting,2,0,0,"Polyp, Adenomatous|Colo-rectal Cancer",device,Others,200,All,AllOther,1,0,2,2019,2019,574,1,Others,0,NA,0,5.298317366548036,"(5,6]"
1652,1818,improving quality of care with a digital behavioral program in ibd patient centered medical home,Completed,4,0,0,Anxiety|Irritable Bowel Disease,behavioral,Others,90,All,AllOther,1,0,4,2017,2017,744,1,Others,0,NA,0,4.499809670330265,"(4,5]"
1370,1465,electronic monitoring device of patient-reported outcomes and function in improving patient-centered care in patients with gastrointestinal cancer undergoing surgery,Completed,4,0,0,Stage I Adult Liver Cancer|Stage I Colorectal Cancer|Stage IA Gastric Cancer|Stage IA Pancreatic Cancer|Stage IB Gastric Cancer|Stage IB Pancreatic Cancer|Stage II Adult Liver Cancer|Stage IIA Colorectal Cancer|Stage IIA Gastric Cancer|Stage IIA Pancreatic Cancer|Stage IIB Colorectal Cancer|Stage IIB Gastric Cancer|Stage IIB Pancreatic Cancer|Stage IIC Colorectal Cancer|Stage III Pancreatic Cancer|Stage IIIA Adult Liver Cancer|Stage IIIA Colorectal Cancer|Stage IIIA Gastric Cancer|Stage IIIB Adult Liver Cancer|Stage IIIB Colorectal Cancer|Stage IIIB Gastric Cancer|Stage IIIC Adult Liver Cancer|Stage IIIC Colorectal Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer|Stage IVA Colorectal Cancer|Stage IVA Liver Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Liver Cancer|Stage IVB Pancreatic Cancer,device,Others,22,All,NIH&Combos,0,NA,NA,2015,2015,375,0,Others,1,NA,1,3.091042453358316,"(3,4]"
162,162,weight loss-independent metabolic effects of roux-en-y gastric bypass in diabetes,"Active, not recruiting",1,0,0,Obesity|Type 2 Diabetes,procedure,Others,70,All,NIH&Combos,1,1,4,2014,2014,2769,1,Others,0,NA,0,4.248495242049359,"(4,5]"
1010,1065,obesity surgery and kidney transplant for patients with obesity and renal failure,Recruiting,2,0,0,Severe Obesity|Renal Failure,procedure,Others,75,All,AllOther,1,0,0,2014,2014,4262,1,Others,0,NA,0,4.31748811353631,"(4,5]"
203,206,feasibility of using ultrasound to track respiration motion,Completed,4,0,0,Pancreatic Neoplasms,device,Others,15,All,AllOther,0,NA,4,2014,2014,2465,0,Others,1,NA,1,2.70805020110221,"(2,3]"
1841,2101,"comparing the adenoma detection rate with air insufflation, water immersion and water exchange",Completed,4,0,0,Adenoma,procedure,Others,651,All,AllOther,1,0,2,2013,2013,944,1,Others,0,NA,0,6.478509642208569,"(6,7]"
1770,1984,massage therapy in reducing chemotherapy-induced peripheral neuropathy in patients with gastrointestinal or breast malignancies,"Active, not recruiting",1,0,0,Malignant Breast Neoplasm|Malignant Digestive System Neoplasm|Peripheral Neuropathy,procedure,Others,90,All,NIH&Combos,1,0,4,2014,2015,2213,1,Others,1,NA,1,4.499809670330265,"(4,5]"
1289,1376,promoting gastrointestinal health and reducing subclinical inflammation in obese individuals,Completed,4,1,1,Obesity|Overweight,other,Others,52,All,AllOther,1,0,4,2015,2015,609,1,Others,0,NA,0,3.9512437185814275,"(3,4]"
3489,5292,a pilot randomized trial of a comprehensive transitional care program for colorectal cancer patients,Withdrawn,7,0,0,Colorectal Cancer|Comprehensive Transitional Care Program,other,Others,NA,All,AllOther,1,0,NA,2014,2015,365,1,Others,NA,NA,NA,NA,NA
3477,5280,mindfulness meditation intervention for colorectal cancer patients and caregivers,Completed,4,0,0,Colorectal Cancer,behavioral,Others,53,All,AllOther,0,NA,4,2015,2015,371,0,Others,1,NA,1,3.970291913552122,"(3,4]"
929,976,"pet-ct in determining the radioembolization dose delivered to patients with liver metastasis, primary liver cancer, or biliary cancer","Active, not recruiting",1,0,0,"Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage D Adult Primary Liver Cancer (BCLC)|Unspecified Adult Solid Tumor, Protocol Specific",procedure,Others,43,All,AllOther,0,NA,2,2014,2014,919,0,Others,1,NA,1,3.7612001156935624,"(3,4]"
1142,1213,comparison of 19g fna and 19g fnb needles for eus-lb,Completed,4,1,1,Abnormal Liver Function,device,Others,40,All,AllOther,1,0,4,2018,2017,319,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
4029,7613,"live kidney donors with positive anti-hcv antibody, but negative hcv pcr",Completed,4,0,0,ESRD|Hepatitis C,procedure,Others,2,All,AllOther,0,NA,0,2016,2016,1432,0,Others,1,NA,1,0.6931471805599453,"(0,1]"
1413,1519,effect of pea fiber supplementation on the gut microbiota and host metabolome and proteome (fib),Completed,4,0,0,Microbial Colonization,other,Others,13,All,AllOther,0,NA,0,2019,2019,198,0,Others,1,NA,1,2.5649493574615367,"(2,3]"
3577,5558,trial to compare econsent with standard consent among prospective biobank participants,Enrolling by invitation,3,0,0,Lynch Syndrome,behavioral,Others,526,All,NIH&Combos,1,0,4,2019,2019,761,1,Others,0,NA,0,6.26530121273771,"(6,7]"
1526,1658,investigation of cecal intubation rates and pain levels between water exchange and air insufflation flexible sigmoidoscopy,Recruiting,2,0,0,Colorectal Cancer,procedure,Others,200,All,AllOther,1,0,4,2017,2017,1638,1,Others,3,NA,2,5.298317366548036,"(5,6]"
849,890,non-invasive quantification of liver iron with mri,Completed,4,1,1,Iron Overload,device,Others,21,All,Industry&Combos,0,NA,2,2015,2015,456,0,Others,1,NA,1,3.044522437723423,"(3,4]"
5,5,parkinson's disease and digestive health,"Active, not recruiting",1,0,0,Parkinson Disease|Constipation|Gastro-Intestinal Disorder,other,Others,25,All,AllOther,0,NA,2,2019,2017,1030,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
2355,2998,endorotor resection in refractory barrett's dysplasia patients,Recruiting,2,0,0,Barrett's Esophagus With Dysplasia,device,Others,120,All,Industry&Combos,0,0,0,2017,2018,1725,0,Others,1,NA,1,4.787491742782046,"(4,5]"
2280,2843,sensory evaluation of oral nutrition supplements in patients at risk for mucositis undergoing cancer treatment,Completed,4,0,0,Esophagitis|Malignant Neoplasm|Mucositis,other,Others,30,All,NIH&Combos,0,NA,4,2017,2017,98,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
574,598,collaborative cognitive behavioral therapy / hypnotherapy for treatment of pediatric functional gastrointestinal disease,Withdrawn,7,0,0,Irritable Bowel Syndrome (IBS),drug or biologic,NA,NA,All,AllOther,1,0,0,2013,2014,731,1,NA,0,NA,0,NA,NA
1196,1273,enteral nutrition as stress ulcer prophylaxis in critically ill patients.,Completed,4,1,1,Gastrointestinal Hemorrhage|Clostridium Difficile Colitis,drug or biologic,NA,124,All,Industry&Combos,1,0,1,2011,2013,1034,1,NA,3,NA,2,4.820281565605037,"(4,5]"
2160,2603,mindfulness and support group to improve patient and caregiver burden in cirrhosis,Completed,4,0,0,Cirrhosis,other,Others,20,All,AllOther,0,NA,0,2016,2016,214,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2847,3818,the effect of almonds on facial aesthetics and modulation of the microbiome and lipidome,Completed,4,0,0,Wrinkle,other,Others,60,Female,AllOther,1,0,4,2018,2018,953,1,Others,0,NA,0,4.0943445622221,"(4,5]"
2854,3828,ginger and gut microbiome (ginger),Completed,4,0,0,Colorectal Adenoma,other,Others,68,All,AllOther,1,0,4,2017,2018,590,1,Others,2,NA,2,4.219507705176107,"(4,5]"
2379,3041,mic-key versus mini one family preference comparison,"Active, not recruiting",1,0,0,Gastroesophageal Reflux|Feeding Disorder|Family Satisfaction,other,Others,220,All,AllOther,3,0,4,2017,2016,2922,3,Others,0,NA,0,5.393627546352362,"(5,6]"
3436,5227,geographically clustered mailing of fecal immunochemical test (fit) kits,"Active, not recruiting",1,0,0,Colorectal Cancer,other,Others,25000,All,AllOther,1,0,4,2018,2018,1096,1,Others,0,NA,0,10.126631103850338,"(7,13]"
237,240,fodmap reintroduction in irritable bowel syndrome,Enrolling by invitation,3,0,0,Irritable Bowel Syndrome With Diarrhea|Irritable Bowel Syndrome With Mixed Bowel Habits,other,Others,30,All,AllOther,1,0,0,2017,2017,1559,1,Others,2,NA,2,3.4011973816621555,"(3,4]"
3774,6532,study to evaluate dietary modification in patients with functional dyspepsia.,Withdrawn,7,0,0,Dyspepsia|Dietary Modification,behavioral,Others,NA,All,AllOther,1,0,0,2016,2016,638,1,Others,1,NA,1,NA,NA
2372,3029,a study to see if low level laser light therapy (lllt) can improve the condition of nonalcoholic steatohepatitis (nash),Withdrawn,7,0,0,Nonalcoholic Steatohepatitis,device,Others,NA,All,Industry&Combos,0,NA,0,2017,2017,310,0,Others,1,NA,1,NA,NA
3047,4095,axiosÃ¢âÂ¢ for gallbladder drainage as an alternative to percutaneous drainage ide,Recruiting,2,0,0,"Cholecystitis, Acute",device,Others,30,All,Industry&Combos,0,NA,0,2018,2019,844,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
2915,3908,effects of yoga on cognitive and immune function in colorectal cancer,Completed,4,0,0,Colorectal Neoplasms,other,Others,27,All,AllOther,1,0,4,2015,2015,731,1,Others,1,NA,1,3.295836866004329,"(3,4]"
493,511,prehabilitation in pancreatic surgery,Recruiting,2,0,0,Pancreatic Resection|Preoperative Frailty,behavioral,Others,40,All,AllOther,0,NA,4,2018,2019,897,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
2093,2499,effect of bacillus coagulans and galactomannans on obese patients undergoing sleeve gastrectomy,Unknown status,8,0,0,Obesity|Quality of Life,other,Others,60,All,AllOther,1,0,4,2016,2016,335,1,Others,1,NA,1,4.0943445622221,"(4,5]"
121,121,"reflux-induced oxidative stress in barrett's esophagus: response, repair, and epithelial-mesenchymal-transition",Enrolling by invitation,3,0,0,Barrett's Esophagus|Gastroesophageal Reflux Disease,other,Others,53,All,NA,0,NA,4,2015,2015,2161,0,Others,1,NA,1,3.970291913552122,"(3,4]"
543,565,functional luminal imaging probe (flip) topography use in patients with scleroderma and trouble swallowing,Withdrawn,7,0,0,Scleroderma|Dysphagia|GERD - Gastro-Esophageal Reflux Disease,device,Others,NA,All,AllOther,1,1,2,2017,2018,851,1,Others,0,NA,0,NA,NA
2300,2888,gluten immunity and islet autoimmunity in type-1 diabetes,Completed,4,0,0,Type 1 Diabetes|Celiac Disease,other,Others,7,All,Industry&Combos,1,0,2,2013,2013,487,1,Others,2,NA,2,1.9459101490553132,"(1,2]"
1242,1326,investigation of the ability of a supplement to increase good bacteria in the human intestine and blood sugar levels,Completed,4,0,0,Pre-diabetic,other,Others,18,All,AllOther,1,0,1,2013,2013,334,1,Others,2,NA,2,2.8903717578961645,"(2,3]"
1737,1938,effects of different sports supplements on metabolism and perceptual responses during distance running,Recruiting,2,0,0,Anomalies Gastrointestinal,other,Others,40,All,AllOther,1,0,4,2018,2018,1308,1,Others,1,NA,1,3.6888794541139363,"(3,4]"
1391,1492,beta-cell response to incretin hormones in cystic fibrosis,Recruiting,2,0,0,Cystic Fibrosis|Pancreatic Insufficiency,drug or biologic,NA,45,All,AllOther,1,0,4,2013,2013,3075,1,NA,4,NA,2,3.8066624897703196,"(3,4]"
2459,3211,fast track appendectomy for suppurative appendicitis,Completed,4,1,1,Suppurative Appendicitis,other,Others,36,All,AllOther,1,0,4,2014,2014,244,1,Others,0,NA,0,3.58351893845611,"(3,4]"
2196,2672,rct of screening strategies among patients at high risk for developing hcc in a safety-net health system,Completed,4,0,0,"Carcinoma, Hepatocellular|Liver Neoplasms",other,Others,1800,All,AllOther,1,0,4,2014,2014,974,1,Others,2,safety,2,7.495541943884256,"(7,13]"
2708,3631,benign liver optimal core study (tissue acquisition comparison in benign liver disease),Completed,4,0,0,Liver Diseases,other,Others,175,All,AllOther,1,0,2,2017,2018,922,1,Others,0,NA,0,5.1647859739235145,"(5,6]"
2797,3754,moderate versus aggressive fluids for acute pancreatitis,Completed,4,0,0,Pancreatitis,other,Others,60,All,AllOther,3,0,0,2013,2013,944,3,Others,0,NA,0,4.0943445622221,"(4,5]"
1882,2178,the biologic onset of crohn's disease: a screening study in first degree relatives,Recruiting,2,0,0,Crohn Disease|Genetic Predisposition|IBD,device,Others,144,All,AllOther,1,1,2,2017,2017,1570,1,Others,0,NA,0,4.969813299576001,"(4,5]"
524,545,radiosurgery for resected pancreas,Completed,4,0,0,Adenocarcinoma of the Pancreas,other,Others,50,All,AllOther,0,NA,0,2011,2013,1880,0,Others,1,NA,1,3.912023005428146,"(3,4]"
1249,1334,dietary green tea confection for resolving gut permeability-induced metabolic endotoxemia in obese adults,"Active, not recruiting",1,0,0,Obesity|Endotoxemia|Inflammation,other,Others,40,All,AllOther,1,0,1,2018,2018,1036,1,Others,3,NA,2,3.6888794541139363,"(3,4]"
1492,1616,the effects of a 12 week home-based exercise intervention on physical performance in patients with cancers of the gastrointestinal tract with pre- cachexia or cachexia,Completed,4,0,0,Cachexia|Weight Loss|Gastrointestinal Cancer,other,Others,25,All,AllOther,1,0,4,2021,2016,961,1,Others,0,NA,0,3.2188758248682006,"(3,4]"
211,214,endoscopic ultrasound and endoscopic retrograde cholangiopancreatography for malignant distal biliary obstruction,Completed,4,0,0,Pancreatic Cancer|Pancreatic Neoplasms|Pancreatic Adenocarcinoma,procedure,Others,67,All,AllOther,1,0,0,2017,2016,730,1,Others,1,NA,1,4.204692619390966,"(4,5]"
3394,5077,correlating probiotic dietary supplements during pregnancy with maternal microbiome profiles,Completed,4,0,0,Pregnancy Related,other,Others,48,Female,AllOther,1,0,4,2018,2018,274,1,Others,4,NA,2,3.871201010907891,"(3,4]"
773,810,mobile self-management of irritable bowel syndrome for adolescents,Completed,4,0,0,Irritable Bowel Syndrome|Abdominal Pain,behavioral,Others,26,All,AllOther,0,NA,4,2017,2016,236,0,Others,1,NA,1,3.258096538021482,"(3,4]"
3469,5271,reducing colorectal cancer death through mailed outreach screening,Completed,4,1,1,Colorectal Cancer,other,Others,782,All,AllOther,1,0,4,2015,2017,162,1,Others,0,NA,0,6.661854740545311,"(6,7]"
505,526,cognitive behavioral therapy for insomnia (cbti) in gerd patients with insomnia,Recruiting,2,0,0,Gastroesophageal Reflux Disease,behavioral,Others,35,All,AllOther,0,NA,0,2019,2019,1082,0,Others,1,NA,1,3.5553480614894135,"(3,4]"
1029,1084,"mrcp: a reliable, non invasive method for staging chronic pancreatitis in pediatrics",Completed,4,1,1,Healthy Volunteers,drug or biologic,NA,57,All,Industry&Combos,0,NA,2,2016,2016,239,0,NA,1,NA,1,4.04305126783455,"(4,5]"
375,384,assessment of esophageal epithelium integrity with mucosal impedance,Completed,4,0,0,Gastroesophageal Reflux Disease (GERD)|Non-erosive Reflux Disease (NERD),procedure,Others,15,All,AllOther,1,1,2,2014,2013,1249,1,Others,0,NA,0,2.70805020110221,"(2,3]"
3871,7114,stop hcc: mailed hcv treatment outreach program for hcc prevention,Completed,4,0,0,Hepatitis C|HepatoCellular Carcinoma,behavioral,Others,12386,All,AllOther,1,0,4,2018,2018,342,1,Others,2,NA,2,9.424322081498007,"(7,13]"
2603,3501,endomaxx endoluminal valve technology (evt) compared to endomaxx,Completed,4,1,1,Malignant Esophageal Strictures,device,Others,60,All,Industry&Combos,1,0,0,2014,2015,639,1,Others,1,NA,1,4.0943445622221,"(4,5]"
3642,5767,tubeclear Â® evaluation in pediatric patients (phase i),"Active, not recruiting",1,0,0,Enteral Nutrition,device,Others,15,All,IndustryNIHPartnership,0,NA,0,2016,2016,2007,0,Others,1,NA,1,2.70805020110221,"(2,3]"
377,386,mindfulness - based intervention in the treatment of fatigue in patients with primary biliary cholangitis,Recruiting,2,0,0,Primary Biliary Cholangitis,behavioral,Others,20,All,AllOther,0,NA,0,2018,2018,1504,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2432,3160,suppress ssi - single use negative pressure wound therapy (npwt) to reduce surgical site infections,Enrolling by invitation,3,0,0,Surgical Site Infection|Obesity|Diabetes|Cesarean Section Complications,device,Others,3650,All,AllOther,NA,0,1,2019,2019,700,NA,Others,0,NA,0,8.202482446576537,"(7,13]"
2534,3399,clinical study comparing pillcam Â® crohn's capsule endoscopy to ileocolonoscopy (ic) plus mre for detection of active cd in the small bowel and colon in subjects with known cd and mucosal disease.,Completed,4,1,1,Crohn Disease,device,Others,187,All,Industry&Combos,0,NA,2,2017,2017,546,0,Others,1,NA,1,5.231108616854587,"(5,6]"
1576,1720,intra-corporeal anastomosis result in quicker return of bowel function/earlier discharge,Recruiting,2,0,0,Colorectal Disorders,procedure,Others,125,All,AllOther,1,0,4,2019,2019,1403,1,Others,1,NA,1,4.8283137373023015,"(4,5]"
347,355,anti-inflammatory effects of mango polyphenolics in inflammatory bowel disease,Completed,4,0,0,Intestinal Diseases|Ulcerative Colitis|Crohn Disease,drug or biologic,NA,20,All,AllOther,0,NA,0,2014,2014,1216,0,NA,1,NA,1,2.995732273553991,"(2,3]"
3440,5231,"a (m)ulti-center, prospective, (o)pen label, uncontrolled feasibility (s)tudy to assess the safety and effectiveness of an automatic low flow (a)scites (alfa) pump (i)n patients with (c)irrhosis and refractory or recurrent ascites",Completed,4,0,0,Cirrhosis|Ascites,device,Others,30,All,Industry&Combos,0,NA,0,2015,2015,1055,0,Others,1,safety,1,3.4011973816621555,"(3,4]"
1097,1161,effect of acid suppression medication on pediatric microbiome,Unknown status,8,0,0,Clostridium Difficile Infection,drug or biologic,NA,30,All,AllOther,0,1,4,2013,2014,973,0,NA,1,NA,1,3.4011973816621555,"(3,4]"
1918,2234,pyloroplasty versus no pyloroplasty in patients undergoing esophagectomy,Recruiting,2,0,0,Esophagectomy,procedure,Others,140,All,AllOther,NA,0,0,2018,2018,1129,NA,Others,0,NA,0,4.941642422609304,"(4,5]"
1895,2199,optimizing the previs device for prediction of postoperative ileus,Recruiting,2,0,0,Ileus,device,Others,225,All,AllOther,0,NA,2,2018,2018,1103,0,Others,1,NA,1,5.41610040220442,"(5,6]"
393,404,endoscopic ultrasound guided liver biopsy,Completed,4,0,0,Hepatic Cancer|Hepatic Neoplasm|Hepatic Carcinoma,other,Others,40,All,AllOther,0,NA,2,2017,2017,322,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
2142,2575,optimizing navigation to successful colorectal cancer screening,Completed,4,0,0,Colorectal Cancer Screening,behavioral,Others,156,All,AllOther,3,0,4,2014,2013,396,3,Others,3,NA,2,5.049856007249537,"(5,6]"
2510,3336,snacks and satiety,Recruiting,2,0,0,Eating Behavior|Overweight|Obesity,other,Others,80,Female,AllOther,1,0,4,2019,2019,921,1,Others,1,NA,1,4.382026634673881,"(4,5]"
3324,4745,trial evaluating chemoprophylaxis against travelers' diarrhea - prevent td,"Active, not recruiting",1,0,0,Travelers' Diarrhea|Functional Bowel Disorders|Reactive Arthritis,drug or biologic,NA,449,All,AllOther,1,0,1,2015,2015,1512,1,NA,4,NA,2,6.1070228877422545,"(6,7]"
1211,1289,spontaneous void requirements for patients undergoing ambulatory anorectal surgery,Recruiting,2,0,0,"Complications, Postoperative",other,Others,100,All,AllOther,1,0,0,2019,2018,1443,1,Others,0,NA,0,4.605170185988092,"(4,5]"
2201,2683,effectiveness and implementation of mpath-crc,Recruiting,2,0,0,Colorectal Cancer|Cancer|Rectum Cancer|Colon Cancer,other,Others,10000,All,NIH&Combos,1,0,1,2019,2019,883,1,Others,0,NA,0,9.210340371976184,"(7,13]"
3996,7557,hepatitis c testing in va community-based outpatient clinics,Completed,4,1,1,Hepatitis C,other,Others,2209,All,AllOther,0,NA,2,2016,2015,336,0,Others,1,NA,1,7.700295203420117,"(7,13]"
1583,1732,focus on reducing dose-limiting toxicities in colon cancer with resistance exercise study,Enrolling by invitation,3,0,0,Resistance Training|Colon Cancer|Chemotherapy Effect,behavioral,Others,180,All,AllOther,1,0,4,2017,2018,1200,1,Others,0,NA,0,5.19295685089021,"(5,6]"
1602,1754,"effects of an amino acid mixture on gastrointestinal function, inflammation and fluid balance: a pilot study in patients with inflammatory bowel disease",Terminated,5,0,0,Inflammatory Bowel Diseases|Short Bowel Syndrome|Ileostomy - Stoma,other,Others,7,All,Industry&Combos,1,0,4,2018,2018,1076,1,Others,3,NA,2,1.9459101490553132,"(1,2]"
4154,9063,the effects on growth and tolerance of a routine infant formula fed to term infants,Completed,4,0,0,Growth of Term Infants,other,Others,315,All,Industry&Combos,1,0,NA,2014,2014,304,1,Others,4,NA,2,5.752572638825633,"(5,6]"
1809,2044,three arm rand trial of hd light vs reveal Â® cap vs endocuff cap for detection of colorectal adenomas (trace),Recruiting,2,0,0,Colorectal Adenoma,device,Others,1227,All,AllOther,1,0,2,2019,2018,675,1,Others,3,NA,2,7.112327444710911,"(7,13]"
658,685,optimizing gastrointestinal procedure appointments,"Active, not recruiting",1,0,0,Gastrointestinal Disease,behavioral,Others,15974,All,AllOther,1,0,4,2019,2019,184,1,Others,1,NA,1,9.678717679477334,"(7,13]"
1356,1450,"novel guidance device for image fusion and needle guidance in lung, liver or kidney biopsy",Unknown status,8,0,0,Liver Biopsy|Lung Biopsy|Kidney Biopsy,device,Others,60,All,NA,1,0,4,2019,2019,366,1,Others,0,NA,0,4.0943445622221,"(4,5]"
656,683,the salty gut: effects of high dietary salt intake on the gut microbiota,Recruiting,2,0,0,Cardiovascular Risk Factor,other,Others,35,All,AllOther,3,0,4,2020,2019,1110,3,Others,1,NA,1,3.5553480614894135,"(3,4]"
1013,1068,tea vs. pvb vs. pca in liver resection surgery,Terminated,5,1,1,Pain Management Strategies in Liver Resection Surgery,drug or biologic,NA,10,All,AllOther,0,0,0,2014,2014,639,0,NA,1,NA,1,2.302585092994046,"(2,3]"
3437,5228,views on cancer prevention and daily lifestyle,Unknown status,8,0,0,Colorectal Cancer|Sedentary Lifestyle,behavioral,Others,84,All,AllOther,1,0,1,2018,2018,106,1,Others,1,NA,1,4.430816798843313,"(4,5]"
1670,1840,alcohol biosensor monitoring for alcoholic liver disease,Completed,4,0,0,"Alcohol Use, Unspecified",behavioral,Others,33,All,NIH&Combos,1,0,1,2018,2018,899,1,Others,1,NA,1,3.4965075614664802,"(3,4]"
242,245,loop duodenal switch: outcomes at one year,Enrolling by invitation,3,0,0,"Obesity, Morbid",other,Others,63,All,AllOther,0,NA,4,2017,2018,1087,0,Others,1,NA,1,4.143134726391533,"(4,5]"
1462,1574,intraoperative warming during major surgical procedures using the esophageal temperature management system,Suspended,6,0,0,Hypothermia Following Anesthesia|Hypothermia|Surgery,device,Others,48,All,Industry&Combos,1,0,1,2019,2019,902,1,Others,0,NA,0,3.871201010907891,"(3,4]"
182,183,supportive oncology care at home for patients with pancreatic cancer receiving preoperative folfirinox,"Active, not recruiting",1,0,0,Pancreas Cancer,other,Others,60,All,AllOther,0,NA,4,2019,2019,1309,0,Others,1,NA,1,4.0943445622221,"(4,5]"
970,1021,ymca diabetes prevention program for the treatment of nonalcoholic fatty liver disease (nafld),Recruiting,2,0,0,Weight Loss|NAFLD|Liver Diseases,behavioral,Others,40,All,AllOther,0,NA,4,2018,2018,1366,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
264,268,22 g - 25 g sins trial for pancreatic masses,Completed,4,0,0,Pancreatic Neoplasms,device,Others,352,All,AllOther,1,0,2,2015,2014,615,1,Others,1,NA,1,5.863631175598097,"(5,6]"
2072,2466,gut microbiome and p-inulin in hemodialysis,Completed,4,0,0,End-Stage Renal Disease|Gut Microbiome Dysbiosis,other,Others,13,All,NIH&Combos,3,1,4,2015,2015,481,3,Others,0,NA,0,2.5649493574615367,"(2,3]"
1485,1608,effect of diets on the gut microbiota composition and cardiometabolic wellbeing,Completed,4,0,0,Healthy,other,Others,38,All,AllOther,3,0,4,2018,2018,230,3,Others,0,NA,0,3.6375861597263857,"(3,4]"
2231,2747,minimally-invasive detection of barrett's esophagus and barrett's esophagus related dysplasia/carcinoma,Recruiting,2,0,0,Barrett's Esophagus,device,Others,660,All,Industry&Combos,1,1,4,2015,2015,2070,1,Others,0,NA,0,6.492239835020471,"(6,7]"
2309,2904,novel therapies in moderately severe acute alcoholic hepatitis,Suspended,6,0,0,Acute Alcoholic Hepatitis,drug or biologic,NA,53,All,NIH&Combos,1,0,4,2013,2013,3256,1,NA,3,NA,2,3.970291913552122,"(3,4]"
75,75,simultaneous improvement in colon cancer screening rates and patient-centered care,Completed,4,0,0,Colon Cancer,behavioral,Others,424,All,AllOther,0,0,4,2015,2015,427,0,Others,1,NA,1,6.049733455231958,"(6,7]"
2453,3196,effects of prebiotics on cognition and health,Completed,4,0,0,Physiological Stress|Cognitive Change|Gastrointestinal Health,other,Others,24,All,AllOther,3,0,4,2020,2018,216,3,Others,4,NA,2,3.1780538303479458,"(3,4]"
1140,1211,food preparation effects on gut bacteria in patients on peritoneal dialysis,Completed,4,0,0,End Stage Renal Disease (ESRD),other,Others,103,All,AllOther,1,0,4,2015,2015,334,1,Others,0,NA,0,4.634728988229636,"(4,5]"
1373,1471,probiotics on stress-associated gastrointestinal function in university students,Completed,4,0,0,Healthy,other,Others,634,All,Industry&Combos,1,0,4,2017,2017,107,1,Others,3,NA,2,6.452048954437226,"(6,7]"
3519,5367,cancer screening; access; awareness; navigation,Recruiting,2,0,0,Colorectal Cancer Screening,other,Others,600,All,AllOther,1,1,4,2019,2019,1085,1,Others,0,NA,0,6.396929655216146,"(6,7]"
2804,3761,neuromodulation for accidental bowel leakage,Completed,4,1,1,Fecal Incontinence|Bowel Incontinence,device,Others,166,Female,NIH&Combos,1,0,0,2017,2018,759,1,Others,1,NA,1,5.111987788356544,"(5,6]"
2245,2770,noninvasive markers of functional nausea in children,Enrolling by invitation,3,0,0,Nausea,drug or biologic,NA,130,All,AllOther,1,1,2,2018,2018,1855,1,NA,0,NA,0,4.867534450455582,"(4,5]"
1335,1427,pilot study for imaging of the esophagus using a tethered capsule oct endomicroscopy in the primary care setting,Completed,4,1,1,Healthy,device,Others,60,All,AllOther,0,NA,NA,2015,2014,1232,0,Others,1,NA,1,4.0943445622221,"(4,5]"
2399,3090,feasibility of viit in adults with nash,Completed,4,0,0,Nonalcoholic Steatohepatitis (NASH)|Nonalcoholic Fatty Liver|Nonalcoholic Steatohepatitis|Liver Diseases,behavioral,Others,24,All,AllOther,0,NA,4,2019,2018,340,0,Others,1,NA,1,3.1780538303479458,"(3,4]"
2381,3050,gastrointestinal tract microbiome in healthy term infants receiving mother's-own breast milk or cow's milk-based infant formulas,Recruiting,2,0,0,Gastrointestinal Microbiome,other,Others,111,All,Industry&Combos,1,0,4,2019,2019,1002,1,Others,3,NA,2,4.709530201312334,"(4,5]"
207,210,the role of muscle cachexia in pancreatic cancer,Recruiting,2,0,0,Pancreas Cancer,procedure,Others,200,All,NIH&Combos,1,1,4,2015,2016,3562,1,Others,0,NA,0,5.298317366548036,"(5,6]"
1903,2212,resuscitation of infants with congenital diaphragmatic hernia with an intact umbilical cord,Completed,4,0,0,Congenital Diaphragmatic Hernia,procedure,Others,10,All,AllOther,0,NA,0,2017,2018,1013,0,Others,1,NA,1,2.302585092994046,"(2,3]"
1929,2252,oncology episode payment model in hawaii,"Active, not recruiting",1,0,0,Breast Cancer|Colon Cancer|Lung Cancer,other,Others,7,All,AllOther,1,1,4,2018,2018,1249,1,Others,0,NA,0,1.9459101490553132,"(1,2]"
2062,2449,polyp detection with the endoringsÃ¢âÂ¢: a randomized tandem colonoscopy study,Completed,4,1,1,Colon Cancer,device,Others,126,All,Industry&Combos,3,0,2,2013,2013,365,3,Others,0,NA,0,4.836281906951478,"(4,5]"
269,273,feasibility and safety of transjugular intrahepatic portosystemic shunt (tips) creation using a radiofrequency guidewire,Completed,4,0,0,Portal Hypertension,device,Others,10,All,Industry&Combos,0,NA,NA,2018,2017,461,0,Others,1,safety,1,2.302585092994046,"(2,3]"
1061,1117,minimal risk registry of endoscopic image and pathology correlation for fujiflim,Recruiting,2,0,0,Gastro-Intestinal Disorder,device,Others,500,All,Industry&Combos,0,NA,2,2018,2017,1934,0,Others,1,NA,1,6.214608098422191,"(6,7]"
561,584,"yoga for psychological distress in gynecologic, gastrointestinal, or thoracic cancer",Recruiting,2,0,0,Gynecologic Cancer|Adjustment|Gastrointestinal Cancer|Thoracic Cancer,behavioral,Others,192,Female,AllOther,0,NA,4,2017,2018,1395,0,Others,1,NA,1,5.2574953720277815,"(5,6]"
807,844,a pilot study of cognitive-behavioral therapy for rumination disorder (cbt-rd),Completed,4,0,0,Rumination Disorder,behavioral,Others,10,All,AllOther,0,NA,0,2017,2017,623,0,Others,1,NA,1,2.302585092994046,"(2,3]"
2067,2459,effects of low fat versus low carbohydrate diets on energy metabolism,Completed,4,1,1,Healthy|Healthy Volunteers,other,Others,21,All,NIH&Combos,3,0,4,2019,2019,324,3,Others,0,NA,0,3.044522437723423,"(3,4]"
2199,2681,effects of peep on heart and lungs in obese subjects,Enrolling by invitation,3,0,0,Obesity|Pulmonary Atelectasis|Obesity Hypoventilation Syndrome|Magnetic Resonance Imaging|Respiratory Mechanics|Electrical Impedance Tomography|Trans-Thoracic Echocardiography,procedure,Others,35,All,AllOther,NA,NA,0,2015,2018,1366,NA,Others,0,NA,0,3.5553480614894135,"(3,4]"
1379,1479,"whole grains, gastric emptying and glycemic response",Completed,4,0,0,"Obesity|Diabetes Mellitus, Type 2|Appetitive Behavior",other,Others,16,All,AllOther,3,0,4,2018,2017,104,3,Others,1,NA,1,2.772588722239781,"(2,3]"
4050,7676,web-based intervention to reduce alcohol use in veterans with hepatitis c,Completed,4,1,1,Hepatitis C|Alcohol Abuse,other,Others,138,All,AllOther,1,0,0,2012,2015,1216,1,Others,0,NA,0,4.927253685157205,"(4,5]"
1546,1684,a physical activity program in end-state liver disease,Completed,4,1,1,End-stage Liver Disease (ESLD)|Liver Transplant|Sarcopenia|Poor Physical Fitness|Cirrhosis|Portal Hypertension,behavioral,Others,20,All,AllOther,1,0,0,2016,2016,1430,1,Others,0,NA,0,2.995732273553991,"(2,3]"
52,52,video capsule endoscopy versus colonoscopy in patients with melena and negative upper endoscopy,Terminated,5,1,1,Gastrointestinal Hemorrhage,device,Others,4,All,AllOther,1,0,2,2015,2015,401,1,Others,0,NA,0,1.3862943611198906,"(1,2]"
416,427,the effect of coffee consumption in enhancing recovery of bowel function following colorectal surgery.,Recruiting,2,0,0,Postoperative Ileus,other,Others,300,All,AllOther,1,0,0,2015,2015,2252,1,Others,0,NA,0,5.703782474656201,"(5,6]"
1266,1351,oral amino acid nutrition to improve glucose excursions in pcos,"Active, not recruiting",1,0,0,Polycystic Ovarian Syndrome|Obesity|Hepatic Steatosis,other,Others,27,Female,AllOther,3,0,0,2018,2018,1424,3,Others,4,NA,2,3.295836866004329,"(3,4]"
2503,3320,endocuff vision colonoscopy vs. amplifeye colonoscopy,Completed,4,1,1,Colorectal Adenoma|Colorectal Polyp|Colorectal Cancer,device,Others,634,All,AllOther,1,0,4,2018,2018,250,1,Others,0,NA,0,6.452048954437226,"(6,7]"
3414,5155,deb-tace for hepatocellular carcinoma,Terminated,5,0,0,Hepatocellular Carcinoma,procedure,Others,170,All,Industry&Combos,1,0,0,2016,2015,1018,1,Others,0,NA,0,5.135798437050262,"(5,6]"
87,87,computed tomography in diagnosing patients with pancreatic or hepatobiliary cancer,Unknown status,8,0,0,Pancreatic Cancer,procedure,Others,259,All,NIH&Combos,0,NA,2,2015,2015,2214,0,Others,1,NA,1,5.556828061699537,"(5,6]"
1036,1091,"effects of glutenshield, a prebiotic, probiotic, and enzyme supplement, on the gut microbiome of adults with gi symptoms",Unknown status,8,0,0,Gastrointestinal Symptoms,other,Others,20,All,AllOther,1,0,4,2018,2018,68,1,Others,2,NA,2,2.995732273553991,"(2,3]"
3067,4131,predicting response to vedolizumab in pediatric inflammatory bowel diseases,Recruiting,2,0,0,Crohn's Disease|Ulcerative Colitis|Inflammatory Bowel Disease,drug or biologic,NA,120,All,AllOther,0,NA,0,2016,2017,1826,0,NA,1,NA,1,4.787491742782046,"(4,5]"
2592,3486,impact of carbon dioxide insufflation and water exchange on post-colonoscopy outcomes,Completed,4,0,0,Abdominal Pain,other,Others,246,All,AllOther,1,0,NA,2015,2015,214,1,Others,2,NA,2,5.5053315359323625,"(5,6]"
2643,3547,the lean living study,Completed,4,0,0,Overweight and Obesity,behavioral,Others,100,All,AllOther,1,0,0,2015,2015,670,1,Others,0,NA,0,4.605170185988092,"(4,5]"
1669,1839,hypoglycemia and the gut microbiome,Recruiting,2,0,0,Hypoglycemia,device,Others,28,All,AllOther,0,NA,0,2017,2019,1363,0,Others,1,NA,1,3.332204510175204,"(3,4]"
2147,2583,establishing visualization grading scale on less cholecystectomy,Completed,4,0,0,Cholecystitis,other,Others,30,All,Industry&Combos,0,NA,0,2014,2013,1004,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
4165,9145,"evaluation of growth, safety, and efficacy of an infant formula for healthy term infants",Completed,4,0,0,Infants|Newborn,other,Others,311,All,Industry&Combos,1,0,4,2020,2019,549,1,Others,4,safety/efficacy,2,5.739792912179234,"(5,6]"
430,442,exercise and nutrition to improve pancreatic outcomes,Recruiting,2,0,0,Pancreatic Cancer,behavioral,Others,60,All,AllOther,1,0,4,2017,2016,1612,1,Others,1,NA,1,4.0943445622221,"(4,5]"
1523,1655,person-centered oncology care and choices (p-cocc): piloting and initial randomized testing of a combined values narrative interview and video education advance care planning program in gastrointestinal oncology patients,Completed,4,0,0,Advanced Gastrointestinal Cancer,behavioral,Others,178,All,AllOther,2,0,4,2013,2013,2375,1,Others,0,NA,0,5.181783550292085,"(5,6]"
247,251,microbiota-targeted diet for pediatric uc,Recruiting,2,0,0,Ulcerative Colitis,other,Others,15,All,NIH&Combos,0,NA,0,2016,2017,1699,0,Others,1,NA,1,2.70805020110221,"(2,3]"
2303,2893,per oral endoscopic myotomy (poem) for esophagogastric junction outflow obstruction (egoo),Completed,4,0,0,Esophagogastric Junction Outflow Obstruction,procedure,Others,15,All,AllOther,0,NA,0,2013,2015,1797,0,Others,1,NA,1,2.70805020110221,"(2,3]"
2884,3869,"safety, tolerability and fat absorption using enteral feeding in-line enzyme cartridge (relizorb)",Completed,4,1,1,Exocrine Pancreatic Insufficiency,device,Others,34,All,Industry&Combos,3,0,0,2015,2015,213,3,Others,3,safety,2,3.5263605246161616,"(3,4]"
2270,2827,information with or without numbers for optimizing reasoning about medical decisions,Completed,4,1,1,Colorectal Cancer Screening,behavioral,Others,728,All,AllOther,1,0,4,2015,2015,816,1,Others,0,NA,0,6.590301048196686,"(6,7]"
2125,2548,prospective rct of water exchange (we) vs. we plus cap-assisted colonoscopy,Recruiting,2,0,0,Unsedated Colonoscopy|Water Exchange Colonoscopy|Cap|Colonoscopy Pain,device,Others,256,All,AllOther,1,0,4,2017,2018,1604,1,Others,1,NA,1,5.545177444479562,"(5,6]"
1787,2013,celiac plexus block for chronic pancreatitis rct,Terminated,5,0,0,"Pancreatitis, Chronic|Pancreatitis",drug or biologic,NA,1,All,AllOther,1,0,0,2015,2014,1169,1,NA,2,NA,2,0,NA
3559,5471,laparoscopic three-dimensional versus two-dimensional sacral colpopexy and paravaginal repair,Completed,4,0,0,Pelvic Organ Prolapse|Cystocele,device,Others,194,Female,Industry&Combos,1,0,0,2014,2014,1186,1,Others,1,NA,1,5.267858159063328,"(5,6]"
13,13,bedside ultrasound of gastric contents in pediatric populations,Recruiting,2,0,0,Gastric Contents,other,Others,50,All,AllOther,1,1,2,2018,2018,1368,1,Others,1,NA,1,3.912023005428146,"(3,4]"
2256,2795,adherence to survivorship care guidelines in health care providers for non-small cell lung cancer and colorectal cancer survivor care,Completed,4,0,0,Adenocarcinoma of the Lung|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Squamous Cell Lung Cancer|Stage I Colon Cancer|Stage I Rectal Cancer|Stage IA Non-small Cell Lung Cancer|Stage IB Non-small Cell Lung Cancer|Stage IIA Colon Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer,other,Others,1440,All,AllOther,0,NA,4,2012,2013,911,0,Others,1,NA,1,7.272398392570047,"(7,13]"
841,881,integrative approaches to managing irritable bowel syndrome (ibs),Completed,4,0,0,Irritable Bowel Syndrome|IBS,behavioral,Others,52,All,AllOther,1,0,0,2015,2015,819,1,Others,0,NA,0,3.9512437185814275,"(3,4]"
3499,5304,motivational interviewing for colonoscopy,Completed,4,0,0,Colorectal Cancer,behavioral,Others,57,All,AllOther,1,0,NA,2013,2013,184,1,Others,0,NA,0,4.04305126783455,"(4,5]"
2801,3758,physical activity intervention for older patients during chemotherapy for colorectal cancer,Completed,4,0,0,Colorectal Cancer|Fatigue,behavioral,Others,36,All,AllOther,0,0,4,2014,2014,1935,0,Others,1,NA,1,3.58351893845611,"(3,4]"
1983,2334,b. lactis b94 effects of gastrointestinal function,Completed,4,0,0,Quality of Life,other,Others,28,All,Industry&Combos,3,0,4,2017,2017,327,3,Others,4,NA,2,3.332204510175204,"(3,4]"
1228,1306,adult liver transplant enhanced care,Completed,4,0,0,Liver Transplant Recipients,behavioral,Others,8,All,AllOther,0,NA,0,2014,2015,578,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
468,484,irritable bowel syndrome and food sensitivity,Completed,4,0,0,Irritable Bowel Syndrome,other,Others,58,All,AllOther,1,0,0,2014,2014,549,1,Others,3,NA,2,4.060443010546419,"(4,5]"
1263,1348,a clinical study to assess the effect of increasing intake amounts of two novel glycans on the gut microbiota of healthy subjects,Completed,4,0,0,Healthy,other,Others,36,All,Industry&Combos,1,0,4,2020,2017,71,1,Others,0,NA,0,3.58351893845611,"(3,4]"
1748,1956,improving colon cancer screening for diverse populations,Completed,4,0,0,Colorectal Cancer,behavioral,Others,265,All,AllOther,1,0,4,2014,2014,790,1,Others,0,NA,0,5.579729825986222,"(5,6]"
1481,1597,radiopaque hydrogel spacer in patients undergoing radiotherapy for pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,device,Others,6,All,Industry&Combos,0,NA,0,2019,2018,939,0,Others,1,NA,1,1.791759469228055,"(1,2]"
2568,3449,the shunt-v study for varices,"Active, not recruiting",1,0,0,Chronic Liver Disease,other,Others,420,All,Industry&Combos,0,NA,2,2018,2019,799,0,Others,1,NA,1,6.040254711277414,"(6,7]"
3051,4101,confirmatory efficacy trial of a gluten-free diet in a subgroup of persons with schizophrenia who have high levels of igg anti-gliadin antibodies (aga ig),Recruiting,2,0,0,Schizophrenia|Gluten Sensitivity|Schizo Affective Disorder,other,Others,40,All,AllOther,1,0,0,2017,2017,1846,1,Others,4,efficacy,2,3.6888794541139363,"(3,4]"
1987,2338,hyperspectral endoscopy imaging for the early detection of precancerous lesions in average risk patients,Completed,4,0,0,Patient,device,Others,13,All,NIH&Combos,0,NA,NA,2019,2019,154,0,Others,1,NA,1,2.5649493574615367,"(2,3]"
2368,3024,changes in cerebral oxygenation during laparoscopic pyloromyotomy,Completed,4,1,1,Pyloric Stenosis,device,Others,25,All,AllOther,0,NA,2,2018,2017,458,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
3794,6670,promoting informed decisions about cancer screening in older adults,Enrolling by invitation,3,0,0,Colorectal Cancer Screening,behavioral,Others,60,All,AllOther,1,0,4,2019,2019,852,1,Others,1,NA,1,4.0943445622221,"(4,5]"
2556,3435,colon capsule endoscopy (cce) versus computed tomographic colonography (ctc) in the identification of colonic polyps in a screening population.,Completed,4,1,1,Colorectal Cancer Screening,device,Others,320,All,Industry&Combos,1,0,2,2016,2016,705,1,Others,0,NA,0,5.768320995793772,"(5,6]"
1644,1808,stereotactic body radiation therapy in treating patients with liver cancer carcinoma,Recruiting,2,0,0,Hepatocellular Carcinoma,other,Others,15,All,AllOther,0,NA,0,2019,2019,1058,0,Others,1,NA,1,2.70805020110221,"(2,3]"
229,232,evaluation of tethered capsule endomicroscopy as a screening tool for barrett's esophagus in the primary care setting,Enrolling by invitation,3,0,0,Barrett Esophagus|Barrett's Esophagus Without Dysplasia|Barretts Esophagus With Dysplasia,device,Others,200,All,AllOther,0,NA,4,2020,2019,1094,0,Others,1,NA,1,5.298317366548036,"(5,6]"
894,938,clinical utility of ercp guided cholangiopancreatoscopy with the spyglass ds,Completed,4,1,1,Biliary Tract Disease,procedure,Others,88,All,AllOther,0,NA,2,2015,2015,244,0,Others,1,NA,1,4.477336814478207,"(4,5]"
1807,2042,vitamin k supplementation study in healthy volunteers (aim 2b),Recruiting,2,0,0,Vitamin K Status,other,Others,200,All,NIH&Combos,1,1,4,2020,2017,1436,1,Others,0,NA,0,5.298317366548036,"(5,6]"
1643,1807,clinical hypnosis in pediatric crohn's disease,Completed,4,0,0,Pediatric Crohns Disease,behavioral,Others,40,All,AllOther,1,0,0,2019,2019,228,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
2236,2756,coordinating center: natural history of barrett's esophagus using tethered capsule endomicroscopy,Recruiting,2,0,0,Barrett Esophagus,device,Others,500,All,NA,0,NA,4,2018,2017,1611,0,Others,1,NA,1,6.214608098422191,"(6,7]"
2120,2538,the hepatitis b e-antigen negative disease - directly offered study of treatment withdrawal in patients with e-antigen negative chronic hbv infection (beneg-do).,"Active, not recruiting",1,0,0,Chronic Hepatitis B Virus,other,Others,119,All,AllOther,1,1,4,2016,2016,1826,1,Others,1,NA,1,4.77912349311153,"(4,5]"
881,925,feasibility study to develop sentinel lymph node mapping in rectal cancer patients,Withdrawn,7,0,0,Rectal Cancer,drug or biologic,NA,NA,All,AllOther,0,NA,2,2014,2013,1372,0,NA,1,NA,1,NA,NA
3636,5758,ehr-based decision support for pediatric acute abdominal pain in emergency care,Completed,4,1,1,Appendicitis,other,Others,5940,All,AllOther,1,0,4,2015,2017,790,1,Others,0,NA,0,8.68946441235669,"(7,13]"
720,754,evaluating the number of passes required for diagnostic cell block during eus-fna of solid pancreatic mass lesions,Completed,4,0,0,Pancreatic Cancer,procedure,Others,62,All,AllOther,1,0,2,2013,2013,334,1,Others,1,NA,1,4.127134385045092,"(4,5]"
3147,4278,use of the modified beef tongue model for teaching repair of obstetrical fourth-degree laceration to residents,Completed,4,0,0,Fourth Degree Perineal Laceration Involving Anal Mucosa|Obstetric; Injury|Obstetric Labor Complications,other,Others,32,All,AllOther,1,0,4,2017,2017,135,1,Others,1,NA,1,3.4657359027997265,"(3,4]"
279,284,effect of hmos as nutritional support for normal bowel movements in ibs patients,Completed,4,0,0,Irritable Bowel Syndrome (IBS),other,Others,317,All,Industry&Combos,0,NA,4,2018,2018,310,0,Others,1,NA,1,5.75890177387728,"(5,6]"
43,43,colonic irrigation for colonoscopy preparation,Withdrawn,7,0,0,Colonoscopy,other,Others,NA,All,AllOther,1,0,0,2016,2014,731,1,Others,1,NA,1,NA,NA
1378,1478,vitamin d supplementation in ibs,Terminated,5,0,0,Irritable Bowel Syndrome|Vitamin D Deficiency|Abdominal Pain,other,Others,7,All,AllOther,0,0,4,2017,2017,200,0,Others,1,NA,1,1.9459101490553132,"(1,2]"
352,360,the prevent anal cancer self-swab study,Recruiting,2,0,0,Anal Cancer,behavioral,Others,400,All,NIH&Combos,1,0,4,2018,2019,903,1,Others,0,NA,0,5.991464547107982,"(5,6]"
1897,2202,microbiome diet study,Completed,4,0,0,Healthy,other,Others,34,All,Industry&Combos,1,0,4,2018,2017,180,1,Others,3,NA,2,3.5263605246161616,"(3,4]"
1715,1907,"the effects of a high protein diet on microbiota, gastrointestinal function and wellness in older women",Completed,4,0,0,Aging,other,Others,29,Female,Industry&Combos,3,0,4,2015,2015,122,3,Others,3,NA,2,3.367295829986474,"(3,4]"
3533,5390,rural interventions for screening effectiveness,Recruiting,2,0,0,"Breast, Cervical or Colorectal Cancer Screening Needed",behavioral,Others,1058,Female,NIH&Combos,1,0,4,2016,2016,1764,1,Others,0,NA,0,6.964135612418245,"(6,7]"
2243,2766,"a comparison of air insufflation, water immersion and water exchange colonoscopy in diagnostic patients",Completed,4,0,0,Pain|Colorectal Adenomas|Colorectal Cancer,other,Others,288,All,AllOther,1,0,0,2013,2013,184,1,Others,1,NA,1,5.662960480135946,"(5,6]"
115,115,the summer camp study 2: blood glucose control with a bi-hormonal endocrine pancreas,Completed,4,1,1,Type 1 Diabetes,device,Others,19,All,AllOther,3,0,0,2014,2014,61,3,Others,0,NA,0,2.9444389791664403,"(2,3]"
2075,2470,chicory fiber effect on satiety and gi tolerance,Terminated,5,0,0,"Diet, Healthy",other,Others,30,All,AllOther,3,0,4,2019,2019,242,3,Others,0,NA,0,3.4011973816621555,"(3,4]"
563,586,comparison of radiofrequency ablation and cryotherapy for the treatment of barrett's esophagus with high-grade dysplasia and/or early adenocarcinoma,Unknown status,8,0,0,Barrett's Esophagus,device,Others,50,All,AllOther,1,0,0,2013,2013,2191,1,Others,0,NA,0,3.912023005428146,"(3,4]"
143,143,"comparison bile duct brushings, cholangioscopy-directed biopsies and pediatric forceps biopsies in biliary strictures",Terminated,5,0,0,Cholangiocarcinoma|Stricture; Bile Duct,procedure,Others,12,All,AllOther,1,0,2,2017,2017,764,1,Others,0,NA,0,2.4849066497880004,"(2,3]"
1115,1183,evaluation of 3d visualization for total colectomy,Completed,4,1,1,Ulcerative Colitis,other,Others,53,All,AllOther,1,0,0,2015,2015,1538,1,Others,0,NA,0,3.970291913552122,"(3,4]"
3035,4077,infant microbiota and probiotic intake study,"Active, not recruiting",1,0,0,Healthy,other,Others,120,Female,Industry&Combos,1,0,0,2015,2014,622,1,Others,0,NA,0,4.787491742782046,"(4,5]"
2035,2405,30-to-90 day challenge: effects of alcohol cessation on health outcomes,Recruiting,2,0,0,Alcohol Drinking|Chronic Inflammation|Neurocognitive Dysfunction|Liver Diseases|HIV Infections,behavioral,Others,180,All,NIH&Combos,0,NA,4,2017,2017,1482,0,Others,1,NA,1,5.19295685089021,"(5,6]"
3480,5283,behavior of infants fed formula supplemented with prebiotics,Completed,4,0,0,Gastrointestinal Tolerance,other,Others,59,All,Industry&Combos,0,NA,4,2016,2016,366,0,Others,1,NA,1,4.07753744390572,"(4,5]"
549,571,wet heparin for obtaining liver tissue for eus guided liver biopsy,Completed,4,0,0,Liver Diseases,procedure,Others,40,All,AllOther,1,1,2,2017,2017,511,1,Others,1,NA,1,3.6888794541139363,"(3,4]"
193,195,ultra-high resolution optical coherence tomography in detecting micrometer sized early stage pancreatic cancer in participants with pancreatic cancer,Recruiting,2,0,0,"Pancreatic Carcinoma|Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type",procedure,Others,75,All,NIH&Combos,0,NA,2,2018,2019,1059,0,Others,1,NA,1,4.31748811353631,"(4,5]"
2273,2832,safety study of sic 8000 in subjects undergoing endoscopic mucosal resection (emr) of colonic lesions equal to or larger than 2 cm,Completed,4,0,0,Adenomas,procedure,Others,226,All,Industry&Combos,1,0,0,2016,2016,455,1,Others,2,safety,2,5.420534999272286,"(5,6]"
2471,3245,growth and tolerance trial on infant formula with hmo,Recruiting,2,0,0,Healthy Growth,other,Others,279,All,Industry&Combos,1,0,0,2019,2019,814,1,Others,3,NA,2,5.631211781821365,"(5,6]"
3843,6925,pilot study to improve therapeutic outcomes for dysphagia after radiation therapy,Terminated,5,1,1,Dysphagia|Oral Pharyngeal Cancer,device,Others,26,All,AllOther,3,0,0,2015,2016,1126,3,Others,0,NA,0,3.258096538021482,"(3,4]"
2,2,validation of a totally synthetic high fidelity laparoscopic duodenal atresia (da) surgical simulator,Recruiting,2,0,0,Duodenal Atresia,procedure,Others,40,All,AllOther,0,NA,4,2019,2019,762,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
35,35,"use of esophageal string test to understand symptoms, inflammation, and function in eosinophilic esophagitis",Completed,4,1,1,Eosinophilic Esophagitis,device,Others,21,All,AllOther,0,NA,4,2017,2018,304,0,Others,1,NA,1,3.044522437723423,"(3,4]"
2597,3493,linx reflux management system in subjects with gerd who have previously undergone a laparoscopic sleeve gastrectomy,"Active, not recruiting",1,0,0,GERD|Gastroesophageal Reflux Disease,device,Others,30,All,Industry&Combos,0,NA,0,2015,2017,1731,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
3239,4547,comparing a 25g eus fine needle aspiration (fna) device with a 20g eus,Completed,4,1,1,Pancreatic Masses|Lymph Nodes,device,Others,615,All,Industry&Combos,1,0,2,2014,2015,851,1,Others,1,NA,1,6.421622267806518,"(6,7]"
610,636,beacon bnxÃ¢âÂ¢ endoscopic ultrasound (eus)-needle vs sharkcoreÃ¢âÂ¢ needle,Unknown status,8,0,0,Pancreatic Cancer|Lymphadenopathy|Cholangiocarcinoma,device,Others,376,All,AllOther,1,0,0,2016,2016,365,1,Others,1,NA,1,5.929589143389895,"(5,6]"
2635,3539,psylliumrx dietary fiber study,Recruiting,2,0,0,Obesity|Childhood Obesity,other,Others,120,All,AllOther,0,NA,1,2018,2019,367,0,Others,1,NA,1,4.787491742782046,"(4,5]"
1033,1088,"choline source, gut microbiota and trimethylamine-n-oxide response",Completed,4,0,0,Metabolism,other,Others,44,All,AllOther,3,0,4,2020,2017,219,3,Others,2,NA,2,3.784189633918261,"(3,4]"
3535,5399,impact of family history and decision support on high-risk cancer screening,Completed,4,0,0,Colorectal Cancer,behavioral,Others,505,All,AllOther,1,0,1,2014,2017,1077,1,Others,0,NA,0,6.22455842927536,"(6,7]"
51,51,endoscopic gastric mucosal devitalization (gmd) as a primary obesity therapy,Completed,4,0,0,"Obesity|Obesity, Morbid|Obesity; Endocrine|Bariatric Surgery Candidate",procedure,Others,6,All,AllOther,0,NA,0,2018,2018,175,0,Others,1,NA,1,1.791759469228055,"(1,2]"
311,316,effect of elemental diet on adult patients with eosinophilic gastroenteritis,Completed,4,1,1,Eosinophilic Gastroenteritis,other,Others,18,All,NIH&Combos,0,NA,0,2017,2017,730,0,Others,1,NA,1,2.8903717578961645,"(2,3]"
1501,1627,a new treatment for zenker's diverticulum-submucosal tunneling endoscopic septum division,Unknown status,8,0,0,Zenker Diverticulum,procedure,Others,20,All,AllOther,0,NA,0,2017,2017,713,0,Others,1,NA,1,2.995732273553991,"(2,3]"
4018,7599,hcv group evaluation and treatment uptake (hcv get-up) intervention,Completed,4,0,0,Hepatitis C|Substance Use Disorders,behavioral,Others,96,All,NIH&Combos,1,0,0,2017,2017,1347,1,Others,0,NA,0,4.564348191467836,"(4,5]"
360,368,change in permeability of the small intestine after treatment with gluten,Completed,4,0,0,Gastrointestinal Disorders,drug or biologic,NA,20,All,AllOther,1,0,2,2014,2014,902,1,NA,2,NA,2,2.995732273553991,"(2,3]"
4182,9408,prospective trial to compare the clinical efficiency of g-eyeÃ¢âÂ¢ hd colonoscopy with standard hd colonoscopy,Completed,4,1,1,Adenoma|Polyps|Colorectal Cancer,device,Others,1000,All,Industry&Combos,1,0,2,2013,2014,854,1,Others,0,NA,0,6.907755278982137,"(6,7]"
73,73,utility of an animated bowel biofeedback training routine to improve bowel function in individuals with sci,Completed,4,0,0,Spinal Cord Injury|Constipation|Fecal Incontinence|Neurogenic Bowel,behavioral,Others,50,All,AllOther,0,1,0,2015,2013,1460,0,Others,1,NA,1,3.912023005428146,"(3,4]"
457,472,the effect of fruit/vegetable drinks on the human intestine,Completed,4,1,1,Intestinal Bacteria Flora Disturbance,other,Others,25,All,AllOther,0,NA,4,2015,2015,122,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
641,668,trial comparing eus-guided radiofrequency ablation vs. eus-guided celiac plexus neurolysis,Completed,4,0,0,"Pancreatic Carcinoma Metastatic|Pancreatic Adenocarcinoma|Pancreatic Neoplasms|Pancreatic Cancer|Pancreatic Cancer, Adult",other,Others,28,All,AllOther,1,0,0,2017,2017,342,1,Others,0,NA,0,3.332204510175204,"(3,4]"
993,1048,mushroom effects on satiety and gut health markers,Completed,4,0,0,Diet Modification,other,Others,32,All,AllOther,3,0,4,2017,2015,884,3,Others,0,NA,0,3.4657359027997265,"(3,4]"
3912,7284,the staying safe intervention,Unknown status,8,0,0,Hepatitis C|Opioid Use,behavioral,Others,456,All,AllOther,1,0,1,2018,2018,1216,1,Others,1,NA,1,6.1224928095143865,"(6,7]"
1226,1304,esophageal manometry during recovery from anesthesia: pilot study,Recruiting,2,0,0,Motility Function,device,Others,10,All,AllOther,0,NA,4,2016,2016,2008,0,Others,1,NA,1,2.302585092994046,"(2,3]"
1426,1534,managing side effects in clinical practice,Enrolling by invitation,3,0,0,Functional Gastrointestinal Disorders,other,Others,360,All,AllOther,1,0,4,2018,2017,1198,1,Others,1,NA,1,5.886104031450156,"(5,6]"
1011,1066,film array gastrointestinal panel compared to usual care for ed evaluation of infectious diarrhea,Unknown status,8,0,0,Infectious Diarrhea,other,Others,176,All,Industry&Combos,1,0,0,2019,2018,273,1,Others,0,NA,0,5.170483995038151,"(5,6]"
1100,1164,dietary intervention and gastrointestinal function in patients with parkinson's disease,Completed,4,0,0,Parkinson Disease,other,Others,8,All,AllOther,0,NA,4,2019,2019,212,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
566,590,amino acid-based oral rehydration solution in children with short bowel syndrome,Terminated,5,1,1,Short Bowel Syndrome,other,Others,4,All,Industry&Combos,0,NA,4,2017,2017,157,0,Others,1,NA,1,1.3862943611198906,"(1,2]"
1480,1596,citrus beverages and gastrointestinal function,Completed,4,0,0,Healthy,other,Others,330,All,Industry&Combos,1,0,4,2016,2017,75,1,Others,3,NA,2,5.799092654460526,"(5,6]"
2024,2390,tackling 30-day readmissions in patients with cirrhosis: the saltyfood trial,Completed,4,0,0,Hepatic Encephalopathy|Ascites|Liver Diseases|Cirrhosis,other,Others,44,All,AllOther,1,0,0,2018,2018,482,1,Others,0,NA,0,3.784189633918261,"(3,4]"
133,133,evaluation of a double balloon interventional platform (dilumen) for complex colonic esd,Completed,4,0,0,Colonic Polyp,device,Others,147,All,AllOther,1,0,0,2019,2019,390,1,Others,1,NA,1,4.990432586778736,"(4,5]"
434,446,the effect of coffee after resection of small bowel,Recruiting,2,0,0,Postoperative Ileus,other,Others,120,All,AllOther,1,0,4,2017,2017,1689,1,Others,2,NA,2,4.787491742782046,"(4,5]"
1887,2185,"comparing the adr with air insufflation, water immersion and water exchange during two-endoscopist colonoscopy",Completed,4,0,0,Adenoma,procedure,Others,371,All,AllOther,1,0,2,2016,2015,1523,1,Others,2,NA,2,5.916202062607435,"(5,6]"
605,631,19 versus 22-gauge needle for eus-lb,Completed,4,1,1,Diagnoses Diseases|Ultrasound Therapy; Complications|Liver Diseases,device,Others,20,All,AllOther,3,0,2,2016,2016,334,3,Others,1,NA,1,2.995732273553991,"(2,3]"
3329,4755,standard versus mnemonic counseling for fecal incontinence,Completed,4,0,0,Fecal Incontinence|Counselling|Patient Satisfaction,other,Others,90,Female,AllOther,1,0,0,2013,2013,365,1,Others,1,NA,1,4.499809670330265,"(4,5]"
2751,3693,l-carnitine to treat fatigue associated with crohn's disease,Withdrawn,7,0,0,Crohn's Disease|Fatigue,drug or biologic,NA,NA,All,AllOther,0,0,0,2012,2013,184,0,NA,1,NA,1,NA,NA
401,412,trial comparing 19 and 25g needles for fine needle aspiration (fna) of solid pancreatic mass lesions greater than 35mm,Completed,4,0,0,Pancreatic Cancer,procedure,Others,51,All,AllOther,1,0,2,2013,2013,303,1,Others,1,NA,1,3.9318256327243257,"(3,4]"
1062,1118,central and peripheral effects of cognitive behavioral therapy on brain-gut axis signaling in gastroparetic patients,Recruiting,2,0,0,Gastroparesis,behavioral,Others,17,All,AllOther,0,NA,0,2018,2018,999,0,Others,1,NA,1,2.833213344056216,"(2,3]"
3939,7343,inhalation intervention for nausea in the emergency department,Completed,4,1,1,Nausea|Vomiting,other,Others,80,All,AllOther,1,0,4,2014,2014,214,1,Others,2,NA,2,4.382026634673881,"(4,5]"
497,517,endoscopic ultrasound vs percutaneous route for liver biopsy,Recruiting,2,0,0,Liver Biopsy,other,Others,40,All,AllOther,1,0,2,2019,2019,495,1,Others,1,NA,1,3.6888794541139363,"(3,4]"
2074,2469,comparing interventions to increase colorectal cancer screening,Unknown status,8,0,0,Colorectal Cancer,behavioral,Others,750,All,AllOther,1,0,4,2017,2017,1193,1,Others,0,NA,0,6.620073206530356,"(6,7]"
1296,1383,the effect study: probiotic and hmo supplementation in infants,Completed,4,0,0,Infant Gut Microbiome,other,Others,10,All,Industry&Combos,1,0,4,2019,2019,183,1,Others,0,NA,0,2.302585092994046,"(2,3]"
1846,2113,water exchange (we) vs. we plus cap-assisted colonoscopy,Recruiting,2,0,0,Colonoscopy|Real-time Maximum Insertion Pain,device,Others,256,All,AllOther,1,0,4,2018,2018,1501,1,Others,2,NA,2,5.545177444479562,"(5,6]"
181,182,"flavonoids, exercise, gut-derived phenolics",Completed,4,0,0,Exercise and Gut-derived Phenolics,other,Others,100,All,AllOther,1,0,0,2017,2017,85,1,Others,2,NA,2,4.605170185988092,"(4,5]"
581,605,bowel preparation quality for screening colonoscopy,Completed,4,0,0,Screening Colonoscopies,other,Others,155,All,AllOther,1,0,4,2016,2015,92,1,Others,3,NA,2,5.043425116919247,"(5,6]"
3561,5473,yttrium-90 radioembolization for cirrhosis-associated thrombocytopenia,Recruiting,2,0,0,Thrombocytopenia|Cirrhosis,device,Others,20,All,AllOther,0,NA,0,2017,2017,1842,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2088,2490,relief band as an adjunct to antiemetic therapy in patients who receive mod to highly emetogenic chemotherapy,Withdrawn,7,0,0,Nausea|Vomiting,device,Others,NA,Female,AllOther,1,0,4,2013,2013,730,1,Others,1,NA,1,NA,NA
2034,2404,corticotropin releasing hormone (crh) responsiveness in children with functional dyspepsia,Withdrawn,7,0,0,Functional Dyspepsia,drug or biologic,NA,NA,All,AllOther,1,1,4,2011,2016,0,1,NA,0,NA,0,NA,NA
1741,1948,the united states healthy living study,Completed,4,0,0,Colo-rectal Cancer,behavioral,Others,2218,All,NIH&Combos,2,0,4,2019,2018,129,1,Others,1,NA,1,7.704361167910313,"(7,13]"
1797,2030,neuromodulation therapy for fecal incontinence,Completed,4,0,0,Fecal Incontinence,procedure,Others,44,All,NIH&Combos,2,0,0,2015,2015,1095,1,Others,1,NA,1,3.784189633918261,"(3,4]"
611,637,diagnostic utility of amyl nitrite in patients with suspected achalasia undergoing high resolution esophageal manometry (hrem),Withdrawn,7,0,0,Dysphagia|Achalasia,drug or biologic,NA,NA,All,AllOther,0,NA,2,2015,2014,1644,0,NA,1,NA,1,NA,NA
4010,7583,safety study of the aethlon hemopurifier,Terminated,5,0,0,End Stage Renal Disease|Hepatitis C Infection,device,Others,8,All,Industry&Combos,0,NA,0,2014,2014,830,0,Others,1,safety,1,2.0794415416798357,"(2,3]"
2282,2847,accelerated enhanced recovery following minimally invasive colorectal cancer surgery (recovermi),Unknown status,8,0,0,Colorectal Cancer,behavioral,Others,32,All,AllOther,1,0,0,2015,2016,1449,1,Others,2,NA,2,3.4657359027997265,"(3,4]"
799,836,almonds: digestive health and immune function of adults and children,Completed,4,1,1,Healthy,other,Others,58,All,AllOther,3,0,1,2013,2013,151,3,Others,0,NA,0,4.060443010546419,"(4,5]"
3094,4190,post-resection treatment of large colon polyps,Recruiting,2,0,0,Recurrence,device,Others,380,All,AllOther,1,0,0,2018,2018,959,1,Others,0,NA,0,5.940171252720432,"(5,6]"
1076,1135,a trial of yoga in pediatric inflammatory bowel disease,"Active, not recruiting",1,1,1,Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis,behavioral,Others,66,All,AllOther,0,NA,4,2017,2017,826,0,Others,1,NA,1,4.189654742026425,"(4,5]"
1250,1335,effects of watermelon consumption on satiety and digestive health,Recruiting,2,0,0,Satiety,other,Others,80,All,AllOther,3,0,1,2019,2019,730,3,Others,0,NA,0,4.382026634673881,"(4,5]"
2382,3055,optimizing individual nutrition in preterm very low birth weight infants,"Active, not recruiting",1,1,1,"Infant, Premature, Diseases|Infant, Small for Gestational Age",other,Others,120,All,AllOther,1,0,0,2015,2016,1495,1,Others,4,NA,2,4.787491742782046,"(4,5]"
1204,1282,comparison of different oral rehydration solutions,Completed,4,0,0,Short Bowel Syndrome,other,Others,28,All,AllOther,1,0,4,2014,2014,701,1,Others,4,NA,2,3.332204510175204,"(3,4]"
68,68,cyst fluid glucose for on-site diagnosis of mucinous pancreatic cysts,Recruiting,2,0,0,Pancreatic Cyst,device,Others,400,All,AllOther,0,NA,2,2017,2017,1437,0,Others,1,NA,1,5.991464547107982,"(5,6]"
3223,4516,optimal feeding tube dwell time in vlbw infants to reduce feeding tube contamination,Recruiting,2,0,0,Infection,device,Others,268,All,NIH&Combos,1,0,1,2018,2017,1728,1,Others,1,NA,1,5.5909869805108565,"(5,6]"
537,559,fiber to reduce colon cancer in alaska native people,Recruiting,2,0,0,Colon Cancer,other,Others,60,All,AllOther,1,0,1,2017,2017,1482,1,Others,4,NA,2,4.0943445622221,"(4,5]"
423,435,mediterranean diet and the gut microbiome,"Active, not recruiting",1,0,0,Irritable Bowel Syndrome,other,Others,30,All,AllOther,3,1,0,2017,2017,1513,3,Others,1,NA,1,3.4011973816621555,"(3,4]"
1436,1545,behavioral economic incentives and cancer health risk assessment,Completed,4,0,0,Cancer of the Colon,behavioral,Others,2000,All,NIH&Combos,1,0,4,2017,2017,92,1,Others,1,NA,1,7.600902459542082,"(7,13]"
1688,1865,the exercise and colorectal cancer treatment trial,Recruiting,2,0,0,Colon Cancer|Rectal Cancer,behavioral,Others,60,All,NIH&Combos,1,0,0,2019,2019,714,1,Others,2,NA,2,4.0943445622221,"(4,5]"
3526,5381,u01 crc project for vietnamese americans,Completed,4,0,0,Colorectal Cancer,behavioral,Others,801,All,NIH&Combos,1,0,1,2018,2016,1792,1,Others,3,NA,2,6.68586094706836,"(6,7]"
41,41,comparison of surgery and medicine on the impact of diverticulitis (cosmid) trial,Recruiting,2,0,0,Diverticulitis,procedure,Others,500,All,AllOther,1,0,0,2019,2019,1247,1,Others,0,NA,0,6.214608098422191,"(6,7]"
104,104,the effect of csp01 on chronic idiopathic constipation and irritable bowel syndrome with constipation,Completed,4,1,1,Constipation|Chronic Idiopathic Constipation|Irritable Bowel Syndrome With Constipation,device,Others,52,All,Industry&Combos,1,0,0,2017,2017,429,1,Others,3,NA,2,3.9512437185814275,"(3,4]"
2803,3760,does the cap increase the finding of polyps when water exchange colonoscopy is used,Recruiting,2,0,0,Colonoscopy|Polyp of Colon,device,Others,1630,All,AllOther,1,0,4,2018,2018,730,1,Others,2,NA,2,7.396335293800808,"(7,13]"
1402,1505,"apoa2 gene, diet, inflammation and gut health","Active, not recruiting",1,0,0,Inflammation,other,Others,37,All,AllOther,3,0,1,2017,2017,930,3,Others,1,NA,1,3.6109179126442243,"(3,4]"
1315,1404,mitochondrial function in patients with severe liver disease,Recruiting,2,0,0,Hepatic Insufficiency|Hypoalbuminemia,other,Others,15,All,NIH&Combos,0,NA,4,2015,2015,2983,0,Others,1,NA,1,2.70805020110221,"(2,3]"
476,493,a pilot study to assess theragnostically planned liver radiation to optimize radiation therapy,Completed,4,1,1,Liver Cancer|Hepatocellular Carcinoma|Cholangiocarcinoma,other,Others,15,All,AllOther,0,1,2,2017,2017,811,0,Others,1,NA,1,2.70805020110221,"(2,3]"
1830,2084,reverse engineering of exclusive enteral nutrition,Recruiting,2,0,0,Crohn Disease,other,Others,10,All,AllOther,0,NA,0,2018,2017,1488,0,Others,1,NA,1,2.302585092994046,"(2,3]"
2205,2694,legume diet satiety pilot study,Completed,4,1,1,Obesity|Colorectal Carcinoma,device,Others,12,Male,AllOther,1,0,1,2014,2014,1096,1,Others,1,NA,1,2.4849066497880004,"(2,3]"
2124,2545,virtual reality in sod,Recruiting,2,0,0,Sphincter of Oddi Dysfunction,device,Others,20,All,AllOther,0,NA,0,2019,2019,742,0,Others,1,NA,1,2.995732273553991,"(2,3]"
3298,4675,irreversible electroporation ablation for colorectal metastases to the lung,Completed,4,1,1,Colorectal Metastases to the Lung,device,Others,2,All,AllOther,0,NA,0,2015,2015,642,0,Others,1,NA,1,0.6931471805599453,"(0,1]"
1091,1153,evaluation of proposed ez2go complete bowel cleansing system,Completed,4,0,0,Screening Colonoscopy|Surveillance Colonoscopy|Colonoscopy,other,Others,185,All,AllOther,1,0,NA,2013,2013,365,1,Others,1,NA,1,5.220355825078324,"(5,6]"
2721,3646,the role of hydration on exercise performance - odin,Completed,4,0,0,Dehydration,other,Others,11,Male,AllOther,3,0,1,2016,2016,137,3,Others,1,NA,1,2.3978952727983707,"(2,3]"
597,623,dignity therapy/life plan in patients with pancreatic or advanced lung cancer,Completed,4,0,0,Pancreatic Cancer|Non-Small-Cell Lung Cancer,behavioral,Others,19,All,AllOther,0,NA,4,2014,2014,1406,0,Others,1,NA,1,2.9444389791664403,"(2,3]"
3431,5222,predicting and addressing colonoscopy in safety net settings,Enrolling by invitation,3,0,0,Colorectal Cancer,behavioral,Others,252,All,NIH&Combos,3,0,4,2019,2019,976,3,Others,0,safety,0,5.529429087511423,"(5,6]"
3128,4251,endpoint determination study protocol,Recruiting,2,0,0,Irritable Bowel Syndrome,other,Others,180,All,Industry&Combos,1,0,0,2018,2018,1015,1,Others,3,NA,2,5.19295685089021,"(5,6]"
1946,2280,utilization of negative pressure suction to reduce aspiration in oropharyngeal dysphagia,Recruiting,2,0,0,Oropharyngeal Dysphagia,device,Others,10,All,AllOther,0,NA,4,2017,2016,2101,0,Others,1,NA,1,2.302585092994046,"(2,3]"
3833,6851,effects of reduced environmental stimulation on eating disorders,Completed,4,0,0,Anorexia Nervosa,behavioral,Others,21,All,AllOther,0,NA,4,2016,2016,566,0,Others,1,NA,1,3.044522437723423,"(3,4]"
1202,1280,resistant starch wheat for improved metabolic health,Completed,4,0,0,Gut Microbiota|Metabolism|Metabolic Health,other,Others,36,All,AllOther,3,0,4,2017,2017,700,3,Others,2,NA,2,3.58351893845611,"(3,4]"
212,215,biologic mesh in preventing hernia in patients with bladder cancer undergoing radical cystectomy with ileal conduit diversion,Recruiting,2,0,0,Bladder Carcinoma|Hernia,other,Others,110,All,NIH&Combos,1,0,4,2015,2015,1827,1,Others,0,NA,0,4.700480365792417,"(4,5]"
627,654,liver health and metabolic function in people with obesity,Recruiting,2,0,0,Non-Alcoholic Fatty Liver Disease,procedure,Others,30,All,AllOther,0,NA,2,2018,2019,1734,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
2269,2825,a trial of three types of enemas used to treat functional constipation in children,Terminated,5,0,0,Functional Constipation,drug or biologic,NA,40,All,AllOther,0,0,0,2013,2013,1705,0,NA,1,NA,1,3.6888794541139363,"(3,4]"
553,575,randomized trial for extraction of difficult bile duct stones,Completed,4,0,0,Common Bile Duct Stones,procedure,Others,66,All,AllOther,1,0,0,2009,2016,974,1,Others,0,NA,0,4.189654742026425,"(4,5]"
771,808,non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon of the esophagus in screening for barrett esophagus,Completed,4,1,1,Barrett Esophagus,device,Others,156,All,NIH&Combos,0,NA,4,2015,2015,407,0,Others,1,NA,1,5.049856007249537,"(5,6]"
210,213,endoscopic gastric plication for weight loss in morbidly obese patients prior to incisional hernia repair,Withdrawn,7,0,0,Morbid Obesity|Weight Loss|Complex Incisional Hernias,procedure,Others,NA,All,AllOther,0,NA,0,2014,2015,2283,0,Others,1,NA,1,NA,NA
1825,2077,anterior gastropexy vs. no anterior gastropexy for paraesophageal hernia repair,Recruiting,2,0,0,Paraesophageal Hernia|Hiatal Hernia Large,procedure,Others,240,All,AllOther,1,0,0,2019,2019,1466,1,Others,2,NA,2,5.480638923341991,"(5,6]"
1488,1611,comparison of standard and endoscope assisted endotracheal intubation,Recruiting,2,0,0,Biliary Tract Diseases|Pancreatic Diseases,procedure,Others,100,All,AllOther,1,0,0,2019,2018,763,1,Others,0,NA,0,4.605170185988092,"(4,5]"
986,1040,low carbohydrate diet: the effects on non alcoholic fatty liver disease in obese teens with metabolic syndrome,"Active, not recruiting",1,0,0,"NAFLD|Fatty Liver|Obesity|Metabolic Syndrome",other,Others,54,All,AllOther,1,0,0,2015,2014,974,1,Others,0,NA,0,3.9889840465642745,"(3,4]"
2242,2765,"a 4-arm clinical trial of fuse Â®, endocuffÃ¢âÂ¢, endoringsÃ¢âÂ¢ and standard colonoscopy",Completed,4,1,1,Colorectal Neoplasms,device,Others,1262,All,AllOther,1,0,4,2015,2015,1034,1,Others,1,NA,1,7.140453043101158,"(7,13]"
1409,1514,non-invasive markers of esophageal function in adults,Enrolling by invitation,3,0,0,Dysphagia,other,Others,90,All,AllOther,1,1,2,2019,2019,1824,1,Others,0,NA,0,4.499809670330265,"(4,5]"
3578,5560,gastrointestinal tolerance evaluation of an infant formula,Completed,4,0,0,"Healthy, Full-term Infants Who Are Formula-fed",other,Others,79,All,Industry&Combos,1,0,0,2017,2017,120,1,Others,4,NA,2,4.3694478524670215,"(4,5]"
1244,1328,"age-associated arterial dysfunction, western diet, and aerobic exercise: role of the gut microbiome",Unknown status,8,0,0,Aging,other,Others,120,All,AllOther,3,0,4,2017,2018,1023,3,Others,1,NA,1,4.787491742782046,"(4,5]"
1720,1913,effects of an intermittent reduced calorie diet on crohn's disease,Recruiting,2,0,0,Inflammatory Bowel Diseases|Crohn Disease|Diet Modification,other,Others,75,All,AllOther,1,0,0,2019,2019,939,1,Others,0,NA,0,4.31748811353631,"(4,5]"
1327,1417,colonoscopy in the prone position for patients with bmi greater than 30,Completed,4,0,0,Obesity,procedure,Others,141,All,AllOther,1,0,4,2017,2017,547,1,Others,0,NA,0,4.948759890378168,"(4,5]"
2169,2623,teen and young adult connections for support from multidisciplinary professionals & peers,Completed,4,0,0,Short Bowel Syndrome|Malabsorption|Malnutrition,behavioral,Others,83,All,NIH&Combos,1,0,4,2016,2016,1248,1,Others,0,NA,0,4.418840607796598,"(4,5]"
1046,1101,impact of swaddle blanket on gastroesophageal reflux,Unknown status,8,0,0,Gastroesophageal Reflux|Apnea|Bradycardia|Oxygen Desaturations,other,Others,50,All,AllOther,3,0,1,2014,2014,668,3,Others,0,NA,0,3.912023005428146,"(3,4]"
3273,4611,fetal endotracheal occlusion (feto) in the resolution of pulmonary hypertension in fetuses with severe cdh,Recruiting,2,0,0,Congenital Diaphragmatic Hernia,device,Others,80,Female,AllOther,1,1,0,2019,2019,3402,1,Others,0,NA,0,4.382026634673881,"(4,5]"
2577,3466,an investigation of the endostim Â® lower esophageal sphincter (les) stimulation system for the treatment of reflux,Terminated,5,0,0,"Gastroesophageal Reflux Disease (GERD)|Reflux, Gastroesophageal|Gastroesophageal Reflux|Acid Reflux",device,Others,161,All,Industry&Combos,3,0,0,2016,2016,1248,3,Others,4,NA,2,5.081404364984463,"(5,6]"
4000,7561,vbmi to increase treatment completion with mk-mk-5172/mk-8742 among veterans with active substance use disorders genotype 1 chronic hepatitis c,Completed,4,1,1,"Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders",behavioral,Others,20,All,Industry&Combos,0,NA,0,2016,2017,1030,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2071,2464,sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery,Completed,4,0,0,Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Hepatocellular Carcinoma|Stage III Childhood Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Childhood Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma,drug or biologic,NA,30,All,NIH&Combos,0,NA,4,2014,2013,2069,0,NA,1,NA,1,3.4011973816621555,"(3,4]"
1023,1078,90y transarterial radioembolization (tare) plus gemcitabine and cisplatin in unresectable intrahepatic cholangiocarcinoma,Recruiting,2,0,0,Intrahepatic Cholangiocarcinoma,drug or biologic,NA,24,All,AllOther,0,NA,0,2015,2015,2223,0,NA,1,NA,1,3.1780538303479458,"(3,4]"
707,741,evaluation of pet/mri in patients with pancreatic adenocarcinoma,Completed,4,0,0,Adenocarcinoma Pancreas,procedure,Others,25,All,AllOther,0,NA,2,2014,2013,1663,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
3705,6154,ems use of isopropyl alcohol aromatherapy versus ondansetron,Completed,4,1,1,Nausea,drug or biologic,NA,51,All,AllOther,1,0,0,2015,2016,878,1,NA,0,NA,0,3.9318256327243257,"(3,4]"
1845,2111,pilot study of the effect of rifaximin on b-cell dysregulation in cirrhosis,Terminated,5,0,0,Liver Cirrhosis|Chronic Hepatitis C,drug or biologic,NA,13,All,Industry&Combos,3,0,4,2013,2016,0,3,NA,4,NA,2,2.5649493574615367,"(2,3]"
3434,5225,does knowing one's estimated colorectal cancer risk influence screening behavior?,Completed,4,0,0,Colorectal Cancer,behavioral,Others,229,All,AllOther,1,0,1,2019,2015,1186,1,Others,0,NA,0,5.43372200355424,"(5,6]"
1985,2336,gastric electrical stimulation (ges) for the treatment of obesity,Completed,4,0,0,Obesity,device,Others,32,All,Industry&Combos,0,NA,0,2013,2013,1386,0,Others,1,NA,1,3.4657359027997265,"(3,4]"
1838,2095,"effects of a calorie restricted, very low fat plant-based diet and multi-component exercise program on metabolic health","Active, not recruiting",1,0,0,Obesity|Insulin Resistance,other,Others,20,All,AllOther,0,NA,4,2016,2016,1918,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1064,1120,effects on quality of life with zinc supplementation in patients with gastrointestinal cancer,Recruiting,2,0,0,Gastric Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Unresectable Esophageal Carcinoma|Unresectable Pancreatic Carcinoma,other,Others,100,All,AllOther,1,0,4,2019,2019,744,1,Others,0,NA,0,4.605170185988092,"(4,5]"
3032,4073,multicenter phase ii study of transanal tme (tatme),Recruiting,2,0,0,Rectal Cancer|Surgery,procedure,Others,100,All,AllOther,0,NA,0,2017,2017,1685,0,Others,1,NA,1,4.605170185988092,"(4,5]"
1924,2245,internet-based motivational interviewing for colonoscopy,Completed,4,1,1,Colorectal Neoplasms,behavioral,Others,78,All,NIH&Combos,1,0,1,2018,2017,900,1,Others,1,NA,1,4.356708826689592,"(4,5]"
2267,2819,cap assisted upper endoscopy versus high definition white light endoscopy and narrow band imaging alone in the detection of visible lesions barrett's esophagus: a randomized tandem study,Recruiting,2,0,0,Barrett Esophagus,device,Others,170,All,AllOther,1,0,2,2018,2017,1470,1,Others,0,NA,0,5.135798437050262,"(5,6]"
2168,2616,radioembolization for hcc patients with personalized yttrium-90 dosimetry for curative intent (rapy90d),Recruiting,2,0,0,Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma,procedure,Others,40,All,NIH&Combos,0,NA,0,2019,2019,752,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
345,352,liver biopsy using a 19 gauge fine needle biopsy needle,Withdrawn,7,0,0,Liver Biopsy,device,Others,NA,All,AllOther,0,NA,2,2019,2019,247,0,Others,1,NA,1,NA,NA
921,967,low glycemic load diet in patients with stage i-iii colon cancer,Completed,4,0,0,Stage I Colon Cancer|Stage II Colon Cancer|Stage III Colon Cancer|Stage I Rectal Cancer|Stage II Rectal Cancer|Stage III Rectal Cancer,behavioral,Others,18,All,NIH&Combos,1,1,4,2014,2015,1214,1,Others,0,NA,0,2.8903717578961645,"(2,3]"
3442,5233,screening to prevent colorectal cancer (stop crc) among at-risk chinese and korean american primary care patients,"Active, not recruiting",1,0,0,Colorectal Cancer,behavioral,Others,400,All,NIH&Combos,1,0,1,2018,2018,1319,1,Others,1,NA,1,5.991464547107982,"(5,6]"
917,963,community-based continence promotion: sustaining healthy aging in place (shaip) through mind over matter (mom),Completed,4,0,0,Fecal Incontinence in Old Age|Urinary Incontinence in Old Age,behavioral,Others,122,Female,NIH&Combos,NA,0,0,2017,2017,190,NA,Others,0,NA,0,4.804021044733257,"(4,5]"
1014,1069,confocal laser probe to treat barrett's esophagus,Completed,4,0,0,Barrett's Esophagus,device,Others,29,All,AllOther,0,NA,0,2016,2014,668,0,Others,1,NA,1,3.367295829986474,"(3,4]"
2354,2993,randomized clinical trial of early delivery in fetal gastroschisis vs. routine care,Terminated,5,0,0,Gastroschisis,other,Others,21,Female,AllOther,1,0,0,2013,2013,1310,1,Others,0,NA,0,3.044522437723423,"(3,4]"
3615,5700,"enhanced, ehr-facilitated cancer symptom control (e2c2) pragmatic clinical trial",Recruiting,2,0,0,Sleep Disturbance|Pain|Anxiety|Depression|Fatigue,other,Others,15000,All,NIH&Combos,0,NA,4,2019,2019,1190,0,Others,1,NA,1,9.615805480084347,"(7,13]"
297,302,gut-microbiota targeted nutritional intervention for gut barrier integrity at high altitude,Recruiting,2,0,0,Gastrointestinal Injury|Acute Mountain Sickness,other,Others,15,All,AllOther,3,0,1,2019,2019,787,3,Others,3,NA,2,2.70805020110221,"(2,3]"
3828,6833,"a randomized controlled trial to evaluate the efficacy of acupuncture versus aromatherapy as treatments to lessen nausea, vomiting and anxiety associated with adriamycin and cytoxan",Recruiting,2,0,0,Nausea|Vomiting|Anxiety,other,Others,60,Female,AllOther,1,0,4,2019,2019,495,1,Others,0,efficacy,0,4.0943445622221,"(4,5]"
1996,2348,promoting veteran-centered colorectal cancer screening,Completed,4,1,1,Colorectal Cancer,behavioral,Others,436,All,AllOther,1,0,4,2014,2015,992,1,Others,1,NA,1,6.077642243349034,"(6,7]"
1549,1688,mri-guided stereotactic body radiation therapy in treating patients with liver metastases or liver cancer,"Active, not recruiting",1,0,0,Adult Hepatocellular Carcinoma|Metastatic Malignant Neoplasm in the Liver,other,Others,20,All,Industry&Combos,0,NA,0,2016,2015,2192,0,Others,1,NA,1,2.995732273553991,"(2,3]"
785,822,a randomized pilot/pharmacodynamic/genomic study of neoadjuvant paricalcitol to target the microenvironment in resectable pancreatic cancer,Completed,4,0,0,Adenocarcinoma of the Pancreas,drug or biologic,NA,15,All,AllOther,1,0,0,2014,2014,699,1,NA,0,NA,0,2.70805020110221,"(2,3]"
4015,7590,technology-based application to improve the triple therapy adherence rate in subjects with hepatitis c infection,Withdrawn,7,0,0,Hepatitis C,other,Others,NA,All,Industry&Combos,0,NA,4,2014,2014,700,0,Others,1,NA,1,NA,NA
3730,6246,neuromuscular electrical stimulation (nmes) for dysphagia in neonates,Terminated,5,0,0,Dysphagia,device,Others,12,All,AllOther,1,0,0,2013,2013,973,1,Others,3,NA,2,2.4849066497880004,"(2,3]"
217,220,small bowel microbiota characterization in healthy individuals before and after consumption of a western diet,"Active, not recruiting",1,0,0,Small Intestine Bacteria,behavioral,Others,16,All,AllOther,1,1,4,2017,2017,151,1,Others,0,NA,0,2.772588722239781,"(2,3]"
364,372,growth hormone and intrahepatic lipid content in patients with nonalcoholic fatty liver disease,"Active, not recruiting",1,0,0,Nonalcoholic Fatty Liver Disease (NAFLD),drug or biologic,NA,50,All,AllOther,1,0,0,2014,2015,2192,1,NA,4,NA,2,3.912023005428146,"(3,4]"
932,979,molecularly tailored therapy for patients with metastatic cancer of the esophagus and stomach,Terminated,5,1,1,Esophageal Cancer|Gastric Cancer,drug or biologic,NA,13,All,AllOther,0,NA,0,2015,2015,639,0,NA,1,NA,1,2.5649493574615367,"(2,3]"
262,266,pilot study of short-course preoperative stereotactic body radiation therapy for resectable pancreatic cancer,"Active, not recruiting",1,0,0,Pancreatic Cancer|Adenocarcinoma,other,Others,18,All,AllOther,0,NA,0,2015,2014,3104,0,Others,1,NA,1,2.8903717578961645,"(2,3]"
552,574,magnetic resonance imaging for detection of peritoneal mesothelioma,Recruiting,2,0,0,Mesothelioma|Peritoneal Mesothelioma,other,Others,24,All,AllOther,NA,1,4,2019,2018,1200,NA,Others,0,NA,0,3.1780538303479458,"(3,4]"
604,630,cegir 7808: use of unsedated transnasal esophagoscopy (tne) to monitor dietary management of eosinophilic esophagitis in children,Completed,4,0,0,Eosinophilic Esophagitis,other,Others,5,All,NIH&Combos,0,NA,0,2017,2017,1065,0,Others,1,NA,1,1.6094379124341003,"(1,2]"
2274,2833,randomized trial comparing stereotactic body radiation therapy to microwave ablation for the treatment of localized hepatocellular carcinoma,Withdrawn,7,0,0,"Carcinoma, Hepatocellular",other,Others,NA,All,AllOther,1,0,0,2017,2017,1786,1,Others,0,NA,0,NA,NA
868,910,effects of consuming red meat on the gut microbiota in young adults,Completed,4,0,0,Diet Modification,other,Others,23,All,AllOther,3,0,4,2019,2018,804,3,Others,1,NA,1,3.1354942159291497,"(3,4]"
2077,2473,spectroscopy from duodenum,Completed,4,0,0,Pancreatic Adenocarcinoma,device,Others,445,All,Industry&Combos,0,NA,2,2012,2013,1276,0,Others,1,NA,1,6.09807428216624,"(6,7]"
848,889,what's hopping? cricket protein and human gut microbiota,Completed,4,0,0,Healthy,other,Others,20,All,AllOther,3,0,4,2017,2017,98,3,Others,3,NA,2,2.995732273553991,"(2,3]"
2478,3258,time-restricted eating and muscle hypertrophy,Suspended,6,0,0,Muscle Hypertrophy|Healthy and Well-Trained Men and Women,other,Others,40,All,AllOther,1,0,4,2019,2019,738,1,Others,2,NA,2,3.6888794541139363,"(3,4]"
933,980,physical therapy for anal incontinence,Recruiting,2,0,0,Anal Incontinence|Fecal Incontinence,behavioral,Others,300,Female,AllOther,1,0,0,2017,2017,1734,1,Others,1,NA,1,5.703782474656201,"(5,6]"
1693,1872,effects of triphala and vsl#3 probiotic supplementation on stool microbiome profiles and inflammation,Enrolling by invitation,3,0,0,Human Microbiome,other,Others,75,All,AllOther,1,0,1,2019,2019,1096,1,Others,3,NA,2,4.31748811353631,"(4,5]"
2295,2875,dairy fat as a mediator of vitamin e adequacy in individuals with metabolic syndrome,Completed,4,1,1,Non-alcoholic Fatty Liver|Metabolic Syndrome,other,Others,21,All,AllOther,3,0,4,2013,2013,640,3,Others,3,NA,2,3.044522437723423,"(3,4]"
704,738,"kiwifruit, prunes, & fiber for abdominal and bowel symptoms in us patients with chronic constipation",Completed,4,0,0,Chronic Constipation,other,Others,78,All,AllOther,1,0,0,2018,2018,486,1,Others,0,NA,0,4.356708826689592,"(4,5]"
903,948,endoesophageal brachytherapy for patients with esophageal cancer,Completed,4,0,0,Esophageal Cancer,device,Others,7,All,AllOther,0,NA,4,2017,2018,984,0,Others,1,NA,1,1.9459101490553132,"(1,2]"
501,522,latino peers as patient navigators for colon cancer screening,Completed,4,0,0,Colon Cancer,behavioral,Others,85,All,AllOther,1,0,1,2014,2014,424,1,Others,0,NA,0,4.442651256490317,"(4,5]"
2330,2949,assessing the effect of a blood-based colorectal cancer screening test on screening adherence and colonoscopy completion,"Active, not recruiting",1,0,0,Colorectal Cancer,other,Others,360,All,AllOther,1,0,4,2018,2018,752,1,Others,0,NA,0,5.886104031450156,"(5,6]"
844,885,resilience and exercise in advanced cancer treatment,Completed,4,0,0,Pancreatic Adenocarcinoma|Gastric Adenocarcinoma|Adenocarcinoma of the Gastroesophageal Junction,behavioral,Others,14,All,AllOther,1,0,0,2016,2015,578,1,Others,0,NA,0,2.6390573296152584,"(2,3]"
3095,4192,"study to evaluate performance of the organ recovery systems lifeport Â® liver transporter system, a machine perfusion system, for liver transplant",Recruiting,2,0,0,Liver Transplantation,device,Others,140,All,Industry&Combos,1,0,0,2018,2019,1184,1,Others,1,NA,1,4.941642422609304,"(4,5]"
2383,3056,effect of probiotic supplementation on endothelial function ii,Recruiting,2,0,0,"Cardiovascular Disease|Diabetes Mellitus, Type 2",other,Others,215,All,AllOther,3,0,1,2017,2018,1174,3,Others,3,NA,2,5.3706380281276624,"(5,6]"
2393,3076,fat grafting technique for fecal incontinence,Recruiting,2,0,0,Fecal Incontinence,device,Others,10,All,AllOther,0,NA,0,2019,2019,721,0,Others,1,NA,1,2.302585092994046,"(2,3]"
2229,2744,implementation of a molecular diagnostic for pediatric acute gastroenteritis: the filmarray gi panel impact study,Completed,4,1,1,Infectious Gastroenteritis,device,Others,1545,All,IndustryNIHPartnership,1,1,2,2014,2015,488,1,Others,0,NA,0,7.3427791893318455,"(7,13]"
1813,2049,ingestion of simethicone after capsule ingestion and its impact on quality of video capsule endoscopy- a pilot study,Unknown status,8,0,0,Video Capsule Endoscopy,drug or biologic,NA,36,All,AllOther,1,0,2,2017,2017,667,1,NA,2,NA,2,3.58351893845611,"(3,4]"
783,820,screen to save: a colorectal cancer educational intervention,Completed,4,1,1,Colorectal Cancer,behavioral,Others,100,All,NIH&Combos,0,NA,4,2019,2017,98,0,Others,1,NA,1,4.605170185988092,"(4,5]"
840,879,diagnosis and monitoring of eosinophilic esophagitis using the cytosponge,Terminated,5,1,1,Eosinophilic Esophagitis|EoE,device,Others,86,All,AllOther,0,NA,2,2014,2015,336,0,Others,1,NA,1,4.454347296253507,"(4,5]"
2645,3550,vitamin d to improve nutrition prior to bariatric surgery and investigate the relationship with negative outcomes,Terminated,5,0,0,Vitamin D Deficiency|Vitamin D Insufficiency,other,Others,70,All,AllOther,1,0,0,2014,2017,90,1,Others,3,NA,2,4.248495242049359,"(4,5]"
715,749,pilot study for oct guided in vivo laser capture microdissection for assessing the prognosis of barrett's esophagus,"Active, not recruiting",1,0,0,Barrett Esophagus,device,Others,30,All,NIH&Combos,0,NA,NA,2019,2017,1096,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
1122,1192,characterization of the neo-squamous epithelial barrier,"Active, not recruiting",1,0,0,Barrett's Esophagus With Dysplasia,device,Others,53,All,AllOther,0,1,2,2017,2016,1131,0,Others,1,NA,1,3.970291913552122,"(3,4]"
2334,2954,use of peppermint oil during screening colonoscopy to improve visibility,Completed,4,0,0,Enhancement of the ADR During Colonoscopy,other,Others,48,All,AllOther,1,0,2,2017,2016,1043,1,Others,3,NA,2,3.871201010907891,"(3,4]"
2378,3039,low carbohydrate/high protein diet to improve metabolic health,Recruiting,2,0,0,Spinal Cord|Metabolic Syndrome|Diabetes,other,Others,100,All,AllOther,1,0,4,2017,2017,1368,1,Others,1,NA,1,4.605170185988092,"(4,5]"
823,862,reducing perinatal anal incontinence through early pelvic floor muscle training: a prospective pilot study,Completed,4,0,0,Perinatal and Postpartum Anal Incontinence,other,Others,15,Female,AllOther,1,0,1,2014,2014,243,1,Others,0,NA,0,2.70805020110221,"(2,3]"
1403,1506,effects of a novel food product containing microbiota accessible carbohydrates on the human microbiome,Completed,4,0,0,Gut Microbiome,other,Others,30,All,Industry&Combos,3,0,4,2017,2017,176,3,Others,1,NA,1,3.4011973816621555,"(3,4]"
2986,4003,metabolic response to chardonnay grape marc powder,Completed,4,0,0,Dyslipidemia|Obesity,other,Others,31,All,AllOther,3,0,4,2017,2017,696,3,Others,2,NA,2,3.4339872044851463,"(3,4]"
3696,6127,patient-centered models of hcv care for people who inject drugs,Completed,4,0,0,Hepatitis C|Medication Adherence,behavioral,Others,754,All,AllOther,1,0,0,2016,2016,1282,1,Others,0,NA,0,6.625392368007956,"(6,7]"
1999,2351,outcomes of disposable distal attachment device (endocuff and transparent plastic cap) assisted colonoscopy,Withdrawn,7,0,0,Colorectal Neoplasms,device,Others,NA,All,AllOther,1,0,2,2015,2015,550,1,Others,4,NA,2,NA,NA
619,646,a study of the efficacy of ons to reduce postoperative complications associated with pancreatic surgery,Terminated,5,0,0,Pancreatic Cancer|Chronic Pancreatitis,other,Others,8,All,Industry&Combos,1,0,0,2017,2017,338,1,Others,0,efficacy,0,2.0794415416798357,"(2,3]"
452,465,pancfit: multimodal exercise during preoperative therapy for pancreatic cancer,Recruiting,2,0,0,Other Disorders of Glucose Regulation and Pancreatic Internal Secretion|Pancreatic Cancer,behavioral,Others,128,All,AllOther,1,0,0,2017,2017,1662,1,Others,0,NA,0,4.852030263919617,"(4,5]"
3064,4124,gastrointestinal tolerance of infant formula,Completed,4,0,0,Gastrointestinal Tolerance,other,Others,131,All,Industry&Combos,1,0,NA,2014,2015,151,1,Others,4,NA,2,4.875197323201151,"(4,5]"
1554,1693,healthy eating through reduction of excess sugar,Recruiting,2,0,0,"NAFLD",other,Others,120,All,AllOther,1,0,0,2016,2016,1491,1,Others,3,NA,2,4.787491742782046,"(4,5]"
1645,1809,effects of adding chickpeas to the american diet on fecal microbiota composition and markers of inflammation,Completed,4,1,1,Inflammation,other,Others,13,All,AllOther,0,NA,NA,2015,2015,153,0,Others,1,NA,1,2.5649493574615367,"(2,3]"
515,536,mailed fit outreach to improve colon cancer screening in the safety-net system,Completed,4,0,0,Colonic Neoplasms,behavioral,Others,13470,All,AllOther,1,0,1,2015,2016,1095,1,Others,0,safety,0,9.50822026940441,"(7,13]"
2632,3535,the role of vac therapy devices in promoting closure of enterocutaneous fistulae,Withdrawn,7,0,0,Fistulae,device,Others,NA,All,Industry&Combos,1,0,4,2015,2016,366,1,Others,0,NA,0,NA,NA
2360,3006,rib raising for post-operative ileus,Completed,4,0,0,"Intestinal Pseudo-Obstruction|Manipulation, Osteopathic|Postoperative Care|Postoperative Nausea and Vomiting|Postoperative Complications|Osteopathic Medicine",procedure,Others,102,All,AllOther,1,0,0,2018,2018,322,1,Others,2,NA,2,4.624972813284271,"(4,5]"
936,984,transmitted light tissue thickness analysis (tiltt),Completed,4,1,1,Morbid Obesity,device,Others,10,All,Industry&Combos,0,NA,4,2016,2016,365,0,Others,1,NA,1,2.302585092994046,"(2,3]"
2407,3104,understanding and intervening with heavy drinking among patients with hiv and hcv,Completed,4,0,0,Alcohol Use Disorder|HIV/AIDS|Hepatitis C|Binge Drinking,behavioral,Others,31,All,NIH&Combos,1,0,0,2018,2018,585,1,Others,1,NA,1,3.4339872044851463,"(3,4]"
709,743,a pilot study of neoadjuvant therapy with gemcitabine and cisplatin in patients with resectable or unresectable intrahepatic cholangiocarcinoma,Terminated,5,1,1,Unresectable Intrahepatic Cholangiocarcinoma|Resectable Intrahepatic Cholangiocarcinoma,drug or biologic,NA,3,All,AllOther,0,1,0,2014,2014,517,0,NA,1,NA,1,1.0986122886681098,"(1,2]"
2233,2751,"an examination of infants' microbiome, nutrition, and development study.","Active, not recruiting",1,0,0,Microbial Colonization|Infant Development,other,Others,102,Female,AllOther,3,0,0,2017,2017,1057,3,Others,0,NA,0,4.624972813284271,"(4,5]"
950,999,late evening and early morning protein supplement to reduce readmissions for hepatic encephalopathy,Recruiting,2,0,0,Hepatic Encephalopathy,other,Others,40,All,AllOther,1,0,1,2019,2019,1018,1,Others,1,NA,1,3.6888794541139363,"(3,4]"
290,295,mesenteric sparing for the prevention of recurrent crohn's disease,Terminated,5,0,0,Crohn Disease,procedure,Others,2,All,AllOther,1,0,1,2017,2017,476,1,Others,0,NA,0,0.6931471805599453,"(0,1]"
241,244,"swallowable sponge cell sampling device and next generation sequencing in detecting esophageal cancer in patients with low or high grade dysplasia, barrett esophagus, or gastroesophageal reflux disease",Completed,4,0,0,Barrett Esophagus|Dysplasia|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Gastroesophageal Reflux Disease|Metaplasia,device,Others,11,All,AllOther,0,NA,NA,2016,2016,433,0,Others,1,NA,1,2.3978952727983707,"(2,3]"
1870,2156,sham feeding post-operative infants,Completed,4,0,0,Newborn Morbidity|Oral Aversion|Gastroschisis|Bowel Obstruction|Short Bowel Syndrome,procedure,Others,102,All,AllOther,0,NA,1,2017,2018,602,0,Others,1,NA,1,4.624972813284271,"(4,5]"
1120,1188,pancreatic nutritional program for weight loss in overweight/obese patients with stage i-iii breast cancer,"Active, not recruiting",1,0,0,Obesity|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer,other,Others,20,Female,NIH&Combos,0,NA,4,2015,2016,617,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1910,2222,third eye panoramic device feasibility evaluation,Unknown status,8,0,0,Colorectal Neoplasms,device,Others,40,All,Industry&Combos,0,NA,2,2015,2013,1429,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
3457,5249,implementing preemptive pharmacogenomic testing for colorectal cancer patients in a community oncology clinic,Completed,4,0,0,Colorectal Cancer,device,Others,40,All,AllOther,0,NA,2,2017,2017,579,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
3345,4849,endorotor Â® endoscopic mucosal resection system for the colon,Completed,4,0,0,Polyp of Colon|Endoscopic Mucosal Resection|Recurrent Colon Adenoma,device,Others,60,All,Industry&Combos,0,NA,0,2019,2018,718,0,Others,1,NA,1,4.0943445622221,"(4,5]"
2078,2474,effect of osteopathic manipulative medicine on constipation in parkinson's disease,Recruiting,2,0,0,Parkinson's Disease|Constipation,procedure,Others,20,All,AllOther,0,1,0,2015,2015,2191,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1791,2023,targeting the microbiome to improve clinical outcomes in bipolar disorder,Completed,4,0,0,Bipolar Disorder,other,Others,10,All,AllOther,0,NA,4,2016,2016,875,0,Others,1,NA,1,2.302585092994046,"(2,3]"
2506,3327,fecal incontinence treatment (fit) study,Recruiting,2,0,0,Fecal Incontinence|Bowel Incontinence,device,Others,285,All,NIH&Combos,1,0,0,2019,2019,1034,1,Others,0,NA,0,5.652489180268651,"(5,6]"
1333,1425,randomized controlled trial of endoscopic dilation: triamcinolone injection,Completed,4,0,0,Dysphagia,procedure,Others,10,All,AllOther,3,0,0,2013,2013,1134,3,Others,0,NA,0,2.302585092994046,"(2,3]"
755,791,human milk for congenital gastrointestinal disorders,Recruiting,2,0,0,Congenital Gastrointestinal Disorders,other,Others,150,All,Industry&Combos,0,1,4,2015,2018,1224,0,Others,1,NA,1,5.0106352940962555,"(5,6]"
3986,7544,hepatitis c education for pregnant women with opiate dependence - phase 2,Completed,4,0,0,Hepatitis C,other,Others,115,Female,AllOther,1,0,4,2017,2017,665,1,Others,0,NA,0,4.74493212836325,"(4,5]"
2479,3262,post sustained virological response (svr) hepatocellular carcinoma (hcc) screening,Completed,4,0,0,Hepatocellular Carcinoma|HCC|Hepatitis C|HCV,behavioral,Others,25,All,AllOther,1,0,1,2016,2016,516,1,Others,0,NA,0,3.2188758248682006,"(3,4]"
1410,1516,resistant maltodextrin supplementation: gastrointestinal health,Completed,4,0,0,Healthy,other,Others,64,All,AllOther,3,0,1,2016,2016,60,3,Others,3,NA,2,4.1588830833596715,"(4,5]"
3142,4273,the detect hcv linkage to care trial,Enrolling by invitation,3,0,0,Hepatitis C,other,Others,432,All,NIH&Combos,1,0,4,2019,2019,681,1,Others,0,NA,0,6.068425588244111,"(6,7]"
370,378,bariatric embolization of arteries in obese patients with hcc to allow salvage liver transplantation,Suspended,6,0,0,Obesity|Weight Loss|Body Weight|Hepatocellular Carcinoma|HCC|Hepatitis C|Cirrhosis,device,Others,8,All,AllOther,0,NA,0,2016,2017,1505,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
295,300,the feasibility of self or partner-assisted digital anal exam screening,Completed,4,0,0,Anus Neoplasms,other,Others,201,Male,NIH&Combos,0,NA,4,2015,2015,425,0,Others,1,NA,1,5.303304908059076,"(5,6]"
2311,2907,randomized trial of rectal indomethacin and papillary spray of epinephrine versus rectal indomethacin to prevent post-ercp pancreatitis,Completed,4,1,1,Post-ERCP Acute Pancreatitis,drug or biologic,NA,948,All,AllOther,1,0,1,2014,2014,854,1,NA,4,NA,2,6.854354502255021,"(6,7]"
1145,1216,effects of juice on gastrointestinal tolerance and breath hydrogen response in human subjects,Completed,4,0,0,Food Selection,other,Others,40,All,AllOther,3,0,1,2015,2015,61,3,Others,2,NA,2,3.6888794541139363,"(3,4]"
3447,5238,tailored messaging for crc screening,Recruiting,2,0,0,Colorectal Cancer,behavioral,Others,600,All,AllOther,1,0,4,2017,2017,1544,1,Others,0,NA,0,6.396929655216146,"(6,7]"
474,491,the liver health study for patients with nafld,Recruiting,2,0,0,Nonalcoholic Fatty Liver|Nonalcoholic Steatohepatitis|Obesity,behavioral,Others,90,All,AllOther,1,0,4,2017,2017,1724,1,Others,0,NA,0,4.499809670330265,"(4,5]"
175,176,"exercise, hypertension, and gut dysbiosis in african americans",Recruiting,2,0,0,Hypertension,behavioral,Others,36,All,AllOther,0,NA,4,2019,2019,1096,0,Others,1,NA,1,3.58351893845611,"(3,4]"
125,125,study to compare the incidence of biliary complications after liver transplantation,Completed,4,1,1,Liver Transplant; Complications,device,Others,146,All,AllOther,1,0,1,2017,2014,1841,1,Others,0,NA,0,4.983606621708336,"(4,5]"
3382,5007,usefulness of a scope guide assisted colonoscopy versus conventional colonoscopy,Completed,4,0,0,"Colonoscopy, Colorectal",procedure,Others,300,All,AllOther,1,0,2,2016,2016,1133,1,Others,1,NA,1,5.703782474656201,"(5,6]"
1446,1555,"exendin-9,39 and satiety after bariatric surgery",Completed,4,1,1,Obesity,drug or biologic,NA,29,All,AllOther,3,0,4,2016,2016,1125,3,NA,0,NA,0,3.367295829986474,"(3,4]"
1840,2097,precision pain management for major abdominal surgery in colorectal surgery,Terminated,5,0,0,Colorectal Cancer|Diverticular Disease|Crohn Disease|Ulcerative Colitis,other,Others,10,All,AllOther,1,0,4,2018,2018,267,1,Others,1,NA,1,2.302585092994046,"(2,3]"
169,170,an interactive video educational tool improves the quality of bowel preparation for colonoscopy,Completed,4,0,0,Colon Cancer Screening,other,Others,270,All,AllOther,1,0,4,2020,2019,86,1,Others,1,NA,1,5.598421958998375,"(5,6]"
665,693,precision ifx: using a dashboard to individualize infliximab dosage,Completed,4,0,0,Inflammatory Bowel Disease,other,Others,189,All,Industry&Combos,0,NA,0,2015,2015,2120,0,Others,1,NA,1,5.241747015059643,"(5,6]"
3318,4731,trial of specific carbohydrate and mediterranean diets to induce remission of crohn's disease,"Active, not recruiting",1,0,0,Crohn Disease,other,Others,194,All,AllOther,1,0,0,2017,2017,884,1,Others,0,NA,0,5.267858159063328,"(5,6]"
1126,1196,colorectal cancer screening in a community health setting,Completed,4,0,0,Cancer of the Colon,behavioral,Others,281,All,AllOther,1,0,4,2017,2017,108,1,Others,1,NA,1,5.638354669333745,"(5,6]"
118,118,comparison of two fine needle biopsy needles for solid pancreatic masses,Completed,4,0,0,Pancreatic Neoplasm,device,Others,50,All,AllOther,1,0,2,2016,2016,604,1,Others,1,NA,1,3.912023005428146,"(3,4]"
3473,5276,message framing and colorectal cancer screening,Completed,4,0,0,Colorectal Neoplasms,behavioral,Others,640,All,AllOther,1,0,1,2015,2015,204,1,Others,0,NA,0,6.461468176353717,"(6,7]"
2329,2948,adherence/outcomes after use of constipation action plan,Completed,4,0,0,Constipation - Functional,other,Others,25,All,AllOther,1,0,0,2019,2016,506,1,Others,3,NA,2,3.2188758248682006,"(3,4]"
1259,1344,human pilot study - ha35 (hyaluronan molecular weight 35) dietary supplement for promoting intestinal health,Completed,4,1,1,Gastrointestinal Microbiome,other,Others,20,All,AllOther,0,NA,4,2016,2016,446,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1772,1989,effectiveness of high dose vitamin d supplementation in stage iii colorectal cancer,Completed,4,0,0,Colon Cancer|Rectal Cancer,other,Others,70,All,AllOther,1,0,0,2015,2016,1553,1,Others,0,NA,0,4.248495242049359,"(4,5]"
3277,4618,milk oriented microbiota,Withdrawn,7,0,0,Microbial Colonization,other,Others,NA,Female,Industry&Combos,1,1,4,2017,2017,309,1,Others,0,NA,0,NA,NA
1422,1530,developing an mhealth application to improve cancer chemotherapy symptom management,Completed,4,1,1,Colon Cancer|Rectal Cancer,device,Others,16,All,AllOther,0,NA,4,2015,2014,396,0,Others,1,NA,1,2.772588722239781,"(2,3]"
2359,3004,improving goals of care discussion in advanced cancer patients,Completed,4,1,1,Primary Stage IV Hepatobiliary|Esophageal|Colorectal Cancer|Glioblastoma|Cancer of Stomach|Cancer of Pancreas|Melanoma|Head or Neck Cancer|Stage III|Stage IV|Lung Cancers|Pancreatic Cancers,behavioral,Others,265,All,AllOther,1,0,4,2015,2016,792,1,Others,0,NA,0,5.579729825986222,"(5,6]"
3907,7266,evaluation of probiotics and the development of clostridium difficile associated diarrhea in patients receiving antibiotics,Unknown status,8,0,0,Development of Clostridium Difficile Associated Diarrhea,other,Others,120,All,AllOther,1,0,1,2013,2013,243,1,Others,4,NA,2,4.787491742782046,"(4,5]"
317,322,rapid assessment of esophageal adenocarcinoma risk test,Enrolling by invitation,3,0,0,Barrett Esophagus|Esophageal Adenocarcinoma,device,Others,100,All,AllOther,0,NA,4,2017,2018,1096,0,Others,1,NA,1,4.605170185988092,"(4,5]"
2187,2657,short-infusion ziv-aflibercept in treating patients with metastatic colorectal cancer receiving combination chemotherapy,Withdrawn,7,0,0,Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,drug or biologic,NA,NA,All,NIH&Combos,0,NA,0,2013,2014,181,0,NA,1,NA,1,NA,NA
1716,1908,carbon dioxide insufflation versus conventional air insufflation,Completed,4,0,0,Abdominal Pain,other,Others,100,All,AllOther,1,0,1,2016,2015,366,1,Others,2,NA,2,4.605170185988092,"(4,5]"
3377,4986,eus-fnb with rose vs. eus-fnb without rose,Completed,4,0,0,"Biopsy, Fine-needle|Pancreatic Neoplasm",other,Others,800,All,AllOther,1,0,2,2017,2018,624,1,Others,0,NA,0,6.684611727667927,"(6,7]"
2137,2568,use of a distal colonoscope attachment to increase detection of sessile serrated adenomas,Recruiting,2,0,0,Sessile Serrated Adenoma,device,Others,1374,All,AllOther,1,0,2,2018,2019,884,1,Others,1,NA,1,7.2254814727822945,"(7,13]"
603,629,use of intra-operative shear wave ultrasound vibrometry for characterization of esophageal malignant tumors,Terminated,5,0,0,Esophageal Cancer,device,Others,3,All,AllOther,0,NA,NA,2017,2017,581,0,Others,1,NA,1,1.0986122886681098,"(1,2]"
2746,3684,dietary incorporation of lentils to improve metabolic health,Completed,4,0,0,"Waist, Hypertriglyceridemic",behavioral,Others,35,All,AllOther,1,0,1,2020,2019,328,1,Others,0,NA,0,3.5553480614894135,"(3,4]"
144,144,pancreaticoduodenectomy with or without preoperative hyperbaric oxygen therapy,Enrolling by invitation,3,0,0,Periampullary Tumor|Common Bile Duct Neoplasms|Duodenal Neoplasms,drug or biologic,NA,50,All,AllOther,1,0,1,2015,2013,1887,1,NA,0,NA,0,3.912023005428146,"(3,4]"
1268,1354,clinical study to evaluate cryoballoonÃ¢âÂ¢ full and swipe ablation systems for ablation of human esophageal epithelium,Completed,4,1,1,Esophageal Cancer,device,Others,10,All,Industry&Combos,0,1,4,2016,2016,206,0,Others,1,NA,1,2.302585092994046,"(2,3]"
20,20,fine needle biopsy of solid pancreatic mass lesions,Recruiting,2,0,0,Pancreatic Neoplasms,other,Others,130,All,AllOther,0,0,2,2019,2019,290,0,Others,1,NA,1,4.867534450455582,"(4,5]"
2511,3338,safety and efficacy study of het bipolar system for treatment of stage i and stage ii hemorrhoids,Completed,4,1,1,"Hemorrhoids, Internal",device,Others,20,All,Industry&Combos,0,NA,0,2013,2013,579,0,Others,1,safety/efficacy,1,2.995732273553991,"(2,3]"
2500,3316,food and crohn's exacerbation study (faces),Completed,4,0,0,Crohn's Disease,other,Others,216,All,NIH&Combos,1,0,0,2013,2013,943,1,Others,0,NA,0,5.375278407684165,"(5,6]"
1820,2069,diet and metabolic inflammation,Completed,4,0,0,Insulin Resistance|Diabetes|Cancer|Obesity|Inflammation,other,Others,16,All,AllOther,1,0,1,2015,2015,397,1,Others,1,NA,1,2.772588722239781,"(2,3]"
2294,2874,assessment of augmented reality in minimally invasive surgery,Unknown status,8,0,0,Laparoscopic Hepatectomy|Laparoscopic Liver Thermal Ablation,device,Others,30,All,IndustryNIHPartnership,0,NA,4,2018,2019,335,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
572,596,vancomycin treatment in recurrent psc in liver transplant patients,Withdrawn,7,0,0,Primary Sclerosing Cholangitis|Post- Orthotopic Liver Transplantation,drug or biologic,NA,NA,All,AllOther,0,NA,1,2017,2016,810,0,NA,1,NA,1,NA,NA
1024,1079,fish oil and nonalcoholic fatty liver disease (nafld) study,Completed,4,0,0,Non-Alcoholic Fatty Liver Disease,drug or biologic,NA,8,All,Industry&Combos,1,0,0,2011,2013,549,1,NA,4,NA,2,2.0794415416798357,"(2,3]"
3343,4827,initial case series with exalt single-use duodenoscope,Completed,4,0,0,Endoscopic Retrograde Cholangiopancreatography,device,Others,60,All,Industry&Combos,0,NA,NA,2018,2019,21,0,Others,1,NA,1,4.0943445622221,"(4,5]"
3981,7539,"community access, retention in care, and engagement for hepatitis c treatment",Recruiting,2,0,0,Hepatitis C,behavioral,Others,600,All,AllOther,2,0,4,2018,2018,1319,1,Others,0,NA,0,6.396929655216146,"(6,7]"
38,38,"ellagic acid, urolithin and colonic microbial communities affected by walnut consumption",Recruiting,2,0,0,Colo-rectal Cancer|Colon Cancer|Diet Habit,other,Others,50,All,AllOther,0,NA,1,2019,2019,956,0,Others,1,NA,1,3.912023005428146,"(3,4]"
2002,2356,observation vs early removal of lams in eus guided cholecystoenterostomy,Withdrawn,7,0,0,"Cholecystitis, Acute|Cholecystitis; Gallstone",procedure,Others,NA,All,AllOther,1,0,0,2019,2019,457,1,Others,0,NA,0,NA,NA
621,648,4d phase contrast mr: hypertrophy in liver cancer,Terminated,5,0,0,Liver Cancer|Cancer of the Liver,device,Others,10,All,AllOther,0,NA,NA,2015,2014,548,0,Others,1,NA,1,2.302585092994046,"(2,3]"
33,33,diet modulation of bacterial sulfur and bile acid metabolism and colon cancer risk,Recruiting,2,0,0,Colorectal Cancer,other,Others,44,All,NIH&Combos,3,0,4,2018,2018,1249,3,Others,1,NA,1,3.784189633918261,"(3,4]"
1503,1629,fructose-induced hepatic de novo lipogenesis in adolescents with obesity,Recruiting,2,0,0,Adolescent Obesity,other,Others,35,All,AllOther,1,1,4,2018,2018,1480,1,Others,0,NA,0,3.5553480614894135,"(3,4]"
2611,3510,evaluation of the national randomized proton pump inhibitor de-prescribing (rappid) program,"Active, not recruiting",1,0,0,Proton Pump Inhibitors,behavioral,Others,10000,All,AllOther,1,0,4,2018,2019,653,1,Others,0,NA,0,9.210340371976184,"(7,13]"
2089,2492,modulating early life microbiome through dietary intervention in crohn's disease,Recruiting,2,0,0,Crohn Disease|Pregnancy,other,Others,396,Female,AllOther,1,1,4,2019,2019,1432,1,Others,0,NA,0,5.981414211254481,"(5,6]"
103,103,hygieacare procedure for chronic constipation,Withdrawn,7,0,0,Constipation - Functional,device,Others,NA,All,Industry&Combos,1,1,0,2017,2018,365,1,Others,0,NA,0,NA,NA
985,1039,gut microbiota changes in obese individuals undergoing dedicated lifestyle modification programs,"Active, not recruiting",1,0,0,Obesity,behavioral,Others,1000,All,AllOther,1,1,0,2016,2016,2159,1,Others,0,NA,0,6.907755278982137,"(6,7]"
1713,1904,the gut-brain axis: a novel target for treating behavioral alterations in obesity,Completed,4,0,0,Neural Response in Caudate|Weight Loss Trial|Impulsivity,other,Others,100,All,NIH&Combos,1,0,4,2013,2013,1461,1,Others,3,NA,2,4.605170185988092,"(4,5]"
875,919,impact of blueberry consumption on gastrointestinal health,Enrolling by invitation,3,0,0,Obesity|Circadian Dysregulation,other,Others,28,All,AllOther,3,0,0,2019,2019,1162,3,Others,3,NA,2,3.332204510175204,"(3,4]"
4046,7658,the detect hcv screening trial,Enrolling by invitation,3,0,0,Hepatitis C,other,Others,10000,All,AllOther,1,0,4,2019,2019,924,1,Others,0,NA,0,9.210340371976184,"(7,13]"
1357,1451,feasibility 3d perfusion ultrasound for liver cancer sabr planning and response evaluation,Recruiting,2,0,0,Liver Cancer|Liver Tumor|Hepatocellular Carcinoma|Liver Carcinoma,drug or biologic,NA,20,All,AllOther,0,NA,2,2015,2014,2570,0,NA,1,NA,1,2.995732273553991,"(2,3]"
2214,2712,cirrhosis readmission telehealth project,Terminated,5,0,0,Cirrhosis,behavioral,Others,10,All,AllOther,1,0,1,2014,2014,701,1,Others,0,NA,0,2.302585092994046,"(2,3]"
1455,1566,impact of cranberry juice consumption on gut and vaginal microbiota in post-menopausal women,Completed,4,0,0,Urinary Tract Infections,other,Others,23,Female,Industry&Combos,3,0,4,2020,2017,137,3,Others,2,NA,2,3.1354942159291497,"(3,4]"
202,205,the use of small bowel ultrasound to predict response to remicade induction,Completed,4,1,1,Crohn's Disease,device,Others,15,All,Industry&Combos,0,NA,2,2015,2016,503,0,Others,1,NA,1,2.70805020110221,"(2,3]"
1148,1219,pre-habilitation exercise intervention,Recruiting,2,0,0,Inflammatory Bowel Diseases|Colon Cancer|Rectal Cancer|Diverticular Disease,behavioral,Others,83,All,AllOther,1,0,4,2016,2016,2191,1,Others,1,NA,1,4.418840607796598,"(4,5]"
1065,1121,nasogastric tube clamping trial vs. immediate removal,Recruiting,0,0,0,Small Bowel Obstruction|Ileus,other,Others,150,All,AllOther,1,0,0,2019,2019,279,1,Others,0,NA,0,5.0106352940962555,"(5,6]"
1808,2043,safety and efficacy of the swallow expansion device (sed) for improvement of swallowing in patients,Recruiting,2,0,0,Oropharyngeal Dysphagia (OPD)|Dysphagia,device,Others,5,All,AllOther,0,NA,0,2014,2014,2861,0,Others,1,safety/efficacy,1,1.6094379124341003,"(1,2]"
887,931,use of sbi in ibs subjects following a successful treatment of small intestinal bacterial overgrowth,Completed,4,0,0,Diarrhea Predominant Irritable Bowel Syndrome|Small Intestinal Bacterial Overgrowth,other,Others,2,All,Industry&Combos,1,0,4,2014,2014,303,1,Others,2,NA,2,0.6931471805599453,"(0,1]"
2401,3094,effect of spice consumption on the microbiome,Completed,4,1,1,Microbiota,other,Others,31,All,AllOther,1,0,4,2018,2017,106,1,Others,1,NA,1,3.4339872044851463,"(3,4]"
3432,5223,polyp measurement device,Terminated,5,1,1,Colorectal Cancer,device,Others,36,All,AllOther,0,NA,4,2019,2019,343,0,Others,1,NA,1,3.58351893845611,"(3,4]"
1525,1657,intestinal inflammatory and metabolic responses to a high fat meal and plant polyphenol blend,Completed,4,0,0,Anthocyanins,other,Others,27,All,Industry&Combos,3,0,4,2017,2017,162,3,Others,3,NA,2,3.295836866004329,"(3,4]"
368,376,mre consumption and gut health,Completed,4,0,0,Gastrointestinal Tract,other,Others,71,All,AllOther,1,0,4,2015,2015,672,1,Others,0,NA,0,4.2626798770413155,"(4,5]"
3497,5301,diagnostic accuracy of ferumoxytol-enhanced mri for detecting lymph node metastases in colorectal cancer,Withdrawn,7,0,0,Colorectal Cancer,drug or biologic,NA,NA,All,AllOther,0,NA,2,2013,2013,913,0,NA,1,NA,1,NA,NA
717,751,optimal dose of proton pump inhibitors following an upper gastrointestinal bleed,Terminated,5,1,1,Upper Gastrointestinal Bleed,drug or biologic,NA,3,All,AllOther,1,0,0,2014,2014,320,1,NA,1,NA,1,1.0986122886681098,"(1,2]"
1293,1380,ani versus standard care in surgical patients receiving balanced sevoflurane-fentanyl anesthesia,"Active, not recruiting",1,0,0,Acute Pain,device,Others,60,All,AllOther,1,0,0,2018,2019,855,1,Others,2,NA,2,4.0943445622221,"(4,5]"
1494,1618,fecal microbiome transplant,"Active, not recruiting",1,0,0,Clostridium Difficile|Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis,drug or biologic,NA,250,All,AllOther,1,1,0,2015,2015,2922,1,NA,0,NA,0,5.521460917862246,"(5,6]"
972,1024,endoscopic vs. suction device calibration in sleeve gastrectomy,Recruiting,2,0,0,Gastrectomy|Obesity,device,Others,125,All,AllOther,1,0,0,2019,2019,641,1,Others,0,NA,0,4.8283137373023015,"(4,5]"
632,659,oct pilot in esophagus,Completed,4,1,1,Barrett Esophagus,device,Others,53,All,NIH&Combos,0,NA,2,2018,2018,518,0,Others,1,NA,1,3.970291913552122,"(3,4]"
1556,1695,ehr-embedded ocdt in breast or gi cancer,Recruiting,2,0,0,Oral Cancer Directed Therapy|Breast Cancer|Gastrointestinal Cancer|Oral Chemotherapy,other,Others,200,All,AllOther,NA,1,4,2019,2019,933,NA,Others,0,NA,0,5.298317366548036,"(5,6]"
2023,2389,stereotactic body radiation therapy and transarterial chemoembolization in treating patients with liver cancer that cannot be removed by surgery,Completed,4,0,0,Child-Pugh Class A|Child-Pugh Class B|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma,procedure,Others,16,All,Industry&Combos,0,NA,0,2015,2015,1297,0,Others,1,NA,1,2.772588722239781,"(2,3]"
539,561,"effectiveness and safety of the colonoscopy with ""visualization"" balloon",Completed,4,0,0,Colonic Adenomatous Polyps,device,Others,216,All,AllOther,1,0,2,2014,2014,1371,1,Others,1,safety,1,5.375278407684165,"(5,6]"
827,866,effect of a short message service intervention on patients with short bowel syndrome,Terminated,5,0,0,Short Bowel Syndrome,other,Others,5,All,Industry&Combos,0,NA,4,2018,2018,307,0,Others,1,NA,1,1.6094379124341003,"(1,2]"
422,434,smart program in irritable bowel syndrome (ibs),Completed,4,0,0,Irritable Bowel Syndrome,behavioral,Others,39,All,AllOther,1,1,0,2018,2018,494,1,Others,0,NA,0,3.6635616461296463,"(3,4]"
837,876,"berries, inflammation, and gut microbiome",Recruiting,2,0,0,Overweight or Obesity|Healthy,other,Others,88,All,NA,1,0,4,2019,2019,725,1,Others,1,NA,1,4.477336814478207,"(4,5]"
1131,1201,rct of caloric restriction vs. alternate-day fasting in non-alcoholic fatty liver disease,Terminated,5,0,0,"NAFLD|Obesity|Diabetes Mellitus, Type 2",other,Others,7,All,AllOther,1,0,0,2017,2018,487,1,Others,0,NA,0,1.9459101490553132,"(1,2]"
1005,1060,stress management for irritable bowel syndrome,Completed,4,0,0,Irritable Bowel Syndrome,behavioral,Others,106,All,AllOther,1,0,0,2013,2013,638,1,Others,0,NA,0,4.663439094112067,"(4,5]"
2390,3069,aspirin intervention for the reduction of colorectal cancer risk,"Active, not recruiting",1,1,1,Colorectal Cancer,drug or biologic,NA,180,All,NIH&Combos,1,0,1,2015,2015,1375,1,NA,2,NA,2,5.19295685089021,"(5,6]"
1711,1898,underwater resection of non-pedunculated colorectal lesions,Completed,4,0,0,Colorectal Neoplasms,procedure,Others,600,All,AllOther,1,0,0,2016,2016,760,1,Others,0,NA,0,6.396929655216146,"(6,7]"
55,55,effect of gum arabic on gastrointestinal transit and permeability,Recruiting,2,0,0,Diverticulitis,other,Others,81,All,AllOther,1,0,4,2018,2018,1288,1,Others,3,NA,2,4.394449154672439,"(4,5]"
1424,1532,decentralized dietary uc pilot trial,Unknown status,8,0,0,"Colitis, Ulcerative",behavioral,Others,51,All,Industry&Combos,1,0,4,2015,2015,700,1,Others,2,NA,2,3.9318256327243257,"(3,4]"
3529,5384,exercise program during chemotherapy in metastatic colorectal cancer,Terminated,5,0,0,Stage IV Colorectal Cancer,behavioral,Others,2,All,NIH&Combos,0,NA,4,2017,2016,728,0,Others,1,NA,1,0.6931471805599453,"(0,1]"
1864,2143,near infrared fluorescence cholangiography (nirf-c) during cholecystectomy,Completed,4,1,1,Cholecystitis,drug or biologic,NA,99,All,Industry&Combos,0,NA,2,2014,2013,577,0,NA,1,NA,1,4.59511985013459,"(4,5]"
3793,6668,does aromatherapy decrease postoperative nausea and vomiting?,Completed,4,0,0,"Nausea, Postoperative",other,Others,50,All,AllOther,0,NA,1,2018,2018,183,0,Others,1,NA,1,3.912023005428146,"(3,4]"
218,221,modernization of in vivo-in vitro oral bioperformance prediction and assessment,Completed,4,1,1,Human Gastrointestinal Physiology Data,drug or biologic,NA,48,All,AllOther,1,0,4,2016,2015,670,1,NA,0,NA,0,3.871201010907891,"(3,4]"
1755,1964,cost analysis for endoscopic retrograde cholangiopancreatography (ercp),Withdrawn,7,0,0,Biliary Obstruction,procedure,Others,NA,All,AllOther,0,1,4,2014,2014,153,0,Others,1,NA,1,NA,NA
1593,1743,carnitine and liver mitochondria fatty acid processing,Unknown status,8,0,0,"Diabetes Mellitus, Type 2|Insulin Resistance|Obesity",other,Others,24,All,AllOther,1,0,1,2017,2017,364,1,Others,4,NA,2,3.1780538303479458,"(3,4]"
1197,1275,preoperative nutrition with immune enhancing nutritional supplement (immunomodulation),Unknown status,8,0,0,Pancreatic Adenocarcinoma,other,Others,20,All,Industry&Combos,1,0,4,2016,2014,1673,1,Others,0,NA,0,2.995732273553991,"(2,3]"
30,30,nec screening abdominal radiograph vs bowel ultrasound in preemies,"Active, not recruiting",1,0,0,"Enterocolitis, Necrotizing|Premature Infant",other,Others,80,All,AllOther,1,0,2,2019,2018,1016,1,Others,0,NA,0,4.382026634673881,"(4,5]"
2753,3698,anal hpv tests in screening for cell changes in the anus in patients with hiv,Completed,4,0,0,Anal Cancer|HIV Infection|Human Papilloma Virus Infection,procedure,Others,276,Female,NIH&Combos,0,NA,4,2013,2013,1792,0,Others,1,NA,1,5.62040086571715,"(5,6]"
776,813,intervention to motivate standing &walking in gastrointestinal cancer surgical patients,Completed,4,0,0,Gastrointestinal Neoplasms,behavioral,Others,32,All,AllOther,1,0,4,2013,2013,638,1,Others,3,NA,2,3.4657359027997265,"(3,4]"
440,452,prevention of parastomal hernia by mesh placement,Terminated,5,1,1,Parastomal Hernia,device,Others,12,All,Industry&Combos,1,0,1,2015,2015,353,1,Others,0,NA,0,2.4849066497880004,"(2,3]"
1269,1355,telephone support for advanced gastrointestinal cancer patients and caregivers,"Active, not recruiting",1,0,0,Gastrointestinal Neoplasms,behavioral,Others,84,All,NIH&Combos,1,0,4,2019,2019,676,1,Others,1,NA,1,4.430816798843313,"(4,5]"
1085,1146,brief behavioral treatment for sleep problems in ibs study,Completed,4,0,0,Irritable Bowel Syndrome|Sleep Disturbance,behavioral,Others,25,All,AllOther,1,0,0,2017,2017,888,1,Others,0,NA,0,3.2188758248682006,"(3,4]"
2343,2971,barrett's dysplasia detection pilot trial using the nvisionvle Â® imaging system,"Active, not recruiting",1,0,0,Barrett's Esophagus,device,Others,150,All,Industry&Combos,0,NA,2,2016,2016,1369,0,Others,1,NA,1,5.0106352940962555,"(5,6]"
1077,1136,corn and heart health study,Recruiting,2,0,0,"Gut Microbiome|Cholesterol, LDL|Cholesterol, HDL",other,Others,45,All,AllOther,3,0,1,2019,2018,1199,3,Others,1,NA,1,3.8066624897703196,"(3,4]"
2222,2736,axios lumen apposing metal stent for walled off necrosis drainage ide study,Completed,4,0,0,Walled Off Pancreatic Necrosis,device,Others,40,All,Industry&Combos,0,NA,0,2018,2018,555,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
406,417,nutrition support to improve outcomes in patients with unresectable pancreatic cancer,"Active, not recruiting",1,0,0,Cancer of Pancreas,other,Others,2,Male,AllOther,1,0,0,2016,2016,1826,1,Others,0,NA,0,0.6931471805599453,"(0,1]"
2391,3071,detecting activity to support healing,Completed,4,0,0,Colorectal Cancer|Peritoneal Cancer|Sedentary Lifestyle,device,Others,26,All,NIH&Combos,1,0,4,2017,2019,708,1,Others,0,NA,0,3.258096538021482,"(3,4]"
527,548,hybrid apc assisted emr for large colon polyps,Completed,4,0,0,Colon Polyp|Colon Adenoma|Colon Cancer,device,Others,45,All,AllOther,0,NA,0,2018,2018,760,0,Others,1,NA,1,3.8066624897703196,"(3,4]"
891,935,bilateral thoracoscopic splanchnicectomy for pain relief in patients with unresectable pancreatic cancer,Withdrawn,7,0,0,Unresectable Pancreatic Cancer,procedure,Others,NA,All,AllOther,1,0,4,2017,2017,228,1,Others,0,NA,0,NA,NA
1981,2331,project hero: health empowerment & recovery outcomes,Recruiting,2,0,0,Prostate Cancer|Bladder Cancer|Kidney Cancer|Colon Cancer|Rectum Cancer|Thyroid Cancer|Lung Cancer|Small Intestine Cancer|Soft Tissue Cancer,behavioral,Others,210,Male,AllOther,1,0,4,2017,2017,1460,1,Others,2,NA,2,5.3471075307174685,"(5,6]"
2451,3191,a dose-optimization study for the initial treatment of dysplastic barrett's esophagus with tr Â«freezeÃ¢âÂ¢ spray cryotherapy,Terminated,5,0,0,Barrett's Esophagus,device,Others,36,All,Industry&Combos,0,1,0,2013,2013,579,0,Others,1,NA,1,3.58351893845611,"(3,4]"
419,431,care coordination and proactive care to improve utilization of resources and reduce expenditure in high risk inflammatory bowel disease (ibd) patients,Completed,4,0,0,Inflammatory Bowel Diseases,behavioral,Others,425,All,AllOther,1,0,4,2021,2019,425,1,Others,2,NA,2,6.052089168924417,"(6,7]"
1779,2001,"mechanisms of idelalisib-associated diarrhea in patients with relapsed chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma",Terminated,5,0,0,Absence of Signs or Symptoms|B-Cell Non-Hodgkin Lymphoma|Digestive System Signs and Symptoms|Indolent Adult Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma,drug or biologic,NA,1,All,Industry&Combos,0,NA,4,2016,2016,855,0,NA,1,NA,1,0,NA
1037,1092,palliative care for non-malignant diseases (compass trial),Terminated,5,1,1,Liver Diseases|Liver Cirrhosis|NASH (Non-Alcoholic Steatohepatitis),other,Others,63,All,AllOther,1,0,4,2017,2017,500,1,Others,0,NA,0,4.143134726391533,"(4,5]"
2444,3177,breath and blood ammonia response to an oral protein challenge,Completed,4,0,0,Cirrhosis,other,Others,12,All,AllOther,0,NA,2,2016,2015,183,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
1860,2139,acidophilus pearls fecal recovery study,Completed,4,0,0,Survival of Probiotics During GI Transit|GI Symptoms,other,Others,13,All,Industry&Combos,1,0,4,2013,2014,61,1,Others,2,NA,2,2.5649493574615367,"(2,3]"
2822,3783,personalized lifestyle intervention for improving functional health outcomes using n-of-1 tent-umbrella-bucket design,"Active, not recruiting",1,0,0,"Health, Subjective|Gastrointestinal Dysfunction|Cardiovascular Risk Factor|Autoimmune Diseases|Dental Diseases|Hormone Disturbance|Neurocognitive Dysfunction",behavioral,Others,400,All,Industry&Combos,3,0,1,2019,2018,486,3,Others,0,NA,0,5.991464547107982,"(5,6]"
4022,7604,project i test: implementing hiv testing in opioid treatment programs,Recruiting,2,0,0,HIV/AIDS|Hepatitis C|Substance Use Disorders|Opioid-use Disorder,other,Others,51,All,NIH&Combos,1,0,4,2017,2017,1146,1,Others,0,NA,0,3.9318256327243257,"(3,4]"
2440,3171,"tolerability, safety and efficacy of a new frequency of vibrant capsule administration",Terminated,5,0,0,Constipation,device,Others,25,All,Industry&Combos,0,NA,0,2016,2016,212,0,Others,1,safety/efficacy,1,3.2188758248682006,"(3,4]"
108,108,comparison study in pancreatic fiducial placement,Withdrawn,7,0,0,Pancreatic Neoplasms,device,Others,NA,All,AllOther,1,0,0,2015,2015,1470,1,Others,0,NA,0,NA,NA
2052,2431,to evaluate the impact of sbi on c. difficile in hospitalized uc patients,Unknown status,8,0,0,Clostridium Difficile,other,Others,100,All,Industry&Combos,1,0,4,2016,2015,640,1,Others,4,NA,2,4.605170185988092,"(4,5]"
744,778,peroral endoscopic myotomy versus botulinum toxin injection in spastic esophageal disorders,Withdrawn,7,0,0,"Esophageal Achalasia|Esophageal Spasm, Diffuse|Esophageal Motility Disorders",procedure,Others,NA,All,AllOther,1,0,0,2016,2016,1399,1,Others,0,NA,0,NA,NA
3049,4098,internet-based pain self-management for persons with acute recurrent and chronic pancreatitis pain,"Active, not recruiting",1,0,0,"Pancreatitis, Chronic|Pancreatitis, Acute Recurrent",behavioral,Others,32,All,NIH&Combos,1,0,0,2017,2018,1064,1,Others,2,NA,2,3.4657359027997265,"(3,4]"
1186,1263,"a 90 day, phase 4,open labeled exploratory study of relizorb",Recruiting,2,0,0,Short Bowel Syndrome|Malabsorption,device,Others,20,All,Industry&Combos,0,NA,0,2018,2018,937,0,Others,1,NA,1,2.995732273553991,"(2,3]"
284,289,endoluminal and needlescopic assisted repair of rectal prolapse,Completed,4,0,0,Rectal Prolapse,procedure,Others,10,All,Industry&Combos,0,NA,0,2013,2013,1767,0,Others,1,NA,1,2.302585092994046,"(2,3]"
3474,5277,monitoring disease activity using video capsule endoscopy (vce) in crohn's disease (cd) subjects,Completed,4,1,1,Known Crohn Disease Subjects,device,Others,74,All,Industry&Combos,0,NA,2,2013,2013,1065,0,Others,1,NA,1,4.30406509320417,"(4,5]"
3933,7326,pilot study: gene expression profiling of immune response to hbv vaccination in healthy volunteers,Completed,4,1,1,Hepatitis B,drug or biologic,NA,10,All,AllOther,0,NA,4,2014,2014,322,0,NA,1,NA,1,2.302585092994046,"(2,3]"
2430,3156,the neoclose abdominal closure vs carter-thomason trial,Completed,4,1,1,Surgical Port Site Hernia,device,Others,70,All,Industry&Combos,1,0,1,2015,2016,803,1,Others,4,NA,2,4.248495242049359,"(4,5]"
2316,2913,does perioperative goal directed therapy using flotrac improve outcomes in esophagectomy patients,Terminated,5,1,1,Esophageal Cancer,device,Others,53,All,AllOther,1,0,0,2016,2016,1369,1,Others,0,NA,0,3.970291913552122,"(3,4]"
2045,2420,comparison between the 19 and 22 gauge needles for core tissue procurement during eus-guided procedures,Withdrawn,7,0,0,Pancreatic Cancer,procedure,Others,NA,All,AllOther,0,1,2,2015,2013,608,0,Others,1,NA,1,NA,NA
673,702,intravital microscopy (ivm) in patients with peritoneal carcinomatosis (pc),"Active, not recruiting",1,0,0,Peritoneal Carcinomatosis,device,Others,30,All,AllOther,0,NA,2,2018,2018,503,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
399,410,lesion detection assessment in the liver: standard vs low radiation dose using varied post-processing techniques,"Active, not recruiting",1,0,0,Diseases of Liver|Colon Carcinoma|Colorectal Carcinoma|Liver Metastases,other,Others,110,All,AllOther,0,1,2,2017,2017,1483,0,Others,1,NA,1,4.700480365792417,"(4,5]"
3283,4634,integrated stepped care for unhealthy alcohol use in hiv,Completed,4,0,0,"Liver Diseases, Alcoholic|Alcoholism|HIV|Hepatitis C",other,Others,319,All,NIH&Combos,1,0,0,2011,2013,2037,1,Others,0,NA,0,5.765191102784844,"(5,6]"
3657,5813,het bipolar system: validation of outpatient hemorrhoid treatment,Completed,4,0,0,Hemorrhoids,procedure,Others,35,All,Industry&Combos,0,NA,0,2016,2015,1249,0,Others,1,NA,1,3.5553480614894135,"(3,4]"
1616,1771,mechanisms and management of infant dysphagia,Completed,4,1,1,Dysphagia|Airway Aspiration|Airway Penetration,other,Others,109,All,NIH&Combos,0,1,2,2015,2015,2009,0,Others,1,NA,1,4.6913478822291435,"(4,5]"
150,150,influence of central obesity on the esophageal epithelial barrier,"Active, not recruiting",1,0,0,Gastroesophageal Reflux|GERD,procedure,Others,40,All,AllOther,0,NA,2,2016,2016,1856,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
1237,1320,cholangiography using carbon dioxide versus iodinated contrast in ercp,Recruiting,2,0,0,Choledocholithiasis|Bile Duct Diseases|Bile Duct Carcinoma,other,Others,40,All,AllOther,0,NA,2,2015,2016,2192,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
2412,3117,feasibility of a constant pressure skin disk (cpsd) in enteral tubes.,Recruiting,2,0,0,Gastrostomy,device,Others,20,All,AllOther,0,NA,NA,2019,2019,855,0,Others,1,NA,1,2.995732273553991,"(2,3]"
2380,3047,effect of prebiotic fiber- enriched (scfos) enteral feeding on the microbiome in neurological injury trauma patients (prefeed microbiome trial),Completed,4,0,0,"Enteral Nutrition|Brain Injuries, Traumatic|ICU Admission",other,Others,20,All,Industry&Combos,1,0,0,2017,2017,1216,1,Others,1,NA,1,2.995732273553991,"(2,3]"
2250,2781,home-based hiit to improve crc survivorship: feasibility and relationship with novel surrogate biomarkers of crc recurrence,Recruiting,2,0,0,Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Colonic Neoplasms|Colonic Cancer|Rectal Neoplasms|Rectal Cancer,behavioral,Others,30,All,AllOther,1,0,4,2019,2019,730,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
472,489,eus fnb versus fna with on-site cytopathology in solid pancreatic masses,Recruiting,2,0,0,Fine Needle Aspiration|Pancreatic Mass,other,Others,132,All,AllOther,1,0,2,2018,2018,1359,1,Others,2,NA,2,4.882801922586371,"(4,5]"
2215,2717,evaluation of injection techniques in celiac plexus neurolysis,Completed,4,0,0,Pancreatic Cancer|Pain,other,Others,51,All,AllOther,0,1,NA,2014,2013,457,0,Others,1,NA,1,3.9318256327243257,"(3,4]"
2003,2357,text message intervention to improve adherence in adolescents and young adults with celiac disease,Completed,4,0,0,Celiac Disease,behavioral,Others,61,All,AllOther,1,0,NA,2015,2015,455,1,Others,0,NA,0,4.110873864173311,"(4,5]"
255,259,effect of curcumin on gut microbiota in ibs,Completed,4,0,0,Irritable Bowel Syndrome,other,Others,4,All,AllOther,1,0,0,2018,2018,519,1,Others,4,NA,2,1.3862943611198906,"(1,2]"
2338,2964,effects of home gluten immunogenic peptide testing on children with celiac disease,Recruiting,2,0,0,Celiac Disease|Gluten Sensitivity|Gluten Enteropathy|Gastrointestinal Disease|Digestive System Disease|Diet Modification|Intestinal Disease|Malabsorption Syndromes|Patient Compliance|Diagnostic Self Evaluation|Quality of Life,device,Others,120,All,AllOther,1,0,4,2018,2018,1356,1,Others,1,NA,1,4.787491742782046,"(4,5]"
2206,2695,adaptive intervention to maximize colorectal screening in safety net populations,Recruiting,2,0,0,Colorectal Cancer,other,Others,550,All,NIH&Combos,1,0,1,2017,2018,952,1,Others,2,safety,2,6.309918278226516,"(6,7]"
1606,1758,prospective evaluation of the ability of spyglass cholangioscopy to facilitate radiation free ercp,Completed,4,0,0,Choledocholithiasis|Biliary Obstruction,device,Others,40,All,Industry&Combos,0,NA,NA,2017,2015,597,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
1132,1202,cytosponge and dietary therapy in eoe,"Active, not recruiting",1,0,0,Eosinophilic Esophagitis,device,Others,20,All,AllOther,0,NA,4,2015,2015,2039,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1453,1563,effects of adding raisins to the american diet on fecal microbiota composition,Completed,4,0,0,Inflammation,other,Others,18,All,AllOther,0,NA,4,2016,2016,121,0,Others,1,NA,1,2.8903717578961645,"(2,3]"
957,1007,enterade in carcinoid/non-carcinoid syndrome neuroendocrine tumor patients with quality of life limiting bowel frequency,Terminated,5,0,0,Neuroendocrine Tumor|Carcinoid Syndrome,other,Others,11,All,Industry&Combos,1,1,4,2019,2019,561,1,Others,0,NA,0,2.3978952727983707,"(2,3]"
910,956,red raspberry polyphenols on gut microbiome,Completed,4,0,0,Healthy Subjects|Pre-diabetes,other,Others,30,All,Industry&Combos,3,0,4,2017,2017,1145,3,Others,1,NA,1,3.4011973816621555,"(3,4]"
2119,2536,quad resection (hot snare vs cold snare vs hot emr vs cold emr),"Active, not recruiting",1,0,0,Colon Cancer|Colon Polyp|Colon Adenoma,procedure,Others,264,All,AllOther,1,0,0,2018,2018,1394,1,Others,0,NA,0,5.575949103146316,"(5,6]"
625,652,effect of celiac plexus block on gastric emptying and symptoms caused by gastroparesis,Withdrawn,7,0,0,Gastroparesis,procedure,Others,NA,All,AllOther,0,NA,0,2015,2014,609,0,Others,1,NA,1,NA,NA
1395,1496,tart cherry supplementation & gut microbiome and inflammation,"Active, not recruiting",1,0,0,Inflammation|Glucose Regulation|Sleep,other,Others,70,All,AllOther,1,0,4,2020,2019,212,1,Others,2,NA,2,4.248495242049359,"(4,5]"
8,8,endoscopic ultrasound determines disease activity in crohn's disease and ulcerative colitis,Recruiting,2,0,0,Crohn Disease|Ulcerative Colitis,procedure,Others,60,All,AllOther,1,1,2,2019,2019,1093,1,Others,0,NA,0,4.0943445622221,"(4,5]"
2812,3771,a study assessing perfusion outcomes with pinpoint Â® near infrared fluorescence imaging in low anterior resection,Terminated,5,1,1,Rectal Cancer|Rectosigmoid Cancer,device,Others,347,All,Industry&Combos,1,0,0,2014,2015,851,1,Others,0,NA,0,5.849324779946859,"(5,6]"
109,109,evaluation of effect of cryoballoon focal ablation system on human esophageal epithelium,"Active, not recruiting",1,0,0,Barrett's Esophagus|Esophageal Squamous Dysplasia|Esophageal Cancer,device,Others,53,All,Industry&Combos,0,NA,0,2015,2015,3044,0,Others,1,NA,1,3.970291913552122,"(3,4]"
4033,7619,evaluation of the immune response to clostridium difficile in adults with clostridium difficile infection (cdi),Completed,4,1,1,"Infections, Clostridium Difficile",procedure,Others,57,All,Industry&Combos,1,1,4,2012,2013,849,1,Others,0,NA,0,4.04305126783455,"(4,5]"
3060,4115,sphincterotomy for acute recurrent pancreatitis,Recruiting,2,0,0,"Pancreatitis|Pancreas Divisum|Pancreatitis, Acute|Pancreatitis Idiopathic|Pancreas Inflamed",procedure,Others,234,All,NIH&Combos,1,0,0,2018,2018,1953,1,Others,2,NA,2,5.455321115357702,"(5,6]"
2059,2444,iron supplementation and side effects,Completed,4,0,0,Iron Deficiency Anemia|Iron Overload,other,Others,17,Female,AllOther,3,0,4,2019,2018,100,3,Others,2,NA,2,2.833213344056216,"(2,3]"
1299,1387,whipple procedure: standard of care vs. thunderbeat,Terminated,5,1,1,Pancreatic Neoplasms|Bile Duct Carcinoma,device,Others,44,All,AllOther,1,0,0,2014,2015,965,1,Others,1,NA,1,3.784189633918261,"(3,4]"
105,105,the effect of a cranberry beverage on intestinal permeability and gastrointestinal function in generally healthy adults,Completed,4,0,0,Intestinal Permeability|Gastrointestinal Function,other,Others,43,All,Industry&Combos,3,0,4,2019,2019,119,3,Others,3,NA,2,3.7612001156935624,"(3,4]"
418,430,postoperative heme oxygenase induction and carbon monoxide production as a novel method to assess hepatic regeneration and predict hepatic related morbidity after partial hepatectomy,Recruiting,2,0,0,Liver Cancer,procedure,Others,30,All,AllOther,0,NA,4,2019,2014,3160,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
1961,2307,impact of almond supplementation on body composition in overweight/obese minority adults,Completed,4,0,0,Obesity|Overweight|Fatty Liver|Metabolic Syndrome X,other,Others,26,All,AllOther,1,0,0,2015,2014,609,1,Others,0,NA,0,3.258096538021482,"(3,4]"
3225,4519,treatment of type i hepatorenal syndrome (hrs) with pentoxyfylline,Terminated,5,1,1,Hepatorenal Syndrome,drug or biologic,NA,12,All,AllOther,1,0,0,2014,2014,1370,1,NA,4,NA,2,2.4849066497880004,"(2,3]"
1689,1866,use of accessory device amplifeye during average risk screening colonoscopy to increase adenoma detection rate,Withdrawn,7,0,0,Colonic Polyps,device,Others,NA,All,AllOther,1,0,4,2016,2017,1671,1,Others,0,NA,0,NA,NA
1262,1347,a multimodal enhanced recovery program in anorectal surgery,Terminated,5,0,0,"Colorectal Disorders|Anorectal Disorder|Patient Satisfaction|Pain, Postoperative|Opioid Use|Opioid Abuse|Opioid Dependence",procedure,Others,60,All,AllOther,1,0,0,2019,2019,336,1,Others,2,NA,2,4.0943445622221,"(4,5]"
3453,5244,magnesium treatment on vitamin d metabolism in participants completed personalized prevention of colorectal cancer trial,Completed,4,0,0,Colorectal Cancer,other,Others,180,All,AllOther,2,0,1,2017,2014,700,1,Others,3,NA,2,5.19295685089021,"(5,6]"
1788,2016,patient portal and navigation program in providing information for asian american cancer patients,Recruiting,2,0,0,Caregiver|Malignant Neoplasm|Physician|Stage I Colorectal Cancer AJCC v8|Stage I Liver Cancer|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Colorectal Cancer AJCC v8|Stage II Liver Cancer|Stage II Lung Cancer AJCC v8|Stage IIA Colorectal Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Colorectal Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIC Colorectal Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Liver Cancer|Stage III Lung Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8,behavioral,Others,203,All,AllOther,0,NA,4,2019,2019,792,0,Others,1,NA,1,5.313205979041787,"(5,6]"
3296,4671,tolerance of infants fed a hydrolysate formula,Completed,4,0,0,Gastrointestinal Tolerance,other,Others,51,All,Industry&Combos,1,0,4,2018,2018,87,1,Others,0,NA,0,3.9318256327243257,"(3,4]"
865,907,the role of obstructive sleep apnea in children with fatty liver disease,Terminated,5,1,1,Non Alcoholic Fatty Liver Disease,device,Others,1,All,AllOther,0,NA,0,2014,2014,1035,0,Others,1,NA,1,0,NA
1138,1208,increasing activity in liver transplant patients,Completed,4,1,1,Liver Transplant,behavioral,Others,12,All,AllOther,0,NA,NA,2014,2014,303,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
2737,3666,use of human dehydrated amnion chorion allograft in closed hemorroidectomy,Completed,4,0,0,External Hemorrhoid|External Hemorrhoid Thrombosed,other,Others,11,All,Industry&Combos,0,NA,0,2018,2018,328,0,Others,1,NA,1,2.3978952727983707,"(2,3]"
1361,1455,dietary therapy and gut microbiome in crohn's disease and ulcerative colitis,Recruiting,2,0,0,Crohn's Disease,other,Others,40,All,AllOther,0,1,0,2015,2014,2557,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
3216,4492,improving medication adherence in adolescents who had a liver transplant,Recruiting,2,0,0,Transplant,behavioral,Others,156,All,NIH&Combos,1,0,0,2018,2018,1781,1,Others,1,NA,1,5.049856007249537,"(5,6]"
3441,5232,systems support mapping in guiding self-management in stage i-iii colorectal cancer survivors,Completed,4,1,1,Cancer Survivor|Stage I Colorectal Cancer AJCC v8|Stage II Colorectal Cancer AJCC v8|Stage IIA Colorectal Cancer AJCC v8|Stage IIB Colorectal Cancer AJCC v8|Stage IIC Colorectal Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8,behavioral,Others,24,All,NIH&Combos,0,NA,4,2018,2018,618,0,Others,1,NA,1,3.1780538303479458,"(3,4]"
1369,1464,dual energy ct as a noninvasive method to screen for gastroesophageal varices,Recruiting,2,0,0,Gastroesophageal Varices,other,Others,50,All,AllOther,0,NA,2,2019,2019,1122,0,Others,1,NA,1,3.912023005428146,"(3,4]"
751,787,fecal microbiota therapy for recurrent clostridium difficile colitis,Unknown status,8,0,0,Clostridium Difficile,drug or biologic,NA,10,All,AllOther,0,NA,0,2013,2013,365,0,NA,1,NA,1,2.302585092994046,"(2,3]"
1243,1327,effects of aronia berries on vascular endothelial function and the gut microbiota in middle-aged/older adults,"Active, not recruiting",1,0,0,Endothelial Dysfunction|Aging,other,Others,24,All,Industry&Combos,3,0,4,2019,2019,1145,3,Others,2,NA,2,3.1780538303479458,"(3,4]"
410,421,effect of diet on gulf war illness,Unknown status,8,0,0,Irritable Bowel Syndrome,behavioral,Others,68,All,AllOther,1,0,0,2016,2016,761,1,Others,2,NA,2,4.219507705176107,"(4,5]"
2149,2585,survivorship care planning in patients with colorectal or non-small cell lung cancer,Completed,4,0,0,Stage I Colon Cancer|Stage I Rectal Cancer|Stage IA Non-small Cell Lung Cancer|Stage IB Non-small Cell Lung Cancer|Stage IIA Colon Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer,procedure,Others,30,All,NIH&Combos,0,NA,4,2012,2013,334,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
1650,1815,stoma tube decompression and postoperative ileus after major colorectal surgery,Terminated,5,1,1,Ileus|Bowel Obstruction,device,Others,6,All,AllOther,1,0,1,2013,2013,365,1,Others,0,NA,0,1.791759469228055,"(1,2]"
1434,1543,effects of open-label vs double-blind treatment in ibs,Completed,4,1,1,Irritable Bowel Syndrome|Placebo Effect|Placebos|Peppermint Oil,drug or biologic,NA,340,All,NIH&Combos,1,0,0,2016,2016,944,1,NA,NA,NA,NA,5.8289456176102075,"(5,6]"
149,149,alateral flow assay to detect qsox1 peptide in patients with or at risk for pancreatic cancer,Completed,4,0,0,Pancreas Cancer|Pancreas Cyst,other,Others,60,All,AllOther,1,1,2,2019,2019,457,1,Others,0,NA,0,4.0943445622221,"(4,5]"
2139,2571,an intraoperative guidance platform for radio frequency ablation,Recruiting,2,0,0,Hepatocellular Carcinoma,device,Others,52,All,NIH&Combos,0,NA,0,2019,2019,603,0,Others,1,NA,1,3.9512437185814275,"(3,4]"
394,405,pet-mri in diagnosing patients with colon or rectal cancer,Completed,4,1,1,Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IIA Colon Cancer|Stage IIA Rectal Cancer|Stage IIB Colon Cancer|Stage IIB Rectal Cancer|Stage IIC Colon Cancer|Stage IIC Rectal Cancer|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer,procedure,Others,15,All,AllOther,0,NA,2,2013,2013,338,0,Others,1,NA,1,2.70805020110221,"(2,3]"
273,277,dce mri in patients with pancreatic cancer,Recruiting,2,0,0,Hereditary Pancreatic Carcinoma|Pancreatic Adenocarcinoma|Pancreatic Intraductal Papillary-Mucinous Neoplasm,drug or biologic,NA,160,All,NIH&Combos,1,1,2,2014,2014,3621,1,NA,1,NA,1,5.075173815233827,"(5,6]"
3482,5285,health literacy interventions to overcome disparities in crc screening,Completed,4,1,1,Colorectal Cancer,behavioral,Others,620,All,AllOther,1,0,1,2015,2015,1374,1,Others,0,NA,0,6.429719478039138,"(6,7]"
3498,5303,acupuncture to prevent chemotherapy dose reduction due to chemotherapy-induced peripheral neuropathy in breast and colorectal cancer patients (gcc1232),Terminated,5,1,1,Breast Cancer|Colorectal Cancer,device,Others,19,All,AllOther,1,0,4,2013,2013,485,1,Others,1,NA,1,2.9444389791664403,"(2,3]"
3320,4739,early progressive feeding in human-milk fed extremely preterm infants: a randomized trial,"Active, not recruiting",1,0,0,"Premature; Infant, Light-for-dates",other,Others,60,All,AllOther,1,0,4,2016,2016,395,1,Others,0,NA,0,4.0943445622221,"(4,5]"
2905,3894,study of the safety and tolerability of axa1665 in subjects with mild and moderate hepatic insufficiency,Completed,4,0,0,Hepatic Insufficiency,other,Others,60,All,Industry&Combos,1,0,4,2019,2019,417,1,Others,1,safety,1,4.0943445622221,"(4,5]"
1662,1831,peer mentoring to improve self-management in youth with ibd,Recruiting,2,0,0,Pediatric Crohns Disease|Pediatric Ulcerative Colitis|Inflammatory Bowel Diseases,behavioral,Others,300,All,AllOther,1,0,1,2019,2019,1352,1,Others,0,NA,0,5.703782474656201,"(5,6]"
518,539,evaluation of the circa monitoring system in prevention of esophageal lesions following rfca,Completed,4,1,1,Atrial Fibrillation,device,Others,40,All,AllOther,0,NA,1,2015,2015,1764,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
1454,1564,the effect of an rbac supplement (brm4) on nafld,Completed,4,0,0,Non-Alcoholic Fatty Liver Disease,other,Others,23,All,AllOther,1,0,4,2015,2016,405,1,Others,4,NA,2,3.1354942159291497,"(3,4]"
3727,6242,anesthetic to reduce dysphagia after anterior cervical discectomy and fusion surgery,Completed,4,0,0,Dysphagia,drug or biologic,NA,150,All,AllOther,2,0,1,2015,2015,1499,1,NA,2,NA,2,5.0106352940962555,"(5,6]"
2251,2782,user testing of the evivo screening test,Terminated,5,0,0,Gut Microbiome,device,Others,231,All,Industry&Combos,0,NA,4,2018,2018,266,0,Others,1,NA,1,5.442417710521793,"(5,6]"
2342,2968,probiotics and health-related quality of life in individuals with seasonal allergies,Completed,4,1,1,Healthy,other,Others,224,All,Industry&Combos,1,0,4,2015,2015,120,1,Others,3,NA,2,5.4116460518550396,"(5,6]"
1116,1184,capsule endoscopy for hemorrhage in the emergency room,Unknown status,8,0,0,Melena|Hematemesis|Peptic Ulcer Hemorrhage|Variceal Hemorrhage,device,Others,100,All,Industry&Combos,1,0,2,2011,2018,122,1,Others,1,NA,1,4.605170185988092,"(4,5]"
3221,4503,comparison of telemedicine to usual care for hcv management for methadone-maintained individuals,"Active, not recruiting",1,0,0,Hepatitis C,other,Others,602,All,AllOther,3,0,4,2016,2017,1444,3,Others,0,NA,0,6.400257445308821,"(6,7]"
502,523,efficacy and safety of ibs digital behavioral treatment,"Active, not recruiting",1,0,0,Irritable Bowel Syndrome,device,Others,378,All,Industry&Combos,1,0,0,2019,2019,371,1,Others,3,safety/efficacy,2,5.934894195619588,"(5,6]"
1221,1299,resistant starch blend gastrointestinal impact,Completed,4,0,0,"Quality of Life|Health, Subjective",other,Others,43,All,Industry&Combos,1,0,4,2019,2019,566,1,Others,1,NA,1,3.7612001156935624,"(3,4]"
1943,2277,probiotic supplementation on weight loss,Recruiting,2,0,0,Bariatric Surgery Candidate,other,Others,40,All,AllOther,1,1,4,2019,2019,1079,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
278,283,bariatric surgery versus diet alone in the bile acid pathway and weight loss,Recruiting,2,0,0,Obesity,procedure,Others,16,All,AllOther,1,1,4,2017,2019,1203,1,Others,0,NA,0,2.772588722239781,"(2,3]"
2254,2790,outcomes in simulated endoscopy training,Recruiting,2,0,0,Impact of Supervision on Endoscopy Simulation Curriculum,behavioral,Others,50,All,AllOther,1,0,4,2018,2018,1761,1,Others,1,NA,1,3.912023005428146,"(3,4]"
2373,3031,treatment of c. difficile infection with fecal microbiota transplantation (fmt),Withdrawn,7,0,0,Clostridium Difficile Infection,other,Others,NA,All,AllOther,0,1,0,2013,2013,1096,0,Others,1,NA,1,NA,NA
3780,6554,probiotics for prevention of antibiotic associated diarrhea and clostridium difficile associated disease,Terminated,5,0,0,Diarrhea,other,Others,110,All,AllOther,1,0,1,2014,2015,243,1,Others,3,NA,2,4.700480365792417,"(4,5]"
2151,2589,antibiotic irrigation for pancreatoduodenectomy,"Active, not recruiting",1,0,0,Surgery|Infection,drug or biologic,NA,164,All,AllOther,1,0,1,2014,2014,2100,1,NA,2,NA,2,5.099866427824199,"(5,6]"
3655,5806,early dha supplementation in very low birth weight infants,Completed,4,0,0,Prematurity,other,Others,30,All,Industry&Combos,1,0,4,2017,2017,373,1,Others,3,NA,2,3.4011973816621555,"(3,4]"
680,711,effects of dietary fructose on gut microbiota and fecal metabolites in obese men and postmenopausal women: a pilot study,Completed,4,1,1,Non-Alcoholic Fatty Liver Disease|Obesity,other,Others,13,All,NIH&Combos,3,0,4,2017,2017,301,3,Others,2,NA,2,2.5649493574615367,"(2,3]"
1818,2066,telehealth intervention in cirrhotics,"Active, not recruiting",1,0,0,"Cirrhosis, Liver|Liver Diseases",behavioral,Others,277,All,AllOther,1,0,4,2019,2017,989,1,Others,0,NA,0,5.6240175061873385,"(5,6]"
1687,1863,routine post-operative supplemental nutrition,Terminated,5,0,0,Esophageal Cancer,other,Others,30,All,AllOther,1,0,4,2014,2014,1581,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
1849,2118,metabolism and bariatric surgery study,Recruiting,2,0,0,Insulin Resistance|Obesity,procedure,Others,75,All,NIH&Combos,1,1,0,2017,2017,1718,1,Others,0,NA,0,4.31748811353631,"(4,5]"
3539,5407,an interactive preventive health record to increase colorectal cancer screening,Completed,4,0,0,Colorectal Cancer Screening,behavioral,Others,683,All,NIH&Combos,1,0,1,2013,2013,2679,1,Others,4,NA,2,6.52649485957079,"(6,7]"
1098,1162,an evaluation of the utility of the exspiron respiratory variation monitor during upper gi endoscopy,Unknown status,8,0,0,"Biliary Tract Diseases|Stomach Neoplasms|Carcinoma, Pancreatic Ductal|Barrett Esophagus",device,Others,100,All,Industry&Combos,1,0,2,2014,2014,639,1,Others,1,NA,1,4.605170185988092,"(4,5]"
1607,1759,programs to support you during chemotherapy,Completed,4,1,1,Depression|Fatigue|Stage IIA Colorectal Cancer|Stage IIB Colorectal Cancer|Stage IIC Colorectal Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer|Pancreatic Cancer|Esophageal Cancer|Appendix Cancer|Stomach Cancer|Gallbladder Cancer|Liver Cancer|Small Intestine Cancer|Large Intestine Cancer|Anal Cancer|Biliary Tract Cancer|Gastrointestinal Stromal Cancer,behavioral,Others,44,All,NIH&Combos,1,0,4,2015,2016,1248,1,Others,0,NA,0,3.784189633918261,"(3,4]"
2637,3541,"performance of the id-cap system, an ingestion event marker, in the clinical setting as an aid to measure medication adherence",Completed,4,0,0,Healthy Volunteers,device,Others,13,All,Industry&Combos,0,NA,4,2018,2018,107,0,Others,1,NA,1,2.5649493574615367,"(2,3]"
1133,1203,effectiveness of diaphragmatic breathing on reflux symptoms in outpatients,Enrolling by invitation,3,0,0,GERD,behavioral,Others,120,All,AllOther,1,0,0,2019,2019,813,1,Others,0,NA,0,4.787491742782046,"(4,5]"
1490,1614,blue light therapy for liver surgery,Terminated,5,0,0,Acute Kidney Injury|Liver Injury|Inflammation,other,Others,6,All,NIH&Combos,1,1,4,2016,2017,729,1,Others,0,NA,0,1.791759469228055,"(1,2]"
2335,2955,chronic hbv management for asian american,"Active, not recruiting",1,0,0,"Hepatitis B, Chronic",behavioral,Others,382,All,NIH&Combos,1,0,1,2019,2019,1036,1,Others,3,NA,2,5.945420608606575,"(5,6]"
4025,7607,integrating hcv and hiv screening during the era of hiv antigen testing,Completed,4,0,0,HIV|Hepatitis C,procedure,Others,200,All,NIH&Combos,1,0,2,2016,2016,328,1,Others,0,NA,0,5.298317366548036,"(5,6]"
2474,3249,molecular biomarkers and adherent and invasive escherichia coli (aiec) detection study in crohn's disease patients,Terminated,5,0,0,Crohn's Disease,other,Others,143,All,Industry&Combos,0,NA,2,2016,2016,456,0,Others,1,NA,1,4.962844630259907,"(4,5]"
1594,1744,iron reduction for the treatment of diabetes and nonalcoholic fatty liver disease,Recruiting,2,0,0,Iron|Diabetes|Nonalcoholic Fatty Liver,procedure,Others,240,All,NIH&Combos,1,0,0,2018,2019,1737,1,Others,1,NA,1,5.480638923341991,"(5,6]"
2484,3272,microbiome survey of preterm infants,Withdrawn,7,0,0,Skin Microbiome,device,Others,NA,All,AllOther,3,1,1,2013,2013,1096,3,Others,0,NA,0,NA,NA
2516,3348,intraoperative acupoint stimulation to prevent post-operative nausea and vomiting (ponv),"Active, not recruiting",1,0,0,Post-Operative Nausea and Vomiting|Breast Cancer,drug or biologic,NA,188,Female,AllOther,1,0,4,2015,2016,2038,1,NA,2,NA,2,5.236441962829949,"(5,6]"
2350,2987,el centro: engaging latinos in the center of cancer treatment options,Recruiting,2,0,0,Metastatic Pancreatic Cancer|Unresectable Pancreatic Cancer|Metastatic Colorectal Cancer,behavioral,Others,308,All,NIH&Combos,1,0,4,2018,2018,852,1,Others,0,NA,0,5.730099782973574,"(5,6]"
1486,1609,the effect of the low fodmap diet in children with autism spectrum disorders,Completed,4,0,0,Autism Spectrum Disorder,other,Others,15,All,AllOther,1,0,0,2019,2019,208,1,Others,0,NA,0,2.70805020110221,"(2,3]"
1986,2337,leucine enriched essential amino acid mixture to reverse muscle loss in cirrhosis,Recruiting,2,0,0,"Cirrhosis, Liver",other,Others,32,All,AllOther,1,0,1,2017,2013,3070,1,Others,0,NA,0,3.4657359027997265,"(3,4]"
335,341,stoma closure and reinforcement trial,"Active, not recruiting",1,0,0,Colon Cancer|Rectal Cancer|Ileostomy - Stoma,device,Others,20,All,AllOther,0,NA,1,2018,2019,760,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1916,2232,survivor choices for eating and drinking - colorectal cancer,Completed,4,0,0,Colon Cancer|Rectal Cancer|ColoRectal Cancer,behavioral,Others,50,All,AllOther,3,0,4,2016,2017,510,3,Others,0,NA,0,3.912023005428146,"(3,4]"
29,29,eus bd vs ercp tp for pancreatic cancer,Unknown status,8,0,0,Pancreatic Cancer|Pancreatic Adenocarcinoma|Biliary Tract Neoplasms|Biliary Duct Obstruction|Unresectable Pancreatic Cancer|Periampullary Cancer|Periampullary Carcinoma Non-Resectable,procedure,Others,120,All,AllOther,1,0,0,2017,2016,683,1,Others,0,NA,0,4.787491742782046,"(4,5]"
1603,1755,papillary balloon dilation versus intraductal lithotripsy,Unknown status,8,0,0,Choledocholithiasis,procedure,Others,90,All,AllOther,1,0,0,2018,2018,816,1,Others,1,NA,1,4.499809670330265,"(4,5]"
1035,1090,endoscopic ultrasound guided fine needle biopsy (eus-fnb-sc) using a novel fork needle,Completed,4,1,1,Pancreatic Cancer,device,Others,50,All,Industry&Combos,3,0,2,2016,2016,908,3,Others,1,NA,1,3.912023005428146,"(3,4]"
77,77,endoscopic stenting across the papilla versus the leak site to treat bile leak,Unknown status,8,0,0,Bile Leak,procedure,Others,92,All,AllOther,1,0,0,2017,2016,1430,1,Others,1,NA,1,4.5217885770490405,"(4,5]"
918,964,remote telemonitoring to improve prehabilitation and surgical outcomes of patients undergoing pancreatic resection or ventral hernia repair,Recruiting,2,0,0,Pancreas Disease|Ventral Hernia,other,Others,240,All,AllOther,1,0,4,2018,2019,1050,1,Others,0,NA,0,5.480638923341991,"(5,6]"
1139,1209,gut-level antiinflammatory activities of green tea in metabolic syndrome,Completed,4,0,0,Dysbiosis|Endotoxemia|Metabolic Syndrome|Inflammation,other,Others,40,All,AllOther,3,0,1,2019,2019,609,3,Others,2,NA,2,3.6888794541139363,"(3,4]"
1718,1911,pilot study: identification of a multi-omic predictive signature for preterm birth in obese african american women,Completed,4,0,0,PREG1|Obesity,other,Others,25,Female,AllOther,0,NA,4,2017,2016,365,0,Others,1,NA,1,3.2188758248682006,"(3,4]"
204,207,a pilot study on the use of prophylactic antibiotics for eus-guided pancreatic cyst aspiration,Completed,4,1,1,Pancreatic Cysts,drug or biologic,NA,26,All,AllOther,1,0,1,2013,2014,304,1,NA,4,NA,2,3.258096538021482,"(3,4]"
178,179,high definition colonoscopy (hdc) vs. dye spraying chromo-colonoscopy (dsc) in screening patients with long-standing inflammatory bowel disease (ibd),Recruiting,2,0,0,Inflammatory Bowel Diseases|Colon Dysplasia|Ulcerative Colitis|Crohn Colitis|Indeterminate Colitis,device,Others,500,All,AllOther,1,0,4,2019,2019,912,1,Others,3,NA,2,6.214608098422191,"(6,7]"
1276,1362,web-based mindfulness meditation in reducing distress in participants with metastatic gastrointestinal cancer and their caregivers,Completed,4,0,0,Caregiver|Metastatic Gastrointestinal Carcinoma,behavioral,Others,68,All,Industry&Combos,0,NA,4,2018,2018,542,0,Others,1,NA,1,4.219507705176107,"(4,5]"
1629,1790,using ultrasound elastography to predict development of hepatic sinusoidal obstruction syndrome,Recruiting,2,0,0,"Bone Marrow Transplant Complications|Sinusoidal Obstruction Syndrome|Veno Occlusive Disease, Hepatic|Stem Cell Transplant Complications",other,Others,250,All,Industry&Combos,0,NA,2,2019,2019,1735,0,Others,1,NA,1,5.521460917862246,"(5,6]"
2183,2650,ambient lighting during colonoscopy and its effect on adenoma detection rate and eye fatigue,Completed,4,0,0,Colorectal Cancer Screening|Colon Adenomatous Polyp,other,Others,1109,All,AllOther,0,1,4,2020,2017,545,0,Others,1,NA,1,7.011213987350367,"(7,13]"
649,676,high volume washing of the abdomen in increasing survival after surgery in patients with pancreatic cancer that can be removed by surgery,Recruiting,2,0,0,"Acinar Cell Carcinoma|Ampulla of Vater Adenocarcinoma|Cholangiocarcinoma|Duodenal Adenocarcinoma|Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type|Periampullary Adenocarcinoma",procedure,Others,667,All,AllOther,1,0,0,2016,2016,1922,1,Others,1,NA,1,6.502790045915623,"(6,7]"
3802,6700,to evaluate sbi in the dietary management of mild to moderate crohn's disease,Terminated,5,0,0,Crohn's Disease,other,Others,7,All,Industry&Combos,1,0,4,2016,2016,547,1,Others,4,NA,2,1.9459101490553132,"(1,2]"
1540,1676,walking for recovery from surgery in improving quality of life in older adults with lung or gastrointestinal cancer and their family caregivers,"Active, not recruiting",1,0,0,Adult Liver Carcinoma|Caregiver|Colorectal Carcinoma|Lung Carcinoma|Malignant Digestive System Neoplasm|Pancreatic Carcinoma,behavioral,Others,80,All,AllOther,0,NA,4,2017,2017,1461,0,Others,1,NA,1,4.382026634673881,"(4,5]"
1901,2207,vitamin d and microbiota in cystic fibrosis,Completed,4,0,0,Vitamin D Deficiency|Cystic Fibrosis,procedure,Others,41,All,AllOther,1,0,4,2015,2015,428,1,Others,3,NA,2,3.713572066704308,"(3,4]"
3316,4725,effect of harvoni on proteinuria and egfr in hepatitis c virus associated chronic kidney disease (ckd),Terminated,5,1,1,Hepatitis C|Chronic Kidney Disease,drug or biologic,NA,14,All,AllOther,0,NA,0,2015,2015,779,0,NA,1,NA,1,2.6390573296152584,"(2,3]"
1245,1329,a patient-centered intervention using technology to reduce colorectal cancer disparities in primary care,Recruiting,2,0,0,Colo-rectal Cancer,other,Others,4000,All,NIH&Combos,1,0,4,2018,2018,1181,1,Others,1,NA,1,8.294049640102028,"(7,13]"
1118,1186,understanding mechanisms of normal and disordered defecation,Recruiting,2,0,0,Constipation,other,Others,160,All,NIH&Combos,1,1,4,2019,2019,1613,1,Others,0,NA,0,5.075173815233827,"(5,6]"
2106,2516,a study to assess the efficacy and safety of the vibrant capsule administered 5 times per week,Unknown status,8,0,0,Constipation,device,Others,190,All,Industry&Combos,1,0,0,2017,2017,515,1,Others,4,safety/efficacy,2,5.247024072160486,"(5,6]"
3875,7135,pilot study on a locally prepared food supplement to support growth and brain health,Completed,4,0,0,Malnutrition,other,Others,80,All,AllOther,1,0,0,2017,2016,92,1,Others,0,NA,0,4.382026634673881,"(4,5]"
990,1044,"comparative effectiveness of fit, colonoscopy, & usual care screening strategies",Completed,4,0,0,Colorectal Cancer,other,Others,5999,All,NIH&Combos,1,0,4,2012,2013,1187,1,Others,1,NA,1,8.699348067653093,"(7,13]"
402,413,"safety,usability and compliance of using c-scan system for providing information on colonic polypoid lesions and masses",Completed,4,0,0,Colo-rectal Cancer,device,Others,45,All,Industry&Combos,0,NA,2,2018,2019,334,0,Others,1,safety,1,3.8066624897703196,"(3,4]"
1489,1613,sharkcore versus acquire fnb,Recruiting,2,0,0,EUS Guided Biopsy,device,Others,150,All,AllOther,1,0,2,2018,2018,429,1,Others,1,NA,1,5.0106352940962555,"(5,6]"
692,723,effect of a nickel free diet and nickel sensitization on gerd patients.,Completed,4,0,0,Gastroesophageal Reflux,other,Others,20,All,AllOther,1,1,0,2018,2019,393,1,Others,1,NA,1,2.995732273553991,"(2,3]"
2667,3577,"s1316, surgery or non-surgical management in treating patients with intra-abdominal cancer and bowel obstruction","Active, not recruiting",1,0,0,"Constipation, Impaction, and Bowel Obstruction|Unspecified Adult Solid Tumor, Protocol Specific",procedure,Others,221,All,NIH&Combos,1,0,4,2014,2015,2253,1,Others,0,NA,0,5.3981627015177525,"(5,6]"
2769,3718,"a prospective, multi-center evaluation of the echelon circular powered stapler in left-sided colorectal anastomoses",Completed,4,1,1,Left-sided Colon Resection,device,Others,168,All,Industry&Combos,0,NA,0,2017,2017,746,0,Others,1,NA,1,5.123963979403259,"(5,6]"
2038,2409,problem solving skills training in adult cancer survivors: bright ideas-ac,Completed,4,0,0,Colo-rectal Cancer,behavioral,Others,51,All,NIH&Combos,1,0,4,2018,2018,872,1,Others,0,NA,0,3.9318256327243257,"(3,4]"
2537,3404,short or long interval to ileostomy reversal after ileal pouch surgery,Terminated,5,0,0,Ulcerative Colitis,procedure,Others,36,All,AllOther,1,0,0,2018,2018,910,1,Others,0,NA,0,3.58351893845611,"(3,4]"
3549,5444,infantile colic: study of the efficacy of lactobacillus gg (atcc 53103) plus chamomile in breastfeeding infants,Terminated,5,0,0,Infantile Colic,other,Others,1,All,AllOther,1,0,0,2018,2018,283,1,Others,3,efficacy,2,0,NA
979,1032,enhancing recovery in children undergoing surgery,Recruiting,2,0,0,Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis,procedure,Others,1260,All,AllOther,NA,0,4,2019,2019,1552,NA,Others,0,NA,0,7.138866999945524,"(7,13]"
1229,1307,microbiome fructan metabolism and symptoms in childhood ibs,Completed,4,0,0,Irritable Bowel Syndrome (IBS),other,Others,55,All,NIH&Combos,3,0,4,2016,2014,1642,3,Others,3,NA,2,4.007333185232471,"(4,5]"
2524,3373,integrating quantitative energetics determines the microbiome's contribution to energy balance,Completed,4,0,0,Obesity,other,Others,16,All,AllOther,3,0,4,2016,2017,766,3,Others,0,NA,0,2.772588722239781,"(2,3]"
132,132,lumen apposing metal stents vs lumen apposing metal stent plus double pigtail stent for endoscopic drainage of pancreatic fluid collections,Enrolling by invitation,3,0,0,Pancreatic Pseudocyst,device,Others,101,All,AllOther,1,0,0,2017,2017,1241,1,Others,0,NA,0,4.61512051684126,"(4,5]"
283,288,mindfulness-based eating in patients with irritable bowel syndrome,Completed,4,0,0,Abdominal Pain|Irritable Bowel Syndrome|IBS,behavioral,Others,20,All,AllOther,1,0,0,2016,2017,178,1,Others,1,NA,1,2.995732273553991,"(2,3]"
1408,1513,"morning-only 4 l peg vs split dose prep for afternoon colonoscopies, endoscopist-blinded prospective study",Completed,4,0,0,Colonoscopy,drug or biologic,NA,200,All,AllOther,1,0,4,2015,2015,1339,1,NA,1,NA,1,5.298317366548036,"(5,6]"
82,82,diet study on ulcerative colitis,Completed,4,0,0,Ulcerative Colitis,other,Others,38,All,AllOther,3,0,4,2019,2015,1294,3,Others,1,NA,1,3.6375861597263857,"(3,4]"
272,276,pancreatic cancer screening of high-risk individuals in arkansas,Withdrawn,7,0,0,"Pancreatic Neoplasms|Peutz-Jegher's Syndrome|BRCA1 Gene Mutation|BRCA2 Gene Mutation|Ataxia Telangiectasia|Familial Atypical Mole-Malignant Melanoma Syndrome|Colorectal Neoplasms, Hereditary Nonpolyposis|Hereditary Pancreatitis",other,Others,NA,All,AllOther,1,1,4,2014,2015,1356,1,Others,0,NA,0,NA,NA
310,315,3d sonographic measurement of volumetric flow in transjugular intrahepatic porto-systemic shunts,Completed,4,0,0,Portal Hypertension|Liver Disease,procedure,Others,18,All,AllOther,0,NA,4,2014,2013,549,0,Others,1,NA,1,2.8903717578961645,"(2,3]"
2475,3254,ostomy rural telehealth training cancer survivors,Recruiting,2,0,0,Ostomy|Quality of Life|Telehealth,behavioral,Others,180,All,NIH&Combos,1,0,4,2019,2019,1491,1,Others,0,NA,0,5.19295685089021,"(5,6]"
3736,6266,tdcs for the management of chronic visceral pain in patients with chronic pancreatitis,Withdrawn,7,0,0,Chronic Pancreatitis|Pain,device,Others,NA,All,AllOther,0,0,0,2013,2013,306,0,Others,1,NA,1,NA,NA
1282,1369,effect of modified time-restricted feeding in preventing progression of non-alcoholic fatty liver disease (nafld).,Unknown status,8,0,0,Non-Alcoholic Fatty Liver Disease,behavioral,Others,40,All,AllOther,1,0,0,2019,2019,395,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
499,519,normal liver stiffness by mr elastography,Completed,4,1,1,Liver Diseases,device,Others,101,All,AllOther,0,NA,2,2017,2018,857,0,Others,1,NA,1,4.61512051684126,"(4,5]"
1051,1106,enteral nutrition tolerance and the gut microbiome study,Recruiting,2,0,0,Enteral Feeding Intolerance,other,Others,50,All,AllOther,1,0,4,2019,2019,1084,1,Others,3,NA,2,3.912023005428146,"(3,4]"
2397,3087,pilot feasibility study of a cognitive behavioral coping skills (cbcs) group intervention for hep c therapy patients,Completed,4,0,0,"Hepatitis C|Hepatitis C, Chronic",behavioral,Others,20,All,NIH&Combos,1,0,0,2017,2014,305,1,Others,0,NA,0,2.995732273553991,"(2,3]"
2155,2594,low-dose y90 treatment planning for hcc,"Active, not recruiting",1,0,0,HCC|Cancer of Liver|Cancer,device,Others,31,All,AllOther,0,NA,0,2019,2019,562,0,Others,1,NA,1,3.4339872044851463,"(3,4]"
1457,1569,ultrasound elastography in diagnosing patients with kidney or liver solid focal lesions,Completed,4,0,0,Adult Primary Liver Cancer|Kidney Tumor,procedure,Others,61,All,NIH&Combos,0,NA,2,2013,2014,1035,0,Others,1,NA,1,4.110873864173311,"(4,5]"
47,47,feasibility bowel dysfunction program after low anterior resection,Completed,4,0,0,Rectal Cancer|Low Anterior Resection,procedure,Others,14,All,AllOther,0,NA,4,2021,2016,565,0,Others,1,NA,1,2.6390573296152584,"(2,3]"
2217,2726,"alcohol, inflammation, and mindfulness study (aim)",Recruiting,2,0,0,Alcohol Use Disorder,behavioral,Others,226,All,AllOther,1,0,0,2016,2016,1665,1,Others,0,NA,0,5.420534999272286,"(5,6]"
1991,2342,the influence of oral probiotics on the microbiome and lipidome,Completed,4,0,0,Gut Microbiome|Skin Microbiome|Gut Lipidome|Skin Lipidome|Blood Lipidome,other,Others,25,All,AllOther,1,1,4,2018,2018,314,1,Others,1,NA,1,3.2188758248682006,"(3,4]"
1319,1409,peroral endoscopic myotomy (poem) for esophageal motility,Completed,4,0,0,Achalasia,procedure,Others,10,All,AllOther,0,NA,0,2014,2014,365,0,Others,1,NA,1,2.302585092994046,"(2,3]"
1281,1368,inspiratory muscle training post-liver transplant,Completed,4,0,0,Liver Disease Chronic|Muscle Weakness|Respiratory Insufficiency,other,Others,37,All,AllOther,1,0,0,2017,2017,1431,1,Others,0,NA,0,3.6109179126442243,"(3,4]"
3154,4297,early feeding following percutaneous gastrostomy tube placement,Completed,4,0,0,Gastrostomy,other,Others,12,All,AllOther,1,0,0,2017,2017,716,1,Others,0,NA,0,2.4849066497880004,"(2,3]"
487,505,evaluation of hemodynamic parameters following transjugular intrahepatic portosystemic shunt (tips),Enrolling by invitation,3,0,0,Refractory Ascites,procedure,Others,24,All,AllOther,1,1,2,2019,2019,1894,1,Others,0,NA,0,3.1780538303479458,"(3,4]"
88,88,impact of transjugular intrahepatic portosystemic shunts on liver stiffness,Terminated,5,1,1,Portal Hypertension|Liver Fibroses,other,Others,1,All,NIH&Combos,0,NA,2,2017,2016,975,0,Others,1,NA,1,0,NA
689,720,the effect of hot cereal on digestive health in children,Completed,4,0,0,Subjective Measures of Digestive Health Post Consumption,other,Others,20,All,Industry&Combos,0,NA,4,2016,2016,167,0,Others,1,NA,1,2.995732273553991,"(2,3]"
145,145,mucosal impedance and eosinophilic esophagitis,Completed,4,1,1,Eosinophilic Esophagitis,device,Others,30,All,AllOther,1,1,2,2013,2013,2108,1,Others,0,NA,0,3.4011973816621555,"(3,4]"
575,599,fibroscan  Â® study: assessing liver fibrosis in patients using methotrexate for psoriasis,Withdrawn,7,0,0,Psoriasis,other,Others,NA,All,AllOther,0,NA,4,2019,2019,94,0,Others,1,NA,1,NA,NA
804,841,anterior orientation vs posterior orientation in per oral endoscopic myotomy poem for the treatment of achalasia,Completed,4,0,0,Achalasia,procedure,Others,89,All,AllOther,1,0,0,2017,2017,298,1,Others,1,NA,1,4.48863636973214,"(4,5]"
433,445,photometric stereo endoscopy (pse) as a tool for imaging the rectum and colon,Completed,4,0,0,Colonic Polyps,device,Others,30,All,AllOther,0,NA,2,2013,2013,212,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
889,933,digestive properties of carbohydrate-based foods,Completed,4,0,0,"Obesity|Diabetes Mellitus, Type 2|Appetitive Behavior",other,Others,15,All,AllOther,3,0,4,2018,2018,50,3,Others,0,NA,0,2.70805020110221,"(2,3]"
39,39,pocus analysis of the gastric emptying time of orange juice with and without pulp,Completed,4,0,0,Preoperative Period|Anesthesia,other,Others,14,All,AllOther,3,1,2,2019,2019,28,3,Others,1,NA,1,2.6390573296152584,"(2,3]"
1705,1889,home versus office biofeedback therapy for fecal incontinence,Completed,4,0,0,Fecal Incontinence,device,Others,33,All,AllOther,1,0,0,2017,2015,882,1,Others,3,NA,2,3.4965075614664802,"(3,4]"
1201,1279,rectal administration of opioids using the macy catheter in reducing pain in patients with advanced cancer,Withdrawn,7,0,0,Advanced Malignant Neoplasm|Pain,device,Others,NA,All,NIH&Combos,0,NA,NA,2018,2018,510,0,Others,1,NA,1,NA,NA
2402,3095,"the milk, growth and microbiota study",Recruiting,2,0,0,Preterm Infant|Growth Delay|Microbial Colonization|Breastfeeding|Breast Milk Substitute Intolerance,other,Others,48,All,AllOther,1,0,1,2017,2017,1339,1,Others,1,NA,1,3.871201010907891,"(3,4]"
4031,7615,effects of sofosbuvir/ledipasvir treatment on the pharmacokinetics and renal safety of tenofovir,"Active, not recruiting",1,0,0,Hepatitis C and HIV Coinfection,other,Others,15,All,AllOther,0,NA,4,2015,2015,700,0,Others,1,safety,1,2.70805020110221,"(2,3]"
541,563,pilot study of a multimodal prehabilitation pancreatic cancer program,Recruiting,2,0,0,Pancreatic Ductal Adenocarcinoma,behavioral,Others,40,All,AllOther,0,NA,4,2019,2019,1449,0,Others,1,NA,1,3.6888794541139363,"(3,4]"
1349,1441,"wheat germ supplementation will improve markers of gut health, inflammation, and insulin resistance in overweight adults","Active, not recruiting",1,0,0,Overweight|Insulin Resistance|Inflammation,other,Others,42,All,AllOther,1,0,1,2019,2019,764,1,Others,1,NA,1,3.7376696182833684,"(3,4]"
684,715,esophageal temperature management during cryo af ablation (ensoetm),Recruiting,2,0,0,Atrial Fibrillation,device,Others,40,All,AllOther,1,0,1,2019,2019,815,1,Others,1,NA,1,3.6888794541139363,"(3,4]"
934,981,tace using doxorubicin-eluting beads for patients with hcc and marginal hepatic reserve,Terminated,5,1,1,Hepatocellular Carcinoma|Chemoembolization,device,Others,17,All,AllOther,0,NA,0,2014,2014,772,0,Others,1,NA,1,2.833213344056216,"(2,3]"
1236,1318,reactive vs. proactive pain control in ibd,Unknown status,8,0,0,Inflammatory Bowel Diseases|Pain|Opioid Use|Crohn Disease|Ulcerative Colitis,behavioral,Others,166,All,AllOther,1,0,4,2019,2019,700,1,Others,2,NA,2,5.111987788356544,"(5,6]"
2428,3153,water-aided colonoscopy vs air insufflation colonoscopy in colorectal cancer screening,Completed,4,0,0,Colorectal Cancer|Colorectal Adenomas|Colorectal Polyps|Pain,other,Others,1224,All,AllOther,1,0,NA,2014,2014,759,1,Others,2,NA,2,7.1098794630722715,"(7,13]"
3887,7166,surefire institutional deb-tace,"Active, not recruiting",1,0,0,Hepatocellular Carcinoma,procedure,Others,15,All,Industry&Combos,0,NA,4,2017,2016,1278,0,Others,1,NA,1,2.70805020110221,"(2,3]"
996,1051,pilot study for tce imaging of the esophagus using an ofdi capsule with a compact imaging system,Recruiting,2,0,0,Barrett's Esophagus,device,Others,20,All,NIH&Combos,0,NA,4,2016,2015,1827,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1786,2012,improving competency and metrics for polypectomy skills using evaluation tools and video feedback (complete),Completed,4,0,0,Colorectal Cancer,behavioral,Others,22,All,AllOther,1,0,4,2017,2017,1035,1,Others,0,NA,0,3.091042453358316,"(3,4]"
2195,2671,does use of topical lidocaine in egd reduce amount of iv midazolam and fentanyl required and shorten recovery time,Unknown status,8,0,0,Dysphagia|GERD|Abdominal Pain,drug or biologic,NA,106,All,AllOther,1,0,0,2015,2015,215,1,NA,4,NA,2,4.663439094112067,"(4,5]"
404,415,intra-portal alone versus intra- and extra-portal transplantation of pancreatic islets after total pancreatectomy for chronic pancreatitis,Recruiting,2,0,0,Chronic Pancreatitis|Diabetes Mellitus|Islet Cell Transplantation,procedure,Others,45,All,AllOther,1,0,0,2018,2019,1613,1,Others,0,NA,0,3.8066624897703196,"(3,4]"
119,119,comparing biopsy needles for endoscopic ultrasound guided samples for pancreatic masses,Completed,4,0,0,Pancreatic Neoplasm,device,Others,48,All,AllOther,1,0,2,2016,2016,334,1,Others,1,NA,1,3.871201010907891,"(3,4]"
395,406,esophageal deviation in atrial fibrillation ablation,Completed,4,1,1,Atrial Fibrillation,device,Others,47,All,AllOther,0,NA,1,2017,2017,941,0,Others,1,NA,1,3.8501476017100584,"(3,4]"
3518,5361,medical and psychosocial issues in adolescents and young adults with colorectal cancer,Recruiting,2,0,0,Stage I Colorectal Cancer AJCC v8|Stage II Colorectal Cancer AJCC v8|Stage IIA Colorectal Cancer AJCC v8|Stage IIB Colorectal Cancer AJCC v8|Stage IIC Colorectal Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,procedure,Others,119,All,NIH&Combos,0,NA,4,2021,2019,1096,0,Others,1,NA,1,4.77912349311153,"(4,5]"
2954,3960,effect of mailed invites of choice of colonoscopy or fit vs. mailed fit alone on colorectal cancer screening,Recruiting,2,0,0,Colorectal Cancer,other,Others,30000,All,AllOther,1,0,4,2018,2018,1059,1,Others,1,NA,1,10.308952660644293,"(7,13]"
2892,3877,study to assess the relationship between daily dosing of nrpt and changes in liver fat in healthy volunteers,Completed,4,0,0,Fatty Liver,other,Others,111,All,Industry&Combos,2,0,0,2018,2018,753,1,Others,4,NA,2,4.709530201312334,"(4,5]"
1826,2079,"prebiotics, gut microbiota, and cardiometabolic health",Completed,4,0,0,Prediabetes,other,Others,22,All,AllOther,1,0,1,2015,2014,1065,1,Others,3,NA,2,3.091042453358316,"(3,4]"
2320,2928,impact of y90 radiation segmentectomy on hcc,Completed,4,0,0,Hepatocellular Carcinoma,other,Others,30,All,AllOther,0,NA,0,2017,2016,1732,0,Others,1,NA,1,3.4011973816621555,"(3,4]"
1207,1285,endoscopic intragastric balloon placement for weight loss in liver transplant waitlist candidates,Terminated,5,1,1,Obesity|Liver Cirrhosis,device,Others,8,All,AllOther,0,NA,4,2015,2015,429,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
2488,3281,qst study: predicting treatment response in chronic pancreatitis using quantitative sensory testing,Recruiting,2,0,0,Chronic Pancreatitis|Chronic Pain,other,Others,500,All,AllOther,1,1,2,2018,2017,1483,1,Others,0,NA,0,6.214608098422191,"(6,7]"
19,19,routine versus no assessment of gastric residual volumes in preterm infants,Recruiting,2,0,0,Gastric Residual Volume|Preterm Infant|Feeding Disorder Neonatal,other,Others,146,All,AllOther,1,0,4,2019,2019,913,1,Others,0,NA,0,4.983606621708336,"(4,5]"
765,801,effects of curcumin supplementation on gut barrier function in patients with metabolic syndrome,Completed,4,0,0,Obesity|High Blood Pressure|High Cholesterol|Type2 Diabetes|Heart Diseases,other,Others,15,All,AllOther,0,NA,1,2018,2018,786,0,Others,1,NA,1,2.70805020110221,"(2,3]"
1428,1537,effects of resistant starch diet on the gut microbiome in chronic kidney disease,Recruiting,2,0,0,Chronic Kidney Diseases,other,Others,60,All,NIH&Combos,0,NA,4,2017,2018,1297,0,Others,1,NA,1,4.0943445622221,"(4,5]"
1209,1287,prospective study of non-operative management of sbo without nasogastric tube placement,Withdrawn,7,0,0,Small Bowel Obstruction,procedure,Others,NA,All,AllOther,1,0,0,2015,2015,613,1,Others,0,NA,0,NA,NA
2415,3125,hernia reduction prior to scheduled tif completion,Terminated,5,1,1,Fundoplication,device,Others,14,All,Industry&Combos,0,NA,0,2017,2018,573,0,Others,1,NA,1,2.6390573296152584,"(2,3]"
1152,1224,the ibd&me randomized controlled trial,Recruiting,2,0,0,Inflammatory Bowel Diseases,other,Others,152,All,AllOther,1,0,4,2018,2019,666,1,Others,1,NA,1,5.0238805208462765,"(5,6]"
1686,1861,evaluation of renal blood flow using contrast enhanced ultrasound for differential diagnosis of acute kidney injury in cirrhotic patients: a pilot study,Unknown status,8,0,0,Liver Cirrhosis and Acute Kidney Injury,drug or biologic,NA,25,All,AllOther,1,NA,2,2014,2013,1033,1,NA,0,NA,0,3.2188758248682006,"(3,4]"
1175,1250,gut microbiome and p-inulin in ckd - targut ckd study,Unknown status,8,0,0,Chronic Kidney Diseases,other,Others,18,All,NIH&Combos,0,NA,4,2017,2016,396,0,Others,1,NA,1,2.8903717578961645,"(2,3]"
2223,2737,effects of prolonged fasting on microbiome and hdl,Completed,4,0,0,Fasting,other,Others,21,All,AllOther,0,NA,4,2018,2018,51,0,Others,1,NA,1,3.044522437723423,"(3,4]"
22,22,the gi binder: a psychoeducational intervention for gastrointestinal cancer patients,Completed,4,0,0,Gastro Intestinal Cancer,other,Others,49,All,AllOther,0,NA,4,2018,2018,448,0,Others,1,NA,1,3.8918202981106265,"(3,4]"
589,615,healing of the esophageal mucosa after rfa of barrett's esophagus,Enrolling by invitation,3,0,0,Barrett Esophagus,procedure,Others,20,All,AllOther,0,NA,4,2016,2016,1887,0,Others,1,NA,1,2.995732273553991,"(2,3]"
49,49,contrast eus of the pancreas,Unknown status,8,0,0,Pancreatic Neoplasms|Pancreatitis|Pancreatic Cyst,other,Others,150,All,AllOther,0,NA,2,2016,2016,1370,0,Others,1,NA,1,5.0106352940962555,"(5,6]"
1782,2006,outcomes and data collection for fecal microbiota transplantation for the treatment of recurrent clostridium difficile,Recruiting,2,0,0,Clostridium Difficile Infection Recurrence|Clostridium Difficile Infection,procedure,Others,500,All,AllOther,0,NA,0,2018,2014,2922,0,Others,1,NA,1,6.214608098422191,"(6,7]"
1685,1860,ibd shared decision making intervention,Completed,4,0,0,Inflammatory Bowel Diseases,other,Others,37,All,AllOther,NA,0,4,2017,2017,686,NA,Others,0,NA,0,3.6109179126442243,"(3,4]"
2389,3067,use of capnography in egd and colonoscopy with moderate sedation.,Completed,4,1,1,Hypoxia|Apnea|Hypotension|Hypopnea,other,Others,452,All,AllOther,1,0,4,2013,2013,457,1,Others,2,NA,2,6.113682179832232,"(6,7]"
851,892,"obesity, iron regulation and colorectal cancer risk",Completed,4,0,0,Colon Inflammation|Iron Malabsorption|Obesity|Diet Modification,other,Others,17,Female,AllOther,3,1,4,2018,2015,1205,3,Others,0,NA,0,2.833213344056216,"(2,3]"
1665,1835,dietary treatment study of pediatric nafld,Completed,4,1,1,Nonalcoholic Fatty Liver Disease,other,Others,40,Male,AllOther,1,0,0,2015,2015,792,1,Others,0,NA,0,3.6888794541139363,"(3,4]"
349,357,cryo balloon for residual barrett's esophagus,Enrolling by invitation,3,0,0,Barrett's Esophagus,device,Others,10,All,Industry&Combos,0,NA,0,2014,2014,2557,0,Others,1,NA,1,2.302585092994046,"(2,3]"
346,353,effect of betaine and food on gastric ph,Completed,4,0,0,Healthy,other,Others,9,All,AllOther,3,0,4,2016,2016,663,3,Others,0,NA,0,2.1972245773362196,"(2,3]"
1921,2240,patient positioning and airway management during ercp,Completed,4,0,0,Airway Management,other,Others,200,All,AllOther,1,0,4,2016,2016,492,1,Others,0,NA,0,5.298317366548036,"(5,6]"
1429,1538,an investigational scan (magnetic resonance elastography) in detecting treatment response in patients with advanced liver cancer,Recruiting,2,0,0,Advanced Adult Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8,procedure,Others,45,All,NIH&Combos,0,NA,2,2019,2019,1283,0,Others,1,NA,1,3.8066624897703196,"(3,4]"
2424,3143,electron beam intraoperative radiation therapy following chemoradiation in patients with pancreatic cancer with vascular involvement,Recruiting,2,0,0,Pancreas Cancer,other,Others,200,All,AllOther,0,NA,0,2018,2019,1717,0,Others,1,NA,1,5.298317366548036,"(5,6]"
1671,1842,study comparing flexible spectral-imaging color enhancement (fice) with olympus narrow band imaging (nbi),Completed,4,1,1,Routine Endoscopy,device,Others,20,All,Industry&Combos,0,NA,2,2013,2013,31,0,Others,1,NA,1,2.995732273553991,"(2,3]"
3438,5229,a culturally-adapted colorectal cancer screening decision aid designed for american indians,Completed,4,0,0,Colorectal Cancer,behavioral,Others,128,All,AllOther,1,0,4,2018,2017,420,1,Others,1,NA,1,4.852030263919617,"(4,5]"
724,758,hepaxa management of non-alcoholic fatty liver disease,Unknown status,8,0,0,Non-Alcoholic Fatty Liver Disease|Non Alcoholic Fatty Liver|NASH - Nonalcoholic Steatohepatitis,other,Others,50,All,Industry&Combos,0,NA,0,2019,2019,242,0,Others,1,NA,1,3.912023005428146,"(3,4]"
999,1054,pet/ct-assessment of liver tumor ablation,Completed,4,1,1,Liver Tumor|Liver Neoplasms,other,Others,33,All,AllOther,0,NA,2,2013,2014,1507,0,Others,1,NA,1,3.4965075614664802,"(3,4]"
3779,6553,the use of aromatherapy for symptom management,Unknown status,8,0,0,"Nausea, Vomiting and Anxiety Associated With Medical Oncology Patients",drug or biologic,NA,40,All,AllOther,0,NA,4,2014,2014,335,0,NA,1,NA,1,3.6888794541139363,"(3,4]"
1442,1551,engineering gut microbiome to target breast cancer,Completed,4,0,0,Breast Cancer,other,Others,7,Female,AllOther,0,NA,4,2017,2017,895,0,Others,1,NA,1,1.9459101490553132,"(1,2]"
517,538,esophageal cytology with fish in detecting esophageal cancer,Completed,4,1,1,Dysphagia|Dysplasia|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Esophagitis|Gastroesophageal Reflux Disease|High Grade Dysplasia in Barrett Esophagus|Weight Loss,procedure,Others,50,All,NIH&Combos,0,NA,4,2014,2014,668,0,Others,1,NA,1,3.912023005428146,"(3,4]"
1562,1702,thoracoabdominal aortic and aortic arch aneurysms with fenestrated and branched stent grafts,Recruiting,2,0,0,Thoracoabdominal Aortic Aneurysm|Aortic Arch Aneurysm,device,Others,300,All,Industry&Combos,0,1,0,2014,2014,4018,0,Others,1,NA,1,5.703782474656201,"(5,6]"
1902,2210,does improving vagal tone increase mitochondrial bioenergetics,Completed,4,1,1,Functional Gastrointestinal Disorders|Irritable Bowel Syndrome|Dyspepsia|Functional Abdominal Pain Syndrome,device,Others,8,All,AllOther,0,NA,0,2019,2019,230,0,Others,1,NA,1,2.0794415416798357,"(2,3]"
1974,2324,ultrasound for the detection of oxaliplatin-induced peripheral neuropathy,Recruiting,2,0,0,Gastrointestinal Cancer|Colorectal Cancer,procedure,Others,20,All,NIH&Combos,0,NA,2,2019,2019,593,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1184,1261,evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with decompensated cirrhosis with ascites,Completed,4,0,0,Cirrhosis of the Liver|Ascites|Spontaneous Bacterial Peritonitis,other,Others,11,All,Industry&Combos,0,NA,4,2015,2016,422,0,Others,1,NA,1,2.3978952727983707,"(2,3]"
354,362,tecr & ecm placement for esophageal high grade dysplasia,Terminated,5,1,1,Barrett Esophagus|Esophagus|High Grade Dysplasia,device,Others,1,All,Industry&Combos,0,NA,0,2015,2016,787,0,Others,1,NA,1,0,NA
1630,1792,system-wide improvement for transitions after surgery: the swift post op program,Completed,4,0,0,Colectomy|Colorectal Surgery|Ileostomy,behavioral,Others,100,All,AllOther,1,0,1,2015,2014,609,1,Others,2,NA,2,4.605170185988092,"(4,5]"
1725,1918,monitoring of symptoms and cognitive function using telehealth,Completed,4,1,1,End Stage Liver Disease,other,Others,45,All,AllOther,0,NA,4,2017,2016,852,0,Others,1,NA,1,3.8066624897703196,"(3,4]"
3299,4680,champs study: chronic hepatitis c management to improve outcomes,Completed,4,1,1,"Hepatitis C Virus Infection, Response to Therapy of|Human Immunodeficiency Virus",other,Others,144,All,NIH&Combos,1,0,0,2015,2015,522,1,Others,0,NA,0,4.969813299576001,"(4,5]"
3628,5736,comparison of medical and surgical treatment of uncomplicated acute appendicitis in children,Completed,4,0,0,Appendicitis,drug or biologic,NA,39,All,AllOther,1,0,0,2016,2016,1461,1,NA,0,NA,0,3.6635616461296463,"(3,4]"
2141,2574,helping empower liver and kidney patients,Completed,4,1,1,Hepatitis C|Chronic Kidney Diseases|Patient Education,behavioral,Others,70,All,Industry&Combos,0,NA,4,2018,2017,384,0,Others,1,NA,1,4.248495242049359,"(4,5]"
992,1047,"effect of dietary flavonoids on intestinal microbiota, intestinal inflammation and metabolic syndrome",Completed,4,0,0,Metabolic Syndrome X|Inflammation,other,Others,30,All,AllOther,3,0,4,2016,2013,485,3,Others,3,NA,2,3.4011973816621555,"(3,4]"
1569,1712,mild hypothermia and acute kidney injury in liver transplantation,Recruiting,2,0,0,Cirrhosis|End Stage Liver Disease|Acute Kidney Injury|Liver Transplant; Complications|Chronic Kidney Diseases|Hepatitis c|Hepatitis B|NASH - Nonalcoholic Steatohepatitis|Alcoholic Cirrhosis|Hepatocellular Carcinoma,device,Others,230,All,AllOther,1,0,1,2018,2018,1425,1,Others,2,NA,2,5.438079308923196,"(5,6]"
1360,1454,compassionate use of domperidone for refractory gastroparesis,Recruiting,2,0,0,GERD|Gastroesophageal Reflux|Gastroparesis,drug or biologic,NA,20,All,AllOther,0,NA,0,2021,2013,3166,0,NA,1,NA,1,2.995732273553991,"(2,3]"
1470,1584,prospective randomized controlled trial comparing water and air colonoscopy in a community based setting,Completed,4,0,0,Tubular Adenoma|Colon Cancer|Hyperplastic Polyp,other,Others,178,All,AllOther,1,0,2,2012,2014,424,1,Others,0,NA,0,5.181783550292085,"(5,6]"
1915,2231,mri only radiation therapy with cpap,Recruiting,2,0,0,"Carcinoma Liver|Carcinoma, Pancreatic",device,Others,42,All,AllOther,1,1,4,2018,2018,1148,1,Others,0,NA,0,3.7376696182833684,"(3,4]"
664,692,a pilot study to evaluate the efficacy of itdd vs. cmm in the treatment of pancreatic cancer pain,Withdrawn,7,0,0,Pain Management|Cancer Pain,drug or biologic,NA,NA,All,Industry&Combos,1,1,0,2015,2016,244,1,NA,0,efficacy,0,NA,NA
850,891,oral gut liver axis in cirrhosis,Completed,4,0,0,Cirrhosis|Periodontitis|Gingivitis,procedure,Others,44,All,AllOther,0,NA,1,2017,2016,516,0,Others,1,NA,1,3.784189633918261,"(3,4]"
120,120,the summer camp study: blood glucose control with a bi-hormonal bionic endocrine pancreas,Completed,4,1,1,Type 1 Diabetes,device,Others,32,All,AllOther,3,0,0,2013,2013,122,3,Others,0,NA,0,3.4657359027997265,"(3,4]"
3475,5278,reducing sedentary behaviors among colorectal cancer survivors,Completed,4,0,0,Colorectal Cancer,other,Others,20,All,AllOther,0,1,0,2015,2015,214,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1318,1408,confocal endomicroscopy for non-erosive reflux disease detection,Recruiting,2,0,0,Non-erosive Reflux Disease|Gastroesophageal Reflux,drug or biologic,NA,140,All,AllOther,3,0,2,2016,2015,1949,3,NA,0,NA,0,4.941642422609304,"(4,5]"
1516,1646,reducing va no-shows: evaluation of predictive overbooking applied to colonoscopy,Completed,4,1,1,Colon Cancer,other,Others,180,All,AllOther,1,0,4,2012,2013,728,1,Others,0,NA,0,5.19295685089021,"(5,6]"
2212,2707,the use of a prebiotic to promote a healthy gut microbiome in pediatric stem cell transplant recipients,Recruiting,2,0,0,Microbial Colonization,drug or biologic,NA,40,All,AllOther,1,0,4,2019,2019,487,1,NA,3,NA,2,3.6888794541139363,"(3,4]"
59,59,gastric electrical stimulation (ges) and pyloroplasty for the treatment of gastroparesis,Recruiting,2,0,0,Gastroparesis,device,Others,50,All,AllOther,1,0,0,2017,2017,1951,1,Others,2,NA,2,3.912023005428146,"(3,4]"
236,239,evaluation of the bowel cleansing in hospitalized patients using pure-vu system,Completed,4,1,1,Gastrointestinal Disease|Colorectal Cancer,device,Others,95,All,Industry&Combos,0,NA,4,2018,2018,368,0,Others,1,NA,1,4.553876891600541,"(4,5]"
343,350,sbi in children with d-ibs,Completed,4,0,0,Irritable Bowel Syndrome,other,Others,20,All,Industry&Combos,1,0,4,2015,2015,486,1,Others,3,NA,2,2.995732273553991,"(2,3]"
475,492,preoperative exercise in pancreatic cancer,Completed,4,0,0,Pancreatic Cancer,behavioral,Others,3,All,AllOther,1,1,4,2016,2016,255,1,Others,0,NA,0,1.0986122886681098,"(1,2]"
3692,6111,"comparison study of transversus abdominal plane, paravertebral and epidural blocks in laparoscopic colectomy",Terminated,5,1,1,Laparoscopic Colorectal Resection,drug or biologic,NA,17,All,AllOther,1,0,0,2014,2013,455,1,NA,0,NA,0,2.833213344056216,"(2,3]"
3541,5416,pursuit: real world use of the eclipse system,Recruiting,2,0,0,Fecal Incontinence,device,Others,150,Female,Industry&Combos,0,NA,0,2019,2019,987,0,Others,1,NA,1,5.0106352940962555,"(5,6]"
699,732,comparison of esophageal clearance times of oral budesonide preparations,Completed,4,0,0,Eosinophilic Esophagitis,other,Others,24,All,AllOther,3,0,NA,2014,2014,31,3,Others,3,NA,2,3.1780538303479458,"(3,4]"
1621,1776,health care coach support in reducing acute care use and cost in patients with cancer,"Active, not recruiting",1,0,0,Acute Myeloid Leukemia|Brain Glioblastoma|Estrogen Receptor Negative|Extensive Stage Small Cell Lung Carcinoma|Head and Neck Carcinoma|HER2/Neu Negative|Hormone-Resistant Prostate Cancer|Limited Stage Small Cell Lung Carcinoma|Myelodysplastic Syndrome|Progesterone Receptor Negative|Progressive Disease|Recurrent Carcinoma|Stage II Pancreatic Cancer|Stage II Rectal Cancer|Stage IIA Pancreatic Cancer|Stage IIA Rectal Cancer|Stage IIB Pancreatic Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage III Colon Cancer|Stage III Esophageal Cancer|Stage III Gastric Cancer|Stage III Non-Small Cell Lung Cancer|Stage III Ovarian Cancer|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Stage III Skin Melanoma|Stage IIIA Colon Cancer|Stage IIIA Esophageal Cancer|Stage IIIA Gastric Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Rectal Cancer|Stage IIIA Skin Melanoma|Stage IIIB Colon Cancer|Stage IIIB Esophageal Cancer|Stage IIIB Gastric Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Rectal Cancer|Stage IIIB Skin Melanoma|Stage IIIC Colon Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Rectal Cancer|Stage IIIC Skin Melanoma|Stage IV Bladder Cancer|Stage IV Bone Sarcoma|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IV Soft Tissue Sarcoma|Stage IVA Bone Sarcoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Bone Sarcoma|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Triple-Negative Breast Carcinoma,procedure,Others,200,All,AllOther,1,0,4,2017,2016,1811,1,Others,0,NA,0,5.298317366548036,"(5,6]"
1472,1586,specialty medical homes to improve outcomes for patients with ibd and behavioral health conditions,Recruiting,2,0,0,Inflammatory Bowel Disease|Behavioral Symptoms,other,Others,990,All,AllOther,1,0,4,2019,2019,1338,1,Others,0,NA,0,6.897704943128636,"(6,7]"
1912,2226,"a prospective, randomized, open label trial of two doses of oral betaine",Recruiting,2,0,0,Non-Alcoholic Fatty Liver Disease|Non Insulin Dependent Diabetes|ALT,other,Others,48,All,AllOther,1,0,0,2017,2013,2970,1,Others,0,NA,0,3.871201010907891,"(3,4]"
2549,3426,management of reflux after sleeve using stretta,Terminated,5,0,0,GERD|Morbid Obesity,device,Others,5,All,AllOther,0,NA,0,2015,2016,1156,0,Others,1,NA,1,1.6094379124341003,"(1,2]"
2033,2403,crossover trial of systemic chemotherapy in patients with metastatic well-differentiated mucinous appendiceal adenocarcinomas with pseudomyxoma peritonei,Recruiting,2,0,0,Gastrointestinal Neoplasms,behavioral,Others,30,All,AllOther,3,1,4,2013,2013,2922,3,Others,0,NA,0,3.4011973816621555,"(3,4]"
3232,4534,evaluation of stool microbiome using hygieacare prep,Completed,4,0,0,Stool Microbiome,other,Others,14,All,Industry&Combos,0,NA,4,2020,2019,175,0,Others,1,NA,1,2.6390573296152584,"(2,3]"
712,746,a biomarker study to identify predictive signatures of response to lde225 (hedgehog inhibitor) in patients with resectable pancreatic cancer,Withdrawn,7,0,0,Pancreatic Ductal Adenocarcinoma,drug or biologic,NA,NA,All,AllOther,0,NA,0,2013,2014,273,0,NA,1,NA,1,NA,NA
314,319,a validated educational video intervention improves the quality of bowel preparation for colonoscopy,Terminated,5,0,0,Bowel Dysfunction,other,Others,298,All,AllOther,1,0,NA,2013,2013,638,1,Others,1,NA,1,5.697093486505405,"(5,6]"
1300,1389,evaluate the efficiency impact of conducting active temperature management during cardiac cryoablation procedures,Completed,4,0,0,Atrial Fibrillation,device,Others,20,All,Industry&Combos,0,NA,1,2019,2019,304,0,Others,1,NA,1,2.995732273553991,"(2,3]"
1101,1165,effect of t6 dermatome electrical stimulation on gastroduodenal motility in healthy volunteers,Terminated,5,1,1,Weight Loss,device,Others,16,All,Industry&Combos,1,0,4,2017,2017,288,1,Others,2,NA,2,2.772588722239781,"(2,3]"
1582,1730,oligosaccharide for cdiff(+) heme-onc patients,Suspended,6,0,0,Clostridium Difficile|Hematologic Diseases,other,Others,12,All,AllOther,0,NA,1,2018,2019,549,0,Others,1,NA,1,2.4849066497880004,"(2,3]"
1962,2308,intralipid versus smoflipid in hpn patients,Recruiting,2,0,0,Short Bowel Syndrome|Intestinal Fistula|Crohn Disease|Intestinal Obstruction,other,Others,100,All,AllOther,1,0,4,2018,2018,1065,1,Others,4,NA,2,4.605170185988092,"(4,5]"
113,113,evaluating strategies to present colon cancer screening information,Completed,4,1,1,Colonic Neoplasms|Colorectal Neoplasms|Colonic Diseases|Gastrointestinal Neoplasms,behavioral,Others,486,All,NIH&Combos,1,0,1,2015,2015,610,1,Others,1,NA,1,6.186208623900494,"(6,7]"
3915,7296,evaluation of hepcure toolkit to improve harvoni adherence,Completed,4,0,0,Hepatitis C|Medication Adherence,device,Others,71,All,Industry&Combos,2,0,4,2016,2016,1154,1,Others,0,NA,0,4.2626798770413155,"(4,5]"
